basic_tfactortx_id;basic_gene_symbol;basic_ensembl_gene_id;basic_hgnc_id;basic_ncbi_gene_id;basic_protein_name;basic_uniprot_id;basic_jaspar_url;basic_open_targets_url;basic_tf_superclass;basic_tf_class;basic_tf_family;sort_disease_ot_ard_aging_sum_rank;sort_disease_ot_ard_aging_overall_rank;sort_disease_ot_total_assoc_score_rank;sort_disease_ot_ard_total_assoc_count_score_rank;sort_aging_summary_total_db_entries_count_rank;sort_dev_summary_dev_level_category;disease_ot_total_assoc_count;disease_ot_total_assoc_score;disease_ot_total_assoc_count_norm;disease_ot_total_assoc_score_norm;disease_ot_lowconf_count;disease_ot_lowconf_score;disease_ot_lowconf_count_norm;disease_ot_lowconf_score_norm;disease_ot_modconf_count;disease_ot_modconf_score;disease_ot_modconf_count_norm;disease_ot_modconf_score_norm;disease_ot_hiconf_count;disease_ot_hiconf_score;disease_ot_hiconf_count_norm;disease_ot_hiconf_score_norm;disease_ot_ard_disease_count;disease_ot_ard_total_score;disease_ot_ard_disease_count_norm;disease_ot_ard_total_score_norm;disease_ot_ard_strongest_linked_disease;disease_age-related hearing impairment;disease_age-related macular degeneration;disease_Alzheimer disease;disease_atherosclerosis;disease_benign prostatic hyperplasia;disease_cancer;disease_chronic obstructive pulmonary disease;disease_heart failure;disease_Ischemic stroke;disease_myocardial infarction;disease_non-alcoholic fatty liver disease;disease_osteoarthritis;disease_Osteoporosis;disease_Parkinson disease;disease_sarcopenia;disease_type 2 diabetes mellitus;aging_summary_total_db_entries_count;aging_summary_total_db_entries_count_norm;aging_summary_human;aging_summary_mm_influence;aging_summary_ce_influence;aging_summary_dm_influence;aging_PMID35343830_ce;aging_PMID35343830_dm;aging_PMID35343830_mm;aging_PMID35343830_human;aging_hagr_genage_human_inclusion;aging_hagr_genage_ce_influence;aging_hagr_genage_dm_influence;aging_hagr_genage_mm_influence;aging_hagr_cellage_effect;aging_hagr_longevitymap_entries;aging_agingreg_human_influence;aging_senequest_total_entries;aging_opengenes_ce_influence;aging_opengenes_dm_influence;aging_opengenes_mm_influence;aging_opengenes_human_longevity_assoc;dev_summary_total_db_entries_count;dev_summary_dev_level_category;dev_summary_dev_level_category_note;dev_pharos_tcrd_tdl;dev_dgidb_all_drugs;dev_dgidb_MOA_drugs;dev_ttd_approved_drugs;dev_chembl_target_id;dev_chembl_target_name;dev_chembl_target_type;dev_chembl_compounds;dev_chembl_activites;dev_chembl_drug_count;dev_chembl_max_phase;dev_chembl_modality_list;dev_chembl_first_approval_min
TFTX_0983;TP53;ENSG00000141510;HGNC:11998;7157;Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53);P04637;https://jaspar.elixir.no/search?q=P04637;https://platform.opentargets.org/target/ENSG00000141510;6 Immunoglobulin fold;6.3 p53 domain factors;6.3.1 p53-related;6;1;1;4;1;2_Medium;3113;271.27;1;1;2555;73.77;1;1;481;149.77;1;1;77;47.72;0.77;0.83;16;2.66;1;0.68;Cancer;0.002751317;0.087417089;0.490947142;0.026461422;0.306567903;0.67821354;0.103413333;0.050052823;0.022237383;0.043272632;0.097875673;0.042683981;0.076932138;0.477067265;0.046718779;0.107137249;15;1;Y;Unclear;Anti-Longevity;Unclear;Anti-Longevity;Anti-Longevity;Anti-Longevity;Unclear;mammal,model,cell;Anti-Longevity;Anti-Longevity;Pro-Longevity;Induces;22;Unclear;252;#N/A;Unclear;Unclear;1;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;547;10;#N/A;"CHEMBL1907611;CHEMBL4096";"Tumour suppressor p53/oncoprotein Mdm2;Cellular tumor antigen p53";"PROTEIN-PROTEIN INTERACTION;SINGLE PROTEIN";"1601;36488";"2107;48517";"4;2";"3;3";"Small molecule;Gene;Small molecule";#N/A
TFTX_0649;NR3C1;ENSG00000113580;HGNC:7978;2908;Glucocorticoid receptor (GR) (Nuclear receptor subfamily 3 group C member 1);P04150;https://jaspar.elixir.no/search?q=P04150;https://platform.opentargets.org/target/ENSG00000113580;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;34;3;2;1;31;1_High;1542;205.67;0.5;0.76;1101;36.95;0.43;0.5;341;111.12;0.71;0.74;100;57.6;1;1;15;3.94;0.94;1;Chronic Obstructive Pulmonary Disease;#N/A;0.373786613;0.380842107;0.042350252;0.023231478;0.608714787;0.704554696;0.297470955;0.354720175;0.079302759;0.025410065;0.60829303;0.009345651;0.326272871;0.006624308;0.096226198;5;0.33;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;downstream;Unclear;#N/A;#N/A;#N/A;2;#N/A;3;#N/A;#N/A;#N/A;1;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;234;74;21;CHEMBL2034;Glucocorticoid receptor;SINGLE PROTEIN;5548;15052;75;4;"Small molecule;Unknown";1950
TFTX_0935;TET2;ENSG00000168769;HGNC:25941;54790;Methylcytosine dioxygenase TET2 (EC 1.14.11.n2);Q6N021;#N/A;https://platform.opentargets.org/target/ENSG00000168769;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;450;82;3;9;438;4_Low;1197;159.92;0.38;0.59;856;36.75;0.34;0.5;292;93.88;0.61;0.63;49;29.29;0.49;0.51;13;1.96;0.81;0.5;Chronic Obstructive Pulmonary Disease;#N/A;0.001478319;0.293915737;0.051351421;0.009054706;0.422029353;0.485356395;0.188620182;0.023019041;0.014545521;0.013089287;#N/A;0.01185489;0.074941776;#N/A;0.366803211;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;13;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0206;ESR1;ENSG00000091831;HGNC:3467;2099;Estrogen receptor (ER) (ER-alpha) (Estradiol receptor) (Nuclear receptor subfamily 3 group A member 1);P03372;https://jaspar.elixir.no/search?q=P03372;https://platform.opentargets.org/target/ENSG00000091831;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;39;4;4;14;21;1_High;2370;150.27;0.76;0.55;2104;55.76;0.82;0.76;239;78.33;0.5;0.52;27;16.18;0.27;0.28;16;1.83;1;0.47;Cancer;0.001478319;0.013235681;0.367587958;0.09116261;0.084777785;0.49224302;0.018166816;0.015786477;0.048859535;0.309921957;0.048627778;0.043954918;0.113764413;0.08146098;0.014539411;0.086428268;6;0.4;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;Unclear;#N/A;#N/A;Inhibits;1;#N/A;6;#N/A;#N/A;#N/A;1;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;376;53;37;"CHEMBL206;CHEMBL2093866";"Estrogen receptor alpha;Estrogen receptor";"SINGLE PROTEIN;PROTEIN FAMILY";"9170;1789";"18287;3070";"22;25";"4;4";"Small molecule;Small molecule;Unknown";"1947;1942"
TFTX_0367;HNF1A;ENSG00000135100;HGNC:11621;6927;Hepatocyte nuclear factor 1-alpha (HNF-1-alpha) (HNF-1A) (Liver-specific transcription factor LF-B1) (LFB1) (Transcription factor 1) (TCF-1);P20823;https://jaspar.elixir.no/search?q=P20823;https://platform.opentargets.org/target/ENSG00000135100;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1189;342;5;16;1168;4_Low;1046;145.27;0.34;0.54;728;27.16;0.28;0.37;280;96.43;0.58;0.64;38;21.68;0.38;0.38;11;1.79;0.69;0.45;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011197859;0.009204448;#N/A;0.102696617;0.005004727;#N/A;0.058917189;0.438573473;0.359398898;0.002217479;0.008479804;0.002217479;#N/A;0.791354694;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0729;PPARG;ENSG00000132170;HGNC:9236;5468;Peroxisome proliferator-activated receptor gamma (PPAR-gamma) (Nuclear receptor subfamily 1 group C member 3);P37231;https://jaspar.elixir.no/search?q=P37231;https://platform.opentargets.org/target/ENSG00000132170;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;15;2;6;3;6;1_High;1681;129.3;0.54;0.48;1406;39.42;0.55;0.53;262;81.99;0.54;0.55;13;7.89;0.13;0.14;16;2.68;1;0.68;Type 2 Diabetes Mellitus;0.008869917;0.031706548;0.408983426;0.39309667;0.039803335;0.12638859;0.086670552;0.027195647;0.048429006;0.068771366;0.419593978;0.035684881;0.053664394;0.087226065;0.004723847;0.840020612;10;0.67;Y;Pro-Longevity;Unclear;#N/A;#N/A;#N/A;Pro-Longevity;Unclear;functional;Unclear;#N/A;Pro-Longevity;Induces;4;#N/A;16;#N/A;#N/A;Pro-Longevity;1;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;144;36;5;"CHEMBL235;CHEMBL3559683";"Peroxisome proliferator-activated receptor gamma;Peroxisome proliferator-activated receptor";"SINGLE PROTEIN;PROTEIN FAMILY";"8010;85";"15429;137";"30;5";"4;4";"Small molecule;Small molecule";1987
TFTX_0789;RUNX1;ENSG00000159216;HGNC:10471;861;Runt-related transcription factor 1 (Acute myeloid leukemia 1 protein) (Core-binding factor subunit alpha-2) (CBF-alpha-2) (Oncogene AML-1) (Polyomavirus enhancer-binding protein 2 alpha B subunit) (PEA2-alpha B) (PEBP2-alpha B) (SL3-3 enhancer factor 1 alpha B subunit) (SL3/AKV core-binding factor alpha B subunit);Q01196;https://jaspar.elixir.no/search?q=Q01196;https://platform.opentargets.org/target/ENSG00000159216;6 Immunoglobulin fold;6.4 Runt domain factors;6.4.1 Runt-related;247;36;7;188;52;4_Low;1266;110.21;0.41;0.41;1055;37.14;0.41;0.5;191;61.41;0.4;0.41;20;11.65;0.2;0.2;15;0.57;0.94;0.15;Cancer;#N/A;0.002751317;0.024583125;0.009786975;0.003695799;0.112714379;0.07087275;0.033219365;0.007391597;0.102418667;0.0950888;0.05092806;0.038492606;0.002936107;0.004791808;0.014210618;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Unclear;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;35;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0022;AR;ENSG00000169083;HGNC:644;367;Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptor subfamily 3 group C member 4);P10275;https://jaspar.elixir.no/search?q=P10275;https://platform.opentargets.org/target/ENSG00000169083;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;58;6;8;19;31;1_High;1900;107.83;0.61;0.4;1724;45.69;0.67;0.62;154;48.02;0.32;0.32;22;14.12;0.22;0.25;15;1.68;0.94;0.43;Cancer;#N/A;0.023725744;0.104357926;0.054099558;0.313450765;0.420142088;0.080252995;0.099323788;0.018986816;0.025674115;0.027441183;0.006821405;0.038989059;0.019513975;0.104070853;0.342186767;5;0.33;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;2;#N/A;#N/A;Pro-Longevity;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;1008;82;18;CHEMBL1871;Androgen Receptor;SINGLE PROTEIN;5994;12499;42;4;Small molecule;1953
TFTX_0535;MLXIPL;ENSG00000009950;HGNC:12744;51085;Carbohydrate-responsive element-binding protein (ChREBP) (Class D basic helix-loop-helix protein 14) (bHLHd14) (MLX interactor) (MLX-interacting protein-like) (WS basic-helix-loop-helix leucine zipper protein) (WS-bHLH) (Williams-Beuren syndrome chromosomal region 14 protein);Q9NP71;https://jaspar.elixir.no/search?q=Q9NP71;https://platform.opentargets.org/target/ENSG00000009950;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;515;100;9;324;182;5_None;515;102.61;0.17;0.38;303;12.37;0.12;0.17;173;69.35;0.36;0.46;39;20.9;0.39;0.36;9;0.35;0.56;0.09;Cancer;#N/A;#N/A;0.01817101;0.005572032;#N/A;0.124447145;#N/A;0.108635054;0.007391597;0.002217479;0.03629063;#N/A;#N/A;#N/A;0.003695799;0.04334718;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0829;SMAD3;ENSG00000166949;HGNC:6769;4088;Mothers against decapentaplegic homolog 3 (MAD homolog 3) (Mad3) (Mothers against DPP homolog 3) (hMAD-3) (JV15-2) (SMAD family member 3) (SMAD 3) (Smad3) (hSMAD3);P84022;https://jaspar.elixir.no/search?q=P84022;https://platform.opentargets.org/target/ENSG00000166949;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;91;11;10;29;52;4_Low;1164;102.34;0.37;0.38;943;26.33;0.37;0.36;210;69.37;0.44;0.46;11;6.65;0.11;0.12;14;1.41;0.88;0.36;Cancer;#N/A;#N/A;0.087691934;0.018847313;0.0115945;0.489199351;0.085512871;0.012065746;0.008941779;0.361639461;0.011563012;0.025395279;0.016258929;0.046084131;0.00518192;0.227292426;4;0.27;Y;#N/A;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;Unclear;#N/A;Induces;#N/A;#N/A;10;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;229;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0280;FOXP1;ENSG00000114861;HGNC:3823;27086;Forkhead box protein P1 (Mac-1-regulated forkhead) (MFH);Q9H334;https://jaspar.elixir.no/search?q=Q9H334;https://platform.opentargets.org/target/ENSG00000114861;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;260;38;11;166;83;5_None;812;95.98;0.26;0.35;591;24.21;0.23;0.33;213;67.13;0.44;0.45;8;4.63;0.08;0.08;12;0.63;0.75;0.16;Cancer;#N/A;0.010861541;0.01649517;0.051420477;#N/A;0.263535641;0.025213559;0.00395512;0.001478319;0.060284018;#N/A;#N/A;0.008387409;0.004876401;0.003695799;0.175745437;3;0.2;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;Inhibits;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1071;ZFHX3;ENSG00000140836;HGNC:777;463;Zinc finger homeobox protein 3 (AT motif-binding factor 1) (AT-binding transcription factor 1) (Alpha-fetoprotein enhancer-binding protein) (Zinc finger homeodomain protein 3) (ZFH-3);Q15911;#N/A;https://platform.opentargets.org/target/ENSG00000140836;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;202;27;12;8;182;3_Medium to Low;463;95.47;0.15;0.35;211;15.11;0.08;0.2;246;77.17;0.51;0.52;6;3.19;0.06;0.06;7;2.22;0.44;0.56;Heart Failure;#N/A;#N/A;0.376198932;#N/A;#N/A;0.369116336;0.330420367;0.442221611;0.278325723;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;0.422341569;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;7;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0419;IKZF1;ENSG00000185811;HGNC:13176;10320;DNA-binding protein Ikaros (Ikaros family zinc finger protein 1) (Lymphoid transcription factor LyF-1);Q13422;https://jaspar.elixir.no/search?q=Q13422;https://platform.opentargets.org/target/ENSG00000185811;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;976;261;13;525;438;4_Low;947;94.97;0.3;0.35;774;37.14;0.3;0.5;160;50.62;0.33;0.34;13;7.22;0.13;0.13;7;0.16;0.44;0.04;Cancer;#N/A;#N/A;0.037379705;#N/A;#N/A;0.070110428;0.009239496;0.010624102;#N/A;0.015591602;#N/A;0.004434958;#N/A;#N/A;#N/A;0.012196135;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0504;MAFB;ENSG00000204103;HGNC:6408;9935;Transcription factor MafB (Maf-B) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog B);Q9Y5Q3;#N/A;https://platform.opentargets.org/target/ENSG00000204103;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;925;242;14;473;438;4_Low;582;94.69;0.19;0.35;332;10.41;0.13;0.14;238;77.5;0.49;0.52;12;6.78;0.12;0.12;9;0.19;0.56;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.033633984;0.031212671;#N/A;0.031922506;0.012350127;0.001478319;0.012311103;#N/A;0.019218152;#N/A;0.004989328;#N/A;#N/A;0.039675729;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0558;MYC;ENSG00000136997;HGNC:7553;4609;Myc proto-oncogene protein (Class E basic helix-loop-helix protein 39) (bHLHe39) (Proto-oncogene c-Myc) (Transcription factor p64);P01106;https://jaspar.elixir.no/search?q=P01106;https://platform.opentargets.org/target/ENSG00000136997;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;71;7;15;52;4;4_Low;1721;94.15;0.55;0.35;1550;35.49;0.61;0.48;158;51.68;0.33;0.35;13;6.99;0.13;0.12;15;1.11;0.94;0.28;Cancer;#N/A;0.011834358;0.060446444;0.010499259;0.044017973;0.379507043;0.026103025;0.057886546;0.004229636;0.040136884;0.054126248;0.027465709;0.006505675;0.050803184;0.002217479;0.3338088;11;0.73;Y;Anti-Longevity;#N/A;Anti-Longevity;#N/A;Anti-Longevity;Anti-Longevity;Unclear;cell,upstream;#N/A;Anti-Longevity;Anti-Longevity;Inhibits;#N/A;Unclear;31;#N/A;Anti-Longevity;Anti-Longevity;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;74;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0924;TCF7L2;ENSG00000148737;HGNC:11641;6934;Transcription factor 7-like 2 (HMG box transcription factor 4) (T-cell-specific transcription factor 4) (T-cell factor 4) (TCF-4) (hTCF-4);Q9NQB0;https://jaspar.elixir.no/search?q=Q9NQB0;https://platform.opentargets.org/target/ENSG00000148737;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.3 TCF7-related;461;89;16;7;438;4_Low;590;92.92;0.19;0.34;377;14.82;0.15;0.2;189;65.23;0.39;0.44;24;12.87;0.24;0.22;13;2.62;0.81;0.67;Type 2 Diabetes Mellitus;#N/A;0.002217479;0.338358594;0.334004884;0.005913278;0.413903594;0.008479804;0.404656242;0.29377476;0.005996844;0.095953097;0.016815883;0.010502228;#N/A;#N/A;0.687818013;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0530;MITF;ENSG00000187098;HGNC:7105;4286;Microphthalmia-associated transcription factor (Class E basic helix-loop-helix protein 32) (bHLHe32);O75030;https://jaspar.elixir.no/search?q=O75030;https://platform.opentargets.org/target/ENSG00000187098;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;273;40;17;173;83;4_Low;1072;91.14;0.34;0.34;912;36.44;0.36;0.49;145;45.27;0.3;0.3;15;9.42;0.15;0.16;10;0.61;0.63;0.15;Type 2 Diabetes Mellitus;#N/A;0.078736235;0.017978652;0.008130757;#N/A;0.058662614;#N/A;0.009603943;#N/A;0.076955547;0.004619748;#N/A;0.01706227;0.004250168;#N/A;0.330281737;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Unclear;#N/A;#N/A;7;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;53;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0989;TRPS1;ENSG00000104447;HGNC:12340;7227;Zinc finger transcription factor Trps1 (Tricho-rhino-phalangeal syndrome type I protein) (Zinc finger protein GC79);Q9UHF7;https://jaspar.elixir.no/search?q=Q9UHF7;https://platform.opentargets.org/target/ENSG00000104447;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;659;140;18;203;438;5_None;646;89.39;0.21;0.33;441;9.38;0.17;0.13;168;59.9;0.35;0.4;37;20.11;0.37;0.35;8;0.55;0.5;0.14;Type 2 Diabetes Mellitus;#N/A;#N/A;0.00842821;#N/A;0.011826555;0.059442289;0.003695799;#N/A;0.010348236;0.002217479;#N/A;#N/A;0.002217479;#N/A;#N/A;0.455738069;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0809;SETBP1;ENSG00000152217;HGNC:15573;26040;SET-binding protein (SEB);Q9Y6X0;#N/A;https://platform.opentargets.org/target/ENSG00000152217;8 beta-Sheet binding to DNA;8.2 A.T hook factors;8.2.0 Uncharacterized/Undefined;721;155;19;264;438;5_None;589;88.91;0.19;0.33;362;13.43;0.14;0.18;211;66.28;0.44;0.44;16;9.2;0.16;0.16;4;0.45;0.25;0.11;Type 2 Diabetes Mellitus;#N/A;#N/A;0.038584108;#N/A;#N/A;0.040931147;0.005913278;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.363234382;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0516;MECOM;ENSG00000085276;HGNC:3498;2122;Histone-lysine N-methyltransferase MECOM (EC 2.1.1.367) (Ecotropic virus integration site 1 protein homolog) (EVI-1) (MDS1 and EVI1 complex locus protein) (Myelodysplasia syndrome 1 protein) (Myelodysplasia syndrome-associated protein 1);Q03112;#N/A;https://platform.opentargets.org/target/ENSG00000085276;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;754;167;20;296;438;3_Medium to Low;656;88.81;0.21;0.33;453;17.97;0.18;0.24;188;62.72;0.39;0.42;15;8.12;0.15;0.14;6;0.4;0.38;0.1;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.026308702;#N/A;#N/A;0.075462243;0.281517242;0.002956639;#N/A;0.007391597;#N/A;#N/A;#N/A;0.002771849;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0291;GATA3;ENSG00000107485;HGNC:4172;2625;Trans-acting T-cell-specific transcription factor GATA-3 (GATA-binding factor 3);P23771;https://jaspar.elixir.no/search?q=P23771;https://platform.opentargets.org/target/ENSG00000107485;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;532;104;21;329;182;3_Medium to Low;1385;88.13;0.44;0.32;1228;33.26;0.48;0.45;141;45.78;0.29;0.31;16;9.08;0.16;0.16;13;0.35;0.81;0.09;Cancer;#N/A;#N/A;0.05534697;0.004322031;0.023653111;0.104798422;0.023757178;0.001478319;0.015891934;0.021905409;0.017739833;0.008818586;0.001478319;0.036541182;#N/A;0.030093709;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;20;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1010;WT1;ENSG00000184937;HGNC:12796;7490;Wilms tumor protein (WT33);P19544;#N/A;https://platform.opentargets.org/target/ENSG00000184937;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;283;43;22;209;52;2_Medium;1109;88.01;0.36;0.32;928;28.7;0.36;0.39;169;51.42;0.35;0.34;12;7.89;0.12;0.14;12;0.55;0.75;0.14;Type 2 Diabetes Mellitus;#N/A;0.007391597;0.080929611;0.002217479;0.010855382;0.079971705;#N/A;0.003642004;0.013304875;0.05463697;0.015522354;#N/A;0.053958659;0.008869917;#N/A;0.215529252;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;22;3;#N/A;CHEMBL4662942;Wilms tumor protein;SINGLE PROTEIN;0;0;2;3;"Cell;Unknown";#N/A
TFTX_0909;TBX3;ENSG00000135111;HGNC:11602;6926;T-box transcription factor TBX3 (T-box protein 3);O15119;https://jaspar.elixir.no/search?q=O15119;https://platform.opentargets.org/target/ENSG00000135111;6 Immunoglobulin fold;6.5 T-Box factors;6.5.4 TBX2-related;129;16;23;54;52;5_None;678;87.02;0.22;0.32;502;24.73;0.2;0.34;160;53.62;0.33;0.36;16;8.67;0.16;0.15;10;1.1;0.63;0.28;Chronic Obstructive Pulmonary Disease;#N/A;0.03225693;0.001478319;#N/A;0.248832007;0.091542732;0.34915407;0.338541286;0.003695799;#N/A;0.001478319;#N/A;0.017739833;0.011087396;#N/A;#N/A;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Unclear;4;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0984;TP63;ENSG00000073282;HGNC:15979;8626;Tumor protein 63 (p63) (Chronic ulcerative stomatitis protein) (CUSP) (Keratinocyte transcription factor KET) (Transformation-related protein 63) (TP63) (Tumor protein p73-like) (p73L) (p40) (p51);Q9H3D4;https://jaspar.elixir.no/search?q=Q9H3D4;https://platform.opentargets.org/target/ENSG00000073282;6 Immunoglobulin fold;6.3 p53 domain factors;6.3.1 p53-related;423;74;24;385;14;5_None;1488;84.72;0.48;0.31;1350;36.22;0.53;0.49;124;38.94;0.26;0.26;14;9.55;0.14;0.17;13;0.27;0.81;0.07;Cancer;#N/A;#N/A;0.060406616;0.001847899;0.016883889;0.072587231;0.046083001;0.004250168;0.01019178;0.003695799;0.009958124;0.017512244;#N/A;0.005779818;0.003695799;0.016623888;7;0.47;Y;Pro-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;mammal;#N/A;Anti-Longevity;Pro-Longevity;Induces;#N/A;Pro-Longevity;9;#N/A;#N/A;Pro-Longevity;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0180;EBF1;ENSG00000164330;HGNC:3126;1879;Transcription factor COE1 (O/E-1) (OE-1) (Early B-cell factor);Q9UH73;https://jaspar.elixir.no/search?q=Q9UH73;https://platform.opentargets.org/target/ENSG00000164330;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.5 EBF-related;230;34;25;122;83;3_Medium to Low;564;84.23;0.18;0.31;371;20.11;0.15;0.27;183;58.94;0.38;0.39;10;5.17;0.1;0.09;7;0.75;0.44;0.19;Type 2 Diabetes Mellitus;#N/A;#N/A;0.028439762;0.007206807;0.005174118;0.344535251;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;#N/A;0.350110337;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;1;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0595;NFE2L2;ENSG00000116044;HGNC:7782;4780;Nuclear factor erythroid 2-related factor 2 (NF-E2-related factor 2) (NFE2-related factor 2) (Nrf-2) (HEBP1) (Nuclear factor, erythroid derived 2, like 2);Q16236;https://jaspar.elixir.no/search?q=Q16236;https://platform.opentargets.org/target/ENSG00000116044;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;78;10;26;44;8;1_High;1765;83.02;0.57;0.31;1645;45.05;0.64;0.61;114;34.46;0.24;0.23;6;3.52;0.06;0.06;16;1.17;1;0.3;Cancer;0.020697909;0.053555615;0.119105153;0.087302775;0.045160145;0.120420338;0.116416119;0.040949101;0.100859937;0.088833556;0.068503087;0.020083359;0.037848116;0.117058174;0.032888672;0.104288096;9;0.6;Y;Pro-Longevity;Pro-Longevity;Unclear;Pro-Longevity;Unclear;Pro-Longevity;Unclear;cell,upstream;Pro-Longevity;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;20;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tchem;852;2;1;"CHEMBL1075094;CHEMBL3038498";"Nuclear factor erythroid 2-related factor 2;Keap1/Nrf2";"SINGLE PROTEIN;PROTEIN-PROTEIN INTERACTION";"86443;989";"95554;1824";"1;1";"4;3";"Small molecule;Small molecule";2023
TFTX_0429;IRF4;ENSG00000137265;HGNC:6119;3662;Interferon regulatory factor 4 (IRF-4) (Lymphocyte-specific interferon regulatory factor) (LSIRF) (Multiple myeloma oncogene 1) (NF-EM5);Q15306;https://jaspar.elixir.no/search?q=Q15306;https://platform.opentargets.org/target/ENSG00000137265;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;1228;356;27;33;1168;5_None;828;81.63;0.27;0.3;661;23.31;0.26;0.32;156;52.44;0.32;0.35;11;5.87;0.11;0.1;12;1.28;0.75;0.33;Cancer;#N/A;#N/A;0.338663165;0.002751317;#N/A;0.518360781;0.01052943;0.003695799;0.032718892;0.002751317;0.002217479;0.002217479;0.018253138;0.333666753;#N/A;0.014177494;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0066;BCL11A;ENSG00000119866;HGNC:13221;53335;B-cell lymphoma/leukemia 11A (BCL-11A) (B-cell CLL/lymphoma 11A) (COUP-TF-interacting protein 1) (Ecotropic viral integration site 9 protein homolog) (EVI-9) (Zinc finger protein 856);Q9H165;https://jaspar.elixir.no/search?q=Q9H165;https://platform.opentargets.org/target/ENSG00000119866;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;227;31;28;17;182;5_None;535;81.44;0.17;0.3;331;14.37;0.13;0.19;198;63.62;0.41;0.42;6;3.45;0.06;0.06;7;1.78;0.44;0.45;Cancer;#N/A;#N/A;0.292369257;#N/A;0.479098294;0.513735629;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002771849;0.003695799;0.481436707;2;0.13;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0889;STAT3;ENSG00000168610;HGNC:11364;6774;Signal transducer and activator of transcription 3 (Acute-phase response factor);P40763;https://jaspar.elixir.no/search?q=P40763;https://platform.opentargets.org/target/ENSG00000168610;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;55;5;29;12;14;2_Medium;1691;80.13;0.54;0.3;1557;35.92;0.61;0.49;126;38.94;0.26;0.26;8;5.27;0.08;0.09;15;1.92;0.94;0.49;Cancer;#N/A;0.027198335;0.323044349;0.074515247;0.0546175;0.626205724;0.06336996;0.021518831;0.044099589;0.072038716;0.050284052;0.022162312;0.041125978;0.303231057;0.046748759;0.147050079;7;0.47;Y;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Pro-Longevity;#N/A;downstream;#N/A;Pro-Longevity;#N/A;Induces;#N/A;Anti-Longevity;24;#N/A;#N/A;#N/A;1;3;2_Medium;DGIDB MOA not >0 and no ChEMBL max phase >0 but approved drugs according to TTD? Development level unclear (TTD entries wrong?) but assume Medium;Tchem;84;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0475;KMT2A;ENSG00000118058;HGNC:7132;4297;"Histone-lysine N-methyltransferase 2A (Lysine N-methyltransferase 2A) (EC 2.1.1.364) (ALL-1) (CXXC-type zinc finger protein 7) (Cysteine methyltransferase KMT2A) (EC 2.1.1.-) (Myeloid/lymphoid or mixed-lineage leukemia) (Myeloid/lymphoid or mixed-lineage leukemia protein 1) (Trithorax-like protein) (Zinc finger protein HRX) [Cleaved into: MLL cleavage product N320 (N-terminal cleavage product of 320 kDa) (p320); MLL cleavage product C180 (C-terminal cleavage product of 180 kDa) (p180)]";Q03164;#N/A;https://platform.opentargets.org/target/ENSG00000118058;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;767;178;30;299;438;2_Medium;1003;79.84;0.32;0.29;841;31.11;0.33;0.42;158;46.21;0.33;0.31;4;2.53;0.04;0.04;13;0.39;0.81;0.1;Cancer;#N/A;0.011025799;0.094867184;0.015663881;#N/A;0.108725283;0.005926919;0.00753993;0.006631905;0.025427296;0.014783194;0.002587059;0.017000673;0.021886331;#N/A;0.057648256;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;66;1;#N/A;CHEMBL2093861;Menin/Histone-lysine N-methyltransferase MLL;PROTEIN-PROTEIN INTERACTION;44370;48161;1;1;Small molecule;#N/A
TFTX_1030;ZBTB16;ENSG00000109906;HGNC:12930;7704;Zinc finger and BTB domain-containing protein 16 (Promyelocytic leukemia zinc finger protein) (Zinc finger protein 145) (Zinc finger protein PLZF);Q05516;#N/A;https://platform.opentargets.org/target/ENSG00000109906;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;951;253;31;482;438;5_None;1000;79.82;0.32;0.29;885;40.21;0.35;0.55;106;34.81;0.22;0.23;9;4.81;0.09;0.08;10;0.18;0.63;0.05;Cancer;#N/A;#N/A;0.034373596;0.002217479;#N/A;0.039110203;#N/A;#N/A;#N/A;0.007391597;0.038867481;0.012457816;0.019731458;0.007692415;0.003695799;0.016446304;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0603;NFKB1;ENSG00000109320;HGNC:7794;4790;Nuclear factor NF-kappa-B p105 subunit (DNA-binding factor KBF1) (EBP-1) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) [Cleaved into: Nuclear factor NF-kappa-B p50 subunit];P19838;https://jaspar.elixir.no/search?q=P19838;https://platform.opentargets.org/target/ENSG00000109320;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.1 NFkappaB-related;76;8;32;35;9;1_High;2493;79.05;0.8;0.29;2401;48.81;0.94;0.66;88;27.92;0.18;0.19;4;2.32;0.04;0.04;16;1.27;1;0.32;Osteoarthritis;0.007576387;0.073563609;0.114700062;0.075070095;0.070690852;0.11743424;0.095522128;0.030858514;0.050925157;0.041547123;0.042782003;0.260011377;0.056283499;0.096162267;0.033131381;0.105667708;8;0.53;Y;Unclear;#N/A;Anti-Longevity;#N/A;Anti-Longevity;Unclear;Unclear;functional;#N/A;#N/A;Pro-Longevity;#N/A;1;#N/A;26;#N/A;#N/A;#N/A;1;12;1_High;TTD approved drug entry was missed in original ID mapping, added manually (12.07.2025). At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;99;2;1;CHEMBL2094258;Nuclear factor NF-kappa-B complex;PROTEIN COMPLEX GROUP;1908;2351;1;3;Small molecule;#N/A
TFTX_0444;JAZF1;ENSG00000153814;HGNC:28917;221895;Juxtaposed with another zinc finger protein 1 (TAK1-interacting protein 27) (Zinc finger protein 802);Q86VZ6;#N/A;https://platform.opentargets.org/target/ENSG00000153814;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1206;347;33;5;1168;5_None;389;78.33;0.12;0.29;228;16.14;0.09;0.22;146;54.27;0.3;0.36;15;7.92;0.15;0.14;11;2.65;0.69;0.67;Type 2 Diabetes Mellitus;#N/A;#N/A;0.446291669;0.030760735;0.28639835;0.298924307;0.001478319;0.002587059;#N/A;#N/A;0.324211448;0.308761934;0.001478319;0.369579855;#N/A;0.577188722;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0830;SMAD4;ENSG00000141646;HGNC:6770;4089;Mothers against decapentaplegic homolog 4 (MAD homolog 4) (Mothers against DPP homolog 4) (Deletion target in pancreatic carcinoma 4) (SMAD family member 4) (SMAD 4) (Smad4) (hSMAD4);Q13485;#N/A;https://platform.opentargets.org/target/ENSG00000141646;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;262;39;34;145;83;4_Low;934;75.14;0.3;0.28;780;23.45;0.31;0.32;138;41.33;0.29;0.28;16;10.35;0.16;0.18;14;0.68;0.88;0.17;Cancer;#N/A;0.002217479;0.034621027;0.015327298;0.009276236;0.390734753;0.063784919;0.009417395;0.002751317;0.01142832;0.082334179;0.014400884;0.016166818;0.003695799;#N/A;0.022139075;3;0.2;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0276;FOXO1;ENSG00000150907;HGNC:3819;2308;Forkhead box protein O1 (Forkhead box protein O1A) (Forkhead in rhabdomyosarcoma);Q12778;https://jaspar.elixir.no/search?q=Q12778;https://platform.opentargets.org/target/ENSG00000150907;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;124;15;35;86;3;4_Low;935;74.73;0.3;0.28;757;18.33;0.3;0.25;176;55.38;0.37;0.37;2;1.03;0.02;0.02;15;0.93;0.94;0.24;Osteoarthritis;#N/A;0.007206807;0.088885302;0.049057704;0.002217479;0.088637762;0.032639935;0.013249166;0.030460462;0.015525026;0.062883584;0.282602275;0.039598797;0.096568512;0.018023659;0.098421147;12;0.8;Y;Pro-Longevity;Pro-Longevity;Unclear;#N/A;#N/A;Pro-Longevity;Unclear;model;Pro-Longevity;Pro-Longevity;#N/A;Induces;3;Unclear;14;Pro-Longevity;Unclear;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0025;ARID2;ENSG00000189079;HGNC:18037;196528;AT-rich interactive domain-containing protein 2 (ARID domain-containing protein 2) (BRG1-associated factor 200) (BAF200) (Zinc finger protein with activation potential) (Zipzap/p200);Q68CP9;#N/A;https://platform.opentargets.org/target/ENSG00000189079;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;844;213;36;370;438;5_None;491;74.39;0.16;0.27;308;18.24;0.12;0.25;178;53.09;0.37;0.35;5;3.06;0.05;0.05;7;0.29;0.44;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002217479;#N/A;#N/A;0.020727829;#N/A;0.003695799;#N/A;#N/A;0.004434958;#N/A;0.002956639;0.003695799;#N/A;0.247763342;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1067;ZEB1;ENSG00000148516;HGNC:11642;6935;Zinc finger E-box-binding homeobox 1 (NIL-2-A zinc finger protein) (Negative regulator of IL2) (Transcription factor 8) (TCF-8);P37275;https://jaspar.elixir.no/search?q=P37275;https://platform.opentargets.org/target/ENSG00000148516;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;409;70;37;289;83;4_Low;1636;73.87;0.53;0.27;1600;63.48;0.63;0.86;34;9;0.07;0.06;2;1.39;0.02;0.02;13;0.41;0.81;0.1;Cancer;#N/A;#N/A;0.055612526;0.033972485;0.023327264;0.115015696;0.078098708;0.010789679;0.009129238;0.029194345;0.001478319;0.013345939;0.023220564;0.004434958;#N/A;0.010470059;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0205;ERG;ENSG00000157554;HGNC:3446;2078;Transcriptional regulator ERG (Transforming protein ERG);P11308;https://jaspar.elixir.no/search?q=P11308;https://platform.opentargets.org/target/ENSG00000157554;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;115;14;38;25;52;3_Medium to Low;785;72.97;0.25;0.27;612;17.19;0.24;0.23;160;48.86;0.33;0.33;13;6.91;0.13;0.12;13;1.52;0.81;0.39;Benign Prostatic Hyperplasia;#N/A;0.001478319;0.305017729;0.012846047;0.374547848;0.119889758;0.006920165;0.002956639;#N/A;0.015676346;0.002217479;0.183969037;0.001478319;0.288348964;#N/A;0.201707482;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;1;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;13;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0567;MYRF;ENSG00000124920;HGNC:1181;745;"Myelin regulatory factor (EC 3.4.-.-) (Myelin gene regulatory factor) [Cleaved into: Myelin regulatory factor, N-terminal; Myelin regulatory factor, C-terminal]";Q9Y2G1;#N/A;https://platform.opentargets.org/target/ENSG00000124920;6 Immunoglobulin fold;6.6 NDT80 domain factors;6.6.1 MYRF-related;913;237;39;436;438;3_Medium to Low;817;72.74;0.26;0.27;739;46.54;0.29;0.63;75;24.33;0.16;0.16;3;1.87;0.03;0.03;6;0.22;0.38;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.017084917;#N/A;#N/A;0.051822171;#N/A;0.049725935;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.003511009;0.096247167;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0277;FOXO3;ENSG00000118689;HGNC:3821;2309;Forkhead box protein O3 (AF6q21 protein) (Forkhead in rhabdomyosarcoma-like 1);O43524;https://jaspar.elixir.no/search?q=O43524;https://platform.opentargets.org/target/ENSG00000118689;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;104;12;40;62;2;4_Low;996;72.58;0.32;0.27;845;23.68;0.33;0.32;149;47.81;0.31;0.32;2;1.09;0.02;0.02;15;1.05;0.94;0.27;Alzheimer Disease;#N/A;0.002217479;0.573580507;0.041838574;0.008343881;0.112585999;0.027453926;0.0404377;0.025956814;0.020965014;0.039663138;0.016111384;0.0196083;0.035196965;0.015989406;0.065827218;14;0.93;Y;Pro-Longevity;Pro-Longevity;Unclear;Pro-Longevity;Pro-Longevity;Pro-Longevity;Unclear;model,human_link;Pro-Longevity;Pro-Longevity;#N/A;Inhibits;8;Unclear;16;Pro-Longevity;Unclear;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0369;HNF4A;ENSG00000101076;HGNC:5024;3172;Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) (Nuclear receptor subfamily 2 group A member 1) (Transcription factor 14) (TCF-14) (Transcription factor HNF-4);P41235;https://jaspar.elixir.no/search?q=P41235;https://platform.opentargets.org/target/ENSG00000101076;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;155;18;41;31;83;2_Medium;809;71.58;0.26;0.26;661;13.22;0.26;0.18;136;50.96;0.28;0.34;12;7.4;0.12;0.13;13;1.33;0.81;0.34;Type 2 Diabetes Mellitus;#N/A;#N/A;0.012005144;0.039047624;0.020388489;0.072768361;0.004229636;0.002217479;0.295664801;0.009137644;0.086024382;0.004229636;0.003867859;0.039356279;#N/A;0.744749252;3;0.2;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;1;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;17;1;#N/A;CHEMBL5398;Hepatocyte nuclear factor 4-alpha;SINGLE PROTEIN;283;305;1;4;Small molecule;#N/A
TFTX_0921;TCF4;ENSG00000196628;HGNC:11634;6925;Transcription factor 4 (TCF-4) (Class B basic helix-loop-helix protein 19) (bHLHb19) (Immunoglobulin transcription factor 2) (ITF-2) (SL3-3 enhancer factor 2) (SEF-2);P15884;https://jaspar.elixir.no/search?q=P15884;https://platform.opentargets.org/target/ENSG00000196628;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.1 E2A;607;124;42;127;438;5_None;606;70.49;0.19;0.26;442;7.97;0.17;0.11;149;54.06;0.31;0.36;15;8.46;0.15;0.15;11;0.72;0.69;0.18;Type 2 Diabetes Mellitus;#N/A;0.091928076;0.015208221;0.007945967;0.003695799;0.049601341;#N/A;0.001478319;#N/A;#N/A;0.00458895;0.054299029;0.00571903;0.007391597;#N/A;0.482287583;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1004;VDR;ENSG00000111424;HGNC:12679;7421;Vitamin D3 receptor (VDR) (1,25-dihydroxyvitamin D3 receptor) (Nuclear receptor subfamily 1 group I member 1);P11473;https://jaspar.elixir.no/search?q=P11473;https://platform.opentargets.org/target/ENSG00000111424;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;76;8;43;2;31;1_High;1413;70.2;0.45;0.26;1305;33.91;0.51;0.46;98;30.22;0.2;0.2;10;6.07;0.1;0.11;15;2.74;0.94;0.7;Type 2 Diabetes Mellitus;#N/A;0.024430871;0.283340979;0.040797904;0.075702337;0.12623815;0.368985274;0.348134127;0.017808711;0.343095299;0.382491953;0.024620706;0.11769326;0.122840893;0.059947984;0.406082053;5;0.33;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Unclear;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;528;18;9;CHEMBL1977;Vitamin D receptor;SINGLE PROTEIN;21772;26593;18;4;Small molecule;1941
TFTX_0220;ETV6;ENSG00000139083;HGNC:3495;2120;Transcription factor ETV6 (ETS translocation variant 6) (ETS-related protein Tel1) (Tel);P41212;https://jaspar.elixir.no/search?q=P41212;https://platform.opentargets.org/target/ENSG00000139083;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;173;22;44;46;83;4_Low;586;70.15;0.19;0.26;418;16.6;0.16;0.23;161;49.3;0.33;0.33;7;4.24;0.07;0.07;5;1.15;0.31;0.29;Cancer;#N/A;#N/A;0.002587059;0.015707144;#N/A;0.598464329;#N/A;#N/A;#N/A;#N/A;0.268623751;#N/A;#N/A;#N/A;#N/A;0.268623751;3;0.2;Y;#N/A;Pro-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0130;CUX1;ENSG00000257923;HGNC:2557;1523;Homeobox protein cut-like 1 (CCAAT displacement protein) (CDP) (CDP/Cux p200) (Homeobox protein cux-1) [Cleaved into: CDP/Cux p110];P39880;https://jaspar.elixir.no/search?q=P39880;https://platform.opentargets.org/target/ENSG00000257923;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;178;24;45;50;83;3_Medium to Low;875;69.85;0.28;0.26;715;19.16;0.28;0.26;156;48.32;0.32;0.32;4;2.36;0.04;0.04;13;1.12;0.81;0.28;Cancer;#N/A;#N/A;0.058515919;0.025871187;0.026917733;0.585189533;0.32523417;0.008923916;0.013388441;0.019279749;#N/A;0.005387242;0.001478319;0.022161843;0.013304875;0.010698377;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0362;HMGA2;ENSG00000149948;HGNC:5009;8091;High mobility group protein HMGI-C (High mobility group AT-hook protein 2);P52926;#N/A;https://platform.opentargets.org/target/ENSG00000149948;8 beta-Sheet binding to DNA;8.2 A.T hook factors;8.2.1 HMGA;167;20;46;38;83;5_None;780;69.53;0.25;0.26;625;21.26;0.24;0.29;152;46.44;0.32;0.31;3;1.83;0.03;0.03;11;1.22;0.69;0.31;Type 2 Diabetes Mellitus;#N/A;#N/A;0.034504386;0.010471907;#N/A;0.109593841;0.165023942;#N/A;0.011087396;0.012524651;0.032523027;0.285857469;0.007915169;0.032099653;#N/A;0.522500621;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Unclear;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0736;PRDM16;ENSG00000142611;HGNC:14000;63976;Histone-lysine N-methyltransferase PRDM16 (EC 2.1.1.367) (PR domain zinc finger protein 16) (PR domain-containing protein 16) (Transcription factor MEL1) (MDS1/EVI1-like gene 1);Q9HAZ2;#N/A;https://platform.opentargets.org/target/ENSG00000142611;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;638;133;47;153;438;4_Low;535;69.49;0.17;0.26;377;16.51;0.15;0.22;147;46.89;0.31;0.31;11;6.08;0.11;0.11;10;0.66;0.63;0.17;Ischemic Stroke;#N/A;0.001478319;0.068136983;0.013353741;#N/A;0.040617029;0.201753827;0.015576354;0.279440324;#N/A;0.008654328;#N/A;#N/A;#N/A;0.002217479;0.028098633;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0305;GLI3;ENSG00000106571;HGNC:4319;2737;Transcriptional activator GLI3 (GLI3 form of 190 kDa) (GLI3-190) (GLI3 full-length protein) (GLI3FL) [Cleaved into: Transcriptional repressor GLI3R (GLI3 C-terminally truncated form) (GLI3 form of 83 kDa) (GLI3-83)];P10071;https://jaspar.elixir.no/search?q=P10071;https://platform.opentargets.org/target/ENSG00000106571;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;746;165;48;260;438;3_Medium to Low;1352;68.42;0.43;0.25;1287;43.02;0.5;0.58;57;20.15;0.12;0.13;8;5.26;0.08;0.09;13;0.45;0.81;0.12;Benign Prostatic Hyperplasia;#N/A;0.002956639;0.022492912;0.002012157;0.328880393;0.047669364;0.013099553;0.001847899;0.001478319;0.004599216;0.003028502;0.008726191;#N/A;0.00311063;#N/A;0.014681107;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;8;8;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0067;BCL11B;ENSG00000127152;HGNC:13222;64919;B-cell lymphoma/leukemia 11B (BCL-11B) (B-cell CLL/lymphoma 11B) (COUP-TF-interacting protein 2) (Radiation-induced tumor suppressor gene 1 protein) (hRit1);Q9C0K0;#N/A;https://platform.opentargets.org/target/ENSG00000127152;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;734;158;49;602;83;5_None;631;68.12;0.2;0.25;496;21.8;0.19;0.3;129;42.77;0.27;0.29;6;3.55;0.06;0.06;9;0.12;0.56;0.03;Cancer;0.006077535;#N/A;0.019016025;0.007391597;#N/A;0.064580812;0.003695799;0.001478319;0.013304875;#N/A;#N/A;#N/A;0.003695799;0.004229636;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0068;BCL6;ENSG00000113916;HGNC:1001;604;B-cell lymphoma 6 protein (BCL-6) (B-cell lymphoma 5 protein) (BCL-5) (Protein LAZ-3) (Zinc finger and BTB domain-containing protein 27) (Zinc finger protein 51);P41182;https://jaspar.elixir.no/search?q=P41182;https://platform.opentargets.org/target/ENSG00000113916;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;413;72;50;280;83;4_Low;858;66.75;0.28;0.25;737;30.23;0.29;0.41;119;35.42;0.25;0.24;2;1.1;0.02;0.02;12;0.42;0.75;0.11;Type 2 Diabetes Mellitus;#N/A;#N/A;0.028945503;0.015016956;#N/A;0.097466147;#N/A;0.011272186;0.003087634;0.005615561;0.036945255;0.017574704;0.004968796;0.016419648;0.004229636;0.18299261;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Unclear;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0233;FLI1;ENSG00000151702;HGNC:3749;2313;Friend leukemia integration 1 transcription factor (Proto-oncogene Fli-1) (Transcription factor ERGB);Q01543;https://jaspar.elixir.no/search?q=Q01543;https://platform.opentargets.org/target/ENSG00000151702;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;480;93;51;346;83;4_Low;752;65.85;0.24;0.24;625;26.21;0.24;0.36;125;38.37;0.26;0.26;2;1.27;0.02;0.02;10;0.32;0.63;0.08;Type 2 Diabetes Mellitus;#N/A;0.003695799;0.027056531;0.001847899;#N/A;0.069362647;0.002956639;0.003695799;0.001478319;#N/A;0.005030392;#N/A;#N/A;0.011087396;#N/A;0.197031602;3;0.2;Y;#N/A;Pro-Longevity;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0893;STAT6;ENSG00000166888;HGNC:11368;6778;Signal transducer and activator of transcription 6 (IL-4 Stat);P42226;#N/A;https://platform.opentargets.org/target/ENSG00000166888;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;539;105;52;404;83;4_Low;896;65.77;0.29;0.24;773;27.63;0.3;0.37;121;36.93;0.25;0.25;2;1.21;0.02;0.02;12;0.25;0.75;0.06;Cancer;#N/A;#N/A;0.030125354;0.018923584;0.009958124;0.066579646;0.056631245;0.010888644;0.014017214;0.015580255;0.005543698;#N/A;#N/A;0.009958124;0.001478319;0.009375099;3;0.2;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Induces;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;15;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0555;MYB;ENSG00000118513;HGNC:7545;4602;Transcriptional activator Myb (Proto-oncogene c-Myb);P10242;https://jaspar.elixir.no/search?q=P10242;https://platform.opentargets.org/target/ENSG00000118513;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;925;242;53;434;438;4_Low;911;64.36;0.29;0.24;799;29.68;0.31;0.4;111;34.17;0.23;0.23;1;0.51;0.01;0.01;10;0.23;0.63;0.06;Cancer;#N/A;#N/A;0.008572199;0.017883559;0.047332221;0.102699917;0.020819665;#N/A;#N/A;0.009978656;0.002771849;0.003695799;0.010142914;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0406;HOXD13;ENSG00000128714;HGNC:5136;3239;Homeobox protein Hox-D13 (Homeobox protein Hox-4I);P35453;https://jaspar.elixir.no/search?q=P35453;https://platform.opentargets.org/target/ENSG00000128714;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1534;483;54;312;1168;3_Medium to Low;1235;63.79;0.4;0.24;1180;44.07;0.46;0.6;47;14.27;0.1;0.1;8;5.45;0.08;0.09;11;0.37;0.69;0.09;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.031776271;0.022432841;0.012750505;0.089764257;0.113801816;0.008871354;#N/A;0.001478319;#N/A;0.002587059;#N/A;0.008736952;0.014783194;0.06593603;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0785;RORA;ENSG00000069667;HGNC:10258;6095;Nuclear receptor ROR-alpha (Nuclear receptor RZR-alpha) (Nuclear receptor subfamily 1 group F member 1) (RAR-related orphan receptor A) (Retinoid-related orphan receptor-alpha);P35398;https://jaspar.elixir.no/search?q=P35398;https://platform.opentargets.org/target/ENSG00000069667;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;434;77;55;197;182;4_Low;805;63.2;0.26;0.23;678;20.41;0.27;0.28;122;39.92;0.25;0.27;5;2.86;0.05;0.05;15;0.56;0.94;0.14;Type 2 Diabetes Mellitus;#N/A;0.024866346;0.044597132;0.045712317;0.006652437;0.055548448;0.027517544;0.014610711;0.004065378;0.013367565;0.03153151;0.019064023;0.011909162;0.089626473;0.004434958;0.170170518;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0501;MAF;ENSG00000178573;HGNC:6776;4094;Transcription factor Maf (Proto-oncogene c-Maf) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog);O75444;https://jaspar.elixir.no/search?q=O75444;https://platform.opentargets.org/target/ENSG00000178573;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;453;86;56;215;182;5_None;574;62.71;0.18;0.23;428;17.27;0.17;0.23;138;40.88;0.29;0.27;8;4.56;0.08;0.08;9;0.54;0.56;0.14;Alzheimer Disease;#N/A;0.002956639;0.244314836;0.003326219;0.1972963;0.061659711;0.002217479;#N/A;#N/A;#N/A;#N/A;0.012072942;0.001847899;#N/A;#N/A;0.009438001;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1092;ZFPM2;ENSG00000169946;HGNC:16700;23414;Zinc finger protein ZFPM2 (Friend of GATA protein 2) (FOG-2) (Friend of GATA 2) (hFOG-2) (Zinc finger protein 89B) (Zinc finger protein multitype 2);Q8WW38;#N/A;https://platform.opentargets.org/target/ENSG00000169946;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.2 FOG;823;203;57;328;438;5_None;548;61.65;0.18;0.23;419;14.34;0.16;0.19;119;41.69;0.25;0.28;10;5.62;0.1;0.1;6;0.35;0.38;0.09;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.017166514;#N/A;#N/A;0.061967004;0.259610124;0.001478319;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;0.002771849;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0304;GLI2;ENSG00000074047;HGNC:4318;2736;Zinc finger protein GLI2 (GLI family zinc finger protein 2) (Tax helper protein);P10070;https://jaspar.elixir.no/search?q=P10070;https://platform.opentargets.org/target/ENSG00000074047;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;696;149;58;200;438;4_Low;1137;61.29;0.37;0.23;1038;30.64;0.41;0.42;95;28.05;0.2;0.19;4;2.6;0.04;0.05;11;0.56;0.69;0.14;Type 2 Diabetes Mellitus;#N/A;0.002956639;0.025160573;0.009054706;0.018979568;0.046023569;0.068832695;#N/A;0.001478319;#N/A;0.010163446;0.012011345;#N/A;0.031732126;#N/A;0.334380757;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0478;L3MBTL3;ENSG00000198945;HGNC:23035;84456;Lethal(3)malignant brain tumor-like protein 3 (H-l(3)mbt-like protein 3) (L(3)mbt-like protein 3) (L3mbt-like 3) (MBT-1);Q96JM7;#N/A;https://platform.opentargets.org/target/ENSG00000198945;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;598;120;59;101;438;4_Low;261;61.09;0.08;0.23;114;3.57;0.04;0.05;124;45.31;0.26;0.3;23;12.21;0.23;0.21;5;0.86;0.31;0.22;Alzheimer Disease;#N/A;#N/A;0.317564005;#N/A;#N/A;0.032868982;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.317564005;#N/A;0.183362073;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0730;PRDM1;ENSG00000057657;HGNC:9346;639;PR domain zinc finger protein 1 (EC 2.1.1.-) (BLIMP-1) (Beta-interferon gene positive regulatory domain I-binding factor) (PR domain-containing protein 1) (Positive regulatory domain I-binding factor 1) (PRDI-BF1) (PRDI-binding factor 1);O75626;https://jaspar.elixir.no/search?q=O75626;https://platform.opentargets.org/target/ENSG00000057657;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;579;114;60;467;52;3_Medium to Low;607;58.74;0.19;0.22;475;19.86;0.19;0.27;131;38.37;0.27;0.26;1;0.51;0.01;0.01;6;0.19;0.38;0.05;Cancer;#N/A;#N/A;0.054617127;0.024076905;0.007391597;0.098070341;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;0.003695799;4;0.27;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Unclear;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;35;35;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0520;MEF2C;ENSG00000081189;HGNC:6996;4208;Myocyte-specific enhancer factor 2C (Myocyte enhancer factor 2C);Q06413;https://jaspar.elixir.no/search?q=Q06413;https://platform.opentargets.org/target/ENSG00000081189;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.1 Regulators of differentiation;562;111;61;63;438;5_None;510;58.7;0.16;0.22;355;4.66;0.14;0.06;139;45.31;0.29;0.3;16;8.73;0.16;0.15;15;1.04;0.94;0.26;Age-Related Macular Degeneration;0.003695799;0.325540642;0.240861743;0.01901626;#N/A;0.03984166;0.006652437;0.015021025;0.023653111;0.00855923;0.005030392;0.007761177;0.026810747;0.017893825;0.002587059;0.297772268;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0969;THRB;ENSG00000151090;HGNC:11799;7068;Thyroid hormone receptor beta (Nuclear receptor subfamily 1 group A member 2) (c-erbA-2) (c-erbA-beta);P10828;https://jaspar.elixir.no/search?q=P10828;https://platform.opentargets.org/target/ENSG00000151090;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;167;20;62;53;52;1_High;689;58.63;0.22;0.22;576;15.36;0.23;0.21;101;36.02;0.21;0.24;12;7.25;0.12;0.13;11;1.1;0.69;0.28;Non-Alcoholic Fatty Liver Disease;#N/A;0.006837227;0.00783304;0.006167466;#N/A;0.037165906;#N/A;0.038269481;#N/A;0.323936743;0.342720843;0.324007603;0.002751317;0.001478319;#N/A;0.005572032;4;0.27;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;Unclear;#N/A;Anti-Longevity;4;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;125;19;1;"CHEMBL1947;CHEMBL2111462";"Thyroid hormone receptor beta-1;Thyroid hormone receptor";"SINGLE PROTEIN;PROTEIN COMPLEX";"6356;127";"7937;146";"3;5";"3;4";"Small molecule;Small molecule";1956
TFTX_0757;RARB;ENSG00000077092;HGNC:9865;5915;Retinoic acid receptor beta (RAR-beta) (HBV-activated protein) (Nuclear receptor subfamily 1 group B member 2) (RAR-epsilon);P10826;https://jaspar.elixir.no/search?q=P10826;https://platform.opentargets.org/target/ENSG00000077092;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;176;23;63;82;31;1_High;665;58.46;0.21;0.22;545;14.63;0.21;0.2;108;37.05;0.22;0.25;12;6.77;0.12;0.12;10;0.93;0.63;0.24;Chronic Obstructive Pulmonary Disease;#N/A;0.008869917;0.103488223;0.00764825;0.016041849;0.038377162;0.475222053;#N/A;#N/A;#N/A;0.003511009;0.001478319;#N/A;0.004065378;#N/A;0.273327241;5;0.33;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;Induces;1;#N/A;3;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;31;10;1;"CHEMBL2008;CHEMBL2363069;CHEMBL2363071";"Retinoic acid receptor beta;Retinoic acid receptor;Retinoid receptor";"SINGLE PROTEIN;PROTEIN FAMILY;PROTEIN FAMILY";"642;29;1";"1239;39;1";"1;5;4";"4;4;4";"Small molecule;Small molecule;Small molecule";"2005;1971;1986"
TFTX_0788;RREB1;ENSG00000124782;HGNC:10449;6239;Ras-responsive element-binding protein 1 (RREB-1) (Finger protein in nuclear bodies) (Raf-responsive zinc finger protein LZ321) (Zinc finger motif enhancer-binding protein 1) (Zep-1);Q92766;https://jaspar.elixir.no/search?q=Q92766;https://platform.opentargets.org/target/ENSG00000124782;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;522;102;64;20;438;5_None;706;57.92;0.23;0.21;606;18.93;0.24;0.26;79;27.87;0.16;0.19;21;11.11;0.21;0.19;11;1.67;0.69;0.42;Type 2 Diabetes Mellitus;#N/A;#N/A;0.009174882;0.002012157;0.001478319;0.361827454;0.440517564;0.001847899;#N/A;0.002956639;0.007391597;0.231904769;#N/A;0.037565636;#N/A;0.571925077;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0677;PAX3;ENSG00000135903;HGNC:8617;5077;Paired box protein Pax-3 (HuP2);P23760;https://jaspar.elixir.no/search?q=P23760;https://platform.opentargets.org/target/ENSG00000135903;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.1 PD+HD;1456;447;65;953;438;5_None;579;57.68;0.19;0.21;457;18.37;0.18;0.25;114;33.97;0.24;0.23;8;5.34;0.08;0.09;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.022970012;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;0.002217479;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0219;ETV5;ENSG00000244405;HGNC:3494;2119;ETS translocation variant 5 (Ets-related protein ERM);P41161;https://jaspar.elixir.no/search?q=P41161;https://platform.opentargets.org/target/ENSG00000244405;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1019;279;66;515;438;4_Low;586;57.59;0.19;0.21;457;14.42;0.18;0.2;122;39.41;0.25;0.26;7;3.76;0.07;0.07;10;0.16;0.63;0.04;Cancer;#N/A;0.014598404;0.014328393;0.002587059;#N/A;0.085826181;0.008726191;0.002217479;#N/A;0.008500337;0.001847899;#N/A;0.001478319;#N/A;#N/A;0.023977567;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0463;KLF14;ENSG00000266265;HGNC:23025;136259;Krueppel-like factor 14 (Basic transcription element-binding protein 5) (BTE-binding protein 5) (Transcription factor BTEB5);Q8TD94;https://jaspar.elixir.no/search?q=Q8TD94;https://platform.opentargets.org/target/ENSG00000266265;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;554;109;67;49;438;5_None;311;55.95;0.1;0.21;149;6.09;0.06;0.08;160;48.79;0.33;0.33;2;1.07;0.02;0.02;8;1.12;0.5;0.28;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011798426;0.021788443;#N/A;0.184865331;#N/A;0.002217479;0.008130757;0.226180096;#N/A;0.196800673;#N/A;#N/A;#N/A;0.469925432;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0361;HMGA1;ENSG00000137309;HGNC:5010;3159;High mobility group protein HMG-I/HMG-Y (HMG-I(Y)) (High mobility group AT-hook protein 1) (High mobility group protein A1) (High mobility group protein R);P17096;#N/A;https://platform.opentargets.org/target/ENSG00000137309;8 beta-Sheet binding to DNA;8.2 A.T hook factors;8.2.1 HMGA;242;35;68;91;83;5_None;691;55.93;0.22;0.21;571;18.65;0.22;0.25;116;35.08;0.24;0.23;4;2.19;0.04;0.04;12;0.91;0.75;0.23;Type 2 Diabetes Mellitus;#N/A;#N/A;0.009533527;0.005897353;0.002217479;0.10237626;0.022544371;#N/A;#N/A;0.007925435;0.308845865;0.003695799;0.007391597;0.058763197;0.001847899;0.375040535;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;9;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0203;EPAS1;ENSG00000116016;HGNC:3374;2034;Endothelial PAS domain-containing protein 1 (EPAS-1) (Basic-helix-loop-helix-PAS protein MOP2) (Class E basic helix-loop-helix protein 73) (bHLHe73) (HIF-1-alpha-like factor) (HLF) (Hypoxia-inducible factor 2-alpha) (HIF-2-alpha) (HIF2-alpha) (Member of PAS protein 2) (PAS domain-containing protein 2);Q99814;https://jaspar.elixir.no/search?q=Q99814;https://platform.opentargets.org/target/ENSG00000116016;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;330;53;69;230;31;1_High;832;55.91;0.27;0.21;721;20.91;0.28;0.28;109;33.64;0.23;0.22;2;1.36;0.02;0.02;14;0.51;0.88;0.13;Non-Alcoholic Fatty Liver Disease;#N/A;0.009329427;0.025803944;0.05671216;0.003695799;0.095135955;0.093795377;0.009691683;0.010974468;0.054368483;0.099471184;0.028571841;0.010327704;0.003326219;#N/A;0.006352256;5;0.33;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;Inhibits;#N/A;Pro-Longevity;8;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;6;3;1;CHEMBL1744522;Endothelial PAS domain-containing protein 1;SINGLE PROTEIN;262;642;1;4;Small molecule;2021
TFTX_0876;SPEN;ENSG00000065526;HGNC:17575;23013;Msx2-interacting protein (SMART/HDAC1-associated repressor protein) (SPEN homolog);Q96T58;#N/A;https://platform.opentargets.org/target/ENSG00000065526;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;388;65;70;136;182;5_None;291;55.83;0.09;0.21;146;12.24;0.06;0.17;142;41.77;0.3;0.28;3;1.82;0.03;0.03;5;0.69;0.31;0.18;Parkinson Disease;#N/A;#N/A;0.293706448;#N/A;#N/A;0.082172826;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;0.305155991;#N/A;0.003695799;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0590;NFATC2;ENSG00000101096;HGNC:7776;4773;Nuclear factor of activated T-cells, cytoplasmic 2 (NF-ATc2) (NFATc2) (NFAT pre-existing subunit) (NF-ATp) (T-cell transcription factor NFAT1);Q13469;https://jaspar.elixir.no/search?q=Q13469;https://platform.opentargets.org/target/ENSG00000101096;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.3 NFAT-related;399;67;71;146;182;4_Low;539;55.76;0.17;0.21;417;15.66;0.16;0.21;117;37.46;0.24;0.25;5;2.64;0.05;0.05;10;0.68;0.63;0.17;Type 2 Diabetes Mellitus;#N/A;#N/A;0.017369229;0.002217479;#N/A;0.061861224;0.011046331;0.012228371;#N/A;0.004065378;#N/A;0.012716089;0.002217479;0.019267019;#N/A;0.533310031;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0244;FOXC1;ENSG00000054598;HGNC:3800;2296;Forkhead box protein C1 (Forkhead-related protein FKHL7) (Forkhead-related transcription factor 3) (FREAC-3);Q12948;https://jaspar.elixir.no/search?q=Q12948;https://platform.opentargets.org/target/ENSG00000054598;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;916;238;72;406;438;5_None;1130;55.25;0.36;0.2;1085;37.56;0.42;0.51;41;15.05;0.09;0.1;4;2.63;0.04;0.05;14;0.25;0.88;0.06;Cancer;#N/A;0.008377143;0.014723983;0.003695799;0.009609076;0.100240472;0.029747243;0.016230715;0.008500337;0.019177897;0.001847899;0.009403754;0.017739833;0.002104552;#N/A;0.005715758;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0349;HIF1A;ENSG00000100644;HGNC:4910;3091;Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8);Q16665;https://jaspar.elixir.no/search?q=Q16665;https://platform.opentargets.org/target/ENSG00000100644;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;107;13;73;28;6;2_Medium;1603;54.87;0.51;0.2;1530;32.71;0.6;0.44;73;22.16;0.15;0.15;#N/A;#N/A;#N/A;#N/A;16;1.43;1;0.36;Alzheimer Disease;0.002587059;0.043365419;0.321233676;0.090679362;0.056201683;0.118536937;0.114510961;0.02600592;0.036322161;0.08916916;0.050437324;0.040754081;0.049613057;0.31800131;0.026859636;0.048041995;10;0.67;Y;Pro-Longevity;Unclear;Anti-Longevity;Unclear;#N/A;Pro-Longevity;#N/A;functional,downstream;Unclear;Anti-Longevity;#N/A;Inhibits;1;Unclear;12;Unclear;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;153;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0680;PAX6;ENSG00000007372;HGNC:8620;5080;Paired box protein Pax-6 (Aniridia type II protein) (Oculorhombin);P26367;https://jaspar.elixir.no/search?q=P26367;https://platform.opentargets.org/target/ENSG00000007372;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.1 PD+HD;917;239;74;405;438;5_None;887;54.74;0.28;0.2;825;27.04;0.32;0.37;44;15.99;0.09;0.11;18;11.7;0.18;0.2;11;0.25;0.69;0.06;Type 2 Diabetes Mellitus;0.001478319;0.008377143;0.060286637;#N/A;#N/A;0.061601388;#N/A;0.001478319;0.007206807;0.004434958;0.003695799;#N/A;0.001847899;0.020296094;#N/A;0.077331215;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0852;SOX2;ENSG00000181449;HGNC:11195;6657;Transcription factor SOX-2;P48431;https://jaspar.elixir.no/search?q=P48431;https://platform.opentargets.org/target/ENSG00000181449;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;452;85;75;325;52;5_None;1137;54.64;0.37;0.2;1054;27.95;0.41;0.38;79;23.93;0.16;0.16;4;2.76;0.04;0.05;14;0.35;0.88;0.09;Cancer;#N/A;0.003695799;0.051310289;0.02550101;0.030964459;0.114036341;0.004065378;0.009699007;0.015860551;0.010163446;0.009609076;0.007761177;0.014639469;0.030623277;#N/A;0.021502958;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;13;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0692;PGR;ENSG00000082175;HGNC:8910;5241;Progesterone receptor (PR) (Nuclear receptor subfamily 3 group C member 3);P06401;https://jaspar.elixir.no/search?q=P06401;https://platform.opentargets.org/target/ENSG00000082175;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;184;25;76;56;52;1_High;1331;54.49;0.43;0.2;1242;22.69;0.49;0.31;76;24.53;0.16;0.16;13;7.27;0.13;0.13;14;1.08;0.88;0.28;Cancer;#N/A;0.021137914;0.303004005;0.006542179;0.091529182;0.42276024;0.079644038;0.002751317;0.001478319;0.002587059;0.015963797;0.008515736;0.004117803;0.007083819;#N/A;0.115605708;4;0.27;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;Induces;#N/A;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;133;34;13;CHEMBL208;Progesterone receptor;SINGLE PROTEIN;4633;8589;34;4;Small molecule;1959
TFTX_0756;RARA;ENSG00000131759;HGNC:9864;5914;Retinoic acid receptor alpha (RAR-alpha) (Nuclear receptor subfamily 1 group B member 1);P10276;https://jaspar.elixir.no/search?q=P10276;https://platform.opentargets.org/target/ENSG00000131759;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;551;108;77;292;182;1_High;774;54.14;0.25;0.2;661;18.66;0.26;0.25;107;32.06;0.22;0.21;6;3.42;0.06;0.06;13;0.4;0.81;0.1;Alzheimer Disease;#N/A;0.025529344;0.101544983;0.052081055;0.011513439;0.097130191;0.028360121;0.006495982;0.007391597;0.004322031;0.025115682;0.016056191;#N/A;0.006495982;#N/A;0.022778028;2;0.13;N;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;12;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;69;11;#N/A;"CHEMBL2055;CHEMBL2363069;CHEMBL2363071";"Retinoic acid receptor alpha;Retinoic acid receptor;Retinoid receptor";"SINGLE PROTEIN;PROTEIN FAMILY;PROTEIN FAMILY";"696;29;1";"1345;39;1";"2;5;4";"4;4;4";"Small molecule;Small molecule;Small molecule";"2005;1971;1986"
TFTX_0934;TET1;ENSG00000138336;HGNC:29484;80312;Methylcytosine dioxygenase TET1 (EC 1.14.11.n2) (CXXC-type zinc finger protein 6) (Leukemia-associated protein with a CXXC domain) (Ten-eleven translocation 1 gene protein);Q8NFU7;#N/A;https://platform.opentargets.org/target/ENSG00000138336;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;431;75;78;171;182;5_None;612;53.94;0.2;0.2;492;18.31;0.19;0.25;119;34.95;0.25;0.23;1;0.68;0.01;0.01;13;0.61;0.81;0.15;Type 2 Diabetes Mellitus;#N/A;0.001478319;0.078309148;0.062486804;0.007576387;0.090706625;0.026301766;#N/A;0.009978656;0.003695799;0.041095705;0.008736457;0.012935295;0.031459115;#N/A;0.232819467;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0679;PAX5;ENSG00000196092;HGNC:8619;5079;Paired box protein Pax-5 (B-cell-specific transcription factor) (BSAP);Q02548;https://jaspar.elixir.no/search?q=Q02548;https://platform.opentargets.org/target/ENSG00000196092;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.2 PD;1710;564;79;463;1168;4_Low;598;53.47;0.19;0.2;488;19.51;0.19;0.26;107;32.34;0.22;0.22;3;1.62;0.03;0.03;11;0.2;0.69;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008957178;0.009958124;0.002217479;0.063686791;#N/A;#N/A;#N/A;0.002587059;0.003695799;0.002217479;0.005340711;0.009793866;0.011641765;0.075894866;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0055;BACH2;ENSG00000112182;HGNC:14078;60468;Transcription regulator protein BACH2 (BTB and CNC homolog 2);Q9BYV9;https://jaspar.elixir.no/search?q=Q9BYV9;https://platform.opentargets.org/target/ENSG00000112182;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;787;189;80;269;438;5_None;569;53.29;0.18;0.2;475;16.8;0.19;0.23;83;30.48;0.17;0.2;11;6.01;0.11;0.1;8;0.44;0.5;0.11;Type 2 Diabetes Mellitus;#N/A;#N/A;0.01358863;#N/A;0.012565715;0.011440371;0.007761177;#N/A;#N/A;0.002956639;0.029915436;#N/A;#N/A;0.004989328;#N/A;0.360919001;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0596;NFE2L3;ENSG00000050344;HGNC:7783;9603;Nuclear factor erythroid 2-related factor 3 (NF-E2-related factor 3) (NFE2-related factor 3) (Nuclear factor, erythroid derived 2, like 3);Q9Y4A8;#N/A;https://platform.opentargets.org/target/ENSG00000050344;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;807;196;81;544;182;5_None;310;53.13;0.1;0.2;189;10.49;0.07;0.14;113;38.43;0.23;0.26;8;4.21;0.08;0.07;4;0.15;0.25;0.04;Cancer;#N/A;#N/A;0.003695799;0.003695799;#N/A;0.113036585;0.029012019;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0011;AHR;ENSG00000106546;HGNC:348;196;Aryl hydrocarbon receptor (Ah receptor) (AhR) (Class E basic helix-loop-helix protein 76) (bHLHe76);P35869;#N/A;https://platform.opentargets.org/target/ENSG00000106546;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;247;36;82;134;31;1_High;1191;53.02;0.38;0.2;1090;25.47;0.43;0.35;98;25.92;0.2;0.17;3;1.64;0.03;0.03;15;0.7;0.94;0.18;Cancer;#N/A;0.018412725;0.114624721;0.04023816;0.025193027;0.116561882;0.088815015;0.010590424;0.017724771;0.039770406;0.079870446;0.012189976;0.012199931;0.02439128;0.012935295;0.085483153;5;0.33;Y;Anti-Longevity;Anti-Longevity;#N/A;Anti-Longevity;#N/A;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;62;1;2;CHEMBL3201;Aryl hydrocarbon receptor;SINGLE PROTEIN;729;1116;1;4;Small molecule;2022
TFTX_0290;GATA2;ENSG00000179348;HGNC:4171;2624;Endothelial transcription factor GATA-2 (GATA-binding protein 2);P23769;https://jaspar.elixir.no/search?q=P23769;https://platform.opentargets.org/target/ENSG00000179348;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;661;142;83;396;182;3_Medium to Low;665;52.96;0.21;0.2;558;16.57;0.22;0.22;98;30.2;0.2;0.2;9;6.19;0.09;0.11;11;0.26;0.69;0.07;Chronic Obstructive Pulmonary Disease;#N/A;0.007391597;0.008518474;0.032464057;#N/A;0.0608057;0.082270118;0.027718489;0.012380925;0.004414426;0.001478319;#N/A;#N/A;0.015878575;#N/A;0.004434958;2;0.13;N;#N/A;Unclear;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;8;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0292;GATA4;ENSG00000136574;HGNC:4173;2626;Transcription factor GATA-4 (GATA-binding factor 4);P43694;https://jaspar.elixir.no/search?q=P43694;https://platform.opentargets.org/target/ENSG00000136574;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;470;91;84;377;9;4_Low;666;52.63;0.21;0.19;563;15.74;0.22;0.21;95;31.55;0.2;0.21;8;5.34;0.08;0.09;14;0.28;0.88;0.07;Myocardial Infarction;#N/A;0.002217479;0.026590655;0.034027923;#N/A;0.041843335;0.014169268;0.036896814;0.002217479;0.045519039;0.013838712;0.008736457;0.001847899;0.001478319;0.010348236;0.041085769;8;0.53;Y;#N/A;#N/A;Pro-Longevity;Pro-Longevity;Pro-Longevity;#N/A;Unclear;#N/A;Anti-Longevity;#N/A;#N/A;Induces;1;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0083;CAMTA1;ENSG00000171735;HGNC:18806;23261;Calmodulin-binding transcription activator 1;Q9Y6Y1;#N/A;https://platform.opentargets.org/target/ENSG00000171735;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1126;326;85;859;182;5_None;295;52.41;0.09;0.19;151;8.55;0.06;0.12;140;41.32;0.29;0.28;4;2.54;0.04;0.04;9;0.05;0.56;0.01;Cancer;#N/A;#N/A;0.001478319;0.002217479;#N/A;0.025623994;0.001478319;#N/A;0.005174118;0.007391597;0.001478319;#N/A;#N/A;0.001478319;#N/A;0.005061191;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0214;ETV1;ENSG00000006468;HGNC:3490;2115;ETS translocation variant 1 (Ets-related protein 81);P50549;https://jaspar.elixir.no/search?q=P50549;https://platform.opentargets.org/target/ENSG00000006468;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;344;55;86;76;182;4_Low;441;52.08;0.14;0.19;323;15.26;0.13;0.21;116;35.76;0.24;0.24;2;1.05;0.02;0.02;8;0.94;0.5;0.24;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004233266;#N/A;0.371150569;0.067362985;0.008315547;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.002956639;0.483864804;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0469;KLF4;ENSG00000136826;HGNC:6348;9314;Krueppel-like factor 4 (Epithelial zinc finger protein EZF) (Gut-enriched krueppel-like factor);O43474;https://jaspar.elixir.no/search?q=O43474;https://platform.opentargets.org/target/ENSG00000136826;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;144;17;87;26;31;4_Low;755;52.04;0.24;0.19;647;16.82;0.25;0.23;103;32.61;0.21;0.22;5;2.61;0.05;0.05;13;1.5;0.81;0.38;Myocardial Infarction;#N/A;0.001478319;0.046775542;0.038180961;0.017736137;0.375015859;0.015828682;0.010445388;0.034162829;0.468377281;0.031735206;0.379813417;#N/A;0.048360497;#N/A;0.030770297;5;0.33;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;10;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0939;TFAP2B;ENSG00000008196;HGNC:11743;7021;Transcription factor AP-2-beta (AP2-beta) (Activating enhancer-binding protein 2-beta);Q92481;https://jaspar.elixir.no/search?q=Q92481;https://platform.opentargets.org/target/ENSG00000008196;1 Basic domains;1.3 Basic helix-span-helix factors (bHSH);1.3.1 AP4;1293;380;88;37;1168;5_None;483;51.85;0.16;0.19;366;11.66;0.14;0.16;108;34.94;0.22;0.23;9;5.24;0.09;0.09;6;1.25;0.38;0.32;Type 2 Diabetes Mellitus;#N/A;#N/A;0.217877162;#N/A;#N/A;0.018355539;#N/A;#N/A;#N/A;#N/A;0.012196135;0.451087297;#N/A;0.001478319;#N/A;0.553127577;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0282;FOXP3;ENSG00000049768;HGNC:6106;50943;"Forkhead box protein P3 (Scurfin) [Cleaved into: Forkhead box protein P3, C-terminally processed; Forkhead box protein P3 41 kDa form]";Q9BZS1;https://jaspar.elixir.no/search?q=Q9BZS1;https://platform.opentargets.org/target/ENSG00000049768;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;325;52;89;184;52;4_Low;1819;51.75;0.58;0.19;1809;47.35;0.71;0.64;7;2.51;0.01;0.02;3;1.9;0.03;0.03;15;0.58;0.94;0.15;Cancer;#N/A;0.053743071;0.060546615;0.059295776;0.034120844;0.1090079;0.105403522;0.002902844;0.013077336;0.033888022;0.023329117;0.009496149;0.006747502;0.011282218;0.001847899;0.05242773;4;0.27;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Anti-Longevity;#N/A;#N/A;Induces;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0289;GATA1;ENSG00000102145;HGNC:4170;2623;Erythroid transcription factor (Eryf1) (GATA-binding factor 1) (GATA-1) (GF-1) (NF-E1 DNA-binding protein);P15976;https://jaspar.elixir.no/search?q=P15976;https://platform.opentargets.org/target/ENSG00000102145;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;1015;276;90;842;83;5_None;636;51.68;0.2;0.19;557;24.3;0.22;0.33;69;20.84;0.14;0.14;10;6.54;0.1;0.11;7;0.06;0.44;0.01;Cancer;#N/A;#N/A;0.005040659;0.008110225;#N/A;0.023958245;0.006837227;#N/A;0.004434958;#N/A;#N/A;0.003823469;0.003695799;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0650;NR3C2;ENSG00000151623;HGNC:7979;4306;Mineralocorticoid receptor (MR) (Nuclear receptor subfamily 3 group C member 2);P08235;https://jaspar.elixir.no/search?q=P08235;https://platform.opentargets.org/target/ENSG00000151623;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;279;41;91;6;182;1_High;864;51.63;0.28;0.19;757;12.65;0.3;0.17;91;29.45;0.19;0.2;16;9.53;0.16;0.17;16;2.62;1;0.67;Myocardial Infarction;0.002217479;0.077681627;0.085684814;0.279458387;0.001478319;0.111944104;0.271108415;0.593593238;0.022822814;0.601548488;0.02632147;0.003511009;0.003169763;0.078049875;0.006447115;0.458706786;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;72;41;8;CHEMBL1994;Mineralocorticoid receptor;SINGLE PROTEIN;1434;2137;17;4;Small molecule;1939
TFTX_0212;ETS1;ENSG00000134954;HGNC:3488;2113;Protein C-ets-1 (p54);P14921;https://jaspar.elixir.no/search?q=P14921;https://platform.opentargets.org/target/ENSG00000134954;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;227;31;92;114;21;5_None;761;51.59;0.24;0.19;664;16.27;0.26;0.22;90;31.65;0.19;0.21;7;3.68;0.07;0.06;14;0.78;0.88;0.2;Type 2 Diabetes Mellitus;#N/A;0.008295015;0.037723498;0.009363784;0.014475211;0.10740968;0.014279128;0.006542179;0.003326219;0.004229636;0.005543698;0.008110225;0.009003376;0.003695799;#N/A;0.55154693;6;0.4;Y;#N/A;Pro-Longevity;Anti-Longevity;#N/A;Anti-Longevity;#N/A;Unclear;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0684;PBX1;ENSG00000185630;HGNC:8632;5087;Pre-B-cell leukemia transcription factor 1 (Homeobox protein PBX1) (Homeobox protein PRL);P40424;https://jaspar.elixir.no/search?q=P40424;https://platform.opentargets.org/target/ENSG00000185630;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;780;186;93;505;182;5_None;434;51.48;0.14;0.19;306;10.74;0.12;0.15;126;39.43;0.26;0.26;2;1.3;0.02;0.02;7;0.17;0.44;0.04;Cancer;#N/A;#N/A;0.005615561;0.009978656;#N/A;0.062905485;0.009978656;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0.018175427;#N/A;0.058028622;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0517;MECP2;ENSG00000169057;HGNC:6990;4204;Methyl-CpG-binding protein 2 (MeCp-2 protein) (MeCp2);P51608;#N/A;https://platform.opentargets.org/target/ENSG00000169057;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;294;45;94;117;83;4_Low;1048;51.09;0.34;0.19;994;29.38;0.39;0.4;42;13.86;0.09;0.09;12;7.86;0.12;0.14;13;0.77;0.81;0.2;Cancer;#N/A;#N/A;0.111024361;0.023041825;0.002956639;0.48598369;0.007022017;0.028669541;0.009137644;0.003490476;0.001847899;0.008295015;0.024112622;0.061576794;#N/A;0.004229636;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0095;CEBPA;ENSG00000245848;HGNC:1833;1050;CCAAT/enhancer-binding protein alpha (C/EBP alpha);P49715;https://jaspar.elixir.no/search?q=P49715;https://platform.opentargets.org/target/ENSG00000245848;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;526;103;95;379;52;3_Medium to Low;842;50.72;0.27;0.19;756;24.56;0.3;0.33;85;25.33;0.18;0.17;1;0.83;0.01;0.01;14;0.28;0.88;0.07;Cancer;#N/A;0.008869917;0.054073499;0.022492903;#N/A;0.062753339;0.027562379;0.002217479;0.002012157;0.004381164;0.031854072;0.004686998;0.015482098;0.014203159;0.001478319;0.026442985;4;0.27;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;functional;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0375;HOXA13;ENSG00000106031;HGNC:5102;3209;Homeobox protein Hox-A13 (Homeobox protein Hox-1J);P31271;https://jaspar.elixir.no/search?q=P31271;https://platform.opentargets.org/target/ENSG00000106031;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1365;410;96;831;438;3_Medium to Low;639;50.69;0.21;0.19;569;28.34;0.22;0.38;68;20.9;0.14;0.14;2;1.45;0.02;0.03;7;0.06;0.44;0.01;Cancer;#N/A;#N/A;0.001478319;0.002587059;#N/A;0.02596263;0.022913951;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;0.001478319;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0309;GLIS3;ENSG00000107249;HGNC:28510;169792;Zinc finger protein GLIS3 (GLI-similar 3) (Zinc finger protein 515);Q8NEA6;https://jaspar.elixir.no/search?q=Q8NEA6;https://platform.opentargets.org/target/ENSG00000107249;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;546;106;97;11;438;5_None;308;50.25;0.1;0.19;188;3.71;0.07;0.05;102;36.83;0.21;0.25;18;9.71;0.18;0.17;6;1.95;0.38;0.49;Type 2 Diabetes Mellitus;#N/A;#N/A;0.382007696;0.003695799;#N/A;0.027852361;0.45994468;#N/A;#N/A;#N/A;#N/A;0.477390707;#N/A;#N/A;#N/A;0.596694961;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0861;SOX9;ENSG00000125398;HGNC:11204;6662;Transcription factor SOX-9;P48436;https://jaspar.elixir.no/search?q=P48436;https://platform.opentargets.org/target/ENSG00000125398;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;651;136;98;115;438;5_None;1147;49.86;0.37;0.18;1073;24.94;0.42;0.34;67;20.84;0.14;0.14;7;4.08;0.07;0.07;13;0.78;0.81;0.2;Alzheimer Disease;#N/A;0.022174791;0.252829168;0.01784003;0.0122372;0.114161274;0.017504624;0.009740072;#N/A;0.012155719;0.011812068;0.050522397;0.012182777;0.23419908;#N/A;0.00784424;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0802;SATB2;ENSG00000119042;HGNC:21637;23314;DNA-binding protein SATB2 (Special AT-rich sequence-binding protein 2);Q9UPW6;#N/A;https://platform.opentargets.org/target/ENSG00000119042;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;694;148;99;512;83;5_None;906;49.76;0.29;0.18;830;23.62;0.32;0.32;68;21.49;0.14;0.14;8;4.65;0.08;0.08;10;0.17;0.63;0.04;Cancer;#N/A;#N/A;0.005067201;0.012565715;#N/A;0.053516967;0.012750505;#N/A;0.002217479;#N/A;0.007761177;0.002904144;0.043624692;0.020142102;#N/A;0.004619748;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0110;CIC;ENSG00000079432;HGNC:14214;23152;Protein capicua homolog;Q96RK0;#N/A;https://platform.opentargets.org/target/ENSG00000079432;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1625;523;100;1087;438;4_Low;312;49.71;0.1;0.18;191;13.04;0.07;0.18;118;34.75;0.25;0.23;3;1.92;0.03;0.03;3;0.02;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.013588054;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.003695799;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1361;ZNF521;ENSG00000198795;HGNC:24605;25925;Zinc finger protein 521 (Early hematopoietic zinc finger protein) (LYST-interacting protein 3);Q96K83;#N/A;https://platform.opentargets.org/target/ENSG00000198795;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1404;433;101;865;438;5_None;255;49.68;0.08;0.18;125;9.45;0.05;0.13;129;39.7;0.27;0.27;1;0.53;0.01;0.01;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.038735211;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1068;ZEB2;ENSG00000169554;HGNC:14881;9839;Zinc finger E-box-binding homeobox 2 (Smad-interacting protein 1) (SMADIP1) (Zinc finger homeobox protein 1b);O60315;#N/A;https://platform.opentargets.org/target/ENSG00000169554;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;355;57;102;71;182;5_None;555;49.65;0.18;0.18;462;12.22;0.18;0.17;78;29.36;0.16;0.2;15;8.08;0.15;0.14;11;0.96;0.69;0.24;Type 2 Diabetes Mellitus;#N/A;#N/A;0.013489665;0.009403754;0.013623124;0.09839051;0.017988254;0.335787665;0.007761177;0.021230309;0.003695799;0.017904091;#N/A;#N/A;#N/A;0.424615803;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0604;NFKB2;ENSG00000077150;HGNC:7795;4791;Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kappa-B p52 subunit];Q00653;https://jaspar.elixir.no/search?q=Q00653;https://platform.opentargets.org/target/ENSG00000077150;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.1 NFkappaB-related;227;31;103;93;31;2_Medium;858;49.6;0.28;0.18;787;27.17;0.31;0.37;69;21.12;0.14;0.14;2;1.3;0.02;0.02;13;0.89;0.81;0.23;Alzheimer Disease;#N/A;0.002956639;0.372930152;0.009209507;#N/A;0.051516101;0.008333615;0.001847899;#N/A;0.001478319;0.00518192;0.004434958;0.019189064;0.37199239;0.002956639;0.042307295;5;0.33;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;functional;#N/A;#N/A;Pro-Longevity;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;38;1;#N/A;CHEMBL2094258;Nuclear factor NF-kappa-B complex;PROTEIN COMPLEX GROUP;1908;2351;1;3;Small molecule;#N/A
TFTX_0560;MYCN;ENSG00000134323;HGNC:7559;4613;N-myc proto-oncogene protein (Class E basic helix-loop-helix protein 37) (bHLHe37);P04198;https://jaspar.elixir.no/search?q=P04198;https://platform.opentargets.org/target/ENSG00000134323;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;398;66;104;242;52;4_Low;572;49.44;0.18;0.18;469;18.24;0.18;0.25;99;28.77;0.21;0.19;4;2.42;0.04;0.04;10;0.5;0.63;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.038857215;#N/A;0.027718489;0.102862581;0.022316956;0.017370253;0.002217479;#N/A;#N/A;0.002956639;#N/A;0.028827229;0.003695799;0.250728712;4;0.27;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;23;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0892;STAT5B;ENSG00000173757;HGNC:11367;6777;Signal transducer and activator of transcription 5B;P51692;#N/A;https://platform.opentargets.org/target/ENSG00000173757;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;219;28;105;100;14;4_Low;799;49.07;0.26;0.18;698;17.03;0.27;0.23;98;29.94;0.2;0.2;3;2.11;0.03;0.04;11;0.86;0.69;0.22;Cancer;#N/A;#N/A;0.088627628;0.041862721;0.010489498;0.610002693;0.026590311;0.008330946;0.034890802;#N/A;0.015401022;0.004229636;0.001478319;#N/A;#N/A;0.015327092;7;0.47;Y;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Pro-Longevity;Unclear;downstream;#N/A;Pro-Longevity;#N/A;Induces;#N/A;#N/A;4;#N/A;Pro-Longevity;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0766;REL;ENSG00000162924;HGNC:9954;5966;Proto-oncogene c-Rel;Q04864;https://jaspar.elixir.no/search?q=Q04864;https://platform.opentargets.org/target/ENSG00000162924;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.0 Uncharacterized/Undefined;818;200;106;274;438;5_None;681;48.82;0.22;0.18;598;24.65;0.23;0.33;83;24.17;0.17;0.16;#N/A;#N/A;#N/A;#N/A;11;0.44;0.69;0.11;Type 2 Diabetes Mellitus;#N/A;0.012935295;0.013999603;0.015832378;0.006652437;0.035090251;0.007915169;#N/A;0.002771849;0.004434958;#N/A;#N/A;0.001847899;0.087274373;#N/A;0.246382622;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0701;PITX2;ENSG00000164093;HGNC:9005;5308;Pituitary homeobox 2 (ALL1-responsive protein ARP1) (Homeobox protein PITX2) (Paired-like homeodomain transcription factor 2) (RIEG bicoid-related homeobox transcription factor) (Solurshin);Q99697;https://jaspar.elixir.no/search?q=Q99697;https://platform.opentargets.org/target/ENSG00000164093;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;566;112;107;21;438;5_None;842;48.67;0.27;0.18;772;23.97;0.3;0.32;61;19.04;0.13;0.13;9;5.65;0.09;0.1;12;1.66;0.75;0.42;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.274923533;0.003980157;0.005174118;0.058396023;0.456979853;0.446394684;0.34302281;0.010056746;0.041313484;0.002217479;#N/A;0.007947404;#N/A;0.01384015;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0077;BNC2;ENSG00000173068;HGNC:30988;54796;Zinc finger protein basonuclin-2;Q6ZN30;https://jaspar.elixir.no/search?q=Q6ZN30;https://platform.opentargets.org/target/ENSG00000173068;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;745;163;108;199;438;5_None;257;47.91;0.08;0.18;136;4.94;0.05;0.07;116;40.12;0.24;0.27;5;2.86;0.05;0.05;4;0.56;0.25;0.14;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.288717226;0.262596441;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0207;ESR2;ENSG00000140009;HGNC:3468;2100;Estrogen receptor beta (ER-beta) (Nuclear receptor subfamily 3 group A member 2);Q92731;https://jaspar.elixir.no/search?q=Q92731;https://platform.opentargets.org/target/ENSG00000140009;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;314;51;109;23;182;1_High;977;47.51;0.31;0.18;908;22.67;0.36;0.31;60;19.86;0.12;0.13;9;4.98;0.09;0.09;16;1.52;1;0.39;Cancer;0.005153586;0.002771849;0.394831906;0.023623808;0.094535872;0.451078971;0.052748748;0.011364854;0.015491155;0.268404285;0.004795081;0.023106543;0.062470054;0.083354047;0.002217479;0.025620567;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;130;60;4;"CHEMBL2093866;CHEMBL242";"Estrogen receptor;Estrogen receptor beta";"PROTEIN FAMILY;SINGLE PROTEIN";"1789;5110";"3070;9511";"25;8";"4;4";"Small molecule;Unknown;Small molecule;Unknown";"1942;1981"
TFTX_0599;NFIB;ENSG00000147862;HGNC:7785;4781;Nuclear factor 1 B-type (NF1-B) (Nuclear factor 1/B) (CCAAT-box-binding transcription factor) (CTF) (Nuclear factor I/B) (NF-I/B) (NFI-B) (TGGCA-binding protein);O00712;https://jaspar.elixir.no/search?q=O00712;https://platform.opentargets.org/target/ENSG00000147862;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;357;59;110;65;182;4_Low;479;47.32;0.15;0.17;405;21.98;0.16;0.3;71;23.41;0.15;0.16;3;1.93;0.03;0.03;7;1.03;0.44;0.26;Alzheimer Disease;#N/A;#N/A;0.344402833;#N/A;0.014783194;0.04170569;#N/A;#N/A;#N/A;0.011826555;#N/A;#N/A;0.002956639;0.333297173;#N/A;0.278374508;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0705;PLAG1;ENSG00000181690;HGNC:9045;5324;Zinc finger protein PLAG1 (Pleiomorphic adenoma gene 1 protein);Q6DJT9;https://jaspar.elixir.no/search?q=Q6DJT9;https://platform.opentargets.org/target/ENSG00000181690;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1547;490;111;268;1168;5_None;939;47.09;0.3;0.17;842;15.8;0.33;0.21;94;29.43;0.2;0.2;3;1.86;0.03;0.03;14;0.44;0.88;0.11;Cancer;#N/A;#N/A;0.029185714;0.002587059;0.11398087;0.116446957;0.023945127;0.001478319;0.001847899;0.01045665;0.021866808;0.00709388;0.009325969;0.029409933;0.011013069;0.065959462;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0790;RUNX2;ENSG00000124813;HGNC:10472;860;Runt-related transcription factor 2 (Acute myeloid leukemia 3 protein) (Core-binding factor subunit alpha-1) (CBF-alpha-1) (Oncogene AML-3) (Osteoblast-specific transcription factor 2) (OSF-2) (Polyomavirus enhancer-binding protein 2 alpha A subunit) (PEA2-alpha A) (PEBP2-alpha A) (SL3-3 enhancer factor 1 alpha A subunit) (SL3/AKV core-binding factor alpha A subunit);Q13950;https://jaspar.elixir.no/search?q=Q13950;https://platform.opentargets.org/target/ENSG00000124813;6 Immunoglobulin fold;6.4 Runt domain factors;6.4.1 Runt-related;624;127;112;74;438;4_Low;1111;46.22;0.36;0.17;1069;31.82;0.42;0.43;38;11.67;0.08;0.08;4;2.74;0.04;0.05;15;0.95;0.94;0.24;Osteoarthritis;#N/A;0.003695799;0.189692266;0.006204033;0.020640008;0.107933611;0.013601565;0.004989328;0.003695799;0.050786432;0.073490839;0.356406178;0.067061916;0.003695799;0.001478319;0.050608128;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;7;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0857;SOX5;ENSG00000134532;HGNC:11201;6660;Transcription factor SOX-5;P35711;#N/A;https://platform.opentargets.org/target/ENSG00000134532;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;300;46;113;156;31;5_None;345;45.66;0.11;0.17;222;4.36;0.09;0.06;119;38.98;0.25;0.26;4;2.32;0.04;0.04;7;0.65;0.44;0.17;Osteoarthritis;#N/A;#N/A;0.014577215;#N/A;#N/A;0.080710971;0.012696711;#N/A;0.012196135;#N/A;#N/A;0.450084616;0.005489903;#N/A;#N/A;0.075188968;5;0.33;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0426;IRF1;ENSG00000125347;HGNC:6116;3659;Interferon regulatory factor 1 (IRF-1);P10914;https://jaspar.elixir.no/search?q=P10914;https://platform.opentargets.org/target/ENSG00000125347;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;431;75;114;135;182;4_Low;783;44.91;0.25;0.17;713;22.89;0.28;0.31;68;20.85;0.14;0.14;2;1.17;0.02;0.02;14;0.69;0.88;0.18;Chronic Obstructive Pulmonary Disease;#N/A;0.003490476;0.027903924;0.055071332;0.008869917;0.098753656;0.243229712;0.003511009;0.185899667;0.011741963;0.009239496;0.024960981;0.004681345;0.008756989;#N/A;0.007298779;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0579;NCOA2;ENSG00000140396;HGNC:7669;10499;Nuclear receptor coactivator 2 (NCoA-2) (Class E basic helix-loop-helix protein 75) (bHLHe75) (Transcriptional intermediary factor 2) (hTIF2);Q15596;#N/A;https://platform.opentargets.org/target/ENSG00000140396;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1406;435;115;853;438;4_Low;408;44.71;0.13;0.16;304;13.84;0.12;0.19;104;30.86;0.22;0.21;#N/A;#N/A;#N/A;#N/A;6;0.05;0.38;0.01;Heart Failure;#N/A;#N/A;#N/A;#N/A;0.004434958;0.016142879;#N/A;0.018478993;#N/A;#N/A;0.009958124;#N/A;0.002217479;#N/A;#N/A;0.002956639;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0508;MAX;ENSG00000125952;HGNC:6913;4149;Protein max (Class D basic helix-loop-helix protein 4) (bHLHd4) (Myc-associated factor X);P61244;https://jaspar.elixir.no/search?q=P61244;https://platform.opentargets.org/target/ENSG00000125952;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1158;335;116;860;182;5_None;328;44.6;0.11;0.16;227;11.2;0.09;0.15;90;27.04;0.19;0.18;11;6.36;0.11;0.11;7;0.05;0.44;0.01;Cancer;#N/A;#N/A;0.004229636;#N/A;0.003695799;0.034625935;0.001478319;#N/A;#N/A;#N/A;0.001478319;#N/A;0.002956639;#N/A;#N/A;0.002771849;2;0.13;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;functional;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0128;CTCF;ENSG00000102974;HGNC:13723;10664;Transcriptional repressor CTCF (11-zinc finger protein) (CCCTC-binding factor) (CTCFL paralog);P49711;https://jaspar.elixir.no/search?q=P49711;https://platform.opentargets.org/target/ENSG00000102974;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;636;131;117;81;438;5_None;471;44.14;0.15;0.16;374;14.33;0.15;0.19;93;27.32;0.19;0.18;4;2.49;0.04;0.04;12;0.93;0.75;0.24;Parkinson Disease;#N/A;#N/A;0.317729507;0.018273671;0.009239496;0.113927401;0.001847899;0.018742945;#N/A;0.007391597;0.075260831;#N/A;0.005913278;0.320495939;0.003695799;0.039845211;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0858;SOX6;ENSG00000110693;HGNC:16421;55553;Transcription factor SOX-6;P35712;#N/A;https://platform.opentargets.org/target/ENSG00000110693;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;632;129;118;431;83;5_None;331;43.71;0.11;0.16;224;3.93;0.09;0.05;95;33.32;0.2;0.22;12;6.46;0.12;0.11;10;0.23;0.63;0.06;Parkinson Disease;#N/A;#N/A;0.012869374;0.007391597;#N/A;0.036786901;0.002587059;0.015761144;#N/A;0.007945967;#N/A;0.014713372;0.052585562;0.062480176;#N/A;0.014660001;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;2;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0800;SALL4;ENSG00000101115;HGNC:15924;57167;Sal-like protein 4 (Zinc finger protein 797) (Zinc finger protein SALL4);Q9UJQ4;#N/A;https://platform.opentargets.org/target/ENSG00000101115;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;997;269;119;440;438;5_None;544;43.52;0.17;0.16;457;15.76;0.18;0.21;84;25.66;0.17;0.17;3;2.1;0.03;0.04;5;0.21;0.31;0.05;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.099869837;0.043517001;#N/A;#N/A;0.065662021;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0914;TCF12;ENSG00000140262;HGNC:11623;6938;Transcription factor 12 (TCF-12) (Class B basic helix-loop-helix protein 20) (bHLHb20) (DNA-binding protein HTF4) (E-box-binding protein) (Transcription factor HTF-4);Q99081;https://jaspar.elixir.no/search?q=Q99081;https://platform.opentargets.org/target/ENSG00000140262;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.1 E2A;876;225;120;318;438;5_None;393;42.95;0.13;0.16;330;22.59;0.13;0.31;62;19.57;0.13;0.13;1;0.79;0.01;0.01;9;0.36;0.56;0.09;Type 2 Diabetes Mellitus;#N/A;0.001478319;0.019776589;0.011695765;#N/A;0.044004037;#N/A;0.001478319;#N/A;#N/A;#N/A;0.007391597;0.005174118;0.002956639;#N/A;0.269591942;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0894;TAL1;ENSG00000162367;HGNC:11556;6886;T-cell acute lymphocytic leukemia protein 1 (TAL-1) (Class A basic helix-loop-helix protein 17) (bHLHa17) (Stem cell protein) (T-cell leukemia/lymphoma protein 5);P17542;https://jaspar.elixir.no/search?q=P17542;https://platform.opentargets.org/target/ENSG00000162367;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;788;190;121;229;438;5_None;607;42.75;0.19;0.16;528;18.87;0.21;0.26;77;22.83;0.16;0.15;2;1.04;0.02;0.02;9;0.51;0.56;0.13;Alzheimer Disease;#N/A;#N/A;0.204854628;0.002956639;#N/A;0.022516449;#N/A;#N/A;#N/A;0.003695799;#N/A;0.002176928;0.009726768;0.201054218;0.003695799;0.05828069;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0421;IKZF3;ENSG00000161405;HGNC:13178;22806;Zinc finger protein Aiolos (Ikaros family zinc finger protein 3);Q9UKT9;#N/A;https://platform.opentargets.org/target/ENSG00000161405;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1479;457;122;919;438;4_Low;540;42.72;0.17;0.16;467;20.82;0.18;0.28;72;21.3;0.15;0.14;1;0.6;0.01;0.01;4;0.04;0.25;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.027484689;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;0.004065378;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0682;PAX8;ENSG00000125618;HGNC:8622;7849;Paired box protein Pax-8;Q06710;https://jaspar.elixir.no/search?q=Q06710;https://platform.opentargets.org/target/ENSG00000125618;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.2 PD;658;139;123;353;182;4_Low;682;42.46;0.22;0.16;627;24.73;0.25;0.34;52;16.04;0.11;0.11;3;1.68;0.03;0.03;8;0.31;0.5;0.08;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.284922046;#N/A;#N/A;#N/A;0.003695799;0.001478319;0.001478319;0.011621233;0.002956639;#N/A;0.006046737;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;66;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0887;STAT1;ENSG00000115415;HGNC:11362;6772;Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84);P42224;https://jaspar.elixir.no/search?q=P42224;https://platform.opentargets.org/target/ENSG00000115415;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;292;44;124;85;83;4_Low;1295;42.19;0.42;0.16;1255;26.66;0.49;0.36;34;11.37;0.07;0.08;6;4.16;0.06;0.07;15;0.93;0.94;0.24;Cancer;#N/A;0.011525849;0.049733646;0.05817109;0.002771849;0.55201028;0.018973346;0.014750284;0.081802115;0.045823261;0.019867541;0.004381164;0.01253;0.016054821;0.002217479;0.036466916;3;0.2;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Induces;#N/A;#N/A;13;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;12;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0801;SATB1;ENSG00000182568;HGNC:10541;6304;DNA-binding protein SATB1 (Special AT-rich sequence-binding protein 1);Q01826;https://jaspar.elixir.no/search?q=Q01826;https://platform.opentargets.org/target/ENSG00000182568;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;360;61;125;152;83;5_None;353;42.17;0.11;0.16;252;5.96;0.1;0.08;92;31.22;0.19;0.21;9;4.99;0.09;0.09;7;0.66;0.44;0.17;Type 2 Diabetes Mellitus;#N/A;#N/A;0.006693502;#N/A;0.011806023;0.101409772;0.014423355;#N/A;0.017370253;#N/A;#N/A;#N/A;#N/A;0.227443392;#N/A;0.280834186;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0374;HOXA11;ENSG00000005073;HGNC:5101;3207;Homeobox protein Hox-A11 (Homeobox protein Hox-1I);P31270;#N/A;https://platform.opentargets.org/target/ENSG00000005073;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;898;231;126;334;438;3_Medium to Low;606;42.13;0.19;0.16;556;26.95;0.22;0.37;49;14.61;0.1;0.1;1;0.57;0.01;0.01;7;0.34;0.44;0.09;Cancer;#N/A;#N/A;0.065970004;0.063149494;#N/A;0.096465358;0.022913951;#N/A;0.006652437;#N/A;#N/A;0.009978656;#N/A;0.074970916;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0856;SOX4;ENSG00000124766;HGNC:11200;6659;Transcription factor SOX-4;Q06945;https://jaspar.elixir.no/search?q=Q06945;https://platform.opentargets.org/target/ENSG00000124766;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;371;62;127;161;83;5_None;539;41.79;0.17;0.15;460;14.43;0.18;0.2;70;22.54;0.15;0.15;9;4.82;0.09;0.08;10;0.64;0.63;0.16;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008130757;0.021435632;0.002217479;0.100340182;0.052535809;0.003511009;#N/A;0.015152774;#N/A;0.010397003;0.066402627;#N/A;#N/A;0.360417517;3;0.2;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0920;TCF3;ENSG00000071564;HGNC:11633;6929;Transcription factor E2-alpha (Class B basic helix-loop-helix protein 21) (bHLHb21) (Immunoglobulin enhancer-binding factor E12/E47) (Immunoglobulin transcription factor 1) (Kappa-E2-binding factor) (Transcription factor 3) (TCF-3) (Transcription factor ITF-1);P15923;https://jaspar.elixir.no/search?q=P15923;https://platform.opentargets.org/target/ENSG00000071564;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.1 E2A;608;125;128;459;21;4_Low;664;41.51;0.21;0.15;577;15.12;0.23;0.2;84;24.57;0.17;0.16;3;1.83;0.03;0.03;10;0.2;0.63;0.05;Alzheimer Disease;#N/A;#N/A;0.05459621;0.00477374;0.026917733;0.046267278;#N/A;0.007391597;0.013299742;0.004250168;#N/A;0.009015683;#N/A;0.022243972;#N/A;0.010146289;6;0.4;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;Unclear;putative;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;Anti-Longevity;#N/A;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0598;NFIA;ENSG00000162599;HGNC:7784;4774;Nuclear factor 1 A-type (NF1-A) (Nuclear factor 1/A) (CCAAT-box-binding transcription factor) (CTF) (Nuclear factor I/A) (NF-I/A) (NFI-A) (TGGCA-binding protein);Q12857;https://jaspar.elixir.no/search?q=Q12857;https://platform.opentargets.org/target/ENSG00000162599;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;521;101;129;210;182;5_None;405;41.01;0.13;0.15;312;6;0.12;0.08;84;30;0.17;0.2;9;5;0.09;0.09;6;0.55;0.38;0.14;Heart Failure;#N/A;#N/A;0.045977444;0.0142168;#N/A;0.031508571;0.156393568;0.292362655;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005338376;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0030;ARID5B;ENSG00000150347;HGNC:17362;84159;AT-rich interactive domain-containing protein 5B (ARID domain-containing protein 5B) (MRF1-like protein) (Modulator recognition factor 2) (MRF-2);Q14865;#N/A;https://platform.opentargets.org/target/ENSG00000150347;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;657;137;130;89;438;4_Low;322;40.48;0.1;0.15;233;6.73;0.09;0.09;81;29.53;0.17;0.2;8;4.23;0.08;0.07;8;0.91;0.5;0.23;Type 2 Diabetes Mellitus;0.3199403;#N/A;0.028881228;0.038466965;0.001478319;0.012869639;#N/A;#N/A;#N/A;0.005543698;#N/A;0.00503674;#N/A;#N/A;#N/A;0.501120715;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0727;PPARA;ENSG00000186951;HGNC:9232;5465;Peroxisome proliferator-activated receptor alpha (PPAR-alpha) (Nuclear receptor subfamily 1 group C member 1);Q07869;https://jaspar.elixir.no/search?q=Q07869;https://platform.opentargets.org/target/ENSG00000186951;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;158;19;131;13;14;1_High;1205;40.26;0.39;0.15;1159;23.75;0.45;0.32;40;13.15;0.08;0.09;6;3.36;0.06;0.06;16;1.86;1;0.47;Type 2 Diabetes Mellitus;0.006652437;0.047315438;0.090439903;0.278598857;0.031606251;0.112267563;0.048174156;0.056927487;0.020506122;0.27156524;0.141224079;0.01275597;0.011320263;0.083713734;0.007799778;0.641531284;7;0.47;Y;Pro-Longevity;Unclear;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;putative;Unclear;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;8;#N/A;#N/A;Pro-Longevity;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;108;27;5;"CHEMBL239;CHEMBL3559683";"Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor";"SINGLE PROTEIN;PROTEIN FAMILY";"4932;85";"9465;137";"22;5";"4;4";"Small molecule;Small molecule";1967
TFTX_0619;NKX2-5;ENSG00000183072;HGNC:2488;1482;Homeobox protein Nkx-2.5 (Cardiac-specific homeobox) (Homeobox protein CSX) (Homeobox protein NK-2 homolog E);P52952;https://jaspar.elixir.no/search?q=P52952;https://platform.opentargets.org/target/ENSG00000183072;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1116;322;132;546;438;3_Medium to Low;568;40.07;0.18;0.15;522;19.77;0.2;0.27;34;12.47;0.07;0.08;12;7.84;0.12;0.14;8;0.15;0.5;0.04;Atherosclerosis;#N/A;#N/A;0.001478319;0.055693631;0.004250168;0.032089865;#N/A;0.023929582;0.004434958;0.02574591;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;11;10;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0638;NR1H3;ENSG00000025434;HGNC:7966;10062;Oxysterols receptor LXR-alpha (Liver X receptor alpha) (Nuclear receptor subfamily 1 group H member 3);Q13133;#N/A;https://platform.opentargets.org/target/ENSG00000025434;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;487;94;133;271;83;2_Medium;517;39.89;0.17;0.15;450;16.69;0.18;0.23;61;19.76;0.13;0.13;6;3.44;0.06;0.06;12;0.44;0.75;0.11;Alzheimer Disease;#N/A;0.007563657;0.078396584;0.07049258;0.004434958;0.065349609;0.058119788;0.011272186;0.008869917;0.0229819;0.069455834;0.00820262;#N/A;#N/A;#N/A;0.037983405;3;0.2;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;30;6;#N/A;"CHEMBL2808;CHEMBL3706564";"LXR-alpha;Liver X receptor";"SINGLE PROTEIN;PROTEIN FAMILY";"1398;124";"2946;311";"4;2";"1;2";"Small molecule;Small molecule";#N/A
TFTX_0484;LEF1;ENSG00000138795;HGNC:6551;51176;Lymphoid enhancer-binding factor 1 (LEF-1) (T cell-specific transcription factor 1-alpha) (TCF1-alpha);Q9UJU2;https://jaspar.elixir.no/search?q=Q9UJU2;https://platform.opentargets.org/target/ENSG00000138795;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.3 TCF7-related;693;146;134;121;438;4_Low;557;39.48;0.18;0.15;466;11.16;0.18;0.15;91;28.32;0.19;0.19;#N/A;#N/A;#N/A;#N/A;10;0.76;0.63;0.19;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.232411981;0.00783304;0.012011345;0.065138528;0.350582284;0.003695799;#N/A;0.047193294;#N/A;0.016048758;0.005358908;#N/A;#N/A;0.015042516;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0615;NKX2-1;ENSG00000136352;HGNC:11825;7080;Homeobox protein Nkx-2.1 (Homeobox protein NK-2 homolog A) (Thyroid nuclear factor 1) (Thyroid transcription factor 1) (TTF-1) (Thyroid-specific enhancer-binding protein) (T/EBP);P43699;#N/A;https://platform.opentargets.org/target/ENSG00000136352;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1931;661;135;628;1168;5_None;576;39.36;0.19;0.15;494;12.98;0.19;0.18;77;22.96;0.16;0.15;5;3.42;0.05;0.06;5;0.11;0.31;0.03;Cancer;#N/A;#N/A;0.009882838;#N/A;#N/A;0.089268526;0.009891991;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0995;TWIST1;ENSG00000122691;HGNC:12428;7291;Twist-related protein 1 (Class A basic helix-loop-helix protein 38) (bHLHa38) (H-twist);Q15672;https://jaspar.elixir.no/search?q=Q15672;https://platform.opentargets.org/target/ENSG00000122691;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;411;71;136;192;83;4_Low;942;39.19;0.3;0.14;907;25.54;0.35;0.35;29;9.79;0.06;0.07;6;3.85;0.06;0.07;14;0.57;0.88;0.14;Ischemic Stroke;#N/A;0.003695799;0.009493068;0.089675583;0.014015905;0.112114415;0.020896834;0.004496555;0.136926183;0.09919791;0.021417769;0.015041322;0.024022691;0.003695799;#N/A;0.013584729;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;14;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0024;ARHGAP35;ENSG00000160007;HGNC:4591;2909;Rho GTPase-activating protein 35 (Glucocorticoid receptor DNA-binding factor 1) (Glucocorticoid receptor repression factor 1) (GRF-1) (Rho GAP p190A) (p190-A);Q9NRY4;#N/A;https://platform.opentargets.org/target/ENSG00000160007;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1412;437;137;837;438;3_Medium to Low;264;39;0.08;0.14;169;10.27;0.07;0.14;94;28.16;0.2;0.19;1;0.56;0.01;0.01;2;0.06;0.13;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.055188338;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1099;ZHX3;ENSG00000174306;HGNC:15935;23051;Zinc fingers and homeoboxes protein 3 (Triple homeobox protein 1) (Zinc finger and homeodomain protein 3);Q9H4I2;#N/A;https://platform.opentargets.org/target/ENSG00000174306;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1667;539;138;361;1168;5_None;175;38.96;0.06;0.14;77;2.69;0.03;0.04;95;34.73;0.2;0.23;3;1.54;0.03;0.03;2;0.3;0.13;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.013927816;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.283586233;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0033;ARNTL;ENSG00000133794;HGNC:701;406;Aryl hydrocarbon receptor nuclear translocator-like protein 1 (Basic-helix-loop-helix-PAS protein MOP3) (Brain and muscle ARNT-like 1) (Class E basic helix-loop-helix protein 5) (bHLHe5) (Member of PAS protein 3) (PAS domain-containing protein 3) (bHLH-PAS protein JAP3);O00327;#N/A;https://platform.opentargets.org/target/ENSG00000133794;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;194;26;139;24;31;5_None;653;38.83;0.21;0.14;580;12.07;0.23;0.16;65;22.57;0.14;0.15;8;4.19;0.08;0.07;14;1.52;0.88;0.39;Osteoarthritis;#N/A;#N/A;0.09419386;0.080617658;0.008130757;0.095266214;0.282018584;0.010052845;0.05621864;0.019697316;0.020572818;0.452556803;0.014412244;0.075435578;0.017743229;0.291344402;5;0.33;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;mammal;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1467;ZNF664;ENSG00000179195;HGNC:25406;144348;Zinc finger protein 664 (Zinc finger protein 176) (Zinc finger protein from organ of Corti);Q8N3J9;#N/A;https://platform.opentargets.org/target/ENSG00000179195;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;944;252;140;366;438;5_None;198;38.7;0.06;0.14;91;9.42;0.04;0.13;107;29.28;0.22;0.2;#N/A;#N/A;#N/A;#N/A;1;0.29;0.06;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.292662278;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0117;CREB3L2;ENSG00000182158;HGNC:23720;64764;Cyclic AMP-responsive element-binding protein 3-like protein 2 (cAMP-responsive element-binding protein 3-like protein 2) (BBF2 human homolog on chromosome 7) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 2];Q70SY1;#N/A;https://platform.opentargets.org/target/ENSG00000182158;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1105;313;141;526;438;5_None;221;38.6;0.07;0.14;124;8.75;0.05;0.12;95;28.79;0.2;0.19;2;1.06;0.02;0.02;2;0.16;0.13;0.04;Cancer;#N/A;#N/A;0.074285551;#N/A;#N/A;0.085224897;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0114;CREB1;ENSG00000118260;HGNC:2345;1385;Cyclic AMP-responsive element-binding protein 1 (CREB-1) (cAMP-responsive element-binding protein 1);P16220;https://jaspar.elixir.no/search?q=P16220;https://platform.opentargets.org/target/ENSG00000118260;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;221;29;142;58;21;3_Medium to Low;864;38.6;0.28;0.14;791;16.77;0.31;0.23;73;21.83;0.15;0.15;#N/A;#N/A;#N/A;#N/A;16;1.08;1;0.27;Alzheimer Disease;0.002217479;0.0067243;0.396626797;0.012283614;0.002217479;0.101158137;0.039192854;0.027307506;0.018881341;0.016429324;0.007638943;0.016141397;0.009312806;0.378767529;0.001478319;0.044893205;6;0.4;Y;Unclear;Unclear;#N/A;Unclear;#N/A;Unclear;#N/A;upstream,putative;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;1;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;11;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0086;CASZ1;ENSG00000130940;HGNC:26002;54897;Zinc finger protein castor homolog 1 (Castor-related protein) (Putative survival-related protein) (Zinc finger protein 693);Q86V15;#N/A;https://platform.opentargets.org/target/ENSG00000130940;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;596;118;143;15;438;5_None;418;38.43;0.13;0.14;330;4.62;0.13;0.06;78;28.56;0.16;0.19;10;5.25;0.1;0.09;13;1.83;0.81;0.46;Ischemic Stroke;#N/A;0.003695799;0.221222404;0.033083339;#N/A;0.071905296;0.390628556;0.329897505;0.44129032;0.014593271;0.05063244;0.008654328;0.003695799;0.218079707;#N/A;0.039750018;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1091;ZFPM1;ENSG00000179588;HGNC:19762;161882;Zinc finger protein ZFPM1 (Friend of GATA protein 1) (FOG-1) (Friend of GATA 1) (Zinc finger protein 89A) (Zinc finger protein multitype 1);Q8IX07;#N/A;https://platform.opentargets.org/target/ENSG00000179588;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.2 FOG;897;229;144;315;438;5_None;428;38.41;0.14;0.14;359;14.39;0.14;0.2;66;22.44;0.14;0.15;3;1.58;0.03;0.03;4;0.37;0.25;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;0.017370253;#N/A;#N/A;0.030292818;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.320396477;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1045;ZBTB38;ENSG00000177311;HGNC:26636;253461;Zinc finger and BTB domain-containing protein 38;Q8NAP3;#N/A;https://platform.opentargets.org/target/ENSG00000177311;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;644;134;145;61;438;5_None;189;38.26;0.06;0.14;86;2.31;0.03;0.03;100;34.39;0.21;0.23;3;1.56;0.03;0.03;7;1.05;0.44;0.27;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;0.27834702;0.055690925;0.315128297;#N/A;#N/A;#N/A;0.002587059;#N/A;0.001478319;#N/A;0.003695799;0.389420511;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0700;PITX1;ENSG00000069011;HGNC:9004;5307;Pituitary homeobox 1 (Hindlimb-expressed homeobox protein backfoot) (Homeobox protein PITX1) (Paired-like homeodomain transcription factor 1);P78337;https://jaspar.elixir.no/search?q=P78337;https://platform.opentargets.org/target/ENSG00000069011;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1092;304;146;508;438;5_None;752;37.97;0.24;0.14;721;25.87;0.28;0.35;26;8.93;0.05;0.06;5;3.16;0.05;0.05;9;0.17;0.56;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011828881;#N/A;#N/A;0.033032834;#N/A;0.003695799;0.016261514;#N/A;#N/A;0.024407885;0.018663783;0.007925435;0.002217479;0.049498035;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0433;IRF8;ENSG00000140968;HGNC:5358;3394;Interferon regulatory factor 8 (IRF-8) (Interferon consensus sequence-binding protein) (H-ICSBP) (ICSBP);Q02556;https://jaspar.elixir.no/search?q=Q02556;https://platform.opentargets.org/target/ENSG00000140968;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;1105;313;147;520;438;5_None;718;37.76;0.23;0.14;665;20.23;0.26;0.27;51;16.31;0.11;0.11;2;1.22;0.02;0.02;12;0.16;0.75;0.04;Cancer;#N/A;0.001847899;0.029211372;0.01687638;0.003695799;0.054473444;#N/A;0.005543698;0.002217479;0.002217479;#N/A;0.006282858;0.006024733;0.028806696;#N/A;0.004065378;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0749;PRRX1;ENSG00000116132;HGNC:9142;5396;Paired mesoderm homeobox protein 1 (Homeobox protein PHOX1) (Paired-related homeobox protein 1) (PRX-1);P54821;https://jaspar.elixir.no/search?q=P54821;https://platform.opentargets.org/target/ENSG00000116132;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;699;150;148;113;438;5_None;625;37.65;0.2;0.14;587;23.47;0.23;0.32;35;12.37;0.07;0.08;3;1.8;0.03;0.03;11;0.78;0.69;0.2;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.279053519;0.002936107;#N/A;0.09915873;0.341776562;0.007391597;0.002012157;0.007391597;#N/A;0.021162881;0.006686611;0.009588544;#N/A;0.006886094;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0256;FOXE3;ENSG00000186790;HGNC:3808;2301;Forkhead box protein E3 (Forkhead-related protein FKHL12) (Forkhead-related transcription factor 8) (FREAC-8);Q13461;#N/A;https://platform.opentargets.org/target/ENSG00000186790;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2665;1027;149;1348;1168;5_None;640;37.56;0.21;0.14;624;29.54;0.24;0.4;9;3.3;0.02;0.02;7;4.73;0.07;0.08;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0368;HNF1B;ENSG00000275410;HGNC:11630;6928;Hepatocyte nuclear factor 1-beta (HNF-1-beta) (HNF-1B) (Homeoprotein LFB3) (Transcription factor 2) (TCF-2) (Variant hepatic nuclear factor 1) (vHNF1);P35680;https://jaspar.elixir.no/search?q=P35680;https://platform.opentargets.org/target/ENSG00000275410;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1336;399;150;18;1168;4_Low;592;37.56;0.19;0.14;519;7.16;0.2;0.1;59;22.23;0.12;0.15;14;8.17;0.14;0.14;9;1.74;0.56;0.44;Type 2 Diabetes Mellitus;#N/A;#N/A;0.012514385;0.008727628;0.410655829;0.459679452;0.045458322;#N/A;#N/A;#N/A;0.009978656;0.001847899;#N/A;0.003695799;#N/A;0.783602142;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0905;TBX2;ENSG00000121068;HGNC:11597;6909;T-box transcription factor TBX2 (T-box protein 2);Q13207;https://jaspar.elixir.no/search?q=Q13207;https://platform.opentargets.org/target/ENSG00000121068;6 Immunoglobulin fold;6.5 T-Box factors;6.5.4 TBX2-related;740;160;151;506;83;4_Low;374;37.3;0.12;0.14;312;13.11;0.12;0.18;49;17.04;0.1;0.11;13;7.15;0.13;0.12;6;0.17;0.38;0.04;Cancer;#N/A;#N/A;0.043566486;0.005235715;#N/A;0.072434116;0.018109413;0.004434958;0.02439227;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;9;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0131;CUX2;ENSG00000111249;HGNC:19347;23316;Homeobox protein cut-like 2 (Homeobox protein cux-2);O14529;https://jaspar.elixir.no/search?q=O14529;https://platform.opentargets.org/target/ENSG00000111249;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;1342;400;152;22;1168;4_Low;204;37.3;0.07;0.14;109;2.79;0.04;0.04;89;31.21;0.19;0.21;6;3.3;0.06;0.06;10;1.59;0.63;0.4;Ischemic Stroke;#N/A;#N/A;0.003124056;0.263389602;#N/A;0.012365731;0.341949278;#N/A;0.403914213;0.347028562;0.005174118;0.002217479;#N/A;0.003695799;#N/A;0.204962829;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0281;FOXP2;ENSG00000128573;HGNC:13875;93986;Forkhead box protein P2 (CAG repeat protein 44) (Trinucleotide repeat-containing gene 10 protein);O15409;https://jaspar.elixir.no/search?q=O15409;https://platform.opentargets.org/target/ENSG00000128573;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;450;82;153;214;83;5_None;394;37.05;0.13;0.14;311;8.19;0.12;0.11;80;27.04;0.17;0.18;3;1.82;0.03;0.03;6;0.54;0.38;0.14;Osteoarthritis;#N/A;#N/A;0.012660779;#N/A;0.021805211;0.076485548;#N/A;#N/A;#N/A;#N/A;#N/A;0.419965788;#N/A;0.001478319;#N/A;0.007761177;3;0.2;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0911;TBX5;ENSG00000089225;HGNC:11604;6910;T-box transcription factor TBX5 (T-box protein 5);Q99593;https://jaspar.elixir.no/search?q=Q99593;https://platform.opentargets.org/target/ENSG00000089225;6 Immunoglobulin fold;6.5 T-Box factors;6.5.4 TBX2-related;1399;429;154;77;1168;5_None;445;37.02;0.14;0.14;372;11.94;0.15;0.16;66;20.92;0.14;0.14;7;4.16;0.07;0.07;9;0.94;0.56;0.24;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.263567986;#N/A;0.270001708;0.037490341;0.323527525;0.024730435;#N/A;0.008887026;#N/A;0.004434958;0.003695799;#N/A;#N/A;0.004619748;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0448;JUN;ENSG00000177606;HGNC:6204;3725;Transcription factor Jun (Activator protein 1) (AP1) (Proto-oncogene c-Jun) (Transcription factor AP-1 subunit Jun) (V-jun avian sarcoma virus 17 oncogene homolog) (p39);P05412;https://jaspar.elixir.no/search?q=P05412;https://platform.opentargets.org/target/ENSG00000177606;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;222;30;155;36;31;4_Low;1207;36.69;0.39;0.14;1151;19.82;0.45;0.27;55;16.32;0.11;0.11;1;0.56;0.01;0.01;15;1.27;0.94;0.32;Cancer;#N/A;0.01076059;0.388245503;0.047192224;0.026117417;0.489916029;0.086575797;0.027565007;0.010231023;0.032957465;0.027987343;0.025637607;0.010469042;0.057716234;0.002217479;0.023959638;5;0.33;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;Pro-Longevity;Inhibits;#N/A;Pro-Longevity;11;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;48;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0711;POU2AF1;ENSG00000110777;HGNC:9211;5450;POU domain class 2-associating factor 1 (B-cell-specific coactivator OBF-1) (BOB-1) (OCA-B) (OCT-binding factor 1);Q16633;#N/A;https://platform.opentargets.org/target/ENSG00000110777;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1259;366;156;665;438;5_None;432;36.69;0.14;0.14;366;17.17;0.14;0.23;66;19.52;0.14;0.13;#N/A;#N/A;#N/A;#N/A;5;0.1;0.31;0.03;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.003695799;0.001478319;#N/A;0.013073748;0.075835733;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0950;TFEB;ENSG00000112561;HGNC:11753;7942;Transcription factor EB (Class E basic helix-loop-helix protein 35) (bHLHe35);P19484;https://jaspar.elixir.no/search?q=P19484;https://platform.opentargets.org/target/ENSG00000112561;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;338;54;157;160;21;5_None;520;36.68;0.17;0.14;437;10.65;0.17;0.14;80;24.48;0.17;0.16;3;1.56;0.03;0.03;15;0.64;0.94;0.16;Alzheimer Disease;0.007391597;0.029374207;0.108349498;0.041029057;#N/A;0.088252023;0.023692417;0.029101321;0.032786854;0.039487997;0.063703679;0.016844218;0.004065378;0.100579804;0.002217479;0.055742889;6;0.4;Y;Pro-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Pro-Longevity;Unclear;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0239;FOXA1;ENSG00000129514;HGNC:5021;3169;Hepatocyte nuclear factor 3-alpha (HNF-3-alpha) (HNF-3A) (Forkhead box protein A1) (Transcription factor 3A) (TCF-3A);P55317;https://jaspar.elixir.no/search?q=P55317;https://platform.opentargets.org/target/ENSG00000129514;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;460;88;158;288;14;3_Medium to Low;461;36.53;0.15;0.13;388;14.47;0.15;0.2;71;20.88;0.15;0.14;2;1.18;0.02;0.02;10;0.41;0.63;0.1;Parkinson Disease;#N/A;#N/A;0.025312265;0.001478319;0.00965281;0.094576846;0.001847899;0.001478319;#N/A;#N/A;0.064369689;#N/A;0.033304689;0.152429066;#N/A;0.023904729;7;0.47;Y;#N/A;Pro-Longevity;Pro-Longevity;Pro-Longevity;#N/A;#N/A;Unclear;#N/A;Pro-Longevity;Pro-Longevity;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0817;SIX1;ENSG00000126778;HGNC:10887;6495;Homeobox protein SIX1 (Sine oculis homeobox homolog 1);Q15475;https://jaspar.elixir.no/search?q=Q15475;https://platform.opentargets.org/target/ENSG00000126778;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;592;116;159;350;83;5_None;557;36.51;0.18;0.13;506;19.89;0.2;0.27;49;15.15;0.1;0.1;2;1.47;0.02;0.03;9;0.32;0.56;0.08;Benign Prostatic Hyperplasia;#N/A;#N/A;0.003511009;0.002217479;0.171658247;0.087718403;0.011087396;0.004434958;#N/A;#N/A;0.026034848;0.003695799;#N/A;#N/A;#N/A;0.007761177;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0116;CREB3L1;ENSG00000157613;HGNC:18856;90993;Cyclic AMP-responsive element-binding protein 3-like protein 1 (cAMP-responsive element-binding protein 3-like protein 1) (Old astrocyte specifically-induced substance) (OASIS) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 1];Q96BA8;https://jaspar.elixir.no/search?q=Q96BA8;https://platform.opentargets.org/target/ENSG00000157613;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1137;328;160;539;438;5_None;334;36.4;0.11;0.13;253;11.63;0.1;0.16;80;24.24;0.17;0.16;1;0.53;0.01;0.01;7;0.15;0.44;0.04;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.092887458;0.01307902;0.001478319;#N/A;#N/A;0.001478319;0.001478319;0.03665493;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0468;KLF3;ENSG00000109787;HGNC:16516;51274;Krueppel-like factor 3 (Basic krueppel-like factor) (CACCC-box-binding protein BKLF) (TEF-2);P57682;https://jaspar.elixir.no/search?q=P57682;https://platform.opentargets.org/target/ENSG00000109787;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1106;316;161;507;438;5_None;353;36.11;0.11;0.13;278;10.24;0.11;0.14;71;23.8;0.15;0.16;4;2.08;0.04;0.04;8;0.17;0.5;0.04;Cancer;#N/A;#N/A;0.009052274;0.011087396;#N/A;0.069761773;0.001478319;#N/A;#N/A;0.027519089;0.004434958;0.019161551;0.025172495;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0483;LCORL;ENSG00000178177;HGNC:30776;254251;Ligand-dependent nuclear receptor corepressor-like protein (LCoR-like protein);Q8N3X6;#N/A;https://platform.opentargets.org/target/ENSG00000178177;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;765;176;162;165;438;5_None;159;35.92;0.05;0.13;70;2.54;0.03;0.03;77;26.4;0.16;0.18;12;6.98;0.12;0.12;2;0.63;0.13;0.16;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.213196024;#N/A;0.413598007;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0357;HLX;ENSG00000136630;HGNC:4978;3142;H2.0-like homeobox protein (Homeobox protein HB24) (Homeobox protein HLX1);Q14774;#N/A;https://platform.opentargets.org/target/ENSG00000136630;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1214;353;163;869;182;5_None;237;35.8;0.08;0.13;155;7.98;0.06;0.11;76;24.66;0.16;0.16;6;3.16;0.06;0.05;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.008130757;#N/A;#N/A;0.018654325;0.012935295;#N/A;#N/A;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0031;ARNT;ENSG00000143437;HGNC:700;405;Aryl hydrocarbon receptor nuclear translocator (ARNT protein) (Class E basic helix-loop-helix protein 2) (bHLHe2) (Dioxin receptor, nuclear translocator) (Hypoxia-inducible factor 1-beta) (HIF-1-beta) (HIF1-beta);P27540;https://jaspar.elixir.no/search?q=P27540;https://platform.opentargets.org/target/ENSG00000143437;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;310;49;164;94;52;3_Medium to Low;418;35.54;0.13;0.13;345;14.07;0.14;0.19;73;21.46;0.15;0.14;#N/A;#N/A;#N/A;#N/A;12;0.88;0.75;0.22;Alzheimer Disease;#N/A;0.003695799;0.353617352;0.002587059;0.004065378;0.087664071;0.004229636;0.002936107;#N/A;0.002936107;0.020213965;#N/A;0.003695799;0.352355297;#N/A;0.04643679;4;0.27;Y;Pro-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;48;43;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0471;KLF6;ENSG00000067082;HGNC:2235;1316;Krueppel-like factor 6 (B-cell-derived protein 1) (Core promoter element-binding protein) (GC-rich sites-binding factor GBF) (Proto-oncogene BCD1) (Suppressor of tumorigenicity 12 protein) (Transcription factor Zf9);Q99612;https://jaspar.elixir.no/search?q=Q99612;https://platform.opentargets.org/target/ENSG00000067082;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;687;145;165;439;83;5_None;490;35.34;0.16;0.13;412;9.52;0.16;0.13;75;24.21;0.16;0.16;3;1.61;0.03;0.03;12;0.22;0.75;0.06;Cancer;#N/A;#N/A;0.022971393;0.015127014;0.004250168;0.048537265;0.019729803;0.004506821;0.012823176;0.030839386;0.037230779;0.004954804;#N/A;0.005707956;#N/A;0.011048372;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1294;ZNF423;ENSG00000102935;HGNC:16762;23090;Zinc finger protein 423 (Olf1/EBF-associated zinc finger protein) (hOAZ) (Smad- and Olf-interacting zinc finger protein);Q2M1K9;#N/A;https://platform.opentargets.org/target/ENSG00000102935;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1292;379;166;688;438;4_Low;429;34.98;0.14;0.13;371;14.96;0.15;0.2;55;18.38;0.11;0.12;3;1.64;0.03;0.03;7;0.09;0.44;0.02;Parkinson Disease;#N/A;#N/A;0.020106403;#N/A;#N/A;0.015320407;0.011087396;#N/A;#N/A;#N/A;#N/A;0.003513409;0.006652437;0.033956997;#N/A;0.002956639;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0791;RUNX3;ENSG00000020633;HGNC:10473;864;Runt-related transcription factor 3 (Acute myeloid leukemia 2 protein) (Core-binding factor subunit alpha-3) (CBF-alpha-3) (Oncogene AML-2) (Polyomavirus enhancer-binding protein 2 alpha C subunit) (PEA2-alpha C) (PEBP2-alpha C) (SL3-3 enhancer factor 1 alpha C subunit) (SL3/AKV core-binding factor alpha C subunit);Q13761;https://jaspar.elixir.no/search?q=Q13761;https://platform.opentargets.org/target/ENSG00000020633;6 Immunoglobulin fold;6.4 Runt domain factors;6.4.1 Runt-related;446;81;167;227;52;4_Low;718;34.72;0.23;0.13;668;19.22;0.26;0.26;49;15;0.1;0.1;1;0.51;0.01;0.01;9;0.51;0.56;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.038825708;0.002217479;#N/A;0.098529838;0.017548883;#N/A;#N/A;0.012575455;#N/A;0.017050977;0.007571254;0.073915971;#N/A;0.24180873;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;2;#N/A;#N/A;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0823;SKI;ENSG00000157933;HGNC:10896;6497;Ski oncogene (Proto-oncogene c-Ski);P12755;#N/A;https://platform.opentargets.org/target/ENSG00000157933;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;659;140;168;309;182;5_None;305;34.69;0.1;0.13;251;15.64;0.1;0.21;53;18.19;0.11;0.12;1;0.85;0.01;0.01;8;0.37;0.5;0.1;Type 2 Diabetes Mellitus;#N/A;0.041051698;0.007602257;0.003695799;#N/A;0.03084612;#N/A;0.002217479;#N/A;0.004065378;#N/A;#N/A;#N/A;0.003695799;#N/A;0.281472603;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0042;ATF1;ENSG00000123268;HGNC:783;466;Cyclic AMP-dependent transcription factor ATF-1 (cAMP-dependent transcription factor ATF-1) (Activating transcription factor 1) (Protein TREB36);P18846;#N/A;https://platform.opentargets.org/target/ENSG00000123268;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1106;316;169;499;438;2_Medium;262;34.62;0.08;0.13;180;9.36;0.07;0.13;82;25.26;0.17;0.17;#N/A;#N/A;#N/A;#N/A;8;0.17;0.5;0.04;Cancer;#N/A;0.001478319;0.004968796;0.002217479;#N/A;0.081236253;#N/A;#N/A;0.064041552;#N/A;#N/A;0.004250168;0.003860056;#N/A;#N/A;0.008869917;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0157;DNMT1;ENSG00000130816;HGNC:2976;1786;DNA (cytosine-5)-methyltransferase 1 (Dnmt1) (EC 2.1.1.37) (CXXC-type zinc finger protein 9) (DNA methyltransferase HsaI) (DNA MTase HsaI) (M.HsaI) (MCMT);P26358;#N/A;https://platform.opentargets.org/target/ENSG00000130816;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;300;46;170;47;83;1_High;915;34.52;0.29;0.13;882;20.3;0.35;0.28;23;8.06;0.05;0.05;10;6.16;0.1;0.11;15;1.14;0.94;0.29;Cancer;#N/A;0.090187658;0.036825709;0.033368527;0.040191597;0.611181175;0.068202549;0.023101067;0.005258573;0.015600444;0.050059967;0.005561138;0.018318976;0.061195943;0.001478319;0.083922599;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;9;#N/A;#N/A;#N/A;#N/A;12;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;77;11;#N/A;CHEMBL1993;DNA (cytosine-5)-methyltransferase 1;SINGLE PROTEIN;783;1002;2;4;Small molecule;2004
TFTX_0404;HOXD11;ENSG00000128713;HGNC:5134;3237;Homeobox protein Hox-D11 (Homeobox protein Hox-4F);P31277;https://jaspar.elixir.no/search?q=P31277;https://platform.opentargets.org/target/ENSG00000128713;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1583;505;171;974;438;3_Medium to Low;451;34.36;0.14;0.13;407;20.51;0.16;0.28;42;12.85;0.09;0.09;2;1;0.02;0.02;2;0.03;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.02331572;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0589;NFATC1;ENSG00000131196;HGNC:7775;4772;Nuclear factor of activated T-cells, cytoplasmic 1 (NF-ATc1) (NFATc1) (NFAT transcription complex cytosolic component) (NF-ATc) (NFATc);O95644;https://jaspar.elixir.no/search?q=O95644;https://platform.opentargets.org/target/ENSG00000131196;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.3 NFAT-related;774;184;172;420;182;4_Low;669;34.32;0.21;0.13;623;16.87;0.24;0.23;40;14.22;0.08;0.09;6;3.24;0.06;0.06;10;0.24;0.63;0.06;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.011947677;0.009570052;#N/A;0.033475655;#N/A;0.007915169;#N/A;0.015891934;0.074470341;0.012240678;0.017787544;0.009054706;#N/A;0.044173529;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0877;SPI1;ENSG00000066336;HGNC:11241;6688;Transcription factor PU.1 (31 kDa-transforming protein);P17947;https://jaspar.elixir.no/search?q=P17947;https://platform.opentargets.org/target/ENSG00000066336;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;282;42;173;57;52;5_None;970;34.18;0.31;0.13;955;29.21;0.37;0.4;13;3.72;0.03;0.02;2;1.24;0.02;0.02;14;1.08;0.88;0.27;Alzheimer Disease;#N/A;0.026917733;0.432907177;0.01206319;#N/A;0.082541901;0.0491442;0.004065378;0.00801783;0.029042679;0.004322031;0.013017834;0.013294609;0.369184048;0.015522354;0.022133012;4;0.27;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0902;TBX15;ENSG00000092607;HGNC:11594;6913;T-box transcription factor TBX15 (T-box protein 15) (T-box transcription factor TBX14) (T-box protein 14);Q96SF7;https://jaspar.elixir.no/search?q=Q96SF7;https://platform.opentargets.org/target/ENSG00000092607;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;1866;629;174;524;1168;5_None;469;33.78;0.15;0.12;418;14.27;0.16;0.19;43;14.98;0.09;0.1;8;4.52;0.08;0.08;7;0.16;0.44;0.04;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.08370578;0.005174118;0.02439227;#N/A;#N/A;#N/A;#N/A;0.039986487;#N/A;0.001478319;0.002936107;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0193;ELF4;ENSG00000102034;HGNC:3319;2000;ETS-related transcription factor Elf-4 (E74-like factor 4) (Myeloid Elf-1-like factor);Q99607;https://jaspar.elixir.no/search?q=Q99607;https://platform.opentargets.org/target/ENSG00000102034;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1231;358;175;618;438;3_Medium to Low;338;31.99;0.11;0.12;265;10.1;0.1;0.14;72;21.26;0.15;0.14;1;0.62;0.01;0.01;7;0.12;0.44;0.03;Cancer;#N/A;0.002217479;0.005153586;0.003695799;#N/A;0.092242657;0.007022017;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1321;ZNF462;ENSG00000148143;HGNC:21684;58499;Zinc finger protein 462 (Zinc finger PBX1-interacting protein) (ZFPIP);Q96JM2;#N/A;https://platform.opentargets.org/target/ENSG00000148143;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;746;165;176;132;438;5_None;135;31.94;0.04;0.12;54;2.44;0.02;0.03;74;25.55;0.15;0.17;7;3.95;0.07;0.07;4;0.71;0.25;0.18;Alzheimer Disease;#N/A;#N/A;0.34786893;#N/A;#N/A;0.012011345;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.345767751;0.003695799;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0505;MAFF;ENSG00000185022;HGNC:6780;23764;Transcription factor MafF (U-Maf) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog F);Q9ULX9;https://jaspar.elixir.no/search?q=Q9ULX9;https://platform.opentargets.org/target/ENSG00000185022;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;1038;284;177;423;438;5_None;223;31.74;0.07;0.12;135;3.65;0.05;0.05;86;27.08;0.18;0.18;2;1.02;0.02;0.02;7;0.23;0.44;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.038050771;0.013353741;#N/A;0.023385463;0.001275859;#N/A;#N/A;#N/A;#N/A;0.008289421;#N/A;0.002751317;#N/A;0.147107472;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1222;ZNF285;ENSG00000267508;HGNC:13079;26974;Zinc finger protein 285 (Zinc finger protein 285A);Q96NJ3;#N/A;https://platform.opentargets.org/target/ENSG00000267508;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;954;256;178;338;438;5_None;90;31.67;0.03;0.12;10;0.28;0;0;70;26.07;0.15;0.17;10;5.32;0.1;0.09;2;0.33;0.13;0.08;Alzheimer Disease;#N/A;#N/A;0.295565847;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.038876923;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0218;ETV4;ENSG00000175832;HGNC:3493;2118;ETS translocation variant 4 (Adenovirus E1A enhancer-binding protein) (E1A-F) (Polyomavirus enhancer activator 3 homolog) (Protein PEA3);P43268;https://jaspar.elixir.no/search?q=P43268;https://platform.opentargets.org/target/ENSG00000175832;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;700;151;179;83;438;3_Medium to Low;349;31.53;0.11;0.12;282;12.06;0.11;0.16;67;19.47;0.14;0.13;#N/A;#N/A;#N/A;#N/A;8;0.93;0.5;0.24;Benign Prostatic Hyperplasia;#N/A;#N/A;0.205959619;#N/A;0.371237831;0.106018937;0.009557746;#N/A;#N/A;#N/A;0.024022691;0.007391597;#N/A;0.204046889;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1459;ZNF652;ENSG00000198740;HGNC:29147;22834;Zinc finger protein 652;Q9Y2D9;https://jaspar.elixir.no/search?q=Q9Y2D9;https://platform.opentargets.org/target/ENSG00000198740;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;759;173;180;141;438;5_None;160;31.39;0.05;0.12;77;3.06;0.03;0.04;79;26.26;0.16;0.18;4;2.07;0.04;0.04;5;0.68;0.31;0.17;Alzheimer Disease;#N/A;#N/A;0.430178669;0.002217479;#N/A;0.019230676;#N/A;#N/A;#N/A;0.225440746;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0522;MEIS1;ENSG00000143995;HGNC:7000;4211;Homeobox protein Meis1;O00470;https://jaspar.elixir.no/search?q=O00470;https://platform.opentargets.org/target/ENSG00000143995;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;745;163;181;382;182;5_None;323;31.28;0.1;0.12;255;4.3;0.1;0.06;61;23.28;0.13;0.16;7;3.7;0.07;0.06;7;0.27;0.44;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004065378;#N/A;#N/A;0.085392941;0.017555043;0.001478319;#N/A;0.076484613;#N/A;0.001478319;#N/A;#N/A;#N/A;0.086593361;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0746;PROX1;ENSG00000117707;HGNC:9459;5629;Prospero homeobox protein 1 (Homeobox prospero-like protein PROX1) (PROX-1);Q92786;https://jaspar.elixir.no/search?q=Q92786;https://platform.opentargets.org/target/ENSG00000117707;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.7 HD-PROS;408;69;182;143;83;4_Low;360;31.09;0.12;0.11;288;4.08;0.11;0.06;60;20.54;0.12;0.14;12;6.46;0.12;0.11;10;0.68;0.63;0.17;Type 2 Diabetes Mellitus;#N/A;0.005913278;0.023046384;0.008700526;#N/A;0.055636191;0.013576927;#N/A;0.008869917;0.007761177;0.003695799;0.001478319;#N/A;#N/A;#N/A;0.551289236;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0770;RERE;ENSG00000142599;HGNC:9965;473;Arginine-glutamic acid dipeptide repeats protein (Atrophin-1-like protein) (Atrophin-1-related protein);Q9P2R6;#N/A;https://platform.opentargets.org/target/ENSG00000142599;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;514;99;183;248;83;5_None;548;30.92;0.18;0.11;486;10.8;0.19;0.15;60;18.86;0.12;0.13;2;1.26;0.02;0.02;12;0.49;0.75;0.12;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.02329909;0.00917994;0.004414426;0.056137091;0.263931948;0.001478319;#N/A;0.011826555;0.002217479;0.085189161;0.011087396;0.008631332;#N/A;0.008736457;3;0.2;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0968;THRA;ENSG00000126351;HGNC:11796;7067;Thyroid hormone receptor alpha (Nuclear receptor subfamily 1 group A member 1) (V-erbA-related protein 7) (EAR-7) (c-erbA-1) (c-erbA-alpha);P10827;https://jaspar.elixir.no/search?q=P10827;https://platform.opentargets.org/target/ENSG00000126351;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;492;95;184;126;182;1_High;616;30.82;0.2;0.11;581;18.4;0.23;0.25;32;10.79;0.07;0.07;3;1.64;0.03;0.03;10;0.73;0.63;0.18;Myocardial Infarction;#N/A;#N/A;0.013969708;0.003326219;#N/A;0.027199594;0.211487645;0.037327565;#N/A;0.323936743;0.001478319;#N/A;0.059520836;#N/A;0.007391597;0.042275726;2;0.13;N;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;16;5;3;CHEMBL2111462;Thyroid hormone receptor;PROTEIN COMPLEX;127;146;5;4;Small molecule;1956
TFTX_0303;GLI1;ENSG00000111087;HGNC:4317;2735;Zinc finger protein GLI1 (Glioma-associated oncogene) (Oncogene GLI);P08151;#N/A;https://platform.opentargets.org/target/ENSG00000111087;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;795;193;185;428;182;2_Medium;700;30.66;0.22;0.11;680;24.88;0.27;0.34;18;4.44;0.04;0.03;2;1.33;0.02;0.02;13;0.23;0.81;0.06;Cancer;#N/A;#N/A;0.014456737;0.001478319;0.021936207;0.112126311;0.019829191;0.001478319;0.002587059;0.009424286;0.002217479;0.009291636;0.010878981;0.00973227;#N/A;0.014796836;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;30;11;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0674;PATZ1;ENSG00000100105;HGNC:13071;23598;POZ-, AT hook-, and zinc finger-containing protein 1 (BTB/POZ domain zinc finger transcription factor) (Protein kinase A RI subunit alpha-associated protein) (Zinc finger and BTB domain-containing protein 19) (Zinc finger protein 278) (Zinc finger sarcoma gene protein);Q9HBE1;https://jaspar.elixir.no/search?q=Q9HBE1;https://platform.opentargets.org/target/ENSG00000100105;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1094;307;186;825;83;5_None;334;30.64;0.11;0.11;279;15.01;0.11;0.2;55;15.63;0.11;0.1;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;#N/A;0.002771849;#N/A;0.045557444;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.009609076;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0681;PAX7;ENSG00000009709;HGNC:8621;5081;Paired box protein Pax-7 (HuP1);P23759;https://jaspar.elixir.no/search?q=P23759;https://platform.opentargets.org/target/ENSG00000009709;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.1 PD+HD;2019;699;187;664;1168;5_None;347;30.6;0.11;0.11;309;17.24;0.12;0.23;36;12.12;0.07;0.08;2;1.24;0.02;0.02;10;0.1;0.63;0.03;Cancer;#N/A;#N/A;0.009947858;#N/A;#N/A;0.036717889;0.014154498;0.003695799;#N/A;0.009239496;0.006652437;0.001478319;#N/A;0.002956639;0.005520199;0.011374847;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0653;NR4A3;ENSG00000119508;HGNC:7982;8013;Nuclear receptor subfamily 4 group A member 3 (Mitogen-induced nuclear orphan receptor) (Neuron-derived orphan receptor 1) (Nuclear hormone receptor NOR-1);Q92570;#N/A;https://platform.opentargets.org/target/ENSG00000119508;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.4 NGFI(NR4A);1082;302;188;456;438;4_Low;380;30.54;0.12;0.11;306;8.25;0.12;0.11;73;21.77;0.15;0.15;1;0.52;0.01;0.01;9;0.2;0.56;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.043198636;0.022366699;#N/A;0.037533202;0.025819259;0.002956639;#N/A;0.003767661;#N/A;0.012991964;#N/A;0.005245981;#N/A;0.048775698;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0675;PAX1;ENSG00000125813;HGNC:8615;5075;Paired box protein Pax-1 (HuP48);P15863;https://jaspar.elixir.no/search?q=P15863;https://platform.opentargets.org/target/ENSG00000125813;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.2 PD;2143;757;189;786;1168;5_None;523;30.19;0.17;0.11;494;19.13;0.19;0.26;24;8.19;0.05;0.05;5;2.87;0.05;0.05;4;0.07;0.25;0.02;Cancer;#N/A;0.001478319;0.011641765;#N/A;#N/A;0.054746648;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0949;TFE3;ENSG00000068323;HGNC:11752;7030;Transcription factor E3 (Class E basic helix-loop-helix protein 33) (bHLHe33);P19532;https://jaspar.elixir.no/search?q=P19532;https://platform.opentargets.org/target/ENSG00000068323;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;861;220;190;489;182;5_None;329;30.1;0.11;0.11;252;6.97;0.1;0.09;76;22.38;0.16;0.15;1;0.75;0.01;0.01;8;0.18;0.5;0.05;Parkinson Disease;#N/A;0.007391597;0.014641584;0.003018235;#N/A;0.031326155;#N/A;#N/A;#N/A;#N/A;0.005954342;#N/A;#N/A;0.096593801;0.015522354;0.003695799;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0578;NCOA1;ENSG00000084676;HGNC:7668;8648;Nuclear receptor coactivator 1 (NCoA-1) (EC 2.3.1.48) (Class E basic helix-loop-helix protein 74) (bHLHe74) (Protein Hin-2) (RIP160) (Renal carcinoma antigen NY-REN-52) (Steroid receptor coactivator 1) (SRC-1);Q15788;#N/A;https://platform.opentargets.org/target/ENSG00000084676;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1234;360;191;605;438;4_Low;382;30.06;0.12;0.11;356;22;0.14;0.3;25;7.53;0.05;0.05;1;0.52;0.01;0.01;6;0.12;0.38;0.03;Alzheimer Disease;#N/A;#N/A;0.051994137;#N/A;0.021385761;0.024587111;#N/A;#N/A;#N/A;#N/A;0.007206807;#N/A;0.004414426;#N/A;#N/A;0.012943097;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0845;SOX11;ENSG00000176887;HGNC:11191;6664;Transcription factor SOX-11;P35716;#N/A;https://platform.opentargets.org/target/ENSG00000176887;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1140;329;192;510;438;5_None;693;29.9;0.22;0.11;655;16.52;0.26;0.22;34;11.12;0.07;0.07;4;2.27;0.04;0.04;9;0.17;0.56;0.04;Cancer;#N/A;#N/A;0.003695799;0.009609076;0.012750505;0.095252374;0.009793866;#N/A;#N/A;#N/A;#N/A;0.023622915;0.003582871;0.003695799;#N/A;0.004065378;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0698;PHOX2B;ENSG00000109132;HGNC:9143;8929;Paired mesoderm homeobox protein 2B (Neuroblastoma Phox) (NBPhox) (PHOX2B homeodomain protein) (Paired-like homeobox 2B);Q99453;https://jaspar.elixir.no/search?q=Q99453;https://platform.opentargets.org/target/ENSG00000109132;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2302;840;193;941;1168;5_None;248;29.88;0.08;0.11;186;8.44;0.07;0.11;55;16.61;0.11;0.11;7;4.83;0.07;0.08;3;0.04;0.19;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.009679558;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012633882;#N/A;0.014783194;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0797;SALL1;ENSG00000103449;HGNC:10524;6299;Sal-like protein 1 (Spalt-like transcription factor 1) (Zinc finger protein 794) (Zinc finger protein SALL1) (Zinc finger protein Spalt-1) (HSal1) (Sal-1);Q9NSC2;#N/A;https://platform.opentargets.org/target/ENSG00000103449;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;863;221;194;586;83;5_None;443;29.77;0.14;0.11;396;12.17;0.15;0.16;41;14.16;0.09;0.09;6;3.45;0.06;0.06;7;0.13;0.44;0.03;Cancer;#N/A;0.003695799;0.025046208;0.007391597;#N/A;0.080709046;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;0.002217479;#N/A;#N/A;0.004619748;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0461;KLF12;ENSG00000118922;HGNC:6346;11278;Krueppel-like factor 12 (Transcriptional repressor AP-2rep);Q9Y4X4;https://jaspar.elixir.no/search?q=Q9Y4X4;https://platform.opentargets.org/target/ENSG00000118922;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1530;482;195;897;438;5_None;192;29.71;0.06;0.11;120;4.65;0.05;0.06;68;22.97;0.14;0.15;4;2.09;0.04;0.04;5;0.05;0.31;0.01;Cancer;#N/A;#N/A;0.004250168;#N/A;#N/A;0.028907448;#N/A;#N/A;0.004434958;#N/A;#N/A;0.004434958;0.004434958;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0270;FOXL2;ENSG00000183770;HGNC:1092;668;Forkhead box protein L2;P58012;#N/A;https://platform.opentargets.org/target/ENSG00000183770;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1565;495;196;931;438;3_Medium to Low;304;29.44;0.1;0.11;246;11.04;0.1;0.15;54;15.74;0.11;0.11;4;2.66;0.04;0.05;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;0.004619748;#N/A;#N/A;0.03401081;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;24;24;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0669;OTX2;ENSG00000165588;HGNC:8522;5015;Homeobox protein OTX2 (Orthodenticle homolog 2);P32243;https://jaspar.elixir.no/search?q=P32243;https://platform.opentargets.org/target/ENSG00000165588;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;780;186;197;531;52;5_None;497;29.22;0.16;0.11;455;14;0.18;0.19;38;12.66;0.08;0.08;4;2.56;0.04;0.04;7;0.16;0.44;0.04;Age-Related Macular Degeneration;#N/A;0.071854585;0.013022557;#N/A;#N/A;0.014919103;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0.008059988;#N/A;0.042871263;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0356;HLF;ENSG00000108924;HGNC:4977;3131;Hepatic leukemia factor;Q16534;https://jaspar.elixir.no/search?q=Q16534;https://platform.opentargets.org/target/ENSG00000108924;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;664;144;198;284;182;5_None;232;29.04;0.07;0.11;162;6.42;0.06;0.09;68;21.55;0.14;0.14;2;1.07;0.02;0.02;5;0.42;0.31;0.11;Heart Failure;#N/A;#N/A;0.005605294;#N/A;#N/A;0.064388594;0.004619748;0.341926304;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0792;RXRA;ENSG00000186350;HGNC:10477;6256;Retinoic acid receptor RXR-alpha (Nuclear receptor subfamily 2 group B member 1) (Retinoid X receptor alpha);P19793;https://jaspar.elixir.no/search?q=P19793;https://platform.opentargets.org/target/ENSG00000186350;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;657;137;199;276;182;1_High;681;29.02;0.22;0.11;647;17.71;0.25;0.24;32;10.2;0.07;0.07;2;1.11;0.02;0.02;15;0.43;0.94;0.11;Alzheimer Disease;#N/A;0.016477102;0.114456169;0.017111788;0.003695799;0.084262615;0.016261514;0.014664608;0.004434958;0.059227841;0.009842493;0.004434958;0.002771849;0.040810342;0.015152774;0.026817429;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;4;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;86;8;2;"CHEMBL2061;CHEMBL2363070;CHEMBL2363071";"Retinoid X receptor alpha;Retinoid X receptor;Retinoid receptor";"SINGLE PROTEIN;PROTEIN FAMILY;PROTEIN FAMILY";"1704;51;1";"3765;115;1";"2;2;4";"4;4;4";"Small molecule;Small molecule;Small molecule";"1999;1986"
TFTX_0869;SP4;ENSG00000105866;HGNC:11209;6671;Transcription factor Sp4 (SPR-1);Q02446;https://jaspar.elixir.no/search?q=Q02446;https://platform.opentargets.org/target/ENSG00000105866;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1050;290;200;668;182;5_None;448;28.92;0.14;0.11;403;14.14;0.16;0.19;44;14.27;0.09;0.1;1;0.51;0.01;0.01;3;0.1;0.19;0.03;Cancer;#N/A;#N/A;0.018550855;#N/A;#N/A;0.078483605;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0344;HEY2;ENSG00000135547;HGNC:4881;23493;Hairy/enhancer-of-split related with YRPW motif protein 2 (Cardiovascular helix-loop-helix factor 1) (hCHF1) (Class B basic helix-loop-helix protein 32) (bHLHb32) (HES-related repressor protein 2) (Hairy and enhancer of split-related protein 2) (HESR-2) (Hairy-related transcription factor 2) (HRT-2) (hHRT2) (Protein gridlock homolog);Q9UBP5;https://jaspar.elixir.no/search?q=Q9UBP5;https://platform.opentargets.org/target/ENSG00000135547;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;809;197;201;170;438;5_None;537;28.85;0.17;0.11;492;14.3;0.19;0.19;43;13.51;0.09;0.09;2;1.04;0.02;0.02;10;0.61;0.63;0.15;Type 2 Diabetes Mellitus;#N/A;#N/A;0.067495165;0.036760466;0.001478319;0.011700232;0.009444819;0.034673353;#N/A;#N/A;0.013653922;0.001100824;#N/A;0.014986759;#N/A;0.418394766;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0938;TFAP2A;ENSG00000137203;HGNC:11742;7020;Transcription factor AP-2-alpha (AP2-alpha) (AP-2 transcription factor) (Activating enhancer-binding protein 2-alpha) (Activator protein 2) (AP-2);P05549;https://jaspar.elixir.no/search?q=P05549;https://platform.opentargets.org/target/ENSG00000137203;1 Basic domains;1.3 Basic helix-span-helix factors (bHSH);1.3.1 AP3;782;188;202;398;182;4_Low;704;28.83;0.23;0.11;669;16.61;0.26;0.23;32;10.32;0.07;0.07;3;1.89;0.03;0.03;12;0.26;0.75;0.07;Cancer;#N/A;#N/A;0.040741023;0.026840242;0.004434958;0.088347504;0.039968624;#N/A;0.001478319;0.004434958;0.008110225;0.013674455;0.006714034;0.002751317;#N/A;0.018682286;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0728;PPARD;ENSG00000112033;HGNC:9235;5467;Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta);Q03181;https://jaspar.elixir.no/search?q=Q03181;https://platform.opentargets.org/target/ENSG00000112033;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;355;57;203;69;83;2_Medium;590;28.75;0.19;0.11;538;12.36;0.21;0.17;52;16.39;0.11;0.11;#N/A;#N/A;#N/A;#N/A;15;0.99;0.94;0.25;Type 2 Diabetes Mellitus;#N/A;0.07309159;0.099322478;0.023550667;0.008295015;0.100222053;0.022436577;0.013513135;0.018661319;0.054860738;0.10725676;0.01575601;0.017099639;0.047989775;0.00580302;0.385095147;3;0.2;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;7;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;149;13;#N/A;"CHEMBL3559683;CHEMBL3979";"Peroxisome proliferator-activated receptor;Peroxisome proliferator-activated receptor delta";"PROTEIN FAMILY;SINGLE PROTEIN";"85;3777";"137;6483";"5;8";"4;3";"Small molecule;Small molecule";#N/A
TFTX_0235;FOS;ENSG00000170345;HGNC:3796;2353;Protein c-Fos (Cellular oncogene fos) (Fos proto-oncogene, AP-1 transcription factor subunit) (G0/G1 switch regulatory protein 7) (Proto-oncogene c-Fos) (Transcription factor AP-1 subunit c-Fos);P01100;https://jaspar.elixir.no/search?q=P01100;https://platform.opentargets.org/target/ENSG00000170345;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;373;63;204;138;31;3_Medium to Low;1437;28.6;0.46;0.11;1412;21.18;0.55;0.29;25;7.41;0.05;0.05;#N/A;#N/A;#N/A;#N/A;14;0.69;0.88;0.17;Cancer;#N/A;0.010819723;0.059462749;0.051166372;0.081245928;0.110464953;0.03270082;0.049255067;0.026664795;0.065322441;0.068286397;0.029770082;0.01283522;0.054238356;#N/A;0.036578665;5;0.33;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Unclear;putative;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;11;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;26;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0737;PRDM2;ENSG00000116731;HGNC:9347;7799;PR domain zinc finger protein 2 (EC 2.1.1.355) (GATA-3-binding protein G3B) (Lysine N-methyltransferase 8) (MTB-ZF) (MTE-binding protein) (PR domain-containing protein 2) (Retinoblastoma protein-interacting zinc finger protein) (Zinc finger protein RIZ);Q13029;#N/A;https://platform.opentargets.org/target/ENSG00000116731;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2154;767;205;781;1168;5_None;319;28.58;0.1;0.11;305;24.38;0.12;0.33;14;4.19;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.07;0.25;0.02;Cancer;#N/A;#N/A;0.008968316;#N/A;#N/A;0.055182527;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0639;NR1H4;ENSG00000012504;HGNC:7967;9971;Bile acid receptor (Farnesoid X-activated receptor) (Farnesol receptor HRR-1) (Nuclear receptor subfamily 1 group H member 4) (Retinoid X receptor-interacting protein 14) (RXR-interacting protein 14);Q96RI1;https://jaspar.elixir.no/search?q=Q96RI1;https://platform.opentargets.org/target/ENSG00000012504;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;443;80;206;55;182;1_High;758;28.54;0.24;0.11;730;16.67;0.29;0.23;20;7.1;0.04;0.05;8;4.77;0.08;0.08;15;1.09;0.94;0.28;Non-Alcoholic Fatty Liver Disease;#N/A;0.003326219;0.032767233;0.038237204;0.007391597;0.072303576;0.037248409;0.046580364;0.008295015;0.070932616;0.317672961;0.007761177;0.048729958;0.088077142;0.005305113;0.308165141;2;0.13;N;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;123;9;3;CHEMBL2047;Bile acid receptor FXR;SINGLE PROTEIN;2889;6633;9;4;Small molecule;1983
TFTX_0617;NKX2-3;ENSG00000119919;HGNC:7836;159296;Homeobox protein Nkx-2.3 (Homeobox protein NK-2 homolog C);Q8TAU0;https://jaspar.elixir.no/search?q=Q8TAU0;https://platform.opentargets.org/target/ENSG00000119919;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1523;479;207;148;1168;5_None;319;28.41;0.1;0.1;264;9.37;0.1;0.13;49;15.9;0.1;0.11;6;3.14;0.06;0.05;3;0.68;0.19;0.17;Alzheimer Disease;#N/A;#N/A;0.333648251;#N/A;#N/A;0.00870657;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.333648251;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0430;IRF5;ENSG00000128604;HGNC:6120;3663;Interferon regulatory factor 5 (IRF-5);Q13568;https://jaspar.elixir.no/search?q=Q13568;https://platform.opentargets.org/target/ENSG00000128604;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;757;171;208;466;83;5_None;415;28.29;0.13;0.1;362;6.35;0.14;0.09;47;18.56;0.1;0.12;6;3.37;0.06;0.06;10;0.19;0.63;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004927206;0.035646104;#N/A;0.041906671;0.00526138;0.006464555;0.006220735;0.033543195;0.002587059;0.007391597;#N/A;#N/A;#N/A;0.049346811;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0093;CDX2;ENSG00000165556;HGNC:1806;1045;Homeobox protein CDX-2 (CDX-3) (Caudal-type homeobox protein 2);Q99626;https://jaspar.elixir.no/search?q=Q99626;https://platform.opentargets.org/target/ENSG00000165556;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1093;306;209;446;438;4_Low;604;28.25;0.19;0.1;554;13.36;0.22;0.18;48;13.86;0.1;0.09;2;1.03;0.02;0.02;10;0.21;0.63;0.05;Cancer;#N/A;#N/A;0.008818586;#N/A;0.002217479;0.105555446;0.004681345;#N/A;#N/A;0.027669828;#N/A;0.002217479;0.041663011;0.001478319;0.002217479;0.013461536;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0200;EN1;ENSG00000163064;HGNC:3342;2019;Homeobox protein engrailed-1 (Homeobox protein en-1) (Hu-En-1);Q05925;https://jaspar.elixir.no/search?q=Q05925;https://platform.opentargets.org/target/ENSG00000163064;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1269;372;210;621;438;3_Medium to Low;418;28;0.13;0.1;367;12.29;0.14;0.17;48;14.07;0.1;0.09;3;1.63;0.03;0.03;5;0.12;0.31;0.03;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.044745598;#N/A;#N/A;#N/A;#N/A;#N/A;0.004013479;0.016980141;0.042686852;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;33;33;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0676;PAX2;ENSG00000075891;HGNC:8616;5076;Paired box protein Pax-2;Q02962;https://jaspar.elixir.no/search?q=Q02962;https://platform.opentargets.org/target/ENSG00000075891;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.2 PD;2202;796;211;823;1168;4_Low;614;27.94;0.2;0.1;580;15.5;0.23;0.21;31;10.19;0.06;0.07;3;2.25;0.03;0.04;6;0.06;0.38;0.02;Cancer;0.007391597;#N/A;0.001478319;0.002217479;0.002217479;0.043877428;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002936107;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0259;FOXG1;ENSG00000176165;HGNC:3811;2290;Forkhead box protein G1 (Brain factor 1) (BF-1) (BF1) (Brain factor 2) (BF-2) (BF2) (hBF-2) (Forkhead box protein G1A) (Forkhead box protein G1B) (Forkhead box protein G1C) (Forkhead-related protein FKHL1) (HFK1) (Forkhead-related protein FKHL2) (HFK2) (Forkhead-related protein FKHL3) (HFK3);P55316;https://jaspar.elixir.no/search?q=P55316;https://platform.opentargets.org/target/ENSG00000176165;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;809;197;212;159;438;3_Medium to Low;305;27.87;0.1;0.1;234;3.88;0.09;0.05;66;21;0.14;0.14;5;2.99;0.05;0.05;5;0.65;0.31;0.16;Alzheimer Disease;0.005707956;#N/A;0.325204667;#N/A;#N/A;0.031201611;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.029196809;#N/A;#N/A;0.254612208;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0819;SIX3;ENSG00000138083;HGNC:10889;6496;Homeobox protein SIX3 (Sine oculis homeobox homolog 3);O95343;#N/A;https://platform.opentargets.org/target/ENSG00000138083;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;1539;486;213;158;1168;5_None;191;27.86;0.06;0.1;116;2.41;0.05;0.03;70;22.41;0.15;0.15;5;3.05;0.05;0.05;4;0.65;0.25;0.16;Type 2 Diabetes Mellitus;#N/A;#N/A;0.212913823;#N/A;#N/A;0.05440047;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.378589114;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0470;KLF5;ENSG00000102554;HGNC:6349;688;Krueppel-like factor 5 (Basic transcription element-binding protein 2) (BTE-binding protein 2) (Colon krueppel-like factor) (GC-box-binding protein 2) (Intestinal-enriched krueppel-like factor) (Transcription factor BTEB2);Q13887;https://jaspar.elixir.no/search?q=Q13887;https://platform.opentargets.org/target/ENSG00000102554;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;601;122;214;304;83;2_Medium;400;27.67;0.13;0.1;344;8.68;0.13;0.12;52;16.92;0.11;0.11;4;2.08;0.04;0.04;13;0.38;0.81;0.1;Chronic Obstructive Pulmonary Disease;#N/A;0.002217479;0.077984827;0.021710881;#N/A;0.065308889;0.078304383;0.025839792;0.020396291;0.01884694;0.003695799;0.014634336;0.02660975;#N/A;0.012311732;0.012556886;3;0.2;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;8;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0647;NR2F2;ENSG00000185551;HGNC:7976;7026;COUP transcription factor 2 (COUP-TF2) (Apolipoprotein A-I regulatory protein 1) (ARP-1) (COUP transcription factor II) (COUP-TF II) (Nuclear receptor subfamily 2 group F member 2);P24468;https://jaspar.elixir.no/search?q=P24468;https://platform.opentargets.org/target/ENSG00000185551;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;467;90;215;70;182;4_Low;419;27.39;0.13;0.1;369;10.92;0.14;0.15;47;14.59;0.1;0.1;3;1.87;0.03;0.03;10;0.99;0.63;0.25;Parkinson Disease;#N/A;#N/A;0.306126089;0.019163604;0.196800673;0.04961486;0.001478319;0.039532314;#N/A;0.024701691;0.019033363;#N/A;#N/A;0.323542539;#N/A;0.009863265;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0910;TBX4;ENSG00000121075;HGNC:11603;9496;T-box transcription factor TBX4 (T-box protein 4);P57082;https://jaspar.elixir.no/search?q=P57082;https://platform.opentargets.org/target/ENSG00000121075;6 Immunoglobulin fold;6.5 T-Box factors;6.5.4 TBX2-related;2263;821;216;879;1168;5_None;464;27.08;0.15;0.1;435;16.48;0.17;0.22;26;8.75;0.05;0.06;3;1.85;0.03;0.03;7;0.05;0.44;0.01;Alzheimer Disease;#N/A;#N/A;0.024045205;#N/A;0.005174118;0.009426102;0.002843712;0.001478319;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0370;HNF4G;ENSG00000164749;HGNC:5026;3174;Hepatocyte nuclear factor 4-gamma (HNF-4-gamma) (Nuclear receptor subfamily 2 group A member 2);Q14541;https://jaspar.elixir.no/search?q=Q14541;https://platform.opentargets.org/target/ENSG00000164749;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;498;96;217;99;182;5_None;132;26.94;0.04;0.1;59;1.82;0.02;0.02;65;20.85;0.14;0.14;8;4.27;0.08;0.07;5;0.87;0.31;0.22;Alzheimer Disease;#N/A;#N/A;0.313722069;#N/A;#N/A;0.225894131;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.3113198;#N/A;0.015816241;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0890;STAT4;ENSG00000138378;HGNC:11365;6775;Signal transducer and activator of transcription 4;Q14765;#N/A;https://platform.opentargets.org/target/ENSG00000138378;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;509;98;218;109;182;4_Low;610;26.81;0.2;0.1;563;11.31;0.22;0.15;44;13.69;0.09;0.09;3;1.81;0.03;0.03;14;0.81;0.88;0.21;Alzheimer Disease;#N/A;0.074285551;0.381203746;0.082550332;#N/A;0.028893056;0.069866926;0.016184095;0.008528671;0.013217613;0.003156828;0.013304875;0.041741991;0.006436849;0.003695799;0.069430187;2;0.13;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0272;FOXN1;ENSG00000109101;HGNC:12765;8456;Forkhead box protein N1 (Winged-helix transcription factor nude);O15353;#N/A;https://platform.opentargets.org/target/ENSG00000109101;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1010;274;219;708;83;5_None;605;26.69;0.19;0.1;591;20.65;0.23;0.28;9;2.73;0.02;0.02;5;3.31;0.05;0.06;7;0.09;0.44;0.02;Osteoporosis;#N/A;#N/A;#N/A;0.004804538;#N/A;0.011288055;0.003695799;#N/A;#N/A;0.003695799;#N/A;#N/A;0.048969331;#N/A;0.002217479;0.015337564;3;0.2;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1034;ZBTB20;ENSG00000181722;HGNC:13503;26137;Zinc finger and BTB domain-containing protein 20 (Dendritic-derived BTB/POZ zinc finger protein) (Zinc finger protein 288);Q9HC78;#N/A;https://platform.opentargets.org/target/ENSG00000181722;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;637;132;220;235;182;5_None;274;26.33;0.09;0.1;209;4.86;0.08;0.07;61;19.08;0.13;0.13;4;2.39;0.04;0.04;9;0.5;0.56;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.037635574;0.007761177;#N/A;0.036811456;#N/A;0.002771849;0.004250168;0.033262187;0.006098068;#N/A;0.001478319;#N/A;#N/A;0.373798704;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0559;MYCL;ENSG00000116990;HGNC:7555;4610;Protein L-Myc (Class E basic helix-loop-helix protein 38) (bHLHe38) (Protein L-Myc-1) (V-myc myelocytomatosis viral oncogene homolog);P12524;#N/A;https://platform.opentargets.org/target/ENSG00000116990;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;937;247;221;633;83;5_None;276;26.22;0.09;0.1;224;10.91;0.09;0.15;51;14.78;0.11;0.1;1;0.53;0.01;0.01;7;0.11;0.44;0.03;Cancer;#N/A;#N/A;0.011826555;#N/A;#N/A;0.073349102;#N/A;0.001847899;#N/A;#N/A;0.001478319;0.001478319;#N/A;0.003695799;#N/A;0.020592258;3;0.2;Y;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;Anti-Longevity;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0787;RORC;ENSG00000143365;HGNC:10260;6097;Nuclear receptor ROR-gamma (Nuclear receptor RZR-gamma) (Nuclear receptor subfamily 1 group F member 3) (RAR-related orphan receptor C) (Retinoid-related orphan receptor-gamma);P51449;https://jaspar.elixir.no/search?q=P51449;https://platform.opentargets.org/target/ENSG00000143365;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;1114;319;222;454;438;2_Medium;635;26.09;0.2;0.1;609;17.41;0.24;0.24;25;8;0.05;0.05;1;0.67;0.01;0.01;10;0.2;0.63;0.05;Cancer;#N/A;#N/A;0.021190923;0.010604889;0.004876401;0.090929307;0.031642811;#N/A;#N/A;#N/A;0.004065378;#N/A;0.002587059;0.011036065;0.001847899;0.024789134;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;99;1;#N/A;CHEMBL1741186;Nuclear receptor ROR-gamma;SINGLE PROTEIN;4371;8867;1;1;Small molecule;#N/A
TFTX_1069;ZFAT;ENSG00000066827;HGNC:19899;57623;Zinc finger protein ZFAT (Zinc finger gene in AITD susceptibility region) (Zinc finger protein 406);Q9P243;#N/A;https://platform.opentargets.org/target/ENSG00000066827;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1804;605;223;1143;438;5_None;111;25.98;0.04;0.1;53;2.19;0.02;0.03;46;15.61;0.1;0.1;12;8.18;0.12;0.14;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.00653951;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.006837227;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0758;RARG;ENSG00000172819;HGNC:9866;5916;Retinoic acid receptor gamma (RAR-gamma) (Nuclear receptor subfamily 1 group B member 3);P13631;https://jaspar.elixir.no/search?q=P13631;https://platform.opentargets.org/target/ENSG00000172819;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;943;250;224;281;438;1_High;347;25.88;0.11;0.1;307;11.27;0.12;0.15;34;11.21;0.07;0.07;6;3.4;0.06;0.06;8;0.42;0.5;0.11;Alzheimer Disease;#N/A;0.004434958;0.186429316;#N/A;#N/A;0.034040236;0.002751317;#N/A;#N/A;#N/A;0.003695799;0.021435632;0.005728488;0.165537789;#N/A;#N/A;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;38;11;5;"CHEMBL2003;CHEMBL2363069;CHEMBL2363071";"Retinoic acid receptor gamma;Retinoic acid receptor;Retinoid receptor";"SINGLE PROTEIN;PROTEIN FAMILY;PROTEIN FAMILY";"653;29;1";"1164;39;1";"2;5;4";"4;4;4";"Small molecule;Small molecule;Small molecule";"2019;1971;1986"
TFTX_0683;PAX9;ENSG00000198807;HGNC:8623;5083;Paired box protein Pax-9;P55771;https://jaspar.elixir.no/search?q=P55771;https://platform.opentargets.org/target/ENSG00000198807;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.2 PD;1650;531;225;257;1168;5_None;514;25.78;0.17;0.1;499;19.76;0.2;0.27;14;5.26;0.03;0.04;1;0.76;0.01;0.01;4;0.46;0.25;0.12;Osteoarthritis;#N/A;#N/A;#N/A;0.008869917;#N/A;0.044260171;0.004322031;#N/A;#N/A;#N/A;#N/A;0.402799037;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0288;GABPA;ENSG00000154727;HGNC:4071;2551;GA-binding protein alpha chain (GABP subunit alpha) (Nuclear respiratory factor 2 subunit alpha) (Transcription factor E4TF1-60);Q06546;https://jaspar.elixir.no/search?q=Q06546;https://platform.opentargets.org/target/ENSG00000154727;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;451;84;226;43;182;4_Low;1363;25.74;0.44;0.09;1363;25.74;0.53;0.35;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;16;1.18;1;0.3;Alzheimer Disease;0.01526837;0.045087693;0.157031087;0.086813029;0.045025257;0.120303141;0.116160503;0.03970902;0.100713102;0.087220455;0.063805076;0.019993685;0.037821074;0.115589082;0.032478864;0.096413012;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;69;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0786;RORB;ENSG00000198963;HGNC:10259;6096;Nuclear receptor ROR-beta (Nuclear receptor RZR-beta) (Nuclear receptor subfamily 1 group F member 2) (Retinoid-related orphan receptor-beta);Q92753;https://jaspar.elixir.no/search?q=Q92753;https://platform.opentargets.org/target/ENSG00000198963;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;841;211;227;176;438;4_Low;403;25.63;0.13;0.09;351;6.96;0.14;0.09;49;16.87;0.1;0.11;3;1.8;0.03;0.03;11;0.6;0.69;0.15;Age-Related Macular Degeneration;#N/A;0.461414976;0.036940337;0.013604758;#N/A;0.048477002;0.007391597;#N/A;#N/A;0.004989328;0.002012157;0.003326219;0.011470617;0.004506821;#N/A;0.007155053;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0498;LMX1B;ENSG00000136944;HGNC:6654;4010;LIM homeobox transcription factor 1-beta (LIM/homeobox protein 1.2) (LMX-1.2) (LIM/homeobox protein LMX1B);O60663;https://jaspar.elixir.no/search?q=O60663;https://platform.opentargets.org/target/ENSG00000136944;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;959;258;228;293;438;5_None;326;25.62;0.1;0.09;285;9.21;0.11;0.12;33;11.51;0.07;0.08;8;4.91;0.08;0.09;5;0.4;0.31;0.1;Osteoarthritis;#N/A;#N/A;0.014783194;#N/A;#N/A;0.014279571;#N/A;#N/A;#N/A;#N/A;#N/A;0.352362926;0.001478319;0.020593719;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0140;DDIT3;ENSG00000175197;HGNC:2726;1649;DNA damage-inducible transcript 3 protein (DDIT-3) (C/EBP zeta) (C/EBP-homologous protein) (CHOP) (C/EBP-homologous protein 10) (CHOP-10) (CCAAT/enhancer-binding protein homologous protein) (Growth arrest and DNA damage-inducible protein GADD153);P35638;#N/A;https://platform.opentargets.org/target/ENSG00000175197;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;702;152;229;291;182;4_Low;778;25.61;0.25;0.09;737;13.21;0.29;0.18;41;12.4;0.09;0.08;#N/A;#N/A;#N/A;#N/A;14;0.41;0.88;0.1;Alzheimer Disease;#N/A;0.005228118;0.074392636;0.025460476;0.011087396;0.063971111;0.058507743;0.023776517;0.012380596;0.014138641;0.016013184;0.014026472;0.008431143;0.030811436;#N/A;0.049797968;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;putative;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;7;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;46;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0588;NFAT5;ENSG00000102908;HGNC:7774;10725;Nuclear factor of activated T-cells 5 (NF-AT5) (T-cell transcription factor NFAT5) (Tonicity-responsive enhancer-binding protein) (TonE-binding protein) (TonEBP);O94916;https://jaspar.elixir.no/search?q=O94916;https://platform.opentargets.org/target/ENSG00000102908;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.3 NFAT-related;775;185;230;107;438;5_None;496;25.61;0.16;0.09;462;15.13;0.18;0.21;34;10.48;0.07;0.07;#N/A;#N/A;#N/A;#N/A;13;0.82;0.81;0.21;Type 2 Diabetes Mellitus;#N/A;0.002587059;0.160808975;0.060476768;#N/A;0.047592927;0.015891934;0.100884289;0.028088069;0.001847899;0.003695799;0.012925838;0.003326219;0.014708868;#N/A;0.365171094;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0722;POU5F1;ENSG00000204531;HGNC:9221;5460;POU domain, class 5, transcription factor 1 (Octamer-binding protein 3) (Oct-3) (Octamer-binding protein 4) (Oct-4) (Octamer-binding transcription factor 3) (OTF-3);Q01860;https://jaspar.elixir.no/search?q=Q01860;https://platform.opentargets.org/target/ENSG00000204531;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;663;143;231;349;83;4_Low;680;25.43;0.22;0.09;636;12.41;0.25;0.17;43;12.48;0.09;0.08;1;0.55;0.01;0.01;12;0.32;0.75;0.08;Cancer;#N/A;0.00580035;0.021216523;0.018926046;0.020257698;0.117275332;0.008079426;0.002217479;0.001478319;0.081775712;#N/A;#N/A;0.003695799;0.011062982;#N/A;0.027760909;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;10;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0771;REST;ENSG00000084093;HGNC:9966;5978;RE1-silencing transcription factor (Neural-restrictive silencer factor) (X2 box repressor);Q13127;https://jaspar.elixir.no/search?q=Q13127;https://platform.opentargets.org/target/ENSG00000084093;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;435;78;232;151;52;5_None;425;25.37;0.14;0.09;381;9.03;0.15;0.12;39;13.46;0.08;0.09;5;2.88;0.05;0.05;10;0.67;0.63;0.17;Myocardial Infarction;0.001478319;0.019350585;0.097879077;0.001478319;#N/A;0.0518418;#N/A;0.008182087;0.005982677;0.420734226;#N/A;#N/A;#N/A;0.061698962;#N/A;0.004619748;4;0.27;Y;Unclear;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0396;HOXC13;ENSG00000123364;HGNC:5125;3229;Homeobox protein Hox-C13 (Homeobox protein Hox-3G);P31276;https://jaspar.elixir.no/search?q=P31276;https://platform.opentargets.org/target/ENSG00000123364;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1579;503;233;908;438;4_Low;279;25.32;0.09;0.09;232;11.82;0.09;0.16;46;12.77;0.1;0.09;1;0.73;0.01;0.01;4;0.04;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.034714164;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0382;HOXA9;ENSG00000078399;HGNC:5109;3205;Homeobox protein Hox-A9 (Homeobox protein Hox-1G);P31269;https://jaspar.elixir.no/search?q=P31269;https://platform.opentargets.org/target/ENSG00000078399;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1005;271;234;589;182;4_Low;328;25.31;0.11;0.09;271;8.25;0.11;0.11;57;17.05;0.12;0.11;#N/A;#N/A;#N/A;#N/A;5;0.13;0.31;0.03;Cancer;#N/A;#N/A;#N/A;0.006495982;#N/A;0.094952307;0.023324595;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0293;GATA5;ENSG00000130700;HGNC:15802;140628;Transcription factor GATA-5 (GATA-binding factor 5);Q9BWX5;https://jaspar.elixir.no/search?q=Q9BWX5;https://platform.opentargets.org/target/ENSG00000130700;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;943;250;235;270;438;5_None;403;25.23;0.13;0.09;373;13.4;0.15;0.18;27;9.84;0.06;0.07;3;2;0.03;0.03;5;0.44;0.31;0.11;Benign Prostatic Hyperplasia;#N/A;0.009116303;#N/A;0.002217479;0.410954499;0.020155381;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0767;RELA;ENSG00000173039;HGNC:9955;5970;Transcription factor p65 (Nuclear factor NF-kappa-B p65 subunit) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3);Q04206;https://jaspar.elixir.no/search?q=Q04206;https://platform.opentargets.org/target/ENSG00000173039;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.1 NFkappaB-related;308;48;236;41;31;2_Medium;1129;25.22;0.36;0.09;1112;19.37;0.44;0.26;16;5.25;0.03;0.04;1;0.6;0.01;0.01;15;1.2;0.94;0.31;Alzheimer Disease;#N/A;0.022574768;0.392667316;0.016511981;0.027081716;0.095756529;0.089718484;0.011107703;0.013720832;0.023220515;0.040159759;0.026813465;0.0148486;0.37582204;0.005756822;0.045962073;5;0.33;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;functional;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;17;#N/A;#N/A;#N/A;1;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;54;1;#N/A;CHEMBL2094258;Nuclear factor NF-kappa-B complex;PROTEIN COMPLEX GROUP;1908;2351;1;3;Small molecule;#N/A
TFTX_0405;HOXD12;ENSG00000170178;HGNC:5135;3238;Homeobox protein Hox-D12 (Homeobox protein Hox-4H);P35452;https://jaspar.elixir.no/search?q=P35452;https://platform.opentargets.org/target/ENSG00000170178;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2657;1020;237;1252;1168;5_None;499;25.16;0.16;0.09;489;21.84;0.19;0.3;10;3.33;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005967277;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1245;ZNF331;ENSG00000130844;HGNC:15489;55422;Zinc finger protein 331 (C2H2-like zinc finger protein rearranged in thyroid adenomas) (Zinc finger protein 361) (Zinc finger protein 463);Q9NQX6;https://jaspar.elixir.no/search?q=Q9NQX6;https://platform.opentargets.org/target/ENSG00000130844;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1731;575;238;1055;438;5_None;147;25.13;0.05;0.09;86;7.35;0.03;0.1;61;17.78;0.13;0.12;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.004250168;#N/A;#N/A;0.014100706;#N/A;#N/A;#N/A;#N/A;#N/A;0.00322294;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0544;MSX2;ENSG00000120149;HGNC:7392;4488;Homeobox protein MSX-2 (Homeobox protein Hox-8);P35548;https://jaspar.elixir.no/search?q=P35548;https://platform.opentargets.org/target/ENSG00000120149;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1114;319;239;437;438;5_None;771;24.9;0.25;0.09;748;15.71;0.29;0.21;17;5.23;0.04;0.03;6;3.96;0.06;0.07;13;0.22;0.81;0.06;Type 2 Diabetes Mellitus;#N/A;0.002217479;0.049755508;0.023681445;0.003695799;0.016077721;#N/A;0.010409833;0.002843712;0.005543698;#N/A;0.012950694;0.004003256;0.011056597;0.001478319;0.076690648;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0079;BPTF;ENSG00000171634;HGNC:3581;2186;Nucleosome-remodeling factor subunit BPTF (Bromodomain and PHD finger-containing transcription factor) (Fetal Alz-50 clone 1 protein) (Fetal Alzheimer antigen);Q12830;#N/A;https://platform.opentargets.org/target/ENSG00000171634;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1527;480;240;119;1168;4_Low;206;24.6;0.07;0.09;151;7.27;0.06;0.1;49;13.98;0.1;0.09;6;3.34;0.06;0.06;6;0.76;0.38;0.19;Type 2 Diabetes Mellitus;#N/A;#N/A;0.018631589;#N/A;#N/A;0.062585544;0.02660975;0.170534913;#N/A;#N/A;0.154195843;#N/A;#N/A;#N/A;#N/A;0.324721026;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0035;ARX;ENSG00000004848;HGNC:18060;170302;Homeobox protein ARX (Aristaless-related homeobox);Q96QS3;#N/A;https://platform.opentargets.org/target/ENSG00000004848;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;706;153;241;283;182;5_None;386;24.55;0.12;0.09;359;11.25;0.14;0.15;15;4.73;0.03;0.03;12;8.56;0.12;0.15;4;0.42;0.25;0.11;Osteoarthritis;#N/A;#N/A;0.003695799;#N/A;#N/A;0.003511009;#N/A;#N/A;#N/A;#N/A;#N/A;0.406627495;#N/A;#N/A;#N/A;0.006752635;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1012;XPA;ENSG00000136936;HGNC:12814;7507;DNA repair protein complementing XP-A cells (Xeroderma pigmentosum group A-complementing protein);P23025;#N/A;https://platform.opentargets.org/target/ENSG00000136936;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;839;210;242;514;83;4_Low;313;24.13;0.1;0.09;273;10.4;0.11;0.14;34;9.95;0.07;0.07;6;3.78;0.06;0.07;6;0.16;0.38;0.04;Cancer;#N/A;#N/A;0.020326892;#N/A;#N/A;0.113490791;0.021805211;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0.003695799;#N/A;0.003695799;3;0.2;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;functional,putative;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0917;TCF21;ENSG00000118526;HGNC:11632;6943;Transcription factor 21 (TCF-21) (Capsulin) (Class A basic helix-loop-helix protein 23) (bHLHa23) (Epicardin) (Podocyte-expressed 1) (Pod-1);O43680;https://jaspar.elixir.no/search?q=O43680;https://platform.opentargets.org/target/ENSG00000118526;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;855;216;243;174;438;5_None;304;24.09;0.1;0.09;247;6.02;0.1;0.08;55;17.06;0.11;0.11;2;1.01;0.02;0.02;6;0.6;0.38;0.15;Myocardial Infarction;#N/A;#N/A;#N/A;0.05033769;#N/A;0.037784335;0.008130757;0.001478319;#N/A;0.466366639;#N/A;#N/A;#N/A;#N/A;#N/A;0.040800179;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0768;RELB;ENSG00000104856;HGNC:9956;5971;Transcription factor RelB (I-Rel);Q01201;https://jaspar.elixir.no/search?q=Q01201;https://platform.opentargets.org/target/ENSG00000104856;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.1 NFkappaB-related;852;215;244;426;182;5_None;720;24.04;0.23;0.09;716;22.55;0.28;0.31;3;0.95;0.01;0.01;1;0.55;0.01;0.01;11;0.23;0.69;0.06;Chronic Obstructive Pulmonary Disease;#N/A;0.003695799;0.010123293;0.00495853;0.001478319;0.090302624;0.092942443;0.007925435;#N/A;0.005697689;0.004876401;#N/A;0.002587059;#N/A;#N/A;0.006706437;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0871;SP6;ENSG00000189120;HGNC:14530;80320;Transcription factor Sp6 (Krueppel-like factor 14);Q3SY56;#N/A;https://platform.opentargets.org/target/ENSG00000189120;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1099;308;245;672;182;5_None;598;24.01;0.19;0.09;591;21.53;0.23;0.29;6;1.92;0.01;0.01;1;0.55;0.01;0.01;10;0.1;0.63;0.03;Cancer;#N/A;#N/A;0.013890043;0.011539104;#N/A;0.039101138;0.001478319;#N/A;0.003695799;0.002217479;0.007391597;0.003003777;0.002217479;#N/A;#N/A;0.014565142;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0723;POU5F1B;ENSG00000212993;HGNC:9223;5462;Putative POU domain, class 5, transcription factor 1B (Oct4-pg1) (Octamer-binding protein 3-like) (Octamer-binding transcription factor 3-like);Q06416;https://jaspar.elixir.no/search?q=Q06416;https://platform.opentargets.org/target/ENSG00000212993;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;714;154;246;30;438;5_None;109;23.84;0.04;0.09;44;1.82;0.02;0.02;61;19.78;0.13;0.13;4;2.24;0.04;0.04;4;1.36;0.25;0.35;Cancer;#N/A;#N/A;0.17307739;#N/A;0.396450147;0.543770531;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.245846688;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0013;AIRE;ENSG00000160224;HGNC:360;326;Autoimmune regulator (Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy protein) (APECED protein);O43918;#N/A;https://platform.opentargets.org/target/ENSG00000160224;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.1 AIRE;2050;715;247;635;1168;3_Medium to Low;561;23.82;0.18;0.09;543;15.79;0.21;0.21;14;5.24;0.03;0.03;4;2.78;0.04;0.05;5;0.11;0.31;0.03;Age-Related Macular Degeneration;#N/A;0.042442551;0.009226264;0.016774819;#N/A;0.038209722;#N/A;#N/A;#N/A;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;20;20;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0278;FOXO4;ENSG00000184481;HGNC:7139;4303;Forkhead box protein O4 (Fork head domain transcription factor AFX1);P98177;https://jaspar.elixir.no/search?q=P98177;https://platform.opentargets.org/target/ENSG00000184481;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;768;181;248;516;4;5_None;336;23.7;0.11;0.09;294;11.67;0.12;0.16;42;12.03;0.09;0.08;#N/A;#N/A;#N/A;#N/A;9;0.16;0.56;0.04;Cancer;#N/A;#N/A;0.01399024;0.025831566;#N/A;0.049522821;0.007945967;#N/A;#N/A;0.042375398;#N/A;0.001478319;0.007186275;#N/A;0.006098068;0.009311359;11;0.73;Y;Pro-Longevity;Pro-Longevity;Unclear;#N/A;#N/A;Pro-Longevity;Unclear;model;Pro-Longevity;Pro-Longevity;#N/A;Induces;1;Anti-Longevity;4;Pro-Longevity;Unclear;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0987;TRAFD1;ENSG00000135148;HGNC:24808;10906;TRAF-type zinc finger domain-containing protein 1 (Protein FLN29);O14545;#N/A;https://platform.opentargets.org/target/ENSG00000135148;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;738;159;249;51;438;5_None;168;23.63;0.05;0.09;118;5.86;0.05;0.08;50;17.77;0.1;0.12;#N/A;#N/A;#N/A;#N/A;7;1.11;0.44;0.28;Ischemic Stroke;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0.340921909;#N/A;0.41787206;0.309081917;#N/A;0.001478319;0.036595797;#N/A;#N/A;0.004619748;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0420;IKZF2;ENSG00000030419;HGNC:13177;22807;Zinc finger protein Helios (Ikaros family zinc finger protein 2);Q9UKS7;https://jaspar.elixir.no/search?q=Q9UKS7;https://platform.opentargets.org/target/ENSG00000030419;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;790;191;250;102;438;5_None;322;23.47;0.1;0.09;269;6.21;0.11;0.08;50;15.67;0.1;0.1;3;1.59;0.03;0.03;6;0.84;0.38;0.21;Parkinson Disease;#N/A;#N/A;0.279725671;0.001478319;#N/A;0.026868984;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;0.279753903;#N/A;0.247395265;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0240;FOXA2;ENSG00000125798;HGNC:5022;3170;Hepatocyte nuclear factor 3-beta (HNF-3-beta) (HNF-3B) (Forkhead box protein A2) (Transcription factor 3B) (TCF-3B);Q9Y261;https://jaspar.elixir.no/search?q=Q9Y261;https://platform.opentargets.org/target/ENSG00000125798;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;415;73;251;112;52;5_None;371;23.46;0.12;0.09;326;7.16;0.13;0.1;41;14.16;0.09;0.09;4;2.14;0.04;0.04;10;0.79;0.63;0.2;Type 2 Diabetes Mellitus;#N/A;0.002217479;0.022594986;0.004065378;#N/A;0.047641152;0.082543679;#N/A;#N/A;#N/A;0.088840219;0.219904909;0.002936107;0.042764587;#N/A;0.278477177;4;0.27;Y;#N/A;Pro-Longevity;Unclear;#N/A;Unclear;#N/A;#N/A;#N/A;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0593;NFE2;ENSG00000123405;HGNC:7780;4778;Transcription factor NF-E2 45 kDa subunit (Leucine zipper protein NF-E2) (Nuclear factor, erythroid-derived 2 45 kDa subunit) (p45 NF-E2);Q16621;https://jaspar.elixir.no/search?q=Q16621;https://platform.opentargets.org/target/ENSG00000123405;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;1330;395;252;896;182;4_Low;317;23.43;0.1;0.09;275;6.51;0.11;0.09;33;12.12;0.07;0.08;9;4.79;0.09;0.08;9;0.05;0.56;0.01;Cancer;#N/A;#N/A;0.005605294;0.004565954;0.001478319;0.009854512;#N/A;#N/A;#N/A;0.003695799;0.003087634;0.005824369;#N/A;0.007761177;#N/A;0.004719317;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1072;ZFHX4;ENSG00000091656;HGNC:30939;79776;Zinc finger homeobox protein 4 (Zinc finger homeodomain protein 4) (ZFH-4);Q86UP3;#N/A;https://platform.opentargets.org/target/ENSG00000091656;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;767;178;253;332;182;5_None;227;23.3;0.07;0.09;172;4.69;0.07;0.06;53;17.53;0.11;0.12;2;1.08;0.02;0.02;3;0.34;0.19;0.09;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.338588763;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0755;RAG1;ENSG00000166349;HGNC:9831;5896;"V(D)J recombination-activating protein 1 (RAG-1) (RING finger protein 74) [Includes: Endonuclease RAG1 (EC 3.1.-.-); E3 ubiquitin-protein ligase RAG1 (EC 2.3.2.27) (RING-type E3 ubiquitin transferase RAG1)]";P15918;#N/A;https://platform.opentargets.org/target/ENSG00000166349;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2184;785;254;762;1168;5_None;616;23.29;0.2;0.09;598;14.25;0.23;0.19;10;3.51;0.02;0.02;8;5.52;0.08;0.1;9;0.08;0.56;0.02;Cancer;#N/A;#N/A;0.015789478;0.012300676;#N/A;0.020170812;0.002771849;0.002217479;0.008315547;0.006037908;#N/A;#N/A;#N/A;0.005122787;#N/A;0.004065378;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0850;SOX17;ENSG00000164736;HGNC:18122;64321;Transcription factor SOX-17;Q9H6I2;#N/A;https://platform.opentargets.org/target/ENSG00000164736;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1353;403;255;660;438;5_None;440;22.93;0.14;0.08;418;16.18;0.16;0.22;21;6.07;0.04;0.04;1;0.69;0.01;0.01;7;0.1;0.44;0.03;Cancer;#N/A;#N/A;0.004619748;0.003695799;#N/A;0.058987361;0.017041738;#N/A;0.005174118;0.009403754;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0435;IRX1;ENSG00000170549;HGNC:14358;79192;Iroquois-class homeodomain protein IRX-1 (Homeodomain protein IRXA1) (Iroquois homeobox protein 1);P78414;#N/A;https://platform.opentargets.org/target/ENSG00000170549;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;831;208;256;137;438;5_None;222;22.92;0.07;0.08;171;5.04;0.07;0.07;49;16.85;0.1;0.11;2;1.03;0.02;0.02;6;0.69;0.38;0.18;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.058504559;#N/A;0.015522354;#N/A;0.413303477;#N/A;0.003962693;#N/A;0.001478319;#N/A;0.198920234;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0564;MYOD1;ENSG00000129152;HGNC:7611;4654;Myoblast determination protein 1 (Class C basic helix-loop-helix protein 1) (bHLHc1) (Myogenic factor 3) (Myf-3);P15172;https://jaspar.elixir.no/search?q=P15172;https://platform.opentargets.org/target/ENSG00000129152;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;1275;376;257;580;438;4_Low;362;22.88;0.12;0.08;316;8.51;0.12;0.12;45;13.7;0.09;0.09;1;0.67;0.01;0.01;10;0.13;0.63;0.03;Cancer;#N/A;#N/A;0.00458895;0.001478319;0.007391597;0.049468624;0.022305629;0.010093624;#N/A;0.002751317;#N/A;#N/A;#N/A;0.008869917;0.009485886;0.016787671;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;18;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0353;HIVEP2;ENSG00000010818;HGNC:4921;3097;Transcription factor HIVEP2 (Human immunodeficiency virus type I enhancer-binding protein 2) (HIV-EP2) (MHC-binding protein 2) (MBP-2);P31629;#N/A;https://platform.opentargets.org/target/ENSG00000010818;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;952;255;258;256;438;3_Medium to Low;146;22.87;0.05;0.08;88;1.99;0.03;0.03;52;17.56;0.11;0.12;6;3.32;0.06;0.06;6;0.46;0.38;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008315547;0.003695799;#N/A;0.006578111;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.435065846;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0181;EBF2;ENSG00000221818;HGNC:19090;64641;Transcription factor COE2 (Early B-cell factor 2) (EBF-2);Q9HAK2;#N/A;https://platform.opentargets.org/target/ENSG00000221818;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.5 EBF-related;1677;547;259;250;1168;5_None;249;22.83;0.08;0.08;207;6.11;0.08;0.08;35;13.06;0.07;0.09;7;3.66;0.07;0.06;5;0.48;0.31;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004065378;#N/A;0.001478319;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;0.472300455;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0347;HIC1;ENSG00000177374;HGNC:4909;3090;Hypermethylated in cancer 1 protein (Hic-1) (Zinc finger and BTB domain-containing protein 29);Q14526;#N/A;https://platform.opentargets.org/target/ENSG00000177374;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;402;68;260;59;83;5_None;384;22.75;0.12;0.08;349;10.87;0.14;0.15;33;10.82;0.07;0.07;2;1.06;0.02;0.02;8;1.06;0.5;0.27;Alzheimer Disease;#N/A;#N/A;0.346137331;#N/A;#N/A;0.090836138;0.021330366;0.01925148;#N/A;0.074055215;#N/A;0.153983322;#N/A;0.345767751;#N/A;0.010717816;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1026;ZBTB10;ENSG00000205189;HGNC:30953;65986;Zinc finger and BTB domain-containing protein 10 (Zinc finger protein RIN ZF);Q96DT7;#N/A;https://platform.opentargets.org/target/ENSG00000205189;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2704;1047;261;1275;1168;5_None;119;22.66;0.04;0.08;56;1.95;0.02;0.03;59;18.5;0.12;0.12;4;2.2;0.04;0.04;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.006967983;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0346;HHEX;ENSG00000152804;HGNC:4901;3087;Hematopoietically-expressed homeobox protein HHEX (Homeobox protein HEX) (Homeobox protein PRH);Q03014;#N/A;https://platform.opentargets.org/target/ENSG00000152804;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;868;223;262;168;438;5_None;326;22.55;0.1;0.08;276;7.31;0.11;0.1;48;14.23;0.1;0.09;2;1.01;0.02;0.02;8;0.62;0.5;0.16;Type 2 Diabetes Mellitus;#N/A;#N/A;0.032034017;0.007391597;0.04414426;0.018959797;0.007022017;#N/A;#N/A;0.004434958;#N/A;0.001847899;#N/A;#N/A;#N/A;0.503103328;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0096;CEBPB;ENSG00000172216;HGNC:1834;1051;CCAAT/enhancer-binding protein beta (C/EBP beta) (Liver activator protein) (LAP) (Liver-enriched inhibitory protein) (LIP) (Nuclear factor NF-IL6) (Transcription factor 5) (TCF-5);P17676;https://jaspar.elixir.no/search?q=P17676;https://platform.opentargets.org/target/ENSG00000172216;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;352;56;263;80;9;3_Medium to Low;921;22.49;0.3;0.08;910;19.42;0.36;0.26;10;2.54;0.02;0.02;1;0.53;0.01;0.01;15;0.93;0.94;0.24;Type 2 Diabetes Mellitus;#N/A;0.009865729;0.114375556;0.028273524;0.011690632;0.09908044;0.052040625;0.05115719;0.015596886;0.024249142;0.043598713;0.037285564;0.011437252;0.101127958;0.013099553;0.319820504;8;0.53;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Unclear;mammal;#N/A;#N/A;Unclear;Induces;#N/A;Anti-Longevity;10;#N/A;#N/A;Anti-Longevity;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0451;KAT7;ENSG00000136504;HGNC:17016;11143;Histone acetyltransferase KAT7 (EC 2.3.1.48) (Histone acetyltransferase binding to ORC1) (Lysine acetyltransferase 7) (MOZ, YBF2/SAS3, SAS2 and TIP60 protein 2) (MYST-2);O95251;#N/A;https://platform.opentargets.org/target/ENSG00000136504;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.3 MYST;506;97;264;60;182;5_None;192;22.38;0.06;0.08;167;14.3;0.07;0.19;24;7.55;0.05;0.05;1;0.52;0.01;0.01;8;1.05;0.5;0.27;Alzheimer Disease;#N/A;0.224394574;0.37125735;#N/A;#N/A;0.039569969;0.038046193;#N/A;#N/A;0.015686612;0.003695799;0.007391597;#N/A;0.352447275;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0135;DACH1;ENSG00000276644;HGNC:2663;1602;Dachshund homolog 1 (Dach1);Q9UI36;#N/A;https://platform.opentargets.org/target/ENSG00000276644;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1222;355;265;519;438;5_None;261;22.37;0.08;0.08;212;5.58;0.08;0.08;47;15.77;0.1;0.11;2;1.03;0.02;0.02;10;0.16;0.63;0.04;Cancer;#N/A;#N/A;0.001478319;0.001478319;0.048784541;0.053517077;0.035479666;0.002587059;#N/A;0.005707956;#N/A;0.001765148;0.001478319;#N/A;#N/A;0.009637411;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0882;SREBF1;ENSG00000072310;HGNC:11289;6720;Sterol regulatory element-binding protein 1 (SREBP-1) (Class D basic helix-loop-helix protein 1) (bHLHd1) (Sterol regulatory element-binding transcription factor 1) [Cleaved into: Processed sterol regulatory element-binding protein 1 (Transcription factor SREBF1)];P36956;https://jaspar.elixir.no/search?q=P36956;https://platform.opentargets.org/target/ENSG00000072310;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;312;50;266;32;14;4_Low;545;21.99;0.18;0.08;515;11.33;0.2;0.15;27;8.82;0.06;0.06;3;1.85;0.03;0.03;16;1.31;1;0.33;Alzheimer Disease;0.001478319;0.020788867;0.37767101;0.036171846;0.005913278;0.09991299;0.056762115;0.003695799;0.007925435;0.028268406;0.045196645;0.004619748;0.003511009;0.375836032;0.002217479;0.238575451;7;0.47;Y;Unclear;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;1;Anti-Longevity;6;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0019;ALX4;ENSG00000052850;HGNC:450;60529;Homeobox protein aristaless-like 4;Q9H161;#N/A;https://platform.opentargets.org/target/ENSG00000052850;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2368;873;267;933;1168;5_None;368;21.99;0.12;0.08;341;10.84;0.13;0.15;21;7.52;0.04;0.05;6;3.63;0.06;0.06;7;0.04;0.44;0.01;Cancer;#N/A;#N/A;0.00561823;0.001847899;0.003695799;0.013531864;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;0.003582871;#N/A;#N/A;0.007645786;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0655;NR5A2;ENSG00000116833;HGNC:7984;2494;Nuclear receptor subfamily 5 group A member 2 (Alpha-1-fetoprotein transcription factor) (B1-binding factor) (hB1F) (CYP7A promoter-binding factor) (Hepatocytic transcription factor) (Liver receptor homolog 1) (LRH-1);O00482;#N/A;https://platform.opentargets.org/target/ENSG00000116833;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.5 FTZF1related(NR5A);903;232;268;453;182;4_Low;380;21.73;0.12;0.08;337;7.15;0.13;0.1;42;14.08;0.09;0.09;1;0.5;0.01;0.01;7;0.2;0.44;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.038210451;0.010705086;#N/A;0.065196766;0.005174118;#N/A;#N/A;#N/A;0.014350824;#N/A;#N/A;0.002217479;#N/A;0.067834078;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0646;NR2F1;ENSG00000175745;HGNC:7975;7025;COUP transcription factor 1 (COUP-TF1) (COUP transcription factor I) (COUP-TF I) (Nuclear receptor subfamily 2 group F member 1) (V-erbA-related protein 3) (EAR-3);P10589;https://jaspar.elixir.no/search?q=P10589;https://platform.opentargets.org/target/ENSG00000175745;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;837;209;269;386;182;5_None;240;21.67;0.08;0.08;197;4.93;0.08;0.07;35;12.28;0.07;0.08;8;4.46;0.08;0.08;4;0.27;0.25;0.07;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.158216306;0.09052634;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.018109413;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0900;TBX1;ENSG00000184058;HGNC:11592;6899;T-box transcription factor TBX1 (T-box protein 1) (Testis-specific T-box protein);O43435;https://jaspar.elixir.no/search?q=O43435;https://platform.opentargets.org/target/ENSG00000184058;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;2041;713;270;603;1168;5_None;624;21.53;0.2;0.08;603;13.1;0.24;0.18;19;7;0.04;0.05;2;1.43;0.02;0.02;8;0.12;0.5;0.03;Cancer;#N/A;#N/A;0.004414426;0.004250168;#N/A;0.056424338;0.002956639;0.004434958;#N/A;0.009403754;#N/A;#N/A;0.001478319;#N/A;#N/A;0.040099414;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1589;ZNF831;ENSG00000124203;HGNC:16167;128611;Zinc finger protein 831;Q5JPB2;#N/A;https://platform.opentargets.org/target/ENSG00000124203;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1786;600;271;347;1168;5_None;121;21.42;0.04;0.08;69;2.83;0.03;0.04;51;18.07;0.11;0.12;1;0.52;0.01;0.01;2;0.32;0.13;0.08;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.028065882;0.294208648;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1483;ZNF682;ENSG00000197124;HGNC:28857;91120;Zinc finger protein 682;O95780;https://jaspar.elixir.no/search?q=O95780;https://platform.opentargets.org/target/ENSG00000197124;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2909;1164;272;1469;1168;5_None;95;21.42;0.03;0.08;35;1.35;0.01;0.02;60;20.07;0.12;0.13;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0993;TSHZ3;ENSG00000121297;HGNC:30700;57616;Teashirt homolog 3 (Zinc finger protein 537);Q63HK5;#N/A;https://platform.opentargets.org/target/ENSG00000121297;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1508;471;273;67;1168;5_None;151;21.35;0.05;0.08;99;2.34;0.04;0.03;48;16.96;0.1;0.11;4;2.05;0.04;0.04;4;1;0.25;0.25;Benign Prostatic Hyperplasia;#N/A;#N/A;0.023573651;#N/A;0.493574819;0.020691339;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.464224898;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0185;EGR1;ENSG00000120738;HGNC:3238;1958;Early growth response protein 1 (EGR-1) (AT225) (Nerve growth factor-induced protein A) (NGFI-A) (Transcription factor ETR103) (Transcription factor Zif268) (Zinc finger protein 225) (Zinc finger protein Krox-24);P18146;https://jaspar.elixir.no/search?q=P18146;https://platform.opentargets.org/target/ENSG00000120738;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;455;87;274;129;52;2_Medium;873;21.31;0.28;0.08;869;19.95;0.34;0.27;4;1.36;0.01;0.01;#N/A;#N/A;#N/A;#N/A;15;0.72;0.94;0.18;Type 2 Diabetes Mellitus;#N/A;0.005174118;0.093965631;0.037343936;0.012781303;0.096294753;0.065404271;0.008987656;0.0084501;0.028249632;0.088287473;0.030304644;0.01951587;0.049525077;0.003490476;0.172942098;4;0.27;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Unclear;upstream;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;2;1;#N/A;CHEMBL3616355;Early growth response protein 1;SINGLE PROTEIN;1;24;1;2;Unknown;#N/A
TFTX_0978;TLX1;ENSG00000107807;HGNC:5056;3195;T-cell leukemia homeobox protein 1 (Homeobox protein Hox-11) (Proto-oncogene TCL-3) (T-cell leukemia/lymphoma protein 3);P31314;https://jaspar.elixir.no/search?q=P31314;https://platform.opentargets.org/target/ENSG00000107807;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1763;589;275;1050;438;3_Medium to Low;224;21.25;0.07;0.08;184;9.53;0.07;0.13;40;11.72;0.08;0.08;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.018347492;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0186;EGR2;ENSG00000122877;HGNC:3239;1959;E3 SUMO-protein ligase EGR2 (EC 2.3.2.-) (AT591) (E3 SUMO-protein transferase ERG2) (Early growth response protein 2) (EGR-2) (Zinc finger protein Krox-20);P11161;https://jaspar.elixir.no/search?q=P11161;https://platform.opentargets.org/target/ENSG00000122877;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;600;121;276;241;83;3_Medium to Low;436;21.18;0.14;0.08;412;11.77;0.16;0.16;18;5.64;0.04;0.04;6;3.77;0.06;0.07;13;0.5;0.81;0.13;Osteoarthritis;#N/A;#N/A;0.033783692;0.004065378;#N/A;0.024004692;0.003695799;0.005174118;0.017686039;0.040633252;0.019587732;0.162829274;0.014105631;0.039585698;0.004434958;0.128413142;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0632;NPAS3;ENSG00000151322;HGNC:19311;64067;Neuronal PAS domain-containing protein 3 (Neuronal PAS3) (Basic-helix-loop-helix-PAS protein MOP6) (Class E basic helix-loop-helix protein 12) (bHLHe12) (Member of PAS protein 6) (PAS domain-containing protein 6);Q8IXF0;#N/A;https://platform.opentargets.org/target/ENSG00000151322;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;762;175;277;402;83;4_Low;216;21.15;0.07;0.08;176;7.81;0.07;0.11;39;12.83;0.08;0.09;1;0.51;0.01;0.01;5;0.25;0.31;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.016866222;0.011087396;#N/A;0.002587059;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.213810646;3;0.2;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0670;OVOL1;ENSG00000172818;HGNC:8525;5017;Putative transcription factor Ovo-like 1 (hOvo1);O14753;https://jaspar.elixir.no/search?q=O14753;https://platform.opentargets.org/target/ENSG00000172818;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;928;244;278;212;438;5_None;285;21.15;0.09;0.08;250;11.63;0.1;0.16;34;8.99;0.07;0.06;1;0.54;0.01;0.01;4;0.54;0.25;0.14;Osteoarthritis;#N/A;#N/A;0.08147994;#N/A;#N/A;0.057321371;#N/A;#N/A;#N/A;0.185883559;#N/A;0.218715691;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0600;NFIC;ENSG00000141905;HGNC:7786;4782;Nuclear factor 1 C-type (NF1-C) (Nuclear factor 1/C) (CCAAT-box-binding transcription factor) (CTF) (Nuclear factor I/C) (NF-I/C) (NFI-C) (TGGCA-binding protein);P08651;https://jaspar.elixir.no/search?q=P08651;https://platform.opentargets.org/target/ENSG00000141905;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;1017;277;279;556;182;5_None;484;21.13;0.16;0.08;451;11.32;0.18;0.15;33;9.81;0.07;0.07;#N/A;#N/A;#N/A;#N/A;7;0.14;0.44;0.04;Cancer;#N/A;#N/A;0.047296339;0.003326219;0.002217479;0.077547586;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.006116136;0.002217479;#N/A;0.003326219;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0462;KLF13;ENSG00000169926;HGNC:13672;51621;Krueppel-like factor 13 (Basic transcription element-binding protein 3) (BTE-binding protein 3) (Novel Sp1-like zinc finger transcription factor 1) (RANTES factor of late activated T-lymphocytes 1) (RFLAT-1) (Transcription factor BTEB3) (Transcription factor NSLP1);Q9Y2Y9;https://jaspar.elixir.no/search?q=Q9Y2Y9;https://platform.opentargets.org/target/ENSG00000169926;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1573;500;280;855;438;5_None;349;21.11;0.11;0.08;319;10.05;0.12;0.14;26;8.92;0.05;0.06;4;2.14;0.04;0.04;6;0.05;0.38;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.024638728;#N/A;0.002771849;#N/A;#N/A;0.014670267;#N/A;#N/A;#N/A;0.004434958;0.005174118;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1137;ZNF142;ENSG00000115568;HGNC:12927;7701;Zinc finger protein 142;P52746;#N/A;https://platform.opentargets.org/target/ENSG00000115568;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2918;1168;281;1469;1168;5_None;117;21.03;0.04;0.08;65;2.73;0.03;0.04;48;15.92;0.1;0.11;4;2.38;0.04;0.04;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0844;SOX10;ENSG00000100146;HGNC:11190;6663;Transcription factor SOX-10;P56693;https://jaspar.elixir.no/search?q=P56693;https://platform.opentargets.org/target/ENSG00000100146;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1473;453;282;753;438;4_Low;618;20.99;0.2;0.08;600;11.77;0.23;0.16;11;4.28;0.02;0.03;7;4.94;0.07;0.09;6;0.08;0.38;0.02;Cancer;0.001478319;#N/A;0.011989786;#N/A;#N/A;0.05304903;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;0.004784006;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0810;SETDB1;ENSG00000143379;HGNC:10761;9869;Histone-lysine N-methyltransferase SETDB1 (EC 2.1.1.366) (ERG-associated protein with SET domain) (ESET) (Histone H3-K9 methyltransferase 4) (H3-K9-HMTase 4) (Lysine N-methyltransferase 1E) (SET domain bifurcated 1);Q15047;#N/A;https://platform.opentargets.org/target/ENSG00000143379;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;846;214;283;381;182;5_None;306;20.95;0.1;0.08;296;18.69;0.12;0.25;10;2.26;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.27;0.38;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004065378;#N/A;0.034001347;0.101683042;0.00526138;#N/A;#N/A;#N/A;#N/A;#N/A;0.012442522;#N/A;#N/A;0.116373202;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0652;NR4A2;ENSG00000153234;HGNC:7981;4929;Nuclear receptor subfamily 4 group A member 2 (Immediate-early response protein NOT) (Orphan nuclear receptor NURR1) (Transcriptionally-inducible nuclear receptor);P43354;https://jaspar.elixir.no/search?q=P43354;https://platform.opentargets.org/target/ENSG00000153234;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.4 NGFI(NR4A);478;92;284;111;83;2_Medium;414;20.91;0.13;0.08;366;4.95;0.14;0.07;46;14.73;0.1;0.1;2;1.24;0.02;0.02;13;0.79;0.81;0.2;Parkinson Disease;#N/A;0.073915971;0.09961988;0.01646793;0.004619748;0.052619206;#N/A;0.009411556;0.013347376;0.033457105;0.01901283;0.008535142;0.002217479;0.441440932;#N/A;0.01991449;3;0.2;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0302;GFI1B;ENSG00000165702;HGNC:4238;8328;Zinc finger protein Gfi-1b (Growth factor independent protein 1B) (Potential regulator of CDKN1A translocated in CML);Q5VTD9;#N/A;https://platform.opentargets.org/target/ENSG00000165702;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1635;525;285;182;1168;5_None;158;20.87;0.05;0.08;113;2.62;0.04;0.04;35;12.21;0.07;0.08;10;6.04;0.1;0.1;3;0.58;0.19;0.15;Alzheimer Disease;#N/A;#N/A;0.287699765;#N/A;#N/A;0.005376348;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.287330185;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0476;KMT2B;ENSG00000272333;HGNC:15840;9757;Histone-lysine N-methyltransferase 2B (Lysine N-methyltransferase 2B) (EC 2.1.1.364) (Myeloid/lymphoid or mixed-lineage leukemia protein 4) (Trithorax homolog 2) (WW domain-binding protein 7) (WBP-7);Q9UMN6;#N/A;https://platform.opentargets.org/target/ENSG00000272333;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;1546;489;286;92;1168;5_None;485;20.73;0.16;0.08;459;11.09;0.18;0.15;24;8.29;0.05;0.06;2;1.35;0.02;0.02;8;0.9;0.5;0.23;Alzheimer Disease;#N/A;#N/A;0.3387231;0.007763503;#N/A;0.099997163;#N/A;0.008910981;#N/A;0.006529244;0.017144399;#N/A;#N/A;0.337893909;#N/A;0.08003298;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0294;GATA6;ENSG00000141448;HGNC:4174;2627;Transcription factor GATA-6 (GATA-binding factor 6);Q92908;https://jaspar.elixir.no/search?q=Q92908;https://platform.opentargets.org/target/ENSG00000141448;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;604;123;287;265;52;3_Medium to Low;384;20.72;0.12;0.08;352;7.76;0.14;0.11;22;6.57;0.05;0.04;10;6.39;0.1;0.11;9;0.45;0.56;0.11;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.003695799;0.043309613;0.036107931;0.046492176;0.220350381;0.017725871;#N/A;0.055565782;#N/A;#N/A;#N/A;0.006652437;#N/A;0.016433334;4;0.27;Y;#N/A;Anti-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0640;NR1I2;ENSG00000144852;HGNC:7968;8856;Nuclear receptor subfamily 1 group I member 2 (Orphan nuclear receptor PAR1) (Orphan nuclear receptor PXR) (Pregnane X receptor) (Steroid and xenobiotic receptor) (SXR);O75469;https://jaspar.elixir.no/search?q=O75469;https://platform.opentargets.org/target/ENSG00000144852;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;595;117;288;125;182;4_Low;1171;20.56;0.38;0.08;1160;16.47;0.45;0.22;11;4.09;0.02;0.03;#N/A;#N/A;#N/A;#N/A;15;0.73;0.94;0.19;Cancer;0.002217479;0.003316761;0.09188015;0.062108026;0.037677707;0.105378357;0.088906117;0.018756964;0.017933084;0.06297326;0.086257797;0.034690712;0.003767661;0.072685574;#N/A;0.041848367;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;117;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1248;ZNF335;ENSG00000198026;HGNC:15807;63925;Zinc finger protein 335 (NRC-interacting factor 1) (NIF-1);Q9H4Z2;#N/A;https://platform.opentargets.org/target/ENSG00000198026;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2134;754;289;677;1168;5_None;267;20.53;0.09;0.08;241;12.94;0.09;0.18;23;5.78;0.05;0.04;3;1.81;0.03;0.03;2;0.1;0.13;0.02;Age-Related Macular Degeneration;#N/A;0.093516535;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0354;HIVEP3;ENSG00000127124;HGNC:13561;59269;Transcription factor HIVEP3 (Human immunodeficiency virus type I enhancer-binding protein 3) (Kappa-B and V(D)J recombination signal sequences-binding protein) (Kappa-binding protein 1) (KBP-1) (Zinc finger protein ZAS3);Q5T1R4;#N/A;https://platform.opentargets.org/target/ENSG00000127124;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1319;390;290;591;438;5_None;175;20.39;0.06;0.08;127;4.29;0.05;0.06;45;14.51;0.09;0.1;3;1.59;0.03;0.03;6;0.13;0.38;0.03;Osteoporosis;#N/A;#N/A;0.002731917;0.004250168;#N/A;0.048628085;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.063413138;0.004434958;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0197;ELK4;ENSG00000158711;HGNC:3326;2005;ETS domain-containing protein Elk-4 (Serum response factor accessory protein 1) (SAP-1) (SRF accessory protein 1);P28324;https://jaspar.elixir.no/search?q=P28324;https://platform.opentargets.org/target/ENSG00000158711;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1388;417;291;915;182;3_Medium to Low;218;20.27;0.07;0.07;178;8.61;0.07;0.12;40;11.66;0.08;0.08;#N/A;#N/A;#N/A;#N/A;4;0.04;0.25;0.01;Alzheimer Disease;#N/A;#N/A;0.017570592;#N/A;#N/A;0.014036336;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;0.005358908;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0238;FOSL2;ENSG00000075426;HGNC:3798;2355;Fos-related antigen 2 (FRA-2);P15408;https://jaspar.elixir.no/search?q=P15408;https://platform.opentargets.org/target/ENSG00000075426;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;1143;332;292;413;438;5_None;371;20.13;0.12;0.07;336;7.35;0.13;0.1;32;11.26;0.07;0.08;3;1.51;0.03;0.03;10;0.24;0.63;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.005543698;0.021066052;#N/A;0.050154602;0.01822891;0.001478319;#N/A;0.010348236;0.01112846;0.044628222;#N/A;0.004065378;#N/A;0.075862207;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0124;CRX;ENSG00000105392;HGNC:2383;1406;Cone-rod homeobox protein;O43186;#N/A;https://platform.opentargets.org/target/ENSG00000105392;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1318;389;293;587;438;5_None;297;19.98;0.1;0.07;282;12.55;0.11;0.17;9;3.48;0.02;0.02;6;3.95;0.06;0.07;4;0.13;0.25;0.03;Age-Related Macular Degeneration;#N/A;0.089585591;0.005253543;#N/A;#N/A;0.031107239;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0500;LYL1;ENSG00000104903;HGNC:6734;4066;Protein lyl-1 (Class A basic helix-loop-helix protein 18) (bHLHa18) (Lymphoblastic leukemia-derived sequence 1);P12980;#N/A;https://platform.opentargets.org/target/ENSG00000104903;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2480;928;294;1018;1168;5_None;204;19.89;0.07;0.07;172;9.89;0.07;0.13;32;10;0.07;0.07;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.022618075;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0441;ISL1;ENSG00000016082;HGNC:6132;3670;Insulin gene enhancer protein ISL-1 (Islet-1);P61371;#N/A;https://platform.opentargets.org/target/ENSG00000016082;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;1671;543;295;208;1168;5_None;335;19.76;0.11;0.07;286;4.03;0.11;0.05;47;14.7;0.1;0.1;2;1.03;0.02;0.02;8;0.55;0.5;0.14;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.008836654;#N/A;#N/A;0.032814121;#N/A;0.004434958;#N/A;0.038580896;0.226739765;0.004065378;#N/A;0.007391597;#N/A;0.224055304;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0223;EVX2;ENSG00000174279;HGNC:3507;344191;Homeobox even-skipped homolog protein 2 (EVX-2);Q03828;https://jaspar.elixir.no/search?q=Q03828;https://platform.opentargets.org/target/ENSG00000174279;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1608;517;296;144;1168;5_None;333;19.73;0.11;0.07;323;16.4;0.13;0.22;10;3.34;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.68;0.13;0.17;Alzheimer Disease;#N/A;#N/A;0.339507594;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.339507594;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0171;E2F1;ENSG00000101412;HGNC:3113;1869;Transcription factor E2F1 (E2F-1) (PBR3) (Retinoblastoma-associated protein 1) (RBAP-1) (Retinoblastoma-binding protein 3) (RBBP-3) (pRB-binding protein E2F-1);Q01094;https://jaspar.elixir.no/search?q=Q01094;https://platform.opentargets.org/target/ENSG00000101412;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;358;60;297;40;21;2_Medium;649;19.7;0.21;0.07;628;13.18;0.25;0.18;21;6.52;0.04;0.04;#N/A;#N/A;#N/A;#N/A;14;1.22;0.88;0.31;Alzheimer Disease;#N/A;0.004434958;0.309942317;0.01130052;0.293137408;0.104101601;0.014548042;0.003028502;0.009963257;0.018079504;0.083143347;0.003490476;0.002217479;0.302022387;#N/A;0.058552318;6;0.4;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;cell,downstream;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;19;Anti-Longevity;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;30;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0654;NR5A1;ENSG00000136931;HGNC:7983;2516;Steroidogenic factor 1 (SF-1) (STF-1) (hSF-1) (Adrenal 4-binding protein) (Fushi tarazu factor homolog 1) (Nuclear receptor subfamily 5 group A member 1) (Steroid hormone receptor Ad4BP);Q13285;https://jaspar.elixir.no/search?q=Q13285;https://platform.opentargets.org/target/ENSG00000136931;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.5 FTZF1related(NR5A);1393;426;298;913;182;4_Low;390;19.59;0.13;0.07;370;9.4;0.14;0.13;12;4.95;0.02;0.03;8;5.24;0.08;0.09;6;0.04;0.38;0.01;Cancer;#N/A;0.001478319;0.008970114;0.003695799;#N/A;0.022042088;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;0.003695799;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;16;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0926;TEAD1;ENSG00000187079;HGNC:11714;7003;Transcriptional enhancer factor TEF-1 (NTEF-1) (Protein GT-IIC) (TEA domain family member 1) (TEAD-1) (Transcription factor 13) (TCF-13);P28347;https://jaspar.elixir.no/search?q=P28347;https://platform.opentargets.org/target/ENSG00000187079;3 Helix-turn-helix domains;3.6 TEA domain factors;3.6.1 TEF1-related;559;110;299;78;182;4_Low;514;19.52;0.17;0.07;484;9.68;0.19;0.13;28;8.8;0.06;0.06;2;1.04;0.02;0.02;13;0.94;0.81;0.24;Osteoarthritis;#N/A;0.067707195;0.254517518;0.059353201;0.004619748;0.048716508;0.007391597;0.051021799;#N/A;0.004065378;0.018848573;0.397973242;0.002217479;0.003490476;#N/A;0.017157334;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1585;ZNF827;ENSG00000151612;HGNC:27193;152485;Zinc finger protein 827;Q17R98;#N/A;https://platform.opentargets.org/target/ENSG00000151612;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1502;470;300;34;1168;5_None;80;19.48;0.03;0.07;32;1.6;0.01;0.02;42;14.68;0.09;0.1;6;3.2;0.06;0.06;6;1.27;0.38;0.32;Alzheimer Disease;#N/A;0.073969334;0.371819405;#N/A;#N/A;0.014044034;#N/A;#N/A;#N/A;0.192136153;0.252160765;#N/A;#N/A;0.369579855;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0458;KLF1;ENSG00000105610;HGNC:6345;10661;Krueppel-like factor 1 (Erythroid krueppel-like transcription factor) (EKLF);Q13351;https://jaspar.elixir.no/search?q=Q13351;https://platform.opentargets.org/target/ENSG00000105610;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1971;679;301;502;1168;5_None;303;19.48;0.1;0.07;286;10.75;0.11;0.15;8;3;0.02;0.02;9;5.72;0.09;0.1;7;0.17;0.44;0.04;Cancer;#N/A;#N/A;0.004619748;#N/A;#N/A;0.07879362;0.001478319;0.001478319;#N/A;0.003695799;#N/A;#N/A;0.001478319;#N/A;#N/A;0.078162352;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0822;SIX6;ENSG00000184302;HGNC:10892;4990;Homeobox protein SIX6 (Homeodomain protein OPTX2) (Optic homeobox 2) (Sine oculis homeobox homolog 6);O95475;#N/A;https://platform.opentargets.org/target/ENSG00000184302;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;903;232;302;163;438;5_None;262;19.37;0.08;0.07;230;7.71;0.09;0.1;28;9.12;0.06;0.06;4;2.53;0.04;0.04;6;0.64;0.38;0.16;Alzheimer Disease;#N/A;0.072646187;0.272021354;#N/A;#N/A;0.0135026;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.272021354;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1103;ZIC4;ENSG00000174963;HGNC:20393;84107;Zinc finger protein ZIC 4 (Zinc finger protein of the cerebellum 4);Q8N9L1;https://jaspar.elixir.no/search?q=Q8N9L1;https://platform.opentargets.org/target/ENSG00000174963;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2587;982;303;1116;1168;4_Low;203;19.36;0.07;0.07;163;4.59;0.06;0.06;34;11.35;0.07;0.08;6;3.41;0.06;0.06;3;0.02;0.19;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.011386588;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1298;ZNF429;ENSG00000197013;HGNC:20817;353088;Zinc finger protein 429;Q86V71;#N/A;https://platform.opentargets.org/target/ENSG00000197013;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1735;578;304;993;438;5_None;135;19.35;0.04;0.07;127;17.11;0.05;0.23;8;2.24;0.02;0.01;#N/A;#N/A;#N/A;#N/A;4;0.03;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.015317032;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0602;NFIX;ENSG00000008441;HGNC:7788;4784;Nuclear factor 1 X-type (NF1-X) (Nuclear factor 1/X) (CCAAT-box-binding transcription factor) (CTF) (Nuclear factor I/X) (NF-I/X) (NFI-X) (TGGCA-binding protein);Q14938;https://jaspar.elixir.no/search?q=Q14938;https://platform.opentargets.org/target/ENSG00000008441;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;1231;358;305;488;438;5_None;393;19.26;0.13;0.07;363;9.58;0.14;0.13;26;7;0.05;0.05;4;2.69;0.04;0.05;7;0.18;0.44;0.05;Osteoarthritis;#N/A;#N/A;0.043589056;#N/A;0.003695799;0.051568984;#N/A;0.001478319;#N/A;0.003326219;#N/A;0.054907015;#N/A;#N/A;#N/A;0.02012157;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0497;LMX1A;ENSG00000162761;HGNC:6653;4009;LIM homeobox transcription factor 1-alpha (LIM/homeobox protein 1.1) (LMX-1.1) (LIM/homeobox protein LMX1A);Q8TE12;https://jaspar.elixir.no/search?q=Q8TE12;https://platform.opentargets.org/target/ENSG00000162761;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;1807;607;306;333;1168;5_None;330;19.21;0.11;0.07;304;10.69;0.12;0.14;24;7.31;0.05;0.05;2;1.2;0.02;0.02;5;0.34;0.31;0.09;Age-Related Hearing Impairment;0.269077758;#N/A;0.004250168;#N/A;#N/A;0.033092638;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.017618624;#N/A;0.016071591;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0134;CXXC5;ENSG00000171604;HGNC:26943;51523;CXXC-type zinc finger protein 5 (CF5) (Putative MAPK-activating protein PM08) (Putative NF-kappa-B-activating protein 102) (Retinoid-inducible nuclear factor) (RINF);Q7LFL8;#N/A;https://platform.opentargets.org/target/ENSG00000171604;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;1399;429;307;654;438;5_None;371;19.16;0.12;0.07;347;11.3;0.14;0.15;24;7.86;0.05;0.05;#N/A;#N/A;#N/A;#N/A;5;0.1;0.31;0.03;Cancer;#N/A;#N/A;0.0201729;#N/A;#N/A;0.051130848;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.017711704;#N/A;#N/A;0.011621233;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0111;CLOCK;ENSG00000134852;HGNC:2082;9575;Circadian locomoter output cycles protein kaput (hCLOCK) (EC 2.3.1.48) (Class E basic helix-loop-helix protein 8) (bHLHe8);O15516;https://jaspar.elixir.no/search?q=O15516;https://platform.opentargets.org/target/ENSG00000134852;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;439;79;308;110;21;4_Low;932;19.13;0.3;0.07;924;16.67;0.36;0.23;8;2.46;0.02;0.02;#N/A;#N/A;#N/A;#N/A;15;0.8;0.94;0.2;Type 2 Diabetes Mellitus;#N/A;0.04431632;0.110020091;0.030435179;0.008700526;0.114954183;0.077283024;0.030402897;0.01655693;0.028208016;0.07424383;0.026024803;0.010338193;0.091999179;0.016237659;0.118603381;6;0.4;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;functional,downstream;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0818;SIX2;ENSG00000170577;HGNC:10888;10736;Homeobox protein SIX2 (Sine oculis homeobox homolog 2);Q9NPC8;https://jaspar.elixir.no/search?q=Q9NPC8;https://platform.opentargets.org/target/ENSG00000170577;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;1057;294;309;310;438;5_None;234;19.13;0.08;0.07;213;12.5;0.08;0.17;21;6.63;0.04;0.04;#N/A;#N/A;#N/A;#N/A;5;0.37;0.31;0.1;Alzheimer Disease;#N/A;#N/A;0.246491628;#N/A;#N/A;0.016294981;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.043610423;#N/A;0.065780957;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0907;TBX21;ENSG00000073861;HGNC:11599;30009;T-box transcription factor TBX21 (T-box protein 21) (T-cell-specific T-box transcription factor T-bet) (Transcription factor TBLYM);Q9UL17;https://jaspar.elixir.no/search?q=Q9UL17;https://platform.opentargets.org/target/ENSG00000073861;6 Immunoglobulin fold;6.5 T-Box factors;6.5.0 Uncharacterized/Undefined;1228;356;310;480;438;4_Low;529;19.11;0.17;0.07;508;11.67;0.2;0.16;20;6.92;0.04;0.05;1;0.52;0.01;0.01;10;0.18;0.63;0.05;Cancer;#N/A;0.003695799;0.032000893;0.002843712;#N/A;0.077034542;0.004619748;#N/A;0.002217479;0.001478319;0.024741318;#N/A;#N/A;0.015275967;#N/A;0.018810177;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0352;HIVEP1;ENSG00000095951;HGNC:4920;3096;Zinc finger protein 40 (Cirhin interaction protein) (CIRIP) (Gate keeper of apoptosis-activating protein) (GAAP) (Human immunodeficiency virus type I enhancer-binding protein 1) (HIV-EP1) (Major histocompatibility complex-binding protein 1) (MBP-1) (Positive regulatory domain II-binding factor 1) (PRDII-BF1);P15822;#N/A;https://platform.opentargets.org/target/ENSG00000095951;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1522;477;311;1029;182;3_Medium to Low;145;19.1;0.05;0.07;92;0.95;0.04;0.01;52;17.64;0.11;0.12;1;0.52;0.01;0.01;4;0.02;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.013874223;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;5;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1011;XBP1;ENSG00000100219;HGNC:12801;7494;"X-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5) [Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal form]";P17861;https://jaspar.elixir.no/search?q=P17861;https://platform.opentargets.org/target/ENSG00000100219;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.5 XBP1-related;610;126;312;246;52;4_Low;673;18.99;0.22;0.07;655;13.44;0.26;0.18;18;5.56;0.04;0.04;#N/A;#N/A;#N/A;#N/A;13;0.49;0.81;0.12;Alzheimer Disease;#N/A;0.012270667;0.10129747;0.021860302;0.004414426;0.074293078;0.022613934;0.045959143;0.021472992;0.003921127;0.053550598;0.0274591;#N/A;0.07329057;#N/A;0.027069339;4;0.27;Y;#N/A;Unclear;Pro-Longevity;Unclear;Pro-Longevity;#N/A;#N/A;#N/A;Unannotated;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;20;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0717;POU3F3;ENSG00000198914;HGNC:9216;5455;POU domain, class 3, transcription factor 3 (Brain-specific homeobox/POU domain protein 1) (Brain-1) (Brn-1) (Octamer-binding protein 8) (Oct-8) (Octamer-binding transcription factor 8) (OTF-8);P20264;https://jaspar.elixir.no/search?q=P20264;https://platform.opentargets.org/target/ENSG00000198914;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1568;497;313;817;438;5_None;214;18.99;0.07;0.07;184;7.25;0.07;0.1;25;8.88;0.05;0.06;5;2.85;0.05;0.05;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;0.009336832;#N/A;#N/A;0.031914485;#N/A;#N/A;#N/A;#N/A;#N/A;0.010348236;#N/A;0.009696338;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0153;DMRTA2;ENSG00000142700;HGNC:13908;63950;Doublesex- and mab-3-related transcription factor A2 (Doublesex- and mab-3-related transcription factor 5);Q96SC8;https://jaspar.elixir.no/search?q=Q96SC8;https://platform.opentargets.org/target/ENSG00000142700;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;860;219;314;108;438;5_None;135;18.94;0.04;0.07;92;7.44;0.04;0.1;43;11.5;0.09;0.08;#N/A;#N/A;#N/A;#N/A;7;0.82;0.44;0.21;Heart Failure;#N/A;#N/A;0.18995005;0.001478319;0.115885555;0.007761177;0.019556199;0.294171636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.187473759;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0192;ELF3;ENSG00000163435;HGNC:3318;1999;ETS-related transcription factor Elf-3 (E74-like factor 3) (Epithelial-restricted with serine box) (Epithelium-restricted Ets protein ESX) (Epithelium-specific Ets transcription factor 1) (ESE-1);P78545;https://jaspar.elixir.no/search?q=P78545;https://platform.opentargets.org/target/ENSG00000163435;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1054;293;315;557;182;3_Medium to Low;386;18.89;0.12;0.07;375;15.85;0.15;0.21;11;3.04;0.02;0.02;#N/A;#N/A;#N/A;#N/A;9;0.14;0.56;0.04;Cancer;#N/A;#N/A;0.006514728;0.002217479;0.028642439;0.067403564;0.016092123;#N/A;0.001478319;#N/A;#N/A;0.011801984;0.002751317;#N/A;#N/A;0.003490476;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0394;HOXC11;ENSG00000123388;HGNC:5123;3227;Homeobox protein Hox-C11 (Homeobox protein Hox-3H);O43248;https://jaspar.elixir.no/search?q=O43248;https://platform.opentargets.org/target/ENSG00000123388;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2411;896;316;927;1168;5_None;174;18.87;0.06;0.07;133;7.32;0.05;0.1;41;11.55;0.09;0.08;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;#N/A;0.005174118;#N/A;0.019813195;0.014506009;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1575;ZNF804A;ENSG00000170396;HGNC:21711;91752;Zinc finger protein 804A;Q7Z570;#N/A;https://platform.opentargets.org/target/ENSG00000170396;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2663;1025;317;1178;1168;4_Low;160;18.79;0.05;0.07;114;2.38;0.04;0.03;44;15.35;0.09;0.1;2;1.06;0.02;0.02;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.011272186;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0120;CREB5;ENSG00000146592;HGNC:16844;9586;Cyclic AMP-responsive element-binding protein 5 (CREB-5) (cAMP-responsive element-binding protein 5) (cAMP-response element-binding protein A) (CRE-BPa);Q02930;#N/A;https://platform.opentargets.org/target/ENSG00000146592;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;1107;318;318;351;438;5_None;208;18.71;0.07;0.07;160;3.13;0.06;0.04;48;15.57;0.1;0.1;#N/A;#N/A;#N/A;#N/A;7;0.32;0.44;0.08;Osteoarthritis;#N/A;#N/A;0.011590435;#N/A;#N/A;0.023951844;0.003695799;#N/A;#N/A;0.003695799;0.001478319;0.258740217;#N/A;0.01473597;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0437;IRX3;ENSG00000177508;HGNC:14360;79191;Iroquois-class homeodomain protein IRX-3 (Homeodomain protein IRXB1) (Iroquois homeobox protein 3);P78415;#N/A;https://platform.opentargets.org/target/ENSG00000177508;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1320;391;319;563;438;5_None;256;18.66;0.08;0.07;223;8.82;0.09;0.12;32;9.34;0.07;0.06;1;0.5;0.01;0.01;7;0.14;0.44;0.04;Osteoarthritis;#N/A;#N/A;0.001478319;#N/A;#N/A;0.004935534;#N/A;0.003695799;#N/A;#N/A;#N/A;0.095681974;0.012196135;#N/A;0.001478319;0.018469821;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0199;EMX2;ENSG00000170370;HGNC:3341;2018;Homeobox protein EMX2 (Empty spiracles homolog 2) (Empty spiracles-like protein 2);Q04743;https://jaspar.elixir.no/search?q=Q04743;https://platform.opentargets.org/target/ENSG00000170370;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1392;424;320;890;182;3_Medium to Low;316;18.61;0.1;0.07;283;7.9;0.11;0.11;31;9.5;0.06;0.06;2;1.21;0.02;0.02;2;0.05;0.13;0.01;Cancer;#N/A;#N/A;0.012941961;#N/A;#N/A;0.034388266;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0173;E2F3;ENSG00000112242;HGNC:3115;1871;Transcription factor E2F3 (E2F-3);O00716;https://jaspar.elixir.no/search?q=O00716;https://platform.opentargets.org/target/ENSG00000112242;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;634;130;321;131;182;2_Medium;267;18.56;0.09;0.07;226;4.71;0.09;0.06;37;11.81;0.08;0.08;4;2.04;0.04;0.04;11;0.72;0.69;0.18;Alzheimer Disease;#N/A;#N/A;0.281548411;0.014783194;0.012011345;0.084863745;0.016856948;0.002217479;#N/A;0.005913278;#N/A;0.011713628;#N/A;0.281548411;0.003695799;0.003511009;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;4;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0930;TEF;ENSG00000167074;HGNC:11722;7008;Thyrotroph embryonic factor;Q10587;https://jaspar.elixir.no/search?q=Q10587;https://platform.opentargets.org/target/ENSG00000167074;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;1723;567;322;963;438;5_None;211;18.44;0.07;0.07;174;6.95;0.07;0.09;36;10.98;0.07;0.07;1;0.51;0.01;0.01;3;0.03;0.19;0.01;Parkinson Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.006363119;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.024205017;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0210;ESRRG;ENSG00000196482;HGNC:3474;2104;Estrogen-related receptor gamma (ERR gamma-2) (Estrogen receptor-related protein 3) (Nuclear receptor subfamily 3 group B member 3);P62508;#N/A;https://platform.opentargets.org/target/ENSG00000196482;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;1209;351;323;448;438;2_Medium;341;18.42;0.11;0.07;312;9.28;0.12;0.13;29;9.14;0.06;0.06;#N/A;#N/A;#N/A;#N/A;9;0.21;0.56;0.05;Cancer;#N/A;#N/A;0.011266171;#N/A;0.002956639;0.083848622;#N/A;0.013637997;#N/A;#N/A;0.011087396;0.002751317;0.001478319;0.066544906;#N/A;0.015307244;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;7;5;#N/A;CHEMBL4245;Estrogen-related receptor gamma;SINGLE PROTEIN;308;593;1;3;Small molecule;#N/A
TFTX_0065;BBX;ENSG00000114439;HGNC:14422;56987;HMG box transcription factor BBX (Bobby sox homolog) (HMG box-containing protein 2);Q8WY36;#N/A;https://platform.opentargets.org/target/ENSG00000114439;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1750;583;324;988;438;5_None;102;18.4;0.03;0.07;54;1.22;0.02;0.02;46;16.14;0.1;0.11;2;1.04;0.02;0.02;3;0.03;0.19;0.01;Alzheimer Disease;#N/A;#N/A;0.026139169;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0431;IRF6;ENSG00000117595;HGNC:6121;3664;Interferon regulatory factor 6 (IRF-6);O14896;https://jaspar.elixir.no/search?q=O14896;https://platform.opentargets.org/target/ENSG00000117595;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;1394;427;325;631;438;4_Low;444;18.32;0.14;0.07;431;11.42;0.17;0.15;5;1.67;0.01;0.01;8;5.23;0.08;0.09;8;0.11;0.5;0.03;Cancer;#N/A;#N/A;0.005595028;0.004496555;0.007391597;0.080549471;0.003695799;#N/A;0.007761177;#N/A;0.002587059;0.002217479;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0091;CDC5L;ENSG00000096401;HGNC:1743;988;Cell division cycle 5-like protein (Cdc5-like protein) (Pombe cdc5-related protein);Q99459;#N/A;https://platform.opentargets.org/target/ENSG00000096401;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;830;207;326;66;438;3_Medium to Low;150;18.32;0.05;0.07;106;5.67;0.04;0.08;44;12.65;0.09;0.08;#N/A;#N/A;#N/A;#N/A;6;1.02;0.38;0.26;Alzheimer Disease;#N/A;#N/A;0.370837453;#N/A;#N/A;0.042295463;0.010789679;#N/A;#N/A;#N/A;#N/A;0.225111242;#N/A;0.370596199;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0301;GFI1;ENSG00000162676;HGNC:4237;2672;Zinc finger protein Gfi-1 (Growth factor independent protein 1) (Zinc finger protein 163);Q99684;https://jaspar.elixir.no/search?q=Q99684;https://platform.opentargets.org/target/ENSG00000162676;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1070;298;327;305;438;5_None;344;18.32;0.11;0.07;322;10.25;0.13;0.14;19;6.15;0.04;0.04;3;1.91;0.03;0.03;7;0.38;0.44;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004229636;0.006282858;#N/A;0.081200556;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.016261514;0.001478319;#N/A;0.268380912;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0271;FOXM1;ENSG00000111206;HGNC:3818;2305;Forkhead box protein M1 (Forkhead-related protein FKHL16) (Hepatocyte nuclear factor 3 forkhead homolog 11) (HFH-11) (HNF-3/fork-head homolog 11) (M-phase phosphoprotein 2) (MPM-2 reactive phosphoprotein 2) (Transcription factor Trident) (Winged-helix factor from INS-1 cells);Q08050;#N/A;https://platform.opentargets.org/target/ENSG00000111206;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;384;64;328;42;14;4_Low;586;18.15;0.19;0.07;572;13.8;0.22;0.19;13;3.84;0.03;0.03;1;0.51;0.01;0.01;12;1.18;0.75;0.3;Cancer;#N/A;#N/A;0.280609716;0.009239496;0.021682018;0.49165627;0.015076084;0.005086856;#N/A;0.037499625;0.012565715;0.013435344;#N/A;0.277945302;0.007391597;0.010250926;7;0.47;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Unclear;functional;#N/A;#N/A;Pro-Longevity;Inhibits;#N/A;Pro-Longevity;20;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0660;OLIG2;ENSG00000205927;HGNC:9398;10215;Oligodendrocyte transcription factor 2 (Oligo2) (Class B basic helix-loop-helix protein 1) (bHLHb1) (Class E basic helix-loop-helix protein 19) (bHLHe19) (Protein kinase C-binding protein 2) (Protein kinase C-binding protein RACK17);Q13516;https://jaspar.elixir.no/search?q=Q13516;https://platform.opentargets.org/target/ENSG00000205927;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;1429;439;329;662;438;5_None;324;18.14;0.1;0.07;292;9.26;0.11;0.13;32;8.88;0.07;0.06;#N/A;#N/A;#N/A;#N/A;4;0.1;0.25;0.03;Ischemic Stroke;#N/A;#N/A;0.026286632;#N/A;#N/A;0.015257143;#N/A;#N/A;0.043504066;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.017000673;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0537;MNX1;ENSG00000130675;HGNC:4979;3110;Motor neuron and pancreas homeobox protein 1 (Homeobox protein HB9);P50219;https://jaspar.elixir.no/search?q=P50219;https://platform.opentargets.org/target/ENSG00000130675;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;767;178;330;255;182;3_Medium to Low;260;18.13;0.08;0.07;249;14.45;0.1;0.2;10;2.87;0.02;0.02;1;0.81;0.01;0.01;3;0.47;0.19;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.097006804;0.043610423;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.324972765;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1100;ZIC1;ENSG00000152977;HGNC:12872;7545;Zinc finger protein ZIC 1 (Zinc finger protein 201) (Zinc finger protein of the cerebellum 1);Q15915;https://jaspar.elixir.no/search?q=Q15915;https://platform.opentargets.org/target/ENSG00000152977;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1617;520;331;848;438;5_None;332;18.03;0.11;0.07;310;10.69;0.12;0.14;20;5.98;0.04;0.04;2;1.37;0.02;0.02;4;0.05;0.25;0.01;Osteoporosis;#N/A;#N/A;0.014853868;#N/A;#N/A;0.011018618;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.022359581;0.006467647;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1266;ZNF366;ENSG00000178175;HGNC:18316;167465;Zinc finger protein 366 (Dendritic cell-specific transcript protein) (DC-SCRIPT);Q8N895;#N/A;https://platform.opentargets.org/target/ENSG00000178175;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2124;746;332;1354;438;5_None;149;18.02;0.05;0.07;107;4.47;0.04;0.06;40;12.53;0.08;0.08;2;1.02;0.02;0.02;2;0;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001763586;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0412;HSF2;ENSG00000025156;HGNC:5225;3298;Heat shock factor protein 2 (HSF 2) (Heat shock transcription factor 2) (HSTF 2);Q03933;https://jaspar.elixir.no/search?q=Q03933;https://platform.opentargets.org/target/ENSG00000025156;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;768;181;333;253;182;5_None;260;18.02;0.08;0.07;229;6.75;0.09;0.09;28;9.73;0.06;0.06;3;1.54;0.03;0.03;3;0.47;0.19;0.12;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.099423656;0.344939283;0.027987449;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0913;TBXT;ENSG00000164458;HGNC:11515;6862;T-box transcription factor T (Brachyury protein) (Protein T);O15178;https://jaspar.elixir.no/search?q=O15178;https://platform.opentargets.org/target/ENSG00000164458;6 Immunoglobulin fold;6.5 T-Box factors;6.5.1 Brachyury-related;1869;630;334;367;1168;4_Low;1121;17.96;0.36;0.07;1108;13.04;0.43;0.18;11;3.86;0.02;0.03;2;1.06;0.02;0.02;14;0.29;0.88;0.07;Cancer;#N/A;0.004414426;0.046104629;0.014330577;0.001478319;0.100438935;0.016168575;0.008479804;0.02463106;0.009680041;0.018404666;0.002587059;0.011898418;0.007276454;#N/A;0.025670366;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0980;TLX3;ENSG00000164438;HGNC:13532;30012;T-cell leukemia homeobox protein 3 (Homeobox protein Hox-11L2);O43711;#N/A;https://platform.opentargets.org/target/ENSG00000164438;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2718;1054;335;1215;1168;5_None;123;17.94;0.04;0.07;84;6.66;0.03;0.09;39;11.27;0.08;0.08;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009273743;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0041;ASH1L;ENSG00000116539;HGNC:19088;55870;Histone-lysine N-methyltransferase ASH1L (EC 2.1.1.359) (EC 2.1.1.367) (ASH1-like protein) (huASH1) (Absent small and homeotic disks protein 1 homolog) (Lysine N-methyltransferase 2H);Q9NR48;#N/A;https://platform.opentargets.org/target/ENSG00000116539;8 beta-Sheet binding to DNA;8.2 A.T hook factors;8.2.0 Uncharacterized/Undefined;2025;703;336;521;1168;5_None;345;17.94;0.11;0.07;317;8.77;0.12;0.12;25;7.26;0.05;0.05;3;1.9;0.03;0.03;7;0.16;0.44;0.04;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.017534511;#N/A;#N/A;0.022368943;0.054935023;0.001478319;#N/A;#N/A;#N/A;0.054935023;0.006652437;#N/A;#N/A;0.002956639;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1329;ZNF479;ENSG00000185177;HGNC:23258;90827;Zinc finger protein 479 (Zinc finger protein Kr19) (HKr19);Q96JC4;#N/A;https://platform.opentargets.org/target/ENSG00000185177;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2861;1128;337;1356;1168;5_None;106;17.86;0.03;0.07;100;15.84;0.04;0.21;6;2.02;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1432;ZNF608;ENSG00000168916;HGNC:29238;57507;Zinc finger protein 608 (Renal carcinoma antigen NY-REN-36);Q9ULD9;#N/A;https://platform.opentargets.org/target/ENSG00000168916;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1206;347;338;430;438;5_None;82;17.83;0.03;0.07;38;2.66;0.01;0.04;41;13.57;0.09;0.09;3;1.6;0.03;0.03;4;0.23;0.25;0.06;Parkinson Disease;#N/A;#N/A;0.002936107;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.217785428;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1574;ZNF800;ENSG00000048405;HGNC:27267;168850;Zinc finger protein 800;Q2TB10;#N/A;https://platform.opentargets.org/target/ENSG00000048405;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;841;211;339;64;438;5_None;82;17.74;0.03;0.07;38;2.11;0.01;0.03;41;13.92;0.09;0.09;3;1.71;0.03;0.03;7;1.04;0.44;0.26;Type 2 Diabetes Mellitus;#N/A;0.001478319;0.284711009;#N/A;#N/A;0.009926299;0.001478319;#N/A;#N/A;#N/A;#N/A;0.172300173;#N/A;0.283470202;#N/A;0.284752646;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0450;JUND;ENSG00000130522;HGNC:6206;3727;Transcription factor JunD (Transcription factor AP-1 subunit JunD);P17535;https://jaspar.elixir.no/search?q=P17535;https://platform.opentargets.org/target/ENSG00000130522;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;649;135;340;300;9;4_Low;895;17.7;0.29;0.07;877;12.75;0.34;0.17;18;4.95;0.04;0.03;#N/A;#N/A;#N/A;#N/A;15;0.39;0.94;0.1;Cancer;#N/A;0.009996096;0.038349121;0.046629642;0.012042144;0.085422268;0.027880608;0.026754732;0.004691611;0.032613575;0.013184148;0.018908185;0.018400262;0.030734967;0.003695799;0.020216971;8;0.53;Y;Pro-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Pro-Longevity;Unclear;mammal,putative;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Pro-Longevity;1;#N/A;#N/A;Pro-Longevity;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0098;CEBPE;ENSG00000092067;HGNC:1836;1053;CCAAT/enhancer-binding protein epsilon (C/EBP epsilon);Q15744;https://jaspar.elixir.no/search?q=Q15744;https://platform.opentargets.org/target/ENSG00000092067;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;2489;932;341;980;1168;5_None;309;17.67;0.1;0.07;296;11.49;0.12;0.16;7;2.62;0.01;0.02;6;3.56;0.06;0.06;4;0.03;0.25;#N/A;Atherosclerosis;#N/A;#N/A;#N/A;0.019957312;#N/A;0.008404952;#N/A;#N/A;#N/A;#N/A;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1095;ZGLP1;ENSG00000220201;HGNC:37245;100125288;GATA-type zinc finger protein 1 (GATA-like protein 1) (GLP-1);P0C6A0;#N/A;https://platform.opentargets.org/target/ENSG00000220201;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;864;222;342;84;438;5_None;889;17.67;0.29;0.07;888;17.47;0.35;0.24;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;14;0.93;0.88;0.24;Type 2 Diabetes Mellitus;#N/A;#N/A;0.097990447;0.056392958;0.002217479;0.098858013;0.033345604;0.069490141;0.04560498;0.068052944;0.095454028;0.009912735;0.053102536;0.110014825;0.069974696;0.117957036;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0257;FOXF1;ENSG00000103241;HGNC:3809;2294;Forkhead box protein F1 (Forkhead-related activator 1) (FREAC-1) (Forkhead-related protein FKHL5) (Forkhead-related transcription factor 1);Q12946;#N/A;https://platform.opentargets.org/target/ENSG00000103241;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1366;412;343;585;438;4_Low;295;17.56;0.09;0.06;260;6.96;0.1;0.09;33;9.13;0.07;0.06;2;1.46;0.02;0.03;7;0.13;0.44;0.03;Osteoporosis;#N/A;#N/A;0.001478319;0.010581893;0.002217479;0.042341113;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.053938127;#N/A;#N/A;0.014783194;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1102;ZIC3;ENSG00000156925;HGNC:12874;7547;Zinc finger protein ZIC 3 (Zinc finger protein 203) (Zinc finger protein of the cerebellum 3);O60481;https://jaspar.elixir.no/search?q=O60481;https://platform.opentargets.org/target/ENSG00000156925;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;972;259;344;190;438;5_None;258;17.43;0.08;0.06;232;7.05;0.09;0.1;19;5.91;0.04;0.04;7;4.46;0.07;0.08;4;0.57;0.25;0.14;Alzheimer Disease;#N/A;#N/A;0.281548411;#N/A;#N/A;0.004804538;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.281548411;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0161;DPF3;ENSG00000205683;HGNC:17427;8110;Zinc finger protein DPF3 (BRG1-associated factor 45C) (BAF45C) (Zinc finger protein cer-d4);Q92784;#N/A;https://platform.opentargets.org/target/ENSG00000205683;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1159;336;345;376;438;5_None;106;17.42;0.03;0.06;59;2.13;0.02;0.03;47;15.29;0.1;0.1;#N/A;#N/A;#N/A;#N/A;5;0.28;0.31;0.07;Age-Related Macular Degeneration;#N/A;0.25209939;0.005153586;#N/A;#N/A;0.011343647;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0472;KLF7;ENSG00000118263;HGNC:6350;8609;Krueppel-like factor 7 (Ubiquitous krueppel-like factor);O75840;https://jaspar.elixir.no/search?q=O75840;https://platform.opentargets.org/target/ENSG00000118263;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;766;177;346;238;182;5_None;169;17.41;0.05;0.06;129;2.65;0.05;0.04;37;13.22;0.08;0.09;3;1.54;0.03;0.03;10;0.5;0.63;0.13;Age-Related Hearing Impairment;0.336126498;#N/A;0.007391597;0.002217479;0.007391597;0.028212217;0.080383618;#N/A;#N/A;#N/A;#N/A;0.001478319;0.008869917;#N/A;0.002217479;0.024923917;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0775;RFX3;ENSG00000080298;HGNC:9984;5991;Transcription factor RFX3 (Regulatory factor X 3);P48380;https://jaspar.elixir.no/search?q=P48380;https://platform.opentargets.org/target/ENSG00000080298;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;897;229;347;368;182;5_None;176;17.34;0.06;0.06;138;5.54;0.05;0.08;37;11.26;0.08;0.08;1;0.54;0.01;0.01;2;0.29;0.13;0.07;Alzheimer Disease;#N/A;#N/A;0.275575271;#N/A;#N/A;0.014883391;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0324;GTF2I;ENSG00000263001;HGNC:4659;2969;General transcription factor II-I (GTFII-I) (TFII-I) (Bruton tyrosine kinase-associated protein 135) (BAP-135) (BTK-associated protein 135) (SRF-Phox1-interacting protein) (SPIN) (Williams-Beuren syndrome chromosomal region 6 protein);P78347;#N/A;https://platform.opentargets.org/target/ENSG00000263001;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;796;194;348;10;438;3_Medium to Low;190;17.31;0.06;0.06;149;2.37;0.06;0.03;40;14.39;0.08;0.1;1;0.55;0.01;0.01;9;1.95;0.56;0.5;Type 2 Diabetes Mellitus;#N/A;0.001478319;0.369579855;#N/A;#N/A;0.019741082;0.297073318;0.374682965;#N/A;0.019218152;0.073915971;#N/A;#N/A;0.369579855;#N/A;0.427454651;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0543;MSX1;ENSG00000163132;HGNC:7391;4487;Homeobox protein MSX-1 (Homeobox protein Hox-7) (Msh homeobox 1-like protein);P28360;https://jaspar.elixir.no/search?q=P28360;https://platform.opentargets.org/target/ENSG00000163132;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1611;518;349;824;438;5_None;375;17.3;0.12;0.06;352;9.1;0.14;0.12;20;5.98;0.04;0.04;3;2.22;0.03;0.04;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;0.02301292;#N/A;#N/A;0.02306796;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0.009650141;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0665;OSR1;ENSG00000143867;HGNC:8111;130497;Protein odd-skipped-related 1;Q8TAX0;https://jaspar.elixir.no/search?q=Q8TAX0;https://platform.opentargets.org/target/ENSG00000143867;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;1812;611;350;294;1168;4_Low;195;17.3;0.06;0.06;147;2.03;0.06;0.03;44;13.18;0.09;0.09;4;2.08;0.04;0.04;9;0.4;0.56;0.1;Alzheimer Disease;#N/A;#N/A;0.215262206;0.007391597;#N/A;0.036394214;0.049523701;0.001478319;0.010132648;#N/A;0.071721693;#N/A;#N/A;0.002217479;#N/A;0.005913278;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0146;DLX5;ENSG00000105880;HGNC:2918;1749;Homeobox protein DLX-5;P56178;https://jaspar.elixir.no/search?q=P56178;https://platform.opentargets.org/target/ENSG00000105880;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1307;386;351;518;438;3_Medium to Low;456;17.26;0.15;0.06;444;12.51;0.17;0.17;9;2.97;0.02;0.02;3;1.78;0.03;0.03;5;0.16;0.31;0.04;Cancer;#N/A;#N/A;0.008849384;0.002587059;#N/A;0.077490561;#N/A;#N/A;#N/A;#N/A;#N/A;0.058854565;0.014524078;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;6;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0645;NR2E3;ENSG00000278570;HGNC:7974;10002;Photoreceptor-specific nuclear receptor (Nuclear receptor subfamily 2 group E member 3) (Retina-specific nuclear receptor);Q9Y5X4;#N/A;https://platform.opentargets.org/target/ENSG00000278570;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;1219;354;352;429;438;4_Low;232;17.19;0.07;0.06;201;4.22;0.08;0.06;24;8.49;0.05;0.06;7;4.49;0.07;0.08;6;0.23;0.38;0.06;Age-Related Macular Degeneration;#N/A;0.090530958;0.004065378;#N/A;#N/A;0.089141597;0.038056011;0.002217479;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;14;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0343;HEY1;ENSG00000164683;HGNC:4880;23462;Hairy/enhancer-of-split related with YRPW motif protein 1 (Cardiovascular helix-loop-helix factor 2) (CHF-2) (Class B basic helix-loop-helix protein 31) (bHLHb31) (HES-related repressor protein 1) (Hairy and enhancer of split-related protein 1) (HESR-1) (Hairy-related transcription factor 1) (HRT-1) (hHRT1);Q9Y5J3;https://jaspar.elixir.no/search?q=Q9Y5J3;https://platform.opentargets.org/target/ENSG00000164683;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;1474;454;353;683;438;5_None;250;17.08;0.08;0.06;212;6.15;0.08;0.08;38;10.93;0.08;0.07;#N/A;#N/A;#N/A;#N/A;9;0.1;0.56;0.02;Cancer;#N/A;0.002217479;0.011267053;#N/A;0.003757395;0.04855427;0.008110225;0.001478319;0.012565715;#N/A;0.003695799;0.004431102;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0495;LIN28B;ENSG00000187772;HGNC:32207;389421;Protein lin-28 homolog B (Lin-28B);Q6ZN17;#N/A;https://platform.opentargets.org/target/ENSG00000187772;9 beta-Barrel DNA-binding domains;9.1 Cold-shock domain factors;9.1.0 Uncharacterized/Undefined;1405;434;354;613;438;5_None;238;17.05;0.08;0.06;193;3.4;0.08;0.05;45;13.65;0.09;0.09;#N/A;#N/A;#N/A;#N/A;5;0.12;0.31;0.03;Cancer;#N/A;#N/A;0.009609076;0.010512494;#N/A;0.090347816;0.007022017;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0057;BARHL2;ENSG00000143032;HGNC:954;343472;BarH-like 2 homeobox protein;Q9NY43;https://jaspar.elixir.no/search?q=Q9NY43;https://platform.opentargets.org/target/ENSG00000143032;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1162;337;355;369;438;5_None;99;16.88;0.03;0.06;50;1.67;0.02;0.02;49;15.21;0.1;0.1;#N/A;#N/A;#N/A;#N/A;2;0.29;0.13;0.07;Alzheimer Disease;#N/A;#N/A;0.281206145;#N/A;#N/A;0.006451722;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1183;ZNF229;ENSG00000278318;HGNC:13022;7772;Zinc finger protein 229;Q9UJW7;#N/A;https://platform.opentargets.org/target/ENSG00000278318;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1392;424;356;854;182;5_None;77;16.88;0.02;0.06;45;5.18;0.02;0.07;27;8.71;0.06;0.06;5;2.99;0.05;0.05;2;0.05;0.13;0.01;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.050213475;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0996;TWIST2;ENSG00000233608;HGNC:20670;117581;Twist-related protein 2 (Class A basic helix-loop-helix protein 39) (bHLHa39) (Dermis-expressed protein 1) (Dermo-1);Q8WVJ9;#N/A;https://platform.opentargets.org/target/ENSG00000233608;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;754;167;357;314;83;5_None;285;16.82;0.09;0.06;259;7.44;0.1;0.1;23;7.3;0.05;0.05;3;2.08;0.03;0.04;7;0.37;0.44;0.09;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.008315547;#N/A;#N/A;0.063949361;0.255082552;#N/A;#N/A;#N/A;0.024823447;0.004434958;0.006282858;#N/A;#N/A;0.008315547;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0331;HAND2;ENSG00000164107;HGNC:4808;9464;Heart- and neural crest derivatives-expressed protein 2 (Class A basic helix-loop-helix protein 26) (bHLHa26) (Deciduum, heart, autonomic nervous system and neural crest derivatives-expressed protein 2) (dHAND);P61296;https://jaspar.elixir.no/search?q=P61296;https://platform.opentargets.org/target/ENSG00000164107;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2017;698;358;491;1168;5_None;314;16.75;0.1;0.06;283;7.56;0.11;0.1;31;9.18;0.06;0.06;#N/A;#N/A;#N/A;#N/A;9;0.18;0.56;0.05;Cancer;#N/A;#N/A;0.003695799;0.00820262;#N/A;0.093885171;0.017834897;0.015689987;#N/A;0.002587059;#N/A;0.013479399;#N/A;0.008869917;0.013304875;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0763;RBPJ;ENSG00000168214;HGNC:5724;3516;Recombining binding protein suppressor of hairless (CBF-1) (J kappa-recombination signal-binding protein) (RBP-J kappa) (RBP-J) (RBP-JK) (Renal carcinoma antigen NY-REN-30);Q06330;https://jaspar.elixir.no/search?q=Q06330;https://platform.opentargets.org/target/ENSG00000168214;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.4 CSL-related;589;115;359;48;182;4_Low;381;16.72;0.12;0.06;351;5.78;0.14;0.08;27;9.05;0.06;0.06;3;1.89;0.03;0.03;12;1.13;0.75;0.29;Cancer;#N/A;0.07563392;0.006077535;0.010050519;#N/A;0.597255635;0.003695799;0.002217479;0.008572199;0.026987132;0.017739833;0.002956639;#N/A;0.05211076;#N/A;0.328416893;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0897;TBPL1;ENSG00000028839;HGNC:11589;9519;TATA box-binding protein-like 1 (TBP-like 1) (21 kDa TBP-like protein) (Second TBP of unique DNA protein) (STUD) (TATA box-binding protein-related factor 2) (TBP-related factor 2) (TBP-like factor) (TBP-related protein);P62380;#N/A;https://platform.opentargets.org/target/ENSG00000028839;8 beta-Sheet binding to DNA;8.1 TATA-binding proteins;8.1.1 TBP-related;821;202;360;378;83;5_None;571;16.65;0.18;0.06;551;11.08;0.22;0.15;20;5.57;0.04;0.04;#N/A;#N/A;#N/A;#N/A;12;0.28;0.75;0.07;Cancer;#N/A;0.015275967;0.050871312;0.008676976;0.01724706;0.108524096;0.006518629;0.009015079;#N/A;0.039377715;0.002956639;0.001478319;#N/A;0.004735345;#N/A;0.014811529;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0862;SP1;ENSG00000185591;HGNC:11205;6667;Transcription factor Sp1;P08047;https://jaspar.elixir.no/search?q=P08047;https://platform.opentargets.org/target/ENSG00000185591;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;626;128;361;244;21;4_Low;730;16.6;0.23;0.06;717;12.71;0.28;0.17;12;3.34;0.02;0.02;1;0.54;0.01;0.01;15;0.49;0.94;0.13;Cancer;#N/A;0.006652437;0.065577575;0.017459259;0.005523166;0.10898542;0.018174076;0.024092253;0.036044042;0.018767447;0.003028502;0.011353834;0.023489789;0.081316644;0.002217479;0.070781083;6;0.4;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;upstream;Pro-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1084;ZFP64;ENSG00000020256;HGNC:15940;55734;Zinc finger protein 64 (Zfp-64) (Zinc finger protein 338);Q9NTW7;#N/A;https://platform.opentargets.org/target/ENSG00000020256;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1077;300;362;277;438;5_None;85;16.46;0.03;0.06;40;1.01;0.02;0.01;40;12.82;0.08;0.09;5;2.62;0.05;0.05;3;0.43;0.19;0.11;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003395608;#N/A;#N/A;0.014078208;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.412242217;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0499;LTF;ENSG00000012223;HGNC:6720;4057;"Lactotransferrin (Lactoferrin) (EC 3.4.21.-) (Growth-inhibiting protein 12) (Talalactoferrin) [Cleaved into: Lactoferricin-H (Lfcin-H); Kaliocin-1; Lactoferroxin-A; Lactoferroxin-B; Lactoferroxin-C]";P02788;#N/A;https://platform.opentargets.org/target/ENSG00000012223;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;951;253;363;150;438;4_Low;867;16.45;0.28;0.06;853;11.14;0.33;0.15;13;4.8;0.03;0.03;1;0.5;0.01;0.01;16;0.67;1;0.17;Alzheimer Disease;0.007391597;0.014095365;0.207254076;0.011811965;0.02304741;0.046829215;0.019572573;0.019787921;0.001478319;0.076934206;0.016705831;0.009926572;0.005397837;0.192367021;0.002104552;0.018716416;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0815;SIM1;ENSG00000112246;HGNC:10882;6492;Single-minded homolog 1 (Class E basic helix-loop-helix protein 14) (bHLHe14);P81133;#N/A;https://platform.opentargets.org/target/ENSG00000112246;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1326;392;364;780;182;5_None;210;16.26;0.07;0.06;183;7;0.07;0.09;23;7.2;0.05;0.05;4;2.05;0.04;0.04;5;0.07;0.31;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;#N/A;#N/A;0.007225267;#N/A;#N/A;#N/A;0.001478319;0.004434958;#N/A;#N/A;#N/A;#N/A;0.055536765;2;0.13;N;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0690;PDX1;ENSG00000139515;HGNC:6107;3651;Pancreas/duodenum homeobox protein 1 (PDX-1) (Glucose-sensitive factor) (GSF) (Insulin promoter factor 1) (IPF-1) (Insulin upstream factor 1) (IUF-1) (Islet/duodenum homeobox-1) (IDX-1) (Somatostatin-transactivating factor 1) (STF-1);P52945;https://jaspar.elixir.no/search?q=P52945;https://platform.opentargets.org/target/ENSG00000139515;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;992;268;365;189;438;5_None;382;16.24;0.12;0.06;361;7.68;0.14;0.1;16;5.41;0.03;0.04;5;3.16;0.05;0.05;6;0.57;0.38;0.15;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008500337;#N/A;#N/A;0.035238262;#N/A;#N/A;#N/A;0.007022017;0.002771849;#N/A;0.001478319;#N/A;#N/A;0.518427788;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0992;TSHZ2;ENSG00000182463;HGNC:13010;128553;Teashirt homolog 2 (Ovarian cancer-related protein 10-2) (OVC10-2) (Zinc finger protein 218);Q9NRE2;#N/A;https://platform.opentargets.org/target/ENSG00000182463;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1032;282;366;228;438;4_Low;105;16.17;0.03;0.06;64;1.51;0.03;0.02;37;12.61;0.08;0.08;4;2.04;0.04;0.04;3;0.51;0.19;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011036065;#N/A;#N/A;0.007892172;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.490953944;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0172;E2F2;ENSG00000007968;HGNC:3114;1870;Transcription factor E2F2 (E2F-2);Q14209;https://jaspar.elixir.no/search?q=Q14209;https://platform.opentargets.org/target/ENSG00000007968;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;1399;429;367;594;438;2_Medium;318;16.11;0.1;0.06;291;6.07;0.11;0.08;24;8.44;0.05;0.06;3;1.6;0.03;0.03;8;0.13;0.5;0.03;Cancer;#N/A;#N/A;0.003326219;#N/A;#N/A;0.054148411;0.003695799;#N/A;#N/A;0.012257732;0.007915169;0.01306629;0.001478319;#N/A;#N/A;0.030305548;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;5;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0245;FOXC2;ENSG00000176692;HGNC:3801;2303;Forkhead box protein C2 (Forkhead-related protein FKHL14) (Mesenchyme fork head protein 1) (MFH-1 protein) (Transcription factor FKH-14);Q99958;https://jaspar.elixir.no/search?q=Q99958;https://platform.opentargets.org/target/ENSG00000176692;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1988;685;368;452;1168;4_Low;440;16.1;0.14;0.06;422;9.47;0.17;0.13;16;5.13;0.03;0.03;2;1.5;0.02;0.03;12;0.21;0.75;0.05;Cancer;#N/A;#N/A;0.005954342;0.013532166;0.004250168;0.08079216;0.001478319;0.011456975;0.001478319;0.002204749;0.004065378;0.015891934;0.014393082;#N/A;#N/A;0.05124975;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0413;HSF4;ENSG00000102878;HGNC:5227;3299;Heat shock factor protein 4 (HSF 4) (hHSF4) (Heat shock transcription factor 4) (HSTF 4);Q9ULV5;https://jaspar.elixir.no/search?q=Q9ULV5;https://platform.opentargets.org/target/ENSG00000102878;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;1312;387;369;761;182;5_None;323;16.06;0.1;0.06;315;12.3;0.12;0.17;4;1.38;0.01;0.01;4;2.38;0.04;0.04;6;0.08;0.38;0.02;Ischemic Stroke;#N/A;#N/A;0.001478319;#N/A;#N/A;0.013717694;0.028642439;0.001478319;0.030120758;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1173;ZNF217;ENSG00000171940;HGNC:13009;7764;Zinc finger protein 217;O75362;#N/A;https://platform.opentargets.org/target/ENSG00000171940;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;819;201;370;267;182;5_None;172;15.9;0.06;0.06;144;4.69;0.06;0.06;24;9.14;0.05;0.06;4;2.07;0.04;0.04;5;0.45;0.31;0.11;Alzheimer Disease;#N/A;#N/A;0.190883002;#N/A;#N/A;0.060781194;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.184193538;#N/A;0.001478319;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0526;MEOX2;ENSG00000106511;HGNC:7014;4223;Homeobox protein MOX-2 (Growth arrest-specific homeobox) (Mesenchyme homeobox 2);P50222;https://jaspar.elixir.no/search?q=P50222;https://platform.opentargets.org/target/ENSG00000106511;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;811;199;371;258;182;5_None;251;15.85;0.08;0.06;215;5.43;0.08;0.07;34;9.4;0.07;0.06;2;1.02;0.02;0.02;6;0.46;0.38;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;0.023107833;0.003087634;#N/A;0.045632587;#N/A;0.002956639;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.381712511;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0952;TGIF1;ENSG00000177426;HGNC:11776;7050;Homeobox protein TGIF1 (5'-TG-3'-interacting factor 1);Q15583;https://jaspar.elixir.no/search?q=Q15583;https://platform.opentargets.org/target/ENSG00000177426;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1103;312;372;549;182;5_None;214;15.74;0.07;0.06;185;4.53;0.07;0.06;27;9.89;0.06;0.07;2;1.32;0.02;0.02;5;0.15;0.31;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.029012019;#N/A;#N/A;0.028304944;#N/A;#N/A;#N/A;#N/A;#N/A;0.003629568;#N/A;0.017370253;#N/A;0.069481013;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1271;ZNF384;ENSG00000126746;HGNC:11955;171017;Zinc finger protein 384 (CAG repeat protein 1) (CAS-interacting zinc finger protein) (Nuclear matrix transcription factor 4) (Nuclear matrix protein 4) (Trinucleotide repeat-containing gene 1 protein);Q8TF68;https://jaspar.elixir.no/search?q=Q8TF68;https://platform.opentargets.org/target/ENSG00000126746;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2117;741;373;576;1168;5_None;369;15.73;0.12;0.06;366;14.84;0.14;0.2;3;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;11;0.13;0.69;0.03;Alzheimer Disease;#N/A;#N/A;0.078798599;0.002587059;0.002217479;0.018758979;0.002217479;0.009096627;#N/A;0.003675266;0.002217479;#N/A;0.006370614;0.004065378;#N/A;0.004414426;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0563;MYNN;ENSG00000085274;HGNC:14955;55892;Myoneurin (Zinc finger and BTB domain-containing protein 31);Q9NPC7;#N/A;https://platform.opentargets.org/target/ENSG00000085274;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1018;278;374;462;182;5_None;110;15.67;0.04;0.06;81;7.26;0.03;0.1;29;8.41;0.06;0.06;#N/A;#N/A;#N/A;#N/A;3;0.2;0.19;0.05;Cancer;#N/A;#N/A;0.004434958;#N/A;#N/A;0.189604707;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1538;ZNF76;ENSG00000065029;HGNC:13149;7629;Zinc finger protein 76 (Zinc finger protein 523);P36508;https://jaspar.elixir.no/search?q=P36508;https://platform.opentargets.org/target/ENSG00000065029;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;859;218;375;302;182;5_None;107;15.63;0.03;0.06;81;7.72;0.03;0.1;25;7.38;0.05;0.05;1;0.52;0.01;0.01;2;0.38;0.13;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.027533699;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.352982624;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0467;KLF2;ENSG00000127528;HGNC:6347;10365;Krueppel-like factor 2 (Lung krueppel-like factor);Q9Y5W3;https://jaspar.elixir.no/search?q=Q9Y5W3;https://platform.opentargets.org/target/ENSG00000127528;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1194;344;376;380;438;5_None;406;15.58;0.13;0.06;380;6.08;0.15;0.08;24;8.45;0.05;0.06;2;1.04;0.02;0.02;12;0.28;0.75;0.07;Cancer;#N/A;0.009239496;0.021557076;0.034026192;#N/A;0.084238839;0.038891492;0.016343608;0.02284803;0.01878645;0.001478319;0.013323708;0.002217479;#N/A;#N/A;0.014257159;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;7;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0906;TBX20;ENSG00000164532;HGNC:11598;57057;T-box transcription factor TBX20 (T-box protein 20);Q9UMR3;https://jaspar.elixir.no/search?q=Q9UMR3;https://platform.opentargets.org/target/ENSG00000164532;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;1865;628;377;320;1168;5_None;201;15.48;0.06;0.06;174;6.01;0.07;0.08;24;7.63;0.05;0.05;3;1.84;0.03;0.03;4;0.36;0.25;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;0.014577872;#N/A;0.015572658;#N/A;0.018887879;#N/A;0.309671548;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0742;PRDM9;ENSG00000164256;HGNC:13994;56979;Histone-lysine N-methyltransferase PRDM9 (PR domain zinc finger protein 9) (PR domain-containing protein 9) (Protein-lysine N-methyltransferase PRDM9) (EC 2.1.1.-) ([histone H3]-lysine36 N-trimethyltransferase PRDM9) (EC 2.1.1.359) ([histone H3]-lysine4 N-trimethyltransferase PRDM9) (EC 2.1.1.354) ([histone H3]-lysine9 N-trimethyltransferase PRDM9) (EC 2.1.1.355) ([histone H4]-N-methyl-L-lysine20 N-methyltransferase PRDM9) (EC 2.1.1.362) ([histone H4]-lysine20 N-methyltransferase PRDM9) (EC 2.1.1.361);Q9NQV7;https://jaspar.elixir.no/search?q=Q9NQV7;https://platform.opentargets.org/target/ENSG00000164256;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1329;394;378;513;438;5_None;526;15.48;0.17;0.06;516;12.45;0.2;0.17;10;3.03;0.02;0.02;#N/A;#N/A;#N/A;#N/A;12;0.16;0.75;0.04;Cancer;#N/A;#N/A;0.009284395;0.008261752;#N/A;0.084620651;0.005615561;0.008284748;0.006652437;0.007391597;0.002771849;0.008020499;0.009847866;0.003695799;#N/A;0.010267201;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0643;NR2C2;ENSG00000177463;HGNC:7972;7182;Nuclear receptor subfamily 2 group C member 2 (Orphan nuclear receptor TAK1) (Orphan nuclear receptor TR4) (Testicular receptor 4);P49116;https://jaspar.elixir.no/search?q=P49116;https://platform.opentargets.org/target/ENSG00000177463;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;827;206;379;266;182;2_Medium;624;15.37;0.2;0.06;620;14.17;0.24;0.19;4;1.2;0.01;0.01;#N/A;#N/A;#N/A;#N/A;14;0.45;0.88;0.11;Cancer;0.007391597;#N/A;0.083312857;0.006900261;#N/A;0.086467024;0.012990001;0.031531004;0.010465283;0.054420195;0.046558392;0.015391315;0.022733557;0.012881501;0.001478319;0.053714479;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1457;ZNF648;ENSG00000179930;HGNC:18190;127665;Zinc finger protein 648;Q5T619;#N/A;https://platform.opentargets.org/target/ENSG00000179930;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3017;1227;380;1469;1168;5_None;79;15.21;0.03;0.06;31;3.25;0.01;0.04;48;11.96;0.1;0.08;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0488;LHX3;ENSG00000107187;HGNC:6595;8022;LIM/homeobox protein Lhx3 (LIM homeobox protein 3);Q9UBR4;#N/A;https://platform.opentargets.org/target/ENSG00000107187;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2339;857;381;790;1168;5_None;247;15.18;0.08;0.06;226;7.52;0.09;0.1;20;6.88;0.04;0.05;1;0.77;0.01;0.01;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.069111433;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0397;HOXC4;ENSG00000198353;HGNC:5126;3221;Homeobox protein Hox-C4 (Homeobox protein CP19) (Homeobox protein Hox-3E);P09017;https://jaspar.elixir.no/search?q=P09017;https://platform.opentargets.org/target/ENSG00000198353;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1211;352;382;647;182;4_Low;338;15.15;0.11;0.06;325;11.32;0.13;0.15;13;3.83;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.11;0.25;0.03;Cancer;#N/A;#N/A;#N/A;0.006652437;#N/A;0.078216191;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.020744745;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;putative;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0916;TCF20;ENSG00000100207;HGNC:11631;6942;Transcription factor 20 (TCF-20) (Nuclear factor SPBP) (Protein AR1) (Stromelysin-1 PDGF-responsive element-binding protein) (SPRE-binding protein);Q9UGU0;#N/A;https://platform.opentargets.org/target/ENSG00000100207;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1886;640;383;335;1168;5_None;158;15.15;0.05;0.06;126;3.43;0.05;0.05;28;9.33;0.06;0.06;4;2.38;0.04;0.04;4;0.34;0.25;0.09;Alzheimer Disease;#N/A;#N/A;0.324955817;0.002217479;0.005523166;0.006725109;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1008;VSX2;ENSG00000119614;HGNC:1975;338917;Visual system homeobox 2 (Ceh-10 homeodomain-containing homolog) (Homeobox protein CHX10);P58304;https://jaspar.elixir.no/search?q=P58304;https://platform.opentargets.org/target/ENSG00000119614;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1588;508;384;766;438;5_None;293;15.12;0.09;0.06;284;11.12;0.11;0.15;6;2.17;0.01;0.01;3;1.83;0.03;0.03;3;0.08;0.19;0.02;Age-Related Macular Degeneration;#N/A;0.070492786;#N/A;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1098;ZHX2;ENSG00000178764;HGNC:18513;22882;Zinc fingers and homeoboxes protein 2 (Alpha-fetoprotein regulator 1) (AFP regulator 1) (Regulator of AFP) (Zinc finger and homeodomain protein 2);Q9Y6X8;#N/A;https://platform.opentargets.org/target/ENSG00000178764;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1025;280;385;202;438;3_Medium to Low;615;15.02;0.2;0.06;593;7.64;0.23;0.1;21;6.87;0.04;0.05;1;0.51;0.01;0.01;13;0.56;0.81;0.14;Atherosclerosis;#N/A;0.001478319;0.012558692;0.304084467;0.004619748;0.101863945;0.005245981;0.004234243;0.001478319;0.004065378;0.076389577;0.004434958;#N/A;0.00458895;#N/A;0.032307439;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;6;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0247;FOXD2;ENSG00000186564;HGNC:3803;2306;Forkhead box protein D2 (Forkhead-related protein FKHL17) (Forkhead-related transcription factor 9) (FREAC-9);O60548;https://jaspar.elixir.no/search?q=O60548;https://platform.opentargets.org/target/ENSG00000186564;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1358;407;386;534;438;5_None;246;15.01;0.08;0.06;228;10.02;0.09;0.14;18;5;0.04;0.03;#N/A;#N/A;#N/A;#N/A;5;0.15;0.31;0.04;Cancer;#N/A;0.06696012;#N/A;#N/A;#N/A;0.071736843;0.004866135;#N/A;0.001478319;#N/A;#N/A;0.009852999;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0778;RFX6;ENSG00000185002;HGNC:21478;222546;DNA-binding protein RFX6 (Regulatory factor X 6) (Regulatory factor X domain-containing protein 1);Q8HWS3;#N/A;https://platform.opentargets.org/target/ENSG00000185002;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;596;118;387;27;182;5_None;121;15;0.04;0.06;88;3.12;0.03;0.04;28;8.69;0.06;0.06;5;3.19;0.05;0.06;5;1.48;0.31;0.38;Type 2 Diabetes Mellitus;#N/A;#N/A;0.317917029;#N/A;0.002751317;0.301469903;0.21896704;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.641369382;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0393;HOXC10;ENSG00000180818;HGNC:5122;3226;Homeobox protein Hox-C10 (Homeobox protein Hox-3I);Q9NYD6;https://jaspar.elixir.no/search?q=Q9NYD6;https://platform.opentargets.org/target/ENSG00000180818;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2200;795;388;644;1168;4_Low;377;14.97;0.12;0.06;373;13.95;0.15;0.19;4;1.02;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.11;0.25;0.03;Cancer;#N/A;#N/A;0.003695799;0.001478319;#N/A;0.098566728;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0428;IRF3;ENSG00000126456;HGNC:6118;3661;Interferon regulatory factor 3 (IRF-3);Q14653;https://jaspar.elixir.no/search?q=Q14653;https://platform.opentargets.org/target/ENSG00000126456;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;744;162;389;272;83;4_Low;556;14.88;0.18;0.05;545;11.09;0.21;0.15;10;3.22;0.02;0.02;1;0.56;0.01;0.01;15;0.44;0.94;0.11;Chronic Obstructive Pulmonary Disease;0.002217479;0.080110449;0.064871101;0.015591409;0.001478319;0.075131205;0.084843569;0.01669269;0.009740072;0.026897289;0.010277196;0.002956639;0.004804538;0.002217479;#N/A;0.04119071;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0922;TCF7;ENSG00000081059;HGNC:11639;6932;Transcription factor 7 (TCF-7) (T-cell-specific transcription factor 1) (T-cell factor 1) (TCF-1);P36402;https://jaspar.elixir.no/search?q=P36402;https://platform.opentargets.org/target/ENSG00000081059;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.3 TCF7-related;1534;483;390;706;438;5_None;378;14.87;0.12;0.05;353;7.67;0.14;0.1;24;6.65;0.05;0.04;1;0.55;0.01;0.01;8;0.09;0.5;0.02;Cancer;#N/A;0.002956639;#N/A;0.009958124;#N/A;0.036378029;0.010717816;0.002956639;#N/A;#N/A;#N/A;0.002217479;0.008713461;#N/A;#N/A;0.016429578;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0591;NFATC3;ENSG00000072736;HGNC:7777;4775;Nuclear factor of activated T-cells, cytoplasmic 3 (NF-ATc3) (NFATc3) (NFATx) (T-cell transcription factor NFAT4) (NF-AT4) (NF-AT4c);Q12968;https://jaspar.elixir.no/search?q=Q12968;https://platform.opentargets.org/target/ENSG00000072736;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.3 NFAT-related;1301;382;391;472;438;5_None;407;14.84;0.13;0.05;403;13.88;0.16;0.19;4;0.97;0.01;0.01;#N/A;#N/A;#N/A;#N/A;9;0.19;0.56;0.05;Chronic Obstructive Pulmonary Disease;#N/A;0.001478319;0.010991199;0.036752663;#N/A;0.035356642;0.061493981;0.008615933;#N/A;0.010047426;#N/A;#N/A;#N/A;0.003695799;#N/A;0.018704847;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0236;FOSB;ENSG00000125740;HGNC:3797;2354;Protein FosB (FosB proto-oncogene, AP-1 transcription factor subunit) (G0/G1 switch regulatory protein 3) (Transcription factor AP-1 subunit FosB);P53539;https://jaspar.elixir.no/search?q=P53539;https://platform.opentargets.org/target/ENSG00000125740;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;1115;321;392;285;438;3_Medium to Low;946;14.82;0.3;0.05;941;13.6;0.37;0.18;5;1.22;0.01;0.01;#N/A;#N/A;#N/A;#N/A;14;0.42;0.88;0.11;Cancer;#N/A;0.012400931;0.031978146;0.046720071;0.012042144;0.085448546;0.027902398;0.026691949;0.004691611;0.032591943;0.062512529;0.017290624;0.004171438;0.031953672;#N/A;0.022325738;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0182;EBF3;ENSG00000108001;HGNC:19087;253738;Transcription factor COE3 (Early B-cell factor 3) (EBF-3) (Olf-1/EBF-like 2) (O/E-2) (OE-2);Q9H4W6;https://jaspar.elixir.no/search?q=Q9H4W6;https://platform.opentargets.org/target/ENSG00000108001;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.5 EBF-related;1560;493;393;729;438;5_None;150;14.76;0.05;0.05;112;1.34;0.04;0.02;36;12.06;0.07;0.08;2;1.36;0.02;0.02;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.018657392;#N/A;#N/A;0.03593801;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;0.027868316;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0854;SOX3;ENSG00000134595;HGNC:11199;6658;Transcription factor SOX-3;P41225;#N/A;https://platform.opentargets.org/target/ENSG00000134595;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;2264;824;394;702;1168;5_None;349;14.75;0.11;0.05;340;10.71;0.13;0.15;6;2.07;0.01;0.01;3;1.97;0.03;0.03;7;0.09;0.44;0.02;Ischemic Stroke;#N/A;0.002936107;0.012235442;#N/A;#N/A;0.028311649;#N/A;0.002217479;0.040920703;#N/A;#N/A;0.002217479;#N/A;0.002956639;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0533;MLX;ENSG00000108788;HGNC:11645;6945;Max-like protein X (Class D basic helix-loop-helix protein 13) (bHLHd13) (Max-like bHLHZip protein) (Protein BigMax) (Transcription factor-like protein 4);Q9UH92;https://jaspar.elixir.no/search?q=Q9UH92;https://platform.opentargets.org/target/ENSG00000108788;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;941;249;395;364;182;4_Low;238;14.62;0.08;0.05;228;11.55;0.09;0.16;10;3.07;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.3;0.38;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;0.020326892;#N/A;#N/A;0.009928146;#N/A;#N/A;#N/A;#N/A;0.008664594;#N/A;#N/A;0.018478993;0.001478319;0.238030126;2;0.13;N;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0985;TP73;ENSG00000078900;HGNC:12003;7161;Tumor protein p73 (p53-like transcription factor) (p53-related protein);O15350;https://jaspar.elixir.no/search?q=O15350;https://platform.opentargets.org/target/ENSG00000078900;6 Immunoglobulin fold;6.3 p53 domain factors;6.3.1 p53-related;825;204;396;408;21;4_Low;505;14.61;0.16;0.05;490;9.51;0.19;0.13;13;3.83;0.03;0.03;2;1.27;0.02;0.02;10;0.24;0.63;0.06;Cancer;#N/A;#N/A;0.058713435;0.009763068;0.02012157;0.082554568;0.028533618;#N/A;#N/A;0.002217479;#N/A;0.003695799;#N/A;0.026004049;0.003695799;0.009070106;6;0.4;Y;Pro-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;functional,putative;#N/A;Anti-Longevity;Pro-Longevity;#N/A;#N/A;Pro-Longevity;6;#N/A;#N/A;Pro-Longevity;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;12;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0803;SCMH1;ENSG00000010803;HGNC:19003;22955;Polycomb protein SCMH1 (Sex comb on midleg homolog 1);Q96GD3;#N/A;https://platform.opentargets.org/target/ENSG00000010803;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2147;759;397;582;1168;5_None;197;14.6;0.06;0.05;179;8.88;0.07;0.12;17;5.17;0.04;0.03;1;0.55;0.01;0.01;4;0.13;0.25;0.03;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.005543698;0.121656965;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0868;SP3;ENSG00000172845;HGNC:11208;6670;Transcription factor Sp3 (SPR-2);Q02447;https://jaspar.elixir.no/search?q=Q02447;https://platform.opentargets.org/target/ENSG00000172845;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1196;345;398;616;182;4_Low;314;14.57;0.1;0.05;289;6.85;0.11;0.09;24;7.22;0.05;0.05;1;0.5;0.01;0.01;8;0.12;0.5;0.03;Cancer;#N/A;#N/A;0.016784947;0.006282858;#N/A;0.070212385;0.007576387;#N/A;0.001478319;0.003511009;#N/A;0.007945967;#N/A;0.002956639;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0255;FOXE1;ENSG00000178919;HGNC:3806;2304;Forkhead box protein E1 (Forkhead box protein E2) (Forkhead-related protein FKHL15) (HFKH4) (HNF-3/fork head-like protein 5) (HFKL5) (Thyroid transcription factor 2) (TTF-2);O00358;https://jaspar.elixir.no/search?q=O00358;https://platform.opentargets.org/target/ENSG00000178919;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1573;500;399;736;438;5_None;215;14.53;0.07;0.05;192;6.79;0.08;0.09;22;6.94;0.05;0.05;1;0.79;0.01;0.01;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;0.004619748;#N/A;#N/A;0.078701491;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0202;EOMES;ENSG00000163508;HGNC:3372;8320;Eomesodermin homolog (T-box brain protein 2) (T-brain-2) (TBR-2);O95936;https://jaspar.elixir.no/search?q=O95936;https://platform.opentargets.org/target/ENSG00000163508;6 Immunoglobulin fold;6.5 T-Box factors;6.5.0 Uncharacterized/Undefined;1674;545;400;836;438;4_Low;267;14.5;0.09;0.05;240;4.65;0.09;0.06;26;9.34;0.05;0.06;1;0.51;0.01;0.01;7;0.06;0.44;0.01;Cancer;#N/A;0.003695799;0.012246439;0.004250168;#N/A;0.029400786;0.002956639;#N/A;#N/A;#N/A;0.003695799;0.001478319;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0859;SOX7;ENSG00000171056;HGNC:18196;83595;Transcription factor SOX-7;Q9BT81;#N/A;https://platform.opentargets.org/target/ENSG00000171056;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1899;646;401;330;1168;5_None;214;14.48;0.07;0.05;184;5.15;0.07;0.07;30;9.33;0.06;0.06;#N/A;#N/A;#N/A;#N/A;6;0.34;0.38;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;0.014783194;0.001478319;#N/A;0.035291269;0.002956639;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.287972329;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0634;NR0B1;ENSG00000169297;HGNC:7960;190;Nuclear receptor subfamily 0 group B member 1 (DSS-AHC critical region on the X chromosome protein 1) (Nuclear receptor DAX-1);P51843;#N/A;https://platform.opentargets.org/target/ENSG00000169297;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.7 DAXrelated(NR0);2244;811;402;674;1168;4_Low;503;14.45;0.16;0.05;497;10.96;0.19;0.15;3;1.28;0.01;0.01;3;2.22;0.03;0.04;12;0.1;0.75;0.02;Cancer;#N/A;#N/A;0.007619492;0.0049811;0.002587059;0.034537813;0.004229636;0.003695799;0.001478319;0.002587059;0.003675266;#N/A;0.003326219;0.024017134;#N/A;0.005449628;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;10;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0036;ASCL1;ENSG00000139352;HGNC:738;429;Achaete-scute homolog 1 (ASH-1) (hASH1) (Class A basic helix-loop-helix protein 46) (bHLHa46);P50553;https://jaspar.elixir.no/search?q=P50553;https://platform.opentargets.org/target/ENSG00000139352;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;1389;422;403;548;438;3_Medium to Low;328;14.43;0.11;0.05;298;5.73;0.12;0.08;29;8.19;0.06;0.05;1;0.51;0.01;0.01;7;0.15;0.44;0.04;Alzheimer Disease;#N/A;#N/A;0.064805561;0.007391597;#N/A;0.029955587;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.001478319;0.0325749;#N/A;0.008130757;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0317;GRHL2;ENSG00000083307;HGNC:2799;79977;Grainyhead-like protein 2 homolog (Brother of mammalian grainyhead) (Transcription factor CP2-like 3);Q6ISB3;https://jaspar.elixir.no/search?q=Q6ISB3;https://platform.opentargets.org/target/ENSG00000083307;6 Immunoglobulin fold;6.7 Grainyhead;6.7.1 Grainyhead-related;1335;397;404;493;438;5_None;228;14.39;0.07;0.05;205;6.03;0.08;0.08;19;5.92;0.04;0.04;4;2.44;0.04;0.04;4;0.18;0.25;0.04;Cancer;0.030007247;#N/A;0.017370253;#N/A;#N/A;0.067017063;#N/A;#N/A;#N/A;#N/A;0.062089416;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1101;ZIC2;ENSG00000043355;HGNC:12873;7546;Zinc finger protein ZIC 2 (Zinc finger protein of the cerebellum 2);O95409;#N/A;https://platform.opentargets.org/target/ENSG00000043355;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1388;417;405;545;438;5_None;301;14.32;0.1;0.05;286;8.43;0.11;0.11;12;3.92;0.02;0.03;3;1.97;0.03;0.03;5;0.15;0.31;0.04;Cancer;#N/A;#N/A;0.011120687;#N/A;0.05174118;0.074177653;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004804538;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0912;TBX6;ENSG00000149922;HGNC:11605;6911;T-box transcription factor TBX6 (T-box protein 6);O95947;https://jaspar.elixir.no/search?q=O95947;https://platform.opentargets.org/target/ENSG00000149922;6 Immunoglobulin fold;6.5 T-Box factors;6.5.5 TBX6-related;1575;502;406;731;438;5_None;232;14.28;0.07;0.05;211;8.15;0.08;0.11;19;4.86;0.04;0.03;2;1.27;0.02;0.02;3;0.08;0.19;0.02;Alzheimer Disease;#N/A;#N/A;0.038415493;#N/A;#N/A;0.009793866;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.036276611;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0213;ETS2;ENSG00000157557;HGNC:3489;2114;Protein C-ets-2;P15036;https://jaspar.elixir.no/search?q=P15036;https://platform.opentargets.org/target/ENSG00000157557;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;798;195;407;339;52;3_Medium to Low;287;14.24;0.09;0.05;262;7.92;0.1;0.11;25;6.32;0.05;0.04;#N/A;#N/A;#N/A;#N/A;8;0.33;0.5;0.08;Benign Prostatic Hyperplasia;#N/A;#N/A;0.034432568;0.005523166;0.182020144;0.076888191;0.009511548;0.012592818;#N/A;#N/A;#N/A;0.008133841;#N/A;#N/A;0.004434958;#N/A;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;5;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0335;HES1;ENSG00000114315;HGNC:5192;3280;Transcription factor HES-1 (Class B basic helix-loop-helix protein 39) (bHLHb39) (Hairy and enhancer of split 1) (Hairy homolog) (Hairy-like protein) (hHL);Q14469;https://jaspar.elixir.no/search?q=Q14469;https://platform.opentargets.org/target/ENSG00000114315;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;1000;270;408;410;182;4_Low;626;14.23;0.2;0.05;610;9.58;0.24;0.13;15;4.11;0.03;0.03;1;0.53;0.01;0.01;14;0.24;0.88;0.06;Cancer;#N/A;0.006652437;0.015217393;0.029748431;0.003695799;0.059616873;0.026332753;0.008869917;0.028457649;0.012743614;0.005613097;0.010015396;0.016158853;0.003695799;#N/A;0.016612019;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;6;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0945;TFCP2L1;ENSG00000115112;HGNC:17925;29842;Transcription factor CP2-like protein 1 (CP2-related transcriptional repressor 1) (CRTR-1) (Transcription factor LBP-9);Q9NZI6;#N/A;https://platform.opentargets.org/target/ENSG00000115112;6 Immunoglobulin fold;6.7 Grainyhead;6.7.0 Uncharacterized/Undefined;937;247;409;90;438;5_None;131;14.13;0.04;0.05;105;2.87;0.04;0.04;19;7.35;0.04;0.05;7;3.91;0.07;0.07;4;0.91;0.25;0.23;Alzheimer Disease;#N/A;#N/A;0.423664924;#N/A;#N/A;0.035688909;0.027718489;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.423664924;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0163;DR1;ENSG00000117505;HGNC:3017;1810;Protein Dr1 (Down-regulator of transcription 1) (Negative cofactor 2-beta) (NC2-beta) (TATA-binding protein-associated phosphoprotein);Q01658;#N/A;https://platform.opentargets.org/target/ENSG00000117505;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2372;876;410;794;1168;3_Medium to Low;191;14.11;0.06;0.05;156;4.25;0.06;0.06;34;9.33;0.07;0.06;1;0.52;0.01;0.01;6;0.07;0.38;0.02;Parkinson Disease;#N/A;#N/A;0.001478319;0.001847899;#N/A;0.007945967;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.053951086;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;21;21;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0814;SHOX2;ENSG00000168779;HGNC:10854;6474;Short stature homeobox protein 2 (Homeobox protein Og12X) (Paired-related homeobox protein SHOT);O60902;#N/A;https://platform.opentargets.org/target/ENSG00000168779;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2062;718;411;483;1168;5_None;319;14.09;0.1;0.05;302;9.18;0.12;0.12;17;4.91;0.04;0.03;#N/A;#N/A;#N/A;#N/A;5;0.18;0.31;0.05;Cancer;#N/A;0.074338914;#N/A;#N/A;#N/A;0.096702039;0.005523166;0.003511009;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0998;UNCX;ENSG00000164853;HGNC:33194;340260;Homeobox protein unc-4 homolog (Homeobox protein Uncx4.1);A6NJT0;https://jaspar.elixir.no/search?q=A6NJT0;https://platform.opentargets.org/target/ENSG00000164853;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2263;821;412;1413;438;5_None;161;14.07;0.05;0.05;138;5.55;0.05;0.08;23;8.53;0.05;0.06;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unannotated;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0740;PRDM6;ENSG00000061455;HGNC:9350;93166;Putative histone-lysine N-methyltransferase PRDM6 (EC 2.1.1.361) (PR domain zinc finger protein 6) (PR domain-containing protein 6);Q9NQX0;#N/A;https://platform.opentargets.org/target/ENSG00000061455;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1728;570;413;877;438;5_None;82;13.97;0.03;0.05;48;0.71;0.02;0.01;29;10.49;0.06;0.07;5;2.77;0.05;0.05;5;0.05;0.31;0.01;Ischemic Stroke;#N/A;#N/A;#N/A;#N/A;#N/A;0.014937186;#N/A;0.001478319;0.02660975;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0554;MXI1;ENSG00000119950;HGNC:7534;4601;Max-interacting protein 1 (Max interactor 1) (Class C basic helix-loop-helix protein 11) (bHLHc11);P50539;https://jaspar.elixir.no/search?q=P50539;https://platform.opentargets.org/target/ENSG00000119950;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1041;285;414;596;31;4_Low;223;13.96;0.07;0.05;194;2.71;0.08;0.04;25;9.08;0.05;0.06;4;2.17;0.04;0.04;5;0.13;0.31;0.03;Cancer;#N/A;#N/A;0.021253413;#N/A;0.009978656;0.084744531;#N/A;#N/A;#N/A;#N/A;#N/A;0.008364007;#N/A;#N/A;#N/A;0.001478319;5;0.33;Y;#N/A;Unclear;Pro-Longevity;Unclear;#N/A;#N/A;#N/A;putative;Anti-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0269;FOXL1;ENSG00000176678;HGNC:3817;2300;Forkhead box protein L1 (Forkhead-related protein FKHL11) (Forkhead-related transcription factor 7) (FREAC-7);Q12952;https://jaspar.elixir.no/search?q=Q12952;https://platform.opentargets.org/target/ENSG00000176678;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1756;587;415;903;438;5_None;209;13.94;0.07;0.05;188;8.17;0.07;0.11;21;5.78;0.04;0.04;#N/A;#N/A;#N/A;#N/A;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.002902844;#N/A;#N/A;0.021323831;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.0195672;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0149;DMRT1;ENSG00000137090;HGNC:2934;1761;Doublesex- and mab-3-related transcription factor 1 (DM domain expressed in testis protein 1);Q9Y5R6;#N/A;https://platform.opentargets.org/target/ENSG00000137090;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;2074;725;416;490;1168;5_None;364;13.91;0.12;0.05;344;7.09;0.13;0.1;18;5.78;0.04;0.04;2;1.03;0.02;0.02;12;0.18;0.75;0.05;Alzheimer Disease;#N/A;0.019105225;0.041803293;0.002587059;#N/A;0.028567512;0.005687423;0.002751317;#N/A;0.002751317;0.001478319;0.008500337;0.020831369;0.030139309;#N/A;0.013572602;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0581;NEUROD1;ENSG00000162992;HGNC:7762;4760;Neurogenic differentiation factor 1 (NeuroD) (NeuroD1) (Class A basic helix-loop-helix protein 3) (bHLHa3);Q13562;https://jaspar.elixir.no/search?q=Q13562;https://platform.opentargets.org/target/ENSG00000162992;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;958;257;417;103;438;4_Low;480;13.91;0.15;0.05;467;8.52;0.18;0.12;9;2.93;0.02;0.02;4;2.46;0.04;0.04;10;0.84;0.63;0.21;Type 2 Diabetes Mellitus;#N/A;#N/A;0.014907668;0.002936107;0.008869917;0.026241929;0.009521903;0.009218964;0.08067044;0.002587059;#N/A;#N/A;#N/A;0.01325108;#N/A;0.670048266;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0899;TBR1;ENSG00000136535;HGNC:11590;10716;T-box brain protein 1 (T-brain-1) (TBR-1) (TES-56);Q16650;https://jaspar.elixir.no/search?q=Q16650;https://platform.opentargets.org/target/ENSG00000136535;6 Immunoglobulin fold;6.5 T-Box factors;6.5.0 Uncharacterized/Undefined;2597;985;418;1011;1168;5_None;148;13.74;0.05;0.05;116;1.75;0.05;0.02;28;9.4;0.06;0.06;4;2.59;0.04;0.05;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.004876401;#N/A;#N/A;0.020090772;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0159;DOT1L;ENSG00000104885;HGNC:24948;84444;Histone-lysine N-methyltransferase, H3 lysine-79 specific (EC 2.1.1.360) (DOT1-like protein) (Histone H3-K79 methyltransferase) (H3-K79-HMTase) (Lysine N-methyltransferase 4);Q8TEK3;#N/A;https://platform.opentargets.org/target/ENSG00000104885;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;693;146;419;191;83;4_Low;258;13.71;0.08;0.05;239;8.08;0.09;0.11;19;5.63;0.04;0.04;#N/A;#N/A;#N/A;#N/A;12;0.57;0.75;0.14;Myocardial Infarction;#N/A;0.0760035;0.003695799;0.020326892;#N/A;0.063698892;0.011641765;0.002217479;0.008869917;0.219676348;#N/A;0.144352494;0.012319328;0.004434958;#N/A;0.001478319;3;0.2;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;Inhibits;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0052;ATOH7;ENSG00000179774;HGNC:13907;220202;Transcription factor ATOH7 (Atonal bHLH transcription factor 7) (Class A basic helix-loop-helix protein 13) (bHLHa13) (Protein atonal homolog 7);Q8N100;https://jaspar.elixir.no/search?q=Q8N100;https://platform.opentargets.org/target/ENSG00000179774;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2316;849;420;728;1168;5_None;182;13.67;0.06;0.05;165;6.88;0.06;0.09;15;5.52;0.03;0.04;2;1.27;0.02;0.02;1;0.08;0.06;0.02;Age-Related Macular Degeneration;#N/A;0.084832275;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1371;ZNF536;ENSG00000198597;HGNC:29025;9745;Zinc finger protein 536;O15090;#N/A;https://platform.opentargets.org/target/ENSG00000198597;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1700;559;421;841;438;5_None;105;13.6;0.03;0.05;68;1.68;0.03;0.02;36;11.41;0.07;0.08;1;0.51;0.01;0.01;1;0.06;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.056597543;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0411;HSF1;ENSG00000185122;HGNC:5224;3297;Heat shock factor protein 1 (HSF 1) (Heat shock transcription factor 1) (HSTF 1);Q00613;https://jaspar.elixir.no/search?q=Q00613;https://platform.opentargets.org/target/ENSG00000185122;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;573;113;422;142;9;4_Low;499;13.59;0.16;0.05;493;12.04;0.19;0.16;6;1.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;15;0.68;0.94;0.17;Type 2 Diabetes Mellitus;0.001478319;0.004065378;0.051645257;0.033058302;0.004434958;0.117706624;0.016117788;0.088095635;#N/A;0.082709097;0.053540418;0.002587059;0.004065378;0.018350462;0.003695799;0.199394102;8;0.53;Y;Pro-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;model;Pro-Longevity;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;4;Pro-Longevity;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0443;ISX;ENSG00000175329;HGNC:28084;91464;Intestine-specific homeobox (RAX-like homeobox);Q2M1V0;https://jaspar.elixir.no/search?q=Q2M1V0;https://platform.opentargets.org/target/ENSG00000175329;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2729;1059;423;1138;1168;5_None;99;13.58;0.03;0.05;93;11.66;0.04;0.16;6;1.92;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01148531;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1048;ZBTB40;ENSG00000184677;HGNC:29045;9923;Zinc finger and BTB domain-containing protein 40;Q9NUA8;#N/A;https://platform.opentargets.org/target/ENSG00000184677;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1785;599;424;193;1168;5_None;83;13.56;0.03;0.05;52;5.26;0.02;0.07;31;8.29;0.06;0.06;#N/A;#N/A;#N/A;#N/A;4;0.57;0.25;0.14;Alzheimer Disease;#N/A;#N/A;0.26076876;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.04350191;0.26076876;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0373;HOXA10;ENSG00000253293;HGNC:5100;3206;Homeobox protein Hox-A10 (Homeobox protein Hox-1.8) (Homeobox protein Hox-1H) (PL);P31260;https://jaspar.elixir.no/search?q=P31260;https://platform.opentargets.org/target/ENSG00000253293;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2128;749;425;535;1168;5_None;503;13.55;0.16;0.05;498;12.17;0.19;0.16;5;1.39;0.01;0.01;#N/A;#N/A;#N/A;#N/A;11;0.15;0.69;0.04;Cancer;#N/A;0.002217479;0.015517841;0.002902844;#N/A;0.087552869;0.022913951;0.003695799;#N/A;0.001847899;0.001478319;#N/A;0.013543664;0.001478319;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0903;TBX18;ENSG00000112837;HGNC:11595;9096;T-box transcription factor TBX18 (T-box protein 18);O95935;https://jaspar.elixir.no/search?q=O95935;https://platform.opentargets.org/target/ENSG00000112837;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;1737;579;426;873;438;5_None;137;13.55;0.04;0.05;106;2.62;0.04;0.04;28;9.09;0.06;0.06;3;1.84;0.03;0.03;7;0.05;0.44;0.01;Ischemic Stroke;#N/A;#N/A;0.001478319;0.002771849;#N/A;#N/A;0.001478319;0.004434958;0.033262187;0.002587059;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0601;NFIL3;ENSG00000165030;HGNC:7787;4783;Nuclear factor interleukin-3-regulated protein (E4 promoter-binding protein 4) (Interleukin-3 promoter transcriptional activator) (Interleukin-3-binding protein 1) (Transcriptional activator NF-IL3A);Q16649;https://jaspar.elixir.no/search?q=Q16649;https://platform.opentargets.org/target/ENSG00000165030;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;1998;690;427;403;1168;5_None;335;13.51;0.11;0.05;318;8.24;0.12;0.11;16;4.74;0.03;0.03;1;0.53;0.01;0.01;11;0.25;0.69;0.06;Cancer;#N/A;#N/A;0.008768167;0.014475211;#N/A;0.100567174;0.052480339;0.016577299;#N/A;0.002587059;0.020052376;0.025162877;#N/A;0.003695799;0.001478319;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0523;MEIS2;ENSG00000134138;HGNC:7001;4212;Homeobox protein Meis2 (Meis1-related protein 1);O14770;https://jaspar.elixir.no/search?q=O14770;https://platform.opentargets.org/target/ENSG00000134138;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1290;378;428;779;83;5_None;172;13.49;0.06;0.05;140;1.69;0.05;0.02;29;10;0.06;0.07;3;1.81;0.03;0.03;5;0.07;0.31;0.02;Cancer;#N/A;#N/A;0.010965311;#N/A;0.002217479;0.030880849;#N/A;#N/A;#N/A;0.025018503;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;Inhibits;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1060;ZBTB7A;ENSG00000178951;HGNC:18078;51341;Zinc finger and BTB domain-containing protein 7A (Factor binding IST protein 1) (FBI-1) (Factor that binds to inducer of short transcripts protein 1) (HIV-1 1st-binding protein 1) (Leukemia/lymphoma-related factor) (POZ and Krueppel erythroid myeloid ontogenic factor) (POK erythroid myeloid ontogenic factor) (Pokemon) (Pokemon 1) (TTF-I-interacting peptide 21) (TIP21) (Zinc finger protein 857A);O95365;https://jaspar.elixir.no/search?q=O95365;https://platform.opentargets.org/target/ENSG00000178951;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1046;288;429;435;182;5_None;209;13.45;0.07;0.05;187;5.82;0.07;0.08;21;6.93;0.04;0.05;1;0.7;0.01;0.01;7;0.22;0.44;0.06;Cancer;#N/A;#N/A;0.00899533;0.002217479;0.009609076;0.091988574;0.004619748;#N/A;#N/A;#N/A;0.072437652;#N/A;#N/A;#N/A;#N/A;0.033262187;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0662;ONECUT1;ENSG00000169856;HGNC:8138;3175;Hepatocyte nuclear factor 6 (HNF-6) (One cut domain family member 1) (One cut homeobox 1);Q9UBC0;https://jaspar.elixir.no/search?q=Q9UBC0;https://platform.opentargets.org/target/ENSG00000169856;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;1888;642;430;290;1168;3_Medium to Low;196;13.41;0.06;0.05;170;4.45;0.07;0.06;21;6.36;0.04;0.04;5;2.61;0.05;0.05;3;0.41;0.19;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.010927924;#N/A;#N/A;#N/A;#N/A;0.014783194;#N/A;#N/A;#N/A;#N/A;0.382357609;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0821;SIX5;ENSG00000177045;HGNC:10891;147912;Homeobox protein SIX5 (DM locus-associated homeodomain protein) (Sine oculis homeobox homolog 5);Q8N196;#N/A;https://platform.opentargets.org/target/ENSG00000177045;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;1681;549;431;812;438;5_None;288;13.39;0.09;0.05;286;12.12;0.11;0.16;1;0.48;0;0;1;0.79;0.01;0.01;3;0.06;0.19;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.007391597;#N/A;#N/A;0.018305278;0.03688394;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0511;MBD2;ENSG00000134046;HGNC:6917;8932;Methyl-CpG-binding domain protein 2 (Demethylase) (DMTase) (Methyl-CpG-binding protein MBD2);Q9UBB5;#N/A;https://platform.opentargets.org/target/ENSG00000134046;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1010;274;432;140;438;4_Low;406;13.35;0.13;0.05;382;6.35;0.15;0.09;24;7;0.05;0.05;#N/A;#N/A;#N/A;#N/A;14;0.69;0.88;0.17;Alzheimer Disease;#N/A;0.025665268;0.2378502;0.002012157;0.002956639;0.041865566;0.081721087;0.005572032;0.001478319;0.002217479;0.004381164;0.004989328;0.012085877;0.235272931;#N/A;0.027567818;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0045;ATF4;ENSG00000128272;HGNC:786;468;Cyclic AMP-dependent transcription factor ATF-4 (cAMP-dependent transcription factor ATF-4) (Activating transcription factor 4) (Cyclic AMP-responsive element-binding protein 2) (CREB-2) (cAMP-responsive element-binding protein 2) (Tax-responsive enhancer element-binding protein 67) (TaxREB67);P18848;https://jaspar.elixir.no/search?q=P18848;https://platform.opentargets.org/target/ENSG00000128272;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.6 ATF4-related;758;172;433;273;52;3_Medium to Low;608;13.34;0.2;0.05;600;10.67;0.23;0.14;7;2.11;0.01;0.01;1;0.55;0.01;0.01;14;0.44;0.88;0.11;Alzheimer Disease;#N/A;0.007761177;0.105117989;0.016194677;#N/A;0.103700249;0.017549509;0.011130501;0.008375386;0.005135094;0.016140741;0.01276344;0.020019762;0.062605239;0.004250168;0.045366716;4;0.27;Y;Unclear;Anti-Longevity;#N/A;Anti-Longevity;#N/A;Unclear;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;29;28;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0571;MYT1L;ENSG00000186487;HGNC:7623;23040;Myelin transcription factor 1-like protein (MyT1-L) (MyT1L);Q9UL68;#N/A;https://platform.opentargets.org/target/ENSG00000186487;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.1 MYT;2005;691;434;1133;438;4_Low;137;13.29;0.04;0.05;105;1.86;0.04;0.03;29;9.55;0.06;0.06;3;1.88;0.03;0.03;3;0.01;0.19;0;Alzheimer Disease;#N/A;#N/A;0.006502961;#N/A;#N/A;0.00526138;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0341;HES7;ENSG00000179111;HGNC:15977;84667;Transcription factor HES-7 (hHes7) (Class B basic helix-loop-helix protein 37) (bHLHb37) (Hairy and enhancer of split 7) (bHLH factor Hes7);Q9BYE0;https://jaspar.elixir.no/search?q=Q9BYE0;https://platform.opentargets.org/target/ENSG00000179111;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;2198;792;435;1325;438;5_None;121;13.26;0.04;0.05;95;3.96;0.04;0.05;24;8.05;0.05;0.05;2;1.25;0.02;0.02;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004681345;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0456;KDM5B;ENSG00000117139;HGNC:18039;10765;Lysine-specific demethylase 5B (EC 1.14.11.67) (Cancer/testis antigen 31) (CT31) (Histone demethylase JARID1B) (Jumonji/ARID domain-containing protein 1B) (PLU-1) (Retinoblastoma-binding protein 2 homolog 1) (RBP2-H1) ([histone H3]-trimethyl-L-lysine(4) demethylase 5B);Q9UGL1;#N/A;https://platform.opentargets.org/target/ENSG00000117139;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;977;262;436;458;83;4_Low;265;13.23;0.09;0.05;246;6.39;0.1;0.09;16;5.02;0.03;0.03;3;1.81;0.03;0.03;8;0.2;0.5;0.05;Cancer;#N/A;#N/A;#N/A;0.030100226;0.002956639;0.077398053;#N/A;0.006652437;#N/A;0.067263534;#N/A;#N/A;0.003695799;0.003695799;#N/A;0.007391597;3;0.2;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;Inhibits;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0074;BHLHE40;ENSG00000134107;HGNC:1046;8553;Class E basic helix-loop-helix protein 40 (bHLHe40) (Class B basic helix-loop-helix protein 2) (bHLHb2) (Differentially expressed in chondrocytes protein 1) (DEC1) (Enhancer-of-split and hairy-related protein 2) (SHARP-2) (Stimulated by retinoic acid gene 13 protein);O14503;https://jaspar.elixir.no/search?q=O14503;https://platform.opentargets.org/target/ENSG00000134107;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;826;205;437;337;52;4_Low;462;13.19;0.15;0.05;454;10.78;0.18;0.15;8;2.41;0.02;0.02;#N/A;#N/A;#N/A;#N/A;12;0.34;0.75;0.09;Alzheimer Disease;#N/A;#N/A;0.084773681;0.022729161;#N/A;0.074278243;0.012011345;0.007391597;0.001478319;0.008664594;0.004804538;0.015522354;0.046220055;0.037512355;#N/A;0.022372517;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;10;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0044;ATF3;ENSG00000162772;HGNC:785;467;Cyclic AMP-dependent transcription factor ATF-3 (cAMP-dependent transcription factor ATF-3) (Activating transcription factor 3);P18847;https://jaspar.elixir.no/search?q=P18847;https://platform.opentargets.org/target/ENSG00000162772;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;726;157;438;205;83;3_Medium to Low;584;13.18;0.19;0.05;574;9.96;0.22;0.13;10;3.23;0.02;0.02;#N/A;#N/A;#N/A;#N/A;15;0.55;0.94;0.14;Cancer;#N/A;0.066935287;0.016130887;0.082504217;0.012006212;0.107082506;0.019043205;0.032808478;0.080869255;0.05510806;0.014992179;0.020870645;0.013253544;0.005061191;0.001847899;0.024908316;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;7;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0891;STAT5A;ENSG00000126561;HGNC:11366;6776;Signal transducer and activator of transcription 5A;P42229;#N/A;https://platform.opentargets.org/target/ENSG00000126561;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;547;107;439;87;21;4_Low;683;13.08;0.22;0.05;677;10.99;0.26;0.15;5;1.48;0.01;0.01;1;0.61;0.01;0.01;14;0.93;0.88;0.24;Cancer;#N/A;#N/A;0.088171299;0.057015495;0.040789387;0.612543997;0.025801396;0.008192353;0.035240242;0.006239329;0.015401022;0.004821978;0.00801783;0.001847899;0.00580035;0.015371967;6;0.4;Y;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;Pro-Longevity;#N/A;downstream;#N/A;Pro-Longevity;#N/A;Induces;#N/A;#N/A;8;#N/A;#N/A;#N/A;1;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0686;PBX3;ENSG00000167081;HGNC:8634;5090;Pre-B-cell leukemia transcription factor 3 (Homeobox protein PBX3);P40426;https://jaspar.elixir.no/search?q=P40426;https://platform.opentargets.org/target/ENSG00000167081;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;974;260;440;352;182;5_None;198;13.05;0.06;0.05;175;4.6;0.07;0.06;22;7.92;0.05;0.05;1;0.53;0.01;0.01;3;0.32;0.19;0.08;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.026686846;0.287743778;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0274;FOXN3;ENSG00000053254;HGNC:1928;1112;Forkhead box protein N3 (Checkpoint suppressor 1);O00409;https://jaspar.elixir.no/search?q=O00409;https://platform.opentargets.org/target/ENSG00000053254;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1301;382;441;422;438;5_None;161;13.02;0.05;0.05;129;2.86;0.05;0.04;32;10.17;0.07;0.07;#N/A;#N/A;#N/A;#N/A;5;0.23;0.31;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.001478319;#N/A;0.026403921;0.007391597;#N/A;#N/A;#N/A;0.005913278;#N/A;#N/A;#N/A;#N/A;0.193681527;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0060;BATF;ENSG00000156127;HGNC:958;10538;Basic leucine zipper transcriptional factor ATF-like (B-cell-activating transcription factor) (B-ATF) (SF-HT-activated gene 2 protein) (SFA-2);Q16520;https://jaspar.elixir.no/search?q=Q16520;https://platform.opentargets.org/target/ENSG00000156127;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.4 B-ATF-related;2179;780;442;569;1168;5_None;312;13;0.1;0.05;299;8.95;0.12;0.12;13;4.05;0.03;0.03;#N/A;#N/A;#N/A;#N/A;8;0.14;0.5;0.03;Cancer;#N/A;#N/A;0.036403616;0.004784006;#N/A;0.064293857;0.001478319;#N/A;#N/A;0.003695799;0.019587732;0.002587059;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0534;MLXIP;ENSG00000175727;HGNC:17055;22877;MLX-interacting protein (Class E basic helix-loop-helix protein 36) (bHLHe36) (Transcriptional activator MondoA);Q9HAP2;#N/A;https://platform.opentargets.org/target/ENSG00000175727;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1494;463;443;968;83;5_None;118;12.98;0.04;0.05;85;2.9;0.03;0.04;32;9.55;0.07;0.06;1;0.53;0.01;0.01;6;0.03;0.38;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;0.001478319;#N/A;#N/A;0.010770581;#N/A;#N/A;#N/A;#N/A;0.003695799;0.001478319;0.003695799;#N/A;#N/A;0.012581923;3;0.2;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0150;DMRT2;ENSG00000173253;HGNC:2935;10655;Doublesex- and mab-3-related transcription factor 2 (Doublesex-like 2 protein) (DSXL-2);Q9Y5R5;#N/A;https://platform.opentargets.org/target/ENSG00000173253;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;1864;627;444;252;1168;5_None;169;12.96;0.05;0.05;150;6.16;0.06;0.08;18;6.26;0.04;0.04;1;0.53;0.01;0.01;2;0.47;0.13;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.470543962;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0283;FOXP4;ENSG00000137166;HGNC:20842;116113;Forkhead box protein P4 (Fork head-related protein-like A);Q8IVH2;https://jaspar.elixir.no/search?q=Q8IVH2;https://platform.opentargets.org/target/ENSG00000137166;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;982;264;445;355;182;5_None;166;12.92;0.05;0.05;139;4.1;0.05;0.06;24;7.23;0.05;0.05;3;1.59;0.03;0.03;3;0.31;0.19;0.08;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.300884205;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0794;RXRG;ENSG00000143171;HGNC:10479;6258;Retinoic acid receptor RXR-gamma (Nuclear receptor subfamily 2 group B member 3) (Retinoid X receptor gamma);P48443;https://jaspar.elixir.no/search?q=P48443;https://platform.opentargets.org/target/ENSG00000143171;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;1702;560;446;88;1168;1_High;189;12.89;0.06;0.05;165;3.74;0.06;0.05;22;8.04;0.05;0.05;2;1.11;0.02;0.02;6;0.92;0.38;0.23;Alzheimer Disease;#N/A;#N/A;0.424464173;#N/A;#N/A;0.040538332;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;0.407334876;0.014228824;0.021572015;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;23;9;2;"CHEMBL2363070;CHEMBL2363071";"Retinoid X receptor;Retinoid receptor";"PROTEIN FAMILY;PROTEIN FAMILY";"51;1";"115;1";"2;4";"4;4";"Small molecule;Small molecule";"1999;1986"
TFTX_0793;RXRB;ENSG00000204231;HGNC:10478;6257;Retinoic acid receptor RXR-beta (Nuclear receptor subfamily 2 group B member 2) (Retinoid X receptor beta);P28702;https://jaspar.elixir.no/search?q=P28702;https://platform.opentargets.org/target/ENSG00000204231;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;2005;691;447;390;1168;1_High;239;12.84;0.08;0.05;223;6.72;0.09;0.09;14;5;0.03;0.03;2;1.12;0.02;0.02;7;0.27;0.44;0.07;Alzheimer Disease;#N/A;0.002217479;0.097517751;0.018478993;#N/A;0.086225981;#N/A;#N/A;#N/A;#N/A;0.005174118;0.018848573;#N/A;0.036957985;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;1_High;At least 2/3 Pharos Tclin, TTD approved drugs, ChEMBL approved drugs;Tclin;18;6;1;"CHEMBL2363070;CHEMBL2363071";"Retinoid X receptor;Retinoid receptor";"PROTEIN FAMILY;PROTEIN FAMILY";"51;1";"115;1";"2;4";"4;4";"Small molecule;Small molecule";"1999;1986"
TFTX_0399;HOXC6;ENSG00000197757;HGNC:5128;3223;Homeobox protein Hox-C6 (Homeobox protein CP25) (Homeobox protein HHO.C8) (Homeobox protein Hox-3C);P09630;#N/A;https://platform.opentargets.org/target/ENSG00000197757;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1390;423;448;504;438;3_Medium to Low;202;12.78;0.06;0.05;172;3.37;0.07;0.05;29;8.87;0.06;0.06;1;0.54;0.01;0.01;7;0.17;0.44;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.007391597;0.004434958;0.010163446;0.045503054;0.005168985;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;0.088943169;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0190;ELF1;ENSG00000120690;HGNC:3316;1997;ETS-related transcription factor Elf-1 (E74-like factor 1);P32519;https://jaspar.elixir.no/search?q=P32519;https://platform.opentargets.org/target/ENSG00000120690;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1719;565;449;832;438;3_Medium to Low;179;12.7;0.06;0.05;153;4;0.06;0.05;25;8.18;0.05;0.05;1;0.52;0.01;0.01;7;0.06;0.44;0.01;Cancer;#N/A;#N/A;0.012695479;#N/A;#N/A;0.020622812;0.006837227;0.001478319;0.002956639;0.003695799;0.0103893;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;6;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0696;PHF21A;ENSG00000135365;HGNC:24156;51317;PHD finger protein 21A (BHC80a) (BRAF35-HDAC complex protein BHC80);Q96BD5;#N/A;https://platform.opentargets.org/target/ENSG00000135365;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3023;1230;450;1405;1168;5_None;80;12.66;0.03;0.05;52;2.51;0.02;0.03;23;7.24;0.05;0.05;5;2.91;0.05;0.05;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0580;NCOA3;ENSG00000124151;HGNC:7670;8202;Nuclear receptor coactivator 3 (NCoA-3) (EC 2.3.1.48) (ACTR) (Amplified in breast cancer 1 protein) (AIB-1) (CBP-interacting protein) (pCIP) (Class E basic helix-loop-helix protein 42) (bHLHe42) (Receptor-associated coactivator 3) (RAC-3) (Steroid receptor coactivator protein 3) (SRC-3) (Thyroid hormone receptor activator molecule 1) (TRAM-1);Q9Y6Q9;#N/A;https://platform.opentargets.org/target/ENSG00000124151;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1121;324;451;232;438;4_Low;363;12.63;0.12;0.05;350;8.77;0.14;0.12;13;3.87;0.03;0.03;#N/A;#N/A;#N/A;#N/A;11;0.5;0.69;0.13;Osteoarthritis;0.001478319;#N/A;0.001478319;0.073915971;#N/A;0.06674549;#N/A;0.001478319;0.002217479;0.002012157;#N/A;0.335437924;0.004434958;#N/A;0.003695799;0.011456975;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;10;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0838;SNAPC4;ENSG00000165684;HGNC:11137;6621;snRNA-activating protein complex subunit 4 (SNAPc subunit 4) (Proximal sequence element-binding transcription factor subunit alpha) (PSE-binding factor subunit alpha) (PTF subunit alpha) (snRNA-activating protein complex 190 kDa subunit) (SNAPc 190 kDa subunit);Q5SXM2;#N/A;https://platform.opentargets.org/target/ENSG00000165684;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;2900;1158;452;1280;1168;5_None;134;12.63;0.04;0.05;115;6.33;0.05;0.09;18;5.64;0.04;0.04;1;0.67;0.01;0.01;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1054;ZBTB46;ENSG00000130584;HGNC:16094;140685;Zinc finger and BTB domain-containing protein 46 (BTB-ZF protein expressed in effector lymphocytes) (BZEL) (BTB/POZ domain-containing protein 4) (Zinc finger protein 340);Q86UZ6;#N/A;https://platform.opentargets.org/target/ENSG00000130584;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;1875;635;453;254;1168;5_None;214;12.49;0.07;0.05;203;9.35;0.08;0.13;11;3.14;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.47;0.25;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.009862636;#N/A;0.199909;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.258183095;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0687;PBX4;ENSG00000105717;HGNC:13403;80714;Pre-B-cell leukemia transcription factor 4 (Homeobox protein PBX4);Q9BYU1;#N/A;https://platform.opentargets.org/target/ENSG00000105717;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;1357;406;454;721;182;5_None;113;12.35;0.04;0.05;90;5.68;0.04;0.08;23;6.68;0.05;0.04;#N/A;#N/A;#N/A;#N/A;4;0.09;0.25;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.07534296;0.007945967;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0.001847899;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0853;SOX21;ENSG00000125285;HGNC:11197;11166;Transcription factor SOX-21 (SOX-A);Q9Y651;https://jaspar.elixir.no/search?q=Q9Y651;https://platform.opentargets.org/target/ENSG00000125285;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1335;397;455;698;182;5_None;200;12.23;0.06;0.05;192;10.26;0.08;0.14;8;1.97;0.02;0.01;#N/A;#N/A;#N/A;#N/A;5;0.09;0.31;0.02;Alzheimer Disease;#N/A;#N/A;0.039584325;#N/A;#N/A;0.025108976;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0.021435632;#N/A;0.003695799;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0556;MYBL1;ENSG00000185697;HGNC:7547;4603;Myb-related protein A (A-Myb) (Myb-like protein 1);P10243;https://jaspar.elixir.no/search?q=P10243;https://platform.opentargets.org/target/ENSG00000185697;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1642;528;456;748;438;5_None;334;12.22;0.11;0.05;332;11.45;0.13;0.16;1;0.25;0;0;1;0.52;0.01;0.01;5;0.08;0.31;0.02;Cancer;#N/A;0.002217479;0.002217479;0.036957985;#N/A;0.037145821;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0835;SNAI2;ENSG00000019549;HGNC:11094;6591;Zinc finger protein SNAI2 (Neural crest transcription factor Slug) (Protein snail homolog 2);O43623;https://jaspar.elixir.no/search?q=O43623;https://platform.opentargets.org/target/ENSG00000019549;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;911;235;457;371;83;5_None;555;12.2;0.18;0.04;548;9.89;0.21;0.13;6;1.78;0.01;0.01;1;0.52;0.01;0.01;13;0.28;0.81;0.07;Cancer;#N/A;0.003695799;0.025726864;0.013298057;0.021950031;0.107613506;0.044010867;0.003695799;0.004065378;0.008315547;0.022988483;0.002217479;#N/A;0.016261514;#N/A;0.011148992;3;0.2;Y;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;4;#N/A;Unclear;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0631;NPAS2;ENSG00000170485;HGNC:7895;4862;Neuronal PAS domain-containing protein 2 (Neuronal PAS2) (Basic-helix-loop-helix-PAS protein MOP4) (Class E basic helix-loop-helix protein 9) (bHLHe9) (Member of PAS protein 4) (PAS domain-containing protein 4);Q99743;#N/A;https://platform.opentargets.org/target/ENSG00000170485;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1042;286;458;501;83;5_None;275;12.18;0.09;0.04;254;6.36;0.1;0.09;21;5.82;0.04;0.04;#N/A;#N/A;#N/A;#N/A;9;0.17;0.56;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011898418;#N/A;#N/A;0.054844054;#N/A;0.002217479;#N/A;0.004434958;0.001478319;0.007391597;0.004065378;0.018786976;#N/A;0.06465942;3;0.2;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1236;ZNF318;ENSG00000171467;HGNC:13578;24149;Zinc finger protein 318 (Endocrine regulatory protein);Q5VUA4;#N/A;https://platform.opentargets.org/target/ENSG00000171467;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1570;498;459;673;438;5_None;158;12.14;0.05;0.04;146;8.83;0.06;0.12;12;3.31;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.1;0.19;0.03;Age-Related Hearing Impairment;0.092583561;#N/A;0.002799081;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0943;TFAP4;ENSG00000090447;HGNC:11745;7023;Transcription factor AP-4 (Activating enhancer-binding protein 4) (Class C basic helix-loop-helix protein 41) (bHLHc41);Q01664;https://jaspar.elixir.no/search?q=Q01664;https://platform.opentargets.org/target/ENSG00000090447;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;754;167;460;263;31;5_None;181;12.08;0.06;0.04;152;2.88;0.06;0.04;29;9.2;0.06;0.06;#N/A;#N/A;#N/A;#N/A;7;0.45;0.44;0.11;Benign Prostatic Hyperplasia;#N/A;#N/A;0.035657281;0.001478319;0.320461508;0.084213316;0.003695799;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;5;0.33;Y;Anti-Longevity;Anti-Longevity;#N/A;Anti-Longevity;#N/A;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1016;YY1;ENSG00000100811;HGNC:12856;7528;Transcriptional repressor protein YY1 (Delta transcription factor) (INO80 complex subunit S) (NF-E1) (Yin and yang 1) (YY-1);P25490;https://jaspar.elixir.no/search?q=P25490;https://platform.opentargets.org/target/ENSG00000100811;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;772;183;461;259;52;4_Low;529;12.08;0.17;0.04;515;7.33;0.2;0.1;12;3.37;0.02;0.02;2;1.37;0.02;0.02;12;0.45;0.75;0.12;Cancer;#N/A;0.003695799;0.04901019;0.024546262;0.009588544;0.111277786;0.0386642;0.018826572;#N/A;0.079281927;0.084124266;0.004250168;#N/A;0.01267912;#N/A;0.018841282;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;1;Pro-Longevity;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0204;ERF;ENSG00000105722;HGNC:3444;2077;ETS domain-containing transcription factor ERF (Ets2 repressor factor) (PE-2);P50548;https://jaspar.elixir.no/search?q=P50548;https://platform.opentargets.org/target/ENSG00000105722;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2339;857;462;709;1168;3_Medium to Low;212;12.06;0.07;0.04;197;5.32;0.08;0.07;8;2.52;0.02;0.02;7;4.22;0.07;0.07;4;0.09;0.25;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;0.001478319;0.080727808;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0739;PRDM5;ENSG00000138738;HGNC:9349;11107;PR domain zinc finger protein 5 (EC 2.1.1.-) (PR domain-containing protein 5);Q9NQX1;#N/A;https://platform.opentargets.org/target/ENSG00000138738;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;980;263;463;79;438;5_None;143;12.05;0.05;0.04;114;2.87;0.04;0.04;28;8.42;0.06;0.06;1;0.77;0.01;0.01;5;0.94;0.31;0.24;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;0.284171827;0.081366332;#N/A;#N/A;#N/A;#N/A;#N/A;0.291172236;0.044423499;#N/A;#N/A;0.234821962;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0851;SOX18;ENSG00000203883;HGNC:11194;54345;Transcription factor SOX-18;P35713;https://jaspar.elixir.no/search?q=P35713;https://platform.opentargets.org/target/ENSG00000203883;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1848;620;464;946;438;5_None;255;12.04;0.08;0.04;250;9.98;0.1;0.14;3;0.72;0.01;0;2;1.34;0.02;0.02;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;#N/A;0.005153586;#N/A;0.029999191;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1061;ZBTB7B;ENSG00000160685;HGNC:18668;51043;Zinc finger and BTB domain-containing protein 7B (Krueppel-related zinc finger protein cKrox) (hcKrox) (T-helper-inducing POZ/Krueppel-like factor) (Zinc finger and BTB domain-containing protein 15) (Zinc finger protein 67 homolog) (Zfp-67) (Zinc finger protein 857B) (Zinc finger protein Th-POK);O15156;https://jaspar.elixir.no/search?q=O15156;https://platform.opentargets.org/target/ENSG00000160685;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1140;329;465;237;438;5_None;150;12.04;0.05;0.04;128;5.48;0.05;0.07;21;6.02;0.04;0.04;1;0.54;0.01;0.01;6;0.5;0.38;0.13;Parkinson Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.013429505;#N/A;#N/A;#N/A;#N/A;0.015522354;0.148940717;#N/A;0.317511737;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0439;IRX5;ENSG00000176842;HGNC:14361;10265;Iroquois-class homeodomain protein IRX-5 (Homeodomain protein IRX-2A) (Homeodomain protein IRXB2) (Iroquois homeobox protein 5);P78411;#N/A;https://platform.opentargets.org/target/ENSG00000176842;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1902;648;466;998;438;5_None;128;12.01;0.04;0.04;101;2.71;0.04;0.04;24;7.33;0.05;0.05;3;1.97;0.03;0.03;5;0.03;0.31;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.01247623;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;0.002587059;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0873;SP8;ENSG00000164651;HGNC:19196;221833;Transcription factor Sp8 (Specificity protein 8);Q8IXZ3;https://jaspar.elixir.no/search?q=Q8IXZ3;https://platform.opentargets.org/target/ENSG00000164651;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;911;235;467;262;182;5_None;174;11.92;0.06;0.04;149;4.37;0.06;0.06;25;7.55;0.05;0.05;#N/A;#N/A;#N/A;#N/A;6;0.45;0.38;0.11;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.219817202;0.00542071;0.213551933;#N/A;#N/A;0.002217479;#N/A;#N/A;0.005174118;0.005913278;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0947;TFDP2;ENSG00000114126;HGNC:11751;7029;Transcription factor Dp-2 (E2F dimerization partner 2);Q14188;#N/A;https://platform.opentargets.org/target/ENSG00000114126;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;2356;867;468;720;1168;5_None;141;11.84;0.05;0.04;114;2.78;0.04;0.04;25;7.96;0.05;0.05;2;1.09;0.02;0.02;5;0.09;0.31;0.02;Type 2 Diabetes Mellitus;#N/A;0.012565715;0.012124272;#N/A;#N/A;0.013443436;0.003326219;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.045345395;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0455;KDM2B;ENSG00000089094;HGNC:13610;84678;Lysine-specific demethylase 2B (EC 1.14.11.27) (CXXC-type zinc finger protein 2) (F-box and leucine-rich repeat protein 10) (F-box protein FBL10) (F-box/LRR-repeat protein 10) (JmjC domain-containing histone demethylation protein 1B) (Jumonji domain-containing EMSY-interactor methyltransferase motif protein) (Protein JEMMA) (Protein-containing CXXC domain 2) ([Histone-H3]-lysine-36 demethylase 1B);Q8NHM5;#N/A;https://platform.opentargets.org/target/ENSG00000089094;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;883;227;469;331;83;4_Low;191;11.79;0.06;0.04;168;4.65;0.07;0.06;23;7.14;0.05;0.05;#N/A;#N/A;#N/A;#N/A;5;0.34;0.31;0.09;Alzheimer Disease;#N/A;#N/A;0.223857535;#N/A;0.003695799;0.023414447;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.088434374;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0319;GSC;ENSG00000133937;HGNC:4612;145258;Homeobox protein goosecoid;P56915;https://jaspar.elixir.no/search?q=P56915;https://platform.opentargets.org/target/ENSG00000133937;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2390;888;470;752;1168;3_Medium to Low;269;11.74;0.09;0.04;264;9.75;0.1;0.13;3;0.73;0.01;0;2;1.25;0.02;0.02;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.075921025;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;5;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1226;ZNF292;ENSG00000188994;HGNC:18410;23036;Zinc finger protein 292;O60281;#N/A;https://platform.opentargets.org/target/ENSG00000188994;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2830;1103;471;1191;1168;5_None;114;11.71;0.04;0.04;91;3.77;0.04;0.05;19;5.58;0.04;0.04;4;2.36;0.04;0.04;2;0.01;0.13;0;Cancer;#N/A;0.001478319;#N/A;#N/A;#N/A;0.009143406;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0493;LHX9;ENSG00000143355;HGNC:14222;56956;LIM/homeobox protein Lhx9 (LIM homeobox protein 9);Q9NQ69;https://jaspar.elixir.no/search?q=Q9NQ69;https://platform.opentargets.org/target/ENSG00000143355;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;1439;440;472;785;182;5_None;248;11.57;0.08;0.04;241;9.28;0.09;0.13;6;1.77;0.01;0.01;1;0.52;0.01;0.01;4;0.07;0.25;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.007391597;#N/A;#N/A;0.016587565;0.035479666;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.011087396;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0017;ALX1;ENSG00000180318;HGNC:1494;8092;ALX homeobox protein 1 (Cartilage homeoprotein 1) (CART-1);Q15699;#N/A;https://platform.opentargets.org/target/ENSG00000180318;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2839;1113;473;1198;1168;5_None;194;11.55;0.06;0.04;180;5.75;0.07;0.08;12;4.39;0.02;0.03;2;1.41;0.02;0.02;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.010281984;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0228;FEV;ENSG00000163497;HGNC:18562;54738;Protein FEV (Fifth Ewing variant protein) (PC12 ETS domain-containing transcription factor 1) (PC12 ETS factor 1) (Pet-1);Q99581;https://jaspar.elixir.no/search?q=Q99581;https://platform.opentargets.org/target/ENSG00000163497;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2719;1056;474;1077;1168;5_None;116;11.54;0.04;0.04;97;5.84;0.04;0.08;19;5.7;0.04;0.04;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0;Cancer;#N/A;#N/A;#N/A;#N/A;0.001478319;0.008964981;#N/A;0.002217479;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0026;ARID3A;ENSG00000116017;HGNC:3031;1820;AT-rich interactive domain-containing protein 3A (ARID domain-containing protein 3A) (B-cell regulator of IgH transcription) (Bright) (Dead ringer-like protein 1) (E2F-binding protein 1);Q99856;#N/A;https://platform.opentargets.org/target/ENSG00000116017;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;1102;310;475;445;182;5_None;283;11.53;0.09;0.04;270;8.16;0.11;0.11;12;2.81;0.02;0.02;1;0.56;0.01;0.01;8;0.21;0.5;0.05;Alzheimer Disease;#N/A;#N/A;0.149807785;0.007761177;#N/A;0.021072167;0.01743185;0.007391597;#N/A;0.005174118;#N/A;0.002217479;#N/A;#N/A;#N/A;0.001478319;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0688;PCGF2;ENSG00000277258;HGNC:12929;7703;Polycomb group RING finger protein 2 (DNA-binding protein Mel-18) (RING finger protein 110) (Zinc finger protein 144);P35227;#N/A;https://platform.opentargets.org/target/ENSG00000277258;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;760;174;476;201;83;5_None;199;11.49;0.06;0.04;181;5.51;0.07;0.07;16;4.78;0.03;0.03;2;1.21;0.02;0.02;6;0.56;0.38;0.14;Alzheimer Disease;#N/A;#N/A;0.207430541;#N/A;#N/A;0.030909954;0.102462444;0.007945967;#N/A;#N/A;#N/A;#N/A;0.001478319;0.207430541;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0726;POU6F2;ENSG00000106536;HGNC:21694;11281;POU domain, class 6, transcription factor 2 (Retina-derived POU domain factor 1) (RPF-1);P78424;https://jaspar.elixir.no/search?q=P78424;https://platform.opentargets.org/target/ENSG00000106536;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;2592;983;477;947;1168;5_None;97;11.49;0.03;0.04;66;1.21;0.03;0.02;31;10.28;0.06;0.07;#N/A;#N/A;#N/A;#N/A;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.001847899;#N/A;#N/A;0.025789372;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0177;E2F7;ENSG00000165891;HGNC:23820;144455;Transcription factor E2F7 (E2F-7);Q96AV8;https://jaspar.elixir.no/search?q=Q96AV8;https://platform.opentargets.org/target/ENSG00000165891;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;1453;446;478;892;83;2_Medium;163;11.46;0.05;0.04;136;2.8;0.05;0.04;24;7.06;0.05;0.05;3;1.6;0.03;0.03;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;0.002771849;0.042865133;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Pro-Longevity;7;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;3;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0072;BHLHE22;ENSG00000180828;HGNC:11963;27319;Class E basic helix-loop-helix protein 22 (bHLHe22) (Class B basic helix-loop-helix protein 5) (bHLHb5) (Trinucleotide repeat-containing gene 20 protein);Q8NFJ8;https://jaspar.elixir.no/search?q=Q8NFJ8;https://platform.opentargets.org/target/ENSG00000180828;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2564;972;479;917;1168;5_None;187;11.46;0.06;0.04;167;4.56;0.07;0.06;18;5.83;0.04;0.04;2;1.08;0.02;0.02;7;0.04;0.44;0.01;Cancer;#N/A;#N/A;0.008467276;0.002217479;0.002587059;0.015729113;0.003695799;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0895;TAL2;ENSG00000186051;HGNC:11557;6887;T-cell acute lymphocytic leukemia protein 2 (TAL-2) (Class A basic helix-loop-helix protein 19) (bHLHa19);Q16559;#N/A;https://platform.opentargets.org/target/ENSG00000186051;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2828;1102;480;1180;1168;5_None;103;11.41;0.03;0.04;83;5.74;0.03;0.08;20;5.67;0.04;0.04;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.007391597;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0267;FOXK1;ENSG00000164916;HGNC:23480;221937;Forkhead box protein K1 (Myocyte nuclear factor) (MNF);P85037;https://jaspar.elixir.no/search?q=P85037;https://platform.opentargets.org/target/ENSG00000164916;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1694;557;481;45;1168;5_None;175;11.39;0.06;0.04;155;5.55;0.06;0.08;19;5.32;0.04;0.04;1;0.52;0.01;0.01;9;1.16;0.56;0.29;Alzheimer Disease;#N/A;#N/A;0.373530971;#N/A;0.008869917;0.040890271;0.179192024;#N/A;#N/A;#N/A;0.012935295;#N/A;0.004989328;0.373241727;0.001478319;0.160842229;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0525;MEOX1;ENSG00000005102;HGNC:7013;4222;Homeobox protein MOX-1 (Mesenchyme homeobox 1);P50221;https://jaspar.elixir.no/search?q=P50221;https://platform.opentargets.org/target/ENSG00000005102;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1447;444;482;882;83;5_None;174;11.39;0.06;0.04;158;6.04;0.06;0.08;14;4.1;0.03;0.03;2;1.25;0.02;0.02;3;0.05;0.19;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.034982967;#N/A;0.004414426;#N/A;0.008685127;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0651;NR4A1;ENSG00000123358;HGNC:7980;3164;Nuclear receptor subfamily 4 group A member 1 (Early response protein NAK1) (Nuclear hormone receptor NUR/77) (Nur77) (Orphan nuclear receptor HMR) (Orphan nuclear receptor TR3) (ST-59) (Testicular receptor 3);P22736;https://jaspar.elixir.no/search?q=P22736;https://platform.opentargets.org/target/ENSG00000123358;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.4 NGFI(NR4A);1075;299;483;154;438;4_Low;867;11.35;0.28;0.04;862;9.92;0.34;0.13;5;1.43;0.01;0.01;#N/A;#N/A;#N/A;#N/A;15;0.66;0.94;0.17;Cancer;#N/A;0.009239496;0.023985669;0.076309247;0.002751317;0.111493487;0.08029253;0.018202902;0.051559765;0.029467595;0.030168136;0.062216132;0.032544533;0.026177497;0.010499764;0.092573505;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;16;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0449;JUNB;ENSG00000171223;HGNC:6205;3726;Transcription factor JunB (Transcription factor AP-1 subunit JunB);P17275;https://jaspar.elixir.no/search?q=P17275;https://platform.opentargets.org/target/ENSG00000171223;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;875;224;484;308;83;4_Low;889;11.35;0.29;0.04;886;10.45;0.35;0.14;3;0.9;0.01;0.01;#N/A;#N/A;#N/A;#N/A;14;0.38;0.88;0.1;Cancer;#N/A;0.009996096;0.030829482;0.047809177;0.012042144;0.08576215;0.027925828;0.027009936;0.009883169;0.032807845;0.020401222;0.012602468;0.005092295;0.035479733;#N/A;0.019881378;3;0.2;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Induces;#N/A;#N/A;7;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0085;CARF;ENSG00000138380;HGNC:14435;79800;Calcium-responsive transcription factor (Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 8 protein) (Calcium-response factor) (CaRF) (Testis development protein NYD-SP24);Q8N187;#N/A;https://platform.opentargets.org/target/ENSG00000138380;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;918;240;485;251;182;5_None;180;11.3;0.06;0.04;171;8.51;0.07;0.12;9;2.79;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.48;0.38;0.12;Myocardial Infarction;#N/A;#N/A;0.064876607;#N/A;#N/A;0.067101689;#N/A;#N/A;0.051926233;0.233382731;0.004250168;0.061619849;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0427;IRF2;ENSG00000168310;HGNC:6117;3660;Interferon regulatory factor 2 (IRF-2);P14316;https://jaspar.elixir.no/search?q=P14316;https://platform.opentargets.org/target/ENSG00000168310;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;1052;291;486;128;438;4_Low;295;11.28;0.09;0.04;283;7.75;0.11;0.11;12;3.53;0.02;0.02;#N/A;#N/A;#N/A;#N/A;7;0.72;0.44;0.18;Alzheimer Disease;#N/A;#N/A;0.286357761;0.008315547;#N/A;0.091230726;0.007391597;#N/A;#N/A;0.049687958;#N/A;#N/A;0.004065378;0.273915855;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0834;SNAI1;ENSG00000124216;HGNC:11128;6615;Zinc finger protein SNAI1 (Protein snail homolog 1) (Protein sna);O95863;https://jaspar.elixir.no/search?q=O95863;https://platform.opentargets.org/target/ENSG00000124216;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;740;160;487;222;31;5_None;584;11.24;0.19;0.04;579;9.37;0.23;0.13;4;1.34;0.01;0.01;1;0.53;0.01;0.01;12;0.52;0.75;0.13;Type 2 Diabetes Mellitus;#N/A;0.005756822;0.007740645;0.026034924;0.011916916;0.116948011;0.039795584;0.004229636;#N/A;0.031507692;0.073944305;0.004804538;#N/A;0.00248744;#N/A;0.195228577;5;0.33;Y;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;Anti-Longevity;#N/A;Inhibits;#N/A;#N/A;5;#N/A;Unclear;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0842;SON;ENSG00000159140;HGNC:11183;6651;Protein SON (Bax antagonist selected in saccharomyces 1) (BASS1) (Negative regulatory element-binding protein) (NRE-binding protein) (Protein DBP-5) (SON3);P18583;#N/A;https://platform.opentargets.org/target/ENSG00000159140;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1729;571;488;73;1168;5_None;210;11.24;0.07;0.04;196;4.91;0.08;0.07;11;4.47;0.02;0.03;3;1.86;0.03;0.03;6;0.96;0.38;0.24;Alzheimer Disease;#N/A;#N/A;0.465103414;0.001478319;#N/A;0.017961537;#N/A;0.005174118;#N/A;#N/A;0.003695799;#N/A;#N/A;0.463822718;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0474;KLF9;ENSG00000119138;HGNC:1123;687;Krueppel-like factor 9 (Basic transcription element-binding protein 1) (BTE-binding protein 1) (GC-box-binding protein 1) (Transcription factor BTEB1);Q13886;https://jaspar.elixir.no/search?q=Q13886;https://platform.opentargets.org/target/ENSG00000119138;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1334;396;489;407;438;3_Medium to Low;238;11.2;0.08;0.04;215;3.89;0.08;0.05;23;7.31;0.05;0.05;#N/A;#N/A;#N/A;#N/A;9;0.25;0.56;0.06;Myocardial Infarction;#N/A;#N/A;0.015529263;#N/A;#N/A;0.040731883;0.052567601;0.012735106;#N/A;0.07631824;0.002587059;0.024281117;#N/A;0.014762662;#N/A;0.006282858;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1324;ZNF469;ENSG00000225614;HGNC:23216;84627;Zinc finger protein 469;Q96JG9;#N/A;https://platform.opentargets.org/target/ENSG00000225614;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2133;752;490;1205;438;5_None;124;11.18;0.04;0.04;101;4.1;0.04;0.06;20;5.26;0.04;0.04;3;1.83;0.03;0.03;3;0.01;0.19;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005030392;#N/A;#N/A;#N/A;#N/A;0.003018235;0.001568646;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0379;HOXA5;ENSG00000106004;HGNC:5106;3202;Homeobox protein Hox-A5 (Homeobox protein Hox-1C);P20719;https://jaspar.elixir.no/search?q=P20719;https://platform.opentargets.org/target/ENSG00000106004;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1471;452;491;542;438;3_Medium to Low;398;11.17;0.13;0.04;394;10.19;0.15;0.14;4;0.98;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.15;0.44;0.04;Cancer;#N/A;#N/A;0.010802614;0.002943909;#N/A;0.047010469;0.024074226;#N/A;#N/A;#N/A;#N/A;#N/A;0.040468994;0.001478319;#N/A;0.023590064;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0260;FOXH1;ENSG00000160973;HGNC:3814;8928;Forkhead box protein H1 (Forkhead activin signal transducer 1) (Fast-1) (hFAST-1) (Forkhead activin signal transducer 2) (Fast-2);O75593;https://jaspar.elixir.no/search?q=O75593;https://platform.opentargets.org/target/ENSG00000160973;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2567;974;492;907;1168;5_None;241;11.15;0.08;0.04;232;7.75;0.09;0.1;8;2.86;0.02;0.02;1;0.55;0.01;0.01;3;0.04;0.19;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.001847899;#N/A;#N/A;0.019694577;0.022174791;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0841;SOHLH2;ENSG00000120669;HGNC:26026;54937;Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 2;Q9NX45;https://jaspar.elixir.no/search?q=Q9NX45;https://platform.opentargets.org/target/ENSG00000120669;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;2938;1181;493;1277;1168;5_None;180;10.91;0.06;0.04;173;8.58;0.07;0.12;7;2.33;0.01;0.02;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.006868026;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0521;MEF2D;ENSG00000116604;HGNC:6997;4209;Myocyte-specific enhancer factor 2D;Q14814;https://jaspar.elixir.no/search?q=Q14814;https://platform.opentargets.org/target/ENSG00000116604;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.1 Regulators of differentiation;1500;468;494;568;438;5_None;178;10.88;0.06;0.04;156;4.86;0.06;0.07;22;6.03;0.05;0.04;#N/A;#N/A;#N/A;#N/A;7;0.14;0.44;0.03;Parkinson Disease;#N/A;#N/A;0.017635802;#N/A;#N/A;0.026313621;0.027882747;0.005728488;0.008869917;#N/A;#N/A;#N/A;#N/A;0.03571732;#N/A;0.014413614;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0308;GLIS2;ENSG00000126603;HGNC:29450;84662;Zinc finger protein GLIS2 (GLI-similar 2) (Neuronal Krueppel-like protein);Q9BZE0;https://jaspar.elixir.no/search?q=Q9BZE0;https://platform.opentargets.org/target/ENSG00000126603;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1564;494;495;986;83;5_None;286;10.75;0.09;0.04;280;8.45;0.11;0.11;5;1.67;0.01;0.01;1;0.63;0.01;0.01;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.030249463;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0496;LIN54;ENSG00000189308;HGNC:25397;132660;Protein lin-54 homolog (CXC domain-containing protein 1);Q6MZP7;https://jaspar.elixir.no/search?q=Q6MZP7;https://platform.opentargets.org/target/ENSG00000189308;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1985;683;496;1307;182;5_None;65;10.72;0.02;0.04;41;3.49;0.02;0.05;24;7.23;0.05;0.05;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0152;DMRTA1;ENSG00000176399;HGNC:13826;63951;Doublesex- and mab-3-related transcription factor A1;Q5VZB9;https://jaspar.elixir.no/search?q=Q5VZB9;https://platform.opentargets.org/target/ENSG00000176399;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;1351;401;497;416;438;5_None;61;10.67;0.02;0.04;29;0.67;0.01;0.01;31;9.5;0.06;0.06;1;0.5;0.01;0.01;1;0.24;0.06;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.239653956;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0133;CXXC4;ENSG00000168772;HGNC:24593;80319;CXXC-type zinc finger protein 4 (Inhibition of the Dvl and axin complex protein);Q9H2H0;#N/A;https://platform.opentargets.org/target/ENSG00000168772;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;1906;651;498;970;438;4_Low;103;10.65;0.03;0.04;75;2.27;0.03;0.03;28;8.38;0.06;0.06;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.019559619;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009793866;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0582;NEUROD2;ENSG00000171532;HGNC:7763;4761;Neurogenic differentiation factor 2 (NeuroD2) (Class A basic helix-loop-helix protein 1) (bHLHa1) (NeuroD-related factor) (NDRF);Q15784;https://jaspar.elixir.no/search?q=Q15784;https://platform.opentargets.org/target/ENSG00000171532;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2336;856;499;669;1168;5_None;232;10.64;0.07;0.04;223;7.71;0.09;0.1;8;2.35;0.02;0.02;1;0.58;0.01;0.01;3;0.1;0.19;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.021969469;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.074221432;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1356;ZNF516;ENSG00000101493;HGNC:28990;9658;Zinc finger protein 516;Q92618;#N/A;https://platform.opentargets.org/target/ENSG00000101493;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2817;1094;500;1149;1168;5_None;58;10.61;0.02;0.04;31;1.58;0.01;0.02;27;9.03;0.06;0.06;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009578278;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0936;TET3;ENSG00000187605;HGNC:28313;200424;Methylcytosine dioxygenase TET3 (EC 1.14.11.n2);O43151;#N/A;https://platform.opentargets.org/target/ENSG00000187605;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;1522;477;501;583;438;5_None;256;10.6;0.08;0.04;236;3.58;0.09;0.05;19;6.23;0.04;0.04;1;0.79;0.01;0.01;8;0.13;0.5;0.03;Cancer;#N/A;#N/A;0.005861947;0.013674455;0.007945967;0.051092005;0.003695799;#N/A;#N/A;0.001478319;0.016261514;#N/A;#N/A;#N/A;#N/A;0.030349923;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0436;IRX2;ENSG00000170561;HGNC:14359;153572;Iroquois-class homeodomain protein IRX-2 (Homeodomain protein IRXA2) (Iroquois homeobox protein 2);Q9BZI1;#N/A;https://platform.opentargets.org/target/ENSG00000170561;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1305;385;502;365;438;5_None;106;10.57;0.03;0.04;77;1.34;0.03;0.02;29;9.22;0.06;0.06;#N/A;#N/A;#N/A;#N/A;6;0.3;0.38;0.08;Age-Related Hearing Impairment;0.215262206;#N/A;0.003695799;#N/A;#N/A;0.009363887;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;0.002956639;0.062089416;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0438;IRX4;ENSG00000113430;HGNC:6129;50805;Iroquois-class homeodomain protein IRX-4 (Homeodomain protein IRXA3) (Iroquois homeobox protein 4);P78413;#N/A;https://platform.opentargets.org/target/ENSG00000113430;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1769;591;503;828;438;5_None;186;10.5;0.06;0.04;176;6.97;0.07;0.09;9;3.02;0.02;0.02;1;0.52;0.01;0.01;8;0.06;0.5;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;0.002771849;0.037871884;0.003695799;0.003695799;0.002217479;#N/A;#N/A;#N/A;0.003695799;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0032;ARNT2;ENSG00000172379;HGNC:16876;9915;Aryl hydrocarbon receptor nuclear translocator 2 (ARNT protein 2) (Class E basic helix-loop-helix protein 1) (bHLHe1);Q9HBZ2;https://jaspar.elixir.no/search?q=Q9HBZ2;https://platform.opentargets.org/target/ENSG00000172379;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;928;244;504;341;83;5_None;184;10.46;0.06;0.04;163;3.64;0.06;0.05;20;6.3;0.04;0.04;1;0.52;0.01;0.01;2;0.33;0.13;0.08;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.024106104;0.308084606;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0745;PROP1;ENSG00000175325;HGNC:9455;5626;Homeobox protein prophet of Pit-1 (PROP-1) (Pituitary-specific homeodomain factor);O75360;https://jaspar.elixir.no/search?q=O75360;https://platform.opentargets.org/target/ENSG00000175325;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1105;313;505;517;83;5_None;199;10.43;0.06;0.04;190;6.16;0.07;0.08;7;2.89;0.01;0.02;2;1.38;0.02;0.02;4;0.16;0.25;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;0.007391597;#N/A;#N/A;0.147030358;3;0.2;Y;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;mammal;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0699;PIN1;ENSG00000127445;HGNC:8988;5300;Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (EC 5.2.1.8) (Peptidyl-prolyl cis-trans isomerase Pin1) (PPIase Pin1) (Rotamase Pin1);Q13526;#N/A;https://platform.opentargets.org/target/ENSG00000127445;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;793;192;506;204;83;4_Low;416;10.41;0.13;0.04;411;9.12;0.16;0.12;5;1.29;0.01;0.01;#N/A;#N/A;#N/A;#N/A;13;0.55;0.81;0.14;Cancer;0.004065378;#N/A;0.105512314;0.050313318;0.005358908;0.11587625;#N/A;0.015214371;0.028049045;0.002217479;0.089653913;0.025156355;0.005643266;0.029195405;#N/A;0.077612863;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;23;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0295;GATAD2A;ENSG00000167491;HGNC:29989;54815;Transcriptional repressor p66-alpha (Hp66alpha) (GATA zinc finger domain-containing protein 2A);Q86YP4;#N/A;https://platform.opentargets.org/target/ENSG00000167491;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;1882;639;507;207;1168;5_None;157;10.4;0.05;0.04;146;7.41;0.06;0.1;10;2.48;0.02;0.02;1;0.51;0.01;0.01;5;0.55;0.31;0.14;Alzheimer Disease;#N/A;#N/A;0.258378851;#N/A;#N/A;0.016907855;#N/A;#N/A;#N/A;#N/A;0.011713628;#N/A;#N/A;0.257061417;#N/A;0.006495982;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0118;CREB3L3;ENSG00000060566;HGNC:18855;84699;Cyclic AMP-responsive element-binding protein 3-like protein 3 (cAMP-responsive element-binding protein 3-like protein 3) (Transcription factor CREB-H) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 3];Q68CJ9;#N/A;https://platform.opentargets.org/target/ENSG00000060566;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1771;593;508;95;1168;5_None;121;10.36;0.04;0.04;106;4.27;0.04;0.06;11;3.78;0.02;0.03;4;2.31;0.04;0.04;7;0.88;0.44;0.22;Alzheimer Disease;#N/A;#N/A;0.391100471;0.062819797;#N/A;0.006701304;#N/A;#N/A;#N/A;#N/A;0.025103365;#N/A;0.002587059;0.387404672;#N/A;0.004434958;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1349;ZNF507;ENSG00000168813;HGNC:23783;22847;Zinc finger protein 507;Q8TCN5;#N/A;https://platform.opentargets.org/target/ENSG00000168813;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2126;747;509;1179;438;5_None;49;10.31;0.02;0.04;26;1.77;0.01;0.02;20;7.02;0.04;0.05;3;1.53;0.03;0.03;3;0.01;0.19;#N/A;Cancer;#N/A;#N/A;#N/A;0.001478319;#N/A;0.008315547;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0016;AKNA;ENSG00000106948;HGNC:24108;80709;Microtubule organization protein AKNA (AT-hook-containing transcription factor);Q7Z591;#N/A;https://platform.opentargets.org/target/ENSG00000106948;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2393;889;510;715;1168;5_None;108;10.27;0.03;0.04;88;2.71;0.03;0.04;17;5.98;0.04;0.04;3;1.58;0.03;0.03;3;0.09;0.19;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011087396;#N/A;#N/A;0.01585291;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.062244186;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0097;CEBPD;ENSG00000221869;HGNC:1835;1052;CCAAT/enhancer-binding protein delta (C/EBP delta) (Nuclear factor NF-IL6-beta) (NF-IL6-beta);P49716;https://jaspar.elixir.no/search?q=P49716;https://platform.opentargets.org/target/ENSG00000221869;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;1154;334;511;461;182;5_None;314;10.25;0.1;0.04;297;4.63;0.12;0.06;17;5.63;0.04;0.04;#N/A;#N/A;#N/A;#N/A;11;0.2;0.69;0.05;Cancer;#N/A;#N/A;0.047514251;0.005523166;#N/A;0.067520663;0.003695799;0.020519484;0.004434958;0.002751317;0.02067594;0.014992644;#N/A;0.004434958;#N/A;0.004496555;2;0.13;Y;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1275;ZNF385D;ENSG00000151789;HGNC:26191;79750;Zinc finger protein 385D (Zinc finger protein 659);Q9H6B1;#N/A;https://platform.opentargets.org/target/ENSG00000151789;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1273;375;512;323;438;4_Low;72;10.22;0.02;0.04;42;0.49;0.02;0.01;29;9.2;0.06;0.06;1;0.52;0.01;0.01;5;0.35;0.31;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;0.001820081;0.001478319;#N/A;0.008500337;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.334658138;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0515;MBNL2;ENSG00000139793;HGNC:16746;10150;Muscleblind-like protein 2 (Muscleblind-like protein 1) (Muscleblind-like protein-like) (Muscleblind-like protein-like 39);Q5VZF2;#N/A;https://platform.opentargets.org/target/ENSG00000139793;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1521;475;513;570;438;5_None;255;10.21;0.08;0.04;244;7.17;0.1;0.1;11;3.04;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.14;0.38;0.03;Cancer;#N/A;#N/A;0.005861947;#N/A;#N/A;0.093729289;0.003695799;0.001478319;#N/A;#N/A;0.003695799;#N/A;#N/A;0.027348909;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0147;DLX6;ENSG00000006377;HGNC:2919;1750;Homeobox protein DLX-6;P56179;https://jaspar.elixir.no/search?q=P56179;https://platform.opentargets.org/target/ENSG00000006377;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2263;821;514;581;1168;3_Medium to Low;215;10.21;0.07;0.04;201;5.83;0.08;0.08;14;4.37;0.03;0.03;#N/A;#N/A;#N/A;#N/A;9;0.13;0.56;0.03;Cancer;#N/A;#N/A;0.001478319;#N/A;0.003695799;0.083710686;0.001478319;#N/A;#N/A;0.003695799;#N/A;0.002346265;0.002956639;0.017739833;#N/A;0.014870456;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;9;9;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0716;POU3F2;ENSG00000184486;HGNC:9215;5454;POU domain, class 3, transcription factor 2 (Brain-specific homeobox/POU domain protein 2) (Brain-2) (Brn-2) (Nervous system-specific octamer-binding transcription factor N-Oct-3) (Octamer-binding protein 7) (Oct-7) (Octamer-binding transcription factor 7) (OTF-7);P20265;https://jaspar.elixir.no/search?q=P20265;https://platform.opentargets.org/target/ENSG00000184486;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1703;561;515;750;438;5_None;140;10.19;0.04;0.04;118;1.88;0.05;0.03;21;7.76;0.04;0.05;1;0.55;0.01;0.01;5;0.08;0.31;0.02;Cancer;#N/A;#N/A;0.015895908;#N/A;#N/A;0.044598376;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.016261514;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0400;HOXC8;ENSG00000037965;HGNC:5129;3224;Homeobox protein Hox-C8 (Homeobox protein Hox-3A);P31273;https://jaspar.elixir.no/search?q=P31273;https://platform.opentargets.org/target/ENSG00000037965;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1775;595;516;821;438;3_Medium to Low;272;10.18;0.09;0.04;265;8.47;0.1;0.11;7;1.71;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.06;0.31;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.043348002;0.009239496;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0372;HOXA1;ENSG00000105991;HGNC:5099;3198;Homeobox protein Hox-A1 (Homeobox protein Hox-1F);P49639;https://jaspar.elixir.no/search?q=P49639;https://platform.opentargets.org/target/ENSG00000105991;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2252;815;517;567;1168;5_None;287;10.16;0.09;0.04;280;7.12;0.11;0.1;5;1.63;0.01;0.01;2;1.41;0.02;0.02;7;0.14;0.44;0.03;Cancer;#N/A;#N/A;0.007391597;0.015589562;#N/A;0.073048083;0.024524703;#N/A;#N/A;#N/A;#N/A;0.011621233;0.002956639;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0518;MEF2A;ENSG00000068305;HGNC:6993;4205;Myocyte-specific enhancer factor 2A (Serum response factor-like protein 1);Q02078;https://jaspar.elixir.no/search?q=Q02078;https://platform.opentargets.org/target/ENSG00000068305;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.1 Regulators of differentiation;756;170;518;155;83;5_None;334;10.11;0.11;0.04;322;5.87;0.13;0.08;11;3.69;0.02;0.02;1;0.55;0.01;0.01;11;0.65;0.69;0.17;Myocardial Infarction;#N/A;#N/A;0.072923653;0.032794063;#N/A;0.029512147;0.003695799;0.016374796;0.002217479;0.459957341;#N/A;0.003695799;#N/A;0.022643665;0.001847899;0.008204329;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Unclear;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0719;POU4F1;ENSG00000152192;HGNC:9218;5457;POU domain, class 4, transcription factor 1 (Brain-specific homeobox/POU domain protein 3A) (Brain-3A) (Brn-3A) (Homeobox/POU domain protein RDC-1) (Oct-T1);Q01851;https://jaspar.elixir.no/search?q=Q01851;https://platform.opentargets.org/target/ENSG00000152192;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1598;515;519;641;438;5_None;171;10.1;0.05;0.04;154;4.47;0.06;0.06;15;4.4;0.03;0.03;2;1.23;0.02;0.02;5;0.11;0.31;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.009609076;#N/A;#N/A;0.028016997;0.022174791;#N/A;#N/A;#N/A;#N/A;0.011087396;#N/A;#N/A;#N/A;0.038056011;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0284;FOXQ1;ENSG00000164379;HGNC:20951;94234;Forkhead box protein Q1 (HNF-3/forkhead-like protein 1) (HFH-1) (Hepatocyte nuclear factor 3 forkhead homolog 1);Q9C009;#N/A;https://platform.opentargets.org/target/ENSG00000164379;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1046;288;520;443;83;5_None;271;10.09;0.09;0.04;261;7.19;0.1;0.1;10;2.9;0.02;0.02;#N/A;#N/A;#N/A;#N/A;8;0.21;0.5;0.05;Cancer;#N/A;#N/A;0.083891635;0.011641765;#N/A;0.091088157;0.001478319;#N/A;#N/A;#N/A;#N/A;0.007391597;0.001478319;0.001478319;#N/A;0.01631038;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0261;FOXI1;ENSG00000168269;HGNC:3815;2299;Forkhead box protein I1 (Forkhead-related protein FKHL10) (Forkhead-related transcription factor 6) (FREAC-6) (Hepatocyte nuclear factor 3 forkhead homolog 3) (HFH-3) (HNF-3/fork-head homolog 3);Q12951;https://jaspar.elixir.no/search?q=Q12951;https://platform.opentargets.org/target/ENSG00000168269;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2860;1127;521;1171;1168;5_None;190;10.08;0.06;0.04;180;6.35;0.07;0.09;10;3.72;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011695765;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0865;SP140;ENSG00000079263;HGNC:17133;11262;Nuclear body protein SP140 (Lymphoid-restricted homolog of Sp100) (LYSp100) (Nuclear autoantigen Sp-140) (Speckled 140 kDa);Q13342;#N/A;https://platform.opentargets.org/target/ENSG00000079263;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.5 Sp140-Sp101;1811;610;522;851;438;5_None;129;10.07;0.04;0.04;110;2.96;0.04;0.04;16;5.5;0.03;0.04;3;1.62;0.03;0.03;2;0.05;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.012565715;0.041998949;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0148;DMBX1;ENSG00000197587;HGNC:19026;127343;Diencephalon/mesencephalon homeobox protein 1 (Orthodenticle homolog 3) (Paired-like homeobox protein DMBX1);Q8NFW5;#N/A;https://platform.opentargets.org/target/ENSG00000197587;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1848;620;523;157;1168;5_None;493;10.05;0.16;0.04;479;6.33;0.19;0.09;14;3.72;0.03;0.02;#N/A;#N/A;#N/A;#N/A;12;0.65;0.75;0.16;Alzheimer Disease;#N/A;#N/A;0.213898747;0.017088867;0.001478319;0.101666436;0.002163685;0.001847899;0.0067243;0.005559097;0.070862053;0.002936107;#N/A;0.207857939;#N/A;0.016851466;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0641;NR1I3;ENSG00000143257;HGNC:7969;9970;Nuclear receptor subfamily 1 group I member 3 (Constitutive activator of retinoid response) (Constitutive active response) (Constitutive androstane receptor) (CAR) (Orphan nuclear receptor MB67);Q14994;https://jaspar.elixir.no/search?q=Q14994;https://platform.opentargets.org/target/ENSG00000143257;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;1163;339;524;457;182;2_Medium;519;9.98;0.17;0.04;513;8.29;0.2;0.11;5;1.2;0.01;0.01;1;0.5;0.01;0.01;10;0.2;0.63;0.05;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.019108817;0.024108195;0.002217479;0.040001343;#N/A;0.007516831;#N/A;0.031185969;0.052352382;#N/A;0.00567654;0.001478319;#N/A;0.01687818;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;2_Medium;DGIDB MOA not >0 and no ChEMBL max phase >0 but approved drugs according to TTD? Development level unclear (TTD entries wrong?) but assume Medium;Tchem;15;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1642;ZZZ3;ENSG00000036549;HGNC:24523;26009;ZZ-type zinc finger-containing protein 3;Q8IYH5;#N/A;https://platform.opentargets.org/target/ENSG00000036549;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;3162;1310;525;1469;1168;5_None;133;9.98;0.04;0.04;121;6.3;0.05;0.09;12;3.68;0.02;0.02;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0258;FOXF2;ENSG00000137273;HGNC:3810;2295;Forkhead box protein F2 (Forkhead-related activator 2) (FREAC-2) (Forkhead-related protein FKHL6) (Forkhead-related transcription factor 2);Q12947;https://jaspar.elixir.no/search?q=Q12947;https://platform.opentargets.org/target/ENSG00000137273;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1243;363;526;279;438;4_Low;226;9.97;0.07;0.04;218;7.66;0.09;0.1;8;2.3;0.02;0.02;#N/A;#N/A;#N/A;#N/A;5;0.42;0.31;0.11;Ischemic Stroke;#N/A;0.003695799;#N/A;#N/A;0.009588544;0.077186334;#N/A;#N/A;0.323802453;#N/A;#N/A;#N/A;0.010348236;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1081;ZFP42;ENSG00000179059;HGNC:30949;132625;Zinc finger protein 42 homolog (Zfp-42) (Reduced expression protein 1) (REX-1) (hREX-1) (Zinc finger protein 754);Q96MM3;https://jaspar.elixir.no/search?q=Q96MM3;https://platform.opentargets.org/target/ENSG00000179059;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1913;655;527;218;1168;5_None;189;9.94;0.06;0.04;176;6.58;0.07;0.09;13;3.35;0.03;0.02;#N/A;#N/A;#N/A;#N/A;5;0.53;0.31;0.14;Alzheimer Disease;#N/A;#N/A;0.250890911;#N/A;#N/A;0.021319174;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.247888074;#N/A;0.002587059;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0316;GRHL1;ENSG00000134317;HGNC:17923;29841;Grainyhead-like protein 1 homolog (Mammalian grainyhead) (NH32) (Transcription factor CP2-like 2) (Transcription factor LBP-32);Q9NZI5;https://jaspar.elixir.no/search?q=Q9NZI5;https://platform.opentargets.org/target/ENSG00000134317;6 Immunoglobulin fold;6.7 Grainyhead;6.7.1 Grainyhead-related;1492;462;528;881;83;5_None;218;9.94;0.07;0.04;209;6.52;0.08;0.09;9;3.42;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;0.007945967;#N/A;#N/A;0.027221127;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012935295;3;0.2;Y;Unclear;Pro-Longevity;#N/A;Pro-Longevity;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0733;PRDM13;ENSG00000112238;HGNC:13998;59336;PR domain zinc finger protein 13 (EC 2.1.1.-) (PR domain-containing protein 13);Q9H4Q3;#N/A;https://platform.opentargets.org/target/ENSG00000112238;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2420;901;529;723;1168;5_None;141;9.92;0.05;0.04;129;5.36;0.05;0.07;10;3.27;0.02;0.02;2;1.29;0.02;0.02;2;0.09;0.13;0.02;Age-Related Macular Degeneration;#N/A;0.07048319;#N/A;#N/A;#N/A;0.015588654;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0407;HOXD3;ENSG00000128652;HGNC:5137;3232;Homeobox protein Hox-D3 (Homeobox protein Hox-4A);P31249;https://jaspar.elixir.no/search?q=P31249;https://platform.opentargets.org/target/ENSG00000128652;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2389;887;530;691;1168;3_Medium to Low;146;9.91;0.05;0.04;129;4.34;0.05;0.06;17;5.57;0.04;0.04;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;#N/A;0.004804538;0.004434958;0.083877383;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1352;ZNF512;ENSG00000243943;HGNC:29380;84450;Zinc finger protein 512;Q96ME7;#N/A;https://platform.opentargets.org/target/ENSG00000243943;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1589;509;531;620;438;5_None;147;9.88;0.05;0.04;133;5.97;0.05;0.08;14;3.91;0.03;0.03;#N/A;#N/A;#N/A;#N/A;5;0.12;0.31;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.00433444;#N/A;#N/A;0.025616332;#N/A;0.025616332;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;0.056706526;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0636;NR1D2;ENSG00000174738;HGNC:7963;9975;Nuclear receptor subfamily 1 group D member 2 (Orphan nuclear hormone receptor BD73) (Rev-erb alpha-related receptor) (RVR) (Rev-erb-beta) (V-erbA-related protein 1-related) (EAR-1R);Q14995;https://jaspar.elixir.no/search?q=Q14995;https://platform.opentargets.org/target/ENSG00000174738;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;1265;369;532;551;182;4_Low;219;9.87;0.07;0.04;205;5.96;0.08;0.08;14;3.91;0.03;0.03;#N/A;#N/A;#N/A;#N/A;8;0.15;0.5;0.04;Cancer;#N/A;#N/A;0.004065378;0.002104552;#N/A;0.069828874;0.007391597;0.004434958;#N/A;0.001478319;#N/A;#N/A;#N/A;0.001478319;#N/A;0.055258145;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0285;FOXR1;ENSG00000176302;HGNC:29980;283150;Forkhead box protein R1 (Forkhead box protein N5);Q6PIV2;#N/A;https://platform.opentargets.org/target/ENSG00000176302;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2875;1139;533;1174;1168;5_None;89;9.85;0.03;0.04;89;9.85;0.03;0.13;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011436443;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0494;LIN28A;ENSG00000131914;HGNC:15986;79727;Protein lin-28 homolog A (Lin-28A) (Zinc finger CCHC domain-containing protein 1);Q9H9Z2;#N/A;https://platform.opentargets.org/target/ENSG00000131914;9 beta-Barrel DNA-binding domains;9.1 Cold-shock domain factors;9.1.0 Uncharacterized/Undefined;1468;451;534;496;438;5_None;373;9.78;0.12;0.04;369;8.22;0.14;0.11;3;0.98;0.01;0.01;1;0.57;0.01;0.01;11;0.17;0.69;0.04;Cancer;#N/A;#N/A;0.003326219;0.015317032;0.007391597;0.098735188;#N/A;0.002217479;#N/A;0.003028502;0.017000673;0.002956639;0.005913278;0.014628176;#N/A;0.001847899;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0410;HOXD9;ENSG00000128709;HGNC:5140;3235;Homeobox protein Hox-D9 (Homeobox protein Hox-4C) (Homeobox protein Hox-5.2);P28356;https://jaspar.elixir.no/search?q=P28356;https://platform.opentargets.org/target/ENSG00000128709;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1733;576;535;760;438;3_Medium to Low;256;9.76;0.08;0.04;251;8.55;0.1;0.12;5;1.21;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.047593068;0.004065378;#N/A;#N/A;#N/A;0.022174791;0.003675266;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0594;NFE2L1;ENSG00000082641;HGNC:7781;4779;Endoplasmic reticulum membrane sensor NFE2L1 (Locus control region-factor 1) (LCR-F1) (Nuclear factor erythroid 2-related factor 1) (NF-E2-related factor 1) (NFE2-related factor 1) (Nuclear factor, erythroid derived 2, like 1) (Protein NRF1, p120 form) (Transcription factor 11) (TCF-11) [Cleaved into: Transcription factor NRF1 (Protein NRF1, p110 form)];Q14494;https://jaspar.elixir.no/search?q=Q14494;https://platform.opentargets.org/target/ENSG00000082641;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;989;266;536;401;52;5_None;221;9.71;0.07;0.04;210;6.66;0.08;0.09;11;3.05;0.02;0.02;#N/A;#N/A;#N/A;#N/A;9;0.25;0.56;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.010723154;0.001478319;#N/A;0.051700222;0.018109413;#N/A;0.002217479;0.004065378;#N/A;#N/A;0.005913278;0.012642711;#N/A;0.144943283;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;model,functional;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;Pro-Longevity;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0855;SOX30;ENSG00000039600;HGNC:30635;11063;Transcription factor SOX-30;O94993;#N/A;https://platform.opentargets.org/target/ENSG00000039600;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1801;602;537;826;438;5_None;171;9.71;0.05;0.04;168;8.9;0.07;0.12;3;0.81;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.06;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.056219101;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0047;ATF6;ENSG00000118217;HGNC:791;22926;Cyclic AMP-dependent transcription factor ATF-6 alpha (cAMP-dependent transcription factor ATF-6 alpha) (Activating transcription factor 6 alpha) (ATF6-alpha) [Cleaved into: Processed cyclic AMP-dependent transcription factor ATF-6 alpha];P18850;https://jaspar.elixir.no/search?q=P18850;https://platform.opentargets.org/target/ENSG00000118217;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1007;272;538;417;52;5_None;452;9.7;0.15;0.04;443;6.42;0.17;0.09;8;2.53;0.02;0.02;1;0.76;0.01;0.01;13;0.24;0.81;0.06;Type 2 Diabetes Mellitus;#N/A;0.005913278;0.033373616;0.008990303;0.008130757;0.031993162;0.019465986;0.016378032;0.019046298;0.012355844;0.015923932;0.01242199;#N/A;0.020657326;#N/A;0.034640197;4;0.27;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;Induces;#N/A;Anti-Longevity;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1265;ZNF365;ENSG00000138311;HGNC:18194;22891;Protein ZNF365 (DISC1-binding zinc-finger protein) (Protein su48);Q70YC5;#N/A;https://platform.opentargets.org/target/ENSG00000138311;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1057;294;539;336;182;5_None;142;9.68;0.05;0.04;112;2.06;0.04;0.03;30;7.62;0.06;0.05;#N/A;#N/A;#N/A;#N/A;5;0.34;0.31;0.09;Cancer;#N/A;#N/A;0.013447438;0.022051598;#N/A;0.275291882;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.025973557;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0224;FAM170A;ENSG00000164334;HGNC:27963;340069;Protein FAM170A (Zinc finger domain-containing protein) (Zinc finger protein ZNFD);A1A519;#N/A;https://platform.opentargets.org/target/ENSG00000164334;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3130;1291;540;1422;1168;5_None;139;9.66;0.04;0.04;129;6.65;0.05;0.09;10;3.01;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0828;SMAD1;ENSG00000170365;HGNC:6767;4086;Mothers against decapentaplegic homolog 1 (MAD homolog 1) (Mothers against DPP homolog 1) (JV4-1) (Mad-related protein 1) (SMAD family member 1) (SMAD 1) (Smad1) (hSMAD1) (Transforming growth factor-beta-signaling protein 1) (BSP-1);Q15797;#N/A;https://platform.opentargets.org/target/ENSG00000170365;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;1162;337;541;538;83;5_None;387;9.65;0.12;0.04;373;4.84;0.15;0.07;13;4.31;0.03;0.03;1;0.5;0.01;0.01;10;0.15;0.63;0.04;Cancer;#N/A;#N/A;0.028738933;0.017463245;#N/A;0.03072064;#N/A;0.003018235;0.003695799;0.005930387;#N/A;0.01033182;0.01764299;0.009054706;#N/A;0.024581668;3;0.2;Y;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Induces;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0119;CREB3L4;ENSG00000143578;HGNC:18854;148327;Cyclic AMP-responsive element-binding protein 3-like protein 4 (cAMP-responsive element-binding protein 3-like protein 4) (Androgen-induced basic leucine zipper protein) (AIbZIP) (Attaching to CRE-like 1) (ATCE1) (Cyclic AMP-responsive element-binding protein 4) (CREB-4) (cAMP-responsive element-binding protein 4) (Transcript induced in spermiogenesis protein 40) (Tisp40) (hJAL) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 4];Q8TEY5;https://jaspar.elixir.no/search?q=Q8TEY5;https://platform.opentargets.org/target/ENSG00000143578;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1871;632;542;891;438;5_None;185;9.63;0.06;0.04;181;8.35;0.07;0.11;4;1.28;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.05;0.31;0.01;Cancer;#N/A;#N/A;0.008214323;#N/A;#N/A;0.027976644;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.002956639;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1025;ZBTB1;ENSG00000126804;HGNC:20259;22890;Zinc finger and BTB domain-containing protein 1;Q9Y2K1;#N/A;https://platform.opentargets.org/target/ENSG00000126804;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3053;1248;543;1342;1168;5_None;163;9.62;0.05;0.04;155;7;0.06;0.09;8;2.62;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0005;ADNP;ENSG00000101126;HGNC:15766;23394;Activity-dependent neuroprotector homeobox protein (Activity-dependent neuroprotective protein);Q9H2P0;#N/A;https://platform.opentargets.org/target/ENSG00000101126;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1480;459;544;498;438;5_None;183;9.62;0.06;0.04;162;1.98;0.06;0.03;17;5.09;0.04;0.03;4;2.55;0.04;0.04;5;0.17;0.31;0.04;Alzheimer Disease;#N/A;#N/A;0.077852014;#N/A;#N/A;0.047585227;0.008500337;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.024197214;#N/A;0.013304875;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0432;IRF7;ENSG00000185507;HGNC:6122;3665;Interferon regulatory factor 7 (IRF-7);Q92985;https://jaspar.elixir.no/search?q=Q92985;https://platform.opentargets.org/target/ENSG00000185507;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;923;241;545;295;83;5_None;460;9.6;0.15;0.04;458;8.75;0.18;0.12;1;0.28;0;0;1;0.57;0.01;0.01;13;0.4;0.81;0.1;Age-Related Macular Degeneration;#N/A;0.091096521;0.086177571;0.009384133;#N/A;0.060695357;0.027663545;0.007761177;0.001478319;0.006098068;0.004250168;0.007761177;#N/A;0.073921104;0.002217479;0.020260862;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;6;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0054;BACH1;ENSG00000156273;HGNC:935;571;Transcription regulator protein BACH1 (BTB and CNC homolog 1) (HA2303);O14867;https://jaspar.elixir.no/search?q=O14867;https://platform.opentargets.org/target/ENSG00000156273;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;1996;688;546;282;1168;5_None;285;9.6;0.09;0.04;271;6.06;0.11;0.08;14;3.53;0.03;0.02;#N/A;#N/A;#N/A;#N/A;13;0.42;0.81;0.11;Cancer;#N/A;#N/A;0.030172404;0.017041126;#N/A;0.108843553;0.016803153;0.098403321;0.009218964;0.012429552;0.025018503;0.014488146;0.008782655;0.077144136;0.001478319;0.004065378;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0237;FOSL1;ENSG00000175592;HGNC:13718;8061;Fos-related antigen 1 (FRA-1);P15407;https://jaspar.elixir.no/search?q=P15407;https://platform.opentargets.org/target/ENSG00000175592;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;1053;292;547;68;438;4_Low;455;9.57;0.15;0.04;447;6.76;0.17;0.09;7;2.3;0.01;0.02;1;0.52;0.01;0.01;12;1;0.75;0.25;Alzheimer Disease;#N/A;#N/A;0.382271449;0.023440785;#N/A;0.087683758;0.00973884;#N/A;0.002217479;0.011749765;0.009627145;0.010214777;0.017398588;0.370688594;0.007391597;0.063198155;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0940;TFAP2C;ENSG00000087510;HGNC:11744;7022;Transcription factor AP-2 gamma (AP2-gamma) (Activating enhancer-binding protein 2 gamma) (Transcription factor ERF-1);Q92754;https://jaspar.elixir.no/search?q=Q92754;https://platform.opentargets.org/target/ENSG00000087510;1 Basic domains;1.3 Basic helix-span-helix factors (bHSH);1.3.1 AP5;1945;667;548;959;438;5_None;166;9.57;0.05;0.04;148;4.84;0.06;0.07;17;4.21;0.04;0.03;1;0.53;0.01;0.01;5;0.03;0.31;0.01;Cancer;#N/A;#N/A;0.004229636;#N/A;#N/A;0.022543829;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1140;ZNF148;ENSG00000163848;HGNC:12933;7707;Zinc finger protein 148 (Transcription factor ZBP-89) (Zinc finger DNA-binding protein 89);Q9UQR1;https://jaspar.elixir.no/search?q=Q9UQR1;https://platform.opentargets.org/target/ENSG00000163848;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1388;417;549;756;83;5_None;211;9.57;0.07;0.04;202;6.18;0.08;0.08;7;2.18;0.01;0.01;2;1.21;0.02;0.02;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.001475075;0.017339455;#N/A;0.05435899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0550;MTF2;ENSG00000143033;HGNC:29535;22823;Metal-response element-binding transcription factor 2 (Metal regulatory transcription factor 2) (Metal-response element DNA-binding protein M96) (Polycomb-like protein 2) (hPCl2);Q9Y483;#N/A;https://platform.opentargets.org/target/ENSG00000143033;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1599;516;550;611;438;5_None;180;9.55;0.06;0.04;169;6.47;0.07;0.09;11;3.09;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.12;0.25;0.03;Parkinson Disease;#N/A;#N/A;0.004619748;#N/A;#N/A;0.025883808;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.0853087;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0825;SKOR1;ENSG00000188779;HGNC:21326;390598;SKI family transcriptional corepressor 1 (Functional Smad-suppressing element on chromosome 15) (Fussel-15) (LBX1 corepressor 1) (Ladybird homeobox corepressor 1);P84550;#N/A;https://platform.opentargets.org/target/ENSG00000188779;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1519;474;551;530;438;5_None;85;9.53;0.03;0.04;70;4.4;0.03;0.06;14;4.59;0.03;0.03;1;0.53;0.01;0.01;3;0.16;0.19;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.151381652;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0459;KLF10;ENSG00000155090;HGNC:11810;7071;Krueppel-like factor 10 (EGR-alpha) (Transforming growth factor-beta-inducible early growth response protein 1) (TGFB-inducible early growth response protein 1) (TIEG-1);Q13118;https://jaspar.elixir.no/search?q=Q13118;https://platform.opentargets.org/target/ENSG00000155090;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1032;282;552;397;83;5_None;276;9.51;0.09;0.04;267;6.15;0.1;0.08;8;2.83;0.02;0.02;1;0.53;0.01;0.01;10;0.26;0.63;0.07;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.005358908;0.015406963;#N/A;0.054875555;0.007391597;#N/A;0.001478319;0.018068348;0.06374787;0.012750505;0.052812494;#N/A;#N/A;0.024584863;3;0.2;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0752;PURA;ENSG00000185129;HGNC:9701;5813;Transcriptional activator protein Pur-alpha (Purine-rich single-stranded DNA-binding protein alpha);Q00577;#N/A;https://platform.opentargets.org/target/ENSG00000185129;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.5 PUR;1121;324;553;130;438;4_Low;143;9.51;0.05;0.04;125;1.86;0.05;0.03;10;3.01;0.02;0.02;8;4.64;0.08;0.08;7;0.72;0.44;0.18;Alzheimer Disease;#N/A;#N/A;0.337282204;#N/A;#N/A;0.045553442;0.003695799;0.001478319;#N/A;#N/A;0.002956639;#N/A;#N/A;0.325093879;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0718;POU3F4;ENSG00000196767;HGNC:9217;5456;POU domain, class 3, transcription factor 4 (Brain-specific homeobox/POU domain protein 4) (Brain-4) (Brn-4) (Octamer-binding protein 9) (Oct-9) (Octamer-binding transcription factor 9) (OTF-9);P49335;https://jaspar.elixir.no/search?q=P49335;https://platform.opentargets.org/target/ENSG00000196767;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1681;549;554;689;438;5_None;153;9.49;0.05;0.03;140;4.19;0.05;0.06;10;3.28;0.02;0.02;3;2.02;0.03;0.04;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;0.004434958;#N/A;#N/A;0.078535719;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0123;CREM;ENSG00000095794;HGNC:2352;1390;cAMP-responsive element modulator (Inducible cAMP early repressor) (ICER);Q03060;https://jaspar.elixir.no/search?q=Q03060;https://platform.opentargets.org/target/ENSG00000095794;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;1692;554;555;699;438;5_None;254;9.47;0.08;0.03;249;8.1;0.1;0.11;5;1.37;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.09;0.44;0.02;Cancer;#N/A;0.002956639;0.028450713;#N/A;#N/A;0.049265194;#N/A;0.001478319;#N/A;0.002771849;#N/A;#N/A;#N/A;#N/A;0.001478319;0.005523166;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0644;NR2E1;ENSG00000112333;HGNC:7973;7101;Nuclear receptor subfamily 2 group E member 1 (Nuclear receptor TLX) (Protein tailless homolog) (Tll) (hTll);Q9Y466;#N/A;https://platform.opentargets.org/target/ENSG00000112333;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;888;228;556;249;83;3_Medium to Low;278;9.46;0.09;0.03;276;8.67;0.11;0.12;2;0.79;0;0.01;#N/A;#N/A;#N/A;#N/A;6;0.49;0.38;0.12;Alzheimer Disease;#N/A;0.039763097;0.199263791;#N/A;#N/A;0.027292952;#N/A;#N/A;#N/A;#N/A;0.011826555;#N/A;#N/A;0.197343762;#N/A;0.009588544;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0923;TCF7L1;ENSG00000152284;HGNC:11640;83439;Transcription factor 7-like 1 (HMG box transcription factor 3) (TCF-3);Q9HCS4;https://jaspar.elixir.no/search?q=Q9HCS4;https://platform.opentargets.org/target/ENSG00000152284;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.3 TCF7-related;1911;653;557;916;438;5_None;149;9.42;0.05;0.03;134;4.69;0.05;0.06;14;4.2;0.03;0.03;1;0.53;0.01;0.01;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.004989328;0.003695799;#N/A;0.020157521;0.0116701;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0635;NR1D1;ENSG00000126368;HGNC:7962;9572;Nuclear receptor subfamily 1 group D member 1 (Rev-erbA-alpha) (V-erbA-related protein 1) (EAR-1);P20393;https://jaspar.elixir.no/search?q=P20393;https://platform.opentargets.org/target/ENSG00000126368;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;1027;281;558;287;182;4_Low;401;9.4;0.13;0.03;398;8.49;0.16;0.12;3;0.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;13;0.41;0.81;0.11;Cancer;#N/A;0.013746317;0.042910258;0.013707682;#N/A;0.089974402;0.028664065;0.014811289;0.019218152;0.009083041;0.009575288;0.027141932;0.013304875;0.053789619;#N/A;0.07852733;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0774;RFX2;ENSG00000087903;HGNC:9983;5990;DNA-binding protein RFX2 (Regulatory factor X 2);P48378;https://jaspar.elixir.no/search?q=P48378;https://platform.opentargets.org/target/ENSG00000087903;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;2291;837;559;1294;438;5_None;160;9.39;0.05;0.03;154;7.4;0.06;0.1;6;2;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.004414426;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1565;ZNF789;ENSG00000198556;HGNC:27801;285989;Zinc finger protein 789;Q5FWF6;#N/A;https://platform.opentargets.org/target/ENSG00000198556;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2340;859;560;1342;438;5_None;56;9.38;0.02;0.03;29;1.39;0.01;0.02;27;7.99;0.06;0.05;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0748;PRR12;ENSG00000126464;HGNC:29217;57479;Proline-rich protein 12;Q9ULL5;#N/A;https://platform.opentargets.org/target/ENSG00000126464;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2382;882;561;653;1168;5_None;72;9.37;0.02;0.03;55;2.48;0.02;0.03;15;5.65;0.03;0.04;2;1.24;0.02;0.02;1;0.1;0.06;#N/A;Heart Failure;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.104513724;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0561;MYF5;ENSG00000111049;HGNC:7565;4617;Myogenic factor 5 (Myf-5) (Class C basic helix-loop-helix protein 2) (bHLHc2);P13349;https://jaspar.elixir.no/search?q=P13349;https://platform.opentargets.org/target/ENSG00000111049;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;2477;927;562;747;1168;5_None;267;9.36;0.09;0.03;263;7.71;0.1;0.1;3;1.06;0.01;0.01;1;0.59;0.01;0.01;6;0.08;0.38;0.02;Type 2 Diabetes Mellitus;#N/A;0.008869917;#N/A;0.002217479;#N/A;0.004637188;0.015634858;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004607018;0.044718204;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0318;GRHL3;ENSG00000158055;HGNC:25839;57822;Grainyhead-like protein 3 homolog (Sister of mammalian grainyhead) (Transcription factor CP2-like 4);Q8TE85;#N/A;https://platform.opentargets.org/target/ENSG00000158055;6 Immunoglobulin fold;6.7 Grainyhead;6.7.1 Grainyhead-related;1667;539;563;666;438;5_None;255;9.34;0.08;0.03;247;5.74;0.1;0.08;5;1.71;0.01;0.01;3;1.89;0.03;0.03;3;0.1;0.19;0.03;Cancer;#N/A;#N/A;0.018873624;#N/A;#N/A;0.062624135;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.019218152;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0885;SRY;ENSG00000184895;HGNC:11311;6736;Sex-determining region Y protein (Testis-determining factor);Q05066;https://jaspar.elixir.no/search?q=Q05066;https://platform.opentargets.org/target/ENSG00000184895;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;2424;902;564;692;1168;4_Low;312;9.32;0.1;0.03;305;6.06;0.12;0.08;5;1.83;0.01;0.01;2;1.43;0.02;0.02;9;0.09;0.56;0.02;Cancer;#N/A;#N/A;0.007072321;0.011641765;0.004496555;0.023431986;#N/A;#N/A;#N/A;0.007453194;#N/A;0.004065378;0.017534511;0.01555435;#N/A;0.001847899;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0908;TBX22;ENSG00000122145;HGNC:11600;50945;T-box transcription factor TBX22 (T-box protein 22);Q9Y458;#N/A;https://platform.opentargets.org/target/ENSG00000122145;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;1902;648;565;169;1168;5_None;198;9.32;0.06;0.03;184;3.87;0.07;0.05;12;4.13;0.02;0.03;2;1.31;0.02;0.02;7;0.61;0.44;0.15;Alzheimer Disease;#N/A;#N/A;0.257197255;#N/A;#N/A;0.054668183;0.001478319;0.004804538;0.004619748;0.031783868;#N/A;#N/A;#N/A;0.255215896;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0695;PHF20;ENSG00000025293;HGNC:16098;51230;PHD finger protein 20 (Glioma-expressed antigen 2) (Hepatocellular carcinoma-associated antigen 58) (Novel zinc finger protein) (Transcription factor TZP);Q9BVI0;#N/A;https://platform.opentargets.org/target/ENSG00000025293;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1135;327;566;387;182;5_None;120;9.3;0.04;0.03;106;5.12;0.04;0.07;14;4.18;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.27;0.25;0.07;Cancer;#N/A;#N/A;0.004619748;#N/A;0.005543698;0.234891492;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.021507494;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0720;POU4F2;ENSG00000151615;HGNC:9219;5458;POU domain, class 4, transcription factor 2 (Brain-specific homeobox/POU domain protein 3B) (Brain-3B) (Brn-3B);Q12837;https://jaspar.elixir.no/search?q=Q12837;https://platform.opentargets.org/target/ENSG00000151615;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;2367;871;567;632;1168;5_None;193;9.29;0.06;0.03;185;6.71;0.07;0.09;8;2.58;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.11;0.38;0.03;Age-Related Macular Degeneration;#N/A;0.073464836;0.003695799;#N/A;#N/A;0.024708557;#N/A;0.001847899;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.009095771;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1218;ZNF281;ENSG00000162702;HGNC:13075;23528;Zinc finger protein 281 (GC-box-binding zinc finger protein 1) (Transcription factor ZBP-99) (Zinc finger DNA-binding protein 99);Q9Y2X9;https://jaspar.elixir.no/search?q=Q9Y2X9;https://platform.opentargets.org/target/ENSG00000162702;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2154;767;568;418;1168;5_None;125;9.29;0.04;0.03;103;2.97;0.04;0.04;21;5.76;0.04;0.04;1;0.56;0.01;0.01;5;0.24;0.31;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.001478319;#N/A;#N/A;0.060057093;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;0.002956639;#N/A;#N/A;0.170827456;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0941;TFAP2D;ENSG00000008197;HGNC:15581;83741;Transcription factor AP-2-delta (AP2-delta) (Activating enhancer-binding protein 2-delta) (Transcription factor AP-2-beta-like 1);Q7Z6R9;#N/A;https://platform.opentargets.org/target/ENSG00000008197;1 Basic domains;1.3 Basic helix-span-helix factors (bHSH);1.3.1 AP6;2501;937;569;764;1168;5_None;58;9.29;0.02;0.03;39;2.99;0.02;0.04;17;5.23;0.04;0.03;2;1.07;0.02;0.02;1;0.08;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.076695622;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1449;ZNF628;ENSG00000197483;HGNC:28054;89887;Zinc finger protein 628;Q5EBL2;#N/A;https://platform.opentargets.org/target/ENSG00000197483;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1910;652;570;172;1168;5_None;108;9.27;0.03;0.03;97;5.48;0.04;0.07;11;3.79;0.02;0.03;#N/A;#N/A;#N/A;#N/A;2;0.61;0.13;0.15;Alzheimer Disease;#N/A;#N/A;0.305447518;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.30101256;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0099;CEBPG;ENSG00000153879;HGNC:1837;1054;CCAAT/enhancer-binding protein gamma (C/EBP gamma);P53567;https://jaspar.elixir.no/search?q=P53567;https://platform.opentargets.org/target/ENSG00000153879;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;930;246;571;307;52;5_None;177;9.26;0.06;0.03;159;3.66;0.06;0.05;18;5.61;0.04;0.04;#N/A;#N/A;#N/A;#N/A;4;0.38;0.25;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.020654976;0.005523166;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0.350297137;4;0.27;Y;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Inhibits;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0460;KLF11;ENSG00000172059;HGNC:11811;8462;Krueppel-like factor 11 (Transforming growth factor-beta-inducible early growth response protein 2) (TGFB-inducible early growth response protein 2) (TIEG-2);O14901;https://jaspar.elixir.no/search?q=O14901;https://platform.opentargets.org/target/ENSG00000172059;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;2397;890;572;657;1168;5_None;161;9.21;0.05;0.03;143;2.4;0.06;0.03;17;6.2;0.04;0.04;1;0.61;0.01;0.01;7;0.1;0.44;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;0.018478993;#N/A;0.020434827;#N/A;0.004434958;0.013861914;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;0.034240678;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0342;HESX1;ENSG00000163666;HGNC:4877;8820;Homeobox expressed in ES cells 1 (Homeobox protein ANF) (hAnf);Q9UBX0;https://jaspar.elixir.no/search?q=Q9UBX0;https://platform.opentargets.org/target/ENSG00000163666;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1403;432;573;648;182;5_None;365;9.19;0.12;0.03;354;4.06;0.14;0.05;8;2.88;0.02;0.02;3;2.25;0.03;0.04;8;0.11;0.5;0.03;Heart Failure;#N/A;#N/A;0.01168283;#N/A;#N/A;0.015222173;0.010674287;0.027460934;#N/A;0.02099782;0.004434958;#N/A;0.009609076;#N/A;#N/A;0.00756693;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1454;ZNF644;ENSG00000122482;HGNC:29222;84146;Zinc finger protein 644 (Zinc finger motif enhancer-binding protein 2) (Zep-2);Q9H582;#N/A;https://platform.opentargets.org/target/ENSG00000122482;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2925;1170;574;1183;1168;5_None;59;9.13;0.02;0.03;35;1.04;0.01;0.01;23;7.37;0.05;0.05;1;0.73;0.01;0.01;2;0.01;0.13;0;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.007391597;0.003675266;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0229;FEZF1;ENSG00000128610;HGNC:22788;389549;Fez family zinc finger protein 1 (Zinc finger protein 312B);A0PJY2;#N/A;https://platform.opentargets.org/target/ENSG00000128610;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1477;456;575;464;438;5_None;116;9.13;0.04;0.03;109;6.17;0.04;0.08;5;1.86;0.01;0.01;2;1.1;0.02;0.02;4;0.2;0.25;0.05;Osteoarthritis;#N/A;#N/A;0.011456975;#N/A;#N/A;0.047097698;#N/A;#N/A;#N/A;#N/A;#N/A;0.124833169;#N/A;#N/A;#N/A;0.011826555;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1305;ZNF438;ENSG00000183621;HGNC:21029;220929;Zinc finger protein 438;Q7Z4V0;#N/A;https://platform.opentargets.org/target/ENSG00000183621;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2427;906;576;1413;438;5_None;71;9.13;0.02;0.03;47;1.78;0.02;0.02;24;7.35;0.05;0.05;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0611;NHLH2;ENSG00000177551;HGNC:7818;4808;Helix-loop-helix protein 2 (HEN-2) (Class A basic helix-loop-helix protein 34) (bHLHa34) (Nescient helix loop helix 2) (NSCL-2);Q02577;https://jaspar.elixir.no/search?q=Q02577;https://platform.opentargets.org/target/ENSG00000177551;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;1975;680;577;960;438;5_None;240;9.04;0.08;0.03;239;8.63;0.09;0.12;1;0.42;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.030615752;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0323;GTF2B;ENSG00000137947;HGNC:4648;2959;Transcription initiation factor IIB (EC 2.3.1.48) (General transcription factor TFIIB) (S300-II);Q00403;#N/A;https://platform.opentargets.org/target/ENSG00000137947;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1692;554;578;676;438;3_Medium to Low;115;9.04;0.04;0.03;97;2.87;0.04;0.04;17;5.59;0.04;0.04;1;0.58;0.01;0.01;6;0.1;0.38;0.02;Age-Related Hearing Impairment;0.038056011;#N/A;0.006979871;#N/A;#N/A;0.021702202;0.025311747;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0424;INSM1;ENSG00000173404;HGNC:6090;3642;Insulinoma-associated protein 1 (Zinc finger protein IA-1);Q01101;https://jaspar.elixir.no/search?q=Q01101;https://platform.opentargets.org/target/ENSG00000173404;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2062;718;579;1045;438;5_None;313;9.03;0.1;0.03;308;6.88;0.12;0.09;4;1.59;0.01;0.01;1;0.56;0.01;0.01;4;0.02;0.25;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.012911588;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1211;ZNF276;ENSG00000158805;HGNC:23330;92822;Zinc finger protein 276 (Zfp-276) (Zinc finger protein 477);Q8N554;#N/A;https://platform.opentargets.org/target/ENSG00000158805;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2136;755;580;388;1168;5_None;88;8.98;0.03;0.03;79;6.03;0.03;0.08;7;1.8;0.01;0.01;2;1.15;0.02;0.02;3;0.27;0.19;#N/A;Cancer;0.038975745;#N/A;#N/A;#N/A;#N/A;0.120916091;#N/A;#N/A;#N/A;#N/A;#N/A;0.106110981;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1373;ZNF541;ENSG00000118156;HGNC:25294;84215;Zinc finger protein 541;Q9H0D2;#N/A;https://platform.opentargets.org/target/ENSG00000118156;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;3171;1315;581;1422;1168;5_None;187;8.94;0.06;0.03;185;8.49;0.07;0.12;2;0.44;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0529;MGA;ENSG00000174197;HGNC:14010;23269;MAX gene-associated protein (MAX dimerization protein 5);Q8IWI9;https://jaspar.elixir.no/search?q=Q8IWI9;https://platform.opentargets.org/target/ENSG00000174197;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1585;506;582;565;438;5_None;137;8.92;0.04;0.03;120;3.59;0.05;0.05;17;5.33;0.04;0.04;#N/A;#N/A;#N/A;#N/A;4;0.14;0.25;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.02204438;0.044513368;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;0.068718144;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0464;KLF15;ENSG00000163884;HGNC:14536;28999;Krueppel-like factor 15 (Kidney-enriched krueppel-like factor);Q9UIH9;https://jaspar.elixir.no/search?q=Q9UIH9;https://platform.opentargets.org/target/ENSG00000163884;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1206;347;583;441;182;5_None;242;8.9;0.08;0.03;230;4.91;0.09;0.07;12;3.98;0.02;0.03;#N/A;#N/A;#N/A;#N/A;10;0.21;0.63;0.05;Heart Failure;#N/A;#N/A;0.021066793;0.032213286;#N/A;0.02484297;0.027348909;0.037939625;#N/A;0.019767389;0.001478319;0.008869917;#N/A;#N/A;0.004065378;0.037319214;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0826;SKOR2;ENSG00000215474;HGNC:32695;652991;SKI family transcriptional corepressor 2 (Functional Smad-suppressing element on chromosome 18) (Fussel-18) (LBX1 corepressor 1-like protein) (Ladybird homeobox corepressor 1-like protein);Q2VWA4;#N/A;https://platform.opentargets.org/target/ENSG00000215474;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.0 Uncharacterized/Undefined;3108;1281;584;1356;1168;4_Low;108;8.82;0.03;0.03;91;3.13;0.04;0.04;16;5.17;0.03;0.03;1;0.51;0.01;0.01;2;0;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0008;AEBP2;ENSG00000139154;HGNC:24051;121536;Zinc finger protein AEBP2 (Adipocyte enhancer-binding protein 2) (AE-binding protein 2);Q6ZN18;#N/A;https://platform.opentargets.org/target/ENSG00000139154;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;1894;644;585;871;438;5_None;76;8.8;0.02;0.03;57;1.85;0.02;0.03;17;5.92;0.04;0.04;2;1.04;0.02;0.02;2;0.05;0.13;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;0.047332351;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0557;MYBL2;ENSG00000101057;HGNC:7548;4605;Myb-related protein B (B-Myb) (Myb-like protein 2);P10244;https://jaspar.elixir.no/search?q=P10244;https://platform.opentargets.org/target/ENSG00000101057;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1009;273;586;340;83;5_None;205;8.8;0.07;0.03;190;3.6;0.07;0.05;14;4.68;0.03;0.03;1;0.52;0.01;0.01;6;0.33;0.38;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.106762394;0.008726191;#N/A;0.005174118;0.008898251;#N/A;#N/A;#N/A;#N/A;0.003695799;0.199525387;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;8;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0178;E2F8;ENSG00000129173;HGNC:24727;79733;Transcription factor E2F8 (E2F-8);A0AVK6;https://jaspar.elixir.no/search?q=A0AVK6;https://platform.opentargets.org/target/ENSG00000129173;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;1495;464;587;470;438;2_Medium;159;8.79;0.05;0.03;141;2.65;0.06;0.04;14;3.72;0.03;0.02;4;2.42;0.04;0.04;5;0.19;0.31;0.05;Osteoarthritis;#N/A;#N/A;0.001478319;#N/A;#N/A;0.026715493;#N/A;#N/A;#N/A;0.003695799;#N/A;0.153560022;#N/A;#N/A;#N/A;0.002587059;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;2;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0832;SMAD9;ENSG00000120693;HGNC:6774;4093;Mothers against decapentaplegic homolog 9 (MAD homolog 9) (Mothers against DPP homolog 9) (Madh6) (SMAD family member 9) (SMAD 9) (Smad9);O15198;#N/A;https://platform.opentargets.org/target/ENSG00000120693;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;1475;455;588;705;182;5_None;163;8.77;0.05;0.03;145;2.29;0.06;0.03;16;5.25;0.03;0.04;2;1.22;0.02;0.02;10;0.09;0.63;0.02;Cancer;#N/A;0.004434958;0.006643476;0.003695799;#N/A;0.039692541;#N/A;0.002217479;0.003695799;#N/A;#N/A;0.003695799;0.021805211;0.003695799;#N/A;0.001478319;2;0.13;Y;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0332;HBP1;ENSG00000105856;HGNC:23200;26959;HMG box-containing protein 1 (HMG box transcription factor 1) (High mobility group box transcription factor 1);O60381;#N/A;https://platform.opentargets.org/target/ENSG00000105856;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1090;303;589;449;52;5_None;143;8.76;0.05;0.03;129;4.33;0.05;0.06;14;4.43;0.03;0.03;#N/A;#N/A;#N/A;#N/A;6;0.21;0.38;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.007391597;0.008687452;#N/A;0.06723687;#N/A;#N/A;#N/A;#N/A;0.037443162;0.012475989;#N/A;#N/A;#N/A;0.075004178;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;downstream;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;6;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0881;SRCAP;ENSG00000080603;HGNC:16974;10847;Helicase SRCAP (EC 3.6.4.-) (Domino homolog 2) (Snf2-related CBP activator);Q6ZRS2;#N/A;https://platform.opentargets.org/target/ENSG00000080603;8 beta-Sheet binding to DNA;8.2 A.T hook factors;8.2.0 Uncharacterized/Undefined;2038;711;590;1010;438;5_None;159;8.73;0.05;0.03;149;4.24;0.06;0.06;6;1.95;0.01;0.01;4;2.54;0.04;0.04;2;0.03;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.015152774;#N/A;#N/A;0.012106254;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0174;E2F4;ENSG00000205250;HGNC:3118;1874;Transcription factor E2F4 (E2F-4);Q16254;https://jaspar.elixir.no/search?q=Q16254;https://platform.opentargets.org/target/ENSG00000205250;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;1416;438;591;643;182;2_Medium;247;8.71;0.08;0.03;235;4.44;0.09;0.06;9;2.34;0.02;0.02;3;1.94;0.03;0.03;6;0.11;0.38;0.03;Alzheimer Disease;#N/A;#N/A;0.052509607;#N/A;#N/A;0.043044622;0.003695799;#N/A;#N/A;#N/A;#N/A;0.002217479;0.005174118;0.001847899;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;4;3;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_1015;YBX3;ENSG00000060138;HGNC:2428;8531;Y-box-binding protein 3 (Cold shock domain-containing protein A) (DNA-binding protein A) (Single-strand DNA-binding protein NF-GMB);P16989;#N/A;https://platform.opentargets.org/target/ENSG00000060138;9 beta-Barrel DNA-binding domains;9.1 Cold-shock domain factors;9.1.1 Dbp;1657;536;592;627;438;5_None;248;8.7;0.08;0.03;243;7.1;0.1;0.1;5;1.61;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.11;0.44;0.03;Cancer;#N/A;#N/A;0.011298753;#N/A;#N/A;0.078942137;0.013489665;#N/A;#N/A;0.001478319;#N/A;0.004281858;#N/A;0.001478319;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0170;DZIP1;ENSG00000134874;HGNC:20908;22873;Cilium assembly protein DZIP1 (DAZ-interacting protein 1/2) (DAZ-interacting zinc finger protein 1);Q86YF9;#N/A;https://platform.opentargets.org/target/ENSG00000134874;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1976;681;593;945;438;5_None;128;8.67;0.04;0.03;121;5.96;0.05;0.08;5;1.66;0.01;0.01;2;1.06;0.02;0.02;3;0.04;0.19;0.01;Parkinson Disease;#N/A;#N/A;0.009301093;#N/A;#N/A;0.010463204;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.017000673;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0279;FOXO6;ENSG00000204060;HGNC:24814;100132074;Forkhead box protein O6;A8MYZ6;https://jaspar.elixir.no/search?q=A8MYZ6;https://platform.opentargets.org/target/ENSG00000204060;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1791;601;594;759;438;5_None;139;8.66;0.04;0.03;126;3.83;0.05;0.05;11;3.77;0.02;0.03;2;1.05;0.02;0.02;6;0.08;0.38;0.02;Cancer;#N/A;#N/A;0.002466851;#N/A;#N/A;0.031765183;0.025431149;#N/A;#N/A;0.004065378;#N/A;0.001527046;#N/A;#N/A;#N/A;0.012311732;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0779;RFX7;ENSG00000181827;HGNC:25777;64864;DNA-binding protein RFX7 (Regulatory factor X 7) (Regulatory factor X domain-containing protein 2);Q2KHR2;https://jaspar.elixir.no/search?q=Q2KHR2;https://platform.opentargets.org/target/ENSG00000181827;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;1730;573;595;697;438;5_None;75;8.6;0.02;0.03;60;2.72;0.02;0.04;13;4.61;0.03;0.03;2;1.28;0.02;0.02;4;0.09;0.25;0.02;Cancer;#N/A;#N/A;0.005543698;0.005543698;#N/A;0.072941499;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008500337;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0666;OSR2;ENSG00000164920;HGNC:15830;116039;Protein odd-skipped-related 2;Q8N2R0;https://jaspar.elixir.no/search?q=Q8N2R0;https://platform.opentargets.org/target/ENSG00000164920;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2011;696;596;977;438;5_None;236;8.6;0.08;0.03;236;8.6;0.09;0.12;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.022159636;0.005352017;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0827;SLC2A4RG;ENSG00000125520;HGNC:15930;56731;SLC2A4 regulator (GLUT4 enhancer factor) (GEF) (Huntington disease gene regulatory region-binding protein 1) (HDBP-1);Q9NR83;#N/A;https://platform.opentargets.org/target/ENSG00000125520;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1571;499;597;536;438;5_None;327;8.6;0.11;0.03;321;7.2;0.13;0.1;6;1.4;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.15;0.38;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.01889514;0.002751317;#N/A;0.028050781;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;0.002012157;#N/A;0.098990636;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0007;AEBP1;ENSG00000106624;HGNC:303;165;Adipocyte enhancer-binding protein 1 (AE-binding protein 1) (Aortic carboxypeptidase-like protein);Q8IUX7;#N/A;https://platform.opentargets.org/target/ENSG00000106624;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2064;720;598;298;1168;3_Medium to Low;161;8.54;0.05;0.03;147;3.43;0.06;0.05;13;4.4;0.03;0.03;1;0.7;0.01;0.01;9;0.39;0.56;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;0.033330148;0.025708161;#N/A;0.057719824;0.079344483;0.016356578;#N/A;#N/A;0.031278364;0.008130757;0.002956639;#N/A;#N/A;0.135230079;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0713;POU2F2;ENSG00000028277;HGNC:9213;5452;POU domain, class 2, transcription factor 2 (Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2) (Octamer-binding protein 2) (Oct-2) (Octamer-binding transcription factor 2) (OTF-2);P09086;https://jaspar.elixir.no/search?q=P09086;https://platform.opentargets.org/target/ENSG00000028277;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1153;333;599;372;182;4_Low;311;8.52;0.1;0.03;304;6.56;0.12;0.09;7;1.96;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.28;0.5;0.07;Alzheimer Disease;#N/A;#N/A;0.220600669;#N/A;#N/A;0.023325595;0.001478319;#N/A;0.002217479;#N/A;#N/A;0.007391597;0.007391597;0.004065378;#N/A;0.018464392;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0012;AHRR;ENSG00000063438;HGNC:346;57491;Aryl hydrocarbon receptor repressor (AhR repressor) (AhRR) (Class E basic helix-loop-helix protein 77) (bHLHe77);A9YTQ3;#N/A;https://platform.opentargets.org/target/ENSG00000063438;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1966;676;600;198;1168;4_Low;234;8.5;0.08;0.03;222;4.99;0.09;0.07;12;3.51;0.02;0.02;#N/A;#N/A;#N/A;#N/A;10;0.56;0.63;0.14;Age-Related Hearing Impairment;0.304875618;0.066935287;0.013991677;0.020213326;0.001478319;0.038907452;0.079333402;0.008130757;#N/A;0.01919762;#N/A;#N/A;#N/A;#N/A;#N/A;0.009239496;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1273;ZNF385B;ENSG00000144331;HGNC:26332;151126;Zinc finger protein 385B (Zinc finger protein 533);Q569K4;#N/A;https://platform.opentargets.org/target/ENSG00000144331;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1356;405;601;317;438;5_None;81;8.5;0.03;0.03;56;0.5;0.02;0.01;25;8;0.05;0.05;#N/A;#N/A;#N/A;#N/A;3;0.36;0.19;0.09;Age-Related Macular Degeneration;#N/A;0.334974575;0.001749148;#N/A;#N/A;0.026979329;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0888;STAT2;ENSG00000170581;HGNC:11363;6773;Signal transducer and activator of transcription 2 (p113);P52630;https://jaspar.elixir.no/search?q=P52630;https://platform.opentargets.org/target/ENSG00000170581;6 Immunoglobulin fold;6.2 STAT domain factors;6.2.1 STAT;1362;409;602;578;182;4_Low;348;8.48;0.11;0.03;342;6;0.13;0.08;4;1.11;0.01;0.01;2;1.37;0.02;0.02;10;0.13;0.63;0.03;Cancer;#N/A;0.004434958;0.006328956;0.013080114;#N/A;0.054144916;0.008923916;0.001478319;#N/A;#N/A;0.006652437;0.001478319;#N/A;0.003695799;#N/A;0.033320155;2;0.13;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0359;HMG20A;ENSG00000140382;HGNC:5001;10363;High mobility group protein 20A (HMG box-containing protein 20A) (HMG domain-containing protein 1) (HMG domain-containing protein HMGX1);Q9NP66;#N/A;https://platform.opentargets.org/target/ENSG00000140382;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.2 TOX-related;1266;371;603;225;438;5_None;88;8.46;0.03;0.03;70;3.25;0.03;0.04;17;4.64;0.04;0.03;1;0.56;0.01;0.01;3;0.52;0.19;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.006643067;#N/A;#N/A;0.009811934;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.49895838;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0112;CPEB1;ENSG00000214575;HGNC:21744;64506;Cytoplasmic polyadenylation element-binding protein 1 (CPE-BP1) (CPE-binding protein 1) (h-CPEB) (hCPEB-1);Q9BZB8;#N/A;https://platform.opentargets.org/target/ENSG00000214575;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1327;393;604;640;83;5_None;245;8.45;0.08;0.03;242;7.76;0.09;0.11;3;0.69;0.01;0;#N/A;#N/A;#N/A;#N/A;6;0.11;0.38;0.03;Cancer;#N/A;#N/A;0.019105225;0.014044034;#N/A;0.06049848;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;0.001478319;#N/A;0.007391597;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0296;GATAD2B;ENSG00000143614;HGNC:30778;57459;Transcriptional repressor p66-beta (GATA zinc finger domain-containing protein 2B) (p66/p68);Q8WXI9;#N/A;https://platform.opentargets.org/target/ENSG00000143614;2 Zinc-coordinating DNA-binding domains;2.2 Other C4 zinc finger-type factors;2.2.1 C4-GATA-related;1264;368;605;221;438;5_None;173;8.44;0.06;0.03;162;4.46;0.06;0.06;8;2.09;0.02;0.01;3;1.89;0.03;0.03;3;0.52;0.19;0.13;Alzheimer Disease;#N/A;#N/A;0.230871454;#N/A;#N/A;0.060609551;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.229947505;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0465;KLF16;ENSG00000129911;HGNC:16857;83855;Krueppel-like factor 16 (Basic transcription element-binding protein 4) (BTE-binding protein 4) (Novel Sp1-like zinc finger transcription factor 2) (Transcription factor BTEB4) (Transcription factor NSLP2);Q9BXK1;https://jaspar.elixir.no/search?q=Q9BXK1;https://platform.opentargets.org/target/ENSG00000129911;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1587;507;606;543;438;5_None;109;8.42;0.04;0.03;95;4.01;0.04;0.05;13;3.86;0.03;0.03;1;0.55;0.01;0.01;5;0.15;0.31;0.04;Alzheimer Disease;#N/A;#N/A;0.087641082;#N/A;#N/A;0.035384616;#N/A;#N/A;#N/A;0.007391597;0.018109413;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0860;SOX8;ENSG00000005513;HGNC:11203;30812;Transcription factor SOX-8;P57073;https://jaspar.elixir.no/search?q=P57073;https://platform.opentargets.org/target/ENSG00000005513;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1852;623;607;807;438;5_None;236;8.38;0.08;0.03;232;6.97;0.09;0.09;4;1.41;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.06;0.38;0.02;Heart Failure;#N/A;#N/A;0.008338302;#N/A;0.003695799;0.022391914;#N/A;0.0230653;#N/A;#N/A;#N/A;0.003326219;0.003695799;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0454;KDM2A;ENSG00000173120;HGNC:13606;22992;Lysine-specific demethylase 2A (EC 1.14.11.27) (CXXC-type zinc finger protein 8) (F-box and leucine-rich repeat protein 11) (F-box protein FBL7) (F-box protein Lilina) (F-box/LRR-repeat protein 11) (JmjC domain-containing histone demethylation protein 1A) ([Histone-H3]-lysine-36 demethylase 1A);Q9Y2K7;#N/A;https://platform.opentargets.org/target/ENSG00000173120;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;2551;964;608;775;1168;4_Low;138;8.37;0.04;0.03;122;3.23;0.05;0.04;15;4.59;0.03;0.03;1;0.56;0.01;0.01;6;0.07;0.38;0.02;Cancer;#N/A;#N/A;0.022356173;0.001478319;#N/A;0.037396732;#N/A;#N/A;#N/A;0.009609076;0.001478319;#N/A;#N/A;#N/A;#N/A;0.001847899;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0327;GTF2IRD2B;ENSG00000174428;HGNC:33125;389524;General transcription factor II-I repeat domain-containing protein 2B (GTF2I repeat domain-containing protein 2B) (Transcription factor GTF2IRD2-beta);Q6EKJ0;#N/A;https://platform.opentargets.org/target/ENSG00000174428;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2402;894;609;625;1168;5_None;55;8.36;0.02;0.03;33;1.49;0.01;0.02;22;6.88;0.05;0.05;#N/A;#N/A;#N/A;#N/A;3;0.12;0.19;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.02541793;0.02504835;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.064949171;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0064;BAZ2B;ENSG00000123636;HGNC:963;29994;Bromodomain adjacent to zinc finger domain protein 2B (hWALp4);Q9UIF8;#N/A;https://platform.opentargets.org/target/ENSG00000123636;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1936;664;610;888;438;4_Low;92;8.36;0.03;0.03;74;2.59;0.03;0.04;17;5.19;0.04;0.03;1;0.58;0.01;0.01;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.006583244;#N/A;#N/A;0.037867973;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001185177;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;344;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0273;FOXN2;ENSG00000170802;HGNC:5281;3344;Forkhead box protein N2 (Human T-cell leukemia virus enhancer factor);P32314;#N/A;https://platform.opentargets.org/target/ENSG00000170802;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2117;741;611;1068;438;5_None;101;8.32;0.03;0.03;82;2.07;0.03;0.03;19;6.25;0.04;0.04;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0.01;Cancer;#N/A;#N/A;0.001847899;#N/A;#N/A;0.01243539;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1249;ZNF337;ENSG00000130684;HGNC:15809;26152;Zinc finger protein 337;Q9Y3M9;#N/A;https://platform.opentargets.org/target/ENSG00000130684;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1567;496;612;773;182;5_None;51;8.3;0.02;0.03;32;0.95;0.01;0.01;18;6.83;0.04;0.05;1;0.52;0.01;0.01;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.074655131;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0129;CTCFL;ENSG00000124092;HGNC:16234;140690;Transcriptional repressor CTCFL (Brother of the regulator of imprinted sites) (CCCTC-binding factor) (CTCF paralog) (CTCF-like protein) (Cancer/testis antigen 27) (CT27) (Zinc finger protein CTCF-T);Q8NI51;https://jaspar.elixir.no/search?q=Q8NI51;https://platform.opentargets.org/target/ENSG00000124092;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1635;525;613;584;438;5_None;187;8.28;0.06;0.03;178;5.1;0.07;0.07;9;3.18;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.13;0.19;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;0.004989328;0.114994904;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009793866;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0188;EGR4;ENSG00000135625;HGNC:3241;1961;Early growth response protein 4 (EGR-4) (AT133);Q05215;https://jaspar.elixir.no/search?q=Q05215;https://platform.opentargets.org/target/ENSG00000135625;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1753;584;614;701;438;3_Medium to Low;196;8.28;0.06;0.03;195;7.96;0.08;0.11;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;5;0.09;0.31;0.02;Cancer;#N/A;#N/A;0.007347932;#N/A;0.007391597;0.057489588;0.003695799;#N/A;0.015891934;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;45;45;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0710;POU1F1;ENSG00000064835;HGNC:9210;5449;Pituitary-specific positive transcription factor 1 (PIT-1) (Growth hormone factor 1) (GHF-1);P28069;https://jaspar.elixir.no/search?q=P28069;https://platform.opentargets.org/target/ENSG00000064835;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1042;286;615;344;83;5_None;204;8.26;0.07;0.03;190;2.65;0.07;0.04;12;4.18;0.02;0.03;2;1.44;0.02;0.02;3;0.33;0.19;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;0.007391597;#N/A;#N/A;0.042162478;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.27595507;3;0.2;Y;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;mammal;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0401;HOXC9;ENSG00000180806;HGNC:5130;3225;Homeobox protein Hox-C9 (Homeobox protein Hox-3B);P31274;https://jaspar.elixir.no/search?q=P31274;https://platform.opentargets.org/target/ENSG00000180806;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2055;717;616;1001;438;5_None;201;8.22;0.06;0.03;195;6.28;0.08;0.09;6;1.95;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.024709746;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0661;OLIG3;ENSG00000177468;HGNC:18003;167826;Oligodendrocyte transcription factor 3 (Oligo3) (Class B basic helix-loop-helix protein 7) (bHLHb7) (Class E basic helix-loop-helix protein 20) (bHLHe20);Q7RTU3;https://jaspar.elixir.no/search?q=Q7RTU3;https://platform.opentargets.org/target/ENSG00000177468;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2735;1062;617;950;1168;5_None;65;8.21;0.02;0.03;48;3.47;0.02;0.05;17;4.74;0.04;0.03;#N/A;#N/A;#N/A;#N/A;4;0.04;0.25;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004866135;#N/A;#N/A;0.003695799;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.019140895;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1014;YBX2;ENSG00000006047;HGNC:17948;51087;Y-box-binding protein 2 (Contrin) (DNA-binding protein C) (Dbpc) (Germ cell-specific Y-box-binding protein) (MSY2 homolog);Q9Y2T7;#N/A;https://platform.opentargets.org/target/ENSG00000006047;9 beta-Barrel DNA-binding domains;9.1 Cold-shock domain factors;9.1.1 Dbp;2032;704;618;976;438;5_None;203;8.14;0.07;0.03;201;7.47;0.08;0.1;2;0.67;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.031966194;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0623;NKX3-2;ENSG00000109705;HGNC:951;579;Homeobox protein Nkx-3.2 (Bagpipe homeobox protein homolog 1) (Homeobox protein NK-3 homolog B);P78367;https://jaspar.elixir.no/search?q=P78367;https://platform.opentargets.org/target/ENSG00000109705;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1669;541;619;612;438;3_Medium to Low;150;8.12;0.05;0.03;139;4.58;0.05;0.06;10;2.8;0.02;0.02;1;0.74;0.01;0.01;4;0.12;0.25;0.03;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;0.045693416;0.003695799;#N/A;#N/A;#N/A;0.001478319;0.068323559;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;10;10;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0762;RBCK1;ENSG00000125826;HGNC:15864;10616;RanBP-type and C3HC4-type zinc finger-containing protein 1 (EC 2.3.2.31) (HBV-associated factor 4) (Heme-oxidized IRP2 ubiquitin ligase 1) (HOIL-1) (Hepatitis B virus X-associated protein 4) (RING finger protein 54) (RING-type E3 ubiquitin transferase HOIL-1) (Ubiquitin-conjugating enzyme 7-interacting protein 3);Q9BYM8;#N/A;https://platform.opentargets.org/target/ENSG00000125826;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1361;408;620;303;438;5_None;125;8.12;0.04;0.03;112;2.36;0.04;0.03;11;4.38;0.02;0.03;2;1.37;0.02;0.02;5;0.38;0.31;0.1;Alzheimer Disease;#N/A;#N/A;0.285738776;#N/A;#N/A;0.086198929;0.005543698;#N/A;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0751;PTF1A;ENSG00000168267;HGNC:23734;256297;Pancreas transcription factor 1 subunit alpha (Class A basic helix-loop-helix protein 29) (bHLHa29) (Pancreas-specific transcription factor 1a) (bHLH transcription factor p48) (p48 DNA-binding subunit of transcription factor PTF1) (PTF1-p48);Q7RTS3;#N/A;https://platform.opentargets.org/target/ENSG00000168267;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2386;885;621;597;1168;5_None;173;8.08;0.06;0.03;163;3.42;0.06;0.05;6;2.01;0.01;0.01;4;2.65;0.04;0.05;5;0.13;0.31;0.03;Age-Related Macular Degeneration;#N/A;0.064668922;0.006631905;#N/A;#N/A;0.029639869;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.022453823;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1023;ZBED6;ENSG00000257315;HGNC:33273;100381270;Zinc finger BED domain-containing protein 6;P86452;#N/A;https://platform.opentargets.org/target/ENSG00000257315;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;1934;663;622;1130;182;5_None;131;8.07;0.04;0.03;120;4.4;0.05;0.06;11;3.67;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Alzheimer Disease;#N/A;#N/A;0.007391597;#N/A;#N/A;0.005859483;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0706;PLAGL1;ENSG00000118495;HGNC:9046;5325;Zinc finger protein PLAGL1 (Lost on transformation 1) (LOT-1) (Pleiomorphic adenoma-like protein 1) (Tumor suppressor ZAC);Q9UM63;#N/A;https://platform.opentargets.org/target/ENSG00000118495;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1801;602;623;740;438;4_Low;208;8.05;0.07;0.03;190;2.45;0.07;0.03;18;5.6;0.04;0.04;#N/A;#N/A;#N/A;#N/A;6;0.08;0.38;0.02;Cancer;#N/A;#N/A;0.003321783;#N/A;#N/A;0.039668599;#N/A;#N/A;#N/A;#N/A;0.023447789;0.007391597;#N/A;0.003695799;#N/A;0.005153586;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0657;NRF1;ENSG00000106459;HGNC:7996;4899;Nuclear respiratory factor 1 (NRF-1) (Alpha palindromic-binding protein) (Alpha-pal);Q16656;https://jaspar.elixir.no/search?q=Q16656;https://platform.opentargets.org/target/ENSG00000106459;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.6 NRF;881;226;624;75;182;5_None;293;8.04;0.09;0.03;279;3.1;0.11;0.04;14;4.94;0.03;0.03;#N/A;#N/A;#N/A;#N/A;14;0.95;0.88;0.24;Type 2 Diabetes Mellitus;#N/A;0.015871402;0.317949231;0.009673734;#N/A;0.056258914;0.077096164;0.007819414;0.008500337;0.020851272;0.019098104;0.009239496;0.001478319;0.061630955;0.002902844;0.342662624;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0049;ATF7;ENSG00000170653;HGNC:792;11016;Cyclic AMP-dependent transcription factor ATF-7 (cAMP-dependent transcription factor ATF-7) (Activating transcription factor 7) (Transcription factor ATF-A);P17544;https://jaspar.elixir.no/search?q=P17544;https://platform.opentargets.org/target/ENSG00000170653;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;2985;1209;625;1192;1168;5_None;73;8.03;0.02;0.03;55;1.35;0.02;0.02;18;6.69;0.04;0.04;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.005240322;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0268;FOXK2;ENSG00000141568;HGNC:6036;3607;Forkhead box protein K2 (G/T-mismatch specific binding protein) (nGTBP) (Interleukin enhancer-binding factor 1);Q01167;https://jaspar.elixir.no/search?q=Q01167;https://platform.opentargets.org/target/ENSG00000141568;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1636;527;626;572;438;5_None;212;8.01;0.07;0.03;201;4.53;0.08;0.06;11;3.48;0.02;0.02;#N/A;#N/A;#N/A;#N/A;7;0.14;0.44;0.03;Cancer;#N/A;#N/A;0.009393559;#N/A;#N/A;0.096883309;0.008726191;#N/A;#N/A;#N/A;0.004434958;#N/A;0.002956639;0.007186275;#N/A;0.005543698;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0715;POU3F1;ENSG00000185668;HGNC:9214;5453;POU domain, class 3, transcription factor 1 (Octamer-binding protein 6) (Oct-6) (Octamer-binding transcription factor 6) (OTF-6) (POU domain transcription factor SCIP);Q03052;https://jaspar.elixir.no/search?q=Q03052;https://platform.opentargets.org/target/ENSG00000185668;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1747;581;627;938;182;5_None;126;8.01;0.04;0.03;110;2.88;0.04;0.04;15;4.59;0.03;0.03;1;0.53;0.01;0.01;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.037740639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0678;PAX4;ENSG00000106331;HGNC:8618;5078;Paired box protein Pax-4;O43316;https://jaspar.elixir.no/search?q=O43316;https://platform.opentargets.org/target/ENSG00000106331;3 Helix-turn-helix domains;3.2 Paired box factors;3.2.1 PD+HD;906;234;628;96;182;5_None;154;7.97;0.05;0.03;145;4.27;0.06;0.06;6;1.88;0.01;0.01;3;1.82;0.03;0.03;5;0.88;0.31;0.22;Type 2 Diabetes Mellitus;#N/A;#N/A;0.031804605;#N/A;#N/A;0.010895715;#N/A;#N/A;#N/A;#N/A;#N/A;0.156393568;0.001478319;#N/A;#N/A;0.676131677;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0058;BARX1;ENSG00000131668;HGNC:955;56033;Homeobox protein BarH-like 1;Q9HBU1;https://jaspar.elixir.no/search?q=Q9HBU1;https://platform.opentargets.org/target/ENSG00000131668;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2872;1135;629;1075;1168;5_None;120;7.95;0.04;0.03;103;3.19;0.04;0.04;17;4.77;0.04;0.03;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.010610275;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009153123;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0663;ONECUT2;ENSG00000119547;HGNC:8139;9480;One cut domain family member 2 (Hepatocyte nuclear factor 6-beta) (HNF-6-beta) (One cut homeobox 2) (Transcription factor ONECUT-2) (OC-2);O95948;https://jaspar.elixir.no/search?q=O95948;https://platform.opentargets.org/target/ENSG00000119547;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;2664;1026;630;866;1168;5_None;138;7.95;0.04;0.03;124;2.85;0.05;0.04;11;3.52;0.02;0.02;3;1.57;0.03;0.03;5;0.05;0.31;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.018238788;#N/A;#N/A;#N/A;#N/A;0.017000673;0.011456975;#N/A;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0932;TERF1;ENSG00000147601;HGNC:11728;7013;Telomeric repeat-binding factor 1 (NIMA-interacting protein 2) (TTAGGG repeat-binding factor 1) (Telomeric protein Pin2/TRF1);P54274;#N/A;https://platform.opentargets.org/target/ENSG00000147601;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1102;310;631;419;52;5_None;287;7.92;0.09;0.03;270;2.8;0.11;0.04;15;3.91;0.03;0.03;2;1.21;0.02;0.02;11;0.24;0.69;0.06;Cancer;#N/A;0.05392786;0.031564229;0.004414426;0.018478993;0.071538726;0.001478319;0.011066863;0.002771849;#N/A;0.015867706;#N/A;#N/A;0.008597865;#N/A;0.017313269;4;0.27;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;functional;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;3;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0075;BHLHE41;ENSG00000123095;HGNC:16617;79365;Class E basic helix-loop-helix protein 41 (bHLHe41) (Class B basic helix-loop-helix protein 3) (bHLHb3) (Differentially expressed in chondrocytes protein 2) (hDEC2) (Enhancer-of-split and hairy-related protein 1) (SHARP-1);Q9C0J9;https://jaspar.elixir.no/search?q=Q9C0J9;https://platform.opentargets.org/target/ENSG00000123095;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;1140;329;632;326;182;5_None;222;7.92;0.07;0.03;207;3.99;0.08;0.05;15;3.92;0.03;0.03;#N/A;#N/A;#N/A;#N/A;8;0.35;0.5;0.09;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.008759659;#N/A;#N/A;0.036728514;0.255207193;#N/A;#N/A;0.002956639;#N/A;0.002217479;0.036957985;0.001478319;#N/A;0.004619748;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0300;GCM2;ENSG00000124827;HGNC:4198;9247;Chorion-specific transcription factor GCMb (hGCMb) (GCM motif protein 2) (Glial cells missing homolog 2);O75603;https://jaspar.elixir.no/search?q=O75603;https://platform.opentargets.org/target/ENSG00000124827;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.2 GCM domain factors;7.2.1 GCM;2928;1171;633;1127;1168;5_None;120;7.9;0.04;0.03;110;2.95;0.04;0.04;4;1.24;0.01;0.01;6;3.71;0.06;0.06;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.004989328;#N/A;#N/A;0.010142914;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0702;PITX3;ENSG00000107859;HGNC:9006;5309;Pituitary homeobox 3 (Homeobox protein PITX3) (Paired-like homeodomain transcription factor 3);O75364;https://jaspar.elixir.no/search?q=O75364;https://platform.opentargets.org/target/ENSG00000107859;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1861;626;634;789;438;5_None;159;7.84;0.05;0.03;151;3.77;0.06;0.05;4;1.47;0.01;0.01;4;2.6;0.04;0.05;4;0.07;0.25;0.02;Parkinson Disease;#N/A;#N/A;0.012267998;#N/A;0.001478319;0.004948264;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.050516485;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0403;HOXD10;ENSG00000128710;HGNC:5133;3236;Homeobox protein Hox-D10 (Homeobox protein Hox-4D) (Homeobox protein Hox-4E);P28358;https://jaspar.elixir.no/search?q=P28358;https://platform.opentargets.org/target/ENSG00000128710;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1844;619;635;771;438;3_Medium to Low;193;7.83;0.06;0.03;185;4.69;0.07;0.06;7;2.61;0.01;0.02;1;0.54;0.01;0.01;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.021250842;#N/A;#N/A;0.039603772;0.012883964;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0880;SPZ1;ENSG00000164299;HGNC:30721;84654;Spermatogenic leucine zipper protein 1 (Testis-specific protein 1) (Testis-specific protein NYD-TSP1);Q9BXG8;#N/A;https://platform.opentargets.org/target/ENSG00000164299;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1352;402;636;278;438;5_None;573;7.82;0.18;0.03;572;7.56;0.22;0.1;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;14;0.43;0.88;0.11;Cancer;#N/A;0.036982952;0.066286682;0.040939304;0.010758428;0.100992604;0.028159932;0.007968587;0.004302593;0.010470503;0.076998448;0.011387782;0.002217479;0.002217479;#N/A;0.028056686;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0734;PRDM14;ENSG00000147596;HGNC:14001;63978;PR domain zinc finger protein 14 (EC 2.1.1.-) (PR domain-containing protein 14);Q9GZV8;#N/A;https://platform.opentargets.org/target/ENSG00000147596;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2102;740;637;297;1168;5_None;189;7.77;0.06;0.03;185;6.36;0.07;0.09;3;0.89;0.01;0.01;1;0.53;0.01;0.01;3;0.39;0.19;0.1;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;#N/A;#N/A;0.090738561;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.300212134;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0712;POU2F1;ENSG00000143190;HGNC:9212;5451;POU domain, class 2, transcription factor 1 (NF-A1) (Octamer-binding protein 1) (Oct-1) (Octamer-binding transcription factor 1) (OTF-1);P14859;https://jaspar.elixir.no/search?q=P14859;https://platform.opentargets.org/target/ENSG00000143190;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1270;373;638;450;182;5_None;279;7.77;0.09;0.03;267;4.64;0.1;0.06;12;3.13;0.02;0.02;#N/A;#N/A;#N/A;#N/A;11;0.21;0.69;0.05;Alzheimer Disease;#N/A;#N/A;0.094637325;0.016590029;0.002217479;0.03260681;0.004619748;#N/A;0.002217479;0.002587059;0.007186275;#N/A;0.002956639;0.003695799;#N/A;0.037949085;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0840;SOHLH1;ENSG00000165643;HGNC:27845;402381;Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 1;Q5JUK2;#N/A;https://platform.opentargets.org/target/ENSG00000165643;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;3060;1253;639;1253;1168;5_None;138;7.76;0.04;0.03;133;5.58;0.05;0.08;3;0.96;0.01;0.01;2;1.22;0.02;0.02;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0328;GTF3A;ENSG00000122034;HGNC:4662;2971;Transcription factor IIIA (TFIIIA);Q92664;#N/A;https://platform.opentargets.org/target/ENSG00000122034;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1303;384;640;481;182;5_None;299;7.75;0.1;0.03;283;2.74;0.11;0.04;15;4.49;0.03;0.03;1;0.53;0.01;0.01;11;0.18;0.69;0.05;Alzheimer Disease;#N/A;#N/A;0.04056834;0.026527792;0.004434958;0.035917441;0.025850058;#N/A;#N/A;0.004434958;0.008110225;0.013674455;0.006714034;0.002587059;#N/A;0.013474992;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0896;TBP;ENSG00000112592;HGNC:11588;6908;TATA-box-binding protein (TATA sequence-binding protein) (TATA-binding factor) (TATA-box factor) (Transcription initiation factor TFIID TBP subunit);P20226;https://jaspar.elixir.no/search?q=P20226;https://platform.opentargets.org/target/ENSG00000112592;8 beta-Sheet binding to DNA;8.1 TATA-binding proteins;8.1.1 TBP-related;1116;322;641;392;83;4_Low;333;7.71;0.11;0.03;328;5.7;0.13;0.08;3;0.84;0.01;0.01;2;1.18;0.02;0.02;8;0.26;0.5;0.07;Parkinson Disease;#N/A;#N/A;0.02058941;0.001478319;0.007391597;0.023917332;#N/A;0.009424286;#N/A;0.004989328;#N/A;#N/A;#N/A;0.188070217;#N/A;0.007391597;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;upstream;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0492;LHX8;ENSG00000162624;HGNC:28838;431707;LIM/homeobox protein Lhx8 (LIM homeobox protein 8);Q68G74;#N/A;https://platform.opentargets.org/target/ENSG00000162624;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2217;800;642;1137;438;5_None;142;7.7;0.05;0.03;128;3.55;0.05;0.05;14;4.16;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.004414426;#N/A;#N/A;0.009337024;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0414;HSF5;ENSG00000176160;HGNC:26862;124535;Heat shock factor protein 5 (HSF 5) (Heat shock transcription factor 5) (HSTF 5);Q4G112;#N/A;https://platform.opentargets.org/target/ENSG00000176160;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;1985;683;643;904;438;5_None;163;7.7;0.05;0.03;162;7.45;0.06;0.1;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Ischemic Stroke;#N/A;#N/A;#N/A;#N/A;#N/A;0.007022017;0.003695799;#N/A;0.034514398;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0816;SIM2;ENSG00000159263;HGNC:10883;6493;Single-minded homolog 2 (Class E basic helix-loop-helix protein 15) (bHLHe15);Q14190;#N/A;https://platform.opentargets.org/target/ENSG00000159263;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1589;509;644;862;83;5_None;130;7.69;0.04;0.03;115;1.71;0.05;0.02;11;3.9;0.02;0.03;4;2.08;0.04;0.04;6;0.05;0.38;0.01;Cancer;#N/A;#N/A;0.002936107;#N/A;0.005358908;0.033860663;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;0.001478319;#N/A;0.004065378;3;0.2;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1062;ZBTB7C;ENSG00000184828;HGNC:31700;201501;Zinc finger and BTB domain-containing protein 7C (Affected by papillomavirus DNA integration in ME180 cells protein 1) (APM-1) (Zinc finger and BTB domain-containing protein 36) (Zinc finger protein 857C);A1YPR0;https://jaspar.elixir.no/search?q=A1YPR0;https://platform.opentargets.org/target/ENSG00000184828;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1807;607;645;724;438;5_None;104;7.69;0.03;0.03;83;1.3;0.03;0.02;20;5.88;0.04;0.04;1;0.51;0.01;0.01;5;0.09;0.31;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.002217479;#N/A;0.028449526;0.017000673;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.036885324;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0010;AHDC1;ENSG00000126705;HGNC:25230;27245;Transcription factor Gibbin (AT-hook DNA-binding motif-containing protein 1);Q5TGY3;#N/A;https://platform.opentargets.org/target/ENSG00000126705;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2431;908;646;1347;438;5_None;66;7.65;0.02;0.03;50;0.65;0.02;0.01;11;4;0.02;0.03;5;3;0.05;0.05;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.002704904;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1007;VSX1;ENSG00000100987;HGNC:12723;30813;Visual system homeobox 1 (Homeodomain protein RINX) (Retinal inner nuclear layer homeobox protein) (Transcription factor VSX1);Q9NZR4;https://jaspar.elixir.no/search?q=Q9NZR4;https://platform.opentargets.org/target/ENSG00000100987;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1877;636;647;792;438;5_None;392;7.64;0.13;0.03;383;4.41;0.15;0.06;7;1.97;0.01;0.01;2;1.26;0.02;0.02;6;0.07;0.38;0.02;Cancer;#N/A;#N/A;0.023940663;#N/A;#N/A;0.032442473;0.001847899;0.004434958;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0.004434958;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1138;ZNF143;ENSG00000166478;HGNC:12928;7702;Zinc finger protein 143 (SPH-binding factor) (Selenocysteine tRNA gene transcription-activating factor) (hStaf);P52747;https://jaspar.elixir.no/search?q=P52747;https://platform.opentargets.org/target/ENSG00000166478;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1353;403;648;523;182;5_None;164;7.63;0.05;0.03;160;5.94;0.06;0.08;4;1.69;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.16;0.25;0.04;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.025243848;0.078581917;#N/A;#N/A;#N/A;0.052459807;#N/A;#N/A;#N/A;#N/A;0.004229636;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0872;SP7;ENSG00000170374;HGNC:17321;121340;Transcription factor Sp7 (Zinc finger protein osterix);Q8TDD2;#N/A;https://platform.opentargets.org/target/ENSG00000170374;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1729;571;649;642;438;4_Low;257;7.61;0.08;0.03;248;4.27;0.1;0.06;8;2.77;0.02;0.02;1;0.57;0.01;0.01;9;0.11;0.56;0.03;Osteoporosis;#N/A;0.008869917;0.004619748;0.001478319;#N/A;0.015942026;#N/A;#N/A;#N/A;0.008869917;0.005174118;0.013373828;0.030761873;#N/A;#N/A;0.019609271;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0875;SPDEF;ENSG00000124664;HGNC:17257;25803;SAM pointed domain-containing Ets transcription factor (Prostate epithelium-specific Ets transcription factor) (Prostate-specific Ets) (Prostate-derived Ets factor);O95238;https://jaspar.elixir.no/search?q=O95238;https://platform.opentargets.org/target/ENSG00000124664;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1379;414;650;547;182;5_None;184;7.58;0.06;0.03;172;3.79;0.07;0.05;12;3.8;0.02;0.03;#N/A;#N/A;#N/A;#N/A;4;0.15;0.25;0.04;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;0.004989328;0.066432214;0.070731217;#N/A;#N/A;#N/A;#N/A;#N/A;0.006652437;#N/A;#N/A;#N/A;2;0.13;N;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0637;NR1H2;ENSG00000131408;HGNC:7965;7376;Oxysterols receptor LXR-beta (Liver X receptor beta) (Nuclear receptor NER) (Nuclear receptor subfamily 1 group H member 2) (Ubiquitously-expressed nuclear receptor);P55055;https://jaspar.elixir.no/search?q=P55055;https://platform.opentargets.org/target/ENSG00000131408;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.2 Thyroid hormone receptor-related factors;721;155;651;39;31;2_Medium;230;7.53;0.07;0.03;221;3.69;0.09;0.05;4;1.29;0.01;0.01;5;2.55;0.05;0.04;12;1.22;0.75;0.31;Alzheimer Disease;0.008869917;0.001478319;0.504748268;0.039016032;#N/A;0.044519755;0.031044708;#N/A;0.002217479;0.011087396;0.005374307;#N/A;0.012380925;0.50364344;#N/A;0.055685358;5;0.33;Y;#N/A;Unclear;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;Inhibits;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;14;7;#N/A;"CHEMBL3706564;CHEMBL4093";"Liver X receptor;LXR-beta";"PROTEIN FAMILY;SINGLE PROTEIN";"124;2134";"311;3883";"2;5";"2;1";"Small molecule;Small molecule";#N/A
TFTX_0721;POU4F3;ENSG00000091010;HGNC:9220;5459;POU domain, class 4, transcription factor 3 (Brain-specific homeobox/POU domain protein 3C) (Brain-3C) (Brn-3C);Q15319;https://jaspar.elixir.no/search?q=Q15319;https://platform.opentargets.org/target/ENSG00000091010;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;3006;1220;652;1186;1168;5_None;121;7.53;0.04;0.03;112;3.88;0.04;0.05;6;1.77;0.01;0.01;3;1.88;0.03;0.03;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.002012157;#N/A;#N/A;0.008844251;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0668;OTX1;ENSG00000115507;HGNC:8521;5013;Homeobox protein OTX1 (Orthodenticle homolog 1);P32242;https://jaspar.elixir.no/search?q=P32242;https://platform.opentargets.org/target/ENSG00000115507;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1806;606;653;971;182;5_None;180;7.5;0.06;0.03;172;4.63;0.07;0.06;7;2.35;0.01;0.02;1;0.52;0.01;0.01;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.024642201;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0951;TFEC;ENSG00000105967;HGNC:11754;22797;Transcription factor EC (TFE-C) (Class E basic helix-loop-helix protein 34) (bHLHe34) (Transcription factor EC-like) (hTFEC-L);O14948;https://jaspar.elixir.no/search?q=O14948;https://platform.opentargets.org/target/ENSG00000105967;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;2101;738;654;1009;438;5_None;122;7.49;0.04;0.03;107;2.42;0.04;0.03;15;5.08;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.03;0.25;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.01101673;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0141;DEAF1;ENSG00000177030;HGNC:14677;10522;Deformed epidermal autoregulatory factor 1 homolog (Nuclear DEAF-1-related transcriptional regulator) (NUDR) (Suppressin) (Zinc finger MYND domain-containing protein 5);O75398;#N/A;https://platform.opentargets.org/target/ENSG00000177030;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.2 DEAF;2619;998;655;796;1168;5_None;124;7.46;0.04;0.03;114;2.67;0.04;0.04;6;2.27;0.01;0.02;4;2.52;0.04;0.04;4;0.07;0.25;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.048715347;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012565715;0.002956639;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0089;CCDC169-SOHLH2;ENSG00000250709;HGNC:38866;100526761;No Entry;No Entry;#N/A;https://platform.opentargets.org/target/ENSG00000250709;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.0 Uncharacterized/Undefined;3293;1393;656;1469;1168;5_None;134;7.46;0.04;0.03;134;7.46;0.05;0.1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0059;BARX2;ENSG00000043039;HGNC:956;8538;Homeobox protein BarH-like 2;Q9UMQ3;https://jaspar.elixir.no/search?q=Q9UMQ3;https://platform.opentargets.org/target/ENSG00000043039;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1911;653;657;816;438;5_None;190;7.44;0.06;0.03;182;5.2;0.07;0.07;8;2.24;0.02;0.01;#N/A;#N/A;#N/A;#N/A;5;0.06;0.31;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.043541974;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.009239496;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0298;GBX2;ENSG00000168505;HGNC:4186;2637;Homeobox protein GBX-2 (Gastrulation and brain-specific homeobox protein 2);P52951;https://jaspar.elixir.no/search?q=P52951;https://platform.opentargets.org/target/ENSG00000168505;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1496;466;658;400;438;3_Medium to Low;115;7.43;0.04;0.03;98;2.91;0.04;0.04;17;4.52;0.04;0.03;#N/A;#N/A;#N/A;#N/A;5;0.25;0.31;0.06;Alzheimer Disease;#N/A;#N/A;0.228002634;#N/A;#N/A;0.012073147;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;0.002217479;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1116;ZMAT4;ENSG00000165061;HGNC:25844;79698;Zinc finger matrin-type protein 4;Q9H898;#N/A;https://platform.opentargets.org/target/ENSG00000165061;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3046;1245;659;1219;1168;4_Low;60;7.43;0.02;0.03;40;0.65;0.02;0.01;20;6.77;0.04;0.05;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.009043908;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0398;HOXC5;ENSG00000172789;HGNC:5127;3222;Homeobox protein Hox-C5 (Homeobox protein CP11) (Homeobox protein Hox-3D);Q00444;#N/A;https://platform.opentargets.org/target/ENSG00000172789;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2008;695;660;180;1168;3_Medium to Low;94;7.42;0.03;0.03;74;1.49;0.03;0.02;19;5.39;0.04;0.04;1;0.54;0.01;0.01;5;0.59;0.31;0.15;Type 2 Diabetes Mellitus;#N/A;#N/A;0.007391597;0.005174118;#N/A;0.077413621;#N/A;#N/A;0.246511289;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.253023463;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0310;GLMP;ENSG00000198715;HGNC:29436;112770;Glycosylated lysosomal membrane protein (Lysosomal protein NCU-G1);Q8WWB7;#N/A;https://platform.opentargets.org/target/ENSG00000198715;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2254;816;661;1155;438;5_None;163;7.4;0.05;0.03;158;5.92;0.06;0.08;5;1.49;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;0.003695799;#N/A;#N/A;#N/A;0.004968796;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0874;SP9;ENSG00000217236;HGNC:30690;100131390;Transcription factor Sp9;P0CG40;https://jaspar.elixir.no/search?q=P0CG40;https://platform.opentargets.org/target/ENSG00000217236;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1206;347;662;362;182;5_None;48;7.4;0.02;0.03;29;1.44;0.01;0.02;19;5.96;0.04;0.04;#N/A;#N/A;#N/A;#N/A;2;0.3;0.13;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.292944731;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0759;RAX;ENSG00000134438;HGNC:18662;30062;Retinal homeobox protein Rx (Retina and anterior neural fold homeobox protein);Q9Y2V3;https://jaspar.elixir.no/search?q=Q9Y2V3;https://platform.opentargets.org/target/ENSG00000134438;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2983;1206;663;1152;1168;5_None;130;7.37;0.04;0.03;120;3.47;0.05;0.05;8;2.57;0.02;0.02;2;1.33;0.02;0.02;3;0.01;0.19;0;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004065378;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0196;ELK3;ENSG00000111145;HGNC:3325;2004;ETS domain-containing protein Elk-3 (ETS-related protein ERP) (ETS-related protein NET) (Serum response factor accessory protein 2) (SAP-2) (SRF accessory protein 2);P41970;https://jaspar.elixir.no/search?q=P41970;https://platform.opentargets.org/target/ENSG00000111145;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1234;360;664;487;83;3_Medium to Low;335;7.35;0.11;0.03;327;4.52;0.13;0.06;8;2.83;0.02;0.02;#N/A;#N/A;#N/A;#N/A;11;0.18;0.69;0.05;Age-Related Macular Degeneration;#N/A;0.075082732;0.011731457;#N/A;0.001478319;0.039283121;0.00403458;0.005120324;0.005174118;0.001478319;0.003695799;#N/A;#N/A;0.013541473;#N/A;0.018140211;3;0.2;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1119;ZNF101;ENSG00000181896;HGNC:12881;94039;Zinc finger protein 101 (Zinc finger protein HZF12);Q8IZC7;#N/A;https://platform.opentargets.org/target/ENSG00000181896;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2864;1131;665;1031;1168;5_None;49;7.33;0.02;0.03;31;0.72;0.01;0.01;17;6.11;0.04;0.04;1;0.5;0.01;0.01;3;0.02;0.19;0.01;Atherosclerosis;#N/A;#N/A;0.001478319;0.019731458;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0062;BATF3;ENSG00000123685;HGNC:28915;55509;Basic leucine zipper transcriptional factor ATF-like 3 (B-ATF-3) (21 kDa small nuclear factor isolated from T-cells) (Jun dimerization protein p21SNFT);Q9NR55;https://jaspar.elixir.no/search?q=Q9NR55;https://platform.opentargets.org/target/ENSG00000123685;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.4 B-ATF-related;1917;657;666;813;438;5_None;206;7.33;0.07;0.03;193;3.26;0.08;0.04;13;4.07;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.02;Atherosclerosis;#N/A;#N/A;0.001478319;0.043033057;#N/A;0.014133398;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0937;TFAM;ENSG00000108064;HGNC:11741;7019;Transcription factor A, mitochondrial (mtTFA) (Mitochondrial transcription factor 1) (MtTF1) (Transcription factor 6) (TCF-6) (Transcription factor 6-like 2);Q00059;#N/A;https://platform.opentargets.org/target/ENSG00000108064;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.7 TFAM;1092;304;667;342;83;5_None;367;7.32;0.12;0.03;361;4.37;0.14;0.06;3;1.15;0.01;0.01;3;1.8;0.03;0.03;13;0.33;0.81;0.08;Chronic Obstructive Pulmonary Disease;#N/A;0.007206807;0.043283112;0.016056191;#N/A;0.046994373;0.097048745;0.005292217;0.004065378;0.024027826;0.012959143;0.004434958;#N/A;0.036965966;0.003169763;0.029045468;3;0.2;Y;Unclear;#N/A;#N/A;#N/A;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0307;GLIS1;ENSG00000174332;HGNC:29525;148979;Zinc finger protein GLIS1 (GLI-similar 1);Q8NBF1;https://jaspar.elixir.no/search?q=Q8NBF1;https://platform.opentargets.org/target/ENSG00000174332;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2641;1010;668;805;1168;5_None;99;7.32;0.03;0.03;82;1.43;0.03;0.02;17;5.89;0.04;0.04;#N/A;#N/A;#N/A;#N/A;3;0.06;0.19;0.02;Cancer;#N/A;#N/A;0.006114337;#N/A;#N/A;0.046245814;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012196135;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1576;ZNF804B;ENSG00000182348;HGNC:21958;219578;Zinc finger protein 804B;A4D1E1;#N/A;https://platform.opentargets.org/target/ENSG00000182348;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2983;1206;669;1146;1168;5_None;40;7.31;0.01;0.03;18;0.89;0.01;0.01;22;6.42;0.05;0.04;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.013304875;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0848;SOX14;ENSG00000168875;HGNC:11193;8403;Transcription factor SOX-14 (Protein SOX-28);O95416;https://jaspar.elixir.no/search?q=O95416;https://platform.opentargets.org/target/ENSG00000168875;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;2835;1110;670;997;1168;5_None;77;7.28;0.02;0.03;57;1.74;0.02;0.02;20;5.54;0.04;0.04;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.028870962;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0195;ELK1;ENSG00000126767;HGNC:3321;2002;ETS domain-containing protein Elk-1;P19419;https://jaspar.elixir.no/search?q=P19419;https://platform.opentargets.org/target/ENSG00000126767;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1388;417;671;634;83;3_Medium to Low;301;7.26;0.1;0.03;300;6.9;0.12;0.09;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;12;0.11;0.75;0.03;Alzheimer Disease;#N/A;#N/A;0.033912335;0.012896271;0.008869917;0.027278184;#N/A;0.004434958;0.001478319;0.001478319;0.002217479;0.004434958;0.005913278;0.002217479;#N/A;0.008449006;3;0.2;Y;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0264;FOXJ1;ENSG00000129654;HGNC:3816;2302;Forkhead box protein J1 (Forkhead-related protein FKHL13) (Hepatocyte nuclear factor 3 forkhead homolog 4) (HFH-4);Q92949;#N/A;https://platform.opentargets.org/target/ENSG00000129654;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1957;673;672;847;438;5_None;243;7.26;0.08;0.03;238;5.14;0.09;0.07;4;1.43;0.01;0.01;1;0.69;0.01;0.01;5;0.05;0.31;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.003695799;#N/A;0.002956639;0.019060689;0.027671555;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0326;GTF2IRD2;ENSG00000196275;HGNC:30775;84163;General transcription factor II-I repeat domain-containing protein 2A (GTF2I repeat domain-containing protein 2A) (Transcription factor GTF2IRD2-alpha);Q86UP8;#N/A;https://platform.opentargets.org/target/ENSG00000196275;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2224;805;673;383;1168;5_None;41;7.26;0.01;0.03;25;1.47;0.01;0.02;16;5.79;0.03;0.04;#N/A;#N/A;#N/A;#N/A;3;0.27;0.19;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.044219763;0.063471648;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.165244051;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0777;RFX5;ENSG00000143390;HGNC:9986;5993;DNA-binding protein RFX5 (Regulatory factor X 5);P48382;https://jaspar.elixir.no/search?q=P48382;https://platform.opentargets.org/target/ENSG00000143390;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;2146;758;674;1034;438;5_None;173;7.25;0.06;0.03;168;4.58;0.07;0.06;3;1.29;0.01;0.01;2;1.38;0.02;0.02;6;0.02;0.38;0.01;Cancer;#N/A;#N/A;0.001847899;0.002217479;#N/A;0.010799229;0.004434958;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1253;ZNF341;ENSG00000131061;HGNC:15992;84905;Zinc finger protein 341;Q9BYN7;https://jaspar.elixir.no/search?q=Q9BYN7;https://platform.opentargets.org/target/ENSG00000131061;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2007;694;675;164;1168;5_None;61;7.2;0.02;0.03;44;1.58;0.02;0.02;15;4.4;0.03;0.03;2;1.22;0.02;0.02;4;0.63;0.25;0.16;Alzheimer Disease;#N/A;#N/A;0.303530032;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.302989111;#N/A;0.02383622;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0946;TFDP1;ENSG00000198176;HGNC:11749;7027;Transcription factor Dp-1 (DRTF1-polypeptide 1) (DRTF1) (E2F dimerization partner 1);Q14186;https://jaspar.elixir.no/search?q=Q14186;https://platform.opentargets.org/target/ENSG00000198176;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;856;217;676;149;31;5_None;220;7.18;0.07;0.03;203;2.1;0.08;0.03;17;5.08;0.04;0.03;#N/A;#N/A;#N/A;#N/A;10;0.67;0.63;0.17;Alzheimer Disease;#N/A;#N/A;0.276315961;0.008869917;#N/A;0.082995405;0.003695799;#N/A;0.006816695;0.004065378;0.001478319;0.009773334;#N/A;0.267294507;#N/A;0.012175603;5;0.33;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;cell,downstream;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0402;HOXD1;ENSG00000128645;HGNC:5132;3231;Homeobox protein Hox-D1 (Homeobox protein Hox-GG);Q9GZZ0;#N/A;https://platform.opentargets.org/target/ENSG00000128645;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2570;976;677;725;1168;3_Medium to Low;118;7.18;0.04;0.03;104;3.06;0.04;0.04;14;4.11;0.03;0.03;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;0.003695799;0.076707335;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0392;HOXB9;ENSG00000170689;HGNC:5120;3219;Homeobox protein Hox-B9 (Homeobox protein Hox-2.5) (Homeobox protein Hox-2E);P17482;https://jaspar.elixir.no/search?q=P17482;https://platform.opentargets.org/target/ENSG00000170689;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1263;367;678;147;438;5_None;188;7.16;0.06;0.03;183;5.49;0.07;0.07;4;1.13;0.01;0.01;1;0.54;0.01;0.01;7;0.68;0.44;0.17;Alzheimer Disease;#N/A;#N/A;0.283470202;0.008869917;0.002217479;0.091900619;0.004866135;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.283470202;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1238;ZNF32;ENSG00000169740;HGNC:13095;7580;Zinc finger protein 32 (C2H2-546) (Zinc finger protein KOX30);P17041;#N/A;https://platform.opentargets.org/target/ENSG00000169740;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2034;706;679;187;1168;5_None;66;7.1;0.02;0.03;51;1.77;0.02;0.02;14;4.8;0.03;0.03;1;0.53;0.01;0.01;3;0.57;0.19;0.15;Myocardial Infarction;#N/A;#N/A;0.001877997;#N/A;#N/A;0.08348241;#N/A;#N/A;#N/A;0.488620442;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0883;SREBF2;ENSG00000198911;HGNC:11290;6721;Sterol regulatory element-binding protein 2 (SREBP-2) (Class D basic helix-loop-helix protein 2) (bHLHd2) (Sterol regulatory element-binding transcription factor 2) [Cleaved into: Processed sterol regulatory element-binding protein 2 (Transcription factor SREBF2)];Q12772;https://jaspar.elixir.no/search?q=Q12772;https://platform.opentargets.org/target/ENSG00000198911;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1440;442;680;322;438;4_Low;340;7.09;0.11;0.03;339;6.63;0.13;0.09;1;0.46;0;0;#N/A;#N/A;#N/A;#N/A;12;0.35;0.75;0.09;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.040632543;0.046586928;#N/A;0.06048128;0.005030392;0.003695799;0.010902606;0.013171415;0.083218952;0.014678069;0.014660001;0.033611235;#N/A;0.025337707;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1284;ZNF408;ENSG00000175213;HGNC:20041;79797;Zinc finger protein 408 (PR domain zinc finger protein 17);Q9H9D4;#N/A;https://platform.opentargets.org/target/ENSG00000175213;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1730;573;681;867;182;5_None;61;7.08;0.02;0.03;47;1.94;0.02;0.03;11;3.32;0.02;0.02;3;1.82;0.03;0.03;3;0.05;0.19;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.004065378;#N/A;#N/A;0.008130757;0.038056011;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0981;TMF1;ENSG00000144747;HGNC:11870;7110;TATA element modulatory factor (TMF) (Androgen receptor coactivator 160 kDa protein) (Androgen receptor-associated protein of 160 kDa);P82094;#N/A;https://platform.opentargets.org/target/ENSG00000144747;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2185;787;682;1065;438;5_None;119;7.06;0.04;0.03;114;5.31;0.04;0.07;5;1.75;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009331468;0.003695799;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0991;TSHZ1;ENSG00000179981;HGNC:10669;10194;Teashirt homolog 1 (Antigen NY-CO-33) (Serologically defined colon cancer antigen 33);Q6ZSZ6;#N/A;https://platform.opentargets.org/target/ENSG00000179981;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;1997;689;683;876;438;5_None;154;7.03;0.05;0.03;148;4.73;0.06;0.06;5;1.73;0.01;0.01;1;0.57;0.01;0.01;4;0.05;0.25;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;0.016631093;#N/A;#N/A;0.008877719;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.01975199;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0384;HOXB13;ENSG00000159184;HGNC:5112;10481;Homeobox protein Hox-B13;Q92826;https://jaspar.elixir.no/search?q=Q92826;https://platform.opentargets.org/target/ENSG00000159184;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2381;881;684;529;1168;5_None;156;7.03;0.05;0.03;143;2.23;0.06;0.03;10;3.06;0.02;0.02;3;1.74;0.03;0.03;6;0.16;0.38;0.04;Cancer;#N/A;#N/A;0.015522354;0.001478319;0.033162195;0.097662156;#N/A;0.003695799;#N/A;0.00598514;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0833;SMYD3;ENSG00000185420;HGNC:15513;64754;Histone-lysine N-methyltransferase SMYD3 (EC 2.1.1.354) (SET and MYND domain-containing protein 3) (Zinc finger MYND domain-containing protein 1);Q9H7B4;#N/A;https://platform.opentargets.org/target/ENSG00000185420;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1534;483;685;411;438;4_Low;205;7.03;0.07;0.03;197;4.82;0.08;0.07;8;2.21;0.02;0.01;#N/A;#N/A;#N/A;#N/A;4;0.24;0.25;0.06;Cancer;#N/A;#N/A;0.043452863;0.011087396;#N/A;0.114667045;0.073915971;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1032;ZBTB18;ENSG00000179456;HGNC:13030;10472;Zinc finger and BTB domain-containing protein 18 (58 kDa repressor protein) (Transcriptional repressor RP58) (Translin-associated zinc finger protein 1) (TAZ-1) (Zinc finger protein 238) (Zinc finger protein C2H2-171);Q99592;https://jaspar.elixir.no/search?q=Q99592;https://platform.opentargets.org/target/ENSG00000179456;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1725;569;686;601;438;5_None;111;7.02;0.04;0.03;100;2.8;0.04;0.04;8;2.53;0.02;0.02;3;1.69;0.03;0.03;3;0.12;0.19;0.03;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.064833135;#N/A;#N/A;#N/A;#N/A;0.057284877;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0878;SPIB;ENSG00000269404;HGNC:11242;6689;Transcription factor Spi-B;Q01892;https://jaspar.elixir.no/search?q=Q01892;https://platform.opentargets.org/target/ENSG00000269404;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1744;580;687;619;438;5_None;228;7.01;0.07;0.03;226;6.16;0.09;0.08;2;0.86;0;0.01;#N/A;#N/A;#N/A;#N/A;5;0.12;0.31;0.03;Cancer;#N/A;#N/A;0.012565715;#N/A;#N/A;0.094662447;0.001478319;0.005913278;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0071;BHLHA9;ENSG00000205899;HGNC:35126;727857;Class A basic helix-loop-helix protein 9 (bHLHa9) (Class F basic helix-loop-helix factor 42) (bHLHf42);Q7RTU4;#N/A;https://platform.opentargets.org/target/ENSG00000205899;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3212;1344;688;1356;1168;5_None;95;7.01;0.03;0.03;89;4.08;0.03;0.06;3;1.08;0.01;0.01;3;1.85;0.03;0.03;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0043;ATF2;ENSG00000115966;HGNC:784;1386;Cyclic AMP-dependent transcription factor ATF-2 (cAMP-dependent transcription factor ATF-2) (Activating transcription factor 2) (Cyclic AMP-responsive element-binding protein 2) (CREB-2) (cAMP-responsive element-binding protein 2) (HB16) (cAMP response element-binding protein CRE-BP1);P15336;https://jaspar.elixir.no/search?q=P15336;https://platform.opentargets.org/target/ENSG00000115966;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.1 Jun-related;1380;415;689;509;182;4_Low;330;7;0.11;0.03;326;5.9;0.13;0.08;4;1.1;0.01;0.01;#N/A;#N/A;#N/A;#N/A;9;0.17;0.56;0.04;Cancer;#N/A;#N/A;0.029398445;0.013928643;0.011046331;0.040053226;#N/A;#N/A;#N/A;#N/A;0.004414426;0.012251572;0.003695799;0.018366066;#N/A;0.033416179;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;downstream;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0565;MYOG;ENSG00000122180;HGNC:7612;4656;Myogenin (Class C basic helix-loop-helix protein 3) (bHLHc3) (Myogenic factor 4) (Myf-4);P15173;https://jaspar.elixir.no/search?q=P15173;https://platform.opentargets.org/target/ENSG00000122180;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;2411;896;690;553;1168;5_None;335;7;0.11;0.03;330;5.38;0.13;0.07;5;1.61;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.14;0.5;0.04;Cancer;#N/A;0.010348236;0.007083614;#N/A;#N/A;0.071527706;0.02640522;0.005926213;#N/A;0.005543698;#N/A;#N/A;#N/A;#N/A;0.009528827;0.006181005;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0532;MKX;ENSG00000150051;HGNC:23729;283078;Homeobox protein Mohawk;Q8IYA7;#N/A;https://platform.opentargets.org/target/ENSG00000150051;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;2219;801;691;360;1168;5_None;88;6.99;0.03;0.03;72;2.48;0.03;0.03;16;4.52;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.3;0.25;0.08;Alzheimer Disease;#N/A;#N/A;0.199273942;#N/A;0.080840581;0.020552746;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0018;ALX3;ENSG00000156150;HGNC:449;257;Homeobox protein aristaless-like 3 (Proline-rich transcription factor ALX3);O95076;https://jaspar.elixir.no/search?q=O95076;https://platform.opentargets.org/target/ENSG00000156150;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2553;967;692;693;1168;5_None;105;6.98;0.03;0.03;93;2.82;0.04;0.04;10;2.84;0.02;0.02;2;1.32;0.02;0.02;2;0.09;0.13;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.029588961;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.063493819;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1304;ZNF436;ENSG00000125945;HGNC:20814;80818;Zinc finger protein 436;Q9C0F3;#N/A;https://platform.opentargets.org/target/ENSG00000125945;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1671;543;693;540;438;5_None;338;6.96;0.11;0.03;326;2.8;0.13;0.04;10;3.12;0.02;0.02;2;1.05;0.02;0.02;10;0.15;0.63;0.04;Cancer;#N/A;#N/A;0.005204072;0.002012157;0.001478319;0.086935675;0.016261514;0.001478319;0.001478319;0.002956639;#N/A;#N/A;#N/A;0.025163322;#N/A;0.007761177;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0457;KIN;ENSG00000151657;HGNC:6327;22944;DNA/RNA-binding protein KIN17 (Binding to curved DNA) (KIN, antigenic determinant of recA protein homolog);O60870;#N/A;https://platform.opentargets.org/target/ENSG00000151657;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1313;388;694;181;438;5_None;192;6.94;0.06;0.03;187;5.57;0.07;0.08;5;1.37;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.59;0.19;0.15;Parkinson Disease;#N/A;#N/A;0.273915855;#N/A;#N/A;0.037289211;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.274655015;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0189;EHF;ENSG00000135373;HGNC:3246;26298;ETS homologous factor (hEHF) (ETS domain-containing transcription factor) (Epithelium-specific Ets transcription factor 3) (ESE-3);Q9NZC4;https://jaspar.elixir.no/search?q=Q9NZC4;https://platform.opentargets.org/target/ENSG00000135373;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1501;469;695;754;52;4_Low;174;6.9;0.06;0.03;169;4.66;0.07;0.06;4;1.7;0.01;0.01;1;0.54;0.01;0.01;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.007022017;#N/A;#N/A;0.065167563;0.003695799;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;4;0.27;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;Induces;#N/A;Unclear;4;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0226;FBXL19;ENSG00000099364;HGNC:25300;54620;F-box/LRR-repeat protein 19 (F-box and leucine-rich repeat protein 19);Q6PCT2;#N/A;https://platform.opentargets.org/target/ENSG00000099364;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;2900;1158;696;1036;1168;4_Low;158;6.89;0.05;0.03;155;6;0.06;0.08;3;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.022762031;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0109;CHCHD3;ENSG00000106554;HGNC:21906;54927;MICOS complex subunit MIC19 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 3);Q9NX63;#N/A;https://platform.opentargets.org/target/ENSG00000106554;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2101;738;697;966;438;5_None;54;6.86;0.02;0.03;34;0.64;0.01;0.01;19;5.69;0.04;0.04;1;0.54;0.01;0.01;5;0.03;0.31;0.01;Cancer;#N/A;#N/A;0.004784006;#N/A;#N/A;0.017000673;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;0.001847899;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0541;MSC;ENSG00000178860;HGNC:7321;9242;Musculin (Activated B-cell factor 1) (ABF-1) (Class A basic helix-loop-helix protein 22) (bHLHa22);O60682;https://jaspar.elixir.no/search?q=O60682;https://platform.opentargets.org/target/ENSG00000178860;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2020;700;698;884;438;5_None;118;6.81;0.04;0.03;98;1.75;0.04;0.02;20;5.07;0.04;0.03;#N/A;#N/A;#N/A;#N/A;6;0.05;0.38;0.01;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.002012157;#N/A;#N/A;#N/A;0.001478319;0.037140162;#N/A;0.001478319;0.003695799;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0248;FOXD3;ENSG00000187140;HGNC:3804;27022;Forkhead box protein D3 (HNF3/FH transcription factor genesis);Q9UJU5;https://jaspar.elixir.no/search?q=Q9UJU5;https://platform.opentargets.org/target/ENSG00000187140;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1495;464;699;358;438;5_None;155;6.77;0.05;0.02;146;3.55;0.06;0.05;9;3.22;0.02;0.02;#N/A;#N/A;#N/A;#N/A;8;0.3;0.5;0.08;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.001478319;#N/A;#N/A;0.036154428;0.002217479;#N/A;0.003695799;#N/A;0.125282632;#N/A;0.001478319;0.009609076;#N/A;0.124728262;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0102;CENPB;ENSG00000125817;HGNC:1852;1059;Major centromere autoantigen B (Centromere protein B) (CENP-B);P07199;#N/A;https://platform.opentargets.org/target/ENSG00000125817;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2766;1074;700;898;1168;5_None;205;6.77;0.07;0.02;204;6.55;0.08;0.09;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.023988959;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;0.014783194;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0325;GTF2IRD1;ENSG00000006704;HGNC:4661;9569;General transcription factor II-I repeat domain-containing protein 1 (GTF2I repeat domain-containing protein 1) (General transcription factor III) (MusTRD1/BEN) (Muscle TFII-I repeat domain-containing protein 1) (Slow-muscle-fiber enhancer-binding protein) (USE B1-binding protein) (Williams-Beuren syndrome chromosomal region 11 protein) (Williams-Beuren syndrome chromosomal region 12 protein);Q9UHL9;#N/A;https://platform.opentargets.org/target/ENSG00000006704;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2890;1150;701;1021;1168;5_None;134;6.76;0.04;0.02;118;2.28;0.05;0.03;16;4.48;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.002217479;#N/A;0.023761816;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0552;MXD3;ENSG00000213347;HGNC:14008;83463;Max dimerization protein 3 (Max dimerizer 3) (Class C basic helix-loop-helix protein 13) (bHLHc13) (Max-associated protein 3) (Max-interacting transcriptional repressor MAD3) (Myx);Q9BW11;#N/A;https://platform.opentargets.org/target/ENSG00000213347;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1271;374;702;486;83;5_None;137;6.74;0.04;0.02;128;4.33;0.05;0.06;9;2.41;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.18;0.38;0.05;Cancer;#N/A;#N/A;0.003695799;0.001478319;#N/A;0.099723848;0.003695799;#N/A;#N/A;#N/A;0.012565715;#N/A;#N/A;#N/A;#N/A;0.058408711;3;0.2;Y;#N/A;Anti-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1108;ZKSCAN1;ENSG00000106261;HGNC:13101;7586;Zinc finger protein with KRAB and SCAN domains 1 (Zinc finger protein 139) (Zinc finger protein 36) (Zinc finger protein KOX18);P17029;https://jaspar.elixir.no/search?q=P17029;https://platform.opentargets.org/target/ENSG00000106261;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;989;266;703;104;182;5_None;89;6.74;0.03;0.02;77;3.04;0.03;0.04;12;3.69;0.02;0.02;#N/A;#N/A;#N/A;#N/A;5;0.84;0.31;0.21;Alzheimer Disease;#N/A;0.004434958;0.382773059;#N/A;#N/A;0.007523256;0.066135706;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.375879368;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0076;BNC1;ENSG00000169594;HGNC:1081;646;Zinc finger protein basonuclin-1;Q01954;#N/A;https://platform.opentargets.org/target/ENSG00000169594;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2189;789;704;1047;438;3_Medium to Low;127;6.73;0.04;0.02;115;3.11;0.05;0.04;11;3.11;0.02;0.02;1;0.51;0.01;0.01;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.008377143;#N/A;#N/A;0.014122692;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0694;PHF19;ENSG00000119403;HGNC:24566;26147;PHD finger protein 19 (Polycomb-like protein 3) (hPCL3);Q5T6S3;#N/A;https://platform.opentargets.org/target/ENSG00000119403;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1870;631;705;727;438;5_None;126;6.73;0.04;0.02;118;4.61;0.05;0.06;8;2.12;0.02;0.01;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.081463593;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0658;NRL;ENSG00000129535;HGNC:8002;4901;Neural retina-specific leucine zipper protein (NRL);P54845;https://jaspar.elixir.no/search?q=P54845;https://platform.opentargets.org/target/ENSG00000129535;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;1901;647;706;757;438;5_None;161;6.69;0.05;0.02;157;4.65;0.06;0.06;2;0.75;0;0;2;1.29;0.02;0.02;4;0.08;0.25;0.02;Age-Related Macular Degeneration;#N/A;0.041415119;0.009683608;#N/A;#N/A;0.026097253;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0928;TEAD3;ENSG00000007866;HGNC:11716;7005;Transcriptional enhancer factor TEF-5 (DTEF-1) (TEA domain family member 3) (TEAD-3);Q99594;https://jaspar.elixir.no/search?q=Q99594;https://platform.opentargets.org/target/ENSG00000007866;3 Helix-turn-helix domains;3.6 TEA domain factors;3.6.1 TEF1-related;1771;593;707;626;438;5_None;82;6.66;0.03;0.02;67;1.57;0.03;0.02;14;4.56;0.03;0.03;1;0.54;0.01;0.01;7;0.11;0.44;0.03;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.003695799;0.001478319;0.004434958;0.009137041;#N/A;#N/A;#N/A;#N/A;0.043281963;#N/A;0.009403754;#N/A;#N/A;0.043281963;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0386;HOXB3;ENSG00000120093;HGNC:5114;3213;Homeobox protein Hox-B3 (Homeobox protein Hox-2.7) (Homeobox protein Hox-2G);P14651;https://jaspar.elixir.no/search?q=P14651;https://platform.opentargets.org/target/ENSG00000120093;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2078;729;708;932;438;3_Medium to Low;157;6.64;0.05;0.02;145;3.43;0.06;0.05;12;3.21;0.02;0.02;#N/A;#N/A;#N/A;#N/A;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.005913278;#N/A;#N/A;0.023001636;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;0.004065378;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0804;SCML4;ENSG00000146285;HGNC:21397;256380;Sex comb on midleg-like protein 4;Q8N228;#N/A;https://platform.opentargets.org/target/ENSG00000146285;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3077;1270;709;1200;1168;5_None;50;6.64;0.02;0.02;33;1.06;0.01;0.01;17;5.58;0.04;0.04;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.004968796;#N/A;0.005153586;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1013;YBX1;ENSG00000065978;HGNC:8014;4904;Y-box-binding protein 1 (YB-1) (CCAAT-binding transcription factor I subunit A) (CBF-A) (DNA-binding protein B) (DBPB) (Enhancer factor I subunit A) (EFI-A) (Nuclease-sensitive element-binding protein 1) (Y-box transcription factor);P67809;#N/A;https://platform.opentargets.org/target/ENSG00000065978;9 beta-Barrel DNA-binding domains;9.1 Cold-shock domain factors;9.1.1 Dbp;1193;343;710;301;182;4_Low;343;6.58;0.11;0.02;343;6.58;0.13;0.09;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;13;0.38;0.81;0.1;Cancer;#N/A;#N/A;0.054636427;0.045902434;0.020696472;0.114381893;0.009612451;0.028488447;0.009054706;0.005643847;0.046218823;0.010327704;0.031319429;0.001478319;#N/A;0.004250168;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;6;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0754;PURG;ENSG00000172733;HGNC:17930;29942;Purine-rich element-binding protein gamma (Purine-rich element-binding protein G);Q9UJV8;#N/A;https://platform.opentargets.org/target/ENSG00000172733;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.5 PUR;1558;492;711;409;438;5_None;41;6.56;0.01;0.02;27;3.13;0.01;0.04;14;3.43;0.03;0.02;#N/A;#N/A;#N/A;#N/A;2;0.24;0.13;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.241313116;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0487;LHX2;ENSG00000106689;HGNC:6594;9355;LIM/homeobox protein Lhx2 (Homeobox protein LH-2) (LIM homeobox protein 2);P50458;https://jaspar.elixir.no/search?q=P50458;https://platform.opentargets.org/target/ENSG00000106689;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;1200;346;712;306;182;4_Low;178;6.54;0.06;0.02;170;3.81;0.07;0.05;6;1.7;0.01;0.01;2;1.04;0.02;0.02;5;0.38;0.31;0.1;Type 2 Diabetes Mellitus;#N/A;0.035849246;0.009242503;#N/A;#N/A;0.022766562;#N/A;#N/A;#N/A;#N/A;#N/A;0.001742679;#N/A;#N/A;#N/A;0.308867621;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0780;RFX8;ENSG00000196460;HGNC:37253;731220;DNA-binding protein RFX8 (Regulatory factor X 8);Q6ZV50;#N/A;https://platform.opentargets.org/target/ENSG00000196460;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;2034;706;713;883;438;5_None;110;6.5;0.04;0.02;105;4.91;0.04;0.07;5;1.59;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.048045381;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1453;ZNF641;ENSG00000167528;HGNC:31834;121274;Zinc finger protein 641;Q96N77;#N/A;https://platform.opentargets.org/target/ENSG00000167528;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1590;512;714;438;438;5_None;69;6.5;0.02;0.02;57;2.62;0.02;0.04;12;3.88;0.02;0.03;#N/A;#N/A;#N/A;#N/A;1;0.22;0.06;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.219372459;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0127;CSRNP3;ENSG00000178662;HGNC:30729;80034;Cysteine/serine-rich nuclear protein 3 (CSRNP-3) (Protein FAM130A2) (TGF-beta-induced apoptosis protein 2) (TAIP-2);Q8WYN3;#N/A;https://platform.opentargets.org/target/ENSG00000178662;0 Yet undefined DNA-binding domains;0.1 AXUD/CSRNP domain factors;0.1.1 CSRNP;2131;751;715;978;438;4_Low;70;6.48;0.02;0.02;55;1.69;0.02;0.02;14;4.28;0.03;0.03;1;0.5;0.01;0.01;4;0.03;0.25;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002217479;0.001478319;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.02657721;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0087;CBX2;ENSG00000173894;HGNC:1552;84733;Chromobox protein homolog 2;Q14781;#N/A;https://platform.opentargets.org/target/ENSG00000173894;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1784;597;716;630;438;4_Low;162;6.48;0.05;0.02;156;4.5;0.06;0.06;5;1.35;0.01;0.01;1;0.64;0.01;0.01;4;0.11;0.25;0.03;Cancer;#N/A;#N/A;#N/A;0.001478319;0.008315547;0.100818004;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0575;NANOG;ENSG00000111704;HGNC:20857;79923;Homeobox protein NANOG (Homeobox transcription factor Nanog) (hNanog);Q9H9S0;#N/A;https://platform.opentargets.org/target/ENSG00000111704;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1265;369;717;465;83;5_None;420;6.47;0.13;0.02;418;5.8;0.16;0.08;2;0.67;0;0;#N/A;#N/A;#N/A;#N/A;8;0.19;0.5;0.05;Cancer;#N/A;#N/A;0.047942055;#N/A;0.010409833;0.107250648;#N/A;0.004434958;#N/A;#N/A;0.001478319;#N/A;0.003695799;0.004619748;#N/A;0.013630926;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;7;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0051;ATOH1;ENSG00000172238;HGNC:797;474;Transcription factor ATOH1 (Atonal bHLH transcription factor 1) (Class A basic helix-loop-helix protein 14) (bHLHa14) (Helix-loop-helix protein hATH-1) (hATH1) (Protein atonal homolog 1);Q92858;https://jaspar.elixir.no/search?q=Q92858;https://platform.opentargets.org/target/ENSG00000172238;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;1630;524;718;474;438;5_None;215;6.47;0.07;0.02;210;5.22;0.08;0.07;5;1.25;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.19;0.44;0.05;Cancer;0.003695799;#N/A;0.003695799;0.016825806;#N/A;0.084939159;0.061699304;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;0.013674455;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0843;SOX1;ENSG00000182968;HGNC:11189;6656;Transcription factor SOX-1;O00570;#N/A;https://platform.opentargets.org/target/ENSG00000182968;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1460;448;719;658;83;5_None;205;6.44;0.07;0.02;200;4.86;0.08;0.07;5;1.58;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.1;0.19;0.03;Cancer;#N/A;#N/A;0.004414426;#N/A;#N/A;0.096578282;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0536;MNT;ENSG00000070444;HGNC:7188;4335;Max-binding protein MNT (Class D basic helix-loop-helix protein 3) (bHLHd3) (Myc antagonist MNT) (Protein ROX);Q99583;https://jaspar.elixir.no/search?q=Q99583;https://platform.opentargets.org/target/ENSG00000070444;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1887;641;720;1084;83;5_None;88;6.44;0.03;0.02;72;0.78;0.03;0.01;15;5.15;0.03;0.03;1;0.51;0.01;0.01;4;0.02;0.25;0;Cancer;#N/A;#N/A;0.003695799;0.003695799;#N/A;0.00817528;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003326219;#N/A;#N/A;3;0.2;N;#N/A;Anti-Longevity;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;Anti-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0776;RFX4;ENSG00000111783;HGNC:9985;5992;Transcription factor RFX4 (Regulatory factor X 4) (Testis development protein NYD-SP10);Q33E94;https://jaspar.elixir.no/search?q=Q33E94;https://platform.opentargets.org/target/ENSG00000111783;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;1943;666;721;1040;182;5_None;88;6.43;0.03;0.02;74;1.47;0.03;0.02;14;4.95;0.03;0.03;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Alzheimer Disease;#N/A;#N/A;0.014021024;#N/A;#N/A;0.005361577;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1217;ZNF280D;ENSG00000137871;HGNC:25953;54816;Zinc finger protein 280D (Suppressor of hairy wing homolog 4) (Zinc finger protein 634);Q6N043;#N/A;https://platform.opentargets.org/target/ENSG00000137871;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1815;612;722;655;438;5_None;87;6.4;0.03;0.02;76;3.5;0.03;0.05;11;2.9;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.1;0.13;0.03;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.100264072;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1096;ZGPAT;ENSG00000197114;HGNC:15948;84619;Zinc finger CCCH-type with G patch domain-containing protein (G patch domain-containing protein 6) (Zinc finger CCCH domain-containing protein 9) (Zinc finger and G patch domain-containing protein);Q8N5A5;#N/A;https://platform.opentargets.org/target/ENSG00000197114;2 Zinc-coordinating DNA-binding domains;2.8 C3H zinc finger factors;2.8.2 ZGPAT;2706;1048;723;815;1168;5_None;173;6.39;0.06;0.02;169;5.53;0.07;0.08;4;0.85;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.06;0.44;0.02;Cancer;#N/A;#N/A;0.009108706;#N/A;0.003695799;0.027535484;0.002956639;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;0.008869917;#N/A;0.006598643;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0622;NKX3-1;ENSG00000167034;HGNC:7838;4824;Homeobox protein Nkx-3.1 (Homeobox protein NK-3 homolog A);Q99801;https://jaspar.elixir.no/search?q=Q99801;https://platform.opentargets.org/target/ENSG00000167034;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1927;658;724;765;438;5_None;178;6.39;0.06;0.02;167;2.79;0.07;0.04;10;3.04;0.02;0.02;1;0.55;0.01;0.01;4;0.08;0.25;0.02;Benign Prostatic Hyperplasia;#N/A;#N/A;0.011087396;#N/A;0.038308991;0.019897566;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0209;ESRRB;ENSG00000119715;HGNC:3473;2103;Steroid hormone receptor ERR2 (ERR beta-2) (Estrogen receptor-like 2) (Estrogen-related receptor beta) (ERR-beta) (Nuclear receptor subfamily 3 group B member 2);O95718;https://jaspar.elixir.no/search?q=O95718;https://platform.opentargets.org/target/ENSG00000119715;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;1545;488;725;737;83;2_Medium;235;6.38;0.08;0.02;225;2.32;0.09;0.03;8;2.77;0.02;0.02;2;1.29;0.02;0.02;11;0.08;0.69;0.02;Cancer;#N/A;0.002587059;0.008261752;0.002943909;#N/A;0.034392058;#N/A;0.003695799;#N/A;0.002587059;0.002956639;0.008869917;0.001478319;0.010489198;#N/A;0.005058727;3;0.2;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;Induces;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;3;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1192;ZNF24;ENSG00000172466;HGNC:13032;7572;Zinc finger protein 24 (Retinoic acid suppression protein A) (RSG-A) (Zinc finger and SCAN domain-containing protein 3) (Zinc finger protein 191) (Zinc finger protein KOX17);P17028;https://jaspar.elixir.no/search?q=P17028;https://platform.opentargets.org/target/ENSG00000172466;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2206;797;726;1042;438;5_None;176;6.37;0.06;0.02;175;6.13;0.07;0.08;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.022930897;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1050;ZBTB42;ENSG00000179627;HGNC:32550;100128927;Zinc finger and BTB domain-containing protein 42;B2RXF5;#N/A;https://platform.opentargets.org/target/ENSG00000179627;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3148;1304;727;1253;1168;5_None;38;6.36;0.01;0.02;22;0.94;0.01;0.01;15;4.88;0.03;0.03;1;0.53;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0703;PKNOX1;ENSG00000160199;HGNC:9022;5316;Homeobox protein PKNOX1 (Homeobox protein PREP-1) (PBX/knotted homeobox 1);P55347;https://jaspar.elixir.no/search?q=P55347;https://platform.opentargets.org/target/ENSG00000160199;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1589;509;728;679;182;5_None;163;6.33;0.05;0.02;158;4.83;0.06;0.07;5;1.49;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.1;0.25;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.001478319;#N/A;0.008954371;#N/A;#N/A;#N/A;#N/A;0.042501683;#N/A;#N/A;#N/A;#N/A;0.044362518;2;0.13;N;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0108;CHAMP1;ENSG00000198824;HGNC:20311;283489;Chromosome alignment-maintaining phosphoprotein 1 (Zinc finger protein 828);Q96JM3;#N/A;https://platform.opentargets.org/target/ENSG00000198824;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2149;762;729;982;438;5_None;76;6.28;0.02;0.02;64;1.15;0.03;0.02;7;2.28;0.01;0.02;5;2.85;0.05;0.05;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.027020394;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0704;PKNOX2;ENSG00000165495;HGNC:16714;63876;Homeobox protein PKNOX2 (Homeobox protein PREP-2) (PBX/knotted homeobox 2);Q96KN3;https://jaspar.elixir.no/search?q=Q96KN3;https://platform.opentargets.org/target/ENSG00000165495;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;1186;341;730;373;83;5_None;62;6.26;0.02;0.02;47;1.72;0.02;0.02;15;4.54;0.03;0.03;#N/A;#N/A;#N/A;#N/A;3;0.28;0.19;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005030392;#N/A;0.031783868;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.247912632;3;0.2;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0569;MYSM1;ENSG00000162601;HGNC:29401;114803;Deubiquitinase MYSM1 (2A-DUB) (EC 3.4.19.-) (Myb-like, SWIRM and MPN domain-containing protein 1);Q5VVJ2;#N/A;https://platform.opentargets.org/target/ENSG00000162601;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1623;522;731;710;182;5_None;152;6.24;0.05;0.02;145;3.09;0.06;0.04;4;1.35;0.01;0.01;3;1.79;0.03;0.03;10;0.09;0.63;0.02;Cancer;#N/A;#N/A;0.006285633;#N/A;0.003695799;0.019658001;0.011087396;0.004619748;#N/A;0.007391597;#N/A;0.007391597;0.013120085;0.003326219;#N/A;0.013304875;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1348;ZNF506;ENSG00000081665;HGNC:23780;440515;Zinc finger protein 506;Q5JVG8;#N/A;https://platform.opentargets.org/target/ENSG00000081665;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3013;1224;732;1113;1168;5_None;55;6.22;0.02;0.02;39;2.31;0.02;0.03;16;3.91;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.014485477;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0241;FOXA3;ENSG00000170608;HGNC:5023;3171;Hepatocyte nuclear factor 3-gamma (HNF-3-gamma) (HNF-3G) (Fork head-related protein FKH H3) (Forkhead box protein A3) (Transcription factor 3G) (TCF-3G);P55318;https://jaspar.elixir.no/search?q=P55318;https://platform.opentargets.org/target/ENSG00000170608;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1439;440;733;623;83;3_Medium to Low;129;6.2;0.04;0.02;126;4.82;0.05;0.07;2;0.76;0;0.01;1;0.62;0.01;0.01;5;0.12;0.31;0.03;Cancer;#N/A;#N/A;#N/A;0.014413614;#N/A;0.038173537;0.008315547;#N/A;#N/A;#N/A;0.032351173;#N/A;#N/A;#N/A;#N/A;0.022174791;3;0.2;Y;#N/A;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;6;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0538;MSANTD1;ENSG00000188981;HGNC:33741;345222;Myb/SANT-like DNA-binding domain-containing protein 1;Q6ZTZ1;#N/A;https://platform.opentargets.org/target/ENSG00000188981;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2883;1145;734;981;1168;4_Low;67;6.19;0.02;0.02;55;2.68;0.02;0.04;12;3.51;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.031251538;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0886;ST18;ENSG00000147488;HGNC:18695;9705;Suppression of tumorigenicity 18 protein (Zinc finger protein 387);O60284;#N/A;https://platform.opentargets.org/target/ENSG00000147488;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.1 MYT;2845;1121;735;942;1168;5_None;99;6.18;0.03;0.02;84;1.93;0.03;0.03;15;4.25;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.04;0.25;0.01;Cancer;#N/A;#N/A;0.009573897;0.003695799;#N/A;0.022253828;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0620;NKX2-6;ENSG00000180053;HGNC:32940;137814;Homeobox protein Nkx-2.6 (Homeobox protein NK-2 homolog F);A6NCS4;#N/A;https://platform.opentargets.org/target/ENSG00000180053;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3324;1404;736;1420;1168;5_None;61;6.18;0.02;0.02;51;3.1;0.02;0.04;10;3.08;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1121;ZNF112;ENSG00000062370;HGNC:12892;7771;Zinc finger protein 112 (Zfp-112) (Zinc finger protein 228);Q9UJU3;#N/A;https://platform.opentargets.org/target/ENSG00000062370;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2597;985;737;1422;438;5_None;33;6.16;0.01;0.02;14;0.09;0.01;0;19;6.06;0.04;0.04;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0616;NKX2-2;ENSG00000125820;HGNC:7835;4821;Homeobox protein Nkx-2.2 (Homeobox protein NK-2 homolog B);O95096;https://jaspar.elixir.no/search?q=O95096;https://platform.opentargets.org/target/ENSG00000125820;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1398;428;738;478;182;5_None;186;6.15;0.06;0.02;180;4.32;0.07;0.06;6;1.82;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.18;0.31;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;0.001478319;#N/A;#N/A;0.007704602;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0.003695799;#N/A;0.164212866;2;0.13;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0994;TTF1;ENSG00000125482;HGNC:12397;7270;Transcription termination factor 1 (TTF-1) (RNA polymerase I termination factor) (Transcription termination factor I) (TTF-I);Q15361;#N/A;https://platform.opentargets.org/target/ENSG00000125482;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1674;545;739;497;438;5_None;445;6.14;0.14;0.02;442;5.25;0.17;0.07;3;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.17;0.25;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.027963501;#N/A;#N/A;0.040963453;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.099030018;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0933;TERF2;ENSG00000132604;HGNC:11729;7014;Telomeric repeat-binding factor 2 (TTAGGG repeat-binding factor 2) (Telomeric DNA-binding protein);Q15554;#N/A;https://platform.opentargets.org/target/ENSG00000132604;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;988;265;740;217;31;4_Low;213;6.09;0.07;0.02;202;3.08;0.08;0.04;11;3.01;0.02;0.02;#N/A;#N/A;#N/A;#N/A;10;0.53;0.63;0.14;Alzheimer Disease;#N/A;0.032523027;0.194553504;0.008317873;0.016815883;0.082053226;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;0.001478319;0.190008887;#N/A;0.005235715;5;0.33;Y;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;functional;#N/A;#N/A;Anti-Longevity;Inhibits;#N/A;Unclear;6;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0982;TOPORS;ENSG00000197579;HGNC:21653;10210;E3 ubiquitin-protein ligase Topors (EC 2.3.2.27) (RING-type E3 ubiquitin transferase Topors) (SUMO1-protein E3 ligase Topors) (Topoisomerase I-binding RING finger protein) (Topoisomerase I-binding arginine/serine-rich protein) (Tumor suppressor p53-binding protein 3) (p53-binding protein 3) (p53BP3);Q9NS56;#N/A;https://platform.opentargets.org/target/ENSG00000197579;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1685;551;741;861;83;5_None;89;6.08;0.03;0.02;84;3.75;0.03;0.05;3;1.06;0.01;0.01;2;1.27;0.02;0.02;2;0.05;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.035849246;#N/A;#N/A;0.014899713;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;1;#N/A;#N/A;Pro-Longevity;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0391;HOXB8;ENSG00000120068;HGNC:5119;3218;Homeobox protein Hox-B8 (Homeobox protein Hox-2.4) (Homeobox protein Hox-2D);P17481;https://jaspar.elixir.no/search?q=P17481;https://platform.opentargets.org/target/ENSG00000120068;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2992;1215;742;1082;1168;5_None;193;6.08;0.06;0.02;193;6.08;0.08;0.08;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.018996604;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0144;DLX3;ENSG00000064195;HGNC:2916;1747;Homeobox protein DLX-3;O60479;#N/A;https://platform.opentargets.org/target/ENSG00000064195;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1241;362;743;415;83;3_Medium to Low;225;6.06;0.07;0.02;217;2.76;0.08;0.04;6;1.89;0.01;0.01;2;1.41;0.02;0.02;8;0.24;0.5;0.06;Alzheimer Disease;#N/A;#N/A;0.08554261;0.056915298;#N/A;0.034425742;#N/A;#N/A;#N/A;0.006652437;0.004434958;#N/A;0.013120085;0.034370926;#N/A;0.005305113;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;12;12;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0956;THAP1;ENSG00000131931;HGNC:20856;55145;THAP domain-containing protein 1;Q9NVV9;https://jaspar.elixir.no/search?q=Q9NVV9;https://platform.opentargets.org/target/ENSG00000131931;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;1650;531;744;468;438;5_None;134;6.06;0.04;0.02;129;3.31;0.05;0.04;1;0.31;0;0;4;2.45;0.04;0.04;4;0.19;0.25;0.05;Alzheimer Disease;#N/A;#N/A;0.156424261;0.014783194;#N/A;0.012741676;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.006652437;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1267;ZNF367;ENSG00000165244;HGNC:18320;195828;Zinc finger protein 367 (C2H2 zinc finger protein ZFF29);Q7RTV3;#N/A;https://platform.opentargets.org/target/ENSG00000165244;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1992;687;745;809;438;5_None;105;6.05;0.03;0.02;95;3.21;0.04;0.04;10;2.84;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.06;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.06308509;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0371;HOMEZ;ENSG00000290292;HGNC:20164;57594;Homeobox and leucine zipper protein Homez (Homeodomain leucine zipper-containing factor);Q8IX15;#N/A;https://platform.opentargets.org/target/ENSG00000290292;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;2127;748;746;213;1168;5_None;32;6.05;0.01;0.02;19;2.55;0.01;0.03;13;3.49;0.03;0.02;#N/A;#N/A;#N/A;#N/A;2;0.54;0.13;0.14;Alzheimer Disease;#N/A;#N/A;0.271076275;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.271076275;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0266;FOXJ3;ENSG00000198815;HGNC:29178;22887;Forkhead box protein J3;Q9UPW0;#N/A;https://platform.opentargets.org/target/ENSG00000198815;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2932;1177;747;1017;1168;5_None;144;6.03;0.05;0.02;141;5.25;0.06;0.07;3;0.78;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Alzheimer Disease;#N/A;#N/A;0.011826555;#N/A;0.003695799;0.01083218;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0587;NEUROG3;ENSG00000122859;HGNC:13806;50674;Neurogenin-3 (NGN-3) (Class A basic helix-loop-helix protein 7) (bHLHa7) (Protein atonal homolog 5);Q9Y4Z2;#N/A;https://platform.opentargets.org/target/ENSG00000122859;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2099;737;748;183;1168;5_None;124;6.02;0.04;0.02;115;2.06;0.05;0.03;5;1.6;0.01;0.01;4;2.36;0.04;0.04;4;0.58;0.25;0.15;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;#N/A;#N/A;0.019402942;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.550674802;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0092;CDX1;ENSG00000113722;HGNC:1805;1044;Homeobox protein CDX-1 (Caudal-type homeobox protein 1);P47902;https://jaspar.elixir.no/search?q=P47902;https://platform.opentargets.org/target/ENSG00000113722;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2933;1178;749;1016;1168;5_None;156;6.02;0.05;0.02;153;4.68;0.06;0.06;2;0.83;0;0.01;1;0.51;0.01;0.01;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.001847899;#N/A;#N/A;0.02102759;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0988;TRERF1;ENSG00000124496;HGNC:18273;55809;Transcriptional-regulating factor 1 (Breast cancer anti-estrogen resistance 2) (Transcriptional-regulating protein 132) (Zinc finger protein rapa) (Zinc finger transcription factor TReP-132);Q96PN7;#N/A;https://platform.opentargets.org/target/ENSG00000124496;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;1825;616;750;637;438;5_None;207;6.01;0.07;0.02;194;1.79;0.08;0.02;13;4.22;0.03;0.03;#N/A;#N/A;#N/A;#N/A;12;0.11;0.75;0.03;Alzheimer Disease;#N/A;0.008869917;0.054059515;0.001847899;0.001478319;0.018489769;0.001478319;#N/A;#N/A;0.004619748;0.005913278;0.001478319;0.002771849;0.003326219;#N/A;0.008923916;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0187;EGR3;ENSG00000179388;HGNC:3240;1960;Early growth response protein 3 (EGR-3) (Zinc finger protein pilot);Q06889;https://jaspar.elixir.no/search?q=Q06889;https://platform.opentargets.org/target/ENSG00000179388;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1871;632;751;682;438;3_Medium to Low;256;6;0.08;0.02;250;4.15;0.1;0.06;6;1.85;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.1;0.44;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.023686689;0.007576387;0.001478319;0.022228199;0.034001347;0.005358908;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;9;9;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0997;UBP1;ENSG00000153560;HGNC:12507;7342;Upstream-binding protein 1 (Transcription factor LBP-1);Q9NZI7;#N/A;https://platform.opentargets.org/target/ENSG00000153560;6 Immunoglobulin fold;6.7 Grainyhead;6.7.2 CP2-related;2160;771;752;240;1168;5_None;72;5.97;0.02;0.02;59;1.61;0.02;0.02;13;4.37;0.03;0.03;#N/A;#N/A;#N/A;#N/A;4;0.5;0.25;0.13;Parkinson Disease;#N/A;#N/A;0.243003491;0.001478319;#N/A;0.0104433;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.24337307;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0879;SPIC;ENSG00000166211;HGNC:29549;121599;Transcription factor Spi-C;Q8N5J4;https://jaspar.elixir.no/search?q=Q8N5J4;https://platform.opentargets.org/target/ENSG00000166211;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2547;961;753;1356;438;5_None;67;5.97;0.02;0.02;56;1.68;0.02;0.02;10;3.76;0.02;0.03;1;0.53;0.01;0.01;2;0;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.001478319;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0931;TERB1;ENSG00000249961;HGNC:26675;283847;Telomere repeats-binding bouquet formation protein 1 (Coiled-coil domain-containing protein 79);Q8NA31;#N/A;https://platform.opentargets.org/target/ENSG00000249961;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;3254;1367;754;1332;1168;5_None;118;5.95;0.04;0.02;116;5.13;0.05;0.07;2;0.83;0;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0208;ESRRA;ENSG00000173153;HGNC:3471;2101;Steroid hormone receptor ERR1 (Estrogen receptor-like 1) (Estrogen-related receptor alpha) (ERR-alpha) (Nuclear receptor subfamily 3 group B member 1);P11474;https://jaspar.elixir.no/search?q=P11474;https://platform.opentargets.org/target/ENSG00000173153;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.1 Steroid hormone receptors;1294;381;755;357;182;2_Medium;294;5.93;0.09;0.02;293;5.71;0.11;0.08;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;13;0.31;0.81;0.08;Cancer;#N/A;0.014783194;0.019381394;0.001478319;0.014783194;0.081708159;#N/A;0.009630547;#N/A;0.001847899;0.080727642;0.004065378;0.013345612;0.018848778;0.015152774;0.02984121;2;0.13;Y;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;2_Medium;DGIDB MOA not >0 and no ChEMBL max phase >0 but approved drugs according to TTD? Development level unclear (TTD entries wrong?) but assume Medium;Tchem;7;#N/A;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0409;HOXD8;ENSG00000175879;HGNC:5139;3234;Homeobox protein Hox-D8 (Homeobox protein Hox-4E) (Homeobox protein Hox-5.4);P13378;https://jaspar.elixir.no/search?q=P13378;https://platform.opentargets.org/target/ENSG00000175879;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2242;810;756;1048;438;3_Medium to Low;103;5.9;0.03;0.02;92;2.66;0.04;0.04;11;3.24;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.014787628;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0155;DMRTC2;ENSG00000142025;HGNC:13911;63946;Doublesex- and mab-3-related transcription factor C2;Q8IXT2;https://jaspar.elixir.no/search?q=Q8IXT2;https://platform.opentargets.org/target/ENSG00000142025;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;3394;1432;757;1469;1168;5_None;96;5.86;0.03;0.02;95;5.5;0.04;0.07;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0648;NR2F6;ENSG00000160113;HGNC:7977;2063;Nuclear receptor subfamily 2 group F member 6 (V-erbA-related protein 2) (EAR-2);P10588;https://jaspar.elixir.no/search?q=P10588;https://platform.opentargets.org/target/ENSG00000160113;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;1803;604;758;607;438;3_Medium to Low;118;5.86;0.04;0.02;111;2.87;0.04;0.04;4;1.41;0.01;0.01;3;1.58;0.03;0.03;4;0.12;0.25;0.03;Cancer;#N/A;#N/A;0.00787164;#N/A;#N/A;0.073604202;#N/A;#N/A;#N/A;#N/A;0.038230983;#N/A;#N/A;#N/A;0.001478319;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;8;8;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0925;TCFL5;ENSG00000101190;HGNC:11646;10732;Transcription factor-like 5 protein (Cha transcription factor) (HPV-16 E2-binding protein 1) (E2BP-1);Q9UL49;https://jaspar.elixir.no/search?q=Q9UL49;https://platform.opentargets.org/target/ENSG00000101190;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;2096;736;759;899;438;5_None;217;5.84;0.07;0.02;217;5.84;0.08;0.08;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.05;0.31;0.01;Heart Failure;#N/A;#N/A;0.006652437;0.009424286;#N/A;0.00749899;#N/A;0.013859245;0.008330946;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1283;ZNF407;ENSG00000215421;HGNC:19904;55628;Zinc finger protein 407;Q9C0G0;#N/A;https://platform.opentargets.org/target/ENSG00000215421;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2520;948;760;1322;438;5_None;60;5.8;0.02;0.02;48;2.33;0.02;0.03;12;3.48;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004804538;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0708;PLSCR1;ENSG00000188313;HGNC:9092;5359;Phospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-dependent phospholipid scramblase 1) (Erythrocyte phospholipid scramblase) (Mg(2+)-dependent nuclease) (EC 3.1.-.-) (MmTRA1b);O15162;#N/A;https://platform.opentargets.org/target/ENSG00000188313;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1694;557;761;751;182;5_None;208;5.8;0.07;0.02;204;4.36;0.08;0.06;4;1.44;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.08;0.19;0.02;Osteoarthritis;#N/A;#N/A;0.003695799;#N/A;#N/A;0.028417066;#N/A;#N/A;#N/A;#N/A;#N/A;0.047570014;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0230;FEZF2;ENSG00000153266;HGNC:13506;55079;Fez family zinc finger protein 2 (Forebrain embryonic zinc finger-like protein 2) (Zinc finger protein 312) (Zinc finger protein Fez-like);Q8TBJ5;https://jaspar.elixir.no/search?q=Q8TBJ5;https://platform.opentargets.org/target/ENSG00000153266;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2302;840;762;1102;438;5_None;123;5.78;0.04;0.02;119;4.33;0.05;0.06;4;1.45;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0;Cancer;#N/A;#N/A;0.001765276;#N/A;#N/A;0.009609076;#N/A;0.003028502;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0813;SHOX;ENSG00000185960;HGNC:10853;6473;Short stature homeobox protein (Pseudoautosomal homeobox-containing osteogenic protein) (Short stature homeobox-containing protein);O15266;https://jaspar.elixir.no/search?q=O15266;https://platform.opentargets.org/target/ENSG00000185960;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3127;1288;763;1196;1168;5_None;156;5.77;0.05;0.02;147;1.05;0.06;0.01;4;1.09;0.01;0.01;5;3.64;0.05;0.06;3;0.01;0.19;0;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0.001478319;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0376;HOXA2;ENSG00000105996;HGNC:5103;3199;Homeobox protein Hox-A2 (Homeobox protein Hox-1K);O43364;https://jaspar.elixir.no/search?q=O43364;https://platform.opentargets.org/target/ENSG00000105996;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2177;777;764;975;438;5_None;135;5.77;0.04;0.02;129;3.25;0.05;0.04;4;1.18;0.01;0.01;2;1.34;0.02;0.02;6;0.03;0.38;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.01205874;#N/A;#N/A;#N/A;#N/A;0.001478319;0.002217479;0.011087396;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0345;HEYL;ENSG00000163909;HGNC:4882;26508;Hairy/enhancer-of-split related with YRPW motif-like protein (hHeyL) (Class B basic helix-loop-helix protein 33) (bHLHb33) (Hairy-related transcription factor 3) (HRT-3) (hHRT3);Q9NQ87;#N/A;https://platform.opentargets.org/target/ENSG00000163909;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;2354;865;765;421;1168;5_None;106;5.76;0.03;0.02;97;2.87;0.04;0.04;9;2.89;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.24;0.25;0.06;Alzheimer Disease;#N/A;#N/A;0.168893781;#N/A;#N/A;0.015097871;0.04806078;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0482;LCOR;ENSG00000196233;HGNC:29503;84458;Ligand-dependent corepressor (LCoR) (Mblk1-related protein 2);Q96JN0;#N/A;https://platform.opentargets.org/target/ENSG00000196233;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2996;1217;766;1062;1168;5_None;50;5.76;0.02;0.02;36;0.72;0.01;0.01;11;3.48;0.02;0.02;3;1.56;0.03;0.03;3;0.02;0.19;0.01;Alzheimer Disease;#N/A;#N/A;0.009696224;0.004989328;#N/A;0.006226872;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0624;NKX6-1;ENSG00000163623;HGNC:7839;4825;Homeobox protein Nkx-6.1 (Homeobox protein NK-6 homolog A);P78426;https://jaspar.elixir.no/search?q=P78426;https://platform.opentargets.org/target/ENSG00000163623;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1185;340;767;236;182;4_Low;123;5.72;0.04;0.02;110;1.53;0.04;0.02;13;4.18;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.5;0.13;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.073347296;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.429601522;2;0.13;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0570;MYT1;ENSG00000196132;HGNC:7622;4661;Myelin transcription factor 1 (MyT1) (Myelin transcription factor I) (MyTI) (PLPB1) (Proteolipid protein-binding protein);Q01538;#N/A;https://platform.opentargets.org/target/ENSG00000196132;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.1 MYT;1482;460;768;532;182;4_Low;94;5.71;0.03;0.02;83;2.44;0.03;0.03;11;3.27;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.16;0.25;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004599216;#N/A;#N/A;0.016793976;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.12753689;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0610;NHLH1;ENSG00000171786;HGNC:7817;4807;Helix-loop-helix protein 1 (HEN-1) (Class A basic helix-loop-helix protein 35) (bHLHa35) (Nescient helix loop helix 1) (NSCL-1);Q02575;https://jaspar.elixir.no/search?q=Q02575;https://platform.opentargets.org/target/ENSG00000171786;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2274;830;769;1323;182;4_Low;135;5.68;0.04;0.02;132;4.93;0.05;0.07;3;0.75;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004784006;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0143;DLX2;ENSG00000115844;HGNC:2915;1746;Homeobox protein DLX-2;Q07687;#N/A;https://platform.opentargets.org/target/ENSG00000115844;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1058;296;770;106;182;5_None;122;5.66;0.04;0.02;112;2.11;0.04;0.03;9;2.99;0.02;0.02;1;0.56;0.01;0.01;6;0.82;0.38;0.21;Alzheimer Disease;#N/A;#N/A;0.369949435;#N/A;#N/A;0.049243098;0.016076724;#N/A;#N/A;#N/A;#N/A;0.007391597;0.009978656;0.369579855;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0898;TBPL2;ENSG00000182521;HGNC:19841;387332;TATA box-binding protein-like 2 (TBP-like 2) (TATA box-binding protein-related factor 3) (TBP-related factor 3);Q6SJ96;#N/A;https://platform.opentargets.org/target/ENSG00000182521;8 beta-Sheet binding to DNA;8.1 TATA-binding proteins;8.1.1 TBP-related;2129;750;771;920;438;5_None;143;5.65;0.05;0.02;135;3.39;0.05;0.05;8;2.26;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.04;0.25;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.002217479;#N/A;0.018568258;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.019477474;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0811;SETDB2;ENSG00000136169;HGNC:20263;83852;Histone-lysine N-methyltransferase SETDB2 (EC 2.1.1.366) (Chronic lymphocytic leukemia deletion region gene 8 protein) (Lysine N-methyltransferase 1F) (SET domain bifurcated 2);Q96T68;#N/A;https://platform.opentargets.org/target/ENSG00000136169;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1954;671;772;744;438;5_None;124;5.62;0.04;0.02;118;3.6;0.05;0.05;6;2.02;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.08;0.31;0.02;Atherosclerosis;#N/A;#N/A;0.011826555;0.027882747;#N/A;0.015897174;#N/A;#N/A;#N/A;#N/A;0.011826555;#N/A;#N/A;#N/A;#N/A;0.014393082;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0377;HOXA3;ENSG00000105997;HGNC:5104;3200;Homeobox protein Hox-A3 (Homeobox protein Hox-1E);O43365;https://jaspar.elixir.no/search?q=O43365;https://platform.opentargets.org/target/ENSG00000105997;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1937;665;773;726;438;3_Medium to Low;133;5.61;0.04;0.02;122;2.63;0.05;0.04;11;2.98;0.02;0.02;#N/A;#N/A;#N/A;#N/A;7;0.09;0.44;0.02;Alzheimer Disease;#N/A;#N/A;0.026496474;0.002751317;0.006652437;0.023023505;0.022913951;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0824;SKIL;ENSG00000136603;HGNC:10897;6498;Ski-like protein (Ski-related oncogene) (Ski-related protein);P12757;#N/A;https://platform.opentargets.org/target/ENSG00000136603;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1497;467;774;541;182;5_None;185;5.59;0.06;0.02;176;2.26;0.07;0.03;8;2.81;0.02;0.02;1;0.52;0.01;0.01;9;0.15;0.56;0.04;Cancer;#N/A;#N/A;0.01883548;0.008020499;#N/A;0.083814907;#N/A;0.002217479;#N/A;0.004065378;#N/A;0.002217479;0.002217479;0.0130247;#N/A;0.016261514;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0863;SP100;ENSG00000067066;HGNC:11206;6672;Nuclear autoantigen Sp-100 (Nuclear dot-associated Sp100 protein) (Speckled 100 kDa);P23497;#N/A;https://platform.opentargets.org/target/ENSG00000067066;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.5 Sp140-Sp104;1932;662;775;719;438;5_None;108;5.57;0.03;0.02;95;1.61;0.04;0.02;13;3.96;0.03;0.03;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.083983242;#N/A;0.001478319;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0137;DBP;ENSG00000105516;HGNC:2697;1628;D site-binding protein (Albumin D box-binding protein) (Albumin D-element-binding protein) (Tax-responsive enhancer element-binding protein 302) (TaxREB302);Q10586;https://jaspar.elixir.no/search?q=Q10586;https://platform.opentargets.org/target/ENSG00000105516;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.8 CEBP-related;1853;624;776;639;438;3_Medium to Low;353;5.54;0.11;0.02;353;5.54;0.14;0.08;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;0.11;0.56;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.015885731;0.001478319;#N/A;0.01731697;0.017739381;#N/A;0.003695799;#N/A;0.003695799;#N/A;0.012610155;0.001478319;#N/A;0.038651034;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;7;6;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0388;HOXB5;ENSG00000120075;HGNC:5116;3215;Homeobox protein Hox-B5 (Homeobox protein HHO.C10) (Homeobox protein Hox-2A) (Homeobox protein Hu-1);P09067;https://jaspar.elixir.no/search?q=P09067;https://platform.opentargets.org/target/ENSG00000120075;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2222;804;777;1007;438;3_Medium to Low;153;5.53;0.05;0.02;149;4.61;0.06;0.06;4;0.92;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.001847899;0.001478319;#N/A;0.024034714;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1047;ZBTB4;ENSG00000174282;HGNC:23847;57659;Zinc finger and BTB domain-containing protein 4 (KAISO-like zinc finger protein 1) (KAISO-L1);Q9P1Z0;#N/A;https://platform.opentargets.org/target/ENSG00000174282;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1685;551;778;469;438;4_Low;119;5.51;0.04;0.02;114;3.81;0.04;0.05;5;1.7;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.19;0.25;0.05;Benign Prostatic Hyperplasia;#N/A;#N/A;0.012914763;#N/A;0.095349443;0.077587486;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1147;ZNF169;ENSG00000175787;HGNC:12957;169841;Zinc finger protein 169;Q14929;#N/A;https://platform.opentargets.org/target/ENSG00000175787;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1388;417;779;427;182;5_None;39;5.5;0.01;0.02;26;1.68;0.01;0.02;13;3.82;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.23;0.13;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.011272186;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.219317212;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1501;ZNF704;ENSG00000164684;HGNC:32291;619279;Zinc finger protein 704;Q6ZNC4;#N/A;https://platform.opentargets.org/target/ENSG00000164684;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2262;820;780;1044;438;5_None;54;5.49;0.02;0.02;39;1.09;0.02;0.01;15;4.4;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.021197047;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1611;ZNF90;ENSG00000213988;HGNC:13165;7643;Zinc finger protein 90 (Zinc finger protein HTF9);Q03938;#N/A;https://platform.opentargets.org/target/ENSG00000213988;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2688;1039;781;1469;438;5_None;31;5.47;0.01;0.02;15;0.42;0.01;0.01;16;5.05;0.03;0.03;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1571;ZNF799;ENSG00000196466;HGNC:28071;90576;Zinc finger protein 799 (Zinc finger protein 842);Q96GE5;#N/A;https://platform.opentargets.org/target/ENSG00000196466;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1283;377;782;319;182;5_None;25;5.47;0.01;0.02;10;0.37;0;0.01;15;5.1;0.03;0.03;#N/A;#N/A;#N/A;#N/A;1;0.36;0.06;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.362197342;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0383;HOXB1;ENSG00000120094;HGNC:5111;3211;Homeobox protein Hox-B1 (Homeobox protein Hox-2I);P14653;https://jaspar.elixir.no/search?q=P14653;https://platform.opentargets.org/target/ENSG00000120094;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;3009;1222;783;1058;1168;3_Medium to Low;87;5.45;0.03;0.02;80;2.82;0.03;0.04;6;1.98;0.01;0.01;1;0.64;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.021393379;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;5;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0330;HAND1;ENSG00000113196;HGNC:4807;9421;Heart- and neural crest derivatives-expressed protein 1 (Class A basic helix-loop-helix protein 27) (bHLHa27) (Extraembryonic tissues, heart, autonomic nervous system and neural crest derivatives-expressed protein 1) (eHAND);O96004;#N/A;https://platform.opentargets.org/target/ENSG00000113196;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2729;1059;784;777;1168;5_None;99;5.41;0.03;0.02;87;1.65;0.03;0.02;12;3.77;0.02;0.03;#N/A;#N/A;#N/A;#N/A;6;0.07;0.38;0.02;Alzheimer Disease;#N/A;#N/A;0.024576731;#N/A;#N/A;0.02309185;#N/A;0.009288363;#N/A;0.004784006;0.004434958;#N/A;#N/A;0.006652437;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0864;SP110;ENSG00000135899;HGNC:5401;3431;Sp110 nuclear body protein (Interferon-induced protein 41/75) (Speckled 110 kDa) (Transcriptional coactivator Sp110);Q9HB58;#N/A;https://platform.opentargets.org/target/ENSG00000135899;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.4 Sp110;2432;909;785;1209;438;5_None;98;5.38;0.03;0.02;90;2.14;0.04;0.03;6;1.81;0.01;0.01;2;1.43;0.02;0.02;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001478319;#N/A;0.003695799;0.004414426;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1334;ZNF485;ENSG00000198298;HGNC:23440;220992;Zinc finger protein 485;Q8NCK3;#N/A;https://platform.opentargets.org/target/ENSG00000198298;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2229;807;786;275;1168;5_None;27;5.38;0.01;0.02;13;0.7;0.01;0.01;14;4.68;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;0.43;0.13;0.11;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.015871402;#N/A;#N/A;#N/A;0.415966481;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0201;EN2;ENSG00000164778;HGNC:3343;2020;Homeobox protein engrailed-2 (Homeobox protein en-2) (Hu-En-2);P19622;https://jaspar.elixir.no/search?q=P19622;https://platform.opentargets.org/target/ENSG00000164778;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2547;961;787;592;1168;3_Medium to Low;172;5.38;0.06;0.02;171;5.15;0.07;0.07;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;4;0.13;0.25;0.03;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.083228767;0.023436559;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012639824;0.007391597;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0445;JDP2;ENSG00000140044;HGNC:17546;122953;Jun dimerization protein 2;Q8WYK2;https://jaspar.elixir.no/search?q=Q8WYK2;https://platform.opentargets.org/target/ENSG00000140044;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.2 Fos-related;1893;643;788;667;438;5_None;160;5.37;0.05;0.02;155;3.71;0.06;0.05;5;1.67;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.1;0.25;0.03;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.047655535;#N/A;0.021813479;#N/A;0.023142475;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0513;MBD4;ENSG00000129071;HGNC:6919;8930;Methyl-CpG-binding domain protein 4 (EC 3.2.2.-) (Methyl-CpG-binding endonuclease 1) (Methyl-CpG-binding protein MBD4) (Mismatch-specific DNA N-glycosylase);O95243;#N/A;https://platform.opentargets.org/target/ENSG00000129071;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2643;1011;789;686;1168;4_Low;132;5.37;0.04;0.02;125;2.01;0.05;0.03;5;2.03;0.01;0.01;2;1.33;0.02;0.02;3;0.09;0.19;0.02;Cancer;#N/A;0.001478319;#N/A;#N/A;0.001847899;0.090703786;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0625;NKX6-2;ENSG00000148826;HGNC:19321;84504;Homeobox protein Nkx-6.2 (Homeobox protein NK-6 homolog B);Q9C056;https://jaspar.elixir.no/search?q=Q9C056;https://platform.opentargets.org/target/ENSG00000148826;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;1955;672;790;983;182;5_None;140;5.37;0.04;0.02;137;3.89;0.05;0.05;2;0.68;0;0;1;0.81;0.01;0.01;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.015912117;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0583;NEUROD4;ENSG00000123307;HGNC:13802;58158;Neurogenic differentiation factor 4 (NeuroD4) (Class A basic helix-loop-helix protein 4) (bHLHa4) (Protein atonal homolog 3) (ATH-3) (Atoh3);Q9HD90;#N/A;https://platform.opentargets.org/target/ENSG00000123307;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2967;1195;791;1008;1168;5_None;143;5.36;0.05;0.02;142;4.97;0.06;0.07;1;0.4;0;0;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Parkinson Disease;#N/A;#N/A;#N/A;0.007391597;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.012565715;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1364;ZNF526;ENSG00000167625;HGNC:29415;116115;Zinc finger protein 526;Q8TF50;#N/A;https://platform.opentargets.org/target/ENSG00000167625;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3429;1440;792;1469;1168;5_None;24;5.35;0.01;0.02;13;0.87;0.01;0.01;11;4.48;0.02;0.03;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0063;BAZ2A;ENSG00000076108;HGNC:962;11176;Bromodomain adjacent to zinc finger domain protein 2A (Transcription termination factor I-interacting protein 5) (TTF-I-interacting protein 5) (Tip5) (hWALp3);Q9UIF9;#N/A;https://platform.opentargets.org/target/ENSG00000076108;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1947;668;793;716;438;4_Low;74;5.33;0.02;0.02;64;1.77;0.03;0.02;9;3.06;0.02;0.02;1;0.51;0.01;0.01;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;0.004065378;#N/A;#N/A;0.083406381;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0350;HIF3A;ENSG00000124440;HGNC:15825;64344;Hypoxia-inducible factor 3-alpha (HIF-3-alpha) (HIF3-alpha) (Basic-helix-loop-helix-PAS protein MOP7) (Class E basic helix-loop-helix protein 17) (bHLHe17) (HIF3-alpha-1) (Inhibitory PAS domain protein) (IPAS) (Member of PAS protein 7) (PAS domain-containing protein 7);Q9Y2N7;#N/A;https://platform.opentargets.org/target/ENSG00000124440;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1251;364;794;374;83;5_None;194;5.33;0.06;0.02;189;3.92;0.07;0.05;5;1.41;0.01;0.01;#N/A;#N/A;#N/A;#N/A;9;0.28;0.56;0.07;Cancer;#N/A;#N/A;0.026368496;#N/A;#N/A;0.087444208;0.085672101;#N/A;0.010533026;#N/A;0.001478319;0.008782655;0.007391597;0.031116571;#N/A;0.025378625;3;0.2;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0442;ISL2;ENSG00000159556;HGNC:18524;64843;Insulin gene enhancer protein ISL-2 (Islet-2);Q96A47;https://jaspar.elixir.no/search?q=Q96A47;https://platform.opentargets.org/target/ENSG00000159556;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2813;1090;795;850;1168;5_None;73;5.32;0.02;0.02;64;2.61;0.03;0.04;8;2.2;0.02;0.01;1;0.51;0.01;0.01;2;0.05;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.050500638;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0562;MYF6;ENSG00000111046;HGNC:7566;4618;Myogenic factor 6 (Myf-6) (Class C basic helix-loop-helix protein 4) (bHLHc4) (Muscle-specific regulatory factor 4);P23409;https://jaspar.elixir.no/search?q=P23409;https://platform.opentargets.org/target/ENSG00000111046;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;2635;1006;796;671;1168;5_None;171;5.31;0.05;0.02;170;5.08;0.07;0.07;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;6;0.1;0.38;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.001478319;#N/A;0.005217223;0.007391597;0.004804538;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;0.077695129;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1450;ZNF629;ENSG00000102870;HGNC:29008;23361;Zinc finger protein 629 (Zinc finger protein 65);Q9UEG4;#N/A;https://platform.opentargets.org/target/ENSG00000102870;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1077;300;797;98;182;5_None;332;5.3;0.11;0.02;326;3.07;0.13;0.04;5;1.69;0.01;0.01;1;0.54;0.01;0.01;11;0.87;0.69;0.22;Parkinson Disease;#N/A;#N/A;0.370880873;0.002012157;0.001478319;0.086935315;0.016261514;0.001478319;0.001478319;0.002956639;#N/A;#N/A;0.001478319;0.375870685;#N/A;0.007761177;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1470;ZNF668;ENSG00000167394;HGNC:25821;79759;Zinc finger protein 668;Q96K58;#N/A;https://platform.opentargets.org/target/ENSG00000167394;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2532;953;798;566;1168;5_None;71;5.3;0.02;0.02;60;1.91;0.02;0.03;10;2.83;0.02;0.02;1;0.56;0.01;0.01;3;0.14;0.19;0.03;Parkinson Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.020829931;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.112250778;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0628;NOBOX;ENSG00000106410;HGNC:22448;135935;Homeobox protein NOBOX;O60393;#N/A;https://platform.opentargets.org/target/ENSG00000106410;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2659;1021;799;1422;438;5_None;89;5.28;0.03;0.02;84;2.9;0.03;0.04;4;1.59;0.01;0.01;1;0.78;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0741;PRDM8;ENSG00000152784;HGNC:13993;56978;PR domain zinc finger protein 8 (EC 2.1.1.-) (PR domain-containing protein 8);Q9NQV8;#N/A;https://platform.opentargets.org/target/ENSG00000152784;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2289;836;800;1051;438;5_None;109;5.27;0.04;0.02;100;2.25;0.04;0.03;8;2.45;0.02;0.02;1;0.57;0.01;0.01;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.016762089;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0528;MESP2;ENSG00000188095;HGNC:29659;145873;Mesoderm posterior protein 2 (Class C basic helix-loop-helix protein 6) (bHLHc6);Q0VG99;#N/A;https://platform.opentargets.org/target/ENSG00000188095;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3276;1384;801;1307;1168;5_None;99;5.24;0.03;0.02;97;4.22;0.04;0.06;1;0.3;0;0;1;0.72;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0798;SALL2;ENSG00000165821;HGNC:10526;6297;Sal-like protein 2 (Zinc finger protein 795) (Zinc finger protein SALL2) (Zinc finger protein Spalt-2) (Sal-2) (hSal2);Q9Y467;#N/A;https://platform.opentargets.org/target/ENSG00000165821;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1664;538;802;680;182;5_None;90;5.23;0.03;0.02;78;1.13;0.03;0.02;12;4.1;0.02;0.03;#N/A;#N/A;#N/A;#N/A;2;0.1;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.093245867;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;2;0.13;Y;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0408;HOXD4;ENSG00000170166;HGNC:5138;3233;Homeobox protein Hox-D4 (Homeobox protein HHO.C13) (Homeobox protein Hox-4B) (Homeobox protein Hox-5.1);P09016;https://jaspar.elixir.no/search?q=P09016;https://platform.opentargets.org/target/ENSG00000170166;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2714;1052;803;743;1168;5_None;103;5.23;0.03;0.02;96;3.19;0.04;0.04;7;2.04;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.006652437;#N/A;0.075250565;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0176;E2F6;ENSG00000169016;HGNC:3120;1876;Transcription factor E2F6 (E2F-6);O75461;https://jaspar.elixir.no/search?q=O75461;https://platform.opentargets.org/target/ENSG00000169016;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;2153;766;804;911;438;2_Medium;156;5.22;0.05;0.02;152;4.15;0.06;0.06;4;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.04;0.38;0.01;Cancer;#N/A;0.002217479;#N/A;#N/A;#N/A;0.028823934;#N/A;0.002587059;#N/A;#N/A;0.003695799;#N/A;#N/A;0.001478319;#N/A;0.004434958;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;3;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_1166;ZNF207;ENSG00000010244;HGNC:12998;7756;BUB3-interacting and GLEBS motif-containing protein ZNF207 (BuGZ) (hBuGZ) (Zinc finger protein 207);O43670;#N/A;https://platform.opentargets.org/target/ENSG00000010244;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1059;297;805;72;182;5_None;91;5.21;0.03;0.02;85;2.57;0.03;0.03;5;2.08;0.01;0.01;1;0.56;0.01;0.01;4;0.96;0.25;0.24;Alzheimer Disease;#N/A;#N/A;0.462898768;#N/A;#N/A;0.027163881;0.005913278;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.461974818;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1272;ZNF385A;ENSG00000161642;HGNC:17521;25946;Zinc finger protein 385A (Hematopoietic zinc finger protein) (Retinal zinc finger protein);Q96PM9;#N/A;https://platform.opentargets.org/target/ENSG00000161642;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2173;776;806;929;438;5_None;92;5.21;0.03;0.02;82;2.13;0.03;0.03;10;3.07;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.035849246;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0053;ATOH8;ENSG00000168874;HGNC:24126;84913;Transcription factor ATOH8 (Class A basic helix-loop-helix protein 21) (bHLHa21) (Helix-loop-helix protein hATH-6) (hATH6) (Protein atonal homolog 8);Q96SQ7;#N/A;https://platform.opentargets.org/target/ENSG00000168874;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;1365;410;807;120;438;5_None;85;5.18;0.03;0.02;74;1.47;0.03;0.02;10;3.21;0.02;0.02;1;0.5;0.01;0.01;4;0.76;0.25;0.19;Alzheimer Disease;#N/A;#N/A;0.362705056;0.009424286;#N/A;0.021369819;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.362705056;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0473;KLF8;ENSG00000102349;HGNC:6351;11279;Krueppel-like factor 8 (Basic krueppel-like factor 3) (Zinc finger protein 741);O95600;#N/A;https://platform.opentargets.org/target/ENSG00000102349;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1591;514;808;345;438;5_None;89;5.17;0.03;0.02;78;2.27;0.03;0.03;11;2.91;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.32;0.19;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;0.021620421;#N/A;#N/A;0.038959868;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.263318781;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0489;LHX4;ENSG00000121454;HGNC:21734;89884;LIM/homeobox protein Lhx4 (LIM homeobox protein 4);Q969G2;#N/A;https://platform.opentargets.org/target/ENSG00000121454;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2457;922;809;1210;438;5_None;86;5.17;0.03;0.02;78;1.21;0.03;0.02;4;1.45;0.01;0.01;4;2.51;0.04;0.04;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005489903;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0549;MTF1;ENSG00000188786;HGNC:7428;4520;Metal regulatory transcription factor 1 (MRE-binding transcription factor) (Transcription factor MTF-1);Q14872;https://jaspar.elixir.no/search?q=Q14872;https://platform.opentargets.org/target/ENSG00000188786;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1387;416;810;494;83;4_Low;201;5.14;0.06;0.02;198;4.33;0.08;0.06;3;0.81;0.01;0.01;#N/A;#N/A;#N/A;#N/A;10;0.18;0.63;0.04;Cancer;#N/A;#N/A;0.02526489;0.005358908;#N/A;0.097714458;0.006098068;#N/A;0.013304875;0.001478319;0.01112846;0.008860459;#N/A;0.005017662;#N/A;0.002217479;3;0.2;Y;#N/A;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1347;ZNF503;ENSG00000165655;HGNC:23589;84858;Zinc finger protein 503;Q96F45;#N/A;https://platform.opentargets.org/target/ENSG00000165655;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1842;618;811;593;438;5_None;97;5.13;0.03;0.02;88;2.94;0.03;0.04;9;2.2;0.02;0.01;#N/A;#N/A;#N/A;#N/A;5;0.13;0.31;0.03;Type 2 Diabetes Mellitus;#N/A;0.033208393;0.004390763;#N/A;#N/A;0.033792795;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.051367891;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0125;CSRNP1;ENSG00000144655;HGNC:14300;64651;Cysteine/serine-rich nuclear protein 1 (CSRNP-1) (Axin-1 up-regulated gene 1 protein) (Protein URAX1) (TGF-beta-induced apoptosis protein 3) (TAIP-3);Q96S65;#N/A;https://platform.opentargets.org/target/ENSG00000144655;0 Yet undefined DNA-binding domains;0.1 AXUD/CSRNP domain factors;0.1.1 CSRNP;2306;843;812;1056;438;5_None;78;5.11;0.03;0.02;65;0.83;0.03;0.01;13;4.28;0.03;0.03;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.007834392;#N/A;#N/A;0.009539357;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1244;ZNF329;ENSG00000181894;HGNC:14209;79673;Zinc finger protein 329;Q86UD4;#N/A;https://platform.opentargets.org/target/ENSG00000181894;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2035;709;813;784;438;5_None;89;5.11;0.03;0.02;87;4.69;0.03;0.06;2;0.42;0;0;#N/A;#N/A;#N/A;#N/A;2;0.07;0.13;0.02;Age-Related Macular Degeneration;#N/A;0.06696012;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0659;OLIG1;ENSG00000184221;HGNC:16983;116448;Oligodendrocyte transcription factor 1 (Oligo1) (Class B basic helix-loop-helix protein 6) (bHLHb6) (Class E basic helix-loop-helix protein 21) (bHLHe21);Q8TAK6;https://jaspar.elixir.no/search?q=Q8TAK6;https://platform.opentargets.org/target/ENSG00000184221;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2817;1094;814;835;1168;5_None;113;5.08;0.04;0.02;102;1.46;0.04;0.02;11;3.62;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.01;Cancer;#N/A;#N/A;0.010452148;#N/A;#N/A;0.024147321;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.019033363;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1622;ZSCAN2;ENSG00000176371;HGNC:20994;54993;Zinc finger and SCAN domain-containing protein 2 (Zinc finger protein 29 homolog) (Zfp-29) (Zinc finger protein 854);Q7Z7L9;#N/A;https://platform.opentargets.org/target/ENSG00000176371;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2082;733;815;1085;182;5_None;43;5.08;0.01;0.02;35;2.75;0.01;0.04;8;2.34;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.017370253;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0390;HOXB7;ENSG00000260027;HGNC:5118;3217;Homeobox protein Hox-B7 (Homeobox protein HHO.C1) (Homeobox protein Hox-2C);P09629;https://jaspar.elixir.no/search?q=P09629;https://platform.opentargets.org/target/ENSG00000260027;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1753;584;816;755;182;5_None;196;5.07;0.06;0.02;191;3.59;0.07;0.05;5;1.48;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.026312032;#N/A;#N/A;0.048057537;0.003695799;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;putative;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0572;MZF1;ENSG00000099326;HGNC:13108;7593;Myeloid zinc finger 1 (MZF-1) (Zinc finger and SCAN domain-containing protein 6) (Zinc finger protein 42);P28698;https://jaspar.elixir.no/search?q=P28698;https://platform.opentargets.org/target/ENSG00000099326;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2679;1035;817;694;1168;5_None;153;5.07;0.05;0.02;149;3.96;0.06;0.05;4;1.11;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.09;0.31;0.02;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.076485629;0.008479804;#N/A;#N/A;0.001478319;#N/A;#N/A;0.004989328;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1044;ZBTB37;ENSG00000185278;HGNC:28365;84614;Zinc finger and BTB domain-containing protein 37;Q5TC79;#N/A;https://platform.opentargets.org/target/ENSG00000185278;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;2182;783;818;196;1168;5_None;36;5.06;0.01;0.02;24;0.87;0.01;0.01;12;4.18;0.02;0.03;#N/A;#N/A;#N/A;#N/A;3;0.56;0.19;0.14;Alzheimer Disease;#N/A;#N/A;0.280556031;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.279632081;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0642;NR2C1;ENSG00000120798;HGNC:7971;7181;Nuclear receptor subfamily 2 group C member 1 (Orphan nuclear receptor TR2) (Testicular receptor 2);P13056;https://jaspar.elixir.no/search?q=P13056;https://platform.opentargets.org/target/ENSG00000120798;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.3 RXR-related receptors;1443;443;819;186;438;4_Low;125;5.04;0.04;0.02;118;3.2;0.05;0.04;7;1.84;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.58;0.38;0.15;Alzheimer Disease;#N/A;#N/A;0.247451468;0.001478319;#N/A;0.043840863;0.008869917;#N/A;#N/A;0.028634971;#N/A;#N/A;#N/A;0.24481106;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0046;ATF5;ENSG00000169136;HGNC:790;22809;Cyclic AMP-dependent transcription factor ATF-5 (cAMP-dependent transcription factor ATF-5) (Activating transcription factor 5) (Transcription factor ATFx);Q9Y2D1;#N/A;https://platform.opentargets.org/target/ENSG00000169136;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.6 ATF4-related;1099;308;820;97;182;4_Low;163;5.03;0.05;0.02;157;2.68;0.06;0.04;6;2.34;0.01;0.02;#N/A;#N/A;#N/A;#N/A;9;0.87;0.56;0.22;Alzheimer Disease;#N/A;#N/A;0.372644288;#N/A;#N/A;0.088637893;0.001478319;#N/A;#N/A;0.007761177;0.007391597;0.007391597;0.011826555;0.369949435;#N/A;0.005358908;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;8;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0101;CENPA;ENSG00000115163;HGNC:1851;1058;Histone H3-like centromeric protein A (Centromere autoantigen A) (Centromere protein A) (CENP-A);P49450;#N/A;https://platform.opentargets.org/target/ENSG00000115163;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1521;475;821;617;83;5_None;184;5.02;0.06;0.02;178;2.89;0.07;0.04;6;2.13;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.12;0.19;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.10448417;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;9;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0069;BCL6B;ENSG00000161940;HGNC:1002;255877;B-cell CLL/lymphoma 6 member B protein (Bcl6-associated zinc finger protein) (Zinc finger protein 62);Q8N143;https://jaspar.elixir.no/search?q=Q8N143;https://platform.opentargets.org/target/ENSG00000161940;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2170;775;822;910;438;5_None;146;5;0.05;0.02;146;5;0.06;0.07;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.039637889;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0246;FOXD1;ENSG00000251493;HGNC:3802;2297;Forkhead box protein D1 (Forkhead-related protein FKHL8) (Forkhead-related transcription factor 4) (FREAC-4);Q16676;https://jaspar.elixir.no/search?q=Q16676;https://platform.opentargets.org/target/ENSG00000251493;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;1611;518;823;606;182;5_None;184;4.98;0.06;0.02;181;4.1;0.07;0.06;3;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.12;0.25;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.062758236;0.011528838;#N/A;#N/A;#N/A;#N/A;0.035610662;#N/A;#N/A;#N/A;0.012175603;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0227;FERD3L;ENSG00000146618;HGNC:16660;222894;Fer3-like protein (Basic helix-loop-helix protein N-twist) (Class A basic helix-loop-helix protein 31) (bHLHa31) (Nephew of atonal 3) (Neuronal twist);Q96RJ6;https://jaspar.elixir.no/search?q=Q96RJ6;https://platform.opentargets.org/target/ENSG00000146618;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3272;1381;824;1280;1168;5_None;47;4.95;0.02;0.02;36;1.95;0.01;0.03;11;2.99;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1002;VAX1;ENSG00000148704;HGNC:12660;11023;Ventral anterior homeobox 1;Q5SQQ9;https://jaspar.elixir.no/search?q=Q5SQQ9;https://platform.opentargets.org/target/ENSG00000148704;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2570;976;825;1307;438;5_None;115;4.93;0.04;0.02;111;3.51;0.04;0.05;3;0.84;0.01;0.01;1;0.58;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0961;THAP3;ENSG00000041988;HGNC:20855;90326;THAP domain-containing protein 3;Q8WTV1;#N/A;https://platform.opentargets.org/target/ENSG00000041988;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;1748;582;826;484;438;5_None;40;4.92;0.01;0.02;34;3.22;0.01;0.04;6;1.69;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.18;0.06;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.180443252;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0781;RHOXF1;ENSG00000101883;HGNC:29993;158800;Rhox homeobox family member 1 (Ovary-, testis- and epididymis-expressed gene protein) (Paired-like homeobox protein PEPP-1);Q8NHV9;https://jaspar.elixir.no/search?q=Q8NHV9;https://platform.opentargets.org/target/ENSG00000101883;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3165;1312;827;1170;1168;5_None;95;4.89;0.03;0.02;95;4.89;0.04;0.07;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011795757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1088;ZFP90;ENSG00000184939;HGNC:23329;146198;Zinc finger protein 90 homolog (Zfp-90) (Zinc finger protein 756);Q8TF47;#N/A;https://platform.opentargets.org/target/ENSG00000184939;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2182;783;828;1172;182;5_None;54;4.88;0.02;0.02;43;1.6;0.02;0.02;11;3.28;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001163069;#N/A;#N/A;0.008295015;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1227;ZNF296;ENSG00000170684;HGNC:15981;162979;Zinc finger protein 296 (ZFP296) (Zinc finger protein 342);Q8WUU4;#N/A;https://platform.opentargets.org/target/ENSG00000170684;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2348;860;829;1081;438;5_None;126;4.87;0.04;0.02;125;4.35;0.05;0.06;#N/A;#N/A;#N/A;#N/A;1;0.53;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01901283;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0866;SP140L;ENSG00000185404;HGNC:25105;93349;Nuclear body protein SP140-like protein;Q9H930;#N/A;https://platform.opentargets.org/target/ENSG00000185404;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.5 Sp140-Sp102;2586;981;830;1318;438;5_None;65;4.87;0.02;0.02;57;2.58;0.02;0.04;8;2.29;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005030392;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0275;FOXN4;ENSG00000139445;HGNC:21399;121643;Forkhead box protein N4;Q96NZ1;#N/A;https://platform.opentargets.org/target/ENSG00000139445;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2388;886;831;389;1168;5_None;52;4.84;0.02;0.02;40;1.01;0.02;0.01;12;3.83;0.02;0.03;#N/A;#N/A;#N/A;#N/A;3;0.27;0.19;0.07;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.011456975;0.003695799;#N/A;#N/A;0.250567147;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0545;MTERF1;ENSG00000127989;HGNC:21463;7978;Transcription termination factor 1, mitochondrial (Mitochondrial transcription termination factor 1) (mTERF) (mTERF1);Q99551;#N/A;https://platform.opentargets.org/target/ENSG00000127989;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3125;1286;832;1125;1168;5_None;49;4.75;0.02;0.02;36;0.67;0.01;0.01;13;4.08;0.03;0.03;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.015324205;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0151;DMRT3;ENSG00000064218;HGNC:13909;58524;Doublesex- and mab-3-related transcription factor 3;Q9NQL9;https://jaspar.elixir.no/search?q=Q9NQL9;https://platform.opentargets.org/target/ENSG00000064218;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;2768;1076;833;767;1168;5_None;96;4.74;0.03;0.02;88;1.72;0.03;0.02;7;2.48;0.01;0.02;1;0.55;0.01;0.01;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.074839921;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1207;ZNF268;ENSG00000090612;HGNC:13061;10795;Zinc finger protein 268 (Zinc finger protein HZF3);Q14587;#N/A;https://platform.opentargets.org/target/ENSG00000090612;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1255;365;834;239;182;5_None;34;4.74;0.01;0.02;24;0.89;0.01;0.01;10;3.86;0.02;0.03;#N/A;#N/A;#N/A;#N/A;4;0.5;0.25;0.13;Osteoarthritis;#N/A;#N/A;0.001478319;#N/A;#N/A;0.014567606;#N/A;#N/A;#N/A;#N/A;#N/A;0.352273992;#N/A;#N/A;#N/A;0.130108162;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1174;ZNF219;ENSG00000165804;HGNC:13011;51222;Zinc finger protein 219;Q9P2Y4;#N/A;https://platform.opentargets.org/target/ENSG00000165804;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2526;950;835;1253;438;5_None;100;4.74;0.03;0.02;94;3.21;0.04;0.04;6;1.53;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.01;0.25;0;Parkinson Disease;#N/A;#N/A;0.001478319;#N/A;#N/A;0.001478319;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1112;ZKSCAN5;ENSG00000196652;HGNC:12867;23660;Zinc finger protein with KRAB and SCAN domains 5 (Zinc finger protein 95 homolog) (Zfp-95);Q9Y2L8;https://jaspar.elixir.no/search?q=Q9Y2L8;https://platform.opentargets.org/target/ENSG00000196652;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3352;1419;836;1348;1168;5_None;50;4.72;0.02;0.02;44;3.19;0.02;0.04;6;1.53;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1481;ZNF680;ENSG00000173041;HGNC:26897;340252;Zinc finger protein 680;Q8NEM1;https://jaspar.elixir.no/search?q=Q8NEM1;https://platform.opentargets.org/target/ENSG00000173041;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1689;553;837;414;438;5_None;25;4.72;0.01;0.02;12;0.73;0;0.01;12;3.47;0.02;0.02;1;0.51;0.01;0.01;2;0.24;0.13;0.06;Alzheimer Disease;#N/A;#N/A;0.238541959;#N/A;#N/A;0.002936107;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0491;LHX6;ENSG00000106852;HGNC:21735;26468;LIM/homeobox protein Lhx6 (LIM homeobox protein 6) (LIM/homeobox protein Lhx6.1);Q9UPM6;https://jaspar.elixir.no/search?q=Q9UPM6;https://platform.opentargets.org/target/ENSG00000106852;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2184;785;838;178;1168;5_None;121;4.72;0.04;0.02;115;3;0.05;0.04;6;1.71;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.6;0.19;0.15;Alzheimer Disease;#N/A;#N/A;0.276739753;#N/A;#N/A;0.042686355;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.275815804;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0799;SALL3;ENSG00000256463;HGNC:10527;27164;Sal-like protein 3 (Zinc finger protein 796) (Zinc finger protein SALL3) (hSALL3);Q9BXA9;#N/A;https://platform.opentargets.org/target/ENSG00000256463;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2360;870;839;1083;438;5_None;79;4.69;0.03;0.02;69;1.1;0.03;0.01;9;3.07;0.02;0.02;1;0.52;0.01;0.01;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.008711621;#N/A;#N/A;0.01025544;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0831;SMAD5;ENSG00000113658;HGNC:6771;4090;Mothers against decapentaplegic homolog 5 (MAD homolog 5) (Mothers against DPP homolog 5) (JV5-1) (SMAD family member 5) (SMAD 5) (Smad5) (hSmad5);Q99717;https://jaspar.elixir.no/search?q=Q99717;https://platform.opentargets.org/target/ENSG00000113658;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.1 SMAD/NF-1 DNA-binding domain factors;7.1.1 SMAD;1658;537;840;735;83;5_None;200;4.68;0.06;0.02;196;3.63;0.08;0.05;4;1.05;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.08;0.5;0.02;Cancer;0.004434958;#N/A;0.001847899;0.001478319;#N/A;0.022625858;0.009609076;#N/A;#N/A;#N/A;#N/A;#N/A;0.016355789;0.020696472;#N/A;0.006344454;3;0.2;Y;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;Induces;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1455;ZNF645;ENSG00000175809;HGNC:26371;158506;E3 ubiquitin-protein ligase CBLL2 (EC 2.3.2.27) (Cbl proto-oncogene-like protein 2) (RING-type E3 ubiquitin transferase ZNF645) (Zinc finger protein 645) (c-Cbl-like protein 2);Q8N7E2;#N/A;https://platform.opentargets.org/target/ENSG00000175809;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2494;933;841;485;1168;5_None;537;4.67;0.17;0.02;534;3.47;0.21;0.05;3;1.19;0.01;0.01;#N/A;#N/A;#N/A;#N/A;14;0.18;0.88;0.05;Cancer;#N/A;#N/A;0.01746032;0.017193408;0.002217479;0.04247805;0.003128699;0.008332987;0.024873751;0.006156789;0.009015683;0.016416308;0.005153586;0.014846653;0.005814278;0.00678309;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1190;ZNF236;ENSG00000130856;HGNC:13028;7776;Zinc finger protein 236;Q9UL36;#N/A;https://platform.opentargets.org/target/ENSG00000130856;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1655;533;842;375;438;5_None;64;4.67;0.02;0.02;57;2.44;0.02;0.03;7;2.22;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.28;0.13;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005030392;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.278616754;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0901;TBX10;ENSG00000167800;HGNC:11593;347853;T-box transcription factor TBX10 (T-box protein 10);O75333;#N/A;https://platform.opentargets.org/target/ENSG00000167800;6 Immunoglobulin fold;6.5 T-Box factors;6.5.3 TBX1-related;3480;1461;843;1469;1168;5_None;118;4.65;0.04;0.02;118;4.65;0.05;0.06;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1354;ZNF513;ENSG00000163795;HGNC:26498;130557;Zinc finger protein 513;Q8N8E2;#N/A;https://platform.opentargets.org/target/ENSG00000163795;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2678;1033;844;1396;438;5_None;136;4.65;0.04;0.02;133;3.16;0.05;0.04;2;0.89;0;0.01;1;0.6;0.01;0.01;2;0;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0479;L3MBTL4;ENSG00000154655;HGNC:26677;91133;Lethal(3)malignant brain tumor-like protein 4 (H-l(3)mbt-like protein 4) (L(3)mbt-like protein 4) (L3mbt-like 4);Q8NA19;#N/A;https://platform.opentargets.org/target/ENSG00000154655;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2246;812;845;233;1168;5_None;57;4.65;0.02;0.02;43;0.95;0.02;0.01;14;3.7;0.03;0.02;#N/A;#N/A;#N/A;#N/A;3;0.5;0.19;0.13;Alzheimer Disease;#N/A;#N/A;0.249711896;#N/A;#N/A;0.004784006;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.249711896;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0551;MXD1;ENSG00000059728;HGNC:6761;4084;Max dimerization protein 1 (Max dimerizer 1) (Protein MAD);Q05195;#N/A;https://platform.opentargets.org/target/ENSG00000059728;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1679;548;846;802;31;5_None;206;4.65;0.07;0.02;202;3.03;0.08;0.04;4;1.62;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.07;0.5;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.010633223;0.002217479;#N/A;0.018538072;0.02457706;0.002217479;#N/A;0.002217479;0.001478319;#N/A;#N/A;0.004250168;#N/A;#N/A;5;0.33;Y;#N/A;Unclear;Unclear;#N/A;#N/A;#N/A;#N/A;functional;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;4;Unclear;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1404;ZNF574;ENSG00000105732;HGNC:26166;64763;Zinc finger protein 574;Q6ZN55;https://jaspar.elixir.no/search?q=Q6ZN55;https://platform.opentargets.org/target/ENSG00000105732;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2178;778;847;893;438;5_None;31;4.65;0.01;0.02;19;0.62;0.01;0.01;11;3.51;0.02;0.02;1;0.52;0.01;0.01;1;0.05;0.06;0.01;Alzheimer Disease;#N/A;#N/A;0.046974501;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0015;AKAP8L;ENSG00000011243;HGNC:29857;26993;A-kinase anchor protein 8-like (AKAP8-like protein) (Helicase A-binding protein 95) (HAP95) (Homologous to AKAP95 protein) (HA95) (Neighbor of A-kinase-anchoring protein 95) (Neighbor of AKAP95);Q9ULX6;#N/A;https://platform.opentargets.org/target/ENSG00000011243;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1410;436;848;124;438;5_None;71;4.63;0.02;0.02;63;2.05;0.02;0.03;8;2.58;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.74;0.25;0.19;Alzheimer Disease;#N/A;#N/A;0.327247013;#N/A;#N/A;0.078741953;0.011826555;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.326877433;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1639;ZXDA;ENSG00000198205;HGNC:13198;7789;Zinc finger X-linked protein ZXDA;P98168;#N/A;https://platform.opentargets.org/target/ENSG00000198205;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1645;530;849;614;182;5_None;23;4.63;0.01;0.02;12;0.94;0;0.01;11;3.69;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.12;0.13;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.116365545;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0812;SGSM2;ENSG00000141258;HGNC:29026;9905;Small G protein signaling modulator 2 (RUN and TBC1 domain-containing protein 1);O43147;#N/A;https://platform.opentargets.org/target/ENSG00000141258;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;2213;798;850;925;438;5_None;47;4.62;0.02;0.02;36;1.28;0.01;0.02;11;3.35;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.029176276;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.010533026;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0088;CC2D1A;ENSG00000132024;HGNC:30237;54862;Coiled-coil and C2 domain-containing protein 1A (Akt kinase-interacting protein 1) (Five prime repressor element under dual repression-binding protein 1) (FRE under dual repression-binding protein 1) (Freud-1) (Putative NF-kappa-B-activating protein 023N);Q6P1N0;#N/A;https://platform.opentargets.org/target/ENSG00000132024;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2332;855;851;313;1168;5_None;61;4.62;0.02;0.02;52;1.51;0.02;0.02;8;2.48;0.02;0.02;1;0.63;0.01;0.01;3;0.37;0.19;0.09;Alzheimer Disease;#N/A;#N/A;0.185432452;#N/A;#N/A;0.003326219;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.182573702;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0385;HOXB2;ENSG00000173917;HGNC:5113;3212;Homeobox protein Hox-B2 (Homeobox protein Hox-2.8) (Homeobox protein Hox-2H) (K8);P14652;https://jaspar.elixir.no/search?q=P14652;https://platform.opentargets.org/target/ENSG00000173917;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1848;620;852;558;438;3_Medium to Low;276;4.62;0.09;0.02;274;4.12;0.11;0.06;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;7;0.14;0.44;0.04;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.004691611;#N/A;#N/A;0.024761002;0.057322246;0.007945967;#N/A;#N/A;0.023468321;#N/A;#N/A;#N/A;0.004434958;0.017739833;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0221;ETV7;ENSG00000010030;HGNC:18160;51513;Transcription factor ETV7 (ETS translocation variant 7) (ETS-related protein Tel2) (Tel-related Ets factor) (Transcription factor Tel-2);Q9Y603;https://jaspar.elixir.no/search?q=Q9Y603;https://platform.opentargets.org/target/ENSG00000010030;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;1720;566;853;685;182;5_None;99;4.61;0.03;0.02;90;1.41;0.04;0.02;9;3.2;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.1;0.13;0.02;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;0.039004188;#N/A;#N/A;#N/A;#N/A;#N/A;0.056358273;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1293;ZNF420;ENSG00000197050;HGNC:20649;147923;Zinc finger protein 420;Q8TAQ5;#N/A;https://platform.opentargets.org/target/ENSG00000197050;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2512;945;854;1220;438;5_None;39;4.57;0.01;0.02;26;1.39;0.01;0.02;13;3.18;0.03;0.02;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0297;GBX1;ENSG00000164900;HGNC:4185;2636;Homeobox protein GBX-1 (Gastrulation and brain-specific homeobox protein 1);Q14549;https://jaspar.elixir.no/search?q=Q14549;https://platform.opentargets.org/target/ENSG00000164900;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;3436;1443;855;1413;1168;3_Medium to Low;119;4.55;0.04;0.02;118;4.31;0.05;0.06;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0697;PHOX2A;ENSG00000165462;HGNC:691;401;Paired mesoderm homeobox protein 2A (ARIX1 homeodomain protein) (Aristaless homeobox protein homolog) (Paired-like homeobox 2A);O14813;https://jaspar.elixir.no/search?q=O14813;https://platform.opentargets.org/target/ENSG00000165462;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1479;457;856;185;438;3_Medium to Low;95;4.53;0.03;0.02;88;2.12;0.03;0.03;6;1.81;0.01;0.01;1;0.6;0.01;0.01;5;0.58;0.31;0.15;Alzheimer Disease;#N/A;#N/A;0.254299753;#N/A;#N/A;0.003675266;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.253745383;#N/A;0.06002716;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0037;ASCL2;ENSG00000183734;HGNC:739;430;Achaete-scute homolog 2 (ASH-2) (hASH2) (Class A basic helix-loop-helix protein 45) (bHLHa45) (Mash2);Q99929;#N/A;https://platform.opentargets.org/target/ENSG00000183734;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;2424;902;857;399;1168;5_None;125;4.53;0.04;0.02;117;1.94;0.05;0.03;8;2.59;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.26;0.25;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;0.003695799;#N/A;#N/A;0.047227767;0.059502357;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.145584743;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0627;NME2;ENSG00000243678;HGNC:7850;4831;Nucleoside diphosphate kinase B (NDK B) (NDP kinase B) (EC 2.7.4.6) (C-myc purine-binding transcription factor PUF) (Histidine protein kinase NDKB) (EC 2.7.13.3) (nm23-H2);P22392;#N/A;https://platform.opentargets.org/target/ENSG00000243678;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1669;541;858;629;182;4_Low;167;4.52;0.05;0.02;162;2.69;0.06;0.04;4;1.3;0.01;0.01;1;0.53;0.01;0.01;7;0.11;0.44;0.03;Cancer;#N/A;#N/A;0.008713461;0.015594217;0.010348236;0.058946609;#N/A;0.007206807;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;0.005913278;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1031;ZBTB17;ENSG00000116809;HGNC:12936;7709;Zinc finger and BTB domain-containing protein 17 (Myc-interacting zinc finger protein 1) (Miz-1) (Zinc finger protein 151) (Zinc finger protein 60);Q13105;https://jaspar.elixir.no/search?q=Q13105;https://platform.opentargets.org/target/ENSG00000116809;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1528;481;859;231;438;5_None;100;4.5;0.03;0.02;92;2.12;0.04;0.03;8;2.39;0.02;0.02;#N/A;#N/A;#N/A;#N/A;6;0.51;0.38;0.13;Heart Failure;#N/A;#N/A;0.090177485;0.012565715;#N/A;0.011243792;0.078966896;0.31212559;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0286;FOXR2;ENSG00000189299;HGNC:30469;139628;Forkhead box protein R2 (Forkhead box protein N6);Q6PJQ5;#N/A;https://platform.opentargets.org/target/ENSG00000189299;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2355;866;860;327;1168;5_None;76;4.5;0.02;0.02;68;2.44;0.03;0.03;8;2.06;0.02;0.01;#N/A;#N/A;#N/A;#N/A;3;0.35;0.19;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.092338895;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.252614607;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1093;ZFX;ENSG00000005889;HGNC:12869;7543;Zinc finger X-chromosomal protein;P17010;#N/A;https://platform.opentargets.org/target/ENSG00000005889;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1754;586;861;455;438;5_None;155;4.49;0.05;0.02;152;3.66;0.06;0.05;3;0.83;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.2;0.25;0.05;Osteoarthritis;#N/A;#N/A;0.004229636;#N/A;0.005358908;0.042758055;#N/A;#N/A;#N/A;#N/A;#N/A;0.150430893;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0592;NFATC4;ENSG00000100968;HGNC:7778;4776;Nuclear factor of activated T-cells, cytoplasmic 4 (NF-ATc4) (NFATc4) (T-cell transcription factor NFAT3) (NF-AT3);Q14934;https://jaspar.elixir.no/search?q=Q14934;https://platform.opentargets.org/target/ENSG00000100968;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.3 NFAT-related;1871;632;862;571;438;5_None;157;4.49;0.05;0.02;151;2.62;0.06;0.04;6;1.86;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.14;0.5;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.023130633;#N/A;#N/A;0.037921981;#N/A;0.002843712;#N/A;0.001478319;#N/A;0.007945967;0.005174118;0.003695799;#N/A;0.052986048;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0795;SAFB;ENSG00000160633;HGNC:10520;6294;Scaffold attachment factor B1 (SAF-B) (SAF-B1) (HSP27 estrogen response element-TATA box-binding protein) (HSP27 ERE-TATA-binding protein);Q15424;#N/A;https://platform.opentargets.org/target/ENSG00000160633;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2181;782;863;880;438;5_None;215;4.49;0.07;0.02;214;3.95;0.08;0.05;#N/A;#N/A;#N/A;#N/A;1;0.54;0.01;0.01;6;0.05;0.38;0.01;Cancer;#N/A;#N/A;0.008849384;#N/A;#N/A;0.015527678;0.008315547;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;0.008869917;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0507;MAFK;ENSG00000198517;HGNC:6782;7975;Transcription factor MafK (Erythroid transcription factor NF-E2 p18 subunit);O60675;https://jaspar.elixir.no/search?q=O60675;https://platform.opentargets.org/target/ENSG00000198517;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;2041;713;864;739;438;4_Low;237;4.48;0.08;0.02;234;3.54;0.09;0.05;3;0.94;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.08;0.5;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.004866135;0.001478319;0.002217479;0.023717352;#N/A;0.003695799;#N/A;0.002217479;0.003695799;#N/A;#N/A;#N/A;#N/A;0.041076813;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0387;HOXB4;ENSG00000182742;HGNC:5115;3214;Homeobox protein Hox-B4 (Homeobox protein Hox-2.6) (Homeobox protein Hox-2F);P17483;https://jaspar.elixir.no/search?q=P17483;https://platform.opentargets.org/target/ENSG00000182742;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;1990;686;865;687;438;3_Medium to Low;164;4.48;0.05;0.02;161;3.67;0.06;0.05;3;0.81;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.029639687;0.064306895;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1127;ZNF131;ENSG00000172262;HGNC:12915;7690;Zinc finger protein 131;P52739;#N/A;https://platform.opentargets.org/target/ENSG00000172262;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3060;1253;866;1026;1168;5_None;46;4.47;0.01;0.02;37;0.86;0.01;0.01;9;3.61;0.02;0.02;#N/A;#N/A;#N/A;#N/A;5;0.03;0.31;0.01;Cancer;#N/A;0.006652437;0.007391597;#N/A;#N/A;0.007555855;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0904;TBX19;ENSG00000143178;HGNC:11596;9095;T-box transcription factor TBX19 (T-box protein 19) (T-box factor, pituitary);O60806;https://jaspar.elixir.no/search?q=O60806;https://platform.opentargets.org/target/ENSG00000143178;6 Immunoglobulin fold;6.5 T-Box factors;6.5.1 Brachyury-related;2653;1019;867;1348;438;5_None;124;4.46;0.04;0.02;119;2.62;0.05;0.04;4;1.09;0.01;0.01;1;0.74;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0222;EVX1;ENSG00000106038;HGNC:3506;2128;Homeobox even-skipped homolog protein 1 (EVX-1);P49640;https://jaspar.elixir.no/search?q=P49640;https://platform.opentargets.org/target/ENSG00000106038;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2635;1006;868;599;1168;5_None;68;4.45;0.02;0.02;62;2.96;0.02;0.04;6;1.49;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.13;0.13;0.03;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.10851149;0.016535003;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0314;GPBP1;ENSG00000062194;HGNC:29520;65056;Vasculin (GC-rich promoter-binding protein 1) (Vascular wall-linked protein);Q86WP2;#N/A;https://platform.opentargets.org/target/ENSG00000062194;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2040;712;869;733;438;5_None;87;4.44;0.03;0.02;82;2.95;0.03;0.04;5;1.49;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;0.025418821;0.008828852;#N/A;0.040920703;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0519;MEF2B;ENSG00000213999;HGNC:6995;100271849;Myocyte-specific enhancer factor 2B (RSRFR2) (Serum response factor-like protein 2);Q02080;https://jaspar.elixir.no/search?q=Q02080;https://platform.opentargets.org/target/ENSG00000213999;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.1 Regulators of differentiation;3133;1292;870;1095;1168;5_None;87;4.43;0.03;0.02;80;1.96;0.03;0.03;6;1.96;0.01;0.01;1;0.52;0.01;0.01;3;0.02;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008912418;0.007391597;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1421;ZNF592;ENSG00000166716;HGNC:28986;9640;Zinc finger protein 592;Q92610;#N/A;https://platform.opentargets.org/target/ENSG00000166716;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2643;1011;871;604;1168;5_None;64;4.4;0.02;0.02;62;3.79;0.02;0.05;2;0.61;0;0;#N/A;#N/A;#N/A;#N/A;3;0.12;0.19;0.03;Heart Failure;#N/A;#N/A;0.001478319;#N/A;#N/A;0.003695799;#N/A;0.117586016;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0999;USF1;ENSG00000158773;HGNC:12593;7391;Upstream stimulatory factor 1 (Class B basic helix-loop-helix protein 11) (bHLHb11) (Major late transcription factor 1);P22415;https://jaspar.elixir.no/search?q=P22415;https://platform.opentargets.org/target/ENSG00000158773;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1821;614;872;511;438;5_None;166;4.4;0.05;0.02;160;2.59;0.06;0.04;6;1.8;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.17;0.44;0.04;Atherosclerosis;#N/A;#N/A;0.027395007;0.057649774;#N/A;0.029616737;#N/A;#N/A;0.002587059;#N/A;0.021807881;#N/A;#N/A;0.003695799;#N/A;0.02316769;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1517;ZNF717;ENSG00000227124;HGNC:29448;100131827;Zinc finger protein 717 (Krueppel-like factor X17);Q9BY31;#N/A;https://platform.opentargets.org/target/ENSG00000227124;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2259;819;873;1204;182;5_None;55;4.39;0.02;0.02;45;1.06;0.02;0.01;10;3.34;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005228118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0395;HOXC12;ENSG00000123407;HGNC:5124;3228;Homeobox protein Hox-C12 (Homeobox protein Hox-3F);P31275;https://jaspar.elixir.no/search?q=P31275;https://platform.opentargets.org/target/ENSG00000123407;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;3183;1326;874;1141;1168;4_Low;82;4.38;0.03;0.02;73;2.09;0.03;0.03;9;2.28;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.003695799;#N/A;0.001478319;0.008387409;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0714;POU2F3;ENSG00000137709;HGNC:19864;25833;POU domain, class 2, transcription factor 3 (Octamer-binding protein 11) (Oct-11) (Octamer-binding transcription factor 11) (OTF-11) (Transcription factor PLA-1) (Transcription factor Skn-1);Q9UKI9;https://jaspar.elixir.no/search?q=Q9UKI9;https://platform.opentargets.org/target/ENSG00000137709;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;1655;533;875;598;182;5_None;191;4.33;0.06;0.02;184;1.99;0.07;0.03;6;1.83;0.01;0.01;1;0.51;0.01;0.01;8;0.13;0.5;0.03;Myocardial Infarction;#N/A;#N/A;0.004065378;0.003087634;0.003695799;0.028161963;#N/A;0.005174118;0.009108706;0.053117365;#N/A;#N/A;#N/A;#N/A;#N/A;0.019169491;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0311;GLYR1;ENSG00000140632;HGNC:24434;84656;Cytokine-like nuclear factor N-PAC (NPAC) (3-hydroxyisobutyrate dehydrogenase-like protein) (Glyoxylate reductase 1 homolog) (Nuclear protein NP60) (Nuclear protein of 60 kDa) (Nucleosome-destabilizing factor) (hNDF) (Putative oxidoreductase GLYR1);Q49A26;#N/A;https://platform.opentargets.org/target/ENSG00000140632;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2382;882;876;1324;182;5_None;112;4.32;0.04;0.02;111;4;0.04;0.05;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004691611;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0480;LBX1;ENSG00000138136;HGNC:16960;10660;Transcription factor LBX1 (Ladybird homeobox protein homolog 1);P52954;https://jaspar.elixir.no/search?q=P52954;https://platform.opentargets.org/target/ENSG00000138136;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2875;1139;877;830;1168;5_None;300;4.32;0.1;0.02;296;2.91;0.12;0.04;4;1.4;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.06;0.5;0.01;Cancer;#N/A;#N/A;0.004920134;0.003028502;#N/A;0.034708777;#N/A;0.002956639;#N/A;#N/A;#N/A;0.005790084;#N/A;0.001847899;0.002217479;0.003582871;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1461;ZNF654;ENSG00000175105;HGNC:25612;55279;Zinc finger protein 654 (Melanoma-associated antigen);Q8IZM8;#N/A;https://platform.opentargets.org/target/ENSG00000175105;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2568;975;878;522;1168;5_None;113;4.31;0.04;0.02;108;2.91;0.04;0.04;5;1.41;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.16;0.13;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.010607169;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.150073685;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1500;ZNF703;ENSG00000183779;HGNC:25883;80139;Zinc finger protein 703 (Zinc finger elbow-related proline domain protein 1);Q9H7S9;#N/A;https://platform.opentargets.org/target/ENSG00000183779;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2440;913;879;393;1168;5_None;75;4.31;0.02;0.02;67;1.85;0.03;0.03;8;2.46;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.26;0.13;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.0337125;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.227462734;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1268;ZNF37A;ENSG00000075407;HGNC:13102;7587;Zinc finger protein 37A (Zinc finger protein KOX21);P17032;#N/A;https://platform.opentargets.org/target/ENSG00000075407;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3145;1300;880;1097;1168;5_None;36;4.31;0.01;0.02;27;1.39;0.01;0.02;9;2.92;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Alzheimer Disease;#N/A;#N/A;0.009605997;#N/A;#N/A;0.004414426;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1369;ZNF532;ENSG00000074657;HGNC:30940;55205;Zinc finger protein 532;Q9HCE3;#N/A;https://platform.opentargets.org/target/ENSG00000074657;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3444;1446;881;1395;1168;5_None;90;4.3;0.03;0.02;86;2.87;0.03;0.04;3;0.92;0.01;0.01;1;0.51;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003028502;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0389;HOXB6;ENSG00000108511;HGNC:5117;3216;Homeobox protein Hox-B6 (Homeobox protein Hox-2.2) (Homeobox protein Hox-2B) (Homeobox protein Hu-2);P17509;https://jaspar.elixir.no/search?q=P17509;https://platform.opentargets.org/target/ENSG00000108511;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2195;790;882;875;438;3_Medium to Low;132;4.28;0.04;0.02;131;4.04;0.05;0.05;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.032740759;#N/A;#N/A;0.016844381;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0378;HOXA4;ENSG00000197576;HGNC:5105;3201;Homeobox protein Hox-A4 (Homeobox protein Hox-1.4) (Homeobox protein Hox-1D);Q00056;https://jaspar.elixir.no/search?q=Q00056;https://platform.opentargets.org/target/ENSG00000197576;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2891;1152;883;840;1168;3_Medium to Low;163;4.27;0.05;0.02;162;4.04;0.06;0.05;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;6;0.06;0.38;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.004599216;0.002587059;#N/A;0.020638141;0.022913951;#N/A;#N/A;0.004414426;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0673;PA2G4;ENSG00000170515;HGNC:8550;5036;Proliferation-associated protein 2G4 (Cell cycle protein p38-2G4 homolog) (hG4-1) (ErbB3-binding protein 1);Q9UQ80;#N/A;https://platform.opentargets.org/target/ENSG00000170515;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2151;764;884;829;438;5_None;146;4.25;0.05;0.02;145;3.74;0.06;0.05;#N/A;#N/A;#N/A;#N/A;1;0.51;0.01;0.01;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;0.016731291;#N/A;0.007391597;0.033473017;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0145;DLX4;ENSG00000108813;HGNC:2917;1748;Homeobox protein DLX-4 (Beta protein 1) (Homeobox protein DLX-7) (Homeobox protein DLX-8);Q92988;#N/A;https://platform.opentargets.org/target/ENSG00000108813;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2095;735;885;772;438;3_Medium to Low;242;4.23;0.08;0.02;239;3.11;0.09;0.04;3;1.12;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.07;0.44;0.02;Cancer;#N/A;#N/A;0.012287918;0.002771849;#N/A;0.043031193;0.003695799;#N/A;#N/A;#N/A;0.002217479;#N/A;0.002956639;#N/A;#N/A;0.007761177;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;8;7;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1409;ZNF579;ENSG00000218891;HGNC:26646;163033;Zinc finger protein 579;Q8NAF0;#N/A;https://platform.opentargets.org/target/ENSG00000218891;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2221;803;886;167;1168;5_None;34;4.22;0.01;0.02;29;2.53;0.01;0.03;5;1.69;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.62;0.13;0.16;Alzheimer Disease;#N/A;#N/A;0.31095022;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.31095022;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1281;ZNF398;ENSG00000197024;HGNC:18373;57541;Zinc finger protein 398 (Zinc finger DNA-binding protein p52/p71);Q8TD17;#N/A;https://platform.opentargets.org/target/ENSG00000197024;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2237;809;887;912;438;5_None;59;4.22;0.02;0.02;51;1.71;0.02;0.02;8;2.5;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;0.007576387;#N/A;#N/A;0.03490478;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0490;LHX5;ENSG00000089116;HGNC:14216;64211;LIM/homeobox protein Lhx5 (LIM homeobox protein 5);Q9H2C1;https://jaspar.elixir.no/search?q=Q9H2C1;https://platform.opentargets.org/target/ENSG00000089116;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;1777;596;888;451;438;5_None;62;4.2;0.02;0.02;55;2.03;0.02;0.03;7;2.17;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.21;0.19;0.05;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.018478993;#N/A;#N/A;0.010717816;0.177852098;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1513;ZNF711;ENSG00000147180;HGNC:13128;7552;Zinc finger protein 711 (Zinc finger protein 6);Q9Y462;#N/A;https://platform.opentargets.org/target/ENSG00000147180;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2272;828;889;1201;182;5_None;86;4.19;0.03;0.02;82;2.31;0.03;0.03;3;1.1;0.01;0.01;1;0.78;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009958124;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0422;IKZF4;ENSG00000123411;HGNC:13179;64375;Zinc finger protein Eos (Ikaros family zinc finger protein 4);Q9H2S9;#N/A;https://platform.opentargets.org/target/ENSG00000123411;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2142;756;890;814;438;5_None;131;4.19;0.04;0.02;129;3.65;0.05;0.05;2;0.53;0;0;#N/A;#N/A;#N/A;#N/A;3;0.06;0.19;0.02;Alzheimer Disease;#N/A;#N/A;0.054101227;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1152;ZNF18;ENSG00000154957;HGNC:12969;7566;Zinc finger protein 18 (Heart development-specific gene 1 protein) (Zinc finger protein 535) (Zinc finger protein KOX11) (Zinc finger protein with KRAB and SCAN domains 6);P17022;#N/A;https://platform.opentargets.org/target/ENSG00000154957;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2540;958;891;1211;438;5_None;41;4.19;0.01;0.02;33;1.96;0.01;0.03;8;2.23;0.02;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009424286;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0070;BHLHA15;ENSG00000180535;HGNC:22265;168620;Class A basic helix-loop-helix protein 15 (bHLHa15) (Class B basic helix-loop-helix protein 8) (bHLHb8) (Muscle, intestine and stomach expression 1) (MIST-1);Q7RTS1;https://jaspar.elixir.no/search?q=Q7RTS1;https://platform.opentargets.org/target/ENSG00000180535;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2946;1186;892;886;1168;5_None;143;4.17;0.05;0.02;142;3.81;0.06;0.05;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.04278881;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0021;ANKZF1;ENSG00000163516;HGNC:25527;55139;Ankyrin repeat and zinc finger domain-containing protein 1 (Zinc finger protein 744);Q9H8Y5;#N/A;https://platform.opentargets.org/target/ENSG00000163516;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2280;832;893;219;1168;5_None;63;4.16;0.02;0.02;56;1.9;0.02;0.03;6;1.72;0.01;0.01;1;0.54;0.01;0.01;5;0.53;0.31;0.14;Alzheimer Disease;#N/A;#N/A;0.240278287;#N/A;#N/A;0.02049397;0.013120085;#N/A;#N/A;#N/A;#N/A;0.025293458;#N/A;0.23349239;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1535;ZNF750;ENSG00000141579;HGNC:25843;79755;Zinc finger protein 750;Q32MQ0;#N/A;https://platform.opentargets.org/target/ENSG00000141579;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2331;854;894;999;438;5_None;84;4.14;0.03;0.02;78;1.71;0.03;0.02;5;1.79;0.01;0.01;1;0.64;0.01;0.01;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.02871354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0972;TIGD2;ENSG00000180346;HGNC:18333;166815;Tigger transposable element-derived protein 2;Q4W5G0;#N/A;https://platform.opentargets.org/target/ENSG00000180346;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2397;890;895;1064;438;5_None;32;4.14;0.01;0.02;21;0.82;0.01;0.01;11;3.32;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.020523932;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0338;HES4;ENSG00000188290;HGNC:24149;57801;Transcription factor HES-4 (hHES4) (Class B basic helix-loop-helix protein 42) (bHLHb42) (Hairy and enhancer of split 4) (bHLH factor Hes4);Q9HCC6;#N/A;https://platform.opentargets.org/target/ENSG00000188290;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;1467;449;896;133;438;5_None;68;4.14;0.02;0.02;57;0.76;0.02;0.01;11;3.38;0.02;0.02;#N/A;#N/A;#N/A;#N/A;5;0.7;0.31;0.18;Alzheimer Disease;#N/A;#N/A;0.338075304;#N/A;0.003695799;0.015174218;0.014824259;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.332162026;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0566;MYPOP;ENSG00000176182;HGNC:20178;339344;Myb-related transcription factor, partner of profilin (Myb-related protein p42POP) (Partner of profilin);Q86VE0;#N/A;https://platform.opentargets.org/target/ENSG00000176182;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;2625;1001;897;560;1168;5_None;40;4.11;0.01;0.02;35;2.35;0.01;0.03;4;1.22;0.01;0.01;1;0.55;0.01;0.01;2;0.14;0.13;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.017739833;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.121936005;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1089;ZFP91;ENSG00000186660;HGNC:14983;80829;E3 ubiquitin-protein ligase ZFP91 (EC 2.3.2.27) (RING-type E3 ubiquitin transferase ZFP91) (Zinc finger protein 757) (Zinc finger protein 91 homolog) (Zfp-91);Q96JP5;#N/A;https://platform.opentargets.org/target/ENSG00000186660;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1761;588;898;425;438;5_None;81;4.11;0.03;0.02;76;2.74;0.03;0.04;5;1.38;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.23;0.31;0.06;Heart Failure;#N/A;#N/A;0.059446804;#N/A;0.027492635;0.034330032;#N/A;0.109875363;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1155;ZNF182;ENSG00000147118;HGNC:13001;7569;Zinc finger protein 182 (Zinc finger protein 21) (Zinc finger protein KOX14);P17025;#N/A;https://platform.opentargets.org/target/ENSG00000147118;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2806;1087;899;1469;438;5_None;93;4.08;0.03;0.02;93;4.08;0.04;0.06;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1433;ZNF609;ENSG00000180357;HGNC:29003;23060;Zinc finger protein 609;O15014;#N/A;https://platform.opentargets.org/target/ENSG00000180357;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3073;1267;900;1005;1168;5_None;81;4.07;0.03;0.02;75;2.23;0.03;0.03;6;1.84;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;#N/A;0.001478319;#N/A;0.021783727;#N/A;#N/A;#N/A;0.004134777;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1583;ZNF821;ENSG00000102984;HGNC:28043;55565;Zinc finger protein 821;O75541;#N/A;https://platform.opentargets.org/target/ENSG00000102984;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2273;829;901;934;438;5_None;76;4.06;0.02;0.01;76;4.06;0.03;0.06;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Alzheimer Disease;#N/A;#N/A;0.038056011;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1037;ZBTB24;ENSG00000112365;HGNC:21143;9841;Zinc finger and BTB domain-containing protein 24 (Zinc finger protein 450);O43167;https://jaspar.elixir.no/search?q=O43167;https://platform.opentargets.org/target/ENSG00000112365;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2081;732;902;741;438;5_None;124;4.06;0.04;0.01;122;2.9;0.05;0.04;1;0.37;0;0;1;0.78;0.01;0.01;6;0.08;0.38;0.02;Alzheimer Disease;#N/A;#N/A;0.028356676;#N/A;0.012196135;0.014436572;#N/A;#N/A;0.007371065;0.018478993;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0586;NEUROG2;ENSG00000178403;HGNC:13805;63973;Neurogenin-2 (NGN-2) (Class A basic helix-loop-helix protein 8) (bHLHa8) (Protein atonal homolog 4);Q9H2A3;https://jaspar.elixir.no/search?q=Q9H2A3;https://platform.opentargets.org/target/ENSG00000178403;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2199;793;903;858;438;5_None;113;4.05;0.04;0.01;105;1.6;0.04;0.02;8;2.45;0.02;0.02;#N/A;#N/A;#N/A;#N/A;4;0.05;0.25;0.01;Parkinson Disease;#N/A;#N/A;0.019899847;#N/A;#N/A;0.002012157;#N/A;#N/A;0.006282858;#N/A;#N/A;#N/A;#N/A;0.024217609;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0667;OTP;ENSG00000171540;HGNC:8518;23440;Homeobox protein orthopedia;Q5XKR4;#N/A;https://platform.opentargets.org/target/ENSG00000171540;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2080;731;904;738;438;5_None;129;4.03;0.04;0.01;128;3.55;0.05;0.05;1;0.48;0;0;#N/A;#N/A;#N/A;#N/A;3;0.08;0.19;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.021120051;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.058502643;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0263;FOXI3;ENSG00000214336;HGNC:35123;344167;Forkhead box protein I3;A8MTJ6;#N/A;https://platform.opentargets.org/target/ENSG00000214336;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2991;1214;905;918;1168;5_None;68;4.01;0.02;0.01;63;2.53;0.02;0.03;5;1.48;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;0.004434958;#N/A;#N/A;0.037471291;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0847;SOX13;ENSG00000143842;HGNC:11192;9580;Transcription factor SOX-13 (Islet cell antigen 12) (SRY (Sex determining region Y)-box 13) (Type 1 diabetes autoantigen ICA12);Q9UN79;https://jaspar.elixir.no/search?q=Q9UN79;https://platform.opentargets.org/target/ENSG00000143842;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;1968;677;906;624;438;5_None;131;4;0.04;0.01;129;3.23;0.05;0.04;2;0.77;0;0.01;#N/A;#N/A;#N/A;#N/A;5;0.12;0.31;0.03;Alzheimer Disease;#N/A;#N/A;0.072437652;0.005913278;#N/A;0.029058725;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;0.005790084;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1104;ZIC5;ENSG00000139800;HGNC:20322;85416;Zinc finger protein ZIC 5 (Zinc finger protein of the cerebellum 5);Q96T25;https://jaspar.elixir.no/search?q=Q96T25;https://platform.opentargets.org/target/ENSG00000139800;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2148;760;907;803;438;5_None;82;3.98;0.03;0.01;75;1.94;0.03;0.03;7;2.04;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.07;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.05472528;0.011087396;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0884;SRF;ENSG00000112658;HGNC:11291;6722;Serum response factor (SRF);P11831;https://jaspar.elixir.no/search?q=P11831;https://platform.opentargets.org/target/ENSG00000112658;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.2 Responders to external signals;1375;413;908;384;83;5_None;342;3.97;0.11;0.01;341;3.43;0.13;0.05;#N/A;#N/A;#N/A;#N/A;1;0.55;0.01;0.01;14;0.27;0.88;0.07;Cancer;#N/A;0.021311068;0.011879813;0.006131295;#N/A;0.102688022;0.022531013;0.011596799;0.006447115;0.037628431;0.010989868;0.003695799;0.002956639;0.01736512;0.007088324;0.010232845;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;Pro-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0626;NKX6-3;ENSG00000165066;HGNC:26328;157848;Homeobox protein Nkx-6.3;A6NJ46;https://jaspar.elixir.no/search?q=A6NJ46;https://platform.opentargets.org/target/ENSG00000165066;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2300;838;909;223;1168;5_None;57;3.96;0.02;0.01;51;1.79;0.02;0.02;6;2.17;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.52;0.19;0.13;Type 2 Diabetes Mellitus;#N/A;#N/A;0.011087396;#N/A;#N/A;0.018594997;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.490377588;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1278;ZNF395;ENSG00000186918;HGNC:18737;55893;Zinc finger protein 395 (HD-regulating factor 2) (HDRF-2) (Huntington disease gene regulatory region-binding protein 2) (HD gene regulatory region-binding protein 2) (HDBP-2) (Papillomavirus regulatory factor 1) (PRF-1) (Papillomavirus-binding factor);Q9H8N7;#N/A;https://platform.opentargets.org/target/ENSG00000186918;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2167;772;910;819;438;5_None;117;3.95;0.04;0.01;111;2.27;0.04;0.03;6;1.68;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.06;0.19;0.02;Cancer;#N/A;#N/A;0.011087396;#N/A;#N/A;0.047094533;#N/A;#N/A;#N/A;#N/A;#N/A;0.003042402;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0351;HINFP;ENSG00000172273;HGNC:17850;25988;Histone H4 transcription factor (Histone nuclear factor P) (HiNF-P) (MBD2-interacting zinc finger protein) (Methyl-CpG-binding protein 2-interacting zinc finger protein);Q9BQA5;https://jaspar.elixir.no/search?q=Q9BQA5;https://platform.opentargets.org/target/ENSG00000172273;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1467;449;911;118;438;5_None;44;3.92;0.01;0.01;38;1.71;0.01;0.02;5;1.69;0.01;0.01;1;0.53;0.01;0.01;5;0.76;0.31;0.19;Alzheimer Disease;#N/A;0.006652437;0.372716144;#N/A;#N/A;0.004506821;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.372381828;#N/A;0.003490476;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1065;ZBTB9;ENSG00000213588;HGNC:28323;221504;Zinc finger and BTB domain-containing protein 9;Q96C00;#N/A;https://platform.opentargets.org/target/ENSG00000213588;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2219;801;912;139;1168;5_None;43;3.91;0.01;0.01;38;2.24;0.01;0.03;5;1.67;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.69;0.31;0.17;Alzheimer Disease;#N/A;#N/A;0.31941739;#N/A;#N/A;0.032523027;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.31941739;#N/A;0.012627312;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1440;ZNF618;ENSG00000157657;HGNC:29416;114991;Zinc finger protein 618;Q5T7W0;#N/A;https://platform.opentargets.org/target/ENSG00000157657;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2744;1068;913;1393;438;5_None;31;3.91;0.01;0.01;22;1.02;0.01;0.01;9;2.89;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Cancer;#N/A;#N/A;0.001391072;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0446;JRK;ENSG00000234616;HGNC:6199;8629;Jerky protein homolog;O75564;#N/A;https://platform.opentargets.org/target/ENSG00000234616;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2518;947;914;1166;438;5_None;46;3.9;0.01;0.01;39;1.82;0.02;0.02;7;2.08;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009806801;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0322;GSX2;ENSG00000180613;HGNC:24959;170825;GS homeobox 2 (Genetic-screened homeobox 2) (Homeobox protein GSH-2);Q9BZM3;https://jaspar.elixir.no/search?q=Q9BZM3;https://platform.opentargets.org/target/ENSG00000180613;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2766;1074;915;1413;438;5_None;34;3.9;0.01;0.01;26;0.8;0.01;0.01;6;1.97;0.01;0.01;2;1.13;0.02;0.02;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0231;FIGLA;ENSG00000183733;HGNC:24669;344018;Factor in the germline alpha (FIGalpha) (Class C basic helix-loop-helix protein 8) (bHLHc8) (Folliculogenesis-specific basic helix-loop-helix protein) (Transcription factor FIGa);Q6QHK4;https://jaspar.elixir.no/search?q=Q6QHK4;https://platform.opentargets.org/target/ENSG00000183733;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3506;1469;916;1422;1168;5_None;50;3.89;0.02;0.01;42;1.28;0.02;0.02;7;1.98;0.01;0.01;1;0.63;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0738;PRDM4;ENSG00000110851;HGNC:9348;11108;PR domain zinc finger protein 4 (EC 2.1.1.-) (PR domain-containing protein 4);Q9UKN5;https://jaspar.elixir.no/search?q=Q9UKN5;https://platform.opentargets.org/target/ENSG00000110851;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2511;943;917;1156;438;5_None;46;3.86;0.01;0.01;39;1.86;0.02;0.03;7;2.01;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.012617046;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0553;MXD4;ENSG00000123933;HGNC:13906;10608;Max dimerization protein 4 (Max dimerizer 4) (Class C basic helix-loop-helix protein 12) (bHLHc12) (Max-associated protein 4) (Max-interacting transcriptional repressor MAD4);Q14582;#N/A;https://platform.opentargets.org/target/ENSG00000123933;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;2037;710;918;1088;31;5_None;81;3.86;0.03;0.01;76;2;0.03;0.03;5;1.86;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.013551261;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;5;0.33;Y;#N/A;Anti-Longevity;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;Unclear;#N/A;Induces;#N/A;Anti-Longevity;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1184;ZNF23;ENSG00000167377;HGNC:13023;7571;Zinc finger protein 23 (Zinc finger protein 359) (Zinc finger protein 612) (Zinc finger protein KOX16);P17027;#N/A;https://platform.opentargets.org/target/ENSG00000167377;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2277;831;919;1176;182;5_None;55;3.85;0.02;0.01;51;2.3;0.02;0.03;4;1.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011300177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1038;ZBTB25;ENSG00000089775;HGNC:13112;7597;Zinc finger and BTB domain-containing protein 25 (Zinc finger protein 46) (Zinc finger protein KUP);P24278;#N/A;https://platform.opentargets.org/target/ENSG00000089775;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3557;1490;920;1469;1168;5_None;37;3.84;0.01;0.01;29;1.56;0.01;0.02;8;2.29;0.02;0.02;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0503;MAFA;ENSG00000182759;HGNC:23145;389692;Transcription factor MafA (Pancreatic beta-cell-specific transcriptional activator) (RIPE3b1 factor) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A);Q8NHW3;https://jaspar.elixir.no/search?q=Q8NHW3;https://platform.opentargets.org/target/ENSG00000182759;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;2150;763;921;791;438;5_None;121;3.84;0.04;0.01;120;3.28;0.05;0.04;#N/A;#N/A;#N/A;#N/A;1;0.56;0.01;0.01;2;0.07;0.13;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.009072775;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.059949224;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1618;ZSCAN10;ENSG00000130182;HGNC:12997;84891;Zinc finger and SCAN domain-containing protein 10 (Zinc finger protein 206);Q96SZ4;#N/A;https://platform.opentargets.org/target/ENSG00000130182;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2780;1077;922;690;1168;5_None;65;3.84;0.02;0.01;62;2.56;0.02;0.03;3;1.28;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Age-Related Macular Degeneration;#N/A;0.091096521;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0477;L3MBTL1;ENSG00000185513;HGNC:15905;26013;Lethal(3)malignant brain tumor-like protein 1 (H-l(3)mbt) (H-l(3)mbt protein) (L(3)mbt-like) (L(3)mbt protein homolog) (L3MBTL1);Q9Y468;#N/A;https://platform.opentargets.org/target/ENSG00000185513;2 Zinc-coordinating DNA-binding domains;2.7 C2HC;2.7.4 L3MBTL2;1704;562;923;343;438;4_Low;52;3.84;0.02;0.01;45;1.86;0.02;0.03;7;1.97;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.33;0.13;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.007533565;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.31865729;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;55;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1066;ZC3H8;ENSG00000144161;HGNC:30941;84524;Zinc finger CCCH domain-containing protein 8;Q8N5P1;#N/A;https://platform.opentargets.org/target/ENSG00000144161;2 Zinc-coordinating DNA-binding domains;2.8 C3H zinc finger factors;2.8.1 ZC3H9;2215;799;924;123;1168;5_None;56;3.82;0.02;0.01;50;1.39;0.02;0.02;5;1.88;0.01;0.01;1;0.55;0.01;0.01;3;0.75;0.19;0.19;Alzheimer Disease;#N/A;#N/A;0.369579855;#N/A;#N/A;0.006098068;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.369579855;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1142;ZNF155;ENSG00000204920;HGNC:12940;7711;Zinc finger protein 155;Q12901;#N/A;https://platform.opentargets.org/target/ENSG00000204920;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2832;1105;925;1469;438;5_None;24;3.79;0.01;0.01;20;2.87;0.01;0.04;4;0.92;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1234;ZNF316;ENSG00000205903;HGNC:13843;100131017;Zinc finger protein 316;A6NFI3;#N/A;https://platform.opentargets.org/target/ENSG00000205903;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2833;1106;926;1469;438;5_None;18;3.79;0.01;0.01;10;0.69;0;0.01;6;2.04;0.01;0.01;2;1.05;0.02;0.02;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0194;ELF5;ENSG00000135374;HGNC:3320;2001;ETS-related transcription factor Elf-5 (E74-like factor 5) (Epithelium-restricted ESE-1-related Ets factor) (Epithelium-specific Ets transcription factor 2) (ESE-2);Q9UKW6;https://jaspar.elixir.no/search?q=Q9UKW6;https://platform.opentargets.org/target/ENSG00000135374;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2024;702;927;659;438;3_Medium to Low;108;3.76;0.03;0.01;102;1.57;0.04;0.02;5;1.68;0.01;0.01;1;0.5;0.01;0.01;4;0.1;0.25;0.03;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.076894508;0.005174118;#N/A;#N/A;0.013489665;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1550;ZNF774;ENSG00000196391;HGNC:33108;342132;Zinc finger protein 774;Q6NX45;#N/A;https://platform.opentargets.org/target/ENSG00000196391;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2872;1135;928;776;1168;5_None;28;3.76;0.01;0.01;20;1.07;0.01;0.01;8;2.68;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.07;0.13;#N/A;Atherosclerosis;#N/A;#N/A;#N/A;0.068377104;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1479;ZNF678;ENSG00000181450;HGNC:28652;339500;Zinc finger protein 678;Q5SXM1;#N/A;https://platform.opentargets.org/target/ENSG00000181450;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2307;845;929;1196;182;5_None;57;3.75;0.02;0.01;52;2.39;0.02;0.03;5;1.36;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0029;ARID5A;ENSG00000196843;HGNC:17361;10865;AT-rich interactive domain-containing protein 5A (ARID domain-containing protein 5A) (Modulator recognition factor 1) (MRF-1);Q03989;#N/A;https://platform.opentargets.org/target/ENSG00000196843;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;2268;827;930;900;438;5_None;89;3.73;0.03;0.01;82;1.59;0.03;0.02;7;2.14;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;0.004250168;#N/A;#N/A;0.039824002;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0107;CGGBP1;ENSG00000163320;HGNC:1888;8545;CGG triplet repeat-binding protein 1 (CGG-binding protein 1) (20 kDa CGG-binding protein) (p20-CGGBP DNA-binding protein);Q9UFW8;#N/A;https://platform.opentargets.org/target/ENSG00000163320;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1769;591;931;656;182;5_None;61;3.7;0.02;0.01;59;2.97;0.02;0.04;2;0.73;0;0;#N/A;#N/A;#N/A;#N/A;2;0.1;0.13;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.027449498;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.076464141;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0979;TLX2;ENSG00000115297;HGNC:5057;3196;T-cell leukemia homeobox protein 2 (Homeobox protein Hox-11L1) (Neural crest homeobox protein);O43763;https://jaspar.elixir.no/search?q=O43763;https://platform.opentargets.org/target/ENSG00000115297;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2592;983;932;492;1168;3_Medium to Low;223;3.69;0.07;0.01;223;3.69;0.09;0.05;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;8;0.18;0.5;0.04;Cancer;#N/A;#N/A;0.031856223;#N/A;#N/A;0.072868853;0.002217479;0.017666559;0.011087396;0.018840465;#N/A;#N/A;#N/A;0.010395871;#N/A;0.011880555;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1020;ZBED3;ENSG00000132846;HGNC:20711;84327;Zinc finger BED domain-containing protein 3 (Axin-interacting protein);Q96IU2;#N/A;https://platform.opentargets.org/target/ENSG00000132846;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;1692;554;933;321;438;5_None;70;3.68;0.02;0.01;63;1.69;0.02;0.02;6;1.48;0.01;0.01;1;0.51;0.01;0.01;4;0.36;0.25;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.064139298;#N/A;#N/A;#N/A;#N/A;0.036218826;0.002217479;#N/A;#N/A;#N/A;0.253558967;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0453;KCNIP3;ENSG00000115041;HGNC:15523;30818;Calsenilin (A-type potassium channel modulatory protein 3) (DRE-antagonist modulator) (DREAM) (Kv channel-interacting protein 3) (KChIP3);Q9Y2W7;#N/A;https://platform.opentargets.org/target/ENSG00000115041;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1927;658;934;555;438;5_None;174;3.65;0.06;0.01;174;3.65;0.07;0.05;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;0.14;0.56;0.04;Cancer;#N/A;#N/A;0.036201152;#N/A;#N/A;0.06934649;0.001478319;#N/A;0.014044034;0.002217479;0.002217479;0.004434958;#N/A;0.008664594;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1316;ZNF45;ENSG00000124459;HGNC:13111;7596;Zinc finger protein 45 (BRC1744) (Zinc finger protein 13) (Zinc finger protein KOX5);Q02386;#N/A;https://platform.opentargets.org/target/ENSG00000124459;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2842;1119;935;1469;438;5_None;34;3.64;0.01;0.01;31;2.92;0.01;0.04;3;0.73;0.01;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0329;GZF1;ENSG00000125812;HGNC:15808;64412;GDNF-inducible zinc finger protein 1 (Zinc finger and BTB domain-containing protein 23) (Zinc finger protein 336);Q9H116;#N/A;https://platform.opentargets.org/target/ENSG00000125812;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3394;1432;936;1290;1168;5_None;88;3.64;0.03;0.01;86;2.4;0.03;0.03;#N/A;#N/A;#N/A;#N/A;2;1.24;0.02;0.02;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.003720074;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0348;HIC2;ENSG00000169635;HGNC:18595;23119;Hypermethylated in cancer 2 protein (Hic-2) (HIC1-related gene on chromosome 22 protein) (Hic-3) (Zinc finger and BTB domain-containing protein 30);Q96JB3;https://jaspar.elixir.no/search?q=Q96JB3;https://platform.opentargets.org/target/ENSG00000169635;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2548;963;937;1173;438;5_None;75;3.61;0.02;0.01;70;2.27;0.03;0.03;4;0.83;0.01;0.01;1;0.51;0.01;0.01;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001817535;#N/A;0.004434958;0.005305113;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0265;FOXJ2;ENSG00000065970;HGNC:24818;55810;Forkhead box protein J2 (Fork head homologous X);Q9P0K8;https://jaspar.elixir.no/search?q=Q9P0K8;https://platform.opentargets.org/target/ENSG00000065970;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2316;849;938;940;438;5_None;77;3.58;0.02;0.01;72;2.2;0.03;0.03;5;1.39;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.001478319;0.013304875;#N/A;0.016833874;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0870;SP5;ENSG00000204335;HGNC:14529;389058;Transcription factor Sp5;Q6BEB4;https://jaspar.elixir.no/search?q=Q6BEB4;https://platform.opentargets.org/target/ENSG00000204335;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;2151;764;939;1129;83;5_None;84;3.58;0.03;0.01;82;2.86;0.03;0.04;2;0.72;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.013324037;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0967;THAP9;ENSG00000168152;HGNC:23192;79725;DNA transposase THAP9 (EC 2.7.7.-) (THAP domain-containing protein 9) (hTh9);Q9H5L6;#N/A;https://platform.opentargets.org/target/ENSG00000168152;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;2820;1100;940;712;1168;5_None;74;3.55;0.02;0.01;70;2.44;0.03;0.03;4;1.11;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;0.002956639;#N/A;#N/A;0.08376578;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0313;GMEB2;ENSG00000101216;HGNC:4371;26205;Glucocorticoid modulatory element-binding protein 2 (GMEB-2) (DNA-binding protein p79PIF) (Parvovirus initiation factor p79) (PIF p79);Q9UKD1;https://jaspar.elixir.no/search?q=Q9UKD1;https://platform.opentargets.org/target/ENSG00000101216;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.3 GMEB;1855;625;941;476;438;5_None;35;3.55;0.01;0.01;31;2.34;0.01;0.03;3;0.71;0.01;0;1;0.5;0.01;0.01;1;0.19;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.186097059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1634;ZSCAN5;ENSG00000131848;HGNC:23710;79149;Zinc finger and SCAN domain-containing protein 5A (Zinc finger protein 495);Q9BUG6;#N/A;https://platform.opentargets.org/target/ENSG00000131848;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3363;1423;942;1253;1168;5_None;55;3.51;0.02;0.01;51;2.23;0.02;0.03;4;1.29;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1516;ZNF716;ENSG00000182111;HGNC:32458;441234;Zinc finger protein 716;A6NP11;#N/A;https://platform.opentargets.org/target/ENSG00000182111;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2684;1036;943;573;1168;5_None;40;3.51;0.01;0.01;35;1.85;0.01;0.03;5;1.66;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.13;0.06;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.134891355;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0440;IRX6;ENSG00000159387;HGNC:14675;79190;Iroquois-class homeodomain protein IRX-6 (Homeodomain protein IRXB3) (Iroquois homeobox protein 6);P78412;#N/A;https://platform.opentargets.org/target/ENSG00000159387;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;2648;1016;944;1266;438;5_None;58;3.5;0.02;0.01;51;1.67;0.02;0.02;7;1.83;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1353;ZNF512B;ENSG00000196700;HGNC:29212;57473;Zinc finger protein 512B;Q96KM6;#N/A;https://platform.opentargets.org/target/ENSG00000196700;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3143;1299;945;1030;1168;5_None;48;3.47;0.02;0.01;43;1.93;0.02;0.03;5;1.54;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Parkinson Disease;#N/A;#N/A;0.004079331;#N/A;#N/A;0.005728488;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.015152774;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1358;ZNF518A;ENSG00000177853;HGNC:29009;9849;Zinc finger protein 518A;Q6AHZ1;#N/A;https://platform.opentargets.org/target/ENSG00000177853;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2740;1065;946;1356;438;5_None;27;3.46;0.01;0.01;18;0.85;0.01;0.01;9;2.61;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1167;ZNF208;ENSG00000160321;HGNC:12999;7757;Zinc finger protein 208 (Zinc finger protein 91-like);O43345;#N/A;https://platform.opentargets.org/target/ENSG00000160321;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2539;957;947;424;1168;5_None;67;3.46;0.02;0.01;62;1.86;0.02;0.03;5;1.59;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.23;0.25;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.034012496;0.018478993;#N/A;0.015468559;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.165593555;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0689;PCGF6;ENSG00000156374;HGNC:21156;84108;Polycomb group RING finger protein 6 (Mel18 and Bmi1-like RING finger) (RING finger protein 134);Q9BYE7;#N/A;https://platform.opentargets.org/target/ENSG00000156374;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2662;1024;948;1276;438;5_None;36;3.41;0.01;0.01;29;1.2;0.01;0.02;7;2.22;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.00690909;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1124;ZNF12;ENSG00000164631;HGNC:12902;7559;Zinc finger protein 12 (Gonadotropin-inducible ovary transcription repressor 3) (GIOT-3) (Zinc finger protein 325) (Zinc finger protein KOX3);P17014;#N/A;https://platform.opentargets.org/target/ENSG00000164631;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2619;998;949;1232;438;5_None;25;3.4;0.01;0.01;16;0.25;0.01;0;8;2.45;0.02;0.02;1;0.7;0.01;0.01;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004496555;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0633;NPAS4;ENSG00000174576;HGNC:18983;266743;Neuronal PAS domain-containing protein 4 (Neuronal PAS4) (Class E basic helix-loop-helix protein 79) (bHLHe79) (HLH-PAS transcription factor NXF) (PAS domain-containing protein 10);Q8IUM7;#N/A;https://platform.opentargets.org/target/ENSG00000174576;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;2118;743;950;730;438;5_None;129;3.4;0.04;0.01;129;3.4;0.05;0.05;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.08;0.31;0.02;Alzheimer Disease;#N/A;#N/A;0.025907682;#N/A;#N/A;0.024584863;#N/A;#N/A;0.015607858;#N/A;#N/A;#N/A;#N/A;#N/A;0.006652437;0.011806023;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0607;NFYA;ENSG00000001167;HGNC:7804;4800;Nuclear transcription factor Y subunit alpha (CAAT box DNA-binding protein subunit A) (Nuclear transcription factor Y subunit A) (NF-YA);P23511;https://jaspar.elixir.no/search?q=P23511;https://platform.opentargets.org/target/ENSG00000001167;4 Other all-alpha-helical DNA-binding domains;4.2 Heteromeric CCAAT-binding factors;4.2.1 Heteromeric CCAAT-binding;1953;670;951;564;438;5_None;158;3.39;0.05;0.01;157;3.07;0.06;0.04;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;7;0.14;0.44;0.03;Cancer;#N/A;#N/A;0.043468821;#N/A;0.003695799;0.048157942;0.001478319;0.010348236;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.029073615;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1554;ZNF778;ENSG00000170100;HGNC:26479;197320;Zinc finger protein 778;Q96MU6;#N/A;https://platform.opentargets.org/target/ENSG00000170100;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2410;895;952;1020;438;5_None;39;3.39;0.01;0.01;35;2.25;0.01;0.03;4;1.14;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.026018035;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1198;ZNF254;ENSG00000213096;HGNC:13047;9534;Zinc finger protein 254 (Bone marrow zinc finger 5) (BMZF-5) (Hematopoietic cell-derived zinc finger protein 1) (HD-ZNF1) (Zinc finger protein 539) (Zinc finger protein 91-like);O75437;#N/A;https://platform.opentargets.org/target/ENSG00000213096;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3477;1460;953;1356;1168;5_None;34;3.39;0.01;0.01;25;0.95;0.01;0.01;9;2.44;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1243;ZNF326;ENSG00000162664;HGNC:14104;284695;DBIRD complex subunit ZNF326 (Zinc finger protein 326) (Zinc finger protein interacting with mRNPs and DBC1);Q5BKZ1;#N/A;https://platform.opentargets.org/target/ENSG00000162664;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2444;917;954;1052;438;5_None;39;3.39;0.01;0.01;31;0.76;0.01;0.01;8;2.63;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.006774851;#N/A;#N/A;0.013624321;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0434;IRF9;ENSG00000213928;HGNC:6131;10379;Interferon regulatory factor 9 (IRF-9) (IFN-alpha-responsive transcription factor subunit) (ISGF3 p48 subunit) (Interferon-stimulated gene factor 3 gamma) (ISGF-3 gamma) (Transcriptional regulator ISGF3 subunit gamma);Q00978;https://jaspar.elixir.no/search?q=Q00978;https://platform.opentargets.org/target/ENSG00000213928;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.3 IRF;1947;668;955;554;438;5_None;240;3.36;0.08;0.01;239;2.88;0.09;0.04;1;0.48;0;0;#N/A;#N/A;#N/A;#N/A;12;0.14;0.75;0.04;Cancer;#N/A;0.004434958;0.006542179;0.011826555;#N/A;0.065388247;0.002217479;0.001478319;0.004434958;0.002217479;0.003695799;#N/A;0.037150167;0.001478319;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0138;DBX1;ENSG00000109851;HGNC:33185;120237;Homeobox protein DBX1 (Developing brain homeobox protein 1);A6NMT0;#N/A;https://platform.opentargets.org/target/ENSG00000109851;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3268;1379;956;1144;1168;5_None;56;3.36;0.02;0.01;54;2.79;0.02;0.04;2;0.57;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.013366471;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1540;ZNF763;ENSG00000197054;HGNC:27614;284390;Zinc finger protein 763;Q0D2J5;#N/A;https://platform.opentargets.org/target/ENSG00000197054;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1590;512;957;195;438;5_None;314;3.36;0.1;0.01;309;2.02;0.12;0.03;5;1.34;0.01;0.01;#N/A;#N/A;#N/A;#N/A;11;0.56;0.69;0.14;Parkinson Disease;#N/A;#N/A;0.219011145;0.002012157;0.001478319;0.086936884;0.016261514;0.001478319;0.001478319;0.002956639;#N/A;#N/A;0.001478319;0.224000958;#N/A;0.007761177;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1624;ZSCAN21;ENSG00000166529;HGNC:13104;7589;Zinc finger and SCAN domain-containing protein 21 (Renal carcinoma antigen NY-REN-21) (Zinc finger protein 38 homolog) (Zfp-38);Q9Y5A6;https://jaspar.elixir.no/search?q=Q9Y5A6;https://platform.opentargets.org/target/ENSG00000166529;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2685;1037;958;1289;438;5_None;88;3.35;0.03;0.01;88;3.35;0.03;0.05;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.006078973;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0732;PRDM12;ENSG00000130711;HGNC:13997;59335;PR domain zinc finger protein 12 (EC 2.1.1.-) (PR domain-containing protein 12);Q9H4Q4;#N/A;https://platform.opentargets.org/target/ENSG00000130711;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2430;907;959;1033;438;5_None;85;3.33;0.03;0.01;82;1.82;0.03;0.02;2;0.68;0;0;1;0.82;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.024543798;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1076;ZFP28;ENSG00000196867;HGNC:17801;140612;Zinc finger protein 28 homolog (Zfp-28) (Krueppel-like zinc finger factor X6);Q8NHY6;#N/A;https://platform.opentargets.org/target/ENSG00000196867;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2611;990;960;1469;182;5_None;55;3.31;0.02;0.01;52;2.4;0.02;0.03;3;0.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0867;SP2;ENSG00000167182;HGNC:11207;6668;Transcription factor Sp2;Q02086;https://jaspar.elixir.no/search?q=Q02086;https://platform.opentargets.org/target/ENSG00000167182;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;3034;1235;961;905;1168;5_None;101;3.31;0.03;0.01;95;1.54;0.04;0.02;6;1.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.04;0.44;0.01;Cancer;#N/A;#N/A;0.004065378;0.002956639;#N/A;0.013515747;#N/A;#N/A;#N/A;0.003695799;0.007391597;#N/A;#N/A;0.011087396;#N/A;0.002217479;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0136;DACH2;ENSG00000126733;HGNC:16814;117154;Dachshund homolog 2 (Dach2);Q96NX9;#N/A;https://platform.opentargets.org/target/ENSG00000126733;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2503;938;962;1103;438;5_None;46;3.29;0.01;0.01;39;0.7;0.02;0.01;6;2.05;0.01;0.01;1;0.53;0.01;0.01;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.013489665;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1555;ZNF780A;ENSG00000197782;HGNC:27603;284323;Zinc finger protein 780A;O75290;#N/A;https://platform.opentargets.org/target/ENSG00000197782;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2356;867;963;955;438;5_None;86;3.29;0.03;0.01;86;3.29;0.03;0.04;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.033979172;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0364;HMX1;ENSG00000215612;HGNC:5017;3166;Homeobox protein HMX1 (Homeobox protein H6);Q9NP08;#N/A;https://platform.opentargets.org/target/ENSG00000215612;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2583;979;964;1181;438;5_None;83;3.28;0.03;0.01;78;0.93;0.03;0.01;3;1.06;0.01;0.01;2;1.28;0.02;0.02;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.002956639;0.002217479;#N/A;0.005913278;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0132;CXXC1;ENSG00000154832;HGNC:24343;30827;CXXC-type zinc finger protein 1 (CpG-binding protein) (PHD finger and CXXC domain-containing protein 1);Q9P0U4;#N/A;https://platform.opentargets.org/target/ENSG00000154832;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;1508;471;965;105;438;5_None;59;3.26;0.02;0.01;53;0.88;0.02;0.01;5;1.85;0.01;0.01;1;0.53;0.01;0.01;5;0.82;0.31;0.21;Alzheimer Disease;#N/A;#N/A;0.369579855;#N/A;#N/A;0.076457641;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;0.002217479;0.369579855;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0691;PEG3;ENSG00000198300;HGNC:8826;5178;Paternally-expressed gene 3 protein (Zinc finger and SCAN domain-containing protein 24);Q9GZU2;#N/A;https://platform.opentargets.org/target/ENSG00000198300;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3002;1219;966;868;1168;5_None;150;3.26;0.05;0.01;145;1.97;0.06;0.03;5;1.28;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.01694831;#N/A;#N/A;#N/A;0.012534917;#N/A;#N/A;#N/A;0.013304875;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0929;TEAD4;ENSG00000197905;HGNC:11717;7004;Transcriptional enhancer factor TEF-3 (TEA domain family member 4) (TEAD-4) (Transcription factor 13-like 1) (Transcription factor RTEF-1);Q15561;https://jaspar.elixir.no/search?q=Q15561;https://platform.opentargets.org/target/ENSG00000197905;3 Helix-turn-helix domains;3.6 TEA domain factors;3.6.1 TEF1-related;1581;504;967;432;182;2_Medium;159;3.23;0.05;0.01;156;2.46;0.06;0.03;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.23;0.44;0.06;Benign Prostatic Hyperplasia;#N/A;0.018520057;#N/A;#N/A;0.083155467;0.081414113;0.016815883;#N/A;#N/A;0.004434958;0.015522354;#N/A;#N/A;#N/A;#N/A;0.007761177;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tchem;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1073;ZFP1;ENSG00000184517;HGNC:23328;162239;Zinc finger protein 1 homolog (Zfp-1) (Zinc finger protein 475);Q6P2D0;#N/A;https://platform.opentargets.org/target/ENSG00000184517;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2528;951;968;1122;438;5_None;40;3.23;0.01;0.01;32;0.38;0.01;0.01;8;2.84;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.015522354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1000;USF2;ENSG00000105698;HGNC:12594;7392;Upstream stimulatory factor 2 (Class B basic helix-loop-helix protein 12) (bHLHb12) (FOS-interacting protein) (FIP) (Major late transcription factor 2) (Upstream transcription factor 2);Q15853;https://jaspar.elixir.no/search?q=Q15853;https://platform.opentargets.org/target/ENSG00000105698;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.6 bHLH-ZIP;1929;660;969;778;182;5_None;115;3.22;0.04;0.01;114;2.69;0.04;0.04;#N/A;#N/A;#N/A;#N/A;1;0.54;0.01;0.01;8;0.07;0.5;0.02;Cancer;#N/A;0.002956639;0.011367956;0.003326219;0.002217479;0.036067565;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0.003695799;#N/A;0.011713628;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1532;ZNF746;ENSG00000181220;HGNC:21948;155061;Zinc finger protein 746 (Parkin-interacting substrate) (PARIS);Q6NUN9;#N/A;https://platform.opentargets.org/target/ENSG00000181220;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2533;955;970;395;1168;5_None;48;3.22;0.02;0.01;42;1.64;0.02;0.02;6;1.58;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.26;0.25;0.07;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005897353;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.050005881;0.001478319;0.201626357;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0158;DNTTIP1;ENSG00000101457;HGNC:16160;116092;Deoxynucleotidyltransferase terminal-interacting protein 1 (Terminal deoxynucleotidyltransferase-interacting factor 1) (TdIF1) (TdT-interacting factor 1);Q9H147;#N/A;https://platform.opentargets.org/target/ENSG00000101457;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2475;926;971;1066;438;5_None;73;3.22;0.02;0.01;71;2.47;0.03;0.03;2;0.74;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.020289013;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1332;ZNF483;ENSG00000173258;HGNC:23384;158399;Zinc finger protein 483 (Zinc finger protein with KRAB and SCAN domains 16);Q8TF39;#N/A;https://platform.opentargets.org/target/ENSG00000173258;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2706;1048;972;1296;438;5_None;24;3.21;0.01;0.01;17;0.54;0.01;0.01;5;1.63;0.01;0.01;2;1.04;0.02;0.02;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005543698;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0584;NEUROD6;ENSG00000164600;HGNC:13804;63974;Neurogenic differentiation factor 6 (NeuroD6) (Class A basic helix-loop-helix protein 2) (bHLHa2) (Protein atonal homolog 2);Q96NK8;#N/A;https://platform.opentargets.org/target/ENSG00000164600;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2858;1125;973;717;1168;5_None;42;3.21;0.01;0.01;30;0.26;0.01;0;12;2.95;0.02;0.02;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Alzheimer Disease;#N/A;#N/A;0.077848256;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.00820262;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1258;ZNF35;ENSG00000169981;HGNC:13099;7584;Zinc finger protein 35 (Zinc finger protein HF.10);P13682;https://jaspar.elixir.no/search?q=P13682;https://platform.opentargets.org/target/ENSG00000169981;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2560;970;974;1148;438;5_None;72;3.18;0.02;0.01;71;2.77;0.03;0.04;1;0.4;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008110225;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0725;POU6F1;ENSG00000184271;HGNC:9224;5463;POU domain, class 6, transcription factor 1 (Brain-specific homeobox/POU domain protein 5) (Brain-5) (Brn-5) (mPOU homeobox protein);Q14863;https://jaspar.elixir.no/search?q=Q14863;https://platform.opentargets.org/target/ENSG00000184271;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;2382;882;975;969;438;5_None;44;3.17;0.01;0.01;37;0.44;0.01;0.01;6;2.22;0.01;0.01;1;0.51;0.01;0.01;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.024453867;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0753;PURB;ENSG00000146676;HGNC:9702;5814;Transcriptional activator protein Pur-beta (Purine-rich element-binding protein B);Q96QR8;#N/A;https://platform.opentargets.org/target/ENSG00000146676;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.5 PUR;2286;835;976;1128;182;5_None;57;3.15;0.02;0.01;54;2.24;0.02;0.03;3;0.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.004226198;#N/A;#N/A;0.006282858;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1441;ZNF619;ENSG00000177873;HGNC:26910;285267;Zinc finger protein 619;Q8N2I2;#N/A;https://platform.opentargets.org/target/ENSG00000177873;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1621;521;977;206;438;5_None;19;3.15;0.01;0.01;12;1.06;0;0.01;7;2.09;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.55;0.13;0.14;Alzheimer Disease;#N/A;#N/A;0.275815804;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.275815804;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0084;CAMTA2;ENSG00000108509;HGNC:18807;23125;Calmodulin-binding transcription activator 2;O94983;#N/A;https://platform.opentargets.org/target/ENSG00000108509;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2416;898;978;1000;438;5_None;52;3.15;0.02;0.01;51;2.93;0.02;0.04;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.024230922;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1094;ZFY;ENSG00000067646;HGNC:12870;7544;Zinc finger Y-chromosomal protein;P08048;#N/A;https://platform.opentargets.org/target/ENSG00000067646;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3221;1349;979;1074;1168;5_None;94;3.15;0.03;0.01;92;2.42;0.04;0.03;1;0.22;0;0;1;0.51;0.01;0.01;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;0.004250168;0.013374274;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0747;PROX2;ENSG00000119608;HGNC:26715;283571;Prospero homeobox protein 2 (Homeobox prospero-like protein PROX2) (PROX-2);Q3B8N5;#N/A;https://platform.opentargets.org/target/ENSG00000119608;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.7 HD-PROS;1734;577;980;316;438;5_None;37;3.15;0.01;0.01;35;2.38;0.01;0.03;2;0.77;0;0.01;#N/A;#N/A;#N/A;#N/A;2;0.37;0.13;0.09;Alzheimer Disease;#N/A;#N/A;0.184747908;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.184193538;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0287;FOXS1;ENSG00000179772;HGNC:3735;2307;Forkhead box protein S1 (Forkhead-like 18 protein) (Forkhead-related transcription factor 10) (FREAC-10);O43638;https://jaspar.elixir.no/search?q=O43638;https://platform.opentargets.org/target/ENSG00000179772;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;2034;706;981;615;438;5_None;60;3.14;0.02;0.01;55;1.6;0.02;0.02;5;1.54;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.12;0.13;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.09006617;0.027348909;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0306;GLI4;ENSG00000250571;HGNC:4320;2738;Zinc finger protein GLI4 (Krueppel-related zinc finger protein 4) (Protein HKR4);P10075;#N/A;https://platform.opentargets.org/target/ENSG00000250571;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2716;1053;982;1296;438;3_Medium to Low;32;3.12;0.01;0.01;26;1.08;0.01;0.01;5;1.53;0.01;0.01;1;0.51;0.01;0.01;2;0.01;0.13;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0175;E2F5;ENSG00000133740;HGNC:3119;1875;Transcription factor E2F5 (E2F-5);Q15329;#N/A;https://platform.opentargets.org/target/ENSG00000133740;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;2248;813;983;827;438;2_Medium;121;3.12;0.04;0.01;118;2.4;0.05;0.03;3;0.72;0.01;0;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;0.006508712;#N/A;0.013674455;0.035246531;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;11;2_Medium;At least 2/3 Pharos Tchem, DGIDB MOA >0, ChEMBL max phase >0;Tbio;3;2;#N/A;CHEMBL4630726;E2F;PROTEIN FAMILY;0;0;2;3;Oligonucleotide;#N/A
TFTX_0671;OVOL2;ENSG00000125850;HGNC:15804;58495;Transcription factor Ovo-like 2 (hOvo2) (Zinc finger protein 339);Q9BRP0;https://jaspar.elixir.no/search?q=Q9BRP0;https://platform.opentargets.org/target/ENSG00000125850;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2032;704;984;610;438;5_None;100;3.11;0.03;0.01;95;1.44;0.04;0.02;4;1.09;0.01;0.01;1;0.58;0.01;0.01;4;0.12;0.25;0.03;Cancer;#N/A;#N/A;0.004434958;#N/A;#N/A;0.08759345;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.023837901;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0760;RAX2;ENSG00000173976;HGNC:18286;84839;Retina and anterior neural fold homeobox protein 2 (Q50-type retinal homeobox protein) (Retina and anterior neural fold homeobox-like protein 1);Q96IS3;https://jaspar.elixir.no/search?q=Q96IS3;https://platform.opentargets.org/target/ENSG00000173976;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2400;893;985;247;1168;5_None;23;3.11;0.01;0.01;16;0.29;0.01;0;6;2.15;0.01;0.01;1;0.67;0.01;0.01;3;0.49;0.19;0.12;Age-Related Macular Degeneration;#N/A;0.483502976;0.001478319;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1118;ZNF100;ENSG00000197020;HGNC:12880;163227;Zinc finger protein 100;Q8IYN0;#N/A;https://platform.opentargets.org/target/ENSG00000197020;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1836;617;986;412;438;4_Low;28;3.1;0.01;0.01;21;0.63;0.01;0.01;6;1.94;0.01;0.01;1;0.53;0.01;0.01;3;0.24;0.19;0.06;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.239909123;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0160;DPF1;ENSG00000011332;HGNC:20225;8193;Zinc finger protein neuro-d4 (BRG1-associated factor 45B) (BAF45B) (D4, zinc and double PHD fingers family 1);Q92782;#N/A;https://platform.opentargets.org/target/ENSG00000011332;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2762;1073;987;1337;438;5_None;40;3.09;0.01;0.01;32;0.49;0.01;0.01;8;2.6;0.02;0.02;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004322031;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0514;MBD6;ENSG00000166987;HGNC:20445;114785;Methyl-CpG-binding domain protein 6 (Methyl-CpG-binding protein MBD6);Q96DN6;#N/A;https://platform.opentargets.org/target/ENSG00000166987;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3302;1394;988;1146;1168;5_None;55;3.09;0.02;0.01;54;2.58;0.02;0.04;#N/A;#N/A;#N/A;#N/A;1;0.5;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.013304875;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1006;VEZF1;ENSG00000136451;HGNC:12949;7716;Vascular endothelial zinc finger 1 (Putative transcription factor DB1) (Zinc finger protein 161);Q14119;https://jaspar.elixir.no/search?q=Q14119;https://platform.opentargets.org/target/ENSG00000136451;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1543;487;989;116;438;5_None;52;3.08;0.02;0.01;46;0.77;0.02;0.01;6;2.31;0.01;0.02;#N/A;#N/A;#N/A;#N/A;7;0.77;0.44;0.2;Alzheimer Disease;#N/A;#N/A;0.372166914;#N/A;#N/A;0.011276565;#N/A;0.010348236;0.002956639;0.002217479;#N/A;#N/A;#N/A;0.369579855;#N/A;0.003326219;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0184;EEA1;ENSG00000102189;HGNC:3185;8411;Early endosome antigen 1 (Endosome-associated protein p162) (Zinc finger FYVE domain-containing protein 2);Q15075;#N/A;https://platform.opentargets.org/target/ENSG00000102189;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2089;734;990;661;438;5_None;122;3.08;0.04;0.01;117;1.72;0.05;0.02;5;1.35;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.1;0.38;0.03;Alzheimer Disease;#N/A;0.011087396;0.061311628;#N/A;#N/A;0.006990192;0.017144399;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0.004065378;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1021;ZBED4;ENSG00000100426;HGNC:20721;9889;Zinc finger BED domain-containing protein 4;O75132;https://jaspar.elixir.no/search?q=O75132;https://platform.opentargets.org/target/ENSG00000100426;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;2898;1155;991;1469;438;5_None;33;3.06;0.01;0.01;27;1.29;0.01;0.02;6;1.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0191;ELF2;ENSG00000109381;HGNC:3317;1998;ETS-related transcription factor Elf-2 (E74-like factor 2) (New ETS-related factor);Q15723;https://jaspar.elixir.no/search?q=Q15723;https://platform.opentargets.org/target/ENSG00000109381;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2169;773;992;995;182;3_Medium to Low;59;3.06;0.02;0.01;53;1.16;0.02;0.02;6;1.9;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.004619748;0.003695799;#N/A;0.020741406;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;5;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1027;ZBTB11;ENSG00000066422;HGNC:16740;27107;Zinc finger and BTB domain-containing protein 11;O95625;https://jaspar.elixir.no/search?q=O95625;https://platform.opentargets.org/target/ENSG00000066422;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2688;1039;993;527;1168;5_None;85;3.05;0.03;0.01;82;1.72;0.03;0.02;2;0.67;0;0;1;0.66;0.01;0.01;5;0.16;0.31;0.04;Cancer;#N/A;0.049399433;0.003695799;#N/A;#N/A;0.096390931;0.007391597;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1158;ZNF19;ENSG00000157429;HGNC:12981;7567;Zinc finger protein 19 (Zinc finger protein KOX12);P17023;#N/A;https://platform.opentargets.org/target/ENSG00000157429;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2901;1160;994;1469;438;5_None;26;3.05;0.01;0.01;20;1.12;0.01;0.02;6;1.93;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1134;ZNF14;ENSG00000105708;HGNC:12924;7561;Zinc finger protein 14 (Gonadotropin-inducible ovary transcription repressor 4) (GIOT-4) (Zinc finger protein KOX6);P17017;#N/A;https://platform.opentargets.org/target/ENSG00000105708;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2650;1017;995;1217;438;5_None;30;3.04;0.01;0.01;24;1.05;0.01;0.01;6;2;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001811611;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0486;LHX1;ENSG00000273706;HGNC:6593;3975;LIM/homeobox protein Lhx1 (LIM homeobox protein 1) (Homeobox protein Lim-1) (hLim-1);P48742;https://jaspar.elixir.no/search?q=P48742;https://platform.opentargets.org/target/ENSG00000273706;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.5 HD-LIM;2646;1015;996;1212;438;5_None;108;3.02;0.03;0.01;103;1.22;0.04;0.02;4;1.25;0.01;0.01;1;0.56;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009404665;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1326;ZNF471;ENSG00000196263;HGNC:23226;57573;Zinc finger protein 471 (EZFIT-related protein 1);Q9BX82;#N/A;https://platform.opentargets.org/target/ENSG00000196263;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2284;833;997;1105;182;5_None;49;3.02;0.02;0.01;43;1.14;0.02;0.02;6;1.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.002425506;#N/A;#N/A;0.014675643;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1573;ZNF80;ENSG00000174255;HGNC:13155;7634;Zinc finger protein 80 (ZNFpT17);P51504;#N/A;https://platform.opentargets.org/target/ENSG00000174255;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3635;1506;998;1469;1168;5_None;32;3.02;0.01;0.01;23;0.73;0.01;0.01;9;2.29;0.02;0.02;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1563;ZNF787;ENSG00000142409;HGNC:26998;126208;Zinc finger protein 787 (TTF-I-interacting peptide 20);Q6DD87;#N/A;https://platform.opentargets.org/target/ENSG00000142409;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2643;1011;999;1206;438;5_None;18;3.01;0.01;0.01;11;0.45;0;0.01;6;2.05;0.01;0.01;1;0.52;0.01;0.01;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.009609076;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0050;ATMIN;ENSG00000166454;HGNC:29034;23300;ATM interactor (ATM/ATR-substrate CHK2-interacting zinc finger protein) (ASCIZ) (Zinc finger protein 822);O43313;#N/A;https://platform.opentargets.org/target/ENSG00000166454;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3222;1351;1000;1054;1168;5_None;64;3;0.02;0.01;59;1.03;0.02;0.01;4;1.45;0.01;0.01;1;0.52;0.01;0.01;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.002471529;#N/A;#N/A;0.019327114;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0707;PLAGL2;ENSG00000126003;HGNC:9047;5326;Zinc finger protein PLAGL2 (Pleiomorphic adenoma-like protein 2);Q9UPG8;https://jaspar.elixir.no/search?q=Q9UPG8;https://platform.opentargets.org/target/ENSG00000126003;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2883;1145;1001;714;1168;5_None;127;2.99;0.04;0.01;126;2.46;0.05;0.03;#N/A;#N/A;#N/A;#N/A;1;0.53;0.01;0.01;4;0.09;0.25;0.02;Cancer;#N/A;#N/A;0.002587059;#N/A;0.013859245;0.066041631;0.006832094;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1090;ZFP92;ENSG00000189420;HGNC:12865;139735;Zinc finger protein 92 homolog (Zfp-92);A6NM28;#N/A;https://platform.opentargets.org/target/ENSG00000189420;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3639;1507;1002;1469;1168;5_None;64;2.99;0.02;0.01;64;2.99;0.03;0.04;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1219;ZNF282;ENSG00000170265;HGNC:13076;8427;Zinc finger protein 282 (HTLV-I U5RE-binding protein 1) (HUB-1);Q9UDV7;https://jaspar.elixir.no/search?q=Q9UDV7;https://platform.opentargets.org/target/ENSG00000170265;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3184;1328;1003;1013;1168;5_None;42;2.97;0.01;0.01;36;0.72;0.01;0.01;6;2.25;0.01;0.02;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.001478319;0.003695799;#N/A;0.021764147;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1456;ZNF646;ENSG00000167395;HGNC:29004;9726;Zinc finger protein 646;O15015;#N/A;https://platform.opentargets.org/target/ENSG00000167395;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;1968;677;1004;782;182;5_None;71;2.97;0.02;0.01;71;2.97;0.03;0.04;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.07;0.19;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.015707144;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.026804237;#N/A;0.029540929;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1074;ZFP14;ENSG00000142065;HGNC:29312;57677;Zinc finger protein 14 homolog (Zfp-14) (Zinc finger protein 531);Q9HCL3;https://jaspar.elixir.no/search?q=Q9HCL3;https://platform.opentargets.org/target/ENSG00000142065;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1961;675;1005;774;182;5_None;67;2.95;0.02;0.01;66;2.66;0.03;0.04;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.074470341;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0512;MBD3;ENSG00000071655;HGNC:6918;53615;Methyl-CpG-binding domain protein 3 (Methyl-CpG-binding protein MBD3);O95983;#N/A;https://platform.opentargets.org/target/ENSG00000071655;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2316;849;1006;872;438;5_None;96;2.93;0.03;0.01;93;2.16;0.04;0.03;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.05;0.31;0.01;Cancer;#N/A;#N/A;0.006777068;#N/A;0.001478319;0.022272641;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008849384;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0425;INSM2;ENSG00000168348;HGNC:17539;84684;Insulinoma-associated protein 2 (Zinc finger protein IA-6);Q96T92;#N/A;https://platform.opentargets.org/target/ENSG00000168348;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2488;929;1007;1043;438;5_None;58;2.88;0.02;0.01;53;1.26;0.02;0.02;4;1.09;0.01;0.01;1;0.53;0.01;0.01;4;0.02;0.25;0.01;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.007391597;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;0.006252868;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1109;ZKSCAN2;ENSG00000155592;HGNC:25677;342357;Zinc finger protein with KRAB and SCAN domains 2 (Zinc finger protein 694);Q63HK3;#N/A;https://platform.opentargets.org/target/ENSG00000155592;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2251;814;1008;1061;182;5_None;21;2.88;0.01;0.01;12;0.65;0;0.01;9;2.23;0.02;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;0.019218152;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0105;CENPT;ENSG00000102901;HGNC:25787;80152;Centromere protein T (CENP-T) (Interphase centromere complex protein 22);Q96BT3;#N/A;https://platform.opentargets.org/target/ENSG00000102901;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2614;992;1009;1167;438;5_None;51;2.87;0.02;0.01;47;1.28;0.02;0.02;3;1.06;0.01;0.01;1;0.53;0.01;0.01;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.006611873;#N/A;#N/A;0.005374512;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1216;ZNF280C;ENSG00000056277;HGNC:25955;55609;Zinc finger protein 280C (Suppressor of hairy wing homolog 3) (Zinc finger protein 633);Q8ND82;#N/A;https://platform.opentargets.org/target/ENSG00000056277;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2814;1093;1010;636;1168;5_None;59;2.86;0.02;0.01;58;2.63;0.02;0.04;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;2;0.11;0.13;0.03;Age-Related Macular Degeneration;#N/A;0.08111129;#N/A;#N/A;#N/A;0.032153447;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0744;PRMT3;ENSG00000185238;HGNC:30163;10196;Protein arginine N-methyltransferase 3 (EC 2.1.1.319) (Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3);O60678;#N/A;https://platform.opentargets.org/target/ENSG00000185238;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2133;752;1011;684;438;4_Low;82;2.83;0.03;0.01;79;2.04;0.03;0.03;3;0.79;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.1;0.38;0.02;Cancer;#N/A;0.009609076;#N/A;0.016425771;#N/A;0.053191142;#N/A;#N/A;#N/A;#N/A;0.00971954;#N/A;0.002956639;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1493;ZNF696;ENSG00000185730;HGNC:25872;79943;Zinc finger protein 696;Q9H7X3;#N/A;https://platform.opentargets.org/target/ENSG00000185730;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2872;1135;1012;1422;438;5_None;40;2.82;0.01;0.01;35;1.06;0.01;0.01;5;1.76;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0709;POGK;ENSG00000143157;HGNC:18800;57645;Pogo transposable element with KRAB domain;Q9P215;#N/A;https://platform.opentargets.org/target/ENSG00000143157;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2739;1063;1013;1288;438;5_None;24;2.81;0.01;0.01;17;0.73;0.01;0.01;7;2.08;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.006313257;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0216;ETV3;ENSG00000117036;HGNC:3492;2117;ETS translocation variant 3 (ETS domain transcriptional repressor PE1) (PE-1) (Mitogenic Ets transcriptional suppressor);P41162;https://jaspar.elixir.no/search?q=P41162;https://platform.opentargets.org/target/ENSG00000117036;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2629;1004;1014;1177;438;3_Medium to Low;69;2.8;0.02;0.01;64;0.82;0.03;0.01;4;1.46;0.01;0.01;1;0.53;0.01;0.01;3;0.01;0.19;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0.004819937;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0154;DMRTB1;ENSG00000143006;HGNC:13913;63948;Doublesex- and mab-3-related transcription factor B1;Q96MA1;#N/A;https://platform.opentargets.org/target/ENSG00000143006;2 Zinc-coordinating DNA-binding domains;2.5 DM-type intertwined zinc finger factors;2.5.1 DMRT;3652;1508;1015;1469;1168;5_None;65;2.77;0.02;0.01;64;2.53;0.03;0.03;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0380;HOXA6;ENSG00000106006;HGNC:5107;3203;Homeobox protein Hox-A6 (Homeobox protein Hox-1B);P31267;https://jaspar.elixir.no/search?q=P31267;https://platform.opentargets.org/target/ENSG00000106006;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2264;824;1016;810;438;3_Medium to Low;93;2.76;0.03;0.01;90;1.7;0.04;0.02;2;0.56;0;0;1;0.5;0.01;0.01;5;0.06;0.31;0.02;Cancer;#N/A;#N/A;0.003695799;0.002587059;#N/A;0.032386503;0.022913951;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1029;ZBTB14;ENSG00000198081;HGNC:12860;7541;Zinc finger and BTB domain-containing protein 14 (Zinc finger protein 161 homolog) (Zfp-161) (Zinc finger protein 478) (Zinc finger protein 5 homolog) (ZF5) (Zfp-5) (hZF5);O43829;https://jaspar.elixir.no/search?q=O43829;https://platform.opentargets.org/target/ENSG00000198081;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3204;1338;1017;1019;1168;5_None;71;2.75;0.02;0.01;68;1.74;0.03;0.02;2;0.46;0;0;1;0.55;0.01;0.01;3;0.03;0.19;0.01;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.009402099;0.003326219;#N/A;#N/A;#N/A;0.013304875;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1200;ZNF257;ENSG00000197134;HGNC:13498;113835;Zinc finger protein 257 (Bone marrow zinc finger 4) (BMZF-4);Q9Y2Q1;https://jaspar.elixir.no/search?q=Q9Y2Q1;https://platform.opentargets.org/target/ENSG00000197134;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2447;918;1018;261;1168;5_None;31;2.75;0.01;0.01;25;0.91;0.01;0.01;6;1.84;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.45;0.19;0.12;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;0.447001981;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1193;ZNF248;ENSG00000198105;HGNC:13041;57209;Zinc finger protein 248;Q8NDW4;#N/A;https://platform.opentargets.org/target/ENSG00000198105;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2510;942;1019;1053;438;5_None;44;2.74;0.01;0.01;40;1.52;0.02;0.02;4;1.23;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.00649536;#N/A;#N/A;0.015317032;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1033;ZBTB2;ENSG00000181472;HGNC:20868;57621;Zinc finger and BTB domain-containing protein 2;Q8N680;#N/A;https://platform.opentargets.org/target/ENSG00000181472;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2321;852;1020;1119;182;5_None;43;2.74;0.01;0.01;36;0.46;0.01;0.01;7;2.29;0.01;0.02;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.016034004;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1416;ZNF585B;ENSG00000245680;HGNC:30948;92285;Zinc finger protein 585B (zinc finger protein 41-like protein);Q52M93;#N/A;https://platform.opentargets.org/target/ENSG00000245680;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1818;613;1021;359;438;5_None;18;2.73;0.01;0.01;11;0.67;0;0.01;7;2.06;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.3;0.13;0.08;Alzheimer Disease;#N/A;#N/A;0.232494957;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.071698492;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1403;ZNF573;ENSG00000189144;HGNC:26420;126231;Zinc finger protein 573;Q86YE8;#N/A;https://platform.opentargets.org/target/ENSG00000189144;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2566;973;1022;1106;438;5_None;33;2.73;0.01;0.01;29;0.99;0.01;0.01;2;0.68;0;0;2;1.06;0.02;0.02;2;0.02;0.13;0;Alzheimer Disease;#N/A;#N/A;0.009256659;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1325;ZNF470;ENSG00000197016;HGNC:22220;388566;Zinc finger protein 470 (Chondrogenesis zinc finger protein 1) (CZF-1);Q6ECI4;#N/A;https://platform.opentargets.org/target/ENSG00000197016;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2674;1032;1023;1469;182;5_None;17;2.72;0.01;0.01;10;0.51;0;0.01;7;2.21;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1635;ZSCAN5B;ENSG00000197213;HGNC:34246;342933;Zinc finger and SCAN domain-containing protein 5B;A6NJL1;#N/A;https://platform.opentargets.org/target/ENSG00000197213;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3483;1462;1024;1291;1168;5_None;59;2.72;0.02;0.01;57;2.05;0.02;0.03;2;0.68;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0990;TSC22D1;ENSG00000102804;HGNC:16826;8848;TSC22 domain family protein 1 (Cerebral protein 2) (Regulatory protein TSC-22) (TGFB-stimulated clone 22 homolog) (Transforming growth factor beta-1-induced transcript 4 protein);Q15714;#N/A;https://platform.opentargets.org/target/ENSG00000102804;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2011;696;1025;804;182;5_None;103;2.72;0.03;0.01;98;1.31;0.04;0.02;5;1.41;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.07;0.31;0.02;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.026386187;#N/A;0.005174118;#N/A;0.015152774;#N/A;#N/A;#N/A;#N/A;#N/A;0.016887746;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Inhibits;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0198;EMX1;ENSG00000135638;HGNC:3340;2016;Homeobox protein EMX1 (Empty spiracles homolog 1) (Empty spiracles-like protein 1);Q04741;https://jaspar.elixir.no/search?q=Q04741;https://platform.opentargets.org/target/ENSG00000135638;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2628;1003;1026;1164;438;3_Medium to Low;94;2.71;0.03;0.01;91;1.64;0.04;0.02;3;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.009086942;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1175;ZNF22;ENSG00000165512;HGNC:13012;7570;Zinc finger protein 22 (Zinc finger protein KOX15) (Zinc finger protein Krox-26);P17026;#N/A;https://platform.opentargets.org/target/ENSG00000165512;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2678;1033;1027;1213;438;5_None;47;2.71;0.02;0.01;44;1.93;0.02;0.03;3;0.78;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009403754;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1322;ZNF467;ENSG00000181444;HGNC:23154;168544;Zinc finger protein 467;Q7Z7K2;#N/A;https://platform.opentargets.org/target/ENSG00000181444;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2551;964;1028;1085;438;5_None;71;2.71;0.02;0.01;69;1.99;0.03;0.03;2;0.71;0;0;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Osteoporosis;#N/A;#N/A;0.003695799;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.011087396;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0735;PRDM15;ENSG00000141956;HGNC:13999;63977;PR domain zinc finger protein 15 (EC 2.1.1.-) (PR domain-containing protein 15) (Zinc finger protein 298);P57071;#N/A;https://platform.opentargets.org/target/ENSG00000141956;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2551;964;1029;354;1168;5_None;46;2.7;0.01;0.01;39;0.73;0.02;0.01;7;1.97;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.31;0.19;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.025258544;0.032943938;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.25306593;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0466;KLF17;ENSG00000171872;HGNC:18830;128209;Krueppel-like factor 17 (Zinc finger protein 393);Q5JT82;https://jaspar.elixir.no/search?q=Q5JT82;https://platform.opentargets.org/target/ENSG00000171872;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.1 Three-zinc finger Krüppel-related;1643;529;1030;175;438;5_None;55;2.7;0.02;0.01;49;1.05;0.02;0.01;6;1.65;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.6;0.19;0.15;Alzheimer Disease;#N/A;#N/A;0.258912373;#N/A;#N/A;0.085030857;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.258912373;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0769;REPIN1;ENSG00000214022;HGNC:17922;29803;Replication initiator 1 (60 kDa origin-specific DNA-binding protein) (60 kDa replication initiation region protein) (ATT-binding protein) (DHFR oribeta-binding protein RIP60) (Zinc finger protein 464);Q9BWE0;#N/A;https://platform.opentargets.org/target/ENSG00000214022;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2119;744;1031;650;438;5_None;131;2.7;0.04;0.01;129;2.09;0.05;0.03;2;0.6;0;0;#N/A;#N/A;#N/A;#N/A;6;0.11;0.38;0.03;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.035629063;0.001478319;#N/A;0.026277939;0.003695799;0.003695799;#N/A;#N/A;0.036218826;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0381;HOXA7;ENSG00000122592;HGNC:5108;3204;Homeobox protein Hox-A7 (Homeobox protein Hox 1.1) (Homeobox protein Hox-1A);P31268;https://jaspar.elixir.no/search?q=P31268;https://platform.opentargets.org/target/ENSG00000122592;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;2070;723;1032;600;438;4_Low;157;2.7;0.05;0.01;155;2.11;0.06;0.03;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;8;0.12;0.5;0.03;Cancer;#N/A;#N/A;#N/A;0.002587059;0.017000673;0.073487535;0.022913951;0.002217479;#N/A;#N/A;0.002217479;#N/A;0.002587059;0.001478319;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1252;ZNF34;ENSG00000196378;HGNC:13098;80778;Zinc finger protein 34 (Zinc finger protein KOX32);Q8IZ26;#N/A;https://platform.opentargets.org/target/ENSG00000196378;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3521;1476;1033;1320;1168;5_None;75;2.7;0.02;0.01;73;2.16;0.03;0.03;2;0.54;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.004922783;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0618;NKX2-4;ENSG00000125816;HGNC:7837;644524;Homeobox protein Nkx-2.4 (Homeobox protein NK-2 homolog D);Q9H2Z4;https://jaspar.elixir.no/search?q=Q9H2Z4;https://platform.opentargets.org/target/ENSG00000125816;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3153;1307;1034;951;1168;5_None;31;2.68;0.01;0.01;26;1.13;0.01;0.02;5;1.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.035742351;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1512;ZNF710;ENSG00000140548;HGNC:25352;374655;Zinc finger protein 710;Q8N1W2;#N/A;https://platform.opentargets.org/target/ENSG00000140548;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2615;994;1035;1142;438;5_None;23;2.68;0.01;0.01;15;0.31;0.01;0;8;2.36;0.02;0.02;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.006098068;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1498;ZNF700;ENSG00000196757;HGNC:25292;90592;Zinc finger protein 700;Q9H0M5;#N/A;https://platform.opentargets.org/target/ENSG00000196757;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1452;445;1036;234;182;5_None;45;2.68;0.01;0.01;40;1.35;0.02;0.02;5;1.33;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.5;0.25;0.13;Alzheimer Disease;#N/A;0.064521984;0.217710127;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.217710127;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0796;SAFB2;ENSG00000130254;HGNC:21605;9667;Scaffold attachment factor B2 (SAF-B2);Q14151;#N/A;https://platform.opentargets.org/target/ENSG00000130254;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3336;1413;1037;1131;1168;5_None;39;2.67;0.01;0.01;35;1.19;0.01;0.02;4;1.48;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.00363515;#N/A;#N/A;0.010920674;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1383;ZNF554;ENSG00000172006;HGNC:26629;115196;Zinc finger protein 554;Q86TJ5;#N/A;https://platform.opentargets.org/target/ENSG00000172006;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2692;1042;1038;1216;438;5_None;28;2.67;0.01;0.01;22;1.07;0.01;0.01;6;1.6;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009239496;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1491;ZNF692;ENSG00000171163;HGNC:26049;55657;Zinc finger protein 692 (AICAR responsive element binding protein);Q9BU19;https://jaspar.elixir.no/search?q=Q9BU19;https://platform.opentargets.org/target/ENSG00000171163;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2005;691;1039;528;438;5_None;50;2.66;0.02;0.01;44;0.98;0.02;0.01;6;1.68;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.16;0.13;0.04;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.078709802;0.079137095;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0358;HMBOX1;ENSG00000147421;HGNC:26137;79618;Homeobox-containing protein 1 (Homeobox telomere-binding protein 1) (Telomere-associated homeobox-containing protein 1);Q6NT76;https://jaspar.elixir.no/search?q=Q6NT76;https://platform.opentargets.org/target/ENSG00000147421;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;2159;770;1040;681;438;5_None;58;2.65;0.02;0.01;53;1.25;0.02;0.02;5;1.4;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.1;0.38;0.02;Cancer;#N/A;#N/A;0.002896782;0.003767661;#N/A;0.079759287;#N/A;0.004434958;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0339;HES5;ENSG00000197921;HGNC:19764;388585;Transcription factor HES-5 (Class B basic helix-loop-helix protein 38) (bHLHb38) (Hairy and enhancer of split 5);Q5TA89;https://jaspar.elixir.no/search?q=Q5TA89;https://platform.opentargets.org/target/ENSG00000197921;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;2154;767;1041;675;438;5_None;154;2.65;0.05;0.01;152;1.82;0.06;0.02;1;0.29;0;0;1;0.53;0.01;0.01;8;0.1;0.5;0.02;Cancer;#N/A;#N/A;0.011599046;#N/A;0.012011345;0.037751047;0.001847899;#N/A;#N/A;0.003695799;0.019218152;0.008071687;#N/A;0.003695799;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1191;ZNF239;ENSG00000196793;HGNC:13031;8187;Zinc finger protein 239 (Zinc finger protein HOK-2) (Zinc finger protein MOK-2);Q16600;#N/A;https://platform.opentargets.org/target/ENSG00000196793;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1766;590;1042;286;438;5_None;35;2.64;0.01;0.01;30;1.5;0.01;0.02;5;1.14;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.42;0.19;0.11;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;0.215641419;#N/A;#N/A;#N/A;#N/A;#N/A;0.197969639;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1323;ZNF468;ENSG00000204604;HGNC:33105;90333;Zinc finger protein 468;Q5VIY5;#N/A;https://platform.opentargets.org/target/ENSG00000204604;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2504;940;1043;1023;438;5_None;27;2.62;0.01;0.01;22;0.63;0.01;0.01;4;1.49;0.01;0.01;1;0.5;0.01;0.01;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.025470212;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1338;ZNF490;ENSG00000188033;HGNC:23705;57474;Zinc finger protein 490;Q9ULM2;#N/A;https://platform.opentargets.org/target/ENSG00000188033;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3551;1487;1044;1339;1168;5_None;45;2.62;0.01;0.01;42;1.67;0.02;0.02;3;0.94;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0750;PRRX2;ENSG00000167157;HGNC:21338;51450;Paired mesoderm homeobox protein 2 (Paired-related homeobox protein 2) (PRX-2);Q99811;https://jaspar.elixir.no/search?q=Q99811;https://platform.opentargets.org/target/ENSG00000167157;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;1707;563;1045;224;438;5_None;152;2.6;0.05;0.01;146;1.26;0.06;0.02;6;1.34;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.52;0.5;0.13;Alzheimer Disease;#N/A;#N/A;0.217278602;#N/A;#N/A;0.010667004;#N/A;0.001478319;0.002012157;0.034535184;#N/A;#N/A;0.028529512;0.215915238;#N/A;0.005543698;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1210;ZNF275;ENSG00000063587;HGNC:13069;10838;Zinc finger protein 275;Q9NSD4;#N/A;https://platform.opentargets.org/target/ENSG00000063587;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2697;1045;1046;1469;182;5_None;34;2.59;0.01;0.01;27;0.77;0.01;0.01;7;1.82;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0061;BATF2;ENSG00000168062;HGNC:25163;116071;Basic leucine zipper transcriptional factor ATF-like 2 (B-ATF-2) (Suppressor of AP-1 regulated by IFN) (SARI);Q8N1L9;#N/A;https://platform.opentargets.org/target/ENSG00000168062;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.4 B-ATF-related;2379;879;1047;894;438;5_None;127;2.59;0.04;0.01;126;2.37;0.05;0.03;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.001847899;0.044865255;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0506;MAFG;ENSG00000197063;HGNC:6781;4097;Transcription factor MafG (V-maf musculoaponeurotic fibrosarcoma oncogene homolog G) (hMAF);O15525;https://jaspar.elixir.no/search?q=O15525;https://platform.opentargets.org/target/ENSG00000197063;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.3 Maf-related;2306;843;1048;820;438;5_None;108;2.59;0.03;0.01;108;2.59;0.04;0.04;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.06;0.31;0.02;Cancer;#N/A;#N/A;0.005030392;#N/A;#N/A;0.043100724;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.005174118;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0849;SOX15;ENSG00000129194;HGNC:11196;6665;Protein SOX-15 (Protein SOX-12) (Protein SOX-20);O60248;https://jaspar.elixir.no/search?q=O60248;https://platform.opentargets.org/target/ENSG00000129194;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;2576;978;1049;1089;438;5_None;81;2.58;0.03;0.01;80;2.05;0.03;0.03;#N/A;#N/A;#N/A;#N/A;1;0.53;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.018588439;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0953;TGIF2;ENSG00000118707;HGNC:15764;60436;Homeobox protein TGIF2 (5'-TG-3'-interacting factor 2) (TGF-beta-induced transcription factor 2) (TGFB-induced factor 2);Q9GZN2;https://jaspar.elixir.no/search?q=Q9GZN2;https://platform.opentargets.org/target/ENSG00000118707;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;2285;834;1050;797;438;5_None;87;2.57;0.03;0.01;84;1.5;0.03;0.02;2;0.56;0;0;1;0.51;0.01;0.01;5;0.07;0.31;0.02;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.037313505;0.003695799;#N/A;#N/A;#N/A;#N/A;0.008500337;0.010291772;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1494;ZNF697;ENSG00000143067;HGNC:32034;90874;Zinc finger protein 697;Q5TEC3;#N/A;https://platform.opentargets.org/target/ENSG00000143067;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2754;1071;1051;1265;438;4_Low;43;2.54;0.01;0.01;38;1;0.01;0.01;4;1.03;0.01;0.01;1;0.51;0.01;0.01;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.003582871;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0215;ETV2;ENSG00000105672;HGNC:3491;2116;ETS translocation variant 2 (Ets-related protein 71);O00321;https://jaspar.elixir.no/search?q=O00321;https://platform.opentargets.org/target/ENSG00000105672;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;2052;716;1052;562;438;3_Medium to Low;65;2.54;0.02;0.01;60;0.92;0.02;0.01;5;1.62;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.14;0.38;0.04;Myocardial Infarction;#N/A;#N/A;0.001478319;0.003695799;#N/A;0.038469144;#N/A;0.001478319;0.001478319;0.092090744;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1613;ZNF92;ENSG00000146757;HGNC:13168;168374;Zinc finger protein 92 (Zinc finger protein HTF12);Q03936;#N/A;https://platform.opentargets.org/target/ENSG00000146757;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2692;1042;1053;471;1168;5_None;38;2.53;0.01;0.01;35;1.74;0.01;0.02;3;0.78;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.19;0.13;0.05;Alzheimer Disease;#N/A;#N/A;0.170157042;#N/A;#N/A;0.017111137;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1442;ZNF620;ENSG00000177842;HGNC:28742;253639;Zinc finger protein 620;Q6ZNG0;#N/A;https://platform.opentargets.org/target/ENSG00000177842;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2848;1122;1054;1356;438;5_None;12;2.53;0;0.01;6;0.68;0;0.01;6;1.85;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1041;ZBTB32;ENSG00000011590;HGNC:16763;27033;Zinc finger and BTB domain-containing protein 32 (FANCC-interacting protein) (Fanconi anemia zinc finger protein) (Testis zinc finger protein) (Zinc finger protein 538);Q9Y2Y4;https://jaspar.elixir.no/search?q=Q9Y2Y4;https://platform.opentargets.org/target/ENSG00000011590;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3524;1478;1055;1301;1168;5_None;69;2.52;0.02;0.01;67;2.06;0.03;0.03;2;0.46;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005420505;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1359;ZNF518B;ENSG00000178163;HGNC:29365;85460;Zinc finger protein 518B;Q9C0D4;#N/A;https://platform.opentargets.org/target/ENSG00000178163;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3345;1416;1056;1121;1168;5_None;26;2.51;0.01;0.01;20;0.6;0.01;0.01;6;1.9;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Cancer;#N/A;0.003695799;#N/A;#N/A;#N/A;0.006008342;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0100;CEBPZ;ENSG00000115816;HGNC:24218;10153;CCAAT/enhancer-binding protein zeta (CCAAT-box-binding transcription factor) (CBF) (CCAAT-binding factor);Q03701;#N/A;https://platform.opentargets.org/target/ENSG00000115816;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2871;1134;1057;646;1168;5_None;215;2.51;0.07;0.01;213;1.73;0.08;0.02;2;0.77;0;0.01;#N/A;#N/A;#N/A;#N/A;10;0.11;0.63;0.03;Alzheimer Disease;#N/A;#N/A;0.046150271;#N/A;#N/A;0.030610849;0.004496555;0.002587059;0.003695799;0.005543698;#N/A;0.003695799;0.001478319;0.004414426;#N/A;0.005305113;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1009;WIZ;ENSG00000011451;HGNC:30917;58525;Protein Wiz (Widely-interspaced zinc finger-containing protein) (Zinc finger protein 803);O95785;#N/A;https://platform.opentargets.org/target/ENSG00000011451;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3533;1484;1058;1307;1168;4_Low;68;2.5;0.02;0.01;67;2.12;0.03;0.03;1;0.38;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Atherosclerosis;#N/A;#N/A;#N/A;0.003695799;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tchem;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1477;ZNF676;ENSG00000196109;HGNC:20429;163223;Zinc finger protein 676;Q8N7Q3;#N/A;https://platform.opentargets.org/target/ENSG00000196109;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2919;1169;1059;1422;438;5_None;40;2.5;0.01;0.01;36;1.38;0.01;0.02;4;1.12;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1397;ZNF568;ENSG00000198453;HGNC:25392;374900;Zinc finger protein 568;Q3ZCX4;#N/A;https://platform.opentargets.org/target/ENSG00000198453;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2739;1063;1060;1241;438;4_Low;31;2.49;0.01;0.01;29;2.04;0.01;0.03;2;0.45;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007945967;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1488;ZNF689;ENSG00000156853;HGNC:25173;115509;Zinc finger protein 689;Q96CS4;#N/A;https://platform.opentargets.org/target/ENSG00000156853;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1881;638;1061;638;182;5_None;54;2.49;0.02;0.01;54;2.49;0.02;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.11;0.13;0.03;Alzheimer Disease;#N/A;#N/A;0.101394859;#N/A;#N/A;0.011713628;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1425;ZNF597;ENSG00000167981;HGNC:26573;146434;Zinc finger protein 597;Q96LX8;#N/A;https://platform.opentargets.org/target/ENSG00000167981;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2831;1104;1062;1331;438;5_None;71;2.48;0.02;0.01;70;2.18;0.03;0.03;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004599216;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0423;IKZF5;ENSG00000095574;HGNC:14283;64376;Zinc finger protein Pegasus (Ikaros family zinc finger protein 5);Q9H5V7;#N/A;https://platform.opentargets.org/target/ENSG00000095574;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3587;1494;1063;1356;1168;5_None;27;2.48;0.01;0.01;22;0.6;0.01;0.01;4;1.31;0.01;0.01;1;0.57;0.01;0.01;1;0;0.06;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1335;ZNF486;ENSG00000256229;HGNC:20807;90649;Zinc finger protein 486 (KRAB domain only protein 2);Q96H40;#N/A;https://platform.opentargets.org/target/ENSG00000256229;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2971;1199;1064;1469;438;5_None;21;2.48;0.01;0.01;17;1.21;0.01;0.02;4;1.26;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1336;ZNF487;ENSG00000243660;HGNC:23488;642819;Putative zinc finger protein 487 (KRAB domain only protein 1);B1APH4;#N/A;https://platform.opentargets.org/target/ENSG00000243660;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3589;1495;1065;1356;1168;5_None;21;2.48;0.01;0.01;15;1.01;0.01;0.01;6;1.47;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1212;ZNF277;ENSG00000198839;HGNC:13070;11179;Zinc finger protein 277 (Nuclear receptor-interacting factor 4);Q9NRM2;#N/A;https://platform.opentargets.org/target/ENSG00000198839;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2528;951;1066;1024;438;5_None;36;2.47;0.01;0.01;30;0.93;0.01;0.01;6;1.54;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.025418144;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1424;ZNF596;ENSG00000172748;HGNC:27268;169270;Zinc finger protein 596;Q8TC21;#N/A;https://platform.opentargets.org/target/ENSG00000172748;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2861;1128;1067;1356;438;5_None;21;2.47;0.01;0.01;13;0.25;0.01;0;8;2.22;0.02;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1039;ZBTB26;ENSG00000171448;HGNC:23383;57684;Zinc finger and BTB domain-containing protein 26 (Zinc finger protein 481) (Zinc finger protein Bioref);Q9HCK0;https://jaspar.elixir.no/search?q=Q9HCK0;https://platform.opentargets.org/target/ENSG00000171448;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2067;721;1068;561;438;5_None;36;2.46;0.01;0.01;31;0.66;0.01;0.01;5;1.79;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.14;0.25;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.003695799;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;0.022917084;#N/A;#N/A;#N/A;0.109364685;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1605;ZNF878;ENSG00000257446;HGNC:37246;729747;Zinc finger protein 878;C9JN71;#N/A;https://platform.opentargets.org/target/ENSG00000257446;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2313;846;1069;806;438;5_None;40;2.46;0.01;0.01;38;1.56;0.01;0.02;2;0.89;0;0.01;#N/A;#N/A;#N/A;#N/A;1;0.06;0.06;0.02;Age-Related Macular Degeneration;#N/A;0.064521984;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0034;ARNTL2;ENSG00000029153;HGNC:18984;56938;Aryl hydrocarbon receptor nuclear translocator-like protein 2 (Basic-helix-loop-helix-PAS protein MOP9) (Brain and muscle ARNT-like 2) (CYCLE-like factor) (CLIF) (Class E basic helix-loop-helix protein 6) (bHLHe6) (Member of PAS protein 9) (PAS domain-containing protein 9);Q8WYA1;#N/A;https://platform.opentargets.org/target/ENSG00000029153;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;1656;535;1070;503;83;5_None;110;2.45;0.04;0.01;108;1.78;0.04;0.02;2;0.67;0;0;#N/A;#N/A;#N/A;#N/A;5;0.17;0.31;0.04;Cancer;#N/A;#N/A;0.036823499;#N/A;#N/A;0.095188508;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.011826555;#N/A;0.021587159;3;0.2;Y;Pro-Longevity;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1082;ZFP57;ENSG00000204644;HGNC:18791;346171;Zinc finger protein 57 homolog (Zfp-57) (Zinc finger protein 698);Q9NU63;https://jaspar.elixir.no/search?q=Q9NU63;https://platform.opentargets.org/target/ENSG00000204644;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3330;1408;1071;1091;1168;5_None;86;2.45;0.03;0.01;83;0.96;0.03;0.01;2;0.7;0;0;1;0.78;0.01;0.01;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.004804538;#N/A;#N/A;0.013545779;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1496;ZNF7;ENSG00000147789;HGNC:13139;7553;Zinc finger protein 7 (Zinc finger protein HF.16) (Zinc finger protein KOX4);P17097;#N/A;https://platform.opentargets.org/target/ENSG00000147789;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2866;1132;1072;1356;438;5_None;50;2.44;0.02;0.01;50;2.44;0.02;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1080;ZFP41;ENSG00000181638;HGNC:26786;286128;Zinc finger protein 41 homolog (Zfp-41);Q8N8Y5;#N/A;https://platform.opentargets.org/target/ENSG00000181638;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3532;1483;1073;1291;1168;5_None;20;2.43;0.01;0.01;15;0.66;0.01;0.01;5;1.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.002217479;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0548;MTERF4;ENSG00000122085;HGNC:28785;130916;Transcription termination factor 4, mitochondrial (Mitochondrial transcription termination factor 4) (mTERF domain-containing protein 2) [Cleaved into: mTERF domain-containing protein 2 processed];Q7Z6M4;#N/A;https://platform.opentargets.org/target/ENSG00000122085;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3431;1441;1074;1189;1168;5_None;28;2.43;0.01;0.01;23;0.79;0.01;0.01;5;1.63;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Alzheimer Disease;#N/A;#N/A;0.004434958;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0568;MYRFL;ENSG00000166268;HGNC:26316;196446;Myelin regulatory factor-like protein;Q96LU7;#N/A;https://platform.opentargets.org/target/ENSG00000166268;6 Immunoglobulin fold;6.6 NDT80 domain factors;6.6.1 MYRF-related;3712;1518;1075;1469;1168;5_None;20;2.42;0.01;0.01;13;0.59;0.01;0.01;7;1.83;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1043;ZBTB34;ENSG00000177125;HGNC:31446;403341;Zinc finger and BTB domain-containing protein 34;Q8NCN2;#N/A;https://platform.opentargets.org/target/ENSG00000177125;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3317;1399;1076;1073;1168;5_None;38;2.42;0.01;0.01;33;0.99;0.01;0.01;5;1.43;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.018478993;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1443;ZNF621;ENSG00000172888;HGNC:24787;285268;Zinc finger protein 621;Q6ZSS3;#N/A;https://platform.opentargets.org/target/ENSG00000172888;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2984;1208;1077;1469;438;5_None;16;2.42;0.01;0.01;11;0.87;0;0.01;5;1.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0142;DLX1;ENSG00000144355;HGNC:2914;1745;Homeobox protein DLX-1;P56177;https://jaspar.elixir.no/search?q=P56177;https://platform.opentargets.org/target/ENSG00000144355;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2327;853;1078;811;438;5_None;114;2.42;0.04;0.01;113;2.17;0.04;0.03;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.02;Cancer;#N/A;#N/A;0.003526639;#N/A;0.001478319;0.055480514;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0959;THAP12;ENSG00000137492;HGNC:9440;5612;52 kDa repressor of the inhibitor of the protein kinase (p52rIPK) (58 kDa interferon-induced protein kinase-interacting protein) (p58IPK-interacting protein) (Death-associated protein 4) (THAP domain-containing protein 0) (THAP domain-containing protein 12);O43422;#N/A;https://platform.opentargets.org/target/ENSG00000137492;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;2555;968;1079;1038;438;5_None;35;2.42;0.01;0.01;31;1.04;0.01;0.01;4;1.38;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Alzheimer Disease;#N/A;#N/A;0.018478993;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0820;SIX4;ENSG00000100625;HGNC:10890;51804;Homeobox protein SIX4 (Sine oculis homeobox homolog 4);Q9UIU6;#N/A;https://platform.opentargets.org/target/ENSG00000100625;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.6 HD-SINE;2301;839;1080;783;438;5_None;67;2.4;0.02;0.01;64;1.29;0.03;0.02;2;0.61;0;0;1;0.5;0.01;0.01;4;0.07;0.25;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.021415099;#N/A;#N/A;0.015139265;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.032426965;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0731;PRDM10;ENSG00000170325;HGNC:13995;56980;PR domain zinc finger protein 10 (EC 2.1.1.-) (PR domain-containing protein 10) (Tristanin);Q9NQV6;#N/A;https://platform.opentargets.org/target/ENSG00000170325;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2440;913;1081;921;438;5_None;84;2.39;0.03;0.01;79;0.65;0.03;0.01;5;1.73;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.04;0.31;0.01;Cancer;#N/A;#N/A;0.004619748;#N/A;#N/A;0.025987409;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;0.005174118;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1341;ZNF493;ENSG00000196268;HGNC:23708;284443;Zinc finger protein 493;Q6ZR52;#N/A;https://platform.opentargets.org/target/ENSG00000196268;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2733;1061;1082;1469;182;5_None;63;2.38;0.02;0.01;61;1.75;0.02;0.02;2;0.63;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1445;ZNF624;ENSG00000197566;HGNC:29254;57547;Zinc finger protein 624;Q9P2J8;#N/A;https://platform.opentargets.org/target/ENSG00000197566;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2853;1124;1083;1332;438;5_None;17;2.38;0.01;0.01;12;0.88;0;0.01;5;1.49;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0;0.13;#N/A;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0724;POU5F2;ENSG00000248483;HGNC:26367;134187;POU domain, class 5, transcription factor 2 (Sperm 1 POU domain transcription factor) (SPRM-1);Q8N7G0;#N/A;https://platform.opentargets.org/target/ENSG00000248483;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;2456;921;1084;934;438;5_None;44;2.37;0.01;0.01;43;2;0.02;0.03;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Benign Prostatic Hyperplasia;#N/A;#N/A;#N/A;#N/A;0.038056011;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0115;CREB3;ENSG00000107175;HGNC:2347;10488;Cyclic AMP-responsive element-binding protein 3 (CREB-3) (cAMP-responsive element-binding protein 3) (Leucine zipper protein) (Luman) (Transcription factor LZIP-alpha) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3 (N-terminal Luman) (Transcriptionally active form)];O43889;https://jaspar.elixir.no/search?q=O43889;https://platform.opentargets.org/target/ENSG00000107175;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;2023;701;1085;500;438;5_None;118;2.36;0.04;0.01;117;2.04;0.05;0.03;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;5;0.17;0.31;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;0.027757796;0.021990001;#N/A;0.040471289;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.011580169;#N/A;#N/A;0.068072299;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0509;MAZ;ENSG00000103495;HGNC:6914;4150;Myc-associated zinc finger protein (MAZI) (Pur-1) (Purine-binding transcription factor) (Serum amyloid A-activating factor-1) (SAF-1) (Transcription factor Zif87) (ZF87) (Zinc finger protein 801);P56270;https://jaspar.elixir.no/search?q=P56270;https://platform.opentargets.org/target/ENSG00000103495;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2169;773;1086;645;438;4_Low;143;2.36;0.05;0.01;142;2.01;0.06;0.03;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;9;0.11;0.56;0.03;Cancer;#N/A;#N/A;0.022386009;0.005870455;0.004434958;0.052937618;#N/A;#N/A;#N/A;#N/A;0.002956639;0.007391597;#N/A;0.003695799;0.001478319;0.006837227;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0915;TCF15;ENSG00000125878;HGNC:11627;6939;Transcription factor 15 (TCF-15) (Class A basic helix-loop-helix protein 40) (bHLHa40) (Paraxis) (Protein bHLH-EC2);Q12870;#N/A;https://platform.opentargets.org/target/ENSG00000125878;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3551;1487;1087;1296;1168;5_None;37;2.35;0.01;0.01;31;0.85;0.01;0.01;6;1.5;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;#N/A;Atherosclerosis;#N/A;#N/A;#N/A;0.002217479;#N/A;0.001847899;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0027;ARID3B;ENSG00000179361;HGNC:14350;10620;AT-rich interactive domain-containing protein 3B (ARID domain-containing protein 3B) (Bright and dead ringer protein) (Bright-like protein);Q8IVW6;#N/A;https://platform.opentargets.org/target/ENSG00000179361;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;2432;909;1088;906;438;5_None;100;2.35;0.03;0.01;97;1.48;0.04;0.02;3;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.041588586;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0225;FAM200B;ENSG00000237765;HGNC:27740;285550;Protein FAM200B;P0CF97;#N/A;https://platform.opentargets.org/target/ENSG00000237765;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;2968;1197;1089;711;1168;5_None;26;2.35;0.01;0.01;22;1.22;0.01;0.02;4;1.13;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Parkinson Disease;#N/A;#N/A;0.014783194;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.07498604;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1593;ZNF84;ENSG00000198040;HGNC:13159;7637;Zinc finger protein 84 (Zinc finger protein HPF2);P51523;#N/A;https://platform.opentargets.org/target/ENSG00000198040;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1483;461;1090;211;182;5_None;30;2.34;0.01;0.01;25;0.9;0.01;0.01;5;1.45;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.54;0.25;0.14;Alzheimer Disease;#N/A;#N/A;0.241711749;#N/A;#N/A;0.037769008;#N/A;#N/A;#N/A;#N/A;#N/A;0.022859857;#N/A;0.241711749;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1511;ZNF71;ENSG00000197951;HGNC:13141;58491;Endothelial zinc finger protein induced by tumor necrosis factor alpha (Zinc finger protein 71);Q9NQZ8;#N/A;https://platform.opentargets.org/target/ENSG00000197951;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2808;1089;1091;1279;438;5_None;23;2.33;0.01;0.01;18;0.95;0.01;0.01;5;1.38;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.006832094;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0081;BSX;ENSG00000188909;HGNC:20450;390259;Brain-specific homeobox protein homolog;Q3C1V8;https://jaspar.elixir.no/search?q=Q3C1V8;https://platform.opentargets.org/target/ENSG00000188909;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2819;1098;1092;559;1168;5_None;27;2.33;0.01;0.01;22;0.68;0.01;0.01;4;1.14;0.01;0.01;1;0.51;0.01;0.01;3;0.14;0.19;0.04;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.069221219;#N/A;0.069221219;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0621;NKX2-8;ENSG00000136327;HGNC:16364;26257;Homeobox protein Nkx-2.8 (Homeobox protein NK-2 homolog H);O15522;https://jaspar.elixir.no/search?q=O15522;https://platform.opentargets.org/target/ENSG00000136327;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2440;913;1093;909;438;5_None;57;2.32;0.02;0.01;54;1.52;0.02;0.02;3;0.81;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.036122735;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0542;MSGN1;ENSG00000151379;HGNC:14907;343930;Mesogenin-1 (Paraxial mesoderm-specific mesogenin1) (pMesogenin1) (pMsgn1);A6NI15;https://jaspar.elixir.no/search?q=A6NI15;https://platform.opentargets.org/target/ENSG00000151379;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3731;1525;1094;1469;1168;5_None;26;2.31;0.01;0.01;21;0.9;0.01;0.01;5;1.41;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0315;GPBP1L1;ENSG00000159592;HGNC:28843;60313;Vasculin-like protein 1 (GC-rich promoter-binding protein 1-like 1);Q9HC44;#N/A;https://platform.opentargets.org/target/ENSG00000159592;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2508;941;1095;245;1168;5_None;41;2.31;0.01;0.01;38;1.3;0.01;0.02;3;1.01;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.49;0.25;0.12;Age-Related Hearing Impairment;0.340215596;#N/A;#N/A;#N/A;#N/A;0.005913278;#N/A;#N/A;#N/A;#N/A;#N/A;0.118160229;#N/A;#N/A;#N/A;0.026432621;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0009;AHCTF1;ENSG00000153207;HGNC:24618;25909;Protein ELYS (Embryonic large molecule derived from yolk sac) (Protein MEL-28) (Putative AT-hook-containing transcription factor 1);Q8WYP5;#N/A;https://platform.opentargets.org/target/ENSG00000153207;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2652;1018;1096;1118;438;5_None;26;2.31;0.01;0.01;22;0.93;0.01;0.01;3;0.86;0.01;0.01;1;0.52;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01613832;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0606;NFXL1;ENSG00000170448;HGNC:18726;152518;NF-X1-type zinc finger protein NFXL1 (Ovarian zinc finger protein) (hOZFP);Q6ZNB6;#N/A;https://platform.opentargets.org/target/ENSG00000170448;0 Yet undefined DNA-binding domains;0.4 NFX1-type putative zinc finger factors;0.4.1 NFX1;2842;1119;1097;1307;438;5_None;58;2.3;0.02;0.01;56;1.7;0.02;0.02;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0321;GSX1;ENSG00000169840;HGNC:20374;219409;GS homeobox 1 (Homeobox protein GSH-1);Q9H4S2;https://jaspar.elixir.no/search?q=Q9H4S2;https://platform.opentargets.org/target/ENSG00000169840;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;3605;1500;1098;1339;1168;5_None;38;2.27;0.01;0.01;35;1.2;0.01;0.02;2;0.54;0;0;1;0.52;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1179;ZNF224;ENSG00000267680;HGNC:13017;7767;Zinc finger protein 224 (Bone marrow zinc finger 2) (BMZF-2) (Zinc finger protein 233) (Zinc finger protein 255) (Zinc finger protein 27) (Zinc finger protein KOX22);Q9NZL3;#N/A;https://platform.opentargets.org/target/ENSG00000267680;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1984;682;1099;703;182;5_None;37;2.27;0.01;0.01;34;1.4;0.01;0.02;3;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Alzheimer Disease;#N/A;#N/A;0.06499226;#N/A;#N/A;0.026782516;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0014;AKAP8;ENSG00000105127;HGNC:378;10270;A-kinase anchor protein 8 (AKAP-8) (A-kinase anchor protein 95 kDa) (AKAP 95);O43823;#N/A;https://platform.opentargets.org/target/ENSG00000105127;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3117;1284;1100;849;1168;5_None;48;2.27;0.02;0.01;43;1.02;0.02;0.01;5;1.24;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.054680432;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1447;ZNF626;ENSG00000188171;HGNC:30461;199777;Zinc finger protein 626;Q68DY1;#N/A;https://platform.opentargets.org/target/ENSG00000188171;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3738;1528;1101;1469;1168;5_None;15;2.25;0;0.01;9;0.25;0;0;6;2.01;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1398;ZNF569;ENSG00000196437;HGNC:24737;148266;Zinc finger protein 569;Q5MCW4;#N/A;https://platform.opentargets.org/target/ENSG00000196437;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2077;728;1102;537;438;5_None;318;2.25;0.1;0.01;317;1.98;0.12;0.03;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;10;0.15;0.63;0.04;Cancer;#N/A;#N/A;0.005204072;0.002012157;0.001478319;0.087587286;0.016261514;0.001478319;#N/A;0.002956639;#N/A;#N/A;0.001478319;0.025163322;#N/A;0.007761177;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0975;TIGD5;ENSG00000179886;HGNC:18336;84948;Tigger transposable element-derived protein 5;Q53EQ6;#N/A;https://platform.opentargets.org/target/ENSG00000179886;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3627;1504;1103;1356;1168;5_None;21;2.21;0.01;0.01;15;0.48;0.01;0.01;6;1.73;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1251;ZNF33B;ENSG00000196693;HGNC:13097;7582;Zinc finger protein 33B (Zinc finger protein 11B) (Zinc finger protein KOX2);Q06732;#N/A;https://platform.opentargets.org/target/ENSG00000196693;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3011;1223;1104;1469;438;5_None;14;2.2;0;0.01;9;0.82;0;0.01;5;1.38;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1524;ZNF729;ENSG00000196350;HGNC:32464;100287226;Zinc finger protein 729;A6NN14;#N/A;https://platform.opentargets.org/target/ENSG00000196350;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3071;1265;1105;798;1168;5_None;51;2.19;0.02;0.01;50;1.82;0.02;0.02;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;1;0.07;0.06;0.02;Age-Related Macular Degeneration;#N/A;0.066935287;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1401;ZNF571;ENSG00000180479;HGNC:25000;51276;Zinc finger protein 571;Q7Z3V5;#N/A;https://platform.opentargets.org/target/ENSG00000180479;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2949;1190;1106;1405;438;5_None;28;2.18;0.01;0.01;24;1.01;0.01;0.01;4;1.18;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0360;HMG20B;ENSG00000064961;HGNC:5002;10362;SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (SMARCE1-related protein) (BRCA2-associated factor 35) (HMG box-containing protein 20B) (HMG domain-containing protein 2) (HMG domain-containing protein HMGX2) (Sox-like transcriptional factor) (Structural DNA-binding protein BRAF35);Q9P0W2;#N/A;https://platform.opentargets.org/target/ENSG00000064961;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.2 TOX-related;3189;1331;1107;914;1168;5_None;42;2.18;0.01;0.01;39;1.29;0.02;0.02;3;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;0.006125439;#N/A;0.004434958;0.031907061;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1139;ZNF146;ENSG00000167635;HGNC:12931;7705;Zinc finger protein OZF (Only zinc finger protein) (Zinc finger protein 146);Q15072;#N/A;https://platform.opentargets.org/target/ENSG00000167635;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2315;848;1108;769;438;5_None;320;2.17;0.1;0.01;320;2.17;0.13;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;9;0.08;0.56;0.02;Cancer;#N/A;0.001478319;0.010042579;#N/A;0.003695799;0.030415339;#N/A;0.001847899;#N/A;0.007925435;#N/A;0.001478319;#N/A;0.008898251;#N/A;0.009811306;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1001;USF3;ENSG00000176542;HGNC:30494;205717;Basic helix-loop-helix domain-containing protein USF3 (Upstream transcription factor 3);Q68DE3;#N/A;https://platform.opentargets.org/target/ENSG00000176542;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.0 Uncharacterized/Undefined;3389;1429;1109;1112;1168;5_None;31;2.16;0.01;0.01;25;0.44;0.01;0.01;6;1.71;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;0.004968796;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.011806023;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0006;ADNP2;ENSG00000101544;HGNC:23803;22850;Activity-dependent neuroprotector homeobox protein 2 (ADNP homeobox protein 2) (Zinc finger protein 508);Q6IQ32;#N/A;https://platform.opentargets.org/target/ENSG00000101544;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;2627;1002;1110;1079;438;5_None;31;2.14;0.01;0.01;27;0.81;0.01;0.01;4;1.33;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0;Alzheimer Disease;#N/A;0.006652437;0.009452621;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0090;CCDC17;ENSG00000159588;HGNC:26574;149483;Coiled-coil domain-containing protein 17;Q96LX7;#N/A;https://platform.opentargets.org/target/ENSG00000159588;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2712;1050;1111;433;1168;5_None;33;2.13;0.01;0.01;32;1.76;0.01;0.02;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;3;0.23;0.19;0.06;Age-Related Hearing Impairment;0.097126666;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.095893981;#N/A;#N/A;#N/A;0.033678837;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1514;ZNF713;ENSG00000178665;HGNC:22043;349075;Zinc finger protein 713;Q8N859;#N/A;https://platform.opentargets.org/target/ENSG00000178665;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2613;991;1112;1063;438;5_None;28;2.12;0.01;0.01;24;0.9;0.01;0.01;4;1.22;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.020542994;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1553;ZNF777;ENSG00000196453;HGNC:22213;27153;Zinc finger protein 777;Q9ULD5;#N/A;https://platform.opentargets.org/target/ENSG00000196453;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2555;968;1113;1004;438;5_None;17;2.11;0.01;0.01;12;0.2;0;0;5;1.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.02595544;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1636;ZSCAN5C;ENSG00000204532;HGNC:34294;649137;Zinc finger and SCAN domain-containing protein 5C (Zinc finger and SCAN domain-containing protein 5C pseudogene);A6NGD5;#N/A;https://platform.opentargets.org/target/ENSG00000204532;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3751;1531;1114;1469;1168;5_None;51;2.11;0.02;0.01;51;2.11;0.02;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1627;ZSCAN25;ENSG00000197037;HGNC:21961;221785;Zinc finger and SCAN domain-containing protein 25 (Zinc finger protein 498);Q6NSZ9;#N/A;https://platform.opentargets.org/target/ENSG00000197037;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2786;1080;1115;1233;438;4_Low;30;2.09;0.01;0.01;29;1.82;0.01;0.02;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1598;ZNF846;ENSG00000196605;HGNC:27260;162993;Zinc finger protein 846;Q147U1;#N/A;https://platform.opentargets.org/target/ENSG00000196605;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3023;1230;1116;1469;438;5_None;15;2.09;0;0.01;12;1.31;0;0.02;3;0.78;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1448;ZNF627;ENSG00000198551;HGNC:30570;199692;Zinc finger protein 627;Q7L945;#N/A;https://platform.opentargets.org/target/ENSG00000198551;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2666;1029;1117;1111;438;5_None;23;2.08;0.01;0.01;21;1.05;0.01;0.01;1;0.47;0;0;1;0.57;0.01;0.01;2;0.02;0.13;0;Myocardial Infarction;#N/A;#N/A;0.001538185;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.0153351;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1597;ZNF845;ENSG00000213799;HGNC:25112;91664;Zinc finger protein 845;Q96IR2;#N/A;https://platform.opentargets.org/target/ENSG00000213799;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2302;840;1118;746;438;5_None;42;2.07;0.01;0.01;41;1.68;0.02;0.02;1;0.39;0;0;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Age-Related Macular Degeneration;#N/A;0.077505162;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0656;NR6A1;ENSG00000148200;HGNC:7985;2649;Nuclear receptor subfamily 6 group A member 1 (Germ cell nuclear factor) (GCNF) (hGCNF) (Retinoid receptor-related testis-specific receptor) (RTR) (hRTR);Q15406;https://jaspar.elixir.no/search?q=Q15406;https://platform.opentargets.org/target/ENSG00000148200;2 Zinc-coordinating DNA-binding domains;2.1 Nuclear receptors with C4 zinc fingers;2.1.6 GCNF(NR6);2542;959;1119;985;438;4_Low;60;2.07;0.02;0.01;57;1.31;0.02;0.02;3;0.76;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;#N/A;0.007206807;#N/A;0.019499422;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1484;ZNF683;ENSG00000176083;HGNC:28495;257101;Tissue-resident T-cell transcription regulator protein ZNF683 (Homolog of Blimp-1 in T-cell) (Hobit) (Zinc finger protein 683);Q8IZ20;#N/A;https://platform.opentargets.org/target/ENSG00000176083;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2353;863;1120;795;438;5_None;87;2.07;0.03;0.01;87;2.07;0.03;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.068097757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0510;MBD1;ENSG00000141644;HGNC:6916;4152;Methyl-CpG-binding domain protein 1 (CXXC-type zinc finger protein 3) (Methyl-CpG-binding protein MBD1) (Protein containing methyl-CpG-binding domain 1);Q9UIS9;#N/A;https://platform.opentargets.org/target/ENSG00000141644;2 Zinc-coordinating DNA-binding domains;2.6 CXXC zinc finger factors;2.6.1 CpG-binding proteins;2543;960;1121;984;438;5_None;115;2.07;0.04;0.01;114;1.86;0.04;0.03;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.007391597;0.023028368;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1545;ZNF77;ENSG00000175691;HGNC:13150;58492;Zinc finger protein 77 (ZNFpT1);Q15935;#N/A;https://platform.opentargets.org/target/ENSG00000175691;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2452;920;1122;162;1168;5_None;108;2.06;0.03;0.01;103;0.56;0.04;0.01;5;1.5;0.01;0.01;#N/A;#N/A;#N/A;#N/A;6;0.64;0.38;0.16;Myocardial Infarction;#N/A;#N/A;0.001478319;#N/A;0.003695799;0.010756434;0.007391597;#N/A;0.30640026;0.309726479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1492;ZNF695;ENSG00000197472;HGNC:30954;57116;Zinc finger protein 695 (Zinc finger protein SBZF3);Q8IW36;#N/A;https://platform.opentargets.org/target/ENSG00000197472;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2500;935;1123;939;438;5_None;53;2.06;0.02;0.01;50;1.36;0.02;0.02;3;0.7;0.01;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.037612552;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0957;THAP10;ENSG00000129028;HGNC:23193;56906;THAP domain-containing protein 10;Q9P2Z0;#N/A;https://platform.opentargets.org/target/ENSG00000129028;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;3226;1354;1124;934;1168;5_None;39;2.06;0.01;0.01;37;1.6;0.01;0.02;2;0.45;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.038056011;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1123;ZNF117;ENSG00000152926;HGNC:12897;51351;Zinc finger protein 117 (Provirus-linked krueppel) (h-PLK) (Zinc finger protein HPF9);Q03924;#N/A;https://platform.opentargets.org/target/ENSG00000152926;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3258;1369;1125;965;1168;5_None;57;2.06;0.02;0.01;56;1.57;0.02;0.02;1;0.49;0;0;#N/A;#N/A;#N/A;#N/A;4;0.03;0.25;0.01;Alzheimer Disease;#N/A;#N/A;0.020402388;#N/A;#N/A;0.002012157;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004989328;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0366;HMX3;ENSG00000188620;HGNC:5019;340784;Homeobox protein HMX3 (Homeobox protein H6 family member 3) (Homeobox protein Nkx-5.1);A6NHT5;#N/A;https://platform.opentargets.org/target/ENSG00000188620;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2782;1078;1126;1218;438;5_None;56;2.06;0.02;0.01;55;1.58;0.02;0.02;1;0.48;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.009131702;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0418;HSFY2;ENSG00000169953;HGNC:23950;159119;Heat shock transcription factor, Y-linked (Heat shock transcription factor 2-like protein) (HSF2-like);Q96LI6;#N/A;https://platform.opentargets.org/target/ENSG00000169953;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;3034;1235;1127;1469;438;5_None;65;2.05;0.02;0.01;65;2.05;0.03;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0417;HSFY1;ENSG00000172468;HGNC:18568;86614;Heat shock transcription factor, Y-linked (Heat shock transcription factor 2-like protein) (HSF2-like);Q96LI6;#N/A;https://platform.opentargets.org/target/ENSG00000172468;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;3035;1237;1128;1469;438;5_None;63;2.05;0.02;0.01;63;2.05;0.02;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1256;ZNF346;ENSG00000113761;HGNC:16403;23567;Zinc finger protein 346 (Just another zinc finger protein);Q9UL40;#N/A;https://platform.opentargets.org/target/ENSG00000113761;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3261;1373;1129;964;1168;5_None;44;2.05;0.01;0.01;42;1.54;0.02;0.02;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.004619748;0.02945613;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1438;ZNF615;ENSG00000197619;HGNC:24740;284370;Zinc finger protein 615;Q8N8J6;#N/A;https://platform.opentargets.org/target/ENSG00000197619;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1784;597;1130;216;438;5_None;28;2.04;0.01;0.01;23;0.71;0.01;0.01;5;1.33;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.53;0.19;0.14;Alzheimer Disease;#N/A;#N/A;0.266370557;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.266370557;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0944;TFCP2;ENSG00000135457;HGNC:11748;7024;Alpha-globin transcription factor CP2 (SAA3 enhancer factor) (Transcription factor LSF);Q12800;https://jaspar.elixir.no/search?q=Q12800;https://platform.opentargets.org/target/ENSG00000135457;6 Immunoglobulin fold;6.7 Grainyhead;6.7.0 Uncharacterized/Undefined;2121;745;1131;552;438;5_None;154;2.04;0.05;0.01;154;2.04;0.06;0.03;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.14;0.31;0.04;Alzheimer Disease;#N/A;#N/A;0.100805832;#N/A;#N/A;0.038193678;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;#N/A;0.002587059;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1097;ZHX1;ENSG00000165156;HGNC:12871;11244;Zinc fingers and homeoboxes protein 1;Q9UKY1;#N/A;https://platform.opentargets.org/target/ENSG00000165156;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;2494;933;1132;194;1168;5_None;46;2.03;0.01;0.01;41;0.68;0.02;0.01;5;1.35;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.57;0.19;0.14;Alzheimer Disease;#N/A;#N/A;0.270132308;#N/A;#N/A;0.025556426;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.270132308;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0039;ASCL4;ENSG00000187855;HGNC:24311;121549;Achaete-scute homolog 4 (ASH-4) (hASH4) (Achaete-scute-like protein 4) (Class A basic helix-loop-helix protein 44) (bHLHa44);Q6XD76;#N/A;https://platform.opentargets.org/target/ENSG00000187855;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;3440;1444;1133;1139;1168;5_None;42;2.03;0.01;0.01;38;1.14;0.01;0.02;4;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Heart Failure;#N/A;#N/A;0.004434958;#N/A;#N/A;0.001847899;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1337;ZNF488;ENSG00000265763;HGNC:23535;118738;Zinc finger protein 488;Q96MN9;#N/A;https://platform.opentargets.org/target/ENSG00000265763;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2562;971;1134;990;438;5_None;29;2.02;0.01;0.01;24;0.66;0.01;0.01;5;1.36;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.030138827;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1022;ZBED5;ENSG00000236287;HGNC:30803;58486;Zinc finger BED domain-containing protein 5 (Transposon-derived Buster1 transposase-like protein);Q49AG3;#N/A;https://platform.opentargets.org/target/ENSG00000236287;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;2798;1084;1135;1225;438;5_None;26;2.01;0.01;0.01;22;0.88;0.01;0.01;4;1.14;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.00456725;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1342;ZNF496;ENSG00000162714;HGNC:23713;84838;Zinc finger protein 496 (Zinc finger protein with KRAB and SCAN domains 17);Q96IT1;#N/A;https://platform.opentargets.org/target/ENSG00000162714;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3709;1517;1136;1405;1168;5_None;43;2.01;0.01;0.01;42;1.66;0.02;0.02;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0839;SNAPC5;ENSG00000174446;HGNC:15484;10302;snRNA-activating protein complex subunit 5 (SNAPc subunit 5) (Small nuclear RNA-activating complex polypeptide 5) (snRNA-activating protein complex 19 kDa subunit) (SNAPc 19 kDa subunit);O75971;#N/A;https://platform.opentargets.org/target/ENSG00000174446;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2881;1143;1137;1306;438;5_None;31;2.01;0.01;0.01;30;1.77;0.01;0.02;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.003339281;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1149;ZNF174;ENSG00000103343;HGNC:12963;7727;Zinc finger protein 174 (AW-1) (Zinc finger and SCAN domain-containing protein 8);Q15697;#N/A;https://platform.opentargets.org/target/ENSG00000103343;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3775;1536;1138;1469;1168;5_None;37;1.99;0.01;0.01;36;1.72;0.01;0.02;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0971;TIGD1;ENSG00000221944;HGNC:14523;200765;Tigger transposable element-derived protein 1;Q96MW7;#N/A;https://platform.opentargets.org/target/ENSG00000221944;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2451;919;1139;874;438;4_Low;30;1.99;0.01;0.01;27;0.79;0.01;0.01;3;1.19;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;0.00666362;#N/A;#N/A;0.039306665;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0976;TIGD6;ENSG00000164296;HGNC:18332;81789;Tigger transposable element-derived protein 6;Q17RP2;#N/A;https://platform.opentargets.org/target/ENSG00000164296;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3730;1524;1140;1422;1168;5_None;20;1.99;0.01;0.01;18;1.33;0.01;0.02;2;0.65;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1420;ZNF589;ENSG00000164048;HGNC:16747;51385;Zinc finger protein 589 (Stem cell zinc finger protein 1);Q86UQ0;#N/A;https://platform.opentargets.org/target/ENSG00000164048;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1913;655;1141;590;182;5_None;36;1.98;0.01;0.01;35;1.72;0.01;0.02;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;2;0.13;0.13;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.013181681;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.11431722;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0609;NFYC;ENSG00000066136;HGNC:7806;4802;Nuclear transcription factor Y subunit gamma (CAAT box DNA-binding protein subunit C) (Nuclear transcription factor Y subunit C) (NF-YC) (Transactivator HSM-1/2);Q13952;https://jaspar.elixir.no/search?q=Q13952;https://platform.opentargets.org/target/ENSG00000066136;4 Other all-alpha-helical DNA-binding domains;4.2 Heteromeric CCAAT-binding factors;4.2.1 Heteromeric CCAAT-binding;2398;892;1142;818;438;5_None;71;1.96;0.02;0.01;68;0.71;0.03;0.01;2;0.72;0;0;1;0.54;0.01;0.01;5;0.06;0.31;0.02;Cancer;#N/A;#N/A;0.007391597;#N/A;#N/A;0.041636699;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;0.004804538;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1313;ZNF445;ENSG00000185219;HGNC:21018;353274;Zinc finger protein 445 (ZFP445) (Zinc finger protein 168) (Zinc finger protein with KRAB and SCAN domains 15);P59923;#N/A;https://platform.opentargets.org/target/ENSG00000185219;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3733;1526;1143;1422;1168;5_None;33;1.96;0.01;0.01;31;1.18;0.01;0.02;2;0.78;0;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0773;RFX1;ENSG00000132005;HGNC:9982;5989;MHC class II regulatory factor RFX1 (Enhancer factor C) (EF-C) (Regulatory factor X 1) (RFX) (Transcription factor RFX1);P22670;https://jaspar.elixir.no/search?q=P22670;https://platform.opentargets.org/target/ENSG00000132005;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.3 RFX;2075;727;1144;749;182;5_None;107;1.95;0.03;0.01;105;1.07;0.04;0.01;2;0.88;0;0.01;#N/A;#N/A;#N/A;#N/A;4;0.08;0.25;0.02;Cancer;#N/A;#N/A;#N/A;0.007391597;#N/A;0.063592118;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.00506386;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1197;ZNF253;ENSG00000256771;HGNC:13497;56242;Zinc finger protein 253 (Bone marrow zinc finger 1) (BMZF-1) (Zinc finger protein 411);O75346;#N/A;https://platform.opentargets.org/target/ENSG00000256771;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3243;1360;1145;930;1168;5_None;228;1.95;0.07;0.01;225;1.15;0.09;0.02;3;0.8;0.01;0.01;#N/A;#N/A;#N/A;#N/A;8;0.04;0.5;0.01;Cancer;#N/A;#N/A;0.00502122;0.002012157;0.001478319;0.014906444;#N/A;0.001478319;#N/A;0.002956639;#N/A;#N/A;#N/A;0.00311063;#N/A;0.007761177;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0630;NPAS1;ENSG00000130751;HGNC:7894;4861;Neuronal PAS domain-containing protein 1 (Neuronal PAS1) (Basic-helix-loop-helix-PAS protein MOP5) (Class E basic helix-loop-helix protein 11) (bHLHe11) (Member of PAS protein 5) (PAS domain-containing protein 5);Q99742;#N/A;https://platform.opentargets.org/target/ENSG00000130751;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.5 PAS;2457;922;1146;1228;83;5_None;35;1.95;0.01;0.01;31;0.76;0.01;0.01;4;1.19;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008392543;#N/A;#N/A;3;0.2;Y;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1588;ZNF830;ENSG00000198783;HGNC:28291;91603;Zinc finger protein 830 (Coiled-coil domain-containing protein 16);Q96NB3;#N/A;https://platform.opentargets.org/target/ENSG00000198783;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2234;808;1147;649;438;5_None;34;1.95;0.01;0.01;32;1.14;0.01;0.02;2;0.81;0;0.01;#N/A;#N/A;#N/A;#N/A;2;0.11;0.13;0.03;Age-Related Macular Degeneration;#N/A;0.066935287;#N/A;#N/A;#N/A;0.040284204;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1402;ZNF572;ENSG00000180938;HGNC:26758;137209;Zinc finger protein 572;Q7Z3I7;#N/A;https://platform.opentargets.org/target/ENSG00000180938;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2839;1113;1148;1253;438;5_None;20;1.94;0.01;0.01;17;1.25;0.01;0.02;3;0.69;0.01;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1182;ZNF227;ENSG00000131115;HGNC:13020;7770;Zinc finger protein 227;Q86WZ6;#N/A;https://platform.opentargets.org/target/ENSG00000131115;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1557;491;1149;226;182;5_None;15;1.92;0;0.01;8;0.14;0;0;7;1.78;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.51;0.13;0.13;Alzheimer Disease;#N/A;#N/A;0.257061417;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.257061417;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0168;DUX4;ENSG00000260596;HGNC:50800;100288687;Double homeobox protein 4 (Double homeobox protein 10);Q9UBX2;https://jaspar.elixir.no/search?q=Q9UBX2;https://platform.opentargets.org/target/ENSG00000260596;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;2258;818;1150;670;438;5_None;147;1.91;0.05;0.01;146;1.52;0.06;0.02;1;0.4;0;0;#N/A;#N/A;#N/A;#N/A;2;0.1;0.13;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.098314153;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1507;ZNF706;ENSG00000120963;HGNC:24992;51123;Zinc finger protein 706;Q9Y5V0;#N/A;https://platform.opentargets.org/target/ENSG00000120963;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2660;1023;1151;1071;438;5_None;39;1.91;0.01;0.01;37;1.5;0.01;0.02;2;0.41;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.016302578;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1202;ZNF260;ENSG00000254004;HGNC:13499;339324;Zinc finger protein 260 (Zfp-260);Q3ZCT1;#N/A;https://platform.opentargets.org/target/ENSG00000254004;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3059;1251;1152;1469;438;5_None;46;1.91;0.01;0.01;44;1.36;0.02;0.02;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1239;ZNF320;ENSG00000182986;HGNC:13842;162967;Zinc finger protein 320;A2RRD8;https://jaspar.elixir.no/search?q=A2RRD8;https://platform.opentargets.org/target/ENSG00000182986;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2690;1041;1153;1099;438;5_None;20;1.9;0.01;0.01;17;0.71;0.01;0.01;2;0.68;0;0;1;0.51;0.01;0.01;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.004065378;#N/A;#N/A;0.013399939;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1423;ZNF595;ENSG00000272602;HGNC:27196;152687;Zinc finger protein 595;Q8IYB9;#N/A;https://platform.opentargets.org/target/ENSG00000272602;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2837;1112;1154;1245;438;5_None;57;1.89;0.02;0.01;56;1.54;0.02;0.02;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0685;PBX2;ENSG00000204304;HGNC:8633;5089;Pre-B-cell leukemia transcription factor 2 (Homeobox protein PBX2) (Protein G17);P40425;https://jaspar.elixir.no/search?q=P40425;https://platform.opentargets.org/target/ENSG00000204304;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;1516;473;1155;179;182;5_None;72;1.88;0.02;0.01;67;0.46;0.03;0.01;5;1.42;0.01;0.01;#N/A;#N/A;#N/A;#N/A;5;0.59;0.31;0.15;Alzheimer Disease;#N/A;#N/A;0.279632081;#N/A;#N/A;0.011760304;0.015522354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.279632081;#N/A;0.003695799;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1051;ZBTB43;ENSG00000169155;HGNC:17908;23099;Zinc finger and BTB domain-containing protein 43 (Zinc finger and BTB domain-containing protein 22B) (Zinc finger protein 297B) (ZnF-x);O43298;#N/A;https://platform.opentargets.org/target/ENSG00000169155;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3016;1225;1156;1422;438;5_None;30;1.88;0.01;0.01;27;0.99;0.01;0.01;3;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1360;ZNF519;ENSG00000175322;HGNC:30574;162655;Zinc finger protein 519;Q8TB69;#N/A;https://platform.opentargets.org/target/ENSG00000175322;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3064;1256;1157;1469;438;5_None;23;1.88;0.01;0.01;19;1;0.01;0.01;4;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1003;VAX2;ENSG00000116035;HGNC:12661;25806;Ventral anterior homeobox 2;Q9UIW0;https://jaspar.elixir.no/search?q=Q9UIW0;https://platform.opentargets.org/target/ENSG00000116035;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2789;1081;1158;1193;438;5_None;53;1.87;0.02;0.01;52;1.66;0.02;0.02;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.010365172;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1078;ZFP30;ENSG00000120784;HGNC:29555;22835;Zinc finger protein 30 homolog (Zfp-30) (Zinc finger protein 745);Q9Y2G7;#N/A;https://platform.opentargets.org/target/ENSG00000120784;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2817;1094;1159;1220;438;5_None;24;1.87;0.01;0.01;20;0.64;0.01;0.01;4;1.24;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1333;ZNF484;ENSG00000127081;HGNC:23385;83744;Zinc finger protein 484;Q5JVG2;#N/A;https://platform.opentargets.org/target/ENSG00000127081;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2747;1069;1160;1405;182;5_None;17;1.87;0.01;0.01;13;0.37;0.01;0;4;1.5;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0080;BRF2;ENSG00000104221;HGNC:17298;55290;Transcription factor IIIB 50 kDa subunit (TFIIIB50) (hTFIIIB50) (B-related factor 2) (BRF-2) (hBRFU);Q9HAW0;#N/A;https://platform.opentargets.org/target/ENSG00000104221;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2980;1204;1161;651;1168;5_None;59;1.86;0.02;0.01;58;1.36;0.02;0.02;1;0.49;0;0;#N/A;#N/A;#N/A;#N/A;3;0.11;0.19;0.03;Cancer;#N/A;#N/A;#N/A;0.002217479;#N/A;0.096706437;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1113;ZKSCAN7;ENSG00000196345;HGNC:12955;55888;Zinc finger protein with KRAB and SCAN domains 7 (Zinc finger protein 167) (Zinc finger protein 448) (Zinc finger protein 64);Q9P0L1;#N/A;https://platform.opentargets.org/target/ENSG00000196345;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2659;1021;1162;1059;438;5_None;89;1.85;0.03;0.01;88;1.6;0.03;0.02;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.008800133;#N/A;0.006652437;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1230;ZNF300;ENSG00000145908;HGNC:13091;91975;Zinc finger protein 300;Q96RE9;#N/A;https://platform.opentargets.org/target/ENSG00000145908;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2188;788;1163;843;182;5_None;66;1.84;0.02;0.01;63;1.08;0.02;0.01;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.042770113;0.007391597;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1246;ZNF333;ENSG00000160961;HGNC:15624;84449;Zinc finger protein 333;Q96JL9;#N/A;https://platform.opentargets.org/target/ENSG00000160961;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3801;1538;1164;1469;1168;5_None;17;1.84;0.01;0.01;11;0.22;0;0;6;1.61;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1260;ZNF354A;ENSG00000169131;HGNC:11628;6940;Zinc finger protein 354A (Transcription factor 17) (TCF-17) (Zinc finger protein eZNF);O60765;https://jaspar.elixir.no/search?q=O60765;https://platform.opentargets.org/target/ENSG00000169131;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3755;1532;1165;1422;1168;5_None;67;1.84;0.02;0.01;67;1.84;0.03;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0056;BARHL1;ENSG00000125492;HGNC:953;56751;BarH-like 1 homeobox protein;Q9BZE3;https://jaspar.elixir.no/search?q=Q9BZE3;https://platform.opentargets.org/target/ENSG00000125492;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2929;1173;1166;595;1168;5_None;45;1.83;0.01;0.01;45;1.83;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.13;0.19;0.03;Ischemic Stroke;#N/A;#N/A;0.021435632;#N/A;#N/A;#N/A;#N/A;#N/A;0.09998902;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1638;ZUFSP;ENSG00000153975;HGNC:21224;221302;Zinc finger-containing ubiquitin peptidase 1 (EC 3.4.19.12) (Lys-63-specific deubiquitinase ZUFSP) (DUB) (Zinc finger with UFM1-specific peptidase domain protein);Q96AP4;#N/A;https://platform.opentargets.org/target/ENSG00000153975;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2944;1183;1167;609;1168;5_None;224;1.83;0.07;0.01;224;1.83;0.09;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;7;0.12;0.44;0.03;Cancer;#N/A;0.001478319;0.009300295;#N/A;#N/A;0.07933963;#N/A;#N/A;0.007391597;0.001478319;#N/A;0.006529244;#N/A;0.014903219;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1153;ZNF180;ENSG00000167384;HGNC:12970;7733;Zinc finger protein 180 (HHZ168);Q9UJW8;#N/A;https://platform.opentargets.org/target/ENSG00000167384;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2859;1126;1168;1253;438;5_None;23;1.83;0.01;0.01;20;0.92;0.01;0.01;3;0.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0447;JRKL;ENSG00000183340;HGNC:6200;8690;Jerky protein homolog-like (Human homolog of mouse jerky gene protein) (HHMJG);Q9Y4A0;#N/A;https://platform.opentargets.org/target/ENSG00000183340;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3182;1325;1169;845;1168;5_None;19;1.77;0.01;0.01;15;0.44;0.01;0.01;4;1.33;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.06;0.19;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.049506634;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0613;NKX1-1;ENSG00000235608;HGNC:24975;54729;NK1 transcription factor-related protein 1 (Homeobox protein 153) (HPX-153) (Homeobox protein SAX-2) (NKX-1.1);Q15270;#N/A;https://platform.opentargets.org/target/ENSG00000235608;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2694;1044;1170;356;1168;5_None;20;1.77;0.01;0.01;17;0.96;0.01;0.01;3;0.8;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.31;0.06;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.307402972;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1056;ZBTB48;ENSG00000204859;HGNC:4930;3104;Telomere zinc finger-associated protein (TZAP) (Krueppel-related zinc finger protein 3) (hKR3) (Zinc finger and BTB domain-containing protein 48) (Zinc finger protein 855);P10074;#N/A;https://platform.opentargets.org/target/ENSG00000204859;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2377;878;1171;768;438;3_Medium to Low;57;1.77;0.02;0.01;54;0.77;0.02;0.01;3;1;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.08;0.19;0.02;Cancer;#N/A;#N/A;0.034584181;#N/A;#N/A;0.03980622;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;1;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1566;ZNF79;ENSG00000196152;HGNC:13153;7633;Zinc finger protein 79 (ZNFpT7);Q15937;#N/A;https://platform.opentargets.org/target/ENSG00000196152;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2958;1192;1172;1348;438;5_None;29;1.77;0.01;0.01;26;0.8;0.01;0.01;3;0.97;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1509;ZNF708;ENSG00000182141;HGNC:12945;7562;Zinc finger protein 708 (Zinc finger protein 15) (Zinc finger protein 15-like 1) (Zinc finger protein KOX8);P17019;https://jaspar.elixir.no/search?q=P17019;https://platform.opentargets.org/target/ENSG00000182141;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1959;674;1173;348;438;5_None;44;1.75;0.01;0.01;42;1.19;0.02;0.02;2;0.56;0;0;#N/A;#N/A;#N/A;#N/A;1;0.32;0.06;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.319887036;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1286;ZNF410;ENSG00000119725;HGNC:20144;57862;Zinc finger protein 410 (Another partner for ARF 1);Q86VK4;https://jaspar.elixir.no/search?q=Q86VK4;https://platform.opentargets.org/target/ENSG00000119725;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2074;725;1174;718;182;5_None;110;1.74;0.04;0.01;106;0.62;0.04;0.01;4;1.12;0.01;0.01;#N/A;#N/A;#N/A;#N/A;7;0.09;0.44;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002936107;#N/A;0.017370253;0.006159828;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0.020170437;0.001478319;#N/A;0.032697766;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0232;FIZ1;ENSG00000179943;HGNC:25917;84922;Flt3-interacting zinc finger protein 1 (Zinc finger protein 798);Q96SL8;#N/A;https://platform.opentargets.org/target/ENSG00000179943;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3082;1273;1175;1469;438;5_None;21;1.73;0.01;0.01;21;1.73;0.01;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0942;TFAP2E;ENSG00000116819;HGNC:30774;339488;Transcription factor AP-2-epsilon (AP2-epsilon) (Activating enhancer-binding protein 2-epsilon);Q6VUC0;https://jaspar.elixir.no/search?q=Q6VUC0;https://platform.opentargets.org/target/ENSG00000116819;1 Basic domains;1.3 Basic helix-span-helix factors (bHSH);1.3.1 AP7;2639;1008;1176;1025;438;5_None;42;1.72;0.01;0.01;41;1.22;0.02;0.02;1;0.5;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;#N/A;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;0.008313263;#N/A;#N/A;#N/A;#N/A;#N/A;0.017000673;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0502;MAF1;ENSG00000179632;HGNC:24966;84232;Repressor of RNA polymerase III transcription MAF1 homolog;Q9H063;#N/A;https://platform.opentargets.org/target/ENSG00000179632;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;1810;609;1177;550;83;5_None;72;1.7;0.02;0.01;72;1.7;0.03;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;6;0.15;0.38;0.04;Alzheimer Disease;#N/A;#N/A;0.074839921;#N/A;#N/A;0.03267332;#N/A;0.013304875;0.021692284;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;0.001478319;3;0.2;N;Anti-Longevity;Anti-Longevity;Pro-Longevity;Anti-Longevity;Pro-Longevity;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0918;TCF23;ENSG00000163792;HGNC:18602;150921;Transcription factor 23 (TCF-23) (Class A basic helix-loop-helix protein 24) (bHLHa24);Q7RTU1;#N/A;https://platform.opentargets.org/target/ENSG00000163792;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3815;1540;1178;1469;1168;5_None;19;1.7;0.01;0.01;18;1.49;0.01;0.02;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1612;ZNF91;ENSG00000167232;HGNC:13166;7644;Zinc finger protein 91 (Zinc finger protein HPF7) (Zinc finger protein HTF10);Q05481;#N/A;https://platform.opentargets.org/target/ENSG00000167232;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2886;1149;1179;1269;438;5_None;63;1.67;0.02;0.01;63;1.67;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001932219;#N/A;#N/A;0.005145989;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1551;ZNF775;ENSG00000196456;HGNC:28501;285971;Zinc finger protein 775;Q96BV0;#N/A;https://platform.opentargets.org/target/ENSG00000196456;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3040;1241;1180;1422;438;5_None;18;1.66;0.01;0.01;14;0.43;0.01;0.01;4;1.23;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1614;ZNF93;ENSG00000184635;HGNC:13169;81931;Zinc finger protein 93 (Zinc finger protein 505) (Zinc finger protein HTF34);P35789;https://jaspar.elixir.no/search?q=P35789;https://platform.opentargets.org/target/ENSG00000184635;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2741;1066;1181;1122;438;5_None;38;1.65;0.01;0.01;37;1.34;0.01;0.02;1;0.31;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.015522354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1462;ZNF655;ENSG00000197343;HGNC:30899;79027;Zinc finger protein 655 (Vav-interacting Krueppel-like protein);Q8N720;#N/A;https://platform.opentargets.org/target/ENSG00000197343;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3440;1444;1182;1090;1168;5_None;43;1.65;0.01;0.01;42;1.44;0.02;0.02;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0;Alzheimer Disease;#N/A;#N/A;0.00727867;#N/A;#N/A;0.005926213;#N/A;#N/A;#N/A;0.003695799;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0365;HMX2;ENSG00000188816;HGNC:5018;3167;Homeobox protein HMX2 (Homeobox protein H6 family member 2);A2RU54;#N/A;https://platform.opentargets.org/target/ENSG00000188816;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3575;1492;1183;1224;1168;5_None;57;1.65;0.02;0.01;57;1.65;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008818586;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1049;ZBTB41;ENSG00000177888;HGNC:24819;360023;Zinc finger and BTB domain-containing protein 41;Q5SVQ8;#N/A;https://platform.opentargets.org/target/ENSG00000177888;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2199;793;1184;577;438;5_None;25;1.65;0.01;0.01;24;1.41;0.01;0.02;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;2;0.13;0.13;0.03;Age-Related Macular Degeneration;#N/A;0.129858515;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1405;ZNF575;ENSG00000176472;HGNC:27606;284346;Zinc finger protein 575;Q86XF7;#N/A;https://platform.opentargets.org/target/ENSG00000176472;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3460;1454;1185;1107;1168;5_None;20;1.64;0.01;0.01;19;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.57;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.017000673;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1263;ZNF358;ENSG00000198816;HGNC:16838;140467;Zinc finger protein 358;Q9NW07;#N/A;https://platform.opentargets.org/target/ENSG00000198816;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3823;1541;1186;1469;1168;5_None;8;1.64;0;0.01;4;0.38;0;0.01;4;1.26;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1393;ZNF564;ENSG00000249709;HGNC:31106;163050;Zinc finger protein 564;Q8TBZ8;#N/A;https://platform.opentargets.org/target/ENSG00000249709;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2069;722;1187;444;438;5_None;12;1.63;0;0.01;10;1.09;0;0.01;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;2;0.21;0.13;0.05;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.208852628;#N/A;#N/A;#N/A;0.003695799;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0481;LBX2;ENSG00000179528;HGNC:15525;85474;Transcription factor LBX2 (Ladybird homeobox 2) (Ladybird homeobox protein homolog 2);Q6XYB7;https://jaspar.elixir.no/search?q=Q6XYB7;https://platform.opentargets.org/target/ENSG00000179528;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3190;1333;1188;834;1168;5_None;68;1.63;0.02;0.01;68;1.63;0.03;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.06;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.053888687;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1087;ZFP82;ENSG00000181007;HGNC:28682;284406;Zinc finger protein 82 homolog (Zfp-82) (Zinc finger protein 545);Q8N141;#N/A;https://platform.opentargets.org/target/ENSG00000181007;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3525;1479;1189;1168;1168;5_None;33;1.63;0.01;0.01;31;1.08;0.01;0.01;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011922326;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1562;ZNF786;ENSG00000197362;HGNC:21806;136051;Zinc finger protein 786;Q8N393;#N/A;https://platform.opentargets.org/target/ENSG00000197362;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2841;1116;1190;1469;182;5_None;20;1.63;0.01;0.01;17;0.88;0.01;0.01;3;0.75;0.01;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0122;CREBZF;ENSG00000137504;HGNC:24905;58487;CREB/ATF bZIP transcription factor (Host cell factor-binding transcription factor Zhangfei) (HCF-binding transcription factor Zhangfei);Q9NS37;#N/A;https://platform.opentargets.org/target/ENSG00000137504;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;2473;925;1191;844;438;5_None;65;1.63;0.02;0.01;63;0.89;0.02;0.01;2;0.74;0;0;#N/A;#N/A;#N/A;#N/A;4;0.06;0.25;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.016895961;#N/A;#N/A;#N/A;0.001478319;0.006631905;#N/A;#N/A;#N/A;#N/A;0.030305548;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1228;ZNF3;ENSG00000166526;HGNC:13089;7551;Zinc finger protein 3 (Zinc finger protein HF.12) (Zinc finger protein HZF3.1) (Zinc finger protein KOX25);P17036;#N/A;https://platform.opentargets.org/target/ENSG00000166526;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2667;1030;1192;1037;438;5_None;25;1.63;0.01;0.01;24;1.29;0.01;0.02;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.006652437;#N/A;0.002217479;0.014837194;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0355;HKR1;ENSG00000181666;HGNC:4928;284459;Zinc finger protein 875 (Krueppel-related zinc finger protein 1) (Protein HKR1);P10072;#N/A;https://platform.opentargets.org/target/ENSG00000181666;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2833;1106;1193;1202;438;5_None;28;1.62;0.01;0.01;26;1.06;0.01;0.01;2;0.56;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.009855463;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0531;MIXL1;ENSG00000185155;HGNC:13363;83881;Homeobox protein MIXL1 (Homeodomain protein MIX) (hMix) (MIX1 homeobox-like protein 1) (Mix.1 homeobox-like protein);Q9H2W2;https://jaspar.elixir.no/search?q=Q9H2W2;https://platform.opentargets.org/target/ENSG00000185155;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3226;1354;1194;864;1168;5_None;104;1.61;0.03;0.01;102;0.95;0.04;0.01;2;0.66;0;0;#N/A;#N/A;#N/A;#N/A;5;0.05;0.31;0.01;Benign Prostatic Hyperplasia;#N/A;#N/A;0.006262325;#N/A;0.028827229;0.011436749;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1415;ZNF585A;ENSG00000196967;HGNC:26305;199704;Zinc finger protein 585A;Q6P3V2;#N/A;https://platform.opentargets.org/target/ENSG00000196967;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2072;724;1195;695;182;5_None;19;1.61;0.01;0.01;17;1.1;0.01;0.01;2;0.51;0;0;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Parkinson Disease;#N/A;#N/A;0.021164193;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.071698492;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1160;ZNF197;ENSG00000186448;HGNC:12988;10168;Zinc finger protein 197 (Zinc finger protein with KRAB and SCAN domains 9) (ZnF20) (pVHL-associated KRAB domain-containing protein);O14709;#N/A;https://platform.opentargets.org/target/ENSG00000186448;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2606;989;1196;972;438;5_None;163;1.61;0.05;0.01;163;1.61;0.06;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.03;0.31;0.01;Cancer;#N/A;#N/A;0.002217479;0.001478319;#N/A;0.023478107;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1042;ZBTB33;ENSG00000177485;HGNC:16682;10009;Transcriptional regulator Kaiso (Zinc finger and BTB domain-containing protein 33);Q86T24;https://jaspar.elixir.no/search?q=Q86T24;https://platform.opentargets.org/target/ENSG00000177485;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;2178;778;1197;799;182;5_None;84;1.6;0.03;0.01;83;1.07;0.03;0.01;#N/A;#N/A;#N/A;#N/A;1;0.54;0.01;0.01;4;0.07;0.25;0.02;Cancer;#N/A;#N/A;0.009003376;#N/A;#N/A;0.046037365;#N/A;#N/A;#N/A;#N/A;0.008869917;0.002956639;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0363;HMGN3;ENSG00000118418;HGNC:12312;9324;High mobility group nucleosome-binding domain-containing protein 3 (Thyroid receptor-interacting protein 7) (TR-interacting protein 7) (TRIP-7);Q15651;#N/A;https://platform.opentargets.org/target/ENSG00000118418;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2488;929;1198;852;438;5_None;55;1.59;0.02;0.01;55;1.59;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.002104552;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.05239164;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1055;ZBTB47;ENSG00000114853;HGNC:26955;92999;Zinc finger and BTB domain-containing protein 47 (Zinc finger protein 651);Q9UFB7;#N/A;https://platform.opentargets.org/target/ENSG00000114853;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2890;1150;1199;1253;438;5_None;22;1.59;0.01;0.01;20;0.98;0.01;0.01;2;0.61;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0577;NANOGP8;ENSG00000255192;HGNC:23106;388112;Homeobox protein NANOGP8;Q6NSW7;#N/A;https://platform.opentargets.org/target/ENSG00000255192;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;2351;862;1200;713;438;5_None;42;1.58;0.01;0.01;41;1.37;0.02;0.02;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;0.01168283;#N/A;#N/A;0.075513377;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0217;ETV3L;ENSG00000253831;HGNC:33834;440695;ETS translocation variant 3-like protein;Q6ZN32;#N/A;https://platform.opentargets.org/target/ENSG00000253831;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.2 Ets-related;3725;1521;1201;1356;1168;5_None;12;1.58;0;0.01;9;0.41;0;0.01;3;1.17;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1247;ZNF334;ENSG00000198185;HGNC:15806;55713;Zinc finger protein 334;Q9HCZ1;#N/A;https://platform.opentargets.org/target/ENSG00000198185;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2488;929;1202;1104;182;5_None;45;1.58;0.01;0.01;44;1.33;0.02;0.02;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.017144399;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1495;ZNF699;ENSG00000196110;HGNC:24750;374879;Zinc finger protein 699 (Hangover homolog);Q32M78;#N/A;https://platform.opentargets.org/target/ENSG00000196110;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2618;996;1203;1233;182;5_None;28;1.58;0.01;0.01;26;0.53;0.01;0.01;1;0.37;0;0;1;0.68;0.01;0.01;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1250;ZNF33A;ENSG00000189180;HGNC:13096;7581;Zinc finger protein 33A (Zinc finger and ZAK-associated protein with KRAB domain) (ZZaPK) (Zinc finger protein 11A) (Zinc finger protein KOX31);Q06730;#N/A;https://platform.opentargets.org/target/ENSG00000189180;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2836;1111;1204;1194;438;5_None;32;1.58;0.01;0.01;31;1.34;0.01;0.02;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.002971396;#N/A;#N/A;0.003695799;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0333;HDX;ENSG00000165259;HGNC:26411;139324;Highly divergent homeobox;Q7Z353;#N/A;https://platform.opentargets.org/target/ENSG00000165259;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.10 POU;3842;1544;1205;1469;1168;5_None;13;1.57;0;0.01;9;0.33;0;0;4;1.24;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0927;TEAD2;ENSG00000074219;HGNC:11715;8463;Transcriptional enhancer factor TEF-4 (TEA domain family member 2) (TEAD-2);Q15562;https://jaspar.elixir.no/search?q=Q15562;https://platform.opentargets.org/target/ENSG00000074219;3 Helix-turn-helix domains;3.6 TEA domain factors;3.6.1 TEF1-related;2350;861;1206;962;182;5_None;107;1.57;0.03;0.01;106;1.2;0.04;0.02;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;4;0.03;0.25;0.01;Cancer;#N/A;0.003695799;0.007391597;#N/A;#N/A;0.014901535;#N/A;#N/A;#N/A;#N/A;0.008295015;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1412;ZNF582;ENSG00000018869;HGNC:26421;147948;Zinc finger protein 582;Q96NG8;https://jaspar.elixir.no/search?q=Q96NG8;https://platform.opentargets.org/target/ENSG00000018869;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3329;1407;1207;954;1168;5_None;54;1.56;0.02;0.01;53;1.35;0.02;0.02;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.035490263;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1523;ZNF728;ENSG00000269067;HGNC:32463;388523;Zinc finger protein 728;P0DKX0;#N/A;https://platform.opentargets.org/target/ENSG00000269067;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3845;1546;1208;1469;1168;5_None;26;1.55;0.01;0.01;23;0.67;0.01;0.01;3;0.88;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1580;ZNF813;ENSG00000198346;HGNC:33257;126017;Zinc finger protein 813;Q6ZN06;#N/A;https://platform.opentargets.org/target/ENSG00000198346;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1824;615;1209;177;438;5_None;12;1.54;0;0.01;7;0.04;0;0;5;1.5;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.6;0.19;0.15;Alzheimer Disease;#N/A;#N/A;0.299041497;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.299041497;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1469;ZNF667;ENSG00000198046;HGNC:28854;63934;Zinc finger protein 667;Q5HYK9;https://jaspar.elixir.no/search?q=Q5HYK9;https://platform.opentargets.org/target/ENSG00000198046;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2179;780;1210;787;182;5_None;66;1.53;0.02;0.01;66;1.53;0.03;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.07;0.19;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.044628342;0.009793866;#N/A;#N/A;0.015522354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1426;ZNF598;ENSG00000167962;HGNC:28079;90850;E3 ubiquitin-protein ligase ZNF598 (EC 2.3.2.27) (Zinc finger protein 598);Q86UK7;#N/A;https://platform.opentargets.org/target/ENSG00000167962;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2419;900;1211;770;438;5_None;31;1.53;0.01;0.01;29;0.61;0.01;0.01;1;0.39;0;0;1;0.53;0.01;0.01;3;0.08;0.19;0.02;Cancer;#N/A;#N/A;0.00477374;#N/A;#N/A;0.057314649;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.013489665;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0139;DBX2;ENSG00000185610;HGNC:33186;440097;Homeobox protein DBX2 (Developing brain homeobox protein 2);Q6ZNG2;#N/A;https://platform.opentargets.org/target/ENSG00000185610;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3281;1387;1212;901;1168;5_None;28;1.53;0.01;0.01;25;0.63;0.01;0.01;3;0.9;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005543698;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.039994866;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1122;ZNF114;ENSG00000178150;HGNC:12894;163071;Zinc finger protein 114;Q8NC26;#N/A;https://platform.opentargets.org/target/ENSG00000178150;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1894;644;1213;243;438;5_None;11;1.53;0;0.01;6;0.29;0;0;5;1.24;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.5;0.13;0.13;Alzheimer Disease;#N/A;#N/A;0.247888074;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.247888074;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1307;ZNF44;ENSG00000197857;HGNC:13110;51710;Zinc finger protein 44 (Gonadotropin-inducible ovary transcription repressor 2) (GIOT-2) (Zinc finger protein 55) (Zinc finger protein 58) (Zinc finger protein KOX7);P15621;#N/A;https://platform.opentargets.org/target/ENSG00000197857;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2226;806;1214;574;438;5_None;178;1.52;0.06;0.01;178;1.52;0.07;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;6;0.13;0.38;0.03;Cancer;#N/A;#N/A;0.003908923;#N/A;#N/A;0.086823755;0.016261514;#N/A;0.001478319;#N/A;#N/A;#N/A;0.001478319;0.024892846;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1262;ZNF354C;ENSG00000177932;HGNC:16736;30832;Zinc finger protein 354C (Kidney, ischemia, and developmentally-regulated protein 3) (hKID3);Q86Y25;https://jaspar.elixir.no/search?q=Q86Y25;https://platform.opentargets.org/target/ENSG00000177932;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2819;1098;1215;1422;182;5_None;23;1.52;0.01;0.01;20;0.68;0.01;0.01;3;0.84;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1165;ZNF205;ENSG00000122386;HGNC:12996;7755;Zinc finger protein 205 (Zinc finger protein 210);O95201;#N/A;https://platform.opentargets.org/target/ENSG00000122386;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2823;1101;1216;1169;438;5_None;37;1.52;0.01;0.01;35;1.02;0.01;0.01;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01192162;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1640;ZXDB;ENSG00000198455;HGNC:13199;158586;Zinc finger X-linked protein ZXDB;P98169;#N/A;https://platform.opentargets.org/target/ENSG00000198455;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1878;637;1217;479;182;5_None;16;1.51;0.01;0.01;15;1.2;0.01;0.02;1;0.31;0;0;#N/A;#N/A;#N/A;#N/A;2;0.18;0.13;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.180252919;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1476;ZNF675;ENSG00000197372;HGNC:30768;171392;Zinc finger protein 675 (TRAF6-binding zinc finger protein) (TRAF6-inhibitory zinc finger protein);Q8TD23;https://jaspar.elixir.no/search?q=Q8TD23;https://platform.opentargets.org/target/ENSG00000197372;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3061;1255;1218;1405;438;5_None;32;1.51;0.01;0.01;29;0.55;0.01;0.01;3;0.96;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1106;ZIM2;ENSG00000269699;HGNC:12875;23619;Zinc finger imprinted 2 (Zinc finger protein 656);Q9NZV7;#N/A;https://platform.opentargets.org/target/ENSG00000269699;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3714;1519;1219;1327;1168;5_None;17;1.51;0.01;0.01;14;0.82;0.01;0.01;3;0.68;0.01;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1522;ZNF727;ENSG00000214652;HGNC:22785;442319;Putative zinc finger protein 727 (Zinc finger protein 727 pseudogene);A8MUV8;#N/A;https://platform.opentargets.org/target/ENSG00000214652;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3245;1362;1220;857;1168;5_None;41;1.5;0.01;0.01;39;0.97;0.02;0.01;2;0.54;0;0;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.042145742;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1128;ZNF132;ENSG00000131849;HGNC:12916;7691;Zinc finger protein 132;P52740;#N/A;https://platform.opentargets.org/target/ENSG00000131849;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2418;899;1221;1015;182;5_None;41;1.5;0.01;0.01;39;0.95;0.02;0.01;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.024550064;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0104;CENPS;ENSG00000175279;HGNC:23163;378708;Centromere protein S (CENP-S) (Apoptosis-inducing TAF9-like domain-containing protein 1) (FANCM-associated histone fold protein 1) (FANCM-interacting histone fold protein 1) (Fanconi anemia-associated polypeptide of 16 kDa);Q8N2Z9;#N/A;https://platform.opentargets.org/target/ENSG00000175279;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2639;1008;1222;979;438;5_None;82;1.5;0.03;0.01;80;0.82;0.03;0.01;2;0.68;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.031442074;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0761;RBAK;ENSG00000146587;HGNC:17680;57786;RB-associated KRAB zinc finger protein (RB-associated KRAB repressor) (hRBaK) (Zinc finger protein 769);Q9NYW8;#N/A;https://platform.opentargets.org/target/ENSG00000146587;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2600;987;1223;1195;182;5_None;23;1.49;0.01;0.01;21;0.88;0.01;0.01;2;0.6;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.010348236;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0974;TIGD4;ENSG00000169989;HGNC:18335;201798;Tigger transposable element-derived protein 4;Q8IY51;#N/A;https://platform.opentargets.org/target/ENSG00000169989;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3861;1550;1224;1469;1168;5_None;11;1.48;0;0.01;8;0.71;0;0.01;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0242;FOXB1;ENSG00000171956;HGNC:3799;27023;Forkhead box protein B1 (Transcription factor FKH-5);Q99853;https://jaspar.elixir.no/search?q=Q99853;https://platform.opentargets.org/target/ENSG00000171956;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3622;1503;1225;1229;1168;5_None;28;1.47;0.01;0.01;26;0.95;0.01;0.01;2;0.51;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1169;ZNF212;ENSG00000170260;HGNC:13004;7988;Zinc finger protein 212 (Zinc finger protein C2H2-150);Q9UDV6;#N/A;https://platform.opentargets.org/target/ENSG00000170260;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3863;1551;1226;1469;1168;5_None;18;1.46;0.01;0.01;15;0.52;0.01;0.01;3;0.93;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1489;ZNF69;ENSG00000198429;HGNC:13138;7620;Zinc finger protein 69 (hZNF3);Q9UC07;#N/A;https://platform.opentargets.org/target/ENSG00000198429;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2511;943;1227;846;438;5_None;17;1.46;0.01;0.01;15;0.8;0.01;0.01;2;0.66;0;0;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.054935023;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0962;THAP4;ENSG00000176946;HGNC:23187;51078;Peroxynitrite isomerase THAP4 (EC 5.99.-.-) (Ferric Homo sapiens nitrobindin) (Hs-Nb(III)) (THAP domain-containing protein 4);Q8WY91;#N/A;https://platform.opentargets.org/target/ENSG00000176946;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;3135;1294;1228;1469;438;5_None;11;1.45;0;0.01;7;0.17;0;0;4;1.28;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0156;DMTF1;ENSG00000135164;HGNC:14603;9988;Cyclin-D-binding Myb-like transcription factor 1 (hDMTF1) (Cyclin-D-interacting Myb-like protein 1) (hDMP1);Q9Y222;#N/A;https://platform.opentargets.org/target/ENSG00000135164;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;2425;904;1229;1014;182;5_None;40;1.44;0.01;0.01;38;0.75;0.01;0.01;2;0.69;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;0.008315547;#N/A;#N/A;0.018483056;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0334;HELT;ENSG00000187821;HGNC:33783;391723;Hairy and enhancer of split-related protein HELT (HES/HEY-like transcription factor);A6NFD8;#N/A;https://platform.opentargets.org/target/ENSG00000187821;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;3237;1359;1230;839;1168;5_None;62;1.44;0.02;0.01;60;0.92;0.02;0.01;2;0.52;0;0;#N/A;#N/A;#N/A;#N/A;5;0.06;0.31;0.01;Cancer;#N/A;#N/A;0.002956639;0.001478319;#N/A;0.043778745;#N/A;#N/A;#N/A;0.007022017;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1515;ZNF714;ENSG00000160352;HGNC:27124;148206;Zinc finger protein 714;Q96N38;#N/A;https://platform.opentargets.org/target/ENSG00000160352;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;1724;568;1231;311;182;5_None;31;1.43;0.01;0.01;28;0.45;0.01;0.01;3;0.99;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.37;0.19;0.09;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008315547;#N/A;#N/A;0.060220984;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.304893101;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0340;HES6;ENSG00000144485;HGNC:18254;55502;Transcription cofactor HES-6 (C-HAIRY1) (Class B basic helix-loop-helix protein 41) (bHLHb41) (Hairy and enhancer of split 6);Q96HZ4;https://jaspar.elixir.no/search?q=Q96HZ4;https://platform.opentargets.org/target/ENSG00000144485;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;2374;877;1232;704;438;5_None;85;1.43;0.03;0.01;84;1.17;0.03;0.02;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;3;0.09;0.19;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.074589724;#N/A;#N/A;#N/A;#N/A;0.014783194;#N/A;#N/A;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0234;FLYWCH1;ENSG00000059122;HGNC:25404;84256;FLYWCH-type zinc finger-containing protein 1;Q4VC44;#N/A;https://platform.opentargets.org/target/ENSG00000059122;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2720;1057;1233;1049;438;5_None;30;1.42;0.01;0.01;29;1.16;0.01;0.02;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0.01;Alzheimer Disease;#N/A;#N/A;0.006760114;0.005174118;#N/A;0.006508712;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1035;ZBTB21;ENSG00000173276;HGNC:13083;49854;Zinc finger and BTB domain-containing protein 21 (Zinc finger protein 295);Q9ULJ3;#N/A;https://platform.opentargets.org/target/ENSG00000173276;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2958;1192;1234;1286;438;5_None;34;1.42;0.01;0.01;30;0.18;0.01;0;4;1.23;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.002889721;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0693;PHF1;ENSG00000112511;HGNC:8919;5252;PHD finger protein 1 (Protein PHF1) (hPHF1) (Polycomb-like protein 1) (hPCl1);O43189;#N/A;https://platform.opentargets.org/target/ENSG00000112511;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2898;1155;1235;495;1168;5_None;109;1.42;0.04;0.01;108;1.2;0.04;0.02;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;4;0.18;0.25;0.04;Alzheimer Disease;#N/A;#N/A;0.0787211;#N/A;#N/A;0.050113269;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.008315547;#N/A;0.038571212;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0106;CENPX;ENSG00000169689;HGNC:11422;201254;Centromere protein X (CENP-X) (FANCM-associated histone fold protein 2) (FANCM-interacting histone fold protein 2) (Fanconi anemia-associated polypeptide of 10 kDa) (Retinoic acid-inducible gene D9 protein homolog) (Stimulated by retinoic acid gene 13 protein homolog);A8MT69;#N/A;https://platform.opentargets.org/target/ENSG00000169689;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3067;1257;1236;663;1168;5_None;66;1.42;0.02;0.01;64;0.9;0.03;0.01;2;0.52;0;0;#N/A;#N/A;#N/A;#N/A;5;0.1;0.31;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.008869917;#N/A;#N/A;0.006277403;0.011087396;0.006467647;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.069275691;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0573;NACC2;ENSG00000148411;HGNC:23846;138151;Nucleus accumbens-associated protein 2 (NAC-2) (BTB/POZ domain-containing protein 14A) (Repressor with BTB domain and BEN domain);Q96BF6;#N/A;https://platform.opentargets.org/target/ENSG00000148411;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2438;912;1237;763;438;5_None;43;1.41;0.01;0.01;40;0.49;0.02;0.01;3;0.92;0.01;0.01;#N/A;#N/A;#N/A;#N/A;4;0.08;0.25;0.02;Alzheimer Disease;#N/A;#N/A;0.060901901;#N/A;#N/A;0.006601107;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0169;DUXA;ENSG00000258873;HGNC:32179;503835;Double homeobox protein A;A6NLW8;https://jaspar.elixir.no/search?q=A6NLW8;https://platform.opentargets.org/target/ENSG00000258873;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3068;1260;1238;1392;438;5_None;14;1.4;0;0.01;10;0.44;0;0.01;4;0.96;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003326219;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1548;ZNF772;ENSG00000197128;HGNC:33106;400720;Zinc finger protein 772;Q68DY9;#N/A;https://platform.opentargets.org/target/ENSG00000197128;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3146;1301;1239;1469;438;5_None;13;1.4;0;0.01;10;0.38;0;0.01;3;1.03;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1482;ZNF681;ENSG00000196172;HGNC:26457;148213;Zinc finger protein 681;Q96N22;#N/A;https://platform.opentargets.org/target/ENSG00000196172;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3147;1302;1240;1469;438;5_None;34;1.4;0.01;0.01;33;1.1;0.01;0.01;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0836;SNAI3;ENSG00000185669;HGNC:18411;333929;Zinc finger protein SNAI3 (Protein snail homolog 3) (Zinc finger protein 293);Q3KNW1;https://jaspar.elixir.no/search?q=Q3KNW1;https://platform.opentargets.org/target/ENSG00000185669;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2813;1090;1241;1134;438;5_None;49;1.4;0.02;0.01;46;0.53;0.02;0.01;3;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;0.003695799;#N/A;#N/A;#N/A;0.008278144;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1609;ZNF888;ENSG00000213793;HGNC:38695;388559;Zinc finger protein 888;P0CJ79;#N/A;https://platform.opentargets.org/target/ENSG00000213793;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3879;1554;1242;1469;1168;5_None;8;1.4;0;0.01;5;0.47;0;0.01;3;0.93;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1485;ZNF684;ENSG00000117010;HGNC:28418;127396;Zinc finger protein 684;Q5T5D7;https://jaspar.elixir.no/search?q=Q5T5D7;https://platform.opentargets.org/target/ENSG00000117010;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3880;1555;1243;1469;1168;5_None;14;1.4;0;0.01;11;0.37;0;0.01;3;1.02;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0743;PREB;ENSG00000138073;HGNC:9356;10113;Prolactin regulatory element-binding protein (Mammalian guanine nucleotide exchange factor mSec12);Q9HCU5;#N/A;https://platform.opentargets.org/target/ENSG00000138073;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2881;1143;1244;1199;438;5_None;33;1.4;0.01;0.01;31;0.54;0.01;0.01;1;0.31;0;0;1;0.55;0.01;0.01;4;0.01;0.25;0;Non-Alcoholic Fatty Liver Disease;#N/A;#N/A;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;0.002751317;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1486;ZNF687;ENSG00000143373;HGNC:29277;57592;Zinc finger protein 687;Q8N1G0;#N/A;https://platform.opentargets.org/target/ENSG00000143373;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3575;1492;1245;1162;1168;5_None;29;1.39;0.01;0.01;27;0.51;0.01;0.01;1;0.26;0;0;1;0.62;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.012175603;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1582;ZNF816;ENSG00000180257;HGNC:26995;125893;Zinc finger protein 816;Q0VGE8;https://jaspar.elixir.no/search?q=Q0VGE8;https://platform.opentargets.org/target/ENSG00000180257;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2897;1154;1246;1469;182;4_Low;8;1.39;0;0.01;4;0.01;0;0;3;0.87;0.01;0.01;1;0.51;0.01;0.01;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;5;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1317;ZNF451;ENSG00000112200;HGNC:21091;26036;E3 SUMO-protein ligase ZNF451 (EC 2.3.2.-) (Coactivator for steroid receptors) (E3 SUMO-protein transferase ZNF451) (Zinc finger protein 451);Q9Y4E5;#N/A;https://platform.opentargets.org/target/ENSG00000112200;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3566;1491;1247;1151;1168;5_None;57;1.39;0.02;0.01;55;0.77;0.02;0.01;2;0.62;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011533294;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1185;ZNF230;ENSG00000159882;HGNC:13024;7773;Zinc finger protein 230 (Zinc finger protein FDZF2);Q9UIE0;#N/A;https://platform.opentargets.org/target/ENSG00000159882;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;1905;650;1248;475;182;5_None;15;1.38;0;0.01;13;0.9;0.01;0.01;2;0.48;0;0;#N/A;#N/A;#N/A;#N/A;2;0.19;0.13;0.05;Alzheimer Disease;#N/A;#N/A;0.182945783;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0585;NEUROG1;ENSG00000181965;HGNC:7764;4762;Neurogenin-1 (NGN-1) (Class A basic helix-loop-helix protein 6) (bHLHa6) (Neurogenic basic-helix-loop-helix protein) (Neurogenic differentiation factor 3) (NeuroD3);Q92886;https://jaspar.elixir.no/search?q=Q92886;https://platform.opentargets.org/target/ENSG00000181965;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3463;1456;1249;1046;1168;5_None;123;1.38;0.04;0.01;122;0.85;0.05;0.01;#N/A;#N/A;#N/A;#N/A;1;0.53;0.01;0.01;5;0.02;0.31;0.01;Cancer;#N/A;#N/A;0.004506821;0.002956639;#N/A;0.011361379;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1561;ZNF785;ENSG00000197162;HGNC:26496;146540;Zinc finger protein 785;A8K8V0;#N/A;https://platform.opentargets.org/target/ENSG00000197162;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2079;730;1250;391;438;5_None;10;1.37;0;0.01;9;1.01;0;0.01;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;2;0.26;0.13;0.07;Alzheimer Disease;#N/A;#N/A;0.132077881;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.132077881;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0664;ONECUT3;ENSG00000205922;HGNC:13399;390874;One cut domain family member 3 (One cut homeobox 3) (Transcription factor ONECUT-3) (OC-3);O60422;https://jaspar.elixir.no/search?q=O60422;https://platform.opentargets.org/target/ENSG00000205922;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.9 HD-CUT;3513;1471;1251;1094;1168;5_None;32;1.37;0.01;0.01;31;0.82;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.55;0.01;0.01;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.017924623;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1345;ZNF501;ENSG00000186446;HGNC:23717;115560;Zinc finger protein 501 (Zinc finger protein 52);Q96CX3;#N/A;https://platform.opentargets.org/target/ENSG00000186446;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2265;826;1252;575;438;4_Low;170;1.36;0.05;0.01;170;1.36;0.07;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;6;0.13;0.38;0.03;Cancer;#N/A;#N/A;0.003908923;#N/A;#N/A;0.086823633;0.016261514;#N/A;0.001478319;#N/A;#N/A;#N/A;0.001478319;0.024892846;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0262;FOXI2;ENSG00000186766;HGNC:32448;399823;Forkhead box protein I2;Q6ZQN5;#N/A;https://platform.opentargets.org/target/ENSG00000186766;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3674;1510;1253;1253;1168;5_None;39;1.36;0.01;0.01;37;0.79;0.01;0.01;2;0.57;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0527;MESP1;ENSG00000166823;HGNC:29658;55897;Mesoderm posterior protein 1 (Class C basic helix-loop-helix protein 5) (bHLHc5);Q9BRJ9;#N/A;https://platform.opentargets.org/target/ENSG00000166823;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;2314;847;1254;622;438;5_None;45;1.36;0.01;0.01;43;0.72;0.02;0.01;2;0.64;0;0;#N/A;#N/A;#N/A;#N/A;3;0.12;0.19;0.03;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.066660502;#N/A;#N/A;#N/A;0.027410506;#N/A;#N/A;#N/A;#N/A;#N/A;0.021656395;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1592;ZNF837;ENSG00000152475;HGNC:25164;116412;Zinc finger protein 837;Q96EG3;#N/A;https://platform.opentargets.org/target/ENSG00000152475;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2643;1011;1255;220;1168;5_None;7;1.34;0;0;2;0.02;0;0;5;1.32;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.53;0.13;0.13;Alzheimer Disease;#N/A;#N/A;0.264497851;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.264497851;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0539;MSANTD3;ENSG00000066697;HGNC:23370;91283;Myb/SANT-like DNA-binding domain-containing protein 3;Q96H12;https://jaspar.elixir.no/search?q=Q96H12;https://platform.opentargets.org/target/ENSG00000066697;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2914;1165;1256;1220;438;5_None;27;1.34;0.01;0;24;0.44;0.01;0.01;3;0.9;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0608;NFYB;ENSG00000120837;HGNC:7805;4801;Nuclear transcription factor Y subunit beta (CAAT box DNA-binding protein subunit B) (Nuclear transcription factor Y subunit B) (NF-YB);P25208;https://jaspar.elixir.no/search?q=P25208;https://platform.opentargets.org/target/ENSG00000120837;4 Other all-alpha-helical DNA-binding domains;4.2 Heteromeric CCAAT-binding factors;4.2.1 Heteromeric CCAAT-binding;2503;938;1257;808;438;5_None;86;1.33;0.03;0;85;0.79;0.03;0.01;#N/A;#N/A;#N/A;#N/A;1;0.54;0.01;0.01;4;0.06;0.25;0.02;Cancer;#N/A;0.017739833;0.001478319;#N/A;#N/A;0.039845158;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1629;ZSCAN29;ENSG00000140265;HGNC:26673;146050;Zinc finger and SCAN domain-containing protein 29 (Zinc finger protein 690);Q8IWY8;https://jaspar.elixir.no/search?q=Q8IWY8;https://platform.opentargets.org/target/ENSG00000140265;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3895;1557;1258;1469;1168;5_None;24;1.32;0.01;0;23;1.1;0.01;0.01;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0958;THAP11;ENSG00000168286;HGNC:23194;57215;THAP domain-containing protein 11;Q96EK4;https://jaspar.elixir.no/search?q=Q96EK4;https://platform.opentargets.org/target/ENSG00000168286;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;2817;1094;1259;1120;438;5_None;45;1.32;0.01;0;43;0.52;0.02;0.01;1;0.27;0;0;1;0.53;0.01;0.01;3;0.02;0.19;0;Cancer;0.002217479;#N/A;#N/A;#N/A;#N/A;0.01047347;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003326219;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1546;ZNF770;ENSG00000198146;HGNC:26061;54989;Zinc finger protein 770;Q6IQ21;https://jaspar.elixir.no/search?q=Q6IQ21;https://platform.opentargets.org/target/ENSG00000198146;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2948;1189;1260;1250;438;5_None;16;1.32;0.01;0;14;0.33;0.01;0;1;0.32;0;0;1;0.67;0.01;0.01;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.004051649;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0846;SOX12;ENSG00000177732;HGNC:11198;6666;Transcription factor SOX-12 (Protein SOX-22);O15370;https://jaspar.elixir.no/search?q=O15370;https://platform.opentargets.org/target/ENSG00000177732;4 Other all-alpha-helical DNA-binding domains;4.1 High-mobility group (HMG) domain factors;4.1.1 SOX-related;2532;953;1261;833;438;5_None;61;1.31;0.02;0;61;1.31;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.06;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.054769748;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0629;NOTO;ENSG00000214513;HGNC:31839;344022;Homeobox protein notochord;A8MTQ0;https://jaspar.elixir.no/search?q=A8MTQ0;https://platform.opentargets.org/target/ENSG00000214513;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;3737;1527;1262;1307;1168;5_None;17;1.31;0.01;0;16;1.04;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005174118;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0784;RLF;ENSG00000117000;HGNC:10025;6018;Zinc finger protein Rlf (Rearranged L-myc fusion gene protein) (Zn-15-related protein);Q13129;#N/A;https://platform.opentargets.org/target/ENSG00000117000;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2992;1215;1263;1291;438;5_None;25;1.3;0.01;0;22;0.23;0.01;0;3;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1129;ZNF133;ENSG00000125846;HGNC:12917;7692;Zinc finger protein 133 (Zinc finger protein 150);P52736;#N/A;https://platform.opentargets.org/target/ENSG00000125846;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2928;1171;1264;1226;438;5_None;20;1.3;0.01;0;18;0.57;0.01;0.01;2;0.73;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008572199;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1528;ZNF736;ENSG00000234444;HGNC:32467;728927;Zinc finger protein 736;B4DX44;#N/A;https://platform.opentargets.org/target/ENSG00000234444;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3902;1558;1265;1469;1168;5_None;34;1.3;0.01;0;33;1.07;0.01;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1188;ZNF234;ENSG00000263002;HGNC:13027;10780;Zinc finger protein 234 (Zinc finger protein 269) (Zinc finger protein HZF4);Q14588;#N/A;https://platform.opentargets.org/target/ENSG00000263002;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2440;913;1266;992;182;5_None;30;1.3;0.01;0;28;0.75;0.01;0.01;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;0.01;Alzheimer Disease;#N/A;#N/A;0.029566388;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1490;ZNF691;ENSG00000164011;HGNC:28028;51058;Zinc finger protein 691;Q5VV52;#N/A;https://platform.opentargets.org/target/ENSG00000164011;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3174;1317;1267;1469;438;5_None;11;1.28;0;0;7;0.18;0;0;4;1.11;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1279;ZNF396;ENSG00000186496;HGNC:18824;252884;Zinc finger protein 396 (Zinc finger and SCAN domain-containing protein 14);Q96N95;#N/A;https://platform.opentargets.org/target/ENSG00000186496;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3905;1560;1268;1469;1168;5_None;11;1.28;0;0;7;0.11;0;0;4;1.17;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1435;ZNF611;ENSG00000213020;HGNC:28766;81856;Zinc finger protein 611;Q8N823;#N/A;https://platform.opentargets.org/target/ENSG00000213020;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2873;1138;1269;1422;182;5_None;29;1.27;0.01;0;27;0.63;0.01;0.01;2;0.64;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1601;ZNF852;ENSG00000178917;HGNC:27713;285346;Zinc finger protein 852;Q6ZMS4;#N/A;https://platform.opentargets.org/target/ENSG00000178917;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3177;1321;1270;1469;438;5_None;37;1.27;0.01;0;37;1.27;0.01;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1292;ZNF419;ENSG00000105136;HGNC:20648;79744;Zinc finger protein 419;Q96HQ0;#N/A;https://platform.opentargets.org/target/ENSG00000105136;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2467;924;1271;758;438;5_None;30;1.27;0.01;0;29;0.99;0.01;0.01;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.076224818;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1602;ZNF853;ENSG00000236609;HGNC:21767;54753;Zinc finger protein 853;P0CG23;#N/A;https://platform.opentargets.org/target/ENSG00000236609;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3179;1324;1272;1469;438;5_None;11;1.26;0;0;9;0.61;0;0.01;2;0.65;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1314;ZNF446;ENSG00000083838;HGNC:21036;55663;Zinc finger protein 446 (Zinc finger protein with KRAB and SCAN domains 20);Q9NWS9;#N/A;https://platform.opentargets.org/target/ENSG00000083838;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3773;1535;1273;1332;1168;5_None;20;1.25;0.01;0;18;0.66;0.01;0.01;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1237;ZNF319;ENSG00000166188;HGNC:13644;57567;Zinc finger protein 319;Q9P2F9;#N/A;https://platform.opentargets.org/target/ENSG00000166188;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2614;992;1274;902;438;5_None;8;1.24;0;0;6;0.42;0;0.01;2;0.82;0;0.01;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.045455923;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1120;ZNF107;ENSG00000196247;HGNC:12887;51427;Zinc finger protein 107 (Zinc finger protein 588) (Zinc finger protein ZFD25);Q9UII5;#N/A;https://platform.opentargets.org/target/ENSG00000196247;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2602;988;1275;1145;182;5_None;49;1.24;0.02;0;47;0.76;0.02;0.01;2;0.47;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;0.004452398;0.005174118;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1264;ZNF362;ENSG00000160094;HGNC:18079;149076;Zinc finger protein 362;Q5T0B9;#N/A;https://platform.opentargets.org/target/ENSG00000160094;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3056;1250;1276;1342;438;5_None;41;1.23;0.01;0;38;0.28;0.01;0;3;0.95;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.002751317;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0963;THAP5;ENSG00000177683;HGNC:23188;168451;THAP domain-containing protein 5;Q7Z6K1;#N/A;https://platform.opentargets.org/target/ENSG00000177683;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;3850;1548;1277;1405;1168;5_None;22;1.22;0.01;0;20;0.76;0.01;0.01;2;0.46;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1610;ZNF891;ENSG00000214029;HGNC:38709;101060200;Zinc finger protein 891;A8MT65;#N/A;https://platform.opentargets.org/target/ENSG00000214029;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2368;873;1278;652;438;5_None;11;1.22;0;0;9;0.72;0;0.01;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;1;0.1;0.06;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.104721875;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0121;CREBL2;ENSG00000111269;HGNC:2350;1389;cAMP-responsive element-binding protein-like 2;O60519;#N/A;https://platform.opentargets.org/target/ENSG00000111269;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;3044;1243;1279;1327;438;3_Medium to Low;19;1.21;0.01;0;15;0.06;0.01;0;4;1.15;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;2;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1046;ZBTB39;ENSG00000166860;HGNC:29014;9880;Zinc finger and BTB domain-containing protein 39;O15060;#N/A;https://platform.opentargets.org/target/ENSG00000166860;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3187;1329;1280;1469;438;5_None;11;1.21;0;0;8;0.38;0;0.01;3;0.84;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1544;ZNF768;ENSG00000169957;HGNC:26273;79724;Zinc finger protein 768;Q9H5H4;https://jaspar.elixir.no/search?q=Q9H5H4;https://platform.opentargets.org/target/ENSG00000169957;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2426;905;1281;707;438;5_None;28;1.21;0.01;0;25;0.42;0.01;0.01;3;0.79;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.09;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.090180154;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1428;ZNF600;ENSG00000189190;HGNC:30951;162966;Zinc finger protein 600;Q6ZNG1;#N/A;https://platform.opentargets.org/target/ENSG00000189190;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3189;1331;1282;1469;438;5_None;19;1.21;0.01;0;16;0.25;0.01;0;3;0.96;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1584;ZNF823;ENSG00000197933;HGNC:30936;55552;Zinc finger protein 823 (Zinc finger protein ZFP-36);P16415;#N/A;https://platform.opentargets.org/target/ENSG00000197933;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3190;1333;1283;1469;438;5_None;20;1.21;0.01;0;18;0.55;0.01;0.01;2;0.65;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1270;ZNF383;ENSG00000188283;HGNC:18609;163087;Zinc finger protein 383;Q8NA42;#N/A;https://platform.opentargets.org/target/ENSG00000188283;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2713;1051;1284;991;438;5_None;18;1.2;0.01;0;15;0.2;0.01;0;3;1;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;0.01;Alzheimer Disease;#N/A;#N/A;0.030099595;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1547;ZNF771;ENSG00000179965;HGNC:29653;51333;Zinc finger protein 771 (Mesenchymal stem cell protein DSC43);Q7L3S4;#N/A;https://platform.opentargets.org/target/ENSG00000179965;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2929;1173;1285;1206;438;5_None;13;1.2;0;0;12;0.75;0;0.01;1;0.45;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009609076;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1623;ZSCAN20;ENSG00000121903;HGNC:13093;7579;Zinc finger and SCAN domain-containing protein 20 (Zinc finger protein 31) (Zinc finger protein 360) (Zinc finger protein KOX29);P17040;#N/A;https://platform.opentargets.org/target/ENSG00000121903;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2884;1147;1286;1160;438;5_None;19;1.2;0.01;0;17;0.59;0.01;0.01;2;0.6;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.012196135;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1213;ZNF28;ENSG00000198538;HGNC:13073;7576;Zinc finger protein 28 (Zinc finger protein KOX24);P17035;#N/A;https://platform.opentargets.org/target/ENSG00000198538;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2938;1181;1287;1469;182;5_None;27;1.18;0.01;0;25;0.64;0.01;0.01;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1599;ZNF85;ENSG00000105750;HGNC:13160;7639;Zinc finger protein 85 (Zinc finger protein HPF4) (Zinc finger protein HTF1);Q03923;https://jaspar.elixir.no/search?q=Q03923;https://platform.opentargets.org/target/ENSG00000105750;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2750;1070;1288;1280;182;5_None;54;1.18;0.02;0;53;0.96;0.02;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;0.001478319;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0038;ASCL3;ENSG00000176009;HGNC:740;56676;Achaete-scute homolog 3 (ASH-3) (hASH3) (Class A basic helix-loop-helix protein 42) (bHLHa42) (bHLH transcriptional regulator Sgn-1);Q9NQ33;#N/A;https://platform.opentargets.org/target/ENSG00000176009;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;3250;1364;1289;793;1168;5_None;36;1.18;0.01;0;36;1.18;0.01;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.068238814;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1187;ZNF233;ENSG00000159915;HGNC:30946;353355;Zinc finger protein 233;A6NK53;#N/A;https://platform.opentargets.org/target/ENSG00000159915;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3067;1257;1290;1339;438;5_None;11;1.18;0;0;8;0.19;0;0;3;0.99;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004250168;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1017;YY2;ENSG00000230797;HGNC:31684;404281;Transcription factor YY2 (Yin and yang 2) (YY-2) (Zinc finger protein 631);O15391;https://jaspar.elixir.no/search?q=O15391;https://platform.opentargets.org/target/ENSG00000230797;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3260;1372;1291;801;1168;5_None;34;1.17;0.01;0;34;1.17;0.01;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.07;0.19;0.02;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;0.012800891;#N/A;0.010348236;#N/A;#N/A;#N/A;#N/A;0.043610423;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0162;DPRX;ENSG00000204595;HGNC:32166;503834;Divergent paired-related homeobox;A6NFQ7;https://jaspar.elixir.no/search?q=A6NFQ7;https://platform.opentargets.org/target/ENSG00000204595;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3199;1337;1292;1469;438;5_None;8;1.17;0;0;6;0.58;0;0.01;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1346;ZNF502;ENSG00000196653;HGNC:23718;91392;Zinc finger protein 502;Q8TBZ5;#N/A;https://platform.opentargets.org/target/ENSG00000196653;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2863;1130;1293;1132;438;5_None;23;1.16;0.01;0;20;0.39;0.01;0.01;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.010348236;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1478;ZNF677;ENSG00000197928;HGNC:28730;342926;Zinc finger protein 677;Q86XU0;https://jaspar.elixir.no/search?q=Q86XU0;https://platform.opentargets.org/target/ENSG00000197928;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3418;1438;1294;956;1168;5_None;43;1.15;0.01;0;43;1.15;0.02;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;0.00426829;#N/A;#N/A;0.027345817;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1578;ZNF808;ENSG00000198482;HGNC:33230;388558;Zinc finger protein 808;Q8N4W9;#N/A;https://platform.opentargets.org/target/ENSG00000198482;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2946;1186;1295;1469;182;5_None;10;1.15;0;0;7;0.07;0;0;3;1.08;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1530;ZNF74;ENSG00000185252;HGNC:13144;7625;Zinc finger protein 74 (Zinc finger protein 520) (hZNF7);Q16587;#N/A;https://platform.opentargets.org/target/ENSG00000185252;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2834;1108;1296;1356;182;5_None;11;1.15;0;0;8;0.27;0;0;3;0.88;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1521;ZNF726;ENSG00000213967;HGNC:32462;730087;Zinc finger protein 726;A6NNF4;#N/A;https://platform.opentargets.org/target/ENSG00000213967;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3037;1238;1297;1302;438;5_None;27;1.14;0.01;0;26;0.86;0.01;0.01;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005358908;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0165;DRGX;ENSG00000165606;HGNC:21536;644168;Dorsal root ganglia homeobox protein (Paired-related homeobox protein-like 1);A6NNA5;https://jaspar.elixir.no/search?q=A6NNA5;https://platform.opentargets.org/target/ENSG00000165606;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3935;1565;1298;1469;1168;5_None;26;1.14;0.01;0;23;0.39;0.01;0.01;3;0.75;0.01;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0337;HES3;ENSG00000173673;HGNC:26226;390992;Transcription factor HES-3 (Class B basic helix-loop-helix protein 43) (bHLHb43) (Hairy and enhancer of split 3);Q5TGS1;#N/A;https://platform.opentargets.org/target/ENSG00000173673;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;3289;1392;1299;822;1168;5_None;30;1.13;0.01;0;28;0.32;0.01;0;1;0.28;0;0;1;0.53;0.01;0.01;2;0.06;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.058957885;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1525;ZNF730;ENSG00000183850;HGNC:32470;100129543;Putative zinc finger protein 730;Q6ZMV8;#N/A;https://platform.opentargets.org/target/ENSG00000183850;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3207;1339;1300;1469;438;5_None;13;1.13;0;0;11;0.54;0;0.01;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1431;ZNF607;ENSG00000198182;HGNC:28192;84775;Zinc finger protein 607;Q96SK3;#N/A;https://platform.opentargets.org/target/ENSG00000198182;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3022;1229;1301;1283;438;5_None;15;1.13;0;0;14;0.77;0.01;0.01;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1141;ZNF154;ENSG00000179909;HGNC:12939;7710;Zinc finger protein 154;Q13106;#N/A;https://platform.opentargets.org/target/ENSG00000179909;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3166;1313;1302;696;1168;5_None;61;1.12;0.02;0;60;0.79;0.02;0.01;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;0.001478319;0.091300299;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0540;MSANTD4;ENSG00000170903;HGNC:29383;84437;Myb/SANT-like DNA-binding domain-containing protein 4 (Myb/SANT-like DNA-binding domain containing 4 with coiled-coils);Q8NCY6;#N/A;https://platform.opentargets.org/target/ENSG00000170903;3 Helix-turn-helix domains;3.5 Tryptophan cluster factors;3.5.1 Myb-SANT;3714;1519;1303;1243;1168;5_None;23;1.11;0.01;0;22;0.6;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0.51;0.01;0.01;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.007833448;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1526;ZNF732;ENSG00000186777;HGNC:37138;654254;Zinc finger protein 732;B4DXR9;#N/A;https://platform.opentargets.org/target/ENSG00000186777;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3894;1556;1304;1422;1168;5_None;25;1.11;0.01;0;25;1.11;0.01;0.02;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0082;C11orf95;ENSG00000188070;HGNC:28449;65998;Zinc finger translocation-associated protein (ZFTA);C9JLR9;#N/A;https://platform.opentargets.org/target/ENSG00000188070;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;3703;1515;1305;1230;1168;5_None;30;1.11;0.01;0;28;0.54;0.01;0.01;2;0.57;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008295015;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1194;ZNF25;ENSG00000175395;HGNC:13043;219749;Zinc finger protein 25 (Zinc finger protein KOX19);P17030;#N/A;https://platform.opentargets.org/target/ENSG00000175395;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3868;1552;1306;1394;1168;5_None;25;1.11;0.01;0;24;0.89;0.01;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.001731742;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1132;ZNF136;ENSG00000196646;HGNC:12920;7695;Zinc finger protein 136;P52737;https://jaspar.elixir.no/search?q=P52737;https://platform.opentargets.org/target/ENSG00000196646;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3214;1345;1307;1469;438;5_None;13;1.11;0;0;13;1.11;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1355;ZNF514;ENSG00000144026;HGNC:25894;84874;Zinc finger protein 514;Q96K75;#N/A;https://platform.opentargets.org/target/ENSG00000144026;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2999;1218;1308;1253;438;5_None;19;1.1;0.01;0;19;1.1;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1641;ZXDC;ENSG00000070476;HGNC:28160;79364;Zinc finger protein ZXDC (ZXD-like zinc finger protein);Q2QGD7;#N/A;https://platform.opentargets.org/target/ENSG00000070476;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2617;995;1309;1126;182;5_None;15;1.1;0;0;13;0.62;0.01;0.01;2;0.48;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.015132242;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1150;ZNF175;ENSG00000105497;HGNC:12964;7728;Zinc finger protein 175 (Zinc finger protein OTK18);Q9Y473;https://jaspar.elixir.no/search?q=Q9Y473;https://platform.opentargets.org/target/ENSG00000105497;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3080;1272;1310;1332;438;5_None;31;1.09;0.01;0;30;0.84;0.01;0.01;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1290;ZNF417;ENSG00000173480;HGNC:20646;147687;Zinc finger protein 417;Q8TAU3;https://jaspar.elixir.no/search?q=Q8TAU3;https://platform.opentargets.org/target/ENSG00000173480;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2898;1155;1311;1405;182;5_None;13;1.09;0;0;10;0.33;0;0;3;0.76;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0547;MTERF3;ENSG00000156469;HGNC:24258;51001;Transcription termination factor 3, mitochondrial (Mitochondrial transcription termination factor 3) (mTERF3) (mTERF domain-containing protein 1, mitochondrial);Q96E29;#N/A;https://platform.opentargets.org/target/ENSG00000156469;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3453;1449;1312;973;1168;5_None;40;1.09;0.01;0;40;1.09;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;0.03;0.25;0.01;Cancer;#N/A;#N/A;0.001170506;#N/A;#N/A;0.014808144;0.014783194;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0179;E4F1;ENSG00000167967;HGNC:3121;1877;Transcription factor E4F1 (EC 2.3.2.27) (E4F transcription factor 1) (Putative E3 ubiquitin-protein ligase E4F1) (RING-type E3 ubiquitin transferase E4F1) (Transcription factor E4F) (p120E4F) (p50E4F);Q66K89;#N/A;https://platform.opentargets.org/target/ENSG00000167967;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3509;1470;1313;1028;1168;3_Medium to Low;41;1.08;0.01;0;40;0.68;0.02;0.01;1;0.41;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.025014567;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;3;2;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1205;ZNF266;ENSG00000174652;HGNC:13059;10781;Zinc finger protein 266 (Zinc finger protein HZF1);Q14584;#N/A;https://platform.opentargets.org/target/ENSG00000174652;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2917;1167;1314;1165;438;5_None;43;1.08;0.01;0;40;0.41;0.02;0.01;3;0.66;0.01;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002780858;#N/A;#N/A;0.002104552;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007150206;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1301;ZNF431;ENSG00000196705;HGNC:20809;170959;Zinc finger protein 431;Q8TF32;#N/A;https://platform.opentargets.org/target/ENSG00000196705;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3222;1351;1315;1469;438;5_None;24;1.07;0.01;0;22;0.48;0.01;0.01;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1053;ZBTB45;ENSG00000119574;HGNC:23715;84878;Zinc finger and BTB domain-containing protein 45 (Zinc finger protein 499);Q96K62;#N/A;https://platform.opentargets.org/target/ENSG00000119574;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3704;1516;1316;1220;1168;5_None;19;1.07;0.01;0;18;0.82;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1389;ZNF560;ENSG00000198028;HGNC:26484;147741;Zinc finger protein 560;Q96MR9;#N/A;https://platform.opentargets.org/target/ENSG00000198028;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2687;1038;1317;1188;182;5_None;22;1.07;0.01;0;21;0.62;0.01;0.01;1;0.45;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.010717816;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1186;ZNF232;ENSG00000167840;HGNC:13026;7775;Zinc finger protein 232 (Zinc finger and SCAN domain-containing protein 11);Q9UNY5;#N/A;https://platform.opentargets.org/target/ENSG00000167840;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3074;1268;1318;588;1168;5_None;22;1.07;0.01;0;22;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.13;0.06;0.03;Alzheimer Disease;#N/A;#N/A;0.128090803;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1559;ZNF783;ENSG00000204946;HGNC:27222;100289678;Zinc finger protein 783;Q6ZMS7;#N/A;https://platform.opentargets.org/target/ENSG00000204946;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3226;1354;1319;1469;438;5_None;14;1.07;0;0;12;0.61;0;0.01;2;0.46;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0048;ATF6B;ENSG00000213676;HGNC:2349;1388;Cyclic AMP-dependent transcription factor ATF-6 beta (cAMP-dependent transcription factor ATF-6 beta) (Activating transcription factor 6 beta) (ATF6-beta) (Protein G13) (cAMP response element-binding protein-related protein) (Creb-rp) (cAMP-responsive element-binding protein-like 1) [Cleaved into: Processed cyclic AMP-dependent transcription factor ATF-6 beta];Q99941;#N/A;https://platform.opentargets.org/target/ENSG00000213676;1 Basic domains;1.1 Basic leucine zipper factors (bZIP);1.1.7 CREB-related;2358;869;1320;856;182;3_Medium to Low;72;1.07;0.02;0;71;0.74;0.03;0.01;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;8;0.05;0.5;0.01;Cancer;#N/A;0.008315547;0.009978656;#N/A;#N/A;0.016187187;0.005913278;0.005543698;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0.004065378;0.001478319;2;0.13;Y;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;3;3_Medium to Low;"DGIDB indicates drugs with known MOA but a ""Medium"" development level (drugs in or en route to the clinic) not supported by the other databases (at most Tbio and no further information).";Tbio;4;4;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1135;ZNF140;ENSG00000196387;HGNC:12925;7699;Zinc finger protein 140;P52738;https://jaspar.elixir.no/search?q=P52738;https://platform.opentargets.org/target/ENSG00000196387;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2367;871;1321;608;438;5_None;28;1.07;0.01;0;28;1.07;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.12;0.19;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.031745974;#N/A;#N/A;#N/A;0.087237622;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1144;ZNF16;ENSG00000170631;HGNC:12947;7564;Zinc finger protein 16 (Zinc finger protein KOX9);P17020;https://jaspar.elixir.no/search?q=P17020;https://platform.opentargets.org/target/ENSG00000170631;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2618;996;1322;1114;182;5_None;27;1.06;0.01;0;26;0.69;0.01;0.01;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.016631093;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1052;ZBTB44;ENSG00000196323;HGNC:25001;29068;Zinc finger and BTB domain-containing protein 44 (BTB/POZ domain-containing protein 15) (Zinc finger protein 851);Q8NCP5;#N/A;https://platform.opentargets.org/target/ENSG00000196323;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3673;1509;1323;1182;1168;5_None;18;1.05;0.01;0;16;0.27;0.01;0;1;0.28;0;0;1;0.51;0.01;0.01;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011066863;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1569;ZNF792;ENSG00000180884;HGNC:24751;126375;Zinc finger protein 792;Q3KQV3;#N/A;https://platform.opentargets.org/target/ENSG00000180884;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2975;1201;1324;1469;182;5_None;5;1.05;0;0;2;0.12;0;0;3;0.93;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0807;SCX;ENSG00000260428;HGNC:32322;642658;Basic helix-loop-helix transcription factor scleraxis (Class A basic helix-loop-helix protein 41) (bHLHa41) (Class A basic helix-loop-helix protein 48) (bHLHa48);Q7RTU7;#N/A;https://platform.opentargets.org/target/ENSG00000260428;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3696;1513;1325;1203;1168;5_None;61;1.05;0.02;0;61;1.05;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1541;ZNF764;ENSG00000169951;HGNC:28200;92595;Zinc finger protein 764;Q96H86;#N/A;https://platform.opentargets.org/target/ENSG00000169951;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3963;1568;1326;1469;1168;5_None;12;1.04;0;0;10;0.41;0;0.01;2;0.63;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1287;ZNF414;ENSG00000133250;HGNC:20630;84330;Zinc finger protein 414;Q96IQ9;#N/A;https://platform.opentargets.org/target/ENSG00000133250;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3018;1228;1327;1253;438;5_None;13;1.04;0;0;11;0.55;0;0.01;2;0.49;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1473;ZNF671;ENSG00000083814;HGNC:26279;79891;Zinc finger protein 671;Q8TAW3;#N/A;https://platform.opentargets.org/target/ENSG00000083814;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3174;1317;1328;678;1168;5_None;52;1.03;0.02;0;52;1.03;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.1;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.097573975;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1452;ZNF639;ENSG00000121864;HGNC:30950;51193;Zinc finger protein 639 (Zinc finger protein ANC_2H01) (Zinc finger protein ZASC1);Q9UID6;#N/A;https://platform.opentargets.org/target/ENSG00000121864;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3741;1530;1329;1244;1168;5_None;29;1.03;0.01;0;27;0.39;0.01;0.01;2;0.64;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007781914;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0312;GMEB1;ENSG00000162419;HGNC:4370;10691;Glucocorticoid modulatory element-binding protein 1 (GMEB-1) (DNA-binding protein p96PIF) (Parvovirus initiation factor p96) (PIF p96);Q9Y692;#N/A;https://platform.opentargets.org/target/ENSG00000162419;5 alpha-Helices exposed by beta-structures;5.3 SAND domain factors;5.3.3 GMEB;2500;935;1330;732;438;5_None;19;1.03;0.01;0;17;0.35;0.01;0;2;0.67;0;0;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.012380925;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.071662699;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1110;ZKSCAN3;ENSG00000189298;HGNC:13853;80317;Zinc finger protein with KRAB and SCAN domains 3 (Zinc finger and SCAN domain-containing protein 13) (Zinc finger protein 306) (Zinc finger protein 309) (Zinc finger protein 47 homolog) (Zf47) (Zfp-47);Q9BRR0;https://jaspar.elixir.no/search?q=Q9BRR0;https://platform.opentargets.org/target/ENSG00000189298;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2148;760;1331;734;83;5_None;54;1.02;0.02;0;54;1.02;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;0.007022017;#N/A;#N/A;0.076841891;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;Pro-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0299;GCM1;ENSG00000137270;HGNC:4197;8521;Chorion-specific transcription factor GCMa (hGCMa) (GCM motif protein 1) (Glial cells missing homolog 1);Q9NP62;https://jaspar.elixir.no/search?q=Q9NP62;https://platform.opentargets.org/target/ENSG00000137270;7 beta-Hairpin exposed by an alpha/beta-scaffold;7.2 GCM domain factors;7.2.1 GCM;3610;1501;1332;1110;1168;5_None;49;1.02;0.02;0;47;0.41;0.02;0.01;2;0.62;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.013217613;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1302;ZNF432;ENSG00000256087;HGNC:20810;9668;Zinc finger protein 432;O94892;#N/A;https://platform.opentargets.org/target/ENSG00000256087;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2937;1179;1333;1422;182;5_None;31;1.02;0.01;0;30;0.66;0.01;0.01;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1295;ZNF425;ENSG00000204947;HGNC:20690;155054;Zinc finger protein 425;Q6IV72;#N/A;https://platform.opentargets.org/target/ENSG00000204947;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2985;1209;1334;1469;182;5_None;14;1.01;0;0;12;0.47;0;0.01;2;0.54;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1311;ZNF443;ENSG00000180855;HGNC:20878;10224;Zinc finger protein 443 (Krueppel-type zinc finger protein ZK1);Q9Y2A4;#N/A;https://platform.opentargets.org/target/ENSG00000180855;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2986;1212;1335;1469;182;5_None;17;1.01;0.01;0;16;0.8;0.01;0.01;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0964;THAP6;ENSG00000174796;HGNC:23189;152815;THAP domain-containing protein 6;Q8TBB0;#N/A;https://platform.opentargets.org/target/ENSG00000174796;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;3973;1571;1336;1469;1168;5_None;16;1;0.01;0;15;0.72;0.01;0.01;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0772;REXO4;ENSG00000148300;HGNC:12820;57109;RNA exonuclease 4 (EC 3.1.-.-) (Exonuclease XPMC2) (Prevents mitotic catastrophe 2 protein homolog) (hPMC2);Q9GZR2;#N/A;https://platform.opentargets.org/target/ENSG00000148300;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2701;1046;1337;926;438;5_None;24;1;0.01;0;23;0.77;0.01;0.01;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.037399428;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1529;ZNF737;ENSG00000237440;HGNC:32468;100129842;Zinc finger protein 737 (Zinc finger protein 102);O75373;#N/A;https://platform.opentargets.org/target/ENSG00000237440;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3928;1564;1338;1422;1168;5_None;14;1;0;0;12;0.56;0;0.01;2;0.44;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1536;ZNF75A;ENSG00000162086;HGNC:13146;7627;Zinc finger protein 75A;Q96N20;https://jaspar.elixir.no/search?q=Q96N20;https://platform.opentargets.org/target/ENSG00000162086;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3833;1542;1339;1326;1168;5_None;16;0.99;0.01;0;16;0.99;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.004631001;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1531;ZNF740;ENSG00000139651;HGNC:27465;283337;Zinc finger protein 740 (OriLyt TD-element-binding protein 7);Q8NDX6;https://jaspar.elixir.no/search?q=Q8NDX6;https://platform.opentargets.org/target/ENSG00000139651;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3904;1559;1340;1396;1168;5_None;24;0.99;0.01;0;23;0.73;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1615;ZNF98;ENSG00000197360;HGNC:13174;148198;Zinc finger protein 98 (Zinc finger protein 739) (Zinc finger protein F7175);A6NK75;#N/A;https://platform.opentargets.org/target/ENSG00000197360;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3978;1573;1341;1469;1168;5_None;11;0.98;0;0;9;0.45;0;0.01;2;0.53;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1208;ZNF273;ENSG00000198039;HGNC:13067;10793;Zinc finger protein 273 (Zinc finger protein HZF9);Q14593;#N/A;https://platform.opentargets.org/target/ENSG00000198039;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3122;1285;1342;1342;438;5_None;26;0.98;0.01;0;23;0.15;0.01;0;3;0.82;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1206;ZNF267;ENSG00000185947;HGNC:13060;10308;Zinc finger protein 267 (Zinc finger protein HZF2);Q14586;#N/A;https://platform.opentargets.org/target/ENSG00000185947;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2585;980;1343;1060;182;5_None;39;0.97;0.01;0;38;0.72;0.01;0.01;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;4;0.02;0.25;0.01;Cancer;#N/A;#N/A;0.00214566;#N/A;#N/A;0.010503036;#N/A;#N/A;#N/A;#N/A;0.007022017;#N/A;0.001478319;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1070;ZFHX2;ENSG00000136367;HGNC:20152;85446;Zinc finger homeobox protein 2 (Zinc finger homeodomain protein 2) (ZFH-2);Q9C0A1;#N/A;https://platform.opentargets.org/target/ENSG00000136367;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;2967;1195;1344;1185;438;5_None;50;0.97;0.02;0;49;0.54;0.02;0.01;1;0.43;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;0.003695799;0.005017662;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1203;ZNF263;ENSG00000006194;HGNC:13056;10127;Zinc finger protein 263 (Zinc finger protein FPM315) (Zinc finger protein with KRAB and SCAN domains 12);O14978;https://jaspar.elixir.no/search?q=O14978;https://platform.opentargets.org/target/ENSG00000006194;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2668;1031;1345;885;438;5_None;48;0.97;0.02;0;48;0.97;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;0.05;0.25;0.01;Cancer;#N/A;#N/A;0.003695799;0.002771849;#N/A;0.023769487;0.017739833;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1136;ZNF141;ENSG00000131127;HGNC:12926;7700;Zinc finger protein 141;Q15928;#N/A;https://platform.opentargets.org/target/ENSG00000131127;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3055;1249;1346;1271;438;5_None;13;0.97;0;0;11;0.1;0;0;2;0.87;0;0.01;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007022017;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1570;ZNF793;ENSG00000188227;HGNC:33115;390927;Zinc finger protein 793;Q6ZN11;#N/A;https://platform.opentargets.org/target/ENSG00000188227;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2907;1163;1347;1122;438;5_None;23;0.97;0.01;0;22;0.58;0.01;0.01;1;0.38;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.003695799;#N/A;#N/A;0.011826555;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0805;SCRT1;ENSG00000261678;HGNC:15950;83482;Transcriptional repressor scratch 1 (Scratch homolog 1 zinc finger protein) (SCRT) (Scratch 1) (hScrt);Q9BWW7;https://jaspar.elixir.no/search?q=Q9BWW7;https://platform.opentargets.org/target/ENSG00000261678;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3503;1468;1348;987;1168;5_None;31;0.97;0.01;0;30;0.47;0.01;0.01;1;0.5;0;0;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.005512899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;0.021758144;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1269;ZNF382;ENSG00000161298;HGNC:17409;84911;Zinc finger protein 382 (KRAB/zinc finger suppressor protein 1) (KS1) (Multiple zinc finger and krueppel-associated box protein KS1);Q96SR6;https://jaspar.elixir.no/search?q=Q96SR6;https://platform.opentargets.org/target/ENSG00000161298;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2974;1200;1349;1187;438;5_None;62;0.96;0.02;0;61;0.69;0.02;0.01;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;0.001478319;#N/A;#N/A;#N/A;0.009244794;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1242;ZNF324B;ENSG00000249471;HGNC:33107;388569;Zinc finger protein 324B;Q6AW86;#N/A;https://platform.opentargets.org/target/ENSG00000249471;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3210;1341;1350;1422;438;5_None;11;0.96;0;0;10;0.73;0;0.01;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0970;THYN1;ENSG00000151500;HGNC:29560;29087;Thymocyte nuclear protein 1 (Thymocyte protein Thy28);Q9P016;#N/A;https://platform.opentargets.org/target/ENSG00000151500;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3694;1512;1351;1175;1168;5_None;29;0.96;0.01;0;29;0.96;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.009948664;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1291;ZNF418;ENSG00000196724;HGNC:20647;147686;Zinc finger protein 418;Q8TF45;https://jaspar.elixir.no/search?q=Q8TF45;https://platform.opentargets.org/target/ENSG00000196724;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2256;817;1352;722;182;5_None;35;0.95;0.01;0;33;0.45;0.01;0.01;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;4;0.09;0.25;0.02;Myocardial Infarction;#N/A;#N/A;0.003695799;#N/A;#N/A;0.001478319;#N/A;0.007391597;#N/A;0.073915971;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1196;ZNF251;ENSG00000198169;HGNC:13045;90987;Zinc finger protein 251;Q9BRH9;#N/A;https://platform.opentargets.org/target/ENSG00000198169;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2536;956;1353;745;438;5_None;20;0.95;0.01;0;19;0.7;0.01;0.01;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.01377999;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.067938691;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1487;ZNF688;ENSG00000229809;HGNC:30489;146542;Zinc finger protein 688;P0C7X2;#N/A;https://platform.opentargets.org/target/ENSG00000229809;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3991;1574;1354;1469;1168;5_None;14;0.95;0;0;13;0.49;0.01;0.01;1;0.46;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1018;ZBED1;ENSG00000214717;HGNC:447;9189;E3 SUMO-protein ligase ZBED1 (EC 2.3.2.-) (DNA replication-related element-binding factor) (Putative Ac-like transposable element) (Zinc finger BED domain-containing protein 1) (dREF homolog);O96006;https://jaspar.elixir.no/search?q=O96006;https://platform.opentargets.org/target/ENSG00000214717;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;3525;1479;1355;1002;1168;5_None;53;0.94;0.02;0;52;0.57;0.02;0.01;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.003058427;#N/A;#N/A;0.023578707;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1178;ZNF223;ENSG00000178386;HGNC:13016;7766;Zinc finger protein 223;Q9UK11;#N/A;https://platform.opentargets.org/target/ENSG00000178386;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3007;1221;1356;1469;182;5_None;8;0.94;0;0;6;0.46;0;0.01;2;0.47;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0023;ARGFX;ENSG00000186103;HGNC:30146;503582;Arginine-fifty homeobox;A6NJG6;https://jaspar.elixir.no/search?q=A6NJG6;https://platform.opentargets.org/target/ENSG00000186103;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3264;1376;1357;1469;438;5_None;6;0.93;0;0;4;0.15;0;0;2;0.78;0;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0020;ANHX;ENSG00000227059;HGNC:40024;647589;Anomalous homeobox protein;E9PGG2;#N/A;https://platform.opentargets.org/target/ENSG00000227059;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.0 Uncharacterized/Undefined;3759;1534;1358;1233;1168;5_None;7;0.93;0;0;4;0.2;0;0;3;0.73;0.01;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1126;ZNF124;ENSG00000196418;HGNC:12907;7678;Zinc finger protein 124 (Zinc finger protein HZF-16);Q15973;#N/A;https://platform.opentargets.org/target/ENSG00000196418;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3219;1348;1359;1422;438;5_None;16;0.93;0.01;0;14;0.35;0.01;0;2;0.58;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1308;ZNF440;ENSG00000171295;HGNC:20874;126070;Zinc finger protein 440;Q8IYI8;#N/A;https://platform.opentargets.org/target/ENSG00000171295;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3031;1233;1360;1233;438;5_None;22;0.93;0.01;0;21;0.63;0.01;0.01;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Parkinson Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1372;ZNF540;ENSG00000171817;HGNC:25331;163255;Zinc finger protein 540;Q8NDQ6;#N/A;https://platform.opentargets.org/target/ENSG00000171817;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2813;1090;1361;1270;182;5_None;32;0.93;0.01;0;32;0.93;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.003380127;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1339;ZNF491;ENSG00000177599;HGNC:23706;126069;Zinc finger protein 491;Q8N8L2;#N/A;https://platform.opentargets.org/target/ENSG00000177599;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3999;1576;1362;1469;1168;5_None;7;0.93;0;0;7;0.93;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1168;ZNF211;ENSG00000121417;HGNC:13003;10520;Zinc finger protein 211 (Zinc finger protein C2H2-25);Q13398;https://jaspar.elixir.no/search?q=Q13398;https://platform.opentargets.org/target/ENSG00000121417;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3128;1290;1363;1327;438;4_Low;6;0.93;0;0;4;0.46;0;0.01;2;0.47;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0612;NKRF;ENSG00000186416;HGNC:19374;55922;NF-kappa-B-repressing factor (NFkB-repressing factor) (NRF) (Protein ITBA4);O15226;#N/A;https://platform.opentargets.org/target/ENSG00000186416;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2196;791;1364;394;438;5_None;107;0.92;0.03;0;107;0.92;0.04;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;11;0.26;0.69;0.07;Alzheimer Disease;#N/A;0.003695799;0.077117626;0.015337564;#N/A;0.0113833;0.060949266;0.016333376;#N/A;0.058565677;0.003326219;#N/A;0.004434958;0.007391597;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1330;ZNF48;ENSG00000180035;HGNC:13114;197407;Zinc finger protein 48 (Zinc finger protein 553);Q96MX3;#N/A;https://platform.opentargets.org/target/ENSG00000180035;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;4002;1577;1365;1469;1168;5_None;8;0.92;0;0;7;0.48;0;0.01;1;0.44;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1232;ZNF304;ENSG00000131845;HGNC:13505;57343;Zinc finger protein 304 (KRAB-containing zinc finger protein);Q9HCX3;#N/A;https://platform.opentargets.org/target/ENSG00000131845;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2944;1183;1366;1140;438;5_None;29;0.92;0.01;0;28;0.67;0.01;0.01;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01138469;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1145;ZNF160;ENSG00000170949;HGNC:12948;90338;Zinc finger protein 160 (Zinc finger protein HZF5) (Zinc finger protein Kr18) (HKr18);Q9HCG1;#N/A;https://platform.opentargets.org/target/ENSG00000170949;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2840;1115;1367;1035;438;5_None;22;0.92;0.01;0;20;0.46;0.01;0.01;2;0.45;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.018478993;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1466;ZNF662;ENSG00000182983;HGNC:31930;389114;Zinc finger protein 662;Q6ZS27;#N/A;https://platform.opentargets.org/target/ENSG00000182983;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3275;1383;1368;1469;438;5_None;13;0.91;0;0;10;0.15;0;0;3;0.76;0.01;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1319;ZNF460;ENSG00000197714;HGNC:21628;10794;Zinc finger protein 460 (Zinc finger protein 272) (Zinc finger protein HZF8);Q14592;https://jaspar.elixir.no/search?q=Q14592;https://platform.opentargets.org/target/ENSG00000197714;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2621;1000;1369;1070;182;5_None;27;0.91;0.01;0;27;0.91;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Alzheimer Disease;#N/A;#N/A;0.012812102;#N/A;#N/A;0.007224876;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1439;ZNF616;ENSG00000204611;HGNC:28062;90317;Zinc finger protein 616;Q08AN1;#N/A;https://platform.opentargets.org/target/ENSG00000204611;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3277;1385;1370;1469;438;5_None;5;0.9;0;0;3;0.25;0;0;2;0.65;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1410;ZNF580;ENSG00000213015;HGNC:29473;51157;Zinc finger protein 580 (LDL-induced EC protein);Q9UK33;#N/A;https://platform.opentargets.org/target/ENSG00000213015;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3728;1523;1371;1189;1168;5_None;22;0.9;0.01;0;21;0.57;0.01;0.01;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;0.004804538;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1161;ZNF2;ENSG00000275111;HGNC:12991;7549;Zinc finger protein 2 (Zinc finger protein 2.2) (Zinc finger protein 661);Q9BSG1;#N/A;https://platform.opentargets.org/target/ENSG00000275111;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3166;1313;1372;1356;438;5_None;23;0.89;0.01;0;22;0.66;0.01;0.01;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Heart Failure;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1586;ZNF829;ENSG00000185869;HGNC:34032;374899;Zinc finger protein 829;Q3KNS6;#N/A;https://platform.opentargets.org/target/ENSG00000185869;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3280;1386;1373;1469;438;5_None;15;0.89;0;0;15;0.89;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1299;ZNF43;ENSG00000198521;HGNC:13109;7594;Zinc finger protein 43 (Zinc finger protein 39) (Zinc finger protein HTF6) (Zinc finger protein KOX27);P17038;#N/A;https://platform.opentargets.org/target/ENSG00000198521;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2834;1108;1374;1278;182;5_None;25;0.88;0.01;0;23;0.39;0.01;0.01;2;0.49;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1170;ZNF213;ENSG00000085644;HGNC:13005;7760;Zinc finger protein 213 (Putative transcription factor CR53) (Zinc finger protein with KRAB and SCAN domains 21);O14771;https://jaspar.elixir.no/search?q=O14771;https://platform.opentargets.org/target/ENSG00000085644;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3693;1511;1375;1150;1168;5_None;18;0.88;0.01;0;17;0.64;0.01;0.01;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.013099553;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1502;ZNF705A;ENSG00000196946;HGNC:32281;440077;Zinc finger protein 705A;Q6ZN79;#N/A;https://platform.opentargets.org/target/ENSG00000196946;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3966;1569;1376;1422;1168;5_None;6;0.87;0;0;3;0.01;0;0;3;0.86;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1475;ZNF674;ENSG00000251192;HGNC:17625;641339;Zinc finger protein 674;Q2M3X9;#N/A;https://platform.opentargets.org/target/ENSG00000251192;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2894;1153;1377;1079;438;5_None;26;0.87;0.01;0;26;0.87;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.019061697;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1255;ZNF345;ENSG00000251247;HGNC:16367;25850;Zinc finger protein 345 (Zinc finger protein HZF10);Q14585;#N/A;https://platform.opentargets.org/target/ENSG00000251247;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2982;1205;1378;1422;182;5_None;8;0.86;0;0;5;0.09;0;0;3;0.77;0.01;0.01;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0765;RBSN;ENSG00000131381;HGNC:20759;64145;Rabenosyn-5 (110 kDa protein) (FYVE finger-containing Rab5 effector protein rabenosyn-5) (RAB effector RBSN) (Zinc finger FYVE domain-containing protein 20);Q9H1K0;#N/A;https://platform.opentargets.org/target/ENSG00000131381;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3614;1502;1379;1067;1168;5_None;24;0.86;0.01;0;24;0.86;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.00542426;#N/A;#N/A;0.014783194;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1386;ZNF557;ENSG00000130544;HGNC:28632;79230;Zinc finger protein 557;Q8N988;#N/A;https://platform.opentargets.org/target/ENSG00000130544;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3554;1489;1380;1006;1168;5_None;23;0.85;0.01;0;22;0.51;0.01;0.01;1;0.34;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.027392963;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1520;ZNF724;ENSG00000196081;HGNC:32460;440519;Zinc finger protein 724;A8MTY0;#N/A;https://platform.opentargets.org/target/ENSG00000196081;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3032;1234;1381;1469;182;5_None;26;0.85;0.01;0;26;0.85;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1280;ZNF397;ENSG00000186812;HGNC:18818;84307;Zinc finger protein 397 (Zinc finger and SCAN domain-containing protein 15) (Zinc finger protein 47);Q8NF99;#N/A;https://platform.opentargets.org/target/ENSG00000186812;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2665;1027;1382;1101;182;5_None;9;0.85;0;0;7;0.22;0;0;2;0.63;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;0.004633866;#N/A;#N/A;0.012750505;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1005;VENTX;ENSG00000151650;HGNC:13639;27287;Homeobox protein VENTX (VENT homeobox homolog) (VENT-like homeobox protein 2);O95231;https://jaspar.elixir.no/search?q=O95231;https://platform.opentargets.org/target/ENSG00000151650;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;2353;863;1383;887;83;5_None;47;0.85;0.02;0;47;0.85;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.047895044;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.2;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Induces;#N/A;Anti-Longevity;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1616;ZNF99;ENSG00000213973;HGNC:13175;7652;Zinc finger protein 99;A8MXY4;#N/A;https://platform.opentargets.org/target/ENSG00000213973;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3244;1361;1384;1422;438;5_None;13;0.84;0;0;11;0.29;0;0;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1274;ZNF385C;ENSG00000187595;HGNC:33722;201181;Zinc finger protein 385C;Q66K41;#N/A;https://platform.opentargets.org/target/ENSG00000187595;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3245;1362;1385;1422;438;5_None;8;0.83;0;0;7;0.56;0;0.01;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0782;RHOXF2;ENSG00000131721;HGNC:30011;84528;Rhox homeobox family member 2 (Paired-like homeobox protein PEPP-2) (Testis homeobox gene 1);Q9BQY4;#N/A;https://platform.opentargets.org/target/ENSG00000131721;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3515;1473;1386;961;1168;5_None;40;0.83;0.01;0;39;0.46;0.02;0.01;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.034548849;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1429;ZNF605;ENSG00000196458;HGNC:28068;100289635;Zinc finger protein 605;Q86T29;#N/A;https://platform.opentargets.org/target/ENSG00000196458;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3038;1239;1387;1469;182;5_None;15;0.82;0;0;13;0.27;0.01;0;2;0.55;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0211;ESX1;ENSG00000123576;HGNC:14865;80712;"Homeobox protein ESX1 (Extraembryonic, spermatogenesis, homeobox 1) [Cleaved into: Homeobox protein ESX1-N; Homeobox protein ESX1-C]";Q8N693;https://jaspar.elixir.no/search?q=Q8N693;https://platform.opentargets.org/target/ENSG00000123576;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3841;1543;1388;1285;1168;5_None;30;0.82;0.01;0;28;0.33;0.01;0;2;0.49;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.002936107;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0003;AC092835.1;ENSG00000233757;No Entry;No Entry;No Entry;No Entry;#N/A;https://platform.opentargets.org/target/ENSG00000233757;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;4026;1581;1389;1469;1168;5_None;5;0.81;0;0;4;0.53;0;0.01;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1063;ZBTB8A;ENSG00000160062;HGNC:24172;653121;Zinc finger and BTB domain-containing protein 8A (BTB/POZ and zinc-finger domain-containing factor) (BTB/POZ and zinc-finger domains factor on chromosome 1) (BOZ-F1);Q96BR9;#N/A;https://platform.opentargets.org/target/ENSG00000160062;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2945;1185;1390;1117;438;5_None;13;0.81;0;0;11;0.05;0;0;2;0.76;0;0.01;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.014762662;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1497;ZNF70;ENSG00000187792;HGNC:13140;7621;Zinc finger protein 70 (Zinc finger protein N27C7-1);Q9UC06;#N/A;https://platform.opentargets.org/target/ENSG00000187792;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3251;1366;1391;1422;438;5_None;10;0.81;0;0;8;0.1;0;0;2;0.71;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1318;ZNF454;ENSG00000178187;HGNC:21200;285676;Zinc finger protein 454;Q8N9F8;https://jaspar.elixir.no/search?q=Q8N9F8;https://platform.opentargets.org/target/ENSG00000178187;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3147;1302;1392;1317;438;5_None;19;0.81;0.01;0;18;0.51;0.01;0.01;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005040659;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0546;MTERF2;ENSG00000120832;HGNC:30779;80298;Transcription termination factor 2, mitochondrial (Mitochondrial transcription termination factor 2) (mTERF2) (Mitochondrial transcription termination factor-like protein) (mTERF-like) (mTERFL) (mTERF domain-containing protein 3, mitochondrial);Q49AM1;#N/A;https://platform.opentargets.org/target/ENSG00000120832;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2929;1173;1393;1098;438;5_None;29;0.8;0.01;0;29;0.8;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Cancer;#N/A;#N/A;0.003073162;#N/A;#N/A;0.012175603;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1312;ZNF444;ENSG00000167685;HGNC:16052;55311;Zinc finger protein 444 (Endothelial zinc finger protein 2) (EZF-2) (Zinc finger and SCAN domain-containing protein 17);Q8N0Y2;#N/A;https://platform.opentargets.org/target/ENSG00000167685;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4031;1582;1394;1469;1168;5_None;8;0.79;0;0;6;0.02;0;0;2;0.77;0;0.01;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0574;NAIF1;ENSG00000171169;HGNC:25446;203245;Nuclear apoptosis-inducing factor 1;Q69YI7;#N/A;https://platform.opentargets.org/target/ENSG00000171169;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2800;1085;1395;967;438;5_None;23;0.79;0.01;0;22;0.57;0.01;0.01;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.016233384;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.017555043;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0028;ARID3C;ENSG00000205143;HGNC:21209;138715;AT-rich interactive domain-containing protein 3C (ARID domain-containing protein 3C);A6NKF2;#N/A;https://platform.opentargets.org/target/ENSG00000205143;3 Helix-turn-helix domains;3.7 ARID;3.7.1 ARID-related;3919;1561;1396;1355;1168;5_None;17;0.79;0.01;0;16;0.57;0.01;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003713238;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1617;ZSCAN1;ENSG00000152467;HGNC:23712;284312;Zinc finger and SCAN domain-containing protein 1;Q8NBB4;#N/A;https://platform.opentargets.org/target/ENSG00000152467;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3068;1260;1397;1233;438;5_None;24;0.79;0.01;0;24;0.79;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1595;ZNF843;ENSG00000176723;HGNC:28710;283933;Zinc finger protein 843;Q8N446;#N/A;https://platform.opentargets.org/target/ENSG00000176723;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3922;1563;1398;1356;1168;5_None;11;0.79;0;0;9;0.25;0;0;2;0.53;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0808;SEBOX;ENSG00000274529;HGNC:32942;645832;Homeobox protein SEBOX (Homeobox OG-9) (Skin-, embryo-, brain- and oocyte-specific homeobox);Q9HB31;#N/A;https://platform.opentargets.org/target/ENSG00000274529;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3306;1395;1399;1469;438;5_None;9;0.79;0;0;8;0.33;0;0;1;0.45;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1189;ZNF235;ENSG00000159917;HGNC:12866;9310;Zinc finger protein 235 (Zinc finger protein 270) (Zinc finger protein 93 homolog) (Zfp-93) (Zinc finger protein HZF6);Q14590;#N/A;https://platform.opentargets.org/target/ENSG00000159917;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3051;1246;1400;1469;182;5_None;9;0.79;0;0;8;0.54;0;0.01;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1077;ZFP3;ENSG00000180787;HGNC:12861;124961;Zinc finger protein 3 homolog (Zfp-3) (Zinc finger protein 752);Q96NJ6;#N/A;https://platform.opentargets.org/target/ENSG00000180787;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3261;1373;1401;1422;438;5_None;16;0.78;0.01;0;15;0.49;0.01;0.01;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Heart Failure;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1407;ZNF577;ENSG00000161551;HGNC:28673;84765;Zinc finger protein 577;Q9BSK1;#N/A;https://platform.opentargets.org/target/ENSG00000161551;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3809;1539;1402;1239;1168;5_None;28;0.78;0.01;0;27;0.42;0.01;0.01;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.00801783;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1306;ZNF439;ENSG00000171291;HGNC:20873;90594;Zinc finger protein 439;Q8NDP4;#N/A;https://platform.opentargets.org/target/ENSG00000171291;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3973;1571;1403;1402;1168;5_None;14;0.77;0;0;13;0.53;0.01;0.01;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.002771849;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1351;ZNF511;ENSG00000198546;HGNC:28445;118472;Zinc finger protein 511;Q8NB15;#N/A;https://platform.opentargets.org/target/ENSG00000198546;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3198;1336;1404;1356;438;5_None;9;0.77;0;0;8;0.25;0;0;#N/A;#N/A;#N/A;#N/A;1;0.52;0.01;0.01;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0973;TIGD3;ENSG00000173825;HGNC:18334;220359;Tigger transposable element-derived protein 3;Q6B0B8;#N/A;https://platform.opentargets.org/target/ENSG00000173825;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3265;1377;1405;1422;438;5_None;18;0.76;0.01;0;16;0.24;0.01;0;2;0.53;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1414;ZNF584;ENSG00000171574;HGNC:27318;201514;Zinc finger protein 584;Q8IVC4;#N/A;https://platform.opentargets.org/target/ENSG00000171574;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3313;1397;1406;1469;438;5_None;14;0.76;0;0;13;0.54;0.01;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0253;FOXD4L5;ENSG00000204779;HGNC:18522;653427;Forkhead box protein D4-like 5 (FOXD4-like 5);Q5VV16;#N/A;https://platform.opentargets.org/target/ENSG00000204779;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3997;1575;1407;1422;1168;5_None;10;0.75;0;0;9;0.42;0;0.01;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1357;ZNF517;ENSG00000197363;HGNC:27984;340385;Zinc finger protein 517;Q6ZMY9;#N/A;https://platform.opentargets.org/target/ENSG00000197363;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3315;1398;1408;1469;438;5_None;10;0.75;0;0;9;0.39;0;0.01;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1172;ZNF215;ENSG00000149054;HGNC:13007;7762;Zinc finger protein 215 (BWSCR2-associated zinc finger protein 2) (BAZ-2) (Zinc finger protein with KRAB and SCAN domains 11);Q9UL58;#N/A;https://platform.opentargets.org/target/ENSG00000149054;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2841;1116;1409;994;438;5_None;22;0.75;0.01;0;20;0.13;0.01;0;2;0.62;0;0;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Cancer;#N/A;#N/A;0.002217479;#N/A;#N/A;0.023283531;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1633;ZSCAN4;ENSG00000180532;HGNC:23709;201516;Zinc finger and SCAN domain-containing protein 4 (Zinc finger protein 494);Q8NAM6;https://jaspar.elixir.no/search?q=Q8NAM6;https://platform.opentargets.org/target/ENSG00000180532;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2718;1054;1410;870;438;5_None;28;0.75;0.01;0;27;0.49;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.04996884;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1181;ZNF226;ENSG00000167380;HGNC:13019;7769;Zinc finger protein 226;Q9NYT6;#N/A;https://platform.opentargets.org/target/ENSG00000167380;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3318;1400;1411;1469;438;5_None;20;0.75;0.01;0;20;0.75;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1558;ZNF782;ENSG00000196597;HGNC:33110;158431;Zinc finger protein 782;Q6ZMW2;#N/A;https://platform.opentargets.org/target/ENSG00000196597;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3016;1225;1412;1422;182;5_None;6;0.74;0;0;4;0.2;0;0;2;0.53;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1468;ZNF665;ENSG00000197497;HGNC:25885;79788;Zinc finger protein 665 (Zinc finger protein 160-like);Q9H7R5;#N/A;https://platform.opentargets.org/target/ENSG00000197497;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3320;1401;1413;1469;438;5_None;5;0.74;0;0;2;0.04;0;0;3;0.69;0.01;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1277;ZNF394;ENSG00000160908;HGNC:18832;84124;Zinc finger protein 394 (Zinc finger protein with KRAB and SCAN domains 14);Q53GI3;#N/A;https://platform.opentargets.org/target/ENSG00000160908;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4051;1586;1414;1469;1168;5_None;10;0.73;0;0;9;0.45;0;0.01;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1400;ZNF570;ENSG00000171827;HGNC:26416;148268;Zinc finger protein 570;Q96NI8;#N/A;https://platform.opentargets.org/target/ENSG00000171827;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3322;1402;1415;1469;438;5_None;6;0.73;0;0;4;0.01;0;0;2;0.72;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1220;ZNF283;ENSG00000167637;HGNC:13077;284349;Zinc finger protein 283 (Zinc finger protein HZF19);Q8N7M2;#N/A;https://platform.opentargets.org/target/ENSG00000167637;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3067;1257;1416;1469;182;5_None;12;0.72;0;0;11;0.51;0;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1579;ZNF81;ENSG00000197779;HGNC:13156;347344;Zinc finger protein 81 (HFZ20);P51508;#N/A;https://platform.opentargets.org/target/ENSG00000197779;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3211;1343;1417;1356;438;5_None;18;0.72;0.01;0;17;0.32;0.01;0;1;0.4;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0243;FOXB2;ENSG00000204612;HGNC:23315;442425;Forkhead box protein B2;Q5VYV0;#N/A;https://platform.opentargets.org/target/ENSG00000204612;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3598;1498;1418;1012;1168;5_None;20;0.72;0.01;0;18;0.2;0.01;0;2;0.52;0;0;#N/A;#N/A;#N/A;#N/A;1;0.03;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.026979329;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1331;ZNF480;ENSG00000198464;HGNC:23305;147657;Zinc finger protein 480;Q8WV37;#N/A;https://platform.opentargets.org/target/ENSG00000198464;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2525;949;1419;924;182;5_None;20;0.72;0.01;0;18;0.17;0.01;0;2;0.54;0;0;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;0.030305548;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1463;ZNF658;ENSG00000274349;HGNC:25226;26149;Zinc finger protein 658;Q5TYW1;#N/A;https://platform.opentargets.org/target/ENSG00000274349;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3071;1265;1420;1469;182;5_None;13;0.71;0;0;13;0.71;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1499;ZNF701;ENSG00000167562;HGNC:25597;55762;Zinc finger protein 701;Q9NV72;https://jaspar.elixir.no/search?q=Q9NV72;https://platform.opentargets.org/target/ENSG00000167562;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3328;1406;1421;1469;438;5_None;3;0.71;0;0;1;0.17;0;0;2;0.54;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1621;ZSCAN18;ENSG00000121413;HGNC:21037;65982;Zinc finger and SCAN domain-containing protein 18 (Zinc finger protein 447);Q8TBC5;#N/A;https://platform.opentargets.org/target/ENSG00000121413;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2901;1160;1422;1041;438;5_None;38;0.71;0.01;0;38;0.71;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.0027225;#N/A;#N/A;0.016606025;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1367;ZNF529;ENSG00000186020;HGNC:29328;57711;Zinc finger protein 529;Q6P280;#N/A;https://platform.opentargets.org/target/ENSG00000186020;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2937;1179;1423;1076;438;5_None;24;0.71;0.01;0;23;0.35;0.01;0;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.00308105;#N/A;#N/A;0.016631093;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1603;ZNF860;ENSG00000197385;HGNC:34513;344787;Zinc finger protein 860;A6NHJ4;#N/A;https://platform.opentargets.org/target/ENSG00000197385;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2976;1202;1424;1114;438;5_None;22;0.71;0.01;0;21;0.45;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.016631093;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1543;ZNF766;ENSG00000196214;HGNC:28063;90321;Zinc finger protein 766;Q5HY98;https://jaspar.elixir.no/search?q=Q5HY98;https://platform.opentargets.org/target/ENSG00000196214;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3332;1409;1425;1469;438;5_None;3;0.71;0;0;1;0.2;0;0;2;0.51;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1328;ZNF474;ENSG00000164185;HGNC:23245;133923;Zinc finger protein 474 (Testis-specific zinc finger protein) (TSZFP);Q6S9Z5;#N/A;https://platform.opentargets.org/target/ENSG00000164185;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3333;1410;1426;1469;438;5_None;18;0.71;0.01;0;17;0.45;0.01;0.01;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1533;ZNF747;ENSG00000169955;HGNC:28350;65988;Zinc finger protein 747;Q9BV97;#N/A;https://platform.opentargets.org/target/ENSG00000169955;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3334;1411;1427;1469;438;5_None;6;0.7;0;0;5;0.46;0;0.01;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0336;HES2;ENSG00000069812;HGNC:16005;54626;Transcription factor HES-2 (Class B basic helix-loop-helix protein 40) (bHLHb40) (Hairy and enhancer of split 2);Q9Y543;https://jaspar.elixir.no/search?q=Q9Y543;https://platform.opentargets.org/target/ENSG00000069812;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.4 Hairy-related;3134;1293;1428;1268;438;5_None;33;0.68;0.01;0;32;0.19;0.01;0;1;0.49;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004876401;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1542;ZNF765;ENSG00000196417;HGNC:25092;91661;Zinc finger protein 765;Q7L2R6;#N/A;https://platform.opentargets.org/target/ENSG00000196417;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3074;1268;1429;477;1168;5_None;12;0.68;0;0;11;0.33;0;0;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;2;0.19;0.13;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.013304875;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.171763857;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1519;ZNF721;ENSG00000182903;HGNC:29425;170960;Zinc finger protein 721;Q8TF20;#N/A;https://platform.opentargets.org/target/ENSG00000182903;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3946;1566;1430;1348;1168;5_None;13;0.67;0;0;11;0.22;0;0;2;0.45;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1259;ZNF350;ENSG00000256683;HGNC:16656;59348;Zinc finger protein 350 (KRAB zinc finger protein ZFQR) (Zinc finger and BRCA1-interacting protein with a KRAB domain 1) (Zinc finger protein ZBRK1);Q9GZX5;#N/A;https://platform.opentargets.org/target/ENSG00000256683;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2797;1083;1431;928;438;5_None;45;0.66;0.01;0;45;0.66;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.04;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.029820832;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009239496;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1577;ZNF805;ENSG00000204524;HGNC:23272;390980;Zinc finger protein 805;Q5CZA5;#N/A;https://platform.opentargets.org/target/ENSG00000204524;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3083;1274;1432;1469;182;5_None;4;0.66;0;0;4;0.66;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0249;FOXD4;ENSG00000170122;HGNC:3805;2298;Forkhead box protein D4 (Forkhead-related protein FKHL9) (Forkhead-related transcription factor 5) (FREAC-5) (Myeloid factor-alpha);Q12950;#N/A;https://platform.opentargets.org/target/ENSG00000170122;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3590;1496;1433;989;1168;5_None;39;0.66;0.01;0;39;0.66;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.008079426;0.022064533;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1392;ZNF563;ENSG00000188868;HGNC:30498;147837;Zinc finger protein 563;Q8TA94;#N/A;https://platform.opentargets.org/target/ENSG00000188868;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3341;1414;1434;1469;438;5_None;4;0.66;0;0;3;0.05;0;0;#N/A;#N/A;#N/A;#N/A;1;0.61;0.01;0.01;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0576;NANOGNB;ENSG00000205857;HGNC:24958;360030;NANOG neighbor homeobox (Homeobox protein C14);Q7Z5D8;#N/A;https://platform.opentargets.org/target/ENSG00000205857;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.8 HD-ZF;3848;1547;1435;1245;1168;5_None;8;0.66;0;0;6;0.08;0;0;2;0.58;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.003695799;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1465;ZNF660;ENSG00000144792;HGNC:26720;285349;Zinc finger protein 660;Q6AZW8;#N/A;https://platform.opentargets.org/target/ENSG00000144792;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2870;1133;1436;996;438;5_None;12;0.65;0;0;11;0.31;0;0;1;0.34;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.014393082;0.014577872;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1560;ZNF784;ENSG00000179922;HGNC:33111;147808;Zinc finger protein 784;Q8NCA9;https://jaspar.elixir.no/search?q=Q8NCA9;https://platform.opentargets.org/target/ENSG00000179922;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;4074;1589;1437;1469;1168;5_None;10;0.65;0;0;9;0.45;0;0.01;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0837;SNAPC2;ENSG00000104976;HGNC:11135;6618;snRNA-activating protein complex subunit 2 (SNAPc subunit 2) (Proximal sequence element-binding transcription factor subunit delta) (PSE-binding factor subunit delta) (PTF subunit delta) (Small nuclear RNA-activating complex polypeptide 2) (snRNA-activating protein complex 45 kDa subunit) (SNAPc 45 kDa subunit);Q13487;#N/A;https://platform.opentargets.org/target/ENSG00000104976;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;2969;1198;1438;363;1168;5_None;13;0.65;0;0;11;0.06;0;0;2;0.59;0;0;#N/A;#N/A;#N/A;#N/A;2;0.3;0.13;0.08;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.295511278;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0485;LEUTX;ENSG00000213921;HGNC:31953;342900;Paired-like homeodomain transcription factor LEUTX (Leucine-twenty homeobox) (Paired-like homeobox transcription factor LEUTX) (PRD-LIKE homeobox transcription factor LEUTX);A8MZ59;#N/A;https://platform.opentargets.org/target/ENSG00000213921;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3196;1335;1439;1319;438;5_None;23;0.65;0.01;0;21;0.15;0.01;0;2;0.5;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004935534;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1344;ZNF500;ENSG00000103199;HGNC:23716;26048;Zinc finger protein 500 (Zinc finger protein with KRAB and SCAN domains 18);O60304;#N/A;https://platform.opentargets.org/target/ENSG00000103199;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3105;1280;1440;1227;438;5_None;17;0.64;0.01;0;17;0.64;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.004023255;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1075;ZFP2;ENSG00000198939;HGNC:26138;80108;Zinc finger protein ZFP2 (Zfp-2) (Zinc finger protein 751);Q6ZN57;#N/A;https://platform.opentargets.org/target/ENSG00000198939;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3348;1418;1441;1469;438;5_None;10;0.64;0;0;9;0.27;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0252;FOXD4L4;ENSG00000184659;HGNC:23762;349334;Forkhead box protein D4-like 4 (FOXD4-like 4) (Forkhead box protein D4-like 2) (Forkhead box protein D4B) (Myeloid factor-gamma);Q8WXT5;#N/A;https://platform.opentargets.org/target/ENSG00000184659;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;3855;1549;1442;1245;1168;5_None;15;0.64;0;0;14;0.3;0.01;0;1;0.34;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1444;ZNF623;ENSG00000183309;HGNC:29084;9831;Zinc finger protein 623;O75123;#N/A;https://platform.opentargets.org/target/ENSG00000183309;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3183;1326;1443;1302;438;5_None;10;0.63;0;0;9;0.14;0;0;1;0.49;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005358908;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0764;RBPJL;ENSG00000124232;HGNC:13761;11317;Recombining binding protein suppressor of hairless-like protein (Transcription factor RBP-L);Q9UBG7;#N/A;https://platform.opentargets.org/target/ENSG00000124232;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.4 CSL-related;3059;1251;1444;447;1168;5_None;32;0.62;0.01;0;32;0.62;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.21;0.13;0.05;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.010296905;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.198832679;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0094;CDX4;ENSG00000131264;HGNC:1808;1046;Homeobox protein CDX-4 (Caudal-type homeobox protein 4);O14627;https://jaspar.elixir.no/search?q=O14627;https://platform.opentargets.org/target/ENSG00000131264;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;4082;1591;1445;1469;1168;5_None;24;0.62;0.01;0;23;0.4;0.01;0.01;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0605;NFX1;ENSG00000086102;HGNC:7803;4799;Transcriptional repressor NF-X1 (EC 2.3.2.-) (Nuclear transcription factor, X box-binding protein 1);Q12986;#N/A;https://platform.opentargets.org/target/ENSG00000086102;0 Yet undefined DNA-binding domains;0.4 NFX1-type putative zinc finger factors;0.4.1 NFX1;2806;1087;1446;922;438;5_None;32;0.62;0.01;0;31;0.38;0.01;0.01;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.040680887;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0524;MEIS3;ENSG00000105419;HGNC:29537;56917;Homeobox protein Meis3 (Meis1-related protein 2);Q99687;https://jaspar.elixir.no/search?q=Q99687;https://platform.opentargets.org/target/ENSG00000105419;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;2957;1191;1447;1072;438;5_None;32;0.62;0.01;0;31;0.24;0.01;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.004619748;#N/A;#N/A;0.015358302;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1156;ZNF184;ENSG00000096654;HGNC:12975;7738;Zinc finger protein 184;Q99676;https://jaspar.elixir.no/search?q=Q99676;https://platform.opentargets.org/target/ENSG00000096654;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2369;875;1448;838;83;5_None;24;0.62;0.01;0;24;0.62;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.06;0.13;0.01;Parkinson Disease;#N/A;#N/A;0.004565507;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.052779699;#N/A;#N/A;3;0.2;Y;#N/A;Pro-Longevity;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1596;ZNF844;ENSG00000223547;HGNC:25932;284391;Zinc finger protein 844;Q08AG5;#N/A;https://platform.opentargets.org/target/ENSG00000223547;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4086;1593;1449;1469;1168;5_None;9;0.6;0;0;8;0.32;0;0;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1282;ZNF404;ENSG00000176222;HGNC:19417;342908;Zinc finger protein 404;Q494X3;#N/A;https://platform.opentargets.org/target/ENSG00000176222;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3357;1420;1450;1469;438;5_None;17;0.6;0.01;0;17;0.6;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1362;ZNF524;ENSG00000171443;HGNC:28322;147807;Zinc finger protein 524;Q96C55;https://jaspar.elixir.no/search?q=Q96C55;https://platform.opentargets.org/target/ENSG00000171443;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4088;1594;1451;1469;1168;5_None;6;0.6;0;0;5;0.23;0;0;1;0.38;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1289;ZNF416;ENSG00000083817;HGNC:20645;55659;Zinc finger protein 416;Q9BWM5;https://jaspar.elixir.no/search?q=Q9BWM5;https://platform.opentargets.org/target/ENSG00000083817;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3871;1553;1452;1251;1168;5_None;17;0.59;0.01;0;17;0.59;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;0.002956639;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1365;ZNF527;ENSG00000189164;HGNC:29385;84503;Zinc finger protein 527;Q8NB42;#N/A;https://platform.opentargets.org/target/ENSG00000189164;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3360;1422;1453;1469;438;5_None;6;0.59;0;0;4;0.12;0;0;2;0.48;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1315;ZNF449;ENSG00000173275;HGNC:21039;203523;Zinc finger protein 449 (Zinc finger and SCAN domain-containing protein 19);Q6P9G9;https://jaspar.elixir.no/search?q=Q6P9G9;https://platform.opentargets.org/target/ENSG00000173275;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3282;1388;1454;1390;438;5_None;6;0.59;0;0;5;0.15;0;0;1;0.44;0;0;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.002087693;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1518;ZNF718;ENSG00000250312;HGNC:26889;255403;Zinc finger protein 718;Q3SXZ3;#N/A;https://platform.opentargets.org/target/ENSG00000250312;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3126;1287;1455;1233;438;5_None;17;0.59;0.01;0;17;0.59;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.006652437;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1630;ZSCAN30;ENSG00000186814;HGNC:33517;100101467;Zinc finger and SCAN domain-containing protein 30 (ZNF-WYM) (Zinc finger protein 397 opposite strand) (Zinc finger protein 397OS);Q86W11;#N/A;https://platform.opentargets.org/target/ENSG00000186814;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4093;1595;1456;1469;1168;5_None;8;0.59;0;0;7;0.37;0;0;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0254;FOXD4L6;ENSG00000273514;HGNC:31986;653404;Forkhead box protein D4-like 6 (FOXD4-like 6);Q3SYB3;#N/A;https://platform.opentargets.org/target/ENSG00000273514;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;4021;1579;1457;1396;1168;5_None;12;0.58;0;0;12;0.58;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1581;ZNF814;ENSG00000204514;HGNC:33258;730051;Zinc finger protein 814;B7Z6K7;#N/A;https://platform.opentargets.org/target/ENSG00000204514;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3109;1282;1458;1469;182;5_None;10;0.57;0;0;9;0.2;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1427;ZNF599;ENSG00000153896;HGNC:26408;148103;Zinc finger protein 599;Q96NL3;#N/A;https://platform.opentargets.org/target/ENSG00000153896;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4049;1585;1459;1422;1168;5_None;3;0.57;0;0;2;0.13;0;0;1;0.44;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1297;ZNF428;ENSG00000131116;HGNC:20804;126299;Zinc finger protein 428 (Enzyme-like protein PIT13);Q96B54;#N/A;https://platform.opentargets.org/target/ENSG00000131116;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2901;1160;1460;1003;438;5_None;7;0.57;0;0;6;0.22;0;0;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;0.025512804;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1418;ZNF587;ENSG00000198466;HGNC:30955;84914;Zinc finger protein 587;Q96SQ5;#N/A;https://platform.opentargets.org/target/ENSG00000198466;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;2884;1147;1461;1241;182;5_None;21;0.57;0.01;0;20;0.32;0.01;0;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007945967;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1340;ZNF492;ENSG00000229676;HGNC:23707;57615;Zinc finger protein 492 (Zinc finger protein 115);Q9P255;#N/A;https://platform.opentargets.org/target/ENSG00000229676;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2433;911;1462;533;438;5_None;14;0.57;0;0;14;0.57;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.16;0.06;0.04;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.156180352;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1396;ZNF567;ENSG00000189042;HGNC:28696;163081;Zinc finger protein 567;Q8N184;#N/A;https://platform.opentargets.org/target/ENSG00000189042;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3112;1283;1463;1467;182;5_None;12;0.57;0;0;11;0.25;0;0;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.00122105;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1620;ZSCAN16;ENSG00000196812;HGNC:20813;80345;Zinc finger and SCAN domain-containing protein 16 (Zinc finger protein 392) (Zinc finger protein 435);Q9H4T2;https://jaspar.elixir.no/search?q=Q9H4T2;https://platform.opentargets.org/target/ENSG00000196812;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3324;1404;1464;1422;438;5_None;18;0.56;0.01;0;18;0.56;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0986;TPRX1;ENSG00000178928;HGNC:32174;284355;Tetra-peptide repeat homeobox protein 1;Q8N7U7;#N/A;https://platform.opentargets.org/target/ENSG00000178928;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;3259;1371;1465;1356;438;5_None;13;0.56;0;0;12;0.29;0;0;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1115;ZMAT1;ENSG00000166432;HGNC:29377;84460;Zinc finger matrin-type protein 1;Q5H9K5;#N/A;https://platform.opentargets.org/target/ENSG00000166432;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2848;1122;1466;944;438;5_None;37;0.55;0.01;0;37;0.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Cancer;#N/A;#N/A;0.004376897;#N/A;#N/A;0.030305548;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1225;ZNF287;ENSG00000141040;HGNC:13502;57336;Zinc finger protein 287 (Zinc finger protein with KRAB and SCAN domains 13);Q9HBT7;#N/A;https://platform.opentargets.org/target/ENSG00000141040;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3261;1373;1467;1356;438;5_None;10;0.55;0;0;10;0.55;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1285;ZNF41;ENSG00000147124;HGNC:13107;7592;Zinc finger protein 41;P51814;#N/A;https://platform.opentargets.org/target/ENSG00000147124;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4105;1600;1468;1469;1168;5_None;12;0.55;0;0;12;0.55;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1549;ZNF773;ENSG00000152439;HGNC:30487;374928;Zinc finger protein 773 (Zinc finger protein 419B);Q6PK81;#N/A;https://platform.opentargets.org/target/ENSG00000152439;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3376;1424;1469;1469;438;5_None;9;0.55;0;0;9;0.55;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0948;TFDP3;ENSG00000183434;HGNC:24603;51270;Transcription factor Dp family member 3 (Cancer/testis antigen 30) (CT30) (Hepatocellular carcinoma-associated antigen 661);Q5H9I0;#N/A;https://platform.opentargets.org/target/ENSG00000183434;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.2 E2F;3501;1467;1470;863;1168;5_None;58;0.55;0.02;0;58;0.55;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.05;0.13;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.046408477;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1085;ZFP69;ENSG00000187815;HGNC:24708;339559;Zinc finger protein 69 homolog (Zinc finger protein 642);Q49AA0;#N/A;https://platform.opentargets.org/target/ENSG00000187815;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3696;1513;1471;1057;1168;5_None;16;0.55;0.01;0;16;0.55;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;0.017700809;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1159;ZNF195;ENSG00000005801;HGNC:12986;7748;Zinc finger protein 195;O14628;#N/A;https://platform.opentargets.org/target/ENSG00000005801;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3210;1341;1472;1300;438;5_None;17;0.54;0.01;0;15;0.06;0.01;0;2;0.48;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005512899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1214;ZNF280A;ENSG00000169548;HGNC:18597;129025;Zinc finger protein 280A (3'OY11.1) (Suppressor of hairy wing homolog 1) (Zinc finger protein 636);P59817;#N/A;https://platform.opentargets.org/target/ENSG00000169548;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3083;1274;1473;442;1168;5_None;21;0.54;0.01;0;20;0.33;0.01;0;1;0.21;0;0;#N/A;#N/A;#N/A;#N/A;2;0.21;0.13;#N/A;Heart Failure;#N/A;#N/A;#N/A;#N/A;#N/A;0.00764825;#N/A;0.207262834;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1215;ZNF280B;ENSG00000275004;HGNC:23022;140883;Zinc finger protein 280B (5'OY11.1) (Suppressor of hairy wing homolog 2) (Zinc finger protein 279) (Zinc finger protein 632);Q86YH2;#N/A;https://platform.opentargets.org/target/ENSG00000275004;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3178;1323;1474;1266;438;5_None;16;0.54;0.01;0;15;0.25;0.01;0;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007186275;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1378;ZNF548;ENSG00000188785;HGNC:26561;147694;Zinc finger protein 548;Q8NEK5;#N/A;https://platform.opentargets.org/target/ENSG00000188785;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4112;1601;1475;1469;1168;5_None;6;0.54;0;0;6;0.54;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1171;ZNF214;ENSG00000149050;HGNC:13006;7761;Zinc finger protein 214 (BWSCR2-associated zinc finger protein 1) (BAZ-1);Q9UL59;https://jaspar.elixir.no/search?q=Q9UL59;https://platform.opentargets.org/target/ENSG00000149050;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2990;1213;1476;1332;182;5_None;10;0.53;0;0;9;0.18;0;0;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1310;ZNF442;ENSG00000198342;HGNC:20877;79973;Zinc finger protein 442;Q9H7R0;#N/A;https://platform.opentargets.org/target/ENSG00000198342;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2793;1082;1477;878;438;5_None;7;0.53;0;0;6;0.27;0;0;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;1;0.05;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.04907366;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1036;ZBTB22;ENSG00000236104;HGNC:13085;9278;Zinc finger and BTB domain-containing protein 22 (Protein BING1) (Zinc finger and BTB domain-containing protein 22A) (Zinc finger protein 297);O15209;#N/A;https://platform.opentargets.org/target/ENSG00000236104;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3738;1528;1478;1092;1168;4_Low;37;0.53;0.01;0;37;0.53;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.016045925;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1377;ZNF547;ENSG00000152433;HGNC:26432;284306;Zinc finger protein 547;Q8IVP9;https://jaspar.elixir.no/search?q=Q8IVP9;https://platform.opentargets.org/target/ENSG00000152433;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3595;1497;1479;948;1168;5_None;38;0.52;0.01;0;37;0.15;0.01;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;4;0.04;0.25;0.01;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;0.001478319;#N/A;0.003695799;0.027348909;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1388;ZNF559;ENSG00000188321;HGNC:28197;84527;Zinc finger protein 559;Q9BR84;#N/A;https://platform.opentargets.org/target/ENSG00000188321;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4117;1603;1480;1469;1168;5_None;12;0.52;0;0;11;0.27;0;0;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1320;ZNF461;ENSG00000197808;HGNC:21629;92283;Zinc finger protein 461 (Gonadotropin-inducible ovary transcription repressor 1) (GIOT-1);Q8TAF7;#N/A;https://platform.opentargets.org/target/ENSG00000197808;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2379;879;1481;460;438;5_None;9;0.51;0;0;8;0.27;0;0;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0.2;0.06;0.05;Alzheimer Disease;#N/A;#N/A;0.197708432;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1350;ZNF510;ENSG00000081386;HGNC:29161;22869;Zinc finger protein 510;Q9Y2H8;#N/A;https://platform.opentargets.org/target/ENSG00000081386;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3389;1429;1482;1469;438;5_None;6;0.51;0;0;6;0.51;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1204;ZNF264;ENSG00000083844;HGNC:13057;9422;Zinc finger protein 264;O43296;#N/A;https://platform.opentargets.org/target/ENSG00000083844;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3208;1340;1483;1287;438;5_None;19;0.5;0.01;0;18;0.26;0.01;0;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.004519768;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0040;ASCL5;ENSG00000232237;HGNC:33169;647219;Achaete-scute homolog 5 (ASH-5) (hASH5) (Class A basic helix-loop-helix protein 47) (bHLHa47);Q7RTU5;#N/A;https://platform.opentargets.org/target/ENSG00000232237;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.2 MyoD-ASC-related;4074;1589;1484;1422;1168;5_None;17;0.5;0.01;0;16;0.14;0.01;0;1;0.35;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1209;ZNF274;ENSG00000171606;HGNC:13068;10782;Neurotrophin receptor-interacting factor homolog (Zinc finger protein 274) (Zinc finger protein HFB101) (Zinc finger protein with KRAB and SCAN domains 19) (Zinc finger protein zfp2) (Zf2);Q96GC6;https://jaspar.elixir.no/search?q=Q96GC6;https://platform.opentargets.org/target/ENSG00000171606;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3136;1295;1485;1213;438;5_None;21;0.5;0.01;0;20;0.27;0.01;0;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007925435;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1572;ZNF8;ENSG00000278129;HGNC:13154;7554;Zinc finger protein 8 (Zinc finger protein HF.18);P17098;https://jaspar.elixir.no/search?q=P17098;https://platform.opentargets.org/target/ENSG00000278129;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3083;1274;1486;1159;438;5_None;12;0.49;0;0;11;0.24;0;0;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.012257732;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1125;ZNF121;ENSG00000197961;HGNC:12904;7675;Zinc finger protein 121 (Zinc finger protein 20);P58317;#N/A;https://platform.opentargets.org/target/ENSG00000197961;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3345;1416;1487;1420;438;5_None;23;0.49;0.01;0;22;0.26;0.01;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1157;ZNF189;ENSG00000136870;HGNC:12980;7743;Zinc finger protein 189;O75820;https://jaspar.elixir.no/search?q=O75820;https://platform.opentargets.org/target/ENSG00000136870;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3139;1298;1488;1469;182;5_None;15;0.48;0;0;14;0.17;0.01;0;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1111;ZKSCAN4;ENSG00000187626;HGNC:13854;387032;Zinc finger protein with KRAB and SCAN domains 4 (P373c6.1) (Zinc finger protein 307) (Zinc finger protein 427);Q969J2;#N/A;https://platform.opentargets.org/target/ENSG00000187626;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3027;1232;1489;1356;182;5_None;26;0.48;0.01;0;25;0.12;0.01;0;1;0.36;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1146;ZNF165;ENSG00000197279;HGNC:12953;7718;Zinc finger protein 165 (Cancer/testis antigen 53) (CT53) (LD65) (Zinc finger and SCAN domain-containing protein 7);P49910;#N/A;https://platform.opentargets.org/target/ENSG00000197279;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3547;1486;1490;889;1168;4_Low;38;0.47;0.01;0;38;0.47;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;0.004434958;0.035600395;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tbio;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1241;ZNF324;ENSG00000083812;HGNC:14096;25799;Zinc finger protein 324A (Zinc finger protein ZF5128);O75467;https://jaspar.elixir.no/search?q=O75467;https://platform.opentargets.org/target/ENSG00000083812;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3342;1415;1491;1413;438;5_None;7;0.47;0;0;6;0.06;0;0;1;0.41;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1539;ZNF761;ENSG00000160336;HGNC:23179;388561;Zinc finger protein 761;Q86XN6;#N/A;https://platform.opentargets.org/target/ENSG00000160336;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3286;1390;1492;1356;438;5_None;4;0.47;0;0;2;0.01;0;0;2;0.46;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1600;ZNF850;ENSG00000267041;HGNC:27994;342892;Zinc finger protein 850;A8MQ14;#N/A;https://platform.opentargets.org/target/ENSG00000267041;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3287;1391;1493;1356;438;5_None;11;0.47;0;0;10;0.24;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1552;ZNF776;ENSG00000152443;HGNC:26765;284309;Zinc finger protein 776;Q68DI1;#N/A;https://platform.opentargets.org/target/ENSG00000152443;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4130;1607;1494;1468;1168;5_None;9;0.47;0;0;9;0.47;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.001166354;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1422;ZNF594;ENSG00000180626;HGNC:29392;84622;Zinc finger protein 594 (Zinc finger protein HZF18);Q96JF6;#N/A;https://platform.opentargets.org/target/ENSG00000180626;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2629;1004;1495;952;182;5_None;8;0.46;0;0;7;0.23;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Alzheimer Disease;#N/A;#N/A;0.035667937;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1059;ZBTB6;ENSG00000186130;HGNC:16764;10773;Zinc finger and BTB domain-containing protein 6 (Zinc finger protein 482) (Zinc finger protein with interaction domain);Q15916;https://jaspar.elixir.no/search?q=Q15916;https://platform.opentargets.org/target/ENSG00000186130;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3601;1499;1496;937;1168;5_None;17;0.46;0.01;0;16;0.17;0.01;0;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.037966823;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1117;ZNF10;ENSG00000256223;HGNC:12879;7556;Zinc finger protein 10 (Zinc finger protein KOX1);P21506;#N/A;https://platform.opentargets.org/target/ENSG00000256223;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2514;946;1497;579;438;5_None;21;0.45;0.01;0;21;0.45;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.13;0.19;0.03;Type 2 Diabetes Mellitus;#N/A;#N/A;0.002081158;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.12738382;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1254;ZNF343;ENSG00000088876;HGNC:16017;79175;Zinc finger protein 343;Q6P1L6;https://jaspar.elixir.no/search?q=Q6P1L6;https://platform.opentargets.org/target/ENSG00000088876;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4135;1608;1498;1469;1168;5_None;2;0.45;0;0;1;0.13;0;0;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0977;TIGD7;ENSG00000140993;HGNC:18331;91151;Tigger transposable element-derived protein 7;Q6NT04;#N/A;https://platform.opentargets.org/target/ENSG00000140993;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3177;1321;1499;1240;438;5_None;16;0.45;0.01;0;16;0.45;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Alzheimer Disease;#N/A;#N/A;0.006520858;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1436;ZNF613;ENSG00000176024;HGNC:25827;79898;Zinc finger protein 613;Q6PF04;#N/A;https://platform.opentargets.org/target/ENSG00000176024;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3038;1239;1500;1356;182;4_Low;8;0.45;0;0;8;0.45;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;3;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1374;ZNF543;ENSG00000178229;HGNC:25281;125919;Zinc finger protein 543;Q08ER8;#N/A;https://platform.opentargets.org/target/ENSG00000178229;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2966;1194;1501;1027;438;5_None;12;0.45;0;0;12;0.45;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.03;0.19;0.01;Parkinson Disease;#N/A;#N/A;0.005174118;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.018478993;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1083;ZFP62;ENSG00000196670;HGNC:23241;643836;Zinc finger protein 62 homolog (Zfp-62);Q8NB50;#N/A;https://platform.opentargets.org/target/ENSG00000196670;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3040;1241;1502;1356;182;5_None;9;0.45;0;0;8;0.22;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1534;ZNF749;ENSG00000186230;HGNC:32783;388567;Zinc finger protein 749;O43361;#N/A;https://platform.opentargets.org/target/ENSG00000186230;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3154;1308;1503;1469;182;5_None;5;0.45;0;0;4;0.2;0;0;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1105;ZIK1;ENSG00000171649;HGNC:33104;284307;Zinc finger protein interacting with ribonucleoprotein K (Zinc finger protein 762);Q3SY52;#N/A;https://platform.opentargets.org/target/ENSG00000171649;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3258;1369;1504;1316;438;5_None;15;0.45;0;0;14;0.16;0.01;0;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005145989;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1430;ZNF606;ENSG00000166704;HGNC:25879;80095;Zinc finger protein 606 (Zinc finger protein 328);Q8WXB4;#N/A;https://platform.opentargets.org/target/ENSG00000166704;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3156;1309;1505;1469;182;5_None;8;0.44;0;0;7;0.19;0;0;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0126;CSRNP2;ENSG00000110925;HGNC:16006;81566;Cysteine/serine-rich nuclear protein 2 (CSRNP-2) (Protein FAM130A1) (TGF-beta-induced apoptosis protein 12) (TAIP-12);Q9H175;#N/A;https://platform.opentargets.org/target/ENSG00000110925;0 Yet undefined DNA-binding domains;0.1 AXUD/CSRNP domain factors;0.1.1 CSRNP;3079;1271;1506;1135;438;5_None;16;0.44;0.01;0;15;0.23;0.01;0;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.004635097;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001847899;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1296;ZNF426;ENSG00000130818;HGNC:20725;79088;Zinc finger protein 426;Q9BUY5;#N/A;https://platform.opentargets.org/target/ENSG00000130818;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3414;1437;1507;1469;438;5_None;9;0.43;0;0;8;0.2;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0183;EBF4;ENSG00000088881;HGNC:29278;57593;Transcription factor COE4 (Early B-cell factor 4) (EBF-4) (Olf-1/EBF-like 4) (O/E-4) (OE-4);Q9BQW3;#N/A;https://platform.opentargets.org/target/ENSG00000088881;6 Immunoglobulin fold;6.1 Rel homology region (RHR) factors;6.1.5 EBF-related;3176;1319;1508;1230;438;5_None;26;0.43;0.01;0;25;0.09;0.01;0;1;0.34;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004599216;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0960;THAP2;ENSG00000173451;HGNC:20854;83591;THAP domain-containing protein 2;Q9H0W7;#N/A;https://platform.opentargets.org/target/ENSG00000173451;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;4099;1597;1509;1422;1168;5_None;14;0.42;0;0;13;0.12;0.01;0;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1480;ZNF679;ENSG00000197123;HGNC:28650;168417;Zinc finger protein 679;Q8IYX0;#N/A;https://platform.opentargets.org/target/ENSG00000197123;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4147;1610;1510;1469;1168;5_None;4;0.42;0;0;3;0.11;0;0;1;0.31;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0073;BHLHE23;ENSG00000125533;HGNC:16093;128408;Class E basic helix-loop-helix protein 23 (bHLHe23) (Class B basic helix-loop-helix protein 4) (bHLHb4);Q8NDY6;https://jaspar.elixir.no/search?q=Q8NDY6;https://platform.opentargets.org/target/ENSG00000125533;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;3842;1544;1511;1163;1168;5_None;57;0.42;0.02;0;57;0.42;0.02;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;4;0.01;0.25;0;Cancer;#N/A;#N/A;0.003695799;0.001478319;#N/A;0.005504071;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0452;KCMF1;ENSG00000176407;HGNC:20589;56888;E3 ubiquitin-protein ligase KCMF1 (EC 2.3.2.27) (FGF-induced in gastric cancer) (Potassium channel modulatory factor) (PCMF) (RING-type E3 ubiquitin transferase KCMF1) (ZZ-type zinc finger-containing protein 1);Q9P0J7;#N/A;https://platform.opentargets.org/target/ENSG00000176407;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3758;1533;1512;1078;1168;5_None;24;0.41;0.01;0;23;0.19;0.01;0;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011888152;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1309;ZNF441;ENSG00000197044;HGNC:20875;126068;Zinc finger protein 441;Q8N8Z8;#N/A;https://platform.opentargets.org/target/ENSG00000197044;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3164;1311;1513;1469;182;5_None;9;0.41;0;0;9;0.41;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1231;ZNF302;ENSG00000089335;HGNC:13848;55900;Zinc finger protein 302 (Zinc finger protein 135-like) (Zinc finger protein 140-like) (Zinc finger protein 327);Q9NR11;#N/A;https://platform.opentargets.org/target/ENSG00000089335;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3045;1244;1514;1093;438;5_None;19;0.41;0.01;0;18;0.1;0.01;0;1;0.31;0;0;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0;Myocardial Infarction;#N/A;#N/A;0.005952275;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1411;ZNF581;ENSG00000171425;HGNC:25017;51545;Zinc finger protein 581;Q9P0T4;#N/A;https://platform.opentargets.org/target/ENSG00000171425;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4152;1611;1515;1469;1168;5_None;7;0.4;0;0;6;0.07;0;0;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1229;ZNF30;ENSG00000168661;HGNC:13090;90075;Zinc finger protein 30 (Zinc finger protein KOX28);P17039;#N/A;https://platform.opentargets.org/target/ENSG00000168661;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3423;1439;1516;1469;438;5_None;6;0.4;0;0;5;0.03;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1590;ZNF835;ENSG00000127903;HGNC:34332;90485;Zinc finger protein 835;Q9Y2P0;#N/A;https://platform.opentargets.org/target/ENSG00000127903;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3357;1420;1517;1402;438;5_None;8;0.4;0;0;7;0.07;0;0;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.002771849;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1390;ZNF561;ENSG00000171469;HGNC:28684;93134;Zinc finger protein 561;Q8N587;#N/A;https://platform.opentargets.org/target/ENSG00000171469;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3052;1247;1518;1096;438;5_None;12;0.4;0;0;12;0.4;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;#N/A;Myocardial Infarction;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;0.016261514;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1303;ZNF433;ENSG00000197647;HGNC:20811;163059;Zinc finger protein 433;Q8N7K0;#N/A;https://platform.opentargets.org/target/ENSG00000197647;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2915;1166;1519;958;438;5_None;16;0.4;0.01;0;16;0.4;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.035110086;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1366;ZNF528;ENSG00000167555;HGNC:29384;84436;Zinc finger protein 528;Q3MIS6;https://jaspar.elixir.no/search?q=Q3MIS6;https://platform.opentargets.org/target/ENSG00000167555;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2741;1066;1520;1039;182;5_None;15;0.39;0;0;14;0.14;0.01;0;1;0.26;0;0;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;0.002012157;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.021435632;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1387;ZNF558;ENSG00000167785;HGNC:26422;148156;Zinc finger protein 558;Q96NG5;https://jaspar.elixir.no/search?q=Q96NG5;https://platform.opentargets.org/target/ENSG00000167785;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4085;1592;1521;1396;1168;5_None;14;0.39;0;0;14;0.39;0.01;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1058;ZBTB5;ENSG00000168795;HGNC:23836;9925;Zinc finger and BTB domain-containing protein 5;O15062;#N/A;https://platform.opentargets.org/target/ENSG00000168795;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3382;1428;1522;1422;438;5_None;14;0.39;0;0;13;0.07;0.01;0;1;0.32;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0320;GSC2;ENSG00000063515;HGNC:4613;2928;Homeobox protein goosecoid-2 (GSC-2) (Homeobox protein goosecoid-like) (GSC-L);O15499;https://jaspar.elixir.no/search?q=O15499;https://platform.opentargets.org/target/ENSG00000063515;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;4160;1613;1523;1469;1168;5_None;10;0.39;0;0;10;0.39;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1419;ZNF587B;ENSG00000269343;HGNC:37142;100293516;Zinc finger protein 587B;E7ETH6;#N/A;https://platform.opentargets.org/target/ENSG00000269343;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3069;1263;1524;1107;438;5_None;9;0.39;0;0;9;0.39;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Alzheimer Disease;#N/A;#N/A;0.015522354;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1568;ZNF791;ENSG00000173875;HGNC:26895;163049;Zinc finger protein 791;Q3KP31;#N/A;https://platform.opentargets.org/target/ENSG00000173875;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3176;1319;1525;1469;182;5_None;9;0.39;0;0;9;0.39;0;0.01;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0783;RHOXF2B;ENSG00000203989;HGNC:33519;727940;Rhox homeobox family member 2B;P0C7M4;#N/A;https://platform.opentargets.org/target/ENSG00000203989;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.1 HOX;4163;1615;1526;1469;1168;5_None;4;0.38;0;0;3;0.01;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1114;ZKSCAN8;ENSG00000198315;HGNC:12983;7745;Zinc finger protein with KRAB and SCAN domains 8 (LD5-1) (Zinc finger protein 192);Q15776;#N/A;https://platform.opentargets.org/target/ENSG00000198315;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3434;1442;1527;1469;438;5_None;2;0.38;0;0;1;0.01;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1148;ZNF17;ENSG00000186272;HGNC:12958;7565;Zinc finger protein 17 (Zinc finger protein HPF3) (Zinc finger protein KOX10);P17021;#N/A;https://platform.opentargets.org/target/ENSG00000186272;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3322;1402;1528;1356;438;5_None;9;0.38;0;0;8;0.14;0;0;1;0.24;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1632;ZSCAN32;ENSG00000140987;HGNC:20812;54925;Zinc finger and SCAN domain-containing protein 32 (Human cervical cancer suppressor gene 5 protein) (HCCS-5) (Zinc finger protein 434);Q9NX65;#N/A;https://platform.opentargets.org/target/ENSG00000140987;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4166;1616;1529;1469;1168;5_None;5;0.38;0;0;4;0.01;0;0;1;0.37;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1370;ZNF534;ENSG00000198633;HGNC:26337;147658;Zinc finger protein 534 (KRAB domain only protein 3);Q76KX8;#N/A;https://platform.opentargets.org/target/ENSG00000198633;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3381;1426;1530;1413;438;5_None;10;0.37;0;0;10;0.37;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1288;ZNF415;ENSG00000170954;HGNC:20636;55786;Zinc finger protein 415;Q09FC8;#N/A;https://platform.opentargets.org/target/ENSG00000170954;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2757;1072;1531;788;438;5_None;63;0.36;0.02;0;63;0.36;0.02;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;5;0.07;0.31;0.02;Cancer;#N/A;#N/A;0.022413577;#N/A;#N/A;0.023068751;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;0.014228824;0.007391597;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1327;ZNF473;ENSG00000142528;HGNC:23239;25888;Zinc finger protein 473 (Zinc finger protein 100 homolog) (Zfp-100);Q8WTR7;#N/A;https://platform.opentargets.org/target/ENSG00000142528;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2985;1209;1532;1271;182;5_None;10;0.35;0;0;10;0.35;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Osteoporosis;#N/A;#N/A;#N/A;#N/A;#N/A;0.003326219;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1394;ZNF565;ENSG00000196357;HGNC:26726;147929;Zinc finger protein 565;Q8N9K5;#N/A;https://platform.opentargets.org/target/ENSG00000196357;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4123;1605;1533;1422;1168;4_Low;12;0.35;0;0;12;0.35;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0806;SCRT2;ENSG00000215397;HGNC:15952;85508;Transcriptional repressor scratch 2 (Scratch homolog 2 zinc finger protein);Q9NQ03;https://jaspar.elixir.no/search?q=Q9NQ03;https://platform.opentargets.org/target/ENSG00000215397;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4171;1617;1534;1469;1168;5_None;7;0.35;0;0;6;0.04;0;0;1;0.31;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0672;OVOL3;ENSG00000105261;HGNC:14186;728361;Putative transcription factor ovo-like protein 3;O00110;#N/A;https://platform.opentargets.org/target/ENSG00000105261;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3395;1434;1535;1422;438;5_None;6;0.35;0;0;5;0.05;0;0;1;0.3;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1057;ZBTB49;ENSG00000168826;HGNC:19883;166793;Zinc finger and BTB domain-containing protein 49 (Zinc finger protein 509);Q6ZSB9;#N/A;https://platform.opentargets.org/target/ENSG00000168826;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3627;1504;1536;923;1168;5_None;8;0.35;0;0;7;0.15;0;0;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.039914624;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1472;ZNF670;ENSG00000277462;HGNC:28167;93474;Zinc finger protein 670;Q9BS34;#N/A;https://platform.opentargets.org/target/ENSG00000277462;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3444;1446;1537;1469;438;5_None;7;0.35;0;0;6;0.07;0;0;1;0.28;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0965;THAP7;ENSG00000184436;HGNC:23190;80764;THAP domain-containing protein 7;Q9BT49;#N/A;https://platform.opentargets.org/target/ENSG00000184436;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;4021;1579;1538;1315;1168;5_None;16;0.34;0.01;0;16;0.34;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005168985;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1019;ZBED2;ENSG00000177494;HGNC:20710;79413;Zinc finger BED domain-containing protein 2;Q9BTP6;https://jaspar.elixir.no/search?q=Q9BTP6;https://platform.opentargets.org/target/ENSG00000177494;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;3282;1388;1539;1305;438;5_None;34;0.34;0.01;0;34;0.34;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005328918;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1537;ZNF75D;ENSG00000186376;HGNC:13145;7626;Zinc finger protein 75D (Zinc finger protein 75) (Zinc finger protein 82);P51815;https://jaspar.elixir.no/search?q=P51815;https://platform.opentargets.org/target/ENSG00000186376;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3223;1353;1540;1245;438;5_None;9;0.34;0;0;9;0.34;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0164;DRAP1;ENSG00000175550;HGNC:3019;10589;Dr1-associated corepressor (Dr1-associated protein 1) (Negative cofactor 2-alpha) (NC2-alpha);Q14919;#N/A;https://platform.opentargets.org/target/ENSG00000175550;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;3136;1295;1541;1157;438;5_None;15;0.33;0;0;15;0.33;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.011087396;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1240;ZNF322;ENSG00000181315;HGNC:23640;79692;Zinc finger protein 322 (Zinc finger protein 322A) (Zinc finger protein 388) (Zinc finger protein 489);Q6U7Q0;#N/A;https://platform.opentargets.org/target/ENSG00000181315;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2875;1139;1542;895;438;5_None;22;0.33;0.01;0;22;0.33;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.05;0.19;0.01;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.035517529;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1434;ZNF610;ENSG00000167554;HGNC:26687;162963;Zinc finger protein 610;Q8N9Z0;https://jaspar.elixir.no/search?q=Q8N9Z0;https://platform.opentargets.org/target/ENSG00000167554;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3450;1448;1543;1469;438;5_None;7;0.33;0;0;6;0.05;0;0;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1471;ZNF669;ENSG00000188295;HGNC:25736;79862;Zinc finger protein 669;Q96BR6;https://jaspar.elixir.no/search?q=Q96BR6;https://platform.opentargets.org/target/ENSG00000188295;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4181;1618;1544;1469;1168;5_None;1;0.33;0;0;#N/A;0;0;0;1;0.33;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0614;NKX1-2;ENSG00000229544;HGNC:31652;390010;NK1 transcription factor-related protein 2 (Homeobox protein SAX-1) (NKX-1.1);Q9UD57;#N/A;https://platform.opentargets.org/target/ENSG00000229544;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.2 NK;4182;1619;1545;1469;1168;5_None;13;0.32;0;0;13;0.32;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1363;ZNF525;ENSG00000203326;HGNC:29423;170958;Zinc finger protein 525;Q8N782;#N/A;https://platform.opentargets.org/target/ENSG00000203326;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3255;1368;1546;1271;438;5_None;6;0.32;0;0;5;0.03;0;0;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.002956639;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1607;ZNF880;ENSG00000221923;HGNC:37249;400713;Zinc finger protein 880;Q6PDB4;#N/A;https://platform.opentargets.org/target/ENSG00000221923;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3457;1452;1547;742;1168;5_None;22;0.32;0.01;0;22;0.32;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.08;0.13;0.02;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.04617695;0.036034036;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1406;ZNF576;ENSG00000124444;HGNC:28357;79177;Zinc finger protein 576;Q9H609;#N/A;https://platform.opentargets.org/target/ENSG00000124444;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3455;1450;1548;1469;438;5_None;2;0.32;0;0;1;0.03;0;0;1;0.29;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1162;ZNF20;ENSG00000132010;HGNC:12992;7568;Zinc finger protein 20 (Zinc finger protein KOX13);P17024;#N/A;https://platform.opentargets.org/target/ENSG00000132010;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3456;1451;1549;1469;438;5_None;12;0.31;0;0;12;0.31;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0250;FOXD4L1;ENSG00000184492;HGNC:18521;200350;Forkhead box protein D4-like 1 (FOXD4-like 1);Q9NU39;#N/A;https://platform.opentargets.org/target/ENSG00000184492;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;4045;1584;1550;1327;1168;5_None;12;0.31;0;0;12;0.31;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004619748;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1143;ZNF157;ENSG00000147117;HGNC:12942;7712;Zinc finger protein 157 (Zinc finger protein HZF22);P51786;https://jaspar.elixir.no/search?q=P51786;https://platform.opentargets.org/target/ENSG00000147117;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3458;1453;1551;1469;438;5_None;17;0.31;0.01;0;17;0.31;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1130;ZNF134;ENSG00000213762;HGNC:12918;7693;Zinc finger protein 134;P52741;#N/A;https://platform.opentargets.org/target/ENSG00000213762;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3148;1304;1552;1158;438;4_Low;11;0.31;0;0;10;0.06;0;0;1;0.25;0;0;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Osteoarthritis;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.004434958;#N/A;0.004229636;#N/A;0.003695799;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;2;4_Low;Possibly targetable with +/- conflicting evidence across databases (e.g. Pharos TDL at least Tchem and/or DGIDB ALL >0) but no indication of drugs with known MOA.;Tdark;1;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1567;ZNF790;ENSG00000197863;HGNC:33114;388536;Zinc finger protein 790;Q6PG37;#N/A;https://platform.opentargets.org/target/ENSG00000197863;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3460;1454;1553;1469;438;5_None;3;0.31;0;0;3;0.31;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1024;ZBED9;ENSG00000232040;HGNC:13851;114821;SCAN domain-containing protein 3 (Transposon-derived Buster4 transposase-like protein) (Zinc finger BED domain-containing protein 9);Q6R2W3;#N/A;https://platform.opentargets.org/target/ENSG00000232040;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.5 BED zinc finger factors;4113;1602;1554;1391;1168;5_None;20;0.3;0.01;0;20;0.3;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.002012157;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1384;ZNF555;ENSG00000186300;HGNC:28382;148254;Zinc finger protein 555;Q8NEP9;#N/A;https://platform.opentargets.org/target/ENSG00000186300;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4119;1604;1555;1396;1168;5_None;7;0.3;0;0;7;0.3;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002956639;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1408;ZNF578;ENSG00000258405;HGNC:26449;147660;Zinc finger protein 578;Q96N58;#N/A;https://platform.opentargets.org/target/ENSG00000258405;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3151;1306;1556;1413;182;5_None;8;0.3;0;0;7;0.06;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002217479;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1395;ZNF566;ENSG00000186017;HGNC:25919;84924;Zinc finger protein 566;Q969W8;#N/A;https://platform.opentargets.org/target/ENSG00000186017;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4194;1620;1557;1469;1168;5_None;12;0.3;0;0;12;0.3;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1631;ZSCAN31;ENSG00000235109;HGNC:14097;64288;Zinc finger and SCAN domain-containing protein 31 (Zinc finger protein 323);Q96LW9;https://jaspar.elixir.no/search?q=Q96LW9;https://platform.opentargets.org/target/ENSG00000235109;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2876;1142;1558;1136;182;5_None;24;0.29;0.01;0;24;0.29;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0.010163446;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1587;ZNF83;ENSG00000167766;HGNC:13158;55769;Zinc finger protein 83 (Zinc finger protein 816B) (Zinc finger protein HPF1);P51522;#N/A;https://platform.opentargets.org/target/ENSG00000167766;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2841;1116;1559;1100;182;5_None;28;0.28;0.01;0;28;0.28;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.02;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.017442116;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1164;ZNF202;ENSG00000166261;HGNC:12994;7753;Zinc finger protein 202 (Zinc finger protein with KRAB and SCAN domains 10);O95125;#N/A;https://platform.opentargets.org/target/ENSG00000166261;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2947;1188;1560;949;438;5_None;24;0.28;0.01;0;24;0.28;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.04;0.19;0.01;Atherosclerosis;#N/A;#N/A;#N/A;0.027953583;#N/A;0.001478319;#N/A;#N/A;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0955;TGIF2LY;ENSG00000176679;HGNC:18569;90655;Homeobox protein TGIF2LY (TGF-beta-induced transcription factor 2-like protein) (TGFB-induced factor 2-like protein, Y-linked) (TGIF-like on the Y);Q8IUE0;https://jaspar.elixir.no/search?q=Q8IUE0;https://platform.opentargets.org/target/ENSG00000176679;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;3468;1458;1561;1469;438;5_None;4;0.28;0;0;3;0.01;0;0;1;0.27;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1040;ZBTB3;ENSG00000185670;HGNC:22918;79842;Zinc finger and BTB domain-containing protein 3;Q9H5J0;#N/A;https://platform.opentargets.org/target/ENSG00000185670;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;2800;1085;1562;800;438;5_None;15;0.28;0;0;15;0.28;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.0667882;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1079;ZFP37;ENSG00000136866;HGNC:12863;7539;Zinc finger protein 37 homolog (Zfp-37);Q9Y6Q3;#N/A;https://platform.opentargets.org/target/ENSG00000136866;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3070;1264;1563;1069;438;5_None;12;0.27;0;0;12;0.27;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0.01;Cancer;#N/A;#N/A;0.002587059;#N/A;#N/A;0.017596108;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1201;ZNF26;ENSG00000198393;HGNC:13053;7574;Zinc finger protein 26 (Zinc finger protein KOX20);P17031;#N/A;https://platform.opentargets.org/target/ENSG00000198393;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3102;1279;1564;1356;182;5_None;11;0.27;0;0;11;0.27;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Alzheimer Disease;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0966;THAP8;ENSG00000161277;HGNC:23191;199745;THAP domain-containing protein 8;Q8NA92;#N/A;https://platform.opentargets.org/target/ENSG00000161277;2 Zinc-coordinating DNA-binding domains;2.9 C2CH THAP-type zinc finger factors;2.9.1 THAP;4202;1621;1565;1469;1168;5_None;4;0.26;0;0;3;0.04;0;0;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1608;ZNF883;ENSG00000228623;HGNC:27271;169834;Zinc finger protein 883;P0CG24;#N/A;https://platform.opentargets.org/target/ENSG00000228623;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3473;1459;1566;1469;438;5_None;8;0.26;0;0;7;0.04;0;0;1;0.22;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1594;ZNF841;ENSG00000197608;HGNC:27611;284371;Zinc finger protein 841;Q6ZN19;#N/A;https://platform.opentargets.org/target/ENSG00000197608;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3218;1347;1567;1469;182;5_None;7;0.26;0;0;6;0.06;0;0;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1233;ZNF311;ENSG00000197935;HGNC:13847;282890;Zinc finger protein 311 (Zinc finger protein zfp-31);Q5JNZ3;#N/A;https://platform.opentargets.org/target/ENSG00000197935;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3411;1435;1568;1405;438;5_None;10;0.25;0;0;10;0.25;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1131;ZNF135;ENSG00000176293;HGNC:12919;7694;Zinc finger protein 135 (Zinc finger protein 61) (Zinc finger protein 78-like 1);P52742;https://jaspar.elixir.no/search?q=P52742;https://platform.opentargets.org/target/ENSG00000176293;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2783;1079;1569;1032;182;5_None;46;0.25;0.01;0;46;0.25;0.02;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.02;0.19;0.01;Cancer;#N/A;#N/A;0.003757395;#N/A;0.007391597;0.013587687;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0251;FOXD4L3;ENSG00000187559;HGNC:18523;286380;Forkhead box protein D4-like 3 (FOXD4-like 3);Q6VB84;#N/A;https://platform.opentargets.org/target/ENSG00000187559;3 Helix-turn-helix domains;3.3 Fork head / winged helix factors;3.3.1 FOX;4094;1596;1570;1356;1168;5_None;10;0.24;0;0;10;0.24;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1177;ZNF222;ENSG00000159885;HGNC:13015;7673;Zinc finger protein 222;Q9UK12;#N/A;https://platform.opentargets.org/target/ENSG00000159885;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4208;1623;1571;1469;1168;5_None;3;0.24;0;0;2;0.01;0;0;1;0.23;0;0;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1557;ZNF781;ENSG00000196381;HGNC:26745;163115;Zinc finger protein 781;Q8N8C0;#N/A;https://platform.opentargets.org/target/ENSG00000196381;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4162;1614;1572;1422;1168;5_None;12;0.23;0;0;12;0.23;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1343;ZNF497;ENSG00000174586;HGNC:23714;162968;Zinc finger protein 497;Q6ZNH5;#N/A;https://platform.opentargets.org/target/ENSG00000174586;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3171;1315;1573;1160;438;5_None;5;0.23;0;0;4;0.02;0;0;1;0.2;0;0;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;0.002587059;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.009609076;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0113;CPXCR1;ENSG00000147183;HGNC:2332;53336;CPX chromosomal region candidate gene 1 protein (Cancer/testis antigen 77) (CT77);Q8N123;#N/A;https://platform.opentargets.org/target/ENSG00000147183;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3948;1567;1574;1206;1168;5_None;13;0.23;0;0;13;0.23;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005913278;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1151;ZNF177;ENSG00000188629;HGNC:12966;7730;Zinc finger protein 177;Q13360;#N/A;https://platform.opentargets.org/target/ENSG00000188629;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3334;1411;1575;1321;438;5_None;22;0.22;0.01;0;22;0.22;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004915001;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1380;ZNF550;ENSG00000251369;HGNC:28643;162972;Zinc finger protein 550;Q7Z398;#N/A;https://platform.opentargets.org/target/ENSG00000251369;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4213;1624;1576;1469;1168;5_None;5;0.22;0;0;5;0.22;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1107;ZIM3;ENSG00000141946;HGNC:16366;114026;Zinc finger imprinted 3 (Zinc finger protein 657);Q96PE6;https://jaspar.elixir.no/search?q=Q96PE6;https://platform.opentargets.org/target/ENSG00000141946;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4214;1625;1577;1469;1168;5_None;7;0.22;0;0;7;0.22;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1064;ZBTB8B;ENSG00000273274;HGNC:37057;728116;Zinc finger and BTB domain-containing protein 8B;Q8NAP8;#N/A;https://platform.opentargets.org/target/ENSG00000273274;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.2 Other factors with up to three adjacent zinc fingers;3269;1380;1578;1253;438;5_None;4;0.21;0;0;4;0.21;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1464;ZNF66;ENSG00000160229;HGNC:13135;7617;Putative zinc finger protein 66 (Zinc finger protein 66 pseudogene);Q6ZN08;#N/A;https://platform.opentargets.org/target/ENSG00000160229;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3413;1436;1579;1396;438;5_None;14;0.21;0;0;14;0.21;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0;0.13;0;Alzheimer Disease;#N/A;#N/A;0.001478319;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1391;ZNF562;ENSG00000171466;HGNC:25950;54811;Zinc finger protein 562;Q6V9R5;#N/A;https://platform.opentargets.org/target/ENSG00000171466;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4104;1599;1580;1356;1168;5_None;7;0.2;0;0;7;0.2;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1375;ZNF544;ENSG00000198131;HGNC:16759;27300;Zinc finger protein 544;Q6NX49;#N/A;https://platform.opentargets.org/target/ENSG00000198131;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3488;1464;1581;1469;438;5_None;8;0.2;0;0;8;0.2;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1176;ZNF221;ENSG00000159905;HGNC:13014;7638;Zinc finger protein 221;Q9UK13;#N/A;https://platform.opentargets.org/target/ENSG00000159905;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3233;1358;1582;1469;182;5_None;4;0.2;0;0;4;0.2;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1261;ZNF354B;ENSG00000178338;HGNC:17197;117608;Zinc finger protein 354B;Q96LW1;#N/A;https://platform.opentargets.org/target/ENSG00000178338;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4220;1626;1583;1469;1168;5_None;7;0.2;0;0;7;0.2;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1385;ZNF556;ENSG00000172000;HGNC:25669;80032;Zinc finger protein 556;Q9HAH1;#N/A;https://platform.opentargets.org/target/ENSG00000172000;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4100;1598;1584;1348;1168;5_None;7;0.19;0;0;7;0.19;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0415;HSFX1;ENSG00000171116;HGNC:29603;100506164;Heat shock transcription factor, X-linked;Q9UBD0;#N/A;https://platform.opentargets.org/target/ENSG00000171116;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;3379;1425;1585;1356;438;5_None;9;0.18;0;0;9;0.18;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1399;ZNF57;ENSG00000171970;HGNC:13125;126295;Zinc finger protein 57 (Zinc finger protein 424);Q68EA5;#N/A;https://platform.opentargets.org/target/ENSG00000171970;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4061;1587;1586;1307;1168;5_None;26;0.17;0.01;0;26;0.17;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0416;HSFX2;ENSG00000268738;HGNC:32701;100130086;Heat shock transcription factor, X-linked;Q9UBD0;#N/A;https://platform.opentargets.org/target/ENSG00000268738;3 Helix-turn-helix domains;3.4 Heat shock factors;3.4.1 HSF;3381;1426;1587;1356;438;5_None;7;0.17;0;0;7;0.17;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0919;TCF24;ENSG00000261787;HGNC:32275;100129654;Transcription factor 24 (TCF-24);Q7RTU0;#N/A;https://platform.opentargets.org/target/ENSG00000261787;1 Basic domains;1.2 Basic helix-loop-helix factors (bHLH);1.2.3 Tal-related;4063;1588;1588;1307;1168;5_None;7;0.17;0;0;7;0.17;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1195;ZNF250;ENSG00000196150;HGNC:13044;58500;Zinc finger protein 250 (Zinc finger protein 647);P15622;#N/A;https://platform.opentargets.org/target/ENSG00000196150;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3272;1381;1589;1245;438;5_None;9;0.16;0;0;9;0.16;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1379;ZNF549;ENSG00000121406;HGNC:26632;256051;Zinc finger protein 549;Q6P9A3;https://jaspar.elixir.no/search?q=Q6P9A3;https://platform.opentargets.org/target/ENSG00000121406;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2728;1058;1590;700;438;5_None;13;0.16;0;0;13;0.16;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.09;0.13;0.02;Chronic Obstructive Pulmonary Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.021866808;0.070035382;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1086;ZFP69B;ENSG00000187801;HGNC:28053;65243;Zinc finger protein 69 homolog B (Zinc finger protein 643);Q9UJL9;#N/A;https://platform.opentargets.org/target/ENSG00000187801;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3068;1260;1591;1295;182;5_None;14;0.15;0;0;14;0.15;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005779818;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;1;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1028;ZBTB12;ENSG00000204366;HGNC:19066;221527;Zinc finger and BTB domain-containing protein 12 (Protein G10);Q9Y330;https://jaspar.elixir.no/search?q=Q9Y330;https://platform.opentargets.org/target/ENSG00000204366;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3137;1297;1592;1107;438;5_None;18;0.15;0.01;0;18;0.15;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.02;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.008869917;#N/A;#N/A;#N/A;0.008130757;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1460;ZNF653;ENSG00000161914;HGNC:25196;115950;Zinc finger protein 653 (67 kDa zinc finger protein) (Zinc finger protein Zip67);Q96CK0;#N/A;https://platform.opentargets.org/target/ENSG00000161914;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4044;1583;1593;1283;1168;5_None;4;0.15;0;0;4;0.15;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;0;Alzheimer Disease;#N/A;#N/A;0.006652437;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0954;TGIF2LX;ENSG00000153779;HGNC:18570;90316;Homeobox protein TGIF2LX (TGF-beta-induced transcription factor 2-like protein) (TGFB-induced factor 2-like protein, X-linked) (TGIF-like on the X);Q8IUE1;https://jaspar.elixir.no/search?q=Q8IUE1;https://platform.opentargets.org/target/ENSG00000153779;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.4 TALE-type HD;3306;1395;1594;1274;438;5_None;16;0.14;0.01;0;16;0.14;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;#N/A;#N/A;0.002751317;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Unclear;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0597;NFE4;ENSG00000230257;HGNC:29902;58160;Transcription factor NF-E4;Q86UQ8;#N/A;https://platform.opentargets.org/target/ENSG00000230257;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;4016;1578;1595;1253;1168;5_None;16;0.14;0.01;0;16;0.14;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.007391597;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tbio;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1510;ZNF709;ENSG00000242852;HGNC:20629;163051;Zinc finger protein 709;Q8N972;#N/A;https://platform.opentargets.org/target/ENSG00000242852;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2931;1176;1596;1153;182;5_None;10;0.14;0;0;10;0.14;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.012935295;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1413;ZNF583;ENSG00000198440;HGNC:26427;147949;Zinc finger protein 583 (Zinc finger protein L3-5);Q96ND8;#N/A;https://platform.opentargets.org/target/ENSG00000198440;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;2978;1203;1597;943;438;5_None;11;0.13;0;0;11;0.13;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.036957985;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1163;ZNF200;ENSG00000010539;HGNC:12993;7752;Zinc finger protein 200;P98182;#N/A;https://platform.opentargets.org/target/ENSG00000010539;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3919;1561;1598;1153;1168;5_None;14;0.13;0;0;14;0.13;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;3;0.01;0.19;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.007761177;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1381;ZNF551;ENSG00000204519;HGNC:25108;90233;Zinc finger protein 551 (Zinc finger protein KOX23);Q7Z340;#N/A;https://platform.opentargets.org/target/ENSG00000204519;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3250;1364;1599;1469;182;5_None;5;0.12;0;0;5;0.12;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1527;ZNF735;ENSG00000223614;HGNC:32466;730291;Putative zinc finger protein 735 (Zinc finger protein 735 pseudogene);P0CB33;#N/A;https://platform.opentargets.org/target/ENSG00000223614;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3725;1521;1600;957;1168;5_None;3;0.11;0;0;3;0.11;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.04;0.06;0.01;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.03511248;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1503;ZNF705B;ENSG00000215356;HGNC:32284;100132396;Putative zinc finger protein 705B;P0CI00;#N/A;https://platform.opentargets.org/target/ENSG00000215356;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;4238;1628;1601;1469;1168;5_None;1;0.09;0;0;1;0.09;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1619;ZSCAN12;ENSG00000158691;HGNC:13172;9753;Zinc finger and SCAN domain-containing protein 12 (Zinc finger protein 305) (Zinc finger protein 96);O43309;#N/A;https://platform.opentargets.org/target/ENSG00000158691;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3188;1330;1602;1404;182;5_None;16;0.09;0.01;0;16;0.09;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.002751317;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1133;ZNF138;ENSG00000197008;HGNC:12922;7697;Zinc finger protein 138;P52744;#N/A;https://platform.opentargets.org/target/ENSG00000197008;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3463;1456;1603;1422;438;5_None;12;0.09;0;0;12;0.09;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1628;ZSCAN26;ENSG00000197062;HGNC:12978;7741;Zinc finger and SCAN domain-containing protein 26 (Protein SRE-ZBP) (Zinc finger protein 187);Q16670;#N/A;https://platform.opentargets.org/target/ENSG00000197062;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4128;1606;1604;1356;1168;5_None;17;0.07;0.01;0;17;0.07;0.01;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Type 2 Diabetes Mellitus;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1257;ZNF347;ENSG00000197937;HGNC:16447;84671;Zinc finger protein 347 (Zinc finger protein 1111);Q96SE7;#N/A;https://platform.opentargets.org/target/ENSG00000197937;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3089;1277;1605;1302;182;5_None;6;0.07;0;0;6;0.07;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.005358908;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1417;ZNF586;ENSG00000083828;HGNC:25949;54807;Zinc finger protein 586;Q9NXT0;#N/A;https://platform.opentargets.org/target/ENSG00000083828;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3513;1471;1606;1469;438;5_None;4;0.07;0;0;4;0.07;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1604;ZNF865;ENSG00000261221;HGNC:38705;100507290;Zinc finger protein 865;P0CJ78;#N/A;https://platform.opentargets.org/target/ENSG00000261221;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3797;1537;1607;1022;1168;5_None;8;0.06;0;0;8;0.06;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.03;0.13;0.01;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.02439227;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1626;ZSCAN23;ENSG00000187987;HGNC:21193;222696;Zinc finger and SCAN domain-containing protein 23 (Zinc finger protein 390) (Zinc finger protein 453);Q3MJ62;#N/A;https://platform.opentargets.org/target/ENSG00000187987;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3127;1288;1608;1337;182;5_None;10;0.06;0;0;10;0.06;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004322031;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1508;ZNF707;ENSG00000181135;HGNC:27815;286075;Zinc finger protein 707;Q96C28;https://jaspar.elixir.no/search?q=Q96C28;https://platform.opentargets.org/target/ENSG00000181135;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3389;1429;1609;1342;438;5_None;8;0.06;0;0;8;0.06;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.004229636;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1199;ZNF256;ENSG00000152454;HGNC:13049;10172;Zinc finger protein 256 (Bone marrow zinc finger 3) (BMZF-3);Q9Y2P7;#N/A;https://platform.opentargets.org/target/ENSG00000152454;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3517;1474;1610;1469;438;5_None;11;0.06;0;0;11;0.06;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1300;ZNF430;ENSG00000118620;HGNC:20808;80264;Zinc finger protein 430;Q9H8G1;#N/A;https://platform.opentargets.org/target/ENSG00000118620;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3518;1475;1611;1469;438;5_None;10;0.06;0;0;10;0.06;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1458;ZNF649;ENSG00000198093;HGNC:25741;65251;Zinc finger protein 649;Q9BS31;#N/A;https://platform.opentargets.org/target/ENSG00000198093;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4202;1621;1612;1422;1168;5_None;9;0.05;0;0;9;0.05;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1451;ZNF630;ENSG00000221994;HGNC:28855;57232;Zinc finger protein 630;Q2M218;#N/A;https://platform.opentargets.org/target/ENSG00000221994;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;3217;1346;1613;1422;182;5_None;5;0.05;0;0;5;0.05;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1591;ZNF836;ENSG00000196267;HGNC:34333;162962;Zinc finger protein 836;Q6ZNA1;#N/A;https://platform.opentargets.org/target/ENSG00000196267;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3265;1377;1614;1469;182;5_None;3;0.05;0;0;3;0.05;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1382;ZNF552;ENSG00000178935;HGNC:26135;79818;Zinc finger protein 552;Q9H707;#N/A;https://platform.opentargets.org/target/ENSG00000178935;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;3522;1477;1615;1469;438;5_None;8;0.05;0;0;8;0.05;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1446;ZNF625;ENSG00000257591;HGNC:30571;90589;Zinc finger protein 625;Q96I27;#N/A;https://platform.opentargets.org/target/ENSG00000257591;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3968;1570;1616;1184;1168;5_None;6;0.04;0;0;6;0.04;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.01;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.01094367;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1276;ZNF391;ENSG00000124613;HGNC:18779;346157;Zinc finger protein 391;Q9UJN7;#N/A;https://platform.opentargets.org/target/ENSG00000124613;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3221;1349;1617;1422;182;5_None;8;0.04;0;0;8;0.04;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;0;Parkinson Disease;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;2;0.13;Y;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Pro-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1625;ZSCAN22;ENSG00000182318;HGNC:4929;342945;Zinc finger and SCAN domain-containing protein 22 (Krueppel-related zinc finger protein 2) (Protein HKR2) (Zinc finger protein 50);P10073;#N/A;https://platform.opentargets.org/target/ENSG00000182318;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3525;1479;1618;1469;438;5_None;4;0.04;0;0;4;0.04;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1180;ZNF225;ENSG00000256294;HGNC:13018;7768;Zinc finger protein 225;Q9UK10;#N/A;https://platform.opentargets.org/target/ENSG00000256294;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3526;1482;1619;1469;438;5_None;4;0.03;0;0;4;0.03;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1368;ZNF530;ENSG00000183647;HGNC:29297;348327;Zinc finger protein 530;Q6P9A1;https://jaspar.elixir.no/search?q=Q6P9A1;https://platform.opentargets.org/target/ENSG00000183647;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3098;1278;1620;1296;182;5_None;3;0.03;0;0;3;0.03;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.01;0.13;0;Cancer;#N/A;#N/A;0.001478319;#N/A;#N/A;0.004065378;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;2;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1637;ZSCAN9;ENSG00000137185;HGNC:12984;7746;Zinc finger and SCAN domain-containing protein 9 (Cell proliferation-inducing gene 12 protein) (PRD51) (Zinc finger protein 193);O15535;#N/A;https://platform.opentargets.org/target/ENSG00000137185;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4145;1609;1621;1356;1168;5_None;6;0.03;0;0;6;0.03;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1376;ZNF546;ENSG00000187187;HGNC:28671;339327;Zinc finger protein 546 (Zinc finger protein 49);Q86UE3;#N/A;https://platform.opentargets.org/target/ENSG00000187187;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3226;1354;1622;1422;182;5_None;7;0.02;0;0;7;0.02;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;2;0.13;Y;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1564;ZNF788;ENSG00000214189;HGNC:33112;388507;Putative KRAB domain-containing protein ZNF788 (Zinc finger family member 788, pseudogene);Q6ZQV5;#N/A;https://platform.opentargets.org/target/ENSG00000214189;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.4 Factors with multiple dispersed zinc fingers;4260;1629;1623;1469;1168;5_None;4;0.02;0;0;4;0.02;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1223;ZNF286A;ENSG00000187607;HGNC:13501;57335;Zinc finger protein 286A;Q9HBT8;#N/A;https://platform.opentargets.org/target/ENSG00000187607;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4261;1630;1624;1469;1168;5_None;5;0.01;0;0;5;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1556;ZNF780B;ENSG00000128000;HGNC:33109;163131;Zinc finger protein 780B (Zinc finger protein 779);Q9Y6R6;#N/A;https://platform.opentargets.org/target/ENSG00000128000;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3485;1463;1625;1422;438;5_None;4;0.01;0;0;4;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1474;ZNF672;ENSG00000171161;HGNC:26179;79894;Zinc finger protein 672;Q499Z4;#N/A;https://platform.opentargets.org/target/ENSG00000171161;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3533;1484;1626;1469;438;5_None;4;0.01;0;0;4;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;Y;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0103;CENPBD1;ENSG00000177946;HGNC:28272;92806;Putative CENPB DNA-binding domain-containing protein 1;B2RD01;#N/A;https://platform.opentargets.org/target/ENSG00000177946;0 Yet undefined DNA-binding domains;0.0 Uncharacterized;0.0.0 Uncharacterized/Undefined;4264;1631;1627;1469;1168;5_None;2;0.01;0;0;2;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1154;ZNF181;ENSG00000197841;HGNC:12971;339318;Zinc finger protein 181 (HHZ181);Q2M3W8;#N/A;https://platform.opentargets.org/target/ENSG00000197841;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4265;1632;1628;1469;1168;5_None;3;0.01;0;0;3;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1235;ZNF317;ENSG00000130803;HGNC:13507;57693;Zinc finger protein 317;Q96PQ6;https://jaspar.elixir.no/search?q=Q96PQ6;https://platform.opentargets.org/target/ENSG00000130803;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4153;1612;1629;1356;1168;5_None;2;0.01;0;0;2;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.003695799;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1437;ZNF614;ENSG00000142556;HGNC:24722;80110;Zinc finger protein 614;Q8N883;#N/A;https://platform.opentargets.org/target/ENSG00000142556;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3490;1465;1630;1422;438;5_None;2;0.01;0;0;2;0.01;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1504;ZNF705D;ENSG00000215343;HGNC:33202;728957;Zinc finger protein 705D;P0CH99;#N/A;https://platform.opentargets.org/target/ENSG00000215343;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4221;1627;1631;1422;1168;5_None;2;0;0;0;2;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1221;ZNF284;ENSG00000186026;HGNC:13078;342909;Zinc finger protein 284;Q2VY69;#N/A;https://platform.opentargets.org/target/ENSG00000186026;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;3492;1466;1632;1422;438;5_None;2;0;0;0;2;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0;0.06;#N/A;Cancer;#N/A;#N/A;#N/A;#N/A;#N/A;0.001478319;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;0.07;N;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;Anti-Longevity;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1606;ZNF879;ENSG00000234284;HGNC:37273;345462;Zinc finger protein 879;B4DU55;#N/A;https://platform.opentargets.org/target/ENSG00000234284;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;4270;1633;1633;1469;1168;5_None;1;0;0;0;1;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0078;BORCS8-MEF2B;ENSG00000064489;HGNC:39979;No Entry;No Entry;No Entry;#N/A;https://platform.opentargets.org/target/ENSG00000064489;5 alpha-Helices exposed by beta-structures;5.1 MADS box factors;5.1.1 Regulators of differentiation;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1505;ZNF705E;ENSG00000214534;HGNC:33203;100131539;Putative zinc finger protein 705EP (zinc finger protein 705E pseudogene);A8MWA4;#N/A;https://platform.opentargets.org/target/ENSG00000214534;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1506;ZNF705G;ENSG00000215372;HGNC:37134;100131980;Putative zinc finger protein 705G;A8MUZ8;#N/A;https://platform.opentargets.org/target/ENSG00000215372;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_1224;ZNF286B;ENSG00000249459;HGNC:33241;729288;Putative zinc finger protein 286B;P0CG31;#N/A;https://platform.opentargets.org/target/ENSG00000249459;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.3 More than 3 adjacent zinc fingers;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;1;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;Tdark;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0004;AC138696.1;ENSG00000264668;No Entry;No Entry;No Entry;No Entry;#N/A;https://platform.opentargets.org/target/ENSG00000264668;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0001;AC008770.3;ENSG00000267179;No Entry;No Entry;No Entry;No Entry;#N/A;https://platform.opentargets.org/target/ENSG00000267179;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0002;AC023509.3;ENSG00000267281;HGNC:55073;114108587;Cyclic AMP-dependent transcription factor ATF-7;K7ELQ4;#N/A;https://platform.opentargets.org/target/ENSG00000267281;2 Zinc-coordinating DNA-binding domains;2.3 C2H2 zinc finger factors;2.3.0 Uncharacterized/Undefined;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0166;DUX1_HUMAN;No Entry;HGNC:3079;26584;Double homeobox protein 1;O43812;#N/A;#N/A;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
TFTX_0167;DUX3_HUMAN;No Entry;HGNC:3081;26582;Putative double homeobox protein 3;Q96PT4;#N/A;#N/A;3 Helix-turn-helix domains;3.1 Homeo domain factors;3.1.3 Paired-related HD;#N/A;#N/A;#N/A;1469;1168;5_None;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;0;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;0;N;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;0;5_None;Pharos TDL at most Tbio and no other database indicates available drugs, with or without known MOA.;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A;#N/A
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;42;212;922;429;287;1353;525;357;250;377;351;352;326;496;133;693;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
